{"title": "PDF", "author": "PDF", "url": "https://www.socium.uni-bremen.de/lib/download.php?file=b4b2aa2178.pdf&filename=Innovationsreport%202021.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": " \n1\u00a0\n\u00a0\n \n \n \n\u00a0\nInnovationsreport\u00a0\n2021\u00a0\n\u00a0\n\u00a0\n\u00a0\nProf.\u00a0Dr.\u00a0Gerd\u00a0Glaeske\u00a0(Hrsg.)\u00a0\n\u00a0\n\u00a0\nUnter\u00a0Mitarbeit\u00a0von\u00a0\u00a0\nDr.\u00a0Dan\u00a0Dammann,\u00a0Dr.\u00a0Iris\u00a0Hi nneburg,\u00a0Friederike\u00a0H\u00f6fel,\u00a0\u00a0\nMona\u00a0Lorenz,\u00a0Berit\u00a0Marquardt, \u00a0Julia\u00a0Misonow,\u00a0Lutz\u00a0Muth,\u00a0\u00a0\nDr.\u00a0Sandra\u00a0Neitemeier,\u00a0Dr.\u00a0Goentje\u2010Gesine\u00a0Schoch,\u00a0Tim\u00a0Steimle,\u00a0 Svenja\u00a0van\u00a0Eijk\u00a0\n\u00a0\nErstellt\u00a0mit\u00a0freundliche r\u00a0Unterst\u00fctzung\u00a0der\u00a0\u00a0\nTechniker\u00a0Krankenkasse\u00a0(TK)\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0 \n2\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\nUniversit\u00e4t\u00a0Bremen,\u00a0SOCIUM,\u00a0Mar y\u2010Somerville\u2010Str.\u00a05,\u00a028359\u00a0Breme n\u00a0\nAus\u00a0Gr\u00fcnden\u00a0der\u00a0besseren\u00a0Lesbarkeit\u00a0wurde\u00a0auf\u00a0die\u00a0Nennung\u00a0beide r\u00a0geschlechtsspezifischer\u00a0\nFormen\u00a0verzichtet.\u00a0Im\u00a0Allgemeine n\u00a0ist\u00a0aber\u00a0das\u00a0jeweils\u00a0andere\u00a0G eschlecht\u00a0mitgemeint.\u00a0\n\u00a0\n\u00a0 \n3\u00a0\n\u00a0Inhaltsverzeichnis\u00a0\n1\u00a0Glossar\u00a0....................................................... ............................................\u00a05 \u00a0\n2\u00a0Vorworte\u00a0...................................................... ........................................\u00a011 \u00a0\n3\u00a0Einleitung\u00a0.................................................... .........................................\u00a015 \u00a0\n\u00a0Preisregulierung\u00a0in\u00a0Deutschland\u00a0............................... .........\u00a020\u00a0 3.1\n\u00a0Kostenkurven\u00a0zu\u00a0Indikationsgebieten\u00a0........................... .....\u00a022\u00a0 3.2\n\u00a0Das\u00a0systemische\u00a0Problem\u00a0der \u00a0Finanzierbarkeit\u00a0von\u00a0\u00a0 3.3\nneuen\u00a0Therapien\u00a0............................................... .................\u00a024 \u00a0\n4\u00a0Welchen\u00a0therapeutischen\u00a0Fortschritt\u00a0bringen\u00a0neue\u00a0Wirkstoffe?\u00a0.. ..........\u00a029\u00a0\n\u00a0Innovationskraft\u00a0der\u00a0pharmazeutischen\u00a0Unternehmen\u00a04.1\nim\u00a0Spiegel\u00a0der\u00a0Innovationsreporte\u00a02013\u00a0bis\u00a02020\u00a0.............\u00a02 9\u00a0\n\u00a0Fortgeschrittenes\u00a0malignes\u00a0Melanom\u00a0............................ ...\u00a045\u00a0 4.2\n\u00a0Immuntherapien\u00a0f\u00fcr\u00a0die\u00a0sch ubf\u00f6rmig\u00a0remittierende\u00a0\u00a0 4.3\nmultiple\u00a0Sklerose\u00a0............................................. ...................\u00a057 \u00a0\n\u00a0Diskussion\u00a0.................................................... ......................\u00a067 \u00a0 4.4\n5\u00a0Schw\u00e4chen\u00a0des\u00a0AMNOG\u00a0\u2013\u00a0\u201eBl\u00fctenlese\u201c\u00a0aus\u00a0acht\u00a0Jahren\u00a0\nInnovationsreport\u00a0............................................. ...................................\u00a073 \u00a0\n\u00a0Analyse\u00a0....................................................... ........................\u00a074 \u00a0 5.1\n\u00a0Kernprobleme\u00a0und\u00a0Forderungen\u00a0aus\u00a0der\u00a0\u00a05.2\nAMNOG\u2010Analyse\u00a0................................................. ...............\u00a082 \u00a0\n\u00a0Das\u00a0Ziel:\u00a0Zentrale\u00a0Preissetz ungsverfahren\u00a0f\u00fcr\u00a0innovative\u00a0\u00a0 5.3\nArzneimittel\u00a0.................................................. ......................\u00a098 \u00a0\n6\u00a0Bestehende\u00a0L\u00f6sungsstrategien\u00a0aus\u00a0anderen\u00a0Gesundheitssystemen\u00a0.. ...\u00a0105\u00a0\n\u00a0Frankreich\u00a0.................................................... ....................\u00a0105 \u00a0 6.1\n\u00a0Belgien\u00a0....................................................... ......................\u00a0109 \u00a0 6.2\n\u00a0Niederlande\u00a0................................................... ..................\u00a0111 \u00a0 6.3\n\u00a0Gro\u00dfbritannien\u00a0................................................ ................\u00a0115 \u00a0 6.4\n\u00a0S\u00fcdkorea\u00a0...................................................... ....................\u00a0120 \u00a0 6.5\n7\u00a0L\u00f6sungsvorschl\u00e4ge\u00a0f\u00fcr\u00a0das\u00a0deutsche\u00a0Gesundheitssystem\u00a0.......... ..........\u00a0131 \u00a0\n\u00a0Dynamischer\u00a0Eviden zpreis\u00a0(dynEP)\u00a0.............................. ....\u00a0131\u00a0 7.1\n\u00a0Modell\u00a0GKV\u2010SV\u00a0................................................. ................\u00a0132 \u00a0 7.2 \n4\u00a0\n\u00a0\u00a0AIM\u00a0Fair\u00a0Pricing\u00a0Calculator \u00a0f\u00fcr\u00a0patentgesch\u00fctzte\u00a0\u00a0 7.3\nArzneimittel\u00a0.................................................. ....................\u00a0132 \u00a0\n8\u00a0Blick\u00a0in\u00a0die\u00a0Zukunft:\u00a0Evidenz\u00a0................................. ..............................\u00a0159 \u00a0\n\u00a0Generierung\u00a0................................................... ...................\u00a0159 \u00a0 8.1\n\u00a0Evidenzindikator\u00a0.............................................. .................\u00a0164 \u00a0 8.2\n9\u00a0Ma\u00dfnahmen\u00a0zur\u00a0Stabilisierung\u00a0und \u00a0Senkung\u00a0von\u00a0Arzneimittelkosten \u00a0..\u00a0179\u00a0\n\u00a0Kurzfristige\u00a0Ma\u00dfnahmen\u00a0........................................ ..........\u00a0179 \u00a0 9.1\n\u00a0Langfristiges\u00a0Ziel\u00a0............................................ ...................\u00a0188 \u00a0 9.2\n10\u00a0Methodik\u00a0...................................................... .....................................\u00a0191 \u00a0\n11\u00a0Abbildungsve rzeichnis\u00a0......................................... ...............................\u00a0196 \u00a0\n12\u00a0Tabellenver zeichnis\u00a0........................................... .................................\u00a0196 \u00a0\n\u00a0\u00a0 \n5\u00a0\n\u00a01 Glossar\u00a0\nA7\u00a0 L\u00e4nderkorb\u00a0des\u00a0Preisvergleiches\u00a0i n\u00a0S\u00fcdkorea:\u00a0USA/J/D/F/CH/UK/I\nAccelerated\u00a0 Assess\u2010\nment\u00a0Beschleunigtes\u00a0Zul assungsverfahren\nAccord\u00a0Cadre\u00a0 Rahmenvertr\u00e4ge\nADTS\u00a0 local\u00a0Area\u00a0Drug\u00a0and\u00a0Therapeutic\u00a0Committees\nAE\u00a0 unerw\u00fcnschte\u00a0Arzneimitteleffekte,\u00a0 Adverse\u00a0effects\nAEK\u00a0 Apothekeneinkaufspreis\nAIDS\u00a0 Akquiriertes\u00a0I mmun\u2010Defizienz\u2010Syndrom\nAIFA\u00a0 italienische Zulassungsbeh\u00f6rde ,\u00a0Agenzia\u00a0Italiana\u00a0del\u00a0Farmaco\nAIM\u00a0 International\u00a0Association\u00a0of\u00a0Mutual\u00a0Benefit\u00a0Societies\nAKd\u00c4\u00a0 Arzneimittelkommission\u00a0der\u00a0deutschen\u00a0\u00c4rzteschaft\nAMG\u00a0 ArzneimittelgesetzAMNOG\u00a0 Arzneimittelmarktneuordnungsgesetz\nAMVSG\u00a0 Gesetz\u00a0zur\u00a0St\u00e4rkung\u00a0der\u00a0Ar zneimittelversorgung\u00a0in\u00a0der\u00a0GKV\nAPU\u00a0 Abgabepreis\u00a0des\u00a0pharma zeutischen\u00a0Unternehmens\nASMR\u00a0\nAm\u00e9lioration\u00a0du\u00a0Service\u00a0M\u00e9dical\u00a0Rendu\nATMPs\u00a0 Advanced\u00a0Therapy\u00a0Medicinal\u00a0Products\nATP\u00a0 Actual\u00a0transaction\u00a0price\nAVP\u00a0 ApothekenverkaufspreisB\u2010CLL\u00a0 Leuk\u00e4mie\u00a0vom\u00a0B\u2010Zell\u2010Typ\nBfArM\u00a0 Bundesinstitut\u00a0f\u00fcr\u00a0Ar zneimittel\u00a0und\u00a0Medizinprodukte\nBIP\u00a0 Bruttoinlandsprodukt\nBMG\u00a0 Bundesministerium\u00a0f\u00fcr\u00a0Gesundheit\nB\u2010RAF\u00a0 Rapidly\u00a0growing\u00a0fibrosarcoma\u00a0\nBRAF\u2010V600\u00a0 Mutation\u00a0des\u00a0Gens\u00a0BRAF\u00a0im\u00a0Codon\u00a0600\nBSC\u00a0 Best\u00a0Supportive\u00a0Care\nBudget\u00a0Impacts\u00a0 Absch\u00e4tzung\u00a0der\u00a0Bezahlbar keit\u00a0von\u00a0neuen\u00a0Produkten\nbu\ny\u2010out\u00a0 Unternehmens\u00fcbernahmen\nCAR\u2010T\u2010Zell\u2010Produkte\u00a0 Eine\u00a0 Form\u00a0der\u00a0Immuntherapie\u00a0\nCD20\u00a0 B\u2010Lymphozyten\u2010Antigen\nCDF\u00a0\u00a0 Cancer\u00a0Drug\u00a0Fun d\nCE\u00a0 Cost\u2010effectiveness\nCEPS\u00a0 Comit\u00e9\u00a0Economique\u00a0des \u00a0Produits\u00a0de\u00a0la\u00a0Sant\u00e9\nCheckpoints\u00a0 Stellen\u00a0in\u00a0Signalwegen\u00a0des\u00a0Immuns ystems,\u00a0die\u00a0die\u00a0 Immunantwort\u00a0f ein\u00a0\nregulieren\u00a0\nCHMP\u00a0 Committee\u00a0for\u00a0Human\u00a0Medicinal\u00a0Products\nclaw\u00a0back\u00a0 R\u00fcckerstattung\u00a0an\u00a0den\u00a0Kostentr\u00e4ger\nclinical\u00a0pathways\u00a0 Leitlinien\nCML\u00a0 Chronische\u00a0myeloische\u00a0Leuk\u00e4mie\u00a0\nConditional\u00a0Marke\u2010\nting\u00a0Authorisation\u00a0Bedingte\u00a0Zulassung\ncost\u2010effectivity\u00a0\nthreshold\u00a0Schwellenwert\u00a0der\u00a0Kosteneffizienz \n6\u00a0\n\u00a0Cost\u2010Sharing\u00a0 Diepharmazeutischen\u00a0Hersteller\u00a0ve reinbarenmit\u00a0Krankenkassen\u00a0ode r\u00a0\nKliniken\u00a0eine\u00a0Preisobergrenze\u00a0f\u00fc r\u00a0kostenintensive\u00a0Arzneimittel. \u00a0\nCRM\u00a0 Commission\u00a0de\u00a0Reimboursement\u00a0des\u00a0M\u00e9dicamen t\nCT\u00a0 Commission\u00a0de\u00a0la\u00a0Transparence\nCTLA\u20104\u00a0 Cytotoxic\u00a0T\u2010Lymphocyte\u2010associated\u00a0antigen\u20104\nDDD\u00a0 defined\u00a0daily\u00a0dose\nDERP\u00a0 Drug\u00a0Expenditure\u00a0Rationalisation\u00a0Plan\nDGN\u00a0 Deutsche\u00a0Gesellschaft\u00a0f\u00fcr\u00a0Neurologie\u00a0\ndirect\u00a0to\u00a0consumer\u00a0 direkt\u00a0zum\u00a0Verbraucher\ndownstream\u00a0path\u2010\nway\u00a0Behandlungspfade\u00a0in\u00a0Studien\u00a0und\u00a0im\u00a0klinischen\u00a0Alltag\nDREC\u00a0 Drug\u00a0Reimbursement\u00a0Evaluation\u00a0Committee\nDRESS\u2010Syndrom\u00a0 maligneErkrankung en\u00a0und\u00a0Arzneimittelausschlag\u00a0mit \u00a0Eosinophilie\u00a0und\u00a0\nsystemischen\u00a0Symptomen\u00a0( Drug\u00a0Rash\u00a0with\u00a0Eosinophilia\u00a0and\u00a0Systemic\u00a0\nSymptoms )\u00a0\nDRG\u00a0 Kostenerstattung\u00a0erfolgt\u00a0i m\u00a0Kontext\u00a0der\u00a0Behandlung\u00a0(Fallpau schale)\nDrug\u00a0Safety\u00a0Mai l\u00a0Risikoinformationen\u00a0per\u00a0Mail\nEADO\u00a0 European\u00a0Association\u00a0of\u00a0Dermato\u2010Oncolog y\nEAN\u00a0 European\u00a0Academy\u00a0of\u00a0Neurolog y\u00a0\nECTRIMS\u00a0 European\u00a0Committee\u00a0of\u00a0Treatment\u00a0and\u00a0Research\u00a0in\u00a0Multiple\u00a0Sclero sis\nEDF\u00a0 European\u00a0Dermatology\u00a0Forum\neffectiveness\u00a0 Wirksamkeit\u00a0f\u00fcr\u00a0Patienten \u00a0unter\u00a0Alltagsbedingungen\nefficacy\u00a0 Wirksamkeit\u00a0eines\u00a0Arzneimittels\u00a0f \u00fcr\u00a0Patienten\u00a0unter\u00a0Idealbeding ungen\nEMA\u00a0 Europ\u00e4ische\u00a0Arzneimittelagentur\u00a0\nEORTC\u00a0 European\u00a0Organization\u00a0of\u00a0Research\u00a0and\u00a0Treatment\u00a0of\u00a0Cancer\nERK\u00a01\u00a0 extrazellul\u00e4reSignal\u2010reg ulierte\u00a0Kinase(Enzyme)\u00a01\u00a0\u20108\u00a0\nERK\u00a02\u00a0 extrazellul\u00e4re\u00a0Signal\u2010regulierte\u00a0Kinase\nESMO\u00a0 European\u00a0Society\u00a0for\u00a0Medical\u00a0Oncolog y\nEUnetHTA\u00a0 Kollaboration\u00a0nationaler\u00a0HTA\u2010Organisationen\nexceptional\u00a0circum\u2010\nstances\u00a0Au\u00dfergew\u00f6hnliche\u00a0Umst\u00e4ndeim\u00a0Kon text\u00a0der\u00a0Arzneimittelzulassung\nEZB\u00a0 Europ\u00e4ische\u00a0Zentralbank\nF&E\u00a0 Forschungs\u2010und\u00a0Entwicklungskosten\u00a0\nFast\u2010track\u00a0 Schnellverfahren\u00a0(z.B. \u00a0bei\u00a0der\u00a0Zulassung)\nFDA\u00a0 Food\u00a0and\u00a0Drug\u00a0Administration\nG\u2010BA\u00a0 Gemeinsamer\u00a0BundesausschussGENEUR\u00a0 externe\u00a0Preisre ferenzierungssysteme\u00a0\nGENMID\u00a0 interne\u00a0Preisre ferenzierungssysteme\u00a0\nGIST\u00a0 Gastrointestinaler\u00a0Stromatumor\nGKV\u00a0 Gesetzliche\u00a0Krankenversicherung\u00a0\nGKV\u2010SV\u00a0 Spitzenverband\u00a0Bund\u00a0der\u00a0Krankenkassen\nGKV\u2010WSG\u00a0 GKV\u2010Wettbewerbsst\u00e4rkungsgesetz\u00a0\u00a0\nGM\u2010CSF\u00a0 humane\nrGranulozyten\u2010und\u00a0Makrophagen\u2010koloniestimulierender\u00a0Faktor\nGSAV\u00a0 Gesetzf\u00fcr\u00a0mehr\u00a0Sicherheit \u00a0in\u00a0der\u00a0Arzneimittelversorgung\nHAP\u00a0 Herstellerabgabepreis \n7\u00a0\n\u00a0HAS\u00a0 Haute\u00a0Autorit\u00e9\u00a0de\u00a0Sant\u00e9\u00a0(franz \u00f6sischen\u00a0\u00c4quivalent\u00a0zum\u00a0IQWiG)\nHER2\u00a0 Wachstumsfaktor\u2010Rezep tor\u00a0(z.\u00a0B.\u00a0bei\u00a0Brustkrebs)\nHIRA\u00a0 Health\u00a0Insurance\u00a0Review\u00a0&\u00a0Assessment\u00a0Service\nHIV\u00a0 HumanesImmundefizienz\u2010Virus\u00a0\nhorizon\u00a0scanning\u00a0 Beobachtung\u00a0der\u00a0Entwickl ung\u00a0neuer\u00a0Arzneimittel\nHRQoL\u00a0 Health\u00a0related\u00a0Q uality\u00a0of\u00a0Life\u00a0\nHTA\u00a0 Health\u00a0Technology\u00a0Appraisa l\u00a0\nICD\u00a0 International\u00a0Classification\u00a0of\u00a0Diagnoses\nICER\u00a0 Incremental\u00a0Cos t\u2010Effectiveness\u00a0Rati o,\u00a0inkrementelle\u00a0Kosteneffektivit\u00e4tsrati o\nICI\u00a0 Imperial\u00a0Chemical\u00a0Industries\u00a0(ehemaliges\u00a0bri tsiches\u00a0Phamaunternehmen )\nIFN\u2010\u03b1\u00a0 Interferon\u2010 \u03b1\nIKK\u00a0 Innungskrankenkassenin\u2010\npatient\u00a0 Arzneimittel\u00a0f\u00fcr\u00a0Krankenh\u00e4user\u00a0\nintention\u00a0to\u00a0trea t\u00a0Daten\u00a0aller\u00a0Patienten,\u00a0die\u00a0 man\u00a0vorher\u00a0beabsichtigte\u00a0( intention)\u00a0zu\u00a0be\u2010\nhandeln\u00a0( to\u00a0treat),\u00a0werden\u00a0nachher\u00a0ausgewertet \u00a0\nIQWiG\u00a0 Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0 Wirtschaftlichkeit\u00a0im\u00a0Gesundhei tswesen\nIV\u00a0 Integrierte\u00a0Versorgung\nJAK\u00a0 JanuskinaseJCV\u00a0 Humanes\u00a0Polyomavirus\njoint\u00a0Health\u00a0Techno\u2010\nlogy\u00a0Assessment\u00a0gemeinsame\u00a0Bewertungen\njudgment\u00a0reserve d\u00a0Urteil\u00a0vorbehalten\nJumbo\u2010Gruppen\u00a0 Festbetragsgruppen, f\u00fcr\u00a0die\u00a0es\u00a0mindestens\u00a0drei\u00a0pha rmakologisch\u2010\ntherapeutisch\u00a0vergleichbare\u00a0patentierte\u00a0Arzneimittel\u00a0im\u00a0Markt\u00a0g ibt\u00a0\nKH\u00a0 Krankenhausware\nKRW\u00a0 Koreanischer\u00a0WonLBI\u00a0 Ludwig\u00a0Boltzmann\u00a0Institut\nLPLD\u00a0 famili\u00e4rer\u00a0Lipoproteinlipasedefizienz\nMAP\u2010Kinase\u00a0 Proteinkinasen\nMEA\u00a0 managed\u00a0entry\u00a0agreements\nmean\u00a0 Mittelwert\nmedian\u00a0 mittlerer\u00a0Wert,\u00a0Zentralwert\nMEK\u00a0 Mitogen\u2010aktivierte\u00a0Signa\nl\u2010regulierte\u00a0Kinasen\nMHRA\u00a0 Medicine\u00a0and\u00a0Healthcare\u00a0products\u00a0Regulatory\u00a0Agenc y\nMRP\u00a0 Maximum\u00a0Reimbursement\u00a0Price\u00a0\nMS\u00a0 Multiple\u00a0Sklerose\nMVZ\u00a0 MedizinischesVersorgungszentrum\nn.\u00a0z.\u00a0 nicht\u00a0zugelassen\nNaevi\u00a0 unregelm\u00e4\u00dfigeLeberflecken\u00a0\nNDC\u00a0 New\u00a0Drug\u00a0Committee\nNGO\u00a0 Nichtregierungsorganisation\u00a0\nNHI\u00a0 National\u00a0Health\u00a0Institute\nNHIC\u00a0 National\u00a0Health\u00a0Information\u00a0Center\nNHIS\u00a0 National\u00a0Health\u00a0Insurance\u00a0Service \n8\u00a0\n\u00a0NHS\u00a0\u00a0 National\u00a0Health\u00a0Service\nNICE\u00a0 National\u00a0Institute\u00a0for\u00a0Health\u00a0and\u00a0Care\u00a0Excellence\u00a0(fr\u00fcher:\u00a0Nati onal\u00a0Insti\u2010\ntute\u00a0for\u00a0Clinical\u00a0Excellence)\u00a0\nnon\u00a0inferiority\u00a0studies\u00a0 Nicht\u2010Unterlegenheitsstudien\nnon\u2010Rx\u00a0 nicht\u2010rezeptpflichtig\nnot\u00a0acceptable\u00a0 nicht\u00a0akzeptabel\nnothing\u00a0new\u00a0 nichts\u00a0Neues\nNrf2\u00a0 Nuclear\u00a0factor\u00a0(erythroi d\u2010derived\u00a02)\u2010like\u00a02\nNUB\u2010System\u00a0 Neue\u00a0Untersuchungs\u2010und\u00a0Behandlungsmethoden\nnumber\u00a0 needed\u00a0 to\u00a0\ntreat\u00a0NNT\u00a0wie\u00a0viele\u00a0Patientenm\u00fcssen\u00a0statis tisch\u00a0behandelt\u00a0werden,\u00a0damit\u00a0e iner\u00a0\ngeheilt\u00a0wird\u00a0\nOECD\u00a0 Organisation\u00a0f\u00fcr\u00a0wirtscha ftliche\u00a0Zusammenarbeit\u00a0und\u00a0Entwic klung\nOpt\u2010out\u00a0\u00a0 Einstellung\u00a0des\u00a0Vertriebs\norphan\u00a0drugs\u00a0 Arzneimittelzur\u00a0Behandlung \u00a0seltener\u00a0Erkrankungen\u00a0\nOS\u00a0 Gesamt\u00fcberleben,\u00a0 overall\u00a0surviva l\u00a0\nOTC\u00a0 freiverk\u00e4ufliche,\u00a0apot hekenpflichtige\u00a0Arzneimittel\noutcome\u00a0 Ertrag\nout\u2010patient\u00a0 Abgabe\u00a0\u00fcber\u00a0\u00f6ffentliche\u00a0b zw.\u00a0Offizin\u2010Apotheken\np.\u00a0a.\u00a0 per\u00a0annum,\u00a0 pro\u00a0Jahr\npU\u00a0 pharmazeutisches\u00a0Unternehmen\u00a0\nPACE\u00a0 Patient\u00a0and\u00a0Clinician\u00a0Engagemen t\u00a0\nPAS\u00a0 Patient\u00a0Access\u00a0Scheme\nPASAG\u00a0 Patient\u00a0Access\u00a0Sche me\u00a0Assessment\u00a0Group\nPayment\u00a0by\u00a0Resul t\u00a0Ergebnisorientierte\u00a0Bezahlung\nPD\u00a0 Programmed\u00a0cell\u00a0death\u00a0protein\nPET\u2010CT\u00a0 Bildgebungsverfahren\nPFS\u00a0 Progression\u00a0free\u00a0Surviva l\nPHIS\u00a0 Pharma\u00a0Intelligence\u00a0Service\nPKV\u00a0 Private\u00a0Kran kenversicherung\nPML\u00a0\u00a0 progressive\u00a0multifokale\u00a0Leukenzephalopathie\npossibly\u00a0helpfu l\u00a0 m\u00f6glicherweise\u00a0hilfreich\nPPRI\u00a0 Pharmaceutical\u00a0Pricing\u00a0and\u00a0Reimbursemen tInformation\nPPMS\u00a0 prim\u00e4r\u00a0progrediente\u00a0MS (primary\u00a0progressive \u00a0multiple\u00a0sclerosis)\nprice\u00a0negotiation\u00a0 Verhandlung\u00a0der\u00a0Preis e\u00a0bei\u00a0Markteintritt\nPrioritization\u00a0Too l\u00a0Methode\u00a0zwischen\u00a0verschiedenen\u00a0Projekten\u00a0eine\u00a0Reihenfolge\u00a0festz ulegen\nPVA\u00a0 Price\u00a0Volume\u00a0Agreemen t\nQALY\u00a0 Quality\u2010adjusted\u00a0life\u00a0years\nQuality\u00a0of\u00a0Life\u00a0Data\u00a0 Daten\u00a0zur\u00a0Lebensqualit\u00e4t\nR&D\u00a0 Research\u00a0and\u00a0Developmen t\nrare\u00a0diseases \u00a0 sehr\u00a0selteneLeiden\nreal\u00a0advance\u00a0 echter\u00a0Fortschritt\nreasoned\u00a0action\u00a0 Ergebnis\u00a0einer\u00a0Abw\u00e4gung\u00a0zwisc hen\u00a0Pro\u2010und\u00a0Kontra\u2010Argumenten\nrelevant\u00a0patient\u00a0\npopulation\u00a0Zusammensetzung\u00a0einer\u00a0relevante n\u00a0Partientenpopulation\u00a0z.B.\u00a0f\u00fcr\u00a0 Risk\u2010\nsharing\u2010Modelle \u00a0 \n9\u00a0\n\u00a0Risk\u2010Sharing\u00a0 In\u00a0Risk\u2010Sharing \u2010Vertr\u00e4gen\u00a0garantiert\u00a0das\u00a0pha rmazeutische\u00a0Unternehmen\u00a0\ndem\u00a0Vertragspartner\u00a0das\u00a0sp\u00e4tere\u00a0 Eintreten\u00a0eines\u00a0bestimmten\u00a0ther apeu\u2010\ntischen\u00a0Zusatznutzens,\u00a0andernfa lls\u00a0(teil\u2010)\u00a0erstattet\u00a0er\u00a0den\u00a0Pre is.\u00a0\nRKI\u00a0 RobertKoch\u2010Institut\nRMS\u00a0 schubf\u00f6rmige\u00a0Mul tiple\u00a0Sklerose\u00a0\nRRMS\u00a0 schubf\u00f6rmig\u00a0remittie rendeMultiple\u00a0Sklerose\nRSA\u00a0 Risk\u00a0Sharing\u00a0Agreemen t\nrSPMS\u00a0 sekund\u00e4r\u00a0progrediente\u00a0Multi ple\u00a0Sklerose\u00a0mit\u00a0aufgesetzten\u00a0 Sch\u00fcben\nRWD\u00a0 Real\u00a0World\u00a0Data\nRx\u00a0 Rezeptpflichtig\nS1P\u00a0 Sphingosin\u20101\u2010Phosphat\nS2k\u00a0 S2\u00a0Leitlinie\u00a0konsentiert\nselective\u00a0reporting \u00a0 selektives\u00a0Publizieren\u00a0'g\u00fcnsti ger\u2018\u00a0Untersuchungsergebnisse\nSGB\u00a0 Sozialgesetzbuch\nSGLT\u00a02\u00a0 Sodium\u2010glucose\u00a0cotransporter\u00a02\u00a0\nSlicing\u00a0 strategische\u00a0Ver kleinerung\u00a0der\u00a0Patientengruppen\nSMA\u00a0 5q\u2010assoziierte\u2010spinaleMuskelatrophie\nSMC\u00a0 Scottish\u00a0Medicines\u00a0Consortium\u00a0\nSMR\u00a0 Service\u00a0Medical\u00a0Rendu\nSolisten\u00a0 Arzneimittel,\u00a0f\u00fcr\u00a0die\u00a0es\u00a0keine\u00a0therapeutische\u00a0Alternat ive\u00a0gibt\u00a0\nSPMS\u00a0 sekund\u00e4r\u00a0progrediente\u00a0MS\u00a0 (secondary\u00a0progressive\u00a0multiple\u00a0sclerosis )\nSVLFG\u00a0 Sozialversicherung\u00a0f\u00fcr\u00a0La ndwirtschaft,\u00a0Forsten\u00a0und\u00a0Garten bau\nSVR\u00a0 Sachverst\u00e4ndigenrat\ntime\u00a0to\u00a0marke t\u00a0 Zeit,\u00a0die\u00a0bis\u00a0zur\u00a0Vermarktung\u00a0vergeht\nTKI\u00a0 Tyrosinkinase\u2010Inhibitoren\nTKM\u00a0 Traditionelle\u00a0koreanische\u00a0Medizin\nTNF\u2010Inhibitoren\u00a0 Tumorn ekrosefaktor\u2010Hemmer\u00a0\ntrial\u00a0design\u00a0 Typ\u00a0der\u00a0Studie\nT\u2010Vec\u00a0 Talimogen\u00a0laherparepvecUAW\u00a0 unerw\u00fcnschte\u00a0Arz neimittelwirkungen\nUN\u00a0 United\u00a0Nations,\u00a0 Vereinte\u00a0Nationen\nultra\u2010rare\u00a0diseases\u00a0 sehr\u00a0seltene\u00a0Leiden\nunmet\u00a0medical\u00a0nee\nd\u00a0bisher\u00a0unerf\u00fcllter\u00a0medizin ischer\u00a0Behandlungsbedarf\nvalue\u2010based\u00a0pricing\u00a0 Wert\u2010basierte\u2010Preisbildung\nvdek\u00a0 Verband\u00a0der\u00a0Ersatzkassen\nVerum\u00a0 wirkstoffhaltiges\u00a0Medikament\u00a0VHI\u00a0 Voluntary\u00a0Health\u00a0Insurances\nWAP\u00a0 Weighted\u00a0Average\u00a0Price\nWHO\u00a0 World\u00a0Health\u00a0Organization\nZN\u00a0 Zusatznutzen\nZNS\u00a0 zentrales\u00a0Nervensystem\nzVT\u00a0 zweckm\u00e4\u00dfige\u00a0Vergleichstherapie\u00a0\n\u00a0 \u00a0 \n10\u00a0\n\u00a0\u00a0 \u00a0 \n11\u00a0\n\u00a02 Vorworte\u00a0\nVorwort\u00a0zum\u00a0Innovationsreport\u00a02021\u00a0\nDr.\u00a0Jens\u00a0Baas,\u00a0Vorsitzender\u00a0des\u00a0 Vorstands\u00a0der\u00a0Techniker\u00a0Kranken kasse\u00a0\nDie\u00a0Bilanz\u00a0der\u00a0ersten\u00a0zehn\u00a0Jahre\u00a0Arzneimittelmarktneuordnungsge setz\u00a0(AMNOG)\u00a0\nkann\u00a0sich\u00a0auf\u00a0den\u00a0ersten\u00a0Blick\u00a0durchaus\u00a0sehen\u00a0lassen:\u00a0Rund\u00a014\u00a0M illiarden\u00a0Euro\u00a0\nEinsparungen\u00a0f\u00fcr\u00a0die\u00a0gesetzliche \u00a0Krankenversicherung\u00a0(GKV)\u00a0steh en\u00a0da\u00a0zu\u00a0Buche.\u00a0\nBetrachtet\u00a0man\u00a0jedoch\u00a0die\u00a0grunds\u00e4tzliche\u00a0Entwicklung\u00a0der\u00a0Preise \u00a0f\u00fcr\u00a0patentge\u2010\nsch\u00fctzte\u00a0Arzneimittel\u00a0sowie\u00a0die\u00a0Ge samtausgaben\u00a0f\u00fcr\u00a0die\u00a0Versorgu ng\u00a0mit\u00a0Arznei\u2010\nmitteln\u00a0in\u00a0den\u00a0vergangenen\u00a0Jahren,\u00a0wird\u00a0deutlich,\u00a0dass\u00a0sich\u00a0die \u00a0Preisspirale\u00a0trotz\u00a0\nverschiedener\u00a0Kostenregulierungsinstrumente\u00a0kontinuierlich\u00a0nach \u00a0oben\u00a0bewegt.\u00a0\n2020\u00a0betrugen\u00a0die\u00a0Arzneimittelausgaben\u00a0der\u00a0GKV\u00a0insgesamt\u00a049,5\u00a0M illiarden\u00a0Euro,\u00a0\neine\u00a0Steigerung\u00a0um\u00a03,8\u00a0Prozent\u00a0im\u00a0Vergleich\u00a0zum\u00a0Vorjahr.\u00a0Mit\u00a021 ,9\u00a0Milliarden\u00a0Euro\u00a0\nentfielen\u00a0 mehr\u00a0 als\u00a0 die\u00a0 H\u00e4lfte\u00a0 der\u00a0 Ausgaben\u00a0 auf\u00a0 patentgesch\u00fctzte \u00a0 Pr\u00e4parate\u00a0\n(53,1\u00a0Prozent),\u00a0obwohl\u00a0deren\u00a0Men ge\u00a0definierter\u00a0Tagesdosen\u00a0nur\u00a01 0,4\u00a0Prozent\u00a0des\u00a0\nGesamtverbrauchs\u00a0ausmachte\u00a0(GKV\u2010SV,\u00a02021).\u00a0Setzt\u00a0sich\u00a0diese\u00a0Ent wicklung\u00a0fort,\u00a0\nsto\u00dfen\u00a0wir\u00a0\u2013\u00a0unabh\u00e4ngig\u00a0von\u00a0den\u00a0zus\u00e4tzlichen\u00a0Belastungen\u00a0durch\u00a0 die\u00a0Corona\u2010\nPandemie\u00a0\u2013\u00a0bald\u00a0an\u00a0die\u00a0Grenzen\u00a0der\u00a0Finanzierbarkeit\u00a0unseres\u00a0Ges undheitssys\u2010\ntems.\u00a0Sp\u00e4testens\u00a0dann\u00a0werden\u00a0wir\u00a0uns\u00a0als\u00a0Gesellschaft\u00a0die\u00a0Frage \u00a0stellen\u00a0m\u00fcssen:\u00a0\nWas\u00a0sind\u00a0wir\u00a0bereit,\u00a0f\u00fcr\u00a0die\u00a0Behandlung\u00a0bzw.\u00a0Heilung\u00a0von\u00a0Krankh eiten\u00a0zu\u00a0zahlen?\u00a0\nIn\u00a0Gro\u00dfbritannien\u00a0wurde\u00a0daf\u00fcr\u00a0bereits\u00a0das\u00a0Konzept\u00a0der\u00a0 Quality\u00a0Adjusted\u00a0Life\u00a0Years \u00a0\n(QALYs)\u00a0eingef\u00fchrt. \u00a0\nHerausgeber\u00a0Prof.\u00a0Gerd\u00a0Glaeske\u00a0vom\u00a0SOCIUM\u00a0\u2013\u00a0Forschungszentrum\u00a0f \u00fcr\u00a0Ungleichheit\u00a0\nund\u00a0Sozialpolitik\u00a0an\u00a0der\u00a0Universit\u00e4t\u00a0Bremen\u00a0und\u00a0sein\u00a0Team\u00a0stell en\u00a0im\u00a0vorliegenden\u00a0\nReport\u00a0neben\u00a0der\u00a0britischen\u00a0weitere\u00a0internationale\u00a0wie\u00a0auch\u00a0nat ionale\u00a0L\u00f6sungsstra\u2010\ntegien\u00a0vor,\u00a0mit\u00a0denen\u00a0eine\u00a0Senkung\u00a0der\u00a0Arzneimittelkosten\u00a0errei cht\u00a0werden\u00a0soll.\u00a0\nDar\u00fcber\u00a0hinaus\u00a0zeigen\u00a0sie\u00a0auf\u00a0Basis\u00a0der\u00a0Ergebnisse\u00a0der\u00a0vorangeg angenen\u00a0acht\u00a0Inno\u2010\nvationsreporte\u00a0die\u00a0Schw\u00e4chen\u00a0des\u00a0AMNOGs\u00a0auf.\u00a0Am\u00a0Bespiel\u00a0der\u00a0Ind ikationen\u00a0Malig\u2010\nnes\u00a0Melanom\u00a0und\u00a0Multiple\u00a0Sklerose\u00a0erl\u00e4utern\u00a0die\u00a0Autorinnen\u00a0und\u00a0 Autoren\u00a0den\u00a0\nEinfluss\u00a0der\u00a0Preisregulierungspolitik\u00a0der\u00a0vergangenen\u00a0Jahre\u00a0und \u00a0gehen\u00a0der\u00a0Frage\u00a0\nnach,\u00a0wie\u00a0der\u00a0Weg\u00a0zu\u00a0fairen\u00a0Preisen\u00a0f\u00fcr\u00a0Arzneimittel\u00a0gelingen\u00a0k ann.\u00a0\nDie\u00a0Weltgesundheitsorganisation\u00a0(WHO)\u00a0definiert\u00a0den\u00a0fairen\u00a0Prei s\u00a0als\u00a0\u201eeinen\u00a0Preis,\u00a0\nder\u00a0erschwinglich\u00a0f\u00fcr\u00a0die\u00a0Gesundheitssysteme\u00a0und\u00a0Patientinnen\u00a0u nd\u00a0Patienten\u00a0ist\u00a0\nund\u00a0gleichzeitig\u00a0genug\u00a0Marktanreize\u00a0setzt,\u00a0damit\u00a0die\u00a0Industrie\u00a0 in\u00a0Innovationen\u00a0und\u00a0\nArzneimittelproduktion\u00a0investier t\u201c\u00a0(WHO,\u00a02019).\u00a0Nat\u00fcrlich\u00a0ist\u00a0k einem\u00a0schwerkran\u2010\nken\u00a0Patienten\u00a0und\u00a0keiner\u00a0schwerkranken\u00a0Patientin\u00a0geholfen,\u00a0wenn \u00a0die\u00a0pharmazeu\u2010\ntische\u00a0 Industrie\u00a0 ihre\u00a0 Forschungsaktivit\u00e4ten\u00a0 einstellt,\u00a0 weil\u00a0 sie \u00a0d i e s e \u00a0n i c h t \u00a0m e h r \u00a0\nfinanzieren\u00a0kann.\u00a0Die\u00a0Zahlungsbe reitschaft\u00a0f\u00fcr\u00a0echte\u00a0Innovation en\u00a0ist\u00a0aufseiten\u00a0der\u00a0 \n12\u00a0\n\u00a0Kostentr\u00e4ger\u00a0gro\u00df.\u00a0Im\u00a0Gegenzug\u00a0bedarf\u00a0es\u00a0aber\u00a0aufseiten\u00a0der\u00a0pha rmazeutischen\u00a0\nUnternehmer\u00a0mehr\u00a0Transparenz\u00a0hin sichtlich\u00a0ihrer\u00a0Forschungs\u2010\u00a0und \u00a0Entwicklungs\u2010\nkosten.\u00a0Nur\u00a0so\u00a0ist\u00a0auf\u00a0Dauer\u00a0eine\u00a0gerechte\u00a0Preisfindung\u00a0m\u00f6glich ,\u00a0die\u00a0die\u00a0Finanzier\u2010\nbarkeit\u00a0der\u00a0Gesundheitssysteme\u00a0aufrechterh\u00e4lt.\u00a0Daher\u00a0unterbreit en\u00a0die\u00a0Autorin\u2010\nnen\u00a0und\u00a0Autoren\u00a0dieses\u00a0Innovationsreportes\u00a0auf\u00a0Basis\u00a0des\u00a0fairen \u00a0Preismodells\u00a0der \u00a0\nInternational\u00a0Association\u00a0of\u00a0Mutual\u00a0Benefit\u00a0Societies \u00a0(AIM)\u00a0sehr\u00a0konkrete\u00a0Vorschl\u00e4ge\u00a0\nzu\u00a0Regeln\u00a0und\u00a0Kriterien,\u00a0die\u00a0zu\u00a0einer\u00a0effizienteren\u00a0Preisbildun g\u00a0beitragen\u00a0k\u00f6nnen.\u00a0\nDennoch\u00a0 braucht\u00a0 es\u00a0 kurzfristige\u00a0 Ma\u00dfnahmen,\u00a0 um\u00a0 die\u00a0 Ausgaben\u00a0 f\u00fcr\u00a0 patentge\u2010\nsch\u00fctzte\u00a0Arzneimittel\u00a0zu\u00a0senken.\u00a0Auch\u00a0die\u00a0Politik\u00a0hat\u00a0dies\u00a0erka nnt.\u00a0So\u00a0hei\u00dft\u00a0es\u00a0im\u00a0\nKoalitionsvertrag\u00a0von\u00a0SPD,\u00a0Gr\u00fcnen\u00a0und\u00a0FDP:\u00a0\u201eDas\u00a0Gesetz\u00a0zur\u00a0Neuo rdnung\u00a0des\u00a0\nArzneimittelmarktes\u00a0(AMNOG)\u00a0entwickeln\u00a0wir\u00a0weiter.\u00a0Wir\u00a0st\u00e4rken\u00a0 die\u00a0M\u00f6glichkei\u2010\nten\u00a0der\u00a0Krankenkassen\u00a0zur\u00a0Begrenzu ng\u00a0der\u00a0Arzneimittelpreise.\u00a0De r\u00a0verhandelte\u00a0\nErstattungspreis\u00a0gilt\u00a0ab\u00a0dem\u00a0siebten\u00a0Monat\u00a0nach\u00a0Markteintritt.\u201c \u00a0(SPD,\u00a0B\u00fcndnis\u00a0\n90/Die\u00a0Gr\u00fcnen,\u00a0FDP,\u00a02021).\u00a0\nEntwickeln\u00a0wir\u00a0also\u00a0gemeinsam\u00a0das\u00a0AMNOG\u00a0weiter\u00a0und\u00a0durchbrechen \u00a0die\u00a0Preis\u2010\nspirale,\u00a0damit\u00a0Deutschland\u00a0in\u00a0Zukunft\u00a0seinem\u00a0Ruf\u00a0als\u00a0\u201eApotheke\u00a0 der\u00a0Welt\u201c\u00a0wieder\u00a0\ngerecht\u00a0werden\u00a0kann.\u00a0\u00a0\n\u00a0Hamburg\u00a0im\u00a0Dezember\u00a02021\u00a0\n\u00a0\nQuellen\u00a0\nGKV\u2010SV\u00a0\u2013\u00a0Spitzenverband\u00a0Bund\u00a0der\u00a0Krankenkassen\u00a0(2021).\u00a0GKV\u2010Arzn eimittel\u2010Schnellinformation\u00a0f\u00fcr\u00a0Deutschland,\u00a0Januar\u00a0bis\u00a0\nDezember\u00a02020.\u00a0www.gkv\u2010gamsi.de/media/dokumente/quartalsbericht e/2020/q4_23/Bundesbericht_GA\u00a0\nmSi_202012_konsolidiert.pdf,\u00a0letzter\u00a0Zugriff:\u00a008.12.2021.\u00a0\nWHO\u00a0\u2013\u00a0World\u00a0Health\u00a0Organization\u00a0 (2019).\u00a0Fair\u00a0pricing\u00a0forum.\u00a0Q&A .\u00a0https://www.who.int/news\u2010room/questions\u2010and\u2010\nanswers/item/medicines\u2010fair\u2010pric ing\u2010forum,\u00a0letzter\u00a0Zugriff:\u00a026. 11.2021.\u00a0\nSPD,\u00a0B\u00fcndnis\u00a090/Die\u00a0Gr\u00fcnen,\u00a0FDP\u00a0(2021).\u00a0Mehr\u00a0Fortschritt\u00a0wagen\u00a0 \u2013\u00a0B\u00fcndnis\u00a0f\u00fcr\u00a0Freiheit,\u00a0Gerechtigkeit\u00a0und\u00a0Nachhaltigkeit.\u00a0\nKoalitionsvertrag\u00a0zwischen\u00a0SPD,\u00a0B\u00fcndnis90/Die\u00a0Gr\u00fcnen\u00a0und\u00a0FDP,\u00a0S .\u00a087.\u00a0\nwww.spd.de/fileadmin/Dokumente/Koalitionsvertrag/Koalitionsvert rag_2021\u20102025.pdf,\u00a0letzter\u00a0Zugriff:\u00a008.12.2021.\u00a0\n\u00a0 \u00a0 \n13\u00a0\n\u00a0Zweites\u00a0Vorwort\u00a0zum\u00a0Innovationsreport\u00a02021\u00a0\nProf.\u00a0Dr.\u00a0Gerd\u00a0Glaeske,\u00a0SOCIUM\u00a0\u2013\u00a0Forschungszentrum\u00a0Ungleichheit \u00a0und\u00a0Sozialpolitik\u00a0\nMittlerweile\u00a0haben\u00a0wir\u00a0in\u00a0Kooperation\u00a0mit\u00a0der\u00a0Techniker\u00a0Kranken kasse\u00a0acht\u00a0Inno\u2010\nvationsreporte\u00a0fertiggestellt\u00a0und\u00a0publiziert.\u00a0Dabei\u00a0lag\u00a0der\u00a0Sch werpunkt\u00a0auf\u00a0der\u00a0\npharmakologischen\u00a0Bewertung\u00a0von\u00a0n euen\u00a0Arzneimitteln,\u00a0die\u00a0drei\u00a0J ahre\u00a0zuvor\u00a0im\u00a0\nMarkt\u00a0zugelassen\u00a0worden\u00a0sind.\u00a0Di ese\u00a0Arzneimittel\u00a0wurden\u00a0mit\u00a0Amp eln\u00a0von\u00a0Gr\u00fcn\u00a0\nnach\u00a0Rot\u00a0f\u00fcr\u00a0verschiedene\u00a0Aspekte\u00a0bewertet.\u00a0Die\u00a0Bewertungen\u00a0f\u00fcr \u00a0die\u00a0unter\u2010\nschiedlichen\u00a0Wirkstoffe\u00a0und\u00a0Arzneimittel\u00a0entstand\u00a0durch\u00a0die\u00a0Aus wertung\u00a0evidenz\u2010\nbasierter\u00a0 Informationen\u00a0 aus\u00a0 einschl\u00e4gigen\u00a0 Journalen,\u00a0 pharmazeut ischen\u00a0 Stan\u2010\ndardwerken\u00a0und\u00a0Datenbanken,\u00a0die\u00a0gesichtet\u00a0und\u00a0analysiert\u00a0wurden .\u00a0Dabei\u00a0ging\u00a0es\u00a0\nuns\u00a0vor\u00a0allem\u00a0darum,\u00a0die\u00a0Wirksamkeit\u00a0und\u00a0die\u00a0Evidenz\u00a0dieser\u00a0neu en\u00a0Arzneimittel\u00a0\nzu\u00a0\u00fcberpr\u00fcfen\u00a0und\u00a0auch\u00a0die\u00a0Frage\u00a0zu\u00a0beantworten,\u00a0ob\u00a0diese\u00a0neuen \u00a0Arzneimittel\u00a0\ngegen\u00fcber\u00a0den\u00a0bisherigen\u00a0verf\u00fcgbaren\u00a0Arzneimitteln\u00a0einen\u00a0besser en\u00a0Patienten\u2010\nnutzen\u00a0bieten.\u00a0\u00a0\nIn\u00a0diesem\u00a0Innovationsreport\u00a0haben\u00a0wir\u00a0ein\u00a0ganz\u00a0anderes\u00a0Schwerpu nktthema\u00a0ge\u2010\nw\u00e4hlt,\u00a0das\u00a0sich\u00a0allerdings\u00a0aus\u00a0den\u00a0vorherigen\u00a0Innovationsreport en\u00a0ableiten\u00a0l\u00e4sst:\u00a0Es\u00a0\ngeht\u00a0um\u00a0die\u00a0Frage\u00a0der\u00a0gerechten\u00a0Preisfindung\u00a0f\u00fcr\u00a0Arzneimittel,\u00a0 die\u00a0neu\u00a0auf\u00a0den\u00a0\nMarkt\u00a0gekommen\u00a0sind\u00a0und\u00a0die\u00a0in\u00a0den\u00a0letzten\u00a0Jahren\u00a0die\u00a0Ausgaben\u00a0 der\u00a0GKV\u00a0domi\u2010\nniert\u00a0haben.\u00a0W\u00e4hrend\u00a0zum\u00a0Beispiel\u00a02011\u00a0noch\u00a0rund\u00a017\u00a0%\u00a0des\u00a0Gesam tumsatzes\u00a0auf\u00a0\nArzneimittel\u00a0mit\u00a0Preisen\u00a0von\u00a01.000\u00a0\u20ac\u00a0oder\u00a0mehr\u00a0entfielen,\u00a0macht en\u00a0neue\u00a0patentge\u2010\nsch\u00fctzte\u00a0Arzneimittel\u00a0im\u00a0Jahre\u00a02020\u00a0f\u00fcr\u00a0die\u00a0GKV\u00a0bereits\u00a043\u00a0%\u00a0de s\u00a0Umsatzes\u00a0aus.\u00a0Die\u00a0\nUms\u00e4tze\u00a0von\u00a0hochpreisigen\u00a0Arzneimittel\u00a0in\u00a0den\u00a0letzten\u00a0zehn\u00a0Jahr en\u00a0haben\u00a0sich\u00a0ver\u2010\nvierfacht\u00a0und\u00a0lagen\u00a02020\u00a0bei\u00a0rund\u00a020,9\u00a0Milliarden\u00a0Euro.\u00a0\u00a0\nDiese\u00a0Entwicklungen\u00a0waren\u00a0auch\u00a0in\u00a0den\u00a0bisherigen\u00a0Innovationsrep orten\u00a0bereits\u00a0zu\u00a0\nfinden,\u00a0 die\u00a0 Jahrestherapiekosten\u00a0 stiegen\u00a0 um\u00a0 ein\u00a0 Vielfaches\u00a0 gege n\u00fcber\u00a0 fr\u00fcheren\u00a0\nJahren,\u00a0insbesondere\u00a0im\u00a0Bereich\u00a0der\u00a0onkologischen\u00a0Therapeutika, \u00a0aber\u00a0auch\u00a0der\u00a0\nTherapeutika,\u00a0die\u00a0bei\u00a0Multipler\u00a0Sklerose,\u00a0bei\u00a0rheumatoider\u00a0Arth ritis\u00a0oder\u00a0auch\u00a0bei\u00a0\nPsoriasis\u00a0eingesetzt\u00a0wurden.\u00a0Insofern\u00a0ist\u00a0es\u00a0nur\u00a0konsequent,\u00a0da ss\u00a0dieser\u00a0aktuelle\u00a0\nInnovationsreport\u00a0die\u00a0Preisgestaltung\u00a0auf\u00a0dem\u00a0Arzneimittelmarkt \u00a0n\u00e4her\u00a0analysiert\u00a0\nund\u00a0auch\u00a0Vorschl\u00e4ge\u00a0zur\u00a0Diskussion\u00a0anbietet,\u00a0wie\u00a0eine\u00a0solche\u00a0Pr eisgestaltung\u00a0ver\u00e4n\u2010\ndert\u00a0werden\u00a0kann.\u00a0Es\u00a0gibt\u00a0eine\u00a0ganze\u00a0Reihe\u00a0von\u00a0Vorschl\u00e4gen,\u00a0die \u00a0der\u00a0Strategie\u00a0fol\u2010\ngen,\u00a0dass\u00a0die\u00a0Evidenz\u00a0den\u00a0Preis\u00a0bestimmen\u00a0muss.\u00a0Diese\u00a0Evidenz\u00a0m uss\u00a0sich\u00a0an\u00a0den\u00a0\nRahmenbedingungen\u00a0 des\u00a0 Patientennutzens\u00a0 orientieren,\u00a0 der\u00a0 im\u00a0 \u00a7\u00a035 b\u00a0 des\u00a0 SGB\u00a0V\u00a0\ndefiniert\u00a0ist.\u00a0Dabei\u00a0geht\u00a0es\u00a0um\u00a0vier\u00a0Kategorien:\u00a0Um\u00a0die\u00a0Verk\u00fcrz ung\u00a0der\u00a0Krankheits\u2010\ndauer,\u00a0um\u00a0die\u00a0Verl\u00e4ngerung\u00a0des\u00a0Lebens,\u00a0um\u00a0die\u00a0Verringerung\u00a0von\u00a0 unerw\u00fcnschten\u00a0\nBegleiterscheinungen\u00a0und\u00a0um\u00a0die\u00a0Verbesserung\u00a0der\u00a0Lebensqualit\u00e4t \u00a0der\u00a0Patienten.\u00a0\nDiese\u00a0Aspekte\u00a0werden\u00a0heute\u00a0noch\u00a0viel\u00a0zu\u00a0wenig\u00a0bei\u00a0der\u00a0Zulassung \u00a0bzw.\u00a0auch\u00a0bei\u00a0der\u00a0\nAMNOG\u2010Bewertung\u00a0ber\u00fccksichtigt,\u00a0wie\u00a0dargestellt\u00a0im\u00a0Kapitel\u00a05\u00a0be z\u00fcglich\u00a0der\u00a0Schw\u00e4\u2010 \n14\u00a0\n\u00a0chen\u00a0der\u00a0derzeitigen\u00a0Regulation\u00a0durch\u00a0das\u00a0AMNOG\u2010System\u00a0bei\u00a0neue n\u00a0Arzneimitteln.\u00a0\nEs\u00a0m\u00fcssen\u00a0also\u00a0Wege\u00a0gefunden\u00a0werden,\u00a0wie\u00a0die\u00a0Evidenz\u00a0neuer\u00a0Arzn eimittel,\u00a0die\u00a0sich\u00a0\nan\u00a0den\u00a0vier\u00a0genannten\u00a0Kriterien\u00a0des\u00a0Patientennutzen\u00a0zu\u00a0orientie ren\u00a0hat,\u00a0besser\u00a0und\u00a0\nintensiver\u00a0analysiert\u00a0werden\u00a0kann.\u00a0In\u00a0diesem\u00a0Innovationsreport\u00a0 wird\u00a0deutlich\u00a0ge\u2010\nmacht,\u00a0dass\u00a0solche\u00a0Kategorien\u00a0in\u00a0der\u00a0Zulassung\u00a0nicht\u00a0unbedingt\u00a0 eine\u00a0Rolle\u00a0spielen\u00a0\nund\u00a0dass\u00a0Zulassungskriterien\u00a0nicht\u00a0unbedingt\u00a0dem\u00a0entsprechen,\u00a0w as\u00a0Patienten\u00a0von\u00a0\nArzneimittelnutzen\u00a0erwarten.\u00a0Daher\u00a0ist\u00a0es\u00a0notwendig,\u00a0die\u00a0Eviden z\u00a0in\u00a0gesonderten\u00a0\nklinischen\u00a0Studien\u00a0 nach\u00a0der\u00a0Zulassung\u00a0zu\u00a0pr\u00fcfen\u00a0und\u00a0daraus\u00a0auch\u00a0den\u00a0Schluss\u00a0zu\u00a0\nziehen,\u00a0welchen\u00a0Wert\u00a0das\u00a0jeweilige\u00a0Arzneimittel\u00a0f\u00fcr\u00a0die\u00a0Patient en\u00a0hat.\u00a0Bisher\u00a0haben\u00a0\ndie\u00a0pharmazeutischen\u00a0Unternehmer\u00a0eher\u00a0die\u00a0Strategie\u00a0verfolgt,\u00a0d ass\u00a0das\u00a0\u201eLeiden\u201c\u00a0\nden\u00a0Preis\u00a0bestimmt.\u00a0Die\u00a0Strategie\u00a0sollte\u00a0allerdings\u00a0lauten,\u00a0das s\u00a0der\u00a0Patientennutzen\u00a0\nausschlaggebend\u00a0f\u00fcr\u00a0den\u00a0Preis\u00a0sein\u00a0muss.\u00a0Es\u00a0geht\u00a0um\u00a0die\u00a0Fragest ellung\u00a0der\u00a0 effec\u2010\ntiveness,\u00a0also\u00a0letzten\u00a0Endes\u00a0um\u00a0den\u00a0Nutzen\u00a0in\u00a0der\u00a0normalen\u00a0Patientenver sorgung,\u00a0\ndie\u00a0nicht\u00a0durch\u00a0die\u00a0Rahmenbedingungen\u00a0klinischer\u00a0Pr\u00fcfungen\u00a0best immt\u00a0wird.\u00a0\nWerden\u00a0Konzepte\u00a0entwickelt,\u00a0die,\u00a0bezogen\u00a0auf\u00a0den\u00a0Patientennutze n\u00a0und\u00a0die\u00a0Evi\u2010\ndenz,\u00a0in\u00a0einem\u00a0fairen\u00a0Arzneimittelpreis\u00a0m\u00fcnden,\u00a0ist\u00a0es\u00a0auch\u00a0not wendig,\u00a0den\u00a0pharma\u2010\nzeutischen\u00a0Unternehmen\u00a0das\u00a0Privileg\u00a0und\u00a0den\u00a0\u201eLuxus\u201c\u00a0zu\u00a0nehmen,\u00a0 im\u00a0ersten\u00a0Jahr\u00a0\nder\u00a0Vermarktung\u00a0den\u00a0Preis\u00a0f\u00fcr\u00a0das\u00a0Arzneimittel\u00a0selber\u00a0bestimmen \u00a0zu\u00a0k\u00f6nnen.\u00a0Dieses\u00a0\nPrivileg\u00a0schw\u00e4chte\u00a0auch\u00a0die\u00a0Verhandlungen\u00a0des\u00a0GKV\u2010Spitzenverban des,\u00a0der\u00a0mit\u00a0dem\u00a0\npharmazeutischen\u00a0Unternehmer\u00a0den\u00a0Erstattungsbetrag\u00a0verhandelt,\u00a0 welcher\u00a0ab\u00a0dem\u00a0\n13.\u00a0Monat\u00a0f\u00fcr\u00a0die\u00a0GKV\u00a0gilt.\u00a0Der\u00a0aktuell\u00a0vorgelegte\u00a0Koalitionsve rtrag\u00a0hat\u00a0dieses\u00a0Prob\u2010\nlem\u00a0zumindest\u00a0erkannt\u00a0und\u00a0den\u00a0Herstellerpreis\u00a0auf\u00a0sechs\u00a0Monate\u00a0 begrenzt,\u00a0sodass\u00a0\nab\u00a0dem\u00a0siebten\u00a0Monat\u00a0der\u00a0verhandelte\u00a0Erstattungspreis\u00a0f\u00fcr\u00a0die\u00a0G KV\u00a0gilt.\u00a0Dies\u00a0ist\u00a0ein\u00a0\nerster\u00a0Schritt\u00a0in\u00a0die\u00a0richtige\u00a0Richtung.\u00a0Wenn\u00a0allerdings\u00a0ein\u00a0ph armazeutischer\u00a0Unter\u2010\nnehmer\u00a050.000\u00a0\u20ac\u00a0Jahrestherapiekosten\u00a0aufruft,\u00a0werden\u00a0die\u00a0Verhan dlungen\u00a0keinen\u00a0\nErstattungsbetrag\u00a0von\u00a025.000\u00a0\u20ac\u00a0erreichen\u00a0k\u00f6nnen.\u00a0Mit\u00a0anderen\u00a0Wo rten:\u00a0Diese\u00a0m\u00f6g\u2010\nliche\u00a0Preisgestaltung\u00a0f\u00fcr\u00a0die\u00a0pharmazeutischen\u00a0Unternehmer\u00a0gilt \u00a0es\u00a0zu\u00a0reduzieren,\u00a0\nhat\u00a0sie\u00a0eben\u00a0auch\u00a0Einfluss\u00a0auf\u00a0die\u00a0Ausgangsbasis\u00a0des\u00a0GKV\u2010Spitze nverbandes,\u00a0der\u00a0mit\u00a0\nden\u00a0Herstellern\u00a0einen\u00a0Erstattungsbetrag\u00a0vereinbaren\u00a0muss.\u00a0\u00a0\nEs\u00a0ist\u00a0daher\u00a0wesentlich,\u00a0neue\u00a0Strategien\u00a0zu\u00a0entwickeln,\u00a0um\u00a0zu\u00a0e inem\u00a0fairen\u00a0Preis\u00a0zu\u00a0\nkommen.\u00a0Und\u00a0diese\u00a0Strategien\u00a0m\u00fcssen\u00a0gut\u00a0ausgearbeitet\u00a0sein,\u00a0dam it,\u00a0wenn\u00a0sich\u00a0\ndas\u00a0\"politische\u00a0Fenster\"\u00a0f\u00fcr\u00a0Ver\u00e4nderungen\u00a0\u00f6ffnet,\u00a0L\u00f6sungsstrat egien\u00a0angeboten\u00a0\nwerden\u00a0k\u00f6nnen.\u00a0Das\u00a0mag\u00a0l\u00e4ngere\u00a0Zeit\u00a0in\u00a0Anspruch\u00a0nehmen\u00a0und\u00a0auch \u00a0viele\u00a0weitere\u00a0\nDiskussionen\u00a0erfordern,\u00a0aber\u00a0wie\u00a0schon\u00a0Lelio\u00a0Basso\u00a0in\u00a0seinem\u00a0B\u00fc chlein\u00a0\u201eDie\u00a0Theo\u2010\nrie\u00a0des\u00a0politischen\u00a0Konflikts\u201c\u00a0deutlich\u00a0gemacht\u00a0hat,\u00a0braucht\u00a0es \u00a0oft\u00a0einen\u00a0langen\u00a0\nAtem,\u00a0um\u00a0bestimmte\u00a0Ver\u00e4nderungen\u00a0zu\u00a0erreichen.\u00a0\u00a0\n\u00a0\nBremen\u00a0im\u00a0Dezember\u00a02021\u00a0 \u00a0 \n15\u00a0\n\u00a03 Einleitung\u00a0\nDie\u00a0\u00f6ffentliche\u00a0F\u00f6rderung\u00a0pharmazeutischer\u00a0Unternehmen\u00a0\u2013\u00a0oder:\u00a0 Warum\u00a0sollte\u00a0\ndie\u00a0Gesellschaft\u00a0hohe\u00a0Arzneimittelpreise\u00a0doppelt\u00a0finanzieren? \u00a01\u00a0\nMehrere\u00a0Studien\u00a0und\u00a0Berichte\u00a0zeigen\u00a0mittlerweile,\u00a0welche\u00a0direkt e\u00a0und\u00a0indirekte\u00a0finanziel\u2010\nle\u00a0Unterst\u00fctzung\u00a0viele\u00a0pharmazeu tische\u00a0Unternehmen\u00a0aus\u00a0\u00f6ffentli chen\u00a0Mitteln\u00a0erhalten\u00a0\nhaben\u00a0(Van\u00a0Hecke\u00a0&\u00a0van\u00a0Gils,\u00a0201 9;\u00a0Schipper\u00a0et\u00a0al.,\u00a02019;\u00a0Gotha m\u00a0et\u00a0al.,\u00a02017).\u00a0\nIm\u00a0Jahr\u00a02016\u00a0erwirtschafteten\u00a0die\u00a020\u00a0gr\u00f6\u00dften\u00a0Pharmaunternehmen\u00a0 rund\u00a0500\u00a0Milli\u2010\narden\u00a0 US\u2010Dollar\u00a0 Arzneimittelums\u00e4tze\u00a0 weltweit.\u00a0 Ihre\u00a0 Forschungs\u2010\u00a0 und\u00a0 Entwick\u2010\nlungs(F&E)\u2010\u00a0Ausgaben\u00a0betrugen\u00a0Berichten\u00a0zufolge\u00a0100\u00a0Milliarden\u00a0 US\u2010Dollar\u00a0und\u00a0\ndamit\u00a0weniger\u00a0als\u00a0ihre\u00a0120\u00a0Milliarden\u00a0US\u2010Dollar\u00a0an\u00a0Gewinnen\u00a0(Ph arma\u00a0Intelligence,\u00a0\n2018).\u00a0Aber\u00a0die\u00a0Pharmaunternehmen\u00a0sind\u00a0nicht\u00a0die\u00a0Einzigen,\u00a0die\u00a0 Arzneimittelfor\u2010\nschung\u00a0finanzieren.\u00a0Laut\u00a0einer\u00a0Studie\u00a0aus\u00a0dem\u00a0Jahr\u00a02018\u00a0erhielt en\u00a0alle\u00a0210\u00a0Medi\u2010\nkamente,\u00a0die\u00a0von\u00a0der\u00a0US\u2010Arzneimittelbeh\u00f6rde\u00a0Food\u00a0and\u00a0Drug\u00a0Admin istration\u00a0(FDA)\u00a0\nzwischen\u00a02010\u00a0und\u00a02016\u00a0zugelassen\u00a0wurden,\u00a0auch\u00a0\u00f6ffentliche\u00a0Mitt el,\u00a090\u00a0%\u00a0davon\u00a0\nf\u00fcr\u00a0die\u00a0Grundlagenforschung\u00a0(Cleary\u00a0et\u00a0al.,\u00a02018). \u00a0Eine\u00a0\u00e4ltere\u00a0Studie\u00a0untersuchte\u00a0\ndie\u00a0FDA\u2010Medikamentenzulassungen\u00a0zwischen\u00a01998\u00a0und\u00a02007\u00a0(Kneller ,\u00a02010).\u00a0Unter\u00a0\nden\u00a0252\u00a0zugelassenen\u00a0Produkten,\u00a0di e\u00a0einen\u00a0neuen\u00a0Wirkstoff\u00a0enthi elten,\u00a0waren\u00a024\u00a0%\u00a0\nvon\u00a0Wissenschaftlern\u00a0einer\u00a0Universit\u00e4t\u00a0oder\u00a0einer\u00a0Forschungsein richtung,\u00a0die\u00a0von\u00a0\neiner\u00a0gemeinn\u00fctzigen\u00a0Organisation\u00a0finanziert\u00a0wurde,\u00a0entdeckt\u00a0wo rden\u00a0(Schipper\u00a0et\u00a0\nal.,\u00a02019;\u00a0Kneller,\u00a02010).\u00a0Zwei\u00a0Drittel\u00a0der\u00a0Lizenzen\u00a0wurden\u00a0an\u00a0 ein\u00a0Biotechnologieun\u2010\nternehmen\u00a0und\u00a0in\u00a0einem\u00a0Drittel\u00a0der\u00a0F\u00e4lle\u00a0an\u00a0ein\u00a0pharmazeutische s\u00a0Unternehmen\u00a0\n\u00fcbertragen\u00a0(Schipper\u00a0et\u00a0al.,\u00a02019;\u00a0Kneller,\u00a02010).\u00a0 \u00a0\nF\u00fcr\u00a0Europa\u00a0zeigt\u00a0sich\u00a0ein\u00a0\u00e4hnliches\u00a0Bild:\u00a0In\u00a0einer\u00a0Studie\u00a0der\u00a09 4\u00a0von\u00a0der\u00a0Europ\u00e4ischen\u00a0\nArzneimittelagentur\u00a0(EMA)\u00a0zwischen\u00a02010\u00a0und\u00a02012\u00a0zugelassenen\u00a0A rzneimittel\u00a0mit\u00a0\neinem\u00a0neuen\u00a0Wirkstoff\u00a0stammten\u00a017\u00a0%\u00a0aus\u00a0der\u00a0Forschung\u00a0des\u00a0\u00f6ffen tlichen\u00a0Sektors\u00a0\noder\u00a0einer\u00a0public\u2010private\u00a0Partnerschaft\u00a0(Schipper\u00a0et\u00a0al.,\u00a02019) .\u00a0\nIn\u00a0Gro\u00dfbritannien\u00a0finanzierten\u00a0die\u00a0britische\u00a0Regierung\u00a0und\u00a0Wohl t\u00e4tigkeitsorganisa\u2010\ntionen\u00a0rund\u00a040\u00a0%\u00a0aller\u00a0pharmazeutischen\u00a0F&E\u2010Ausgaben\u00a0zwischen\u00a02 000\u00a0und\u00a02012.\u00a0\nIn\u00a0der\u00a0Krebsforschung\u00a0\u00fcberstieg\u00a0der\u00a0\u00f6ffentliche\u00a0Aufwand\u00a0in\u00a030\u00a0J ahren\u00a0zwischen\u00a0\n1982\u00a0und\u00a02012\u00a0den\u00a0Beitrag\u00a0des\u00a0privaten\u00a0Sektors.\u00a0Die\u00a0\u00f6ffentliche n\u00a0britischen\u00a0For\u2010\nschungseinrichtungen\u00a0spielten\u00a0bei\u00a0der\u00a0Entdeckung\u00a0von\u00a0Abirateron ,\u00a0Alemtuzumab,\u00a0\nAdalimumab\u00a0und\u00a0Infliximab\u00a0eine\u00a0entscheidende\u00a0Rolle\u00a0(Gotham\u00a0et\u00a0a l.,\u00a02017).\u00a0\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n1\u00a0Der\u00a0kursiv\u00a0gesetzte\u00a0Te xt\u00a0ist\u00a0angelehnt\u00a0an\u00a0 eine\u00a0Publikation\u00a0aus \u00a0Prescrire\u00a0interna tional\u00a0mit\u00a0dem\u00a0\nTitel:\u00a0\u201cDrug\u00a0research:\u00a0public\u00a0f unding,\u00a0private\u00a0profits\u201c\u00a0(Prescr ire\u00a0Editorial\u00a0Staff,\u00a02020) \u00a0\n\u00a0 \n16\u00a0\n\u00a0Im\u00a0 Mai\u00a0 2019\u00a0 genehmigte\u00a0 die\u00a0 FDA\u00a0 das\u00a0 Gentherapieprodukt\u00a0 Onasemnog en\u2010\nAbeparvovec\u00a0(Zolgensma\u00ae)\u00a0f\u00fcr\u00a0die\u00a0Behandlung\u00a0von\u00a0Kindern\u00a0unter\u00a0z wei\u00a0Jahren\u00a0mit\u00a0\nder\u00a0schwersten\u00a0Form\u00a0der\u00a0spinalen\u00a0Muskelatrophie\u00a0(SMA)\u00a0(Prescrir e\u00a0Editorial\u00a0Staff,\u00a0\n2020).\u00a0Bereits\u00a0im\u00a0Jahr\u00a01995\u00a0wurde\u00a0am\u00a0Necker\u00a0Hospital\u00a0in\u00a0Paris\u00a0der\u00a0SMA\u00a0 zu\u00a0Grunde\u00a0\nliegende\u00a0Gendefekt\u00a0entdeckt.\u00a0Die\u00a0Entwicklung\u00a0des\u00a0Gentherapeutik ums\u00a0Onasemno\u2010\ngen\u2010Abeparvovec\u00a0erfolgte\u00a0gemeinsam\u00a0durch\u00a0G\u00e9n\u00e9thon\u00a0und\u00a0das\u00a0natio nale\u00a0franz\u00f6si\u2010\nsche\u00a0Zentrum\u00a0f\u00fcr\u00a0wissenschaftliche\u00a0Forschung,\u00a0Centre\u00a0National\u00a0d e\u00a0le\u00a0Recherche\u00a0\nScientifique\u00a0 (CNRS).\u00a0 Im\u00a0 Jahr\u00a0 2007\u00a0 wurde\u00a0 das\u00a0 Patent\u00a0 \u00fcber\u00a0 Onasemn ogen\u2010\nAbeparvovec\u00a0beantragt.\u00a0Bemerkenswert\u00a0ist\u00a0in\u00a0diesem\u00a0Zusammenhang ,\u00a0dass\u00a0die\u00a0\nFinanzierung\u00a0von\u00a0G\u00e9n\u00e9thon\u00a0\u00fcber\u00a0einen\u00a0Spendenaufrauf\u00a0im\u00a0Fernsehe n\u00a0erfolgte,\u00a0d.\u00a0h.\u00a0\neinen\u00a0sogenannten\u00a0T\u00e9l\u00e9thon.\u00a0Beim\u00a0CNRS\u00a0wiederum\u00a0handelt\u00a0es\u00a0sich\u00a0 um\u00a0die\u00a0nach\u00a0der\u00a0\nHelmholtz\u2010Gemeinschaft\u00a0 zweitgr\u00f6\u00df te\u00a0 europ\u00e4ische\u00a0 Forschungsorgani sation\u00a0 mit\u00a0\ndem\u00a0 franz\u00f6sischen\u00a0 Forschungsministerium\u00a0 als\u00a0 staatlichen\u00a0 Tr\u00e4ger. \u00a0I m \u00a0E r g e b n i s \u00a0\nwurde\u00a0die\u00a0Entwicklung\u00a0bis\u00a0zu\u00a0diesem\u00a0Punkt\u00a0somit\u00a0aus\u00a0Spenden\u00a0und \u00a0staatlichen\u00a0\nMitteln\u00a0 finanziert.\u00a0 Hiernach\u00a0 erfolgte\u00a0 die\u00a0 klinische\u00a0 Pr\u00fcfung\u00a0 dur ch\u00a0 das\u00a0 US\u2010\namerikanische\u00a0Start\u2010Up\u00a0AveXis\u00a0in\u00a0Lizenz\u00a0f\u00fcr\u00a0G\u00e9n\u00e9thon.\u00a0Im\u00a0Mai\u00a020 18\u00a0kaufte\u00a0Novartis\u00a0\nAveXis\u00a0f\u00fcr\u00a08,7\u00a0Milliarden\u00a0US\u2010Dollar\u00a0(7,4\u00a0Milliarden\u00a0Euro)\u00a0und\u00a0s etzte\u00a0den\u00a0Preis\u00a0f\u00fcr\u00a0\nZolgensma\u00ae\u00a0auf\u00a0etwa\u00a02,1\u00a0Millionen\u00a0Dollar\u00a0(1,9\u00a0Millionen\u00a0Euro)\u00a0p ro\u00a0Kind\u00a0fest\u00a0\u2013\u00a0eine\u00a0\nextreme\u00a0Belastung\u00a0f\u00fcr\u00a0die\u00a0Gesundheitssysteme\u00a0und\u00a0f\u00fcr\u00a0Familien\u00a0i n\u00a0den\u00a0USA,\u00a0die\u00a0oft\u00a0\ngenug\u00a0ihr\u00a0Arzneimittel\u00a0selbst\u00a0bezahlen\u00a0m\u00fcssen\u00a0(Prescrire\u00a0Editor ial\u00a0Staff,\u00a02020). \u00a0\u00a0\nDie\u00a0Folgen\u00a0einer\u00a0ver\u00e4nderten\u00a0For schungsstrategie\u00a0von\u00a0pharmazeut ischen\u00a0Unter\u2010\nnehmen\u00a0\nDie\u00a0Strategie\u00a0der\u00a0Pharmaunternehmen\u00a0hat\u00a0sich\u00a0in\u00a0den\u00a02000er\u00a0Jahr en\u00a0ge\u00e4ndert:\u00a0\nViele\u00a0Patente\u00a0f\u00fcr\u00a0Medikamente\u00a0chemischen\u00a0Ursprungs,\u00a0die\u00a0f\u00fcr\u00a0die \u00a0Behandlung\u00a0von\u00a0\nVolkskrankheiten\u00a0 entwickelt\u00a0 wurden,\u00a0 liefen\u00a0 aus.\u00a0 Die\u00a0 Unternehmen \u00a0 verlagerten\u00a0\nihren\u00a0Schwerpunkt\u00a0auf\u00a0biologische\u00a0Produkte\u00a0und\u00a0Nischenkrankheit en\u00a0mit\u00a0\"h\u00f6herem\u00a0\nwirtschaftlichen\u00a0Potenzial\",\u00a0inde m\u00a0sie\u00a0insbesondere\u00a0Biotech\u2010Unt ernehmen\u00a0aufkauf\u2010\nten\u00a0anstatt\u00a0in\u00a0ihre\u00a0eigene\u00a0Forschung\u00a0und\u00a0Entwicklung\u00a0zu\u00a0investi eren\u00a0(Cour\u00a0des\u00a0\nComptes,\u00a02017).\u00a0In\u00a0der\u00a0Regel\u00a0werden\u00a0die\u00a0Rechte\u00a0zur\u00a0Nutzung\u00a0von\u00a0 Entdeckungen\u00a0\naus\u00a0\u00f6ffentlich\u00a0finanzierter\u00a0Forschung\u00a0an\u00a0private\u00a0Unternehmen\u00a0im \u00a0Rahmen\u00a0einer\u00a0\nExklusivlizenz\u00a0\u00fcbertragen\u00a0\u2013\u00a0mit\u00a0bescheidenen\u00a0Lizenzgeb\u00fchren\u00a0f\u00fcr \u00a0die\u00a0\u00f6ffentliche\u00a0\nEinrichtung,\u00a0 die\u00a0 die\u00a0 Entdeckung\u00a0 gemacht\u00a0 hat,\u00a0 die\u00a0 gro\u00dfen\u00a0 Gewinne \u00a0 macht\u00a0 das\u00a0\npharmazeutische\u00a0Unternehmen\u00a0(Gotham\u00a0et\u00a0al.,\u00a02017).\u00a0Die\u00a0Pharmain dustrie\u00a0betont\u00a0\njedoch\u00a0weiterhin\u00a0die\u00a0hohen\u00a0Kosten\u00a0f\u00fcr\u00a0Forschung\u00a0und\u00a0Entwicklung .\u00a0Die\u00a0Tatsache,\u00a0\ndass\u00a0\u00f6ffentliche\u00a0Mittel\u00a0gew\u00e4hrt\u00a0werden,\u00a0ohne\u00a0im\u00a0Gegenzug\u00a0Arznei mittel\u00a0zu\u00a0fairen\u00a0\nPreisen\u00a0anzubieten,\u00a0zeigt\u00a0letztlich\u00a0die\u00a0Absurdit\u00e4t\u00a0der\u00a0finanzie llen\u00a0Unterst\u00fctzung\u00a0f\u00fcr\u00a0\ndie\u00a0Entwicklung\u00a0von\u00a0Arzneimitteln:\u00a0Die\u00a0\u00d6ffentlichkeit\u00a0zahlt\u00a0let ztlich\u00a0zweimal\u00a0f\u00fcr\u00a0\nArzneimittel,\u00a0einmal\u00a0f\u00fcr\u00a0die\u00a0Forschung\u00a0und\u00a0Entwicklung\u00a0und\u00a0dann \u00a0noch\u00a0einmal\u00a0f\u00fcr\u00a0 \n17\u00a0\n\u00a0ihren\u00a0Kauf\u00a0oder\u00a0ihre\u00a0Erstattung\u00a0(Schipper\u00a0et\u00a0al.,\u00a02019;\u00a0Gotham\u00a0 et\u00a0al.,\u00a02017;\u00a0Van\u00a0Gils\u00a0\n&\u00a0van\u00a0Hecke,\u00a02019).\u00a0\nIn\u00a0der\u00a0Zwischenzeit\u00a0wird\u00a0in\u00a0vielen\u00a0L\u00e4ndern\u00a0der\u00a0Mangel\u00a0an\u00a0Transp arenz\u00a0und\u00a0die\u00a0l\u00fc\u2010\nckenhafte\u00a0Information\u00a0\u00fcber\u00a0die\u00a0\u00f6 ffentliche\u00a0Finanzierung\u00a0f\u00fcr\u00a0bio medizinische\u00a0F&E\u00a0\nbeklagt.\u00a0Die\u00a0Autoren\u00a0solcher\u00a0Berichte\u00a0und\u00a0Studien\u00a0haben\u00a0daher\u00a0e ine\u00a0Reihe\u00a0von\u00a0Vor\u2010\nschl\u00e4gen\u00a0 gemacht,\u00a0die\u00a0dazu\u00a0beitr ag en\u00a0so ll en, \u00a0dass\u00a0di e\u00a0\u00d6ffentl ic hkeit\u00a0nicht\u00a0mehr\u00a0\nzweimal\u00a0f\u00fcr\u00a0Arzneimittel\u00a0zahlen\u00a0muss.\u00a0Die\u00a0AIM\u00a0( Association\u00a0Internationale\u00a0de\u00a0la\u00a0\nMutualit\u00e9 )\u00a0hat\u00a0z.\u00a0B.\u00a0ein\u00a0Konzept\u00a0erarbeitet,\u00a0das\u00a0zu\u00a0fairen\u00a0und\u00a0angemesse nen\u00a0Preisen\u00a0\nf\u00fcr\u00a0Arzneimittel\u00a0f\u00fchren\u00a0soll.\u00a0Die\u00a0Anwendung\u00a0dieses\u00a0Vorschlags\u00a0w ird\u00a0im\u00a0Kapitel\u00a07\u00a0f\u00fcr\u00a0\neinige\u00a0Wirkstoffe\u00a0aus\u00a0den\u00a0bisher\u00a0ver\u00f6ffentlichten\u00a0Innovationsre porten\u00a0dargestellt.\u00a0\nIm\u00a0Mai\u00a02019\u00a0hat\u00a0die\u00a0Weltgesundheitsorganisation\u00a0(WHO)\u00a0eine\u00a0Reso lution\u00a0verab\u2010\nschiedet,\u00a0in\u00a0der\u00a0eine\u00a0 gr\u00f6\u00dfere\u00a0Transparenz\u00a0bei\u00a0den\u00a0Medikamentenp reisen\u00a0gefordert\u00a0\nwurde\u00a0(WHO,\u00a02019;\u00a0Prescrire\u00a0Editorial\u00a0Staff,\u00a02020).\u00a0Diese\u00a0Resol ution\u00a0ist\u00a0allerdings\u00a0\nbisher\u00a0viel\u00a0zu\u00a0wenig\u00a0beachtet\u00a0worden.\u00a0Es\u00a0wird\u00a0daher\u00a0h\u00f6chste\u00a0Zei t,\u00a0dass\u00a0sich\u00a0die\u00a0\nPolitik\u00a0dieses\u00a0Themas\u00a0annimmt,\u00a0schlie\u00dflich\u00a0sollte\u00a0nicht\u00a0tatenlo s\u00a0zugesehen\u00a0werden,\u00a0\nwie\u00a0viele\u00a0pharmazeutische\u00a0Unterne hmen\u00a0mit\u00a0Hilfe\u00a0\u00f6ffentlicher\u00a0F\u00f6 rderung\u00a0hohe\u00a0\nGewinne\u00a0 einfahren,\u00a0 aber\u00a0 nicht\u00a0 bereit\u00a0 sind,\u00a0 dieses\u00a0 lukrative\u00a0 \u201eGe sch\u00e4ftsmodell\u201c\u00a0\ntransparent\u00a0zu\u00a0machen\u00a0und\u00a0in\u00a0der\u00a0Konsequenz\u00a0der\u00a0Gesellschaft\u00a0fa ire\u00a0und\u00a0be\u2010\ngr\u00fcndbare\u00a0Preise\u00a0f\u00fcr\u00a0die\u00a0Arzneimittelversorgung\u00a0anzubieten\u00a0\u2013\u00a0da s\u00a0Profitinteresse\u00a0\nist\u00a0nach\u00a0wie\u00a0vor\u00a0h\u00f6her\u00a0als\u00a0die\u00a0Verantwortung\u00a0f\u00fcr\u00a0das\u00a0Gemeinwohl .\u00a0Die\u00a0Vereinten\u00a0\nNationen\u00a0(UN)\u00a0nennen\u00a0als\u00a0drittes\u00a0von\u00a017\u00a0Zielen\u00a0zur\u00a0nachhaltigen \u00a0Entwicklung\u00a0der\u00a0\nWelt\u00a0\u201eGesundheit\u00a0und\u00a0Wohlbefinden\u201c.\u00a0Hierbei\u00a0definieren\u00a0die\u00a0UN\u00a0d en\u00a0Zugang\u00a0zu\u00a0\nArzneimitteln\u00a0als\u00a0Unterziel:\u00a0\u201e Achieve\u00a0universal\u00a0health\u00a0coverage,\u00a0including\u00a0financial\u00a0\nrisk\u00a0protection,\u00a0access\u00a0to\u00a0quality\u00a0essential\u00a0health\u2010care\u00a0servic es\u00a0and\u00a0access\u00a0to\u00a0safe,\u00a0\neffective,\u00a0quality\u00a0and\u00a0affordable\u00a0essential\u00a0medicines\u00a0and\u00a0vacci nes\u00a0for\u00a0all. \u201c\u00a0(UN,\u00a0\n2018).\u00a0Der\u00a0Thematik\u00a0der\u00a0Preisbildung\u00a0von\u00a0Arzneimitteln\u00a0sowie\u00a0de r\u00a0Zugang\u00a0zu\u00a0ihnen\u00a0\nhat\u00a0sich\u00a0auch\u00a0die\u00a0Organisation\u00a0f\u00fcr\u00a0wirtschaftliche\u00a0Zusammenarbe it\u00a0und\u00a0Entwick\u2010\nlung,\u00a0OECD,\u00a0gewidmet\u00a0und\u00a0bereits\u00a0im\u00a0Jahr\u00a02018\u00a0den\u00a0Report\u00a0\u201e Pharmaceutical\u00a0Inno\u2010\nvation\u00a0and\u00a0Acce ss\u00a0to\u00a0Medicines \u201c\u00a0publiziert\u00a0(OECD,\u00a02021).\u00a0\u00a0\nUnser\u00a0Innovationsreport\u00a02021\u00a0besch\u00e4ftigt\u00a0sich\u00a0daher\u00a0mit\u00a0dem\u00a0Sch werpunkt\u00a0\u201ePreis\u2010\ngestaltung\u00a0im\u00a0Pharmamarkt\u201c\u00a0und\u00a0nutzt\u00a0dabei\u00a0immer\u00a0wieder\u00a0Ergebni sse\u00a0der\u00a0seit\u00a0\n2013\u00a0 ver\u00f6ffentlichten\u00a0 acht\u00a0 Innovationsreporte\u00a0 (Schipper\u00a0 et\u00a0 al., \u00a0 2019;\u00a0 Kneller,\u00a0\n2010).\u00a0Die\u00a0hohen\u00a0Arzneimittelpreise\u00a0zeigen\u00a0sich\u00a0auch\u00a0in\u00a0der\u00a0Auf listung\u00a0der\u00a0umsatz\u2010\nst\u00e4rksten\u00a0Arzneimittel\u00a0in\u00a0Deutschland\u00a0(siehe\u00a0Tabelle\u00a03.1),\u00a0den\u00a0 Ums\u00e4tzen\u00a0der\u00a0phar\u2010\nmazeutischen\u00a0Unternehmen\u00a0in\u00a0Deut schland\u00a0(siehe\u00a0Tabelle\u00a03.2)\u00a0und \u00a0an\u00a0den\u00a0Um\u2010\nsatzanteilen\u00a0bestimmter\u00a0Indikationsgruppen,\u00a0vor\u00a0allem\u00a0f\u00fcr\u00a0biolo gisch\u00a0hergestellte\u00a0\nProdukte:\u00a0So\u00a0entfallen\u00a0auf\u00a0Medikamente,\u00a0die\u00a0vor\u00a0allem\u00a0in\u00a0der\u00a0On kologie\u00a0eingesetzt\u00a0\nwerden,\u00a0rund\u00a0ein\u00a0Viertel\u00a0des\u00a0Gesamtumsatzes\u00a0der\u00a0pharmazeutische n\u00a0Unternehmen\u00a0 \n18\u00a0\n\u00a0in\u00a0H\u00f6he\u00a0von\u00a0rund\u00a039\u00a0Mrd.\u00a0Euro\u00a0(siehe\u00a0Tabelle\u00a03.3).\u00a0Die\u00a0Folge:\u00a0K rankenkassen\u00a0m\u00fcssen\u00a0\nimmer\u00a0mehr\u00a0Beitragsgelder\u00a0der\u00a0Versicherten\u00a0f\u00fcr\u00a0immer\u00a0weniger\u00a0Ar zneimittel\u00a0ausge\u2010\nben.\u00a0In\u00a0der\u00a0Zwischenzeit\u00a0hat\u00a0sich\u00a0der\u00a0durchschnittliche\u00a0Preis\u00a0f \u00fcr\u00a0ein\u00a0neu\u00a0eingef\u00fchrtes\u00a0\nMedikament\u00a0seit\u00a02011\u00a0bis\u00a0heute\u00a0um\u00a0das\u00a057\u2010fache\u00a0erh\u00f6ht\u00a0\u2013\u00a0von\u00a0902 \u00a0Euro\u00a0auf\u00a051.189\u00a0\nEuro\u00a0im\u00a0Jahre\u00a02021\u00a0(Gesundheit\u00a0ad\u00a0hoc,\u00a02021).\u00a0Es\u00a0wird\u00a0also\u00a0h\u00f6ch ste\u00a0Zeit,\u00a0dass\u00a0neue\u00a0\nStrategien\u00a0der\u00a0Preisgestaltung\u00a0am\u00a0Arzneimittelmarkt\u00a0eingef\u00fchrt\u00a0 werden.\u00a0Und\u00a0da\u00a0sind\u00a0\nnicht\u00a0nur\u00a0die\u00a0Krankenkassen\u00a0gefragt,\u00a0sondern\u00a0vor\u00a0allem\u00a0die\u00a0Poli tik,\u00a0die\u00a0neue\u00a0Rah\u2010\nmenbedingungen\u00a0f\u00fcr\u00a0Preisverhandlungen\u00a0schaffen\u00a0sollte.\u00a0Ein\u00a0Beis piel\u00a0eines\u00a0europ\u00e4i\u2010\nschen\u00a0Vorschlags\u00a0wird\u00a0im\u00a0Kapitel\u00a07\u00a0dieses\u00a0Reportes\u00a0vorgestellt. \u00a0\nTabelle\u00a03.1:\u00a0Die\u00a020\u00a0umsatzst\u00e4rksten\u00a0Hersteller\u00a0von\u00a0Juli\u00a02020\u00a0bi s\u00a0Juni\u00a02021\u00a0in\u00a0Euro\u00a0\nin\u00a0Deutschland\u00a0\nRang\u00a0 Hersteller\u00a0Umsatz\u00a0\n2020/2021\u00a0\nin\u00a0Mio.\u00a0\u20ac\u00a0\n1\u00a0 Novartis\u00a0Pharma\u00a0\u00a0 2.601,4\u00a0\n2\u00a0 Janssen\u2010Cilag\u00a0 1.689,1\u00a0\n3\u00a0 Sanofi\u2010Aventis\u00a0 1.188,1\u00a0\n4\u00a0 Pfizer\u00a0Pharma\u00a0 1.141,3\u00a0\n5\u00a0 Bayer\u00a0 1.077,8\u00a0\n6\u00a0 MSD\u00a0Sharp&Dohme\u00a0 914,5\u00a0\n7\u00a0 GSK\u00a0 879,6\u00a0\n8\u00a0 Bristol/Pfizer\u00a0 844,7\u00a0\n9\u00a0 Hexal\u00a0 801,6\u00a0\n10\u00a0 AstraZeneca\u00a0 797,8\u00a0\n11\u00a0 Biogen\u00a0 771,7\u00a0\n12\u00a0 Lilly\u00a0 739,3\u00a0\n13\u00a0 Celgene\u00a0 727,3\u00a0\n14\u00a0 Amgen\u00a0 673,0\u00a0\n15\u00a0 Novo\u00a0Nordisk\u00a0 657,2\u00a0\n16\u00a0 Boehringer\u00a0Ingelheim\u00a0 649,7\u00a0\n17\u00a0 Kohlpharma\u00a0 645,0\u00a0\n18\u00a0 Abbvie\u00a0 625,1\u00a0\n19\u00a0 Roche\u00a0Pharma\u00a0 615,3\u00a0\n20\u00a0 Takeda\u00a0 580,1\u00a0\n\u00a0Gesamtmarkt\u00a0 38.217.066,2\u00a0\nQuelle:\u00a0nach\u00a0IMS\u00a0Health,\u00a02021\u00a0 \n19\u00a0\n\u00a0Tabelle\u00a03.2:\u00a0Die\u00a0Herstellerums\u00e4tze\u00a0nach\u00a0Indikationsgebieten\u00a0von \u00a0Juli\u00a02020\u00a0bis\u00a0\nJuni\u00a02021\u00a0in\u00a0Euro\u00a0(Ranking\u00a0in\u00a0%\u00a0vom\u00a0Industrieumsatz)\u00a0\nNr.\u00a0 Indikationsgebiet\u00a0Marktumsatz\u00a0\n2020/2021\nin\u00a0Mio.\u00a0\u20ac\u00a0Anteil\u00a0am\u00a0\nMarktumsatz\u00a0\n2020/2021\u00a0\nin\u00a0%\u00a0\n1\u00a0Antineoplastische\u00a0Mittel\u00a0und\u00a0Immunmodulatoren\u00a0 9.211,6\u00a0 24,1\u00a0\n2\u00a0 Nervensystem\u00a0 5.405,0\u00a0 14,1\u00a0\n3\u00a0Verdauungstrakt\u00a0und\u00a0Stoffwechsel\u00a0 4.472,6\u00a0 11,7\u00a0\n4\u00a0 Blut\u00a0und\u00a0blutbildende\u00a0Organe\u00a0 3.375,5\u00a0 8,8\u00a0\n5\u00a0Kardiovaskul\u00e4res\u00a0System\u00a0 2.883,6\u00a0 7,5\u00a0\n6\u00a0 Antiinfektiva\u00a0systemisch\u00a0 2.864,9\u00a0 7,5\u00a0\n7\u00a0Respirationssystem\u00a0 2.746,2\u00a0 7,2\u00a0\n8\u00a0 Muskel\u2010\u00a0und\u00a0Skelett\u2010System\u00a0 1.412,3\u00a0 3,7\u00a0\n9\u00a0Sinnesorgane\u00a0 1.163,1\u00a0 3,0\u00a0\n10\u00a0 Dermatologika\u00a0 1.160,2\u00a0 3,0\u00a0\n11\u00a0 Urogenit.\u00a0System\u00a0und\u00a0Sexualhormone\u00a0 963,9\u00a0 2,5\u00a0\n12\u00a0 Verschiedenes\u00a0 \u00a0 831,2\u00a0 2,2\u00a0\n13\u00a0 Hormonelles\u00a0System.\u00a0 exkl.\u00a0Sexualhormone\u00a0 774,3\u00a0 2,0\u00a0\n14\u00a0 Diagnostika\u00a0 741,5\u00a0 1,9\u00a0\n15\u00a0 Infusionsl\u00f6sungen\u00a0 143,9\u00a0 0,4\u00a0\n16\u00a0 Parasitologie\u00a0 67,3\u00a0 0,2\u00a0\n\u00a0Gesamtmarkt\u00a0 38.217.066,2\u00a0 99,8*\u00a0\n*Rundungsdifferenz\u00a00,2\u00a0%\u00a0\nQuelle:\u00a0nach\u00a0IMS\u00a0Health,\u00a02021\u00a0\nZusammenfassung\u00a0\n1. Pharmazeutische\u00a0 Unternehmen\u00a0 f\u00fchren\u00a0 oft\u00a0 die\u00a0 hohen\u00a0 Kosten\u00a0 f\u00fcr\u00a0 For \u2010\nschung\u00a0und\u00a0Entwicklung\u00a0(F&E)\u00a0an,\u00a0um\u00a0die\u00a0astronomischen\u00a0Preise,\u00a0 die\u00a0sie\u00a0\nf\u00fcr\u00a0neue\u00a0Medikamente\u00a0verlangen,\u00a0 zu\u00a0rechtfertigen.\u00a0Arzneimittelh erstel\u2010\nler\u00a0finanzieren\u00a0die\u00a0F&E\u2010Kosten\u00a0jedoch\u00a0nicht\u00a0allein.\u00a0\n2. Ein\u00a0Viertel\u00a0der\u00a0neuen\u00a0pharmazeutischen\u00a0Substanzen,\u00a0die\u00a0in\u00a0den\u00a0V ereinig\u2010\nten\u00a0Staaten\u00a0entwickelt\u00a0wurden,\u00a0stammen\u00a0aus\u00a0der\u00a0\u00f6ffentlichen\u00a0For schung.\u00a0\nAuch\u00a0in\u00a0Europa\u00a0spielt\u00a0die\u00a0\u00f6ffentlich\u00a0finanzierte\u00a0Grundlagenfors chung\u00a0eine\u00a0\nentscheidende\u00a0Rolle\u00a0bei\u00a0der\u00a0Ent deckung\u00a0neuer\u00a0Arzneimittel.\u00a0 \n20\u00a0\n\u00a03. \u00d6ffentliche\u00a0Gelder\u00a0in\u00a0H\u00f6he\u00a0von\u00a0me hreren\u00a0zehn\u00a0Milliarden\u00a0Euro\u00a0we rden\u00a0in\u00a0\ndie\u00a0Forschung\u00a0und\u00a0Entwicklung\u00a0neuer\u00a0Medikamente\u00a0investiert.\u00a0Pha rma\u2010\nzeutische\u00a0Unternehmen\u00a0nutzen\u00a0auch\u00a0Steuererleichterungen\u00a0in\u00a0Mill iar\u2010\ndenh\u00f6he;\u00a0ein\u00a0Beispiel\u00a0ist\u00a0die\u00a0Ste uergutschrift\u00a0f\u00fcr\u00a0Forschung\u00a0in \u00a0Frankreich.\u00a0\n4. Regierungen\u00a0und\u00a0B\u00fcrger\u00a0erhalten\u00a0wenig\u00a0Gegenleistung\u00a0f\u00fcr\u00a0ihre\u00a0Gr o\u00dfz\u00fc\u2010\ngigkeit,\u00a0wenn\u00a0man\u00a0die\u00a0steigenden\u00a0Ausgaben\u00a0der\u00a0Gesundheitssystem e\u00a0f\u00fcr\u00a0\nden\u00a0Kauf\u00a0oder\u00a0die\u00a0Erstattung\u00a0von\u00a0immer\u00a0mehr\u00a0teuren\u00a0Medikamenten \u00a0\nanalysiert.\u00a0\n5. Es\u00a0gibt\u00a0zahlreiche\u00a0Beispiele\u00a0f\u00fcr\u00a0\u00fcberteuerte\u00a0Medikamente,\u00a0die\u00a0m it\u00a0Hilfe\u00a0\n\u00f6ffentlicher\u00a0 Mittel\u00a0 entwickelt\u00a0 wurden:\u00a0 Pembrolizumab\u00a0 (Keytruda\u00ae )\u00a0 in\u00a0\nden\u00a0Niederlanden,\u00a0Tenofovir\u00a0(Vir ead\u00ae\u00a0und\u00a0andere\u00a0Marken)\u00a0in\u00a0Belg ien,\u00a0\nAdalimumab\u00a0(Humira\u00ae\u00a0und\u00a0andere\u00a0Marken)\u00a0im\u00a0Vereinigten\u00a0K\u00f6nigreic h\u00a0\nund\u00a0Onasemnogen\u2010Abeparvovec\u00a0(Zolgensma\u00ae)\u00a0in\u00a0Frankreich.\u00a0\n6. In\u00a0vielen\u00a0L\u00e4ndern\u00a0erheben\u00a0die\u00a0Menschen\u00a0ihre\u00a0Stimme\u00a0gegen\u00a0die\u00a0Ta tsa\u2010\nche,\u00a0 dass\u00a0 die\u00a0 \u00d6ffentlichkeit\u00a0 zweimal\u00a0 f\u00fcr\u00a0 Medikamente\u00a0 zahlt:\u00a0 ers tens\u00a0\ndurch\u00a0die\u00a0Finanzierung\u00a0ihrer\u00a0Forschung\u00a0und\u00a0Entwicklung\u00a0und\u00a0ein\u00a0 zweites\u00a0\nMal,\u00a0indem\u00a0sie\u00a0extrem\u00a0hohe\u00a0Preise\u00a0f\u00fcr\u00a0den\u00a0Kauf\u00a0oder\u00a0die\u00a0Erstatt ung\u00a0von\u00a0\nbestimmten\u00a0Medikamenten\u00a0durch\u00a0die\u00a0nationalen\u00a0Krankenversicherun gs\u2010\nsysteme\u00a0zahlt\u00a0(Prescrire\u00a0International,\u00a02020).\u00a0\n Preisregulierung\u00a0in\u00a0Deutschland\u00a03.1\nNach\u00a0der\u00a0Zulassung\u00a0der\u00a0Arzneimi ttel\u00a0durch\u00a0die\u00a0zust\u00e4ndigen\u00a0Beh\u00f6r den,\u00a0sei\u00a0es\u00a0das\u00a0\nBundesinstitut\u00a0f\u00fcr\u00a0Arzneimittel\u00a0und\u00a0Medizinprodukte\u00a0(BfArM),\u00a0da s\u00a0Paul\u2010Ehrlich\u2010\nInstitut\u00a0 (PEI)\u00a0 oder\u00a0 die\u00a0 Europ\u00e4ische\u00a0 Arzneimittel\u2010\u00a0 und\u00a0 Medizinpr odukteagentur,\u00a0\nEuropean\u00a0Medicines\u00a0Agency\u00a0 (EMA),\u00a0k\u00f6nnen\u00a0Arzneimittel,\u00a0wenn\u00a0sie\u00a0nicht\u00a0durch\u00a0die\u00a0\nNegativliste\u00a0oder\u00a0die\u00a0Zugeh\u00f6rigkeit\u00a0zu\u00a0Bagatell\u2010\u00a0oder\u00a0Lifestyle \u2010Arzneimitteln\u00a0ausge\u2010\nschlossen\u00a0sind,\u00a0automatisch\u00a0und\u00a0vom\u00a0ersten\u00a0Tag\u00a0der\u00a0Zulassung\u00a0an \u00a0zu\u00a0Lasten\u00a0der\u00a0\nGesetzlichen\u00a0Krankenversicherung\u00a0(GKV)\u00a0verordnet\u00a0werden.\u00a0Die\u00a0Pr eise\u00a0werden\u00a0\ndabei\u00a0von\u00a0den\u00a0pharmazeutischen\u00a0Unternehmen\u00a0frei\u00a0festgelegt.\u00a0Die s\u00a0ist\u00a0trotz\u00a0der\u00a0\nEinf\u00fchrung\u00a0 des\u00a0 Arzneimittelmarktneuordnungsgesetzes\u00a0 (AMNOG)\u00a0 am\u00a0 1.1.2011,\u00a0\nmit\u00a0dem\u00a0in\u00a0einer\u00a0Fr\u00fchbewertung\u00a0der\u00a0therapeutischen\u00a0Nutzen\u00a0eines \u00a0neuen\u00a0Arznei\u2010\nmittels\u00a0im\u00a0Vergleich\u00a0zu\u00a0einer\u00a0verf\u00fcgbaren\u00a0zweckm\u00e4\u00dfigen\u00a0Vergleic hstherapie\u00a0(zVT)\u00a0\nquantifiziert\u00a0wird,\u00a0f\u00fcr\u00a0das\u00a0erste\u00a0Jahr\u00a0der\u00a0Vermarktung\u00a0beibehal ten\u00a0worden.\u00a0Im\u00a0\nVerlaufe\u00a0des\u00a0ersten\u00a0Jahres\u00a0finden\u00a0dann\u00a0auf\u00a0der\u00a0Basis\u00a0von\u00a0Dossie rs\u00a0der\u00a0Hersteller\u00a0\nund\u00a0 einer\u00a0 Kosten\u2010Nutzen\u2010Bewertung\u00a0 durch\u00a0 das\u00a0 Institut\u00a0 f\u00fcr\u00a0 Qualit \u00e4 t \u00a0u n d \u00a0W i r t \u2010\nschaftlichkeit\u00a0 im\u00a0 Gesundheitswesen\u00a0 (IQWiG)\u00a0 Preisverhandlungen\u00a0 d es\u00a0 GKV\u2010\nSpitzenverbandes\u00a0mit\u00a0dem\u00a0jeweiligen\u00a0Hersteller\u00a0\u00fcber\u00a0den\u00a0ab\u00a0dem\u00a0 zweiten\u00a0Jahr\u00a0 \n21\u00a0\n\u00a0geltenden\u00a0Erstattungsbetrag\u00a0statt\u00a0\u2013\u00a0allerdings\u00a0unter\u00a0dem\u00a0Eindru ck\u00a0des\u00a0vom\u00a0Her\u2010\nsteller\u00a0f\u00fcr\u00a0das\u00a0erste\u00a0Vermarktung sjahr\u00a0festgesetzten\u00a0Preises.\u00a0\nVor\u00a0der\u00a0Einf\u00fchrung\u00a0des\u00a0AMNOG\u00a0wurde\u00a0bereits\u00a0eine\u00a0Reihe\u00a0von\u00a0Versu chen\u00a0unter\u2010\nnommen,\u00a0Instrumente\u00a0zur\u00a0Kostenbegrenzung\u00a0einzuf\u00fchren.\u00a0All\u00a0diese \u00a0Instrumente,\u00a0\nim\u00a0Besonderen\u00a0diejenigen,\u00a0die\u00a0den\u00a0Erstattungspreis\u00a0von\u00a0Arzneimi tteln\u00a0betreffen,\u00a0\nhaben\u00a0sich\u00a0allerdings\u00a0als\u00a0insuffizient\u00a0bei\u00a0der\u00a0Kostenkontrolle\u00a0 von\u00a0neuen\u00a0biotechno\u2010\nlogisch\u00a0entwickelten\u00a0Arzneimitteln\u00a0herausgestellt,\u00a0f\u00fcr\u00a0die\u00a0im\u00a0M arkt\u00a0keine\u00a0Behand\u2010\nlungsalternativen\u00a0existieren.\u00a0\nS o \u00a0h a b e n \u00a0z . \u00a0 B . \u00a0d i e \u00a0F e s t b e t r \u00e4 g e \u00a0( \u00a7 \u00a0 3 5 \u00a0 S G B \u00a0 V ) \u00a0E r s t a t t u n g s g r en z e n \u00a0 gesetzt,\u00a0 bis\u00a0 zu\u00a0\ndenen\u00a0die\u00a0GKV\u00a0die\u00a0Kosten\u00a0der\u00a0Arzneimittel\u00a0\u00fcbernimmt.\u00a0Dieses\u00a0Ref erenzsystem\u00a0\ngruppiert\u00a0Arzneimittel\u00a0zusammen,\u00a0die\u00a0denselben\u00a0oder\u00a0einen\u00a0\u00e4hnli chen\u00a0Wirkstoff\u00a0\nenthalten\u00a0und\u00a0die\u00a0pharmakologisch\u2010therapeutisch\u00a0vergleichbar\u00a0si nd.\u00a0F\u00fcr\u00a0patentier\u2010\nte\u00a0Arzneimittel\u00a0k\u00f6nnen\u00a0Festbetragsgruppen\u00a0etabliert\u00a0werden,\u00a0abe r\u00a0auch\u00a0nur,\u00a0wenn\u00a0\nes\u00a0 mindestens\u00a0 drei\u00a0 pharmakologisch\u2010therapeutisch\u00a0 vergleichbare\u00a0 patentierte\u00a0\nArzneimittel\u00a0im\u00a0Markt\u00a0gibt\u00a0(\u201eJumbo\u2010Gruppen\u201c).\u00a0\nMit\u00a0dem\u00a0\u201eGesetz\u00a0zur\u00a0St\u00e4rkung\u00a0des\u00a0Wettbewerbs\u00a0in\u00a0der\u00a0gesetzliche n\u00a0Krankenversi\u2010\ncherung\u201c\u00a0(GKV\u2010WSG)\u00a0hatte\u00a0der\u00a0Gesetzgeber\u00a0mit\u00a0\u00a7\u00a031\u00a0Abs.\u00a02a\u00a0SGB\u00a0V \u00a0die\u00a0Festlegung\u00a0\nvon\u00a0H\u00f6chstpreisen\u00a0f\u00fcr\u00a0Arzneimitte l\u00a0eingef\u00fchrt,\u00a0die\u00a0keiner\u00a0Festb etragsgruppe\u00a0zuge\u2010\nordnet\u00a0 werden\u00a0 k\u00f6nnen.\u00a0 Der\u00a0 H\u00f6chstbetrag\u00a0 wird\u00a0 nach\u00a0 einer\u00a0 Kosten\u2010N utzen\u2010\nBewertung\u00a0durch\u00a0das\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkei t\u00a0im\u00a0Gesundheits\u2010\nwesen\u00a0(IQWiG)\u00a0vom\u00a0Spitzenverba nd\u00a0der\u00a0Krankenkassen\u00a0bzw.\u00a0im\u00a0Einv ernehmen\u00a0\nzwischen\u00a0 dem\u00a0 pharmazeutischen\u00a0 Unternehmen\u00a0 und\u00a0 dem\u00a0 Spitzenverban d\u00a0 der\u00a0\nKrankenkassen\u00a0festgelegt.\u00a0\nMit\u00a0der\u00a0Einf\u00fchrung\u00a0von\u00a0H\u00f6chstbetr\u00e4gen\u00a0zielt\u00a0der\u00a0Gesetzgeber\u00a0dar auf\u00a0ab,\u00a0die\u00a0Preise\u00a0\nneuer\u00a0und\u00a0innovativer\u00a0Arzneimitte l\u00a0an\u00a0ihren\u00a0tats\u00e4chlichen\u00a0thera peutischen\u00a0Innova\u2010\ntionswert\u00a0anzupassen.\u00a0Ausgenommen\u00a0von\u00a0der\u00a0H\u00f6chstbetragsregelung \u00a0sind\u00a0kos\u2010\nteneffektive\u00a0und\u00a0therapeutisch\u00a0al ternativlose\u00a0Arzneimittel\u00a0(z.\u00a0 B.\u00a0Orphan\u00a0Drugs ).\u00a0\nRabattvertr\u00e4ge\u00a0k\u00f6nnen\u00a0nach\u00a0\u00a7\u00a0130a\u00a0(8)\u00a0SGB\u00a0V\u00a0auf\u00a0freiwilliger\u00a0Ba sis\u00a0zwischen\u00a0Kran\u2010\nkenkassen\u00a0und\u00a0oder\u00a0ihren\u00a0Verb\u00e4nden\u00a0und\u00a0pharmazeutischen\u00a0Unterne hmen\u00a0ge\u2010\nschlossen\u00a0werden.\u00a0Solche\u00a0Rabattvertr\u00e4ge\u00a0sind\u00a0bereits\u00a02002\u00a0durch \u00a0das\u00a0Beitragssatz\u2010\nsicherungsgesetz\u00a0 (BSSichG)\u00a0 eingef\u00fchrt\u00a0 worden.\u00a0 Bis\u00a0 zum\u00a0 GKV\u2010Wettb ewerbsst\u00e4r\u2010\nkungsgesetz\u00a0mit\u00a0Wirkung\u00a0zum\u00a01.\u00a0April\u00a02007\u00a0wurden\u00a0kaum\u00a0Vertr\u00e4ge\u00a0 zwischen\u00a0Kran\u2010\nkenkassen\u00a0und\u00a0der\u00a0pharmazeutischen\u00a0Industrie\u00a0geschlossen,\u00a0weil\u00a0 Krankenkassen\u00a0\nkeinen\u00a0Einfluss\u00a0auf\u00a0die\u00a0Verschreibungs\u2010\u00a0und\u00a0Abgabepraxis\u00a0der\u00a0\u00c4r zte\u00a0und\u00a0Apotheker\u00a0\nhatten,\u00a0wodurch\u00a0die\u00a0Rabattierung\u00a0wenig\u00a0verbindlich\u00a0und\u00a0f\u00fcr\u00a0die\u00a0 pharmazeutische\u00a0\nIndustrie\u00a0unattraktiv\u00a0war.\u00a0Erst\u00a0mit\u00a0der\u00a0Verpflichtung\u00a0zur\u00a0Subst itution\u00a0am\u00a01.4.2007\u00a0\nwurden\u00a0 mehr\u00a0 Vertr\u00e4ge\u00a0 abgeschlossen.\u00a0 Rabattvertr\u00e4ge\u00a0 werden\u00a0 sowoh l\u00a0 f\u00fcr\u00a0 den\u00a0 \n22\u00a0\n\u00a0generikaf\u00e4higen\u00a0Markt\u00a0abgeschlo ssen,\u00a0als\u00a0auch\u00a0f\u00fcr\u00a0patentgesch\u00fct zte\u00a0Arzneimittel,\u00a0\nund\u00a0k\u00f6nnen\u00a0auch\u00a0der\u00a0Abdeckung\u00a0der\u00a0Mehrkosten\u00a0bei\u00a0\u00dcberschreitung \u00a0der\u00a0Festbe\u2010\ntr\u00e4ge\u00a0dienen.\u00a0\u00a0\n Kostenkurven\u00a0zu\u00a0Indikationsgebieten\u00a03.2\n\u201eSolisten\u201c\u00a0im\u00a0deutschen\u00a0Arzneimittelmarkt\u00a0und\u00a0deren\u00a0Preisreguli erung\u00a0\u2013\u00a0am\u00a0\nBeispiel\u00a0der\u00a0Onkologika\u00a0\nDie\u00a0rasant\u00a0steigenden\u00a0Kosten\u00a0f\u00fcr\u00a0Krebstherapien\u00a0(siehe\u00a0auch\u00a0Tab elle\u00a03.2)\u00a0durch\u00a0die\u00a0\nAnwendung\u00a0biotechnologischer\u00a0Arzneimittel\u00a0stellen\u00a0eine\u00a0Herausfo rderung\u00a0f\u00fcr\u00a0die\u00a0\nFinanzierung\u00a0der\u00a0gesetzlichen\u00a0Krankenkasse\u00a0dar.\u00a0Eine\u00a0Kombinatio n\u00a0unterschiedlicher\u00a0\nFaktoren\u00a0f\u00fchrt\u00a0zum\u00a0Anstieg\u00a0der\u00a0Ausgaben:\u00a0Der\u00a0demografische\u00a0Wand el,\u00a0die\u00a0(auch\u00a0\ndamit\u00a0einhergehende)\u00a0ansteigende\u00a0Pr\u00e4valenz\u00a0von\u00a0Krebserkrankunge n,\u00a0der\u00a0Anstieg\u00a0\nder\u00a0Anzahl\u00a0onkologischer\u00a0Arzneimittel\u00a0im\u00a0Markt\u00a0und\u00a0die\u00a0Verl\u00e4nge rung\u00a0der\u00a0Behand\u2010\nlungsdauer,\u00a0in\u00a0der\u00a0Patienten\u00a0erfolgreich\u00a0behandelt\u00a0werden\u00a0k\u00f6nne n.\u00a0Und\u00a0letztlich\u00a0\nsind\u00a0es\u00a0die\u00a0Preise\u00a0f\u00fcr\u00a0die\u00a0neuen \u00a0genetisch\u00a0orientierten\u00a0molekul arbiologischen\u00a0Arz\u2010\nneimitteltherapien,\u00a0die\u00a0zu\u00a0den\u00a0erheblichen\u00a0Ausgabensteigerungen \u00a0beitragen.\u00a0\nChirurgie,\u00a0Strahlentherapie\u00a0und\u00a0zytotoxische\u00a0Chemotherapie\u00a0sind \u00a0die\u00a0klassischen\u00a0\ntherapeutischen\u00a0Interventionen,\u00a0die\u00a0in\u00a0der\u00a0Krebsbehandlung\u00a0ange wendet\u00a0werden.\u00a0\nDaneben\u00a0gewinnen\u00a0neue\u00a0Arzneimitte l,\u00a0sogenannte\u00a0\u201eImmunonkologika \u201c\u00a0an\u00a0Bedeu\u2010\ntung.\u00a0Die\u00a0neuen\u00a0biopharmazeutischen\u00a0Arzneimittel\u00a0k\u00f6nnen\u00a0zwar\u00a0di e\u00a0Lebenserwar\u2010\ntung\u00a0um\u00a0wenige\u00a0bis\u00a0mehrere\u00a0Monate\u00a0verl\u00e4ngern,\u00a0aber\u00a0eine\u00a0Heilung \u00a0bringen\u00a0sie\u00a0\nalleine\u00a0nicht.\u00a0\u00a0\nDie\u00a0beiden\u00a0neuen\u00a0Substanzklassen,\u00a0die\u00a0einen\u00a0Wandel\u00a0in\u00a0die\u00a0Tumor therapie\u00a0ge\u2010\nbracht\u00a0haben,\u00a0sind\u00a0die\u00a0\u201e small\u00a0molecules \u201c\u00a0und\u00a0die\u00a0monoklonalen\u00a0Antik\u00f6rper.\u00a0Unter\u00a0\nden\u00a0\u201esmall\u00a0molecules \u201c\u00a0ist\u00a0vor\u00a0allem\u00a0der\u00a0Wirkstoff\u00a0Imatinib\u00a0bekannt\u00a0geworden.\u00a0\nImatinib\u00a0ist\u00a0ein\u00a0Tyrosinkinase\u2010Hemmer,\u00a0der\u00a0zu\u00a0der\u00a0Gruppe\u00a0der\u00a0Si gnaltransdukti\u2010\nonshemmer\u00a0geh\u00f6rt.\u00a0Tyrosinkinasen\u00a0sind\u00a0an\u00a0der\u00a0Entstehung\u00a0vieler\u00a0 maligner\u00a0Erkran\u2010\nkungen\u00a0beteiligt.\u00a0Durch\u00a0die\u00a0gezie lte\u00a0Hemmung\u00a0dieser\u00a0Enzyme\u00a0wird \u00a0auf\u00a0relativ\u00a0\nvertr\u00e4gliche\u00a0 und\u00a0 effektive\u00a0 Weise\u00a0 das\u00a0 Fortschreiten\u00a0 der\u00a0 Krankhei t\u00a0 verlangsamt.\u00a0\nEinige\u00a0seltene\u00a0Tumorerkrankungen,\u00a0die\u00a0zuvor\u00a0verh\u00e4ltnism\u00e4\u00dfig\u00a0sch nell\u00a0zum\u00a0Tod\u00a0\nf\u00fchrten,\u00a0sind\u00a0heute\u00a0zu\u00a0chronischen\u00a0Erkrankungen\u00a0geworden.\u00a0Imati nib\u00a0wurde\u00a0an\u2010\nf\u00e4nglich\u00a0zur\u00a0Behandlung\u00a0der\u00a0chronischen\u00a0myeloischen\u00a0Leuk\u00e4mie\u00a0ei ngesetzt,\u00a0wird\u00a0\naber\u00a0heute\u00a0nach\u00a0mehreren\u00a0Indikationserweiterung\u00a0u.\u00a0a.\u00a0auch\u00a0beim \u00a0gastrointestina\u2010\nlen\u00a0Stromatumor\u00a0angewendet,\u00a0ein\u00a0seltener\u00a0b\u00f6sartiger\u00a0Bindegewebs tumor\u00a0(Sar\u2010\nk o m ) \u00a0d e s \u00a0M a g e n \u2010 D a r m \u2010 T r a k t e s . \u00a0T y r o s i n k i n a s e h e m m e r \u00a0s i n d \u00a0d i e \u00a0u m s a t zst\u00e4rkste\u00a0\nGruppe\u00a0der\u00a0onkologischen\u00a0Therapeutika\u00a0in\u00a0der\u00a0Gruppe\u00a0der\u00a0Zytosta tika.\u00a0Monoklo\u2010\nnale\u00a0Antik\u00f6rper\u00a0richten\u00a0sich\u00a0gez ielt\u00a0auf\u00a0die\u00a0Strukturen\u00a0der\u00a0Zel loberfl\u00e4che.\u00a0Wirkstof\u2010\nfe\u00a0dieser\u00a0Gruppe\u00a0sind\u00a0z.\u00a0B.\u00a0Trastuzumab\u00a0(Herceptin\u00ae),\u00a0das\u00a0bei\u00a0B rustkrebs\u00a0bei\u00a0Frau\u2010 \n23\u00a0\n\u00a0en\u00a0mit\u00a0einem\u00a0HER2\u2010Wachstumshormo n\u00a0eingesetzt\u00a0wird\u00a0oder\u00a0Rituxima b\u00a0bei\u00a0Lym\u2010\nphomen.\u00a0Bevacizumab,\u00a0Cetuximab\u00a0und\u00a0Panitumab\u00a0werden\u00a0bei\u00a0Darmkre bs\u00a0und\u00a0\nanderen\u00a0 soliden\u00a0 Tumoren\u00a0 eingesetzt.\u00a0 Monoklonale\u00a0 Antik\u00f6rper\u00a0 sind \u00a0d i e \u00a0z w e i t \u2010\nst\u00e4rkste\u00a0Wachstumsgruppe\u00a0der\u00a0Zytostatika.\u00a0Beide\u00a0Substanzklassen \u00a0sind\u00a0mit\u00a0enor\u2010\nmen\u00a0Tagestherapiekosten\u00a0verbunden\u00a0(Tabelle\u00a03.3).\u00a0\nWirkstoffe\u00a0wie\u00a0Imatinib\u00a0und\u00a0Tras tuzumab\u00a0waren\u00a0bei\u00a0ihrer\u00a0Marktei nf\u00fchrung\u00a0soge\u2010\nnannte\u00a0\u201eSolisten\u201c.\u00a0Durch\u00a0ihr\u00a0Wirkprinzip\u00a0er\u00f6ffneten\u00a0sie\u00a0Behandl ungsm\u00f6glichkeiten\u00a0\nf\u00fcr\u00a0die\u00a0Therapie,\u00a0die\u00a0zu\u00a0diesem\u00a0Zeitpunkt\u00a0so\u00a0nicht\u00a0vorhanden\u00a0wa ren.\u00a0\nMit\u00a0Ablauf\u00a0ihrer\u00a0Wirkstoffpatente\u00a0befinden\u00a0sich\u00a0mittlerweile\u00a0au ch\u00a0kosteng\u00fcnstigere\u00a0\nAlternativen,\u00a0d.\u00a0h.\u00a0Generika\u00a0bzw .\u00a0sogenannte\u00a0Biosimilars,\u00a0im\u00a0Ma rkt.\u00a0Die\u00a0Preisunter\u2010\nschiede\u00a0zwischen\u00a0\u201eAlt\u2010Original\u201c\u00a0und\u00a0Generikum\u00a0bzw.\u00a0Biomsimilar\u00a0 sind\u00a0erheblich.\u00a0\u00a0\nTabelle\u00a03.3:\u00a0Jahrestherapiekosten\u00a0(oder\u00a0DDD\u2010Kosten)\u00a0f\u00fcr\u00a0monoklo nale\u00a0Antik\u00f6r\u2010\nper\u00a0und\u00a0Tyrosinkinasehemmer\u00a0\nWirkstoff\u00a0 Kosten\u00a0je\u00a0definierter\u00a0Tagesdosis\u00a0\n(DDD)\u00a0GKV\u00a0netto\u00a0[\u20ac]\u00a0Therapiekosten\u00a0GKV\u00a0netto\u00a0je\u00a0365\u00a0\nTagesdosen\u00a0[\u20ac]\u00a0\nTyrosinkinase\u2010Inhibitoren\u00a0 \u00a0 \u00a0\nErlotinib\u00a0 82,28\u00a0\u20ac\u00a0 30.032,20\u00a0\u20ac\u00a0\nImatinib\u00a0 96,68\u00a0\u20ac\u00a0 35.288,20\u00a0\u20ac\u00a0\nSorafenib\u00a0 163,25\u00a0\u20ac\u00a0 59.586,25\u00a0\u20ac\u00a0\nSunitinib\u00a0 157,04\u00a0\u20ac\u00a0 57.319,60\u00a0\u20ac\u00a0\nNilotinib\u00a0 127,55\u00a0\u20ac\u00a0 46.555,75\u00a0\u20ac\u00a0\nMonoklonale\u00a0Antik\u00f6rper \u00a0 \u00a0\nBevacizumab\u00a0 169,69\u00a0\u20ac\u00a0 61.936,85\u00a0\u20ac\u00a0\nTrastuzumab\u00a0 105,54\u00a0\u20ac\u00a0 38.522,10\u00a0\u20ac\u00a0\nTrastuzumab\u00a0emtansin\u00a0 221,09\u00a0\u20ac\u00a0 80.697,85\u00a0\u20ac\u00a0\nRituximab\u00a0 116,24\u00a0\u20ac\u00a0 42.427,60\u00a0\u20ac\u00a0\nCetuximab\u00a0 176,67\u00a0\u20ac\u00a0 64.484,55\u00a0\u20ac\u00a0\nPD1\u2010Hemmer \u00a0 \u00a0 \u00a0\nNivolumab\u00a0 240,13\u00a0\u20ac\u00a0 87.647,45\u00a0\u20ac\u00a0\nPembrolizumab\u00a0 279,42\u00a0\u20ac\u00a0 101.988,30\u00a0\u20ac\u00a0\nAtezolizumab\u00a0 277,96\u00a0\u20ac\u00a0 101.455,40\u00a0\u20ac\u00a0\nCemiplimab\u00a0 332,45\u00a0\u20ac\u00a0 121.344,25\u00a0\u20ac\u00a0\nDurvalumab\u00a0 226,39\u00a0\u20ac\u00a0 82.632,35\u00a0\u20ac\u00a0\nIpilimumab\u00a0 712,51\u00a0\u20ac\u00a0 260.066,15\u00a0\u20ac\u00a0\nQuelle:\u00a0Schwabe\u00a0&\u00a0Ludwig,\u00a02020\u00a0 \n24\u00a0\n\u00a0Die\u00a0Ausgaben\u00a0f\u00fcr\u00a0die\u00a0neuen\u00a0biote chnologischen\u00a0Arzneimittel\u00a0stel len\u00a0eine\u00a0enorme\u00a0\nfinanzielle\u00a0Belastung\u00a0f\u00fcr\u00a0die\u00a0ges etzliche\u00a0Krankenversicherung\u00a0( GKV)\u00a0dar.\u00a0Folglich\u00a0\nmuss\u00a0nach\u00a0L\u00f6sungen\u00a0gesucht\u00a0werden,\u00a0die\u00a0eine\u00a0wirtschaftliche\u00a0und \u00a0effiziente\u00a0Arz\u2010\nneimittelversorgung\u00a0 (si ehe\u00a0 \u00a7\u00a012\u00a0SGB\u00a0V)\u00a0 entsprechend\u00a0 dem\u00a0 aktuell en\u00a0 Stand\u00a0 des\u00a0\nmedizinischen\u00a0Wissens\u00a0gew\u00e4hrleisten,\u00a0die\u00a0den\u00a0medizinischen\u00a0Fort schritt\u00a0ber\u00fccksich\u2010\ntigen\u00a0(siehe\u00a0\u00a7\u00a02\u00a0SGB\u00a0V)\u00a0und\u00a0die\u00a0Humanit\u00e4t\u00a0in\u00a0der\u00a0Versorgung\u00a0wah ren\u00a0(\u00a7\u00a070\u00a0SGB\u00a0V).\u00a0\n Das\u00a0systemische\u00a0Problem\u00a0der\u00a0Finanzierbarkeit\u00a0von\u00a0neuen\u00a0Therapie n\u00a0 3.3\nStaatliche\u00a0Kontrolle\u00a0hoher\u00a0Monopolpreise\u00a0\u00a0\nDurch\u00a0die\u00a0Vergabe\u00a0von\u00a0Patenten\u00a0besitzt\u00a0der\u00a0Halter\u00a0des\u00a0Patents\u00a0e in\u00a0Monopol\u00a0auf\u00a0die\u00a0\nwirtschaftliche\u00a0Nutzung\u00a0seiner\u00a0Erfindung\u00a0(Wirkstoff,\u00a0Wirkprinzi p,\u00a0Herstellungsverfah\u2010\nren\u00a0etc.),\u00a0aus\u00a0dem\u00a0die\u00a0hohen\u00a0Herstellerpreise\u00a0zugelassener\u00a0Orig inalpr\u00e4parate\u00a0resul\u2010\ntieren.\u00a0Die\u00a0Laufzeit\u00a0eines\u00a0Patents\u00a0f\u00fcr\u00a0einen\u00a0Wirkstoff\u00a0betr\u00e4gt\u00a0 in\u00a0der\u00a0Regel\u00a020\u00a0Jahre.\u00a0\nDas\u00a0Patent\u00a0kann\u00a0um\u00a0f\u00fcnf\u00a0Jahre\u00a0durch\u00a0ein\u00a0zus\u00e4tzliches\u00a0Schutzzert ifikat\u00a0verl\u00e4ngert\u00a0\nwerden,\u00a0das\u00a0den\u00a0Marktzutritt\u00a0von\u00a0Generika\u00a0unterbindet.\u00a0Diese\u00a0Ve rl\u00e4ngerung\u00a0der\u00a0\nPatentlaufzeit\u00a0soll\u00a0die\u00a0Zeit\u00a0ersetzen,\u00a0in\u00a0der\u00a0ein\u00a0Arzneimittel\u00a0 die\u00a0klinischen\u00a0Pr\u00fcfungen\u00a0\ndurchl\u00e4uft\u00a0und\u00a0keinen\u00a0Umsatz\u00a0einbringt.\u00a0Kann\u00a0ein\u00a0Unternehmen\u00a0vo rweisen,\u00a0dass\u00a0es\u00a0\nsein\u00a0Arzneimittel\u00a0auch\u00a0f\u00fcr\u00a0 p\u00e4diatrische\u00a0Indikationen\u00a0 getestet\u00a0h at,\u00a0erh\u00e4lt\u00a0es\u00a0eine\u00a0\nzus\u00e4tzliche\u00a0Marktexklusivit\u00e4t\u00a0von\u00a0sechs\u00a0Monaten.\u00a0\u00a0\nWenn\u00a0ein\u00a0Arzneimittel\u00a0in\u00a0der\u00a0EU\u00a0 zur\u00a0Behandlung\u00a0seltener\u00a0Erkrank ungen\u00a0zugelassen\u00a0\nist,\u00a0erh\u00e4lt\u00a0es\u00a0zudem\u00a0die\u00a0Marktexk lusivit\u00e4t\u00a0f\u00fcr\u00a0zehn\u00a0Jahre,\u00a0d.\u00a0h .\u00a0die\u00a0Zulassungsbe\u2010\nh\u00f6rden\u00a0d\u00fcrfen\u00a0\u00fcber\u00a0eine\u00a0Dauer\u00a0von\u00a0zehn\u00a0Jahren\u00a0keinen\u00a0Zulassungs antrag\u00a0f\u00fcr\u00a0ein\u00a0\n\u00e4hnliches\u00a0Produkt\u00a0desselben\u00a0therapeutischen\u00a0Anwendungsgebietes\u00a0 annehmen.\u00a0Es\u00a0\nsei\u00a0denn,\u00a0dieses\u00a0Pr\u00e4parat\u00a0ist\u00a0\u00fcbe rlegen\u00a0oder\u00a0schlie\u00dft\u00a0einen\u00a0Ver sorgungsengpass.\u00a0\u00a0\nDas\u00a0Recht\u00a0auf\u00a0eine\u00a0exklusive\u00a0Ver marktung,\u00a0das\u00a0dem\u00a0pharmazeutisc hen\u00a0Unterneh\u2010\nmer\u00a0erlaubt,\u00a0den\u00a0Preis\u00a0f\u00fcr\u00a0sein\u00a0Produkt\u00a0nach\u00a0seinem\u00a0eigenen\u00a0Erm essen\u00a0zu\u00a0setzen,\u00a0\nist\u00a0durch\u00a0mehrere\u00a0regulatorische\u00a0Ma\u00dfnahmen\u00a0des\u00a0Staates\u00a0mit\u00a0dem\u00a0 Ziel\u00a0einge\u2010\nschr\u00e4nkt\u00a0worden,\u00a0die\u00a0Finanzkraft\u00a0der\u00a0GKV\u00a0zu\u00a0sch\u00fctzen.\u00a0Indirekte \u00a0und\u00a0direkte\u00a0Preis\u2010\nkontrollen\u00a0setzen\u00a0der\u00a0Marktmacht\u00a0der\u00a0pharmazeutischen\u00a0Unternehm en,\u00a0die\u00a0sie\u00a0\ndurch\u00a0ihre\u00a0Patente\u00a0und\u00a0andere\u00a0Rechte\u00a0auf\u00a0Marktexklusivit\u00e4t\u00a0erha lten,\u00a0Grenzen\u00a0\nund\u00a0wirken\u00a0der\u00a0fehlenden\u00a0Preiselastizit\u00e4t\u00a0der\u00a0Nachfrage\u00a0im\u00a0Kont ext\u00a0der\u00a0GKV\u00a0ent\u2010\ngegen.\u00a0\u00a0\nDer\u00a0Europ\u00e4ische\u00a0Gesetzgeber\u00a0hat\u00a0 2004\u00a0Regelungen\u00a0eingef\u00fchrt,\u00a0die \u00a0es\u00a0Generika\u2010\u00a0\nund\u00a0Biosimilarherstellern\u00a0erlaube n,\u00a0mit\u00a0ihrem\u00a0Entwicklungs\u2010\u00a0und \u00a0Produktionspro\u2010\nzess\u00a0vor\u00a0Ablauf\u00a0der\u00a0Patentlaufzeit\u00a0zu\u00a0beginnen,\u00a0ohne\u00a0Klagen\u00a0weg en\u00a0Patentverlet\u2010\nzungen\u00a0zu\u00a0riskieren.\u00a0Auf\u00a0diesem\u00a0Weg\u00a0kann\u00a0der\u00a0Markteintritt\u00a0dies er\u00a0Produkte\u00a0und\u00a0\ndas\u00a0 Eintreten\u00a0 einer\u00a0 Wettbewerbssi tuation\u00a0 beschleunigt\u00a0 werden,\u00a0 d er\u00a0 zu\u00a0 ver\u2010 \n25\u00a0\n\u00a0gleichsweise\u00a0niedrigeren\u00a0Preisen\u00a0gegen\u00fcber\u00a0dem\u00a0Originator\u2010Produ kt\u00a0f\u00fchren\u00a0soll.\u00a0\nDiese\u00a0Richtlinie\u00a0wurde\u00a02005\u00a0durch\u00a0\u00a7\u00a024b\u00a0der\u00a014.\u00a0Novelle\u00a0in\u00a0das\u00a0 Arzneimittelgesetz\u00a0\neingef\u00fchrt.\u00a0\u00a0\nDer\u00a0Fall\u00a0der\u00a0 Orphan\u00a0Drugs \u00a0\nOrphan\u00a0Drugs \u00a0sind\u00a0Arzneimittel,\u00a0die\u00a0zur\u00a0Behandlung\u00a0seltener\u00a0Erkrankungen\u00a0ei nge\u2010\nsetzt\u00a0werden.\u00a0In\u00a0Europa\u00a0sind\u00a0seltene\u00a0Erkrankungen\u00a0als\u00a0Krankheit en\u00a0definiert,\u00a0von\u00a0\ndenen\u00a0nicht\u00a0mehr\u00a0als\u00a0f\u00fcnf\u00a0unter\u00a010.000\u00a0Personen\u00a0betroffen\u00a0sind. \u00a0Arzneimittelfor\u2010\nschung\u00a0an\u00a0seltenen\u00a0Erkrankungen\u00a0ist\u00a0in\u00a0der\u00a0ferneren\u00a0Vergangenhe it\u00a0von\u00a0pharma\u2010\nzeutischen\u00a0 Unternehmen\u00a0 vernachl\u00e4ssigt\u00a0 worden,\u00a0 weil\u00a0 die\u00a0 kleine\u00a0 P atientenzahl\u00a0\nkeine\u00a0ausreichende\u00a0Marktkraft\u00a0darstellt\u00a0und\u00a0weil\u00a0durch\u00a0die\u00a0klei ne\u00a0Patientenzahl\u00a0\ndie\u00a0Durchf\u00fchrung\u00a0von\u00a0klinischen\u00a0Studien\u00a0erheblich\u00a0erschwert\u00a0ist .\u00a0\u00a0\nArzneimittel\u00a0bekommen\u00a0den\u00a0sogenannten\u00a0 Orphan\u00a0Drug \u00a0Status\u00a0von\u00a0der\u00a0Europ\u00e4i\u2010\nschen\u00a0Arzneimittelagentur\u00a0(EMA)\u00a0zuerkannt,\u00a0wenn\u00a0mit\u00a0ihnen\u00a0eine\u00a0 Behandlungs\u2010\nm\u00f6glichkeit\u00a0f\u00fcr\u00a0seltene\u00a0Erkrank ungen\u00a0auf\u00a0den\u00a0Markt\u00a0gelangt,\u00a0die \u00a0zuvor\u00a0nicht\u00a0exis\u2010\ntierte\u00a0oder\u00a0die\u00a0einen\u00a0Zusatznutzen\u00a0f\u00fcr\u00a0die\u00a0betroffenen\u00a0Patiente n\u00a0im\u00a0Vergleich\u00a0zu\u00a0\nexistierenden\u00a0Therapien\u00a0bringt.\u00a0Dieser\u00a0 Orphan\u00a0Drug \u00a0Status\u00a0ist\u00a0mit\u00a0einigen\u00a0Verg\u00fcns\u2010\ntigungen\u00a0 verkn\u00fcpft:\u00a0 Unterst\u00fctzung\u00a0 bei\u00a0 der\u00a0 Erstellung\u00a0 von\u00a0 Pr\u00fcfpl \u00e4nen\u00a0 und\u00a0 der\u00a0\nFinanzierung\u00a0von\u00a0Studien,\u00a0Befreiung\u00a0oder\u00a0Erm\u00e4\u00dfigung\u00a0von\u00a0Geb\u00fchre n\u00a0des\u00a0Zulas\u2010\nsungsverfahrens,\u00a0 beschleunigte\u00a0 Be arbeitung\u00a0 des\u00a0 Zulassungsantrag s,\u00a0 10\u2010j\u00e4hriges\u00a0\nRecht\u00a0auf\u00a0Marktexklusivit\u00e4t.\u00a0\nViele\u00a0Tumorerkrankungen\u00a0geh\u00f6ren\u00a0z ur\u00a0Gruppe\u00a0der\u00a0seltenen\u00a0Erkrank ungen\u00a0und\u00a0\nviele\u00a0der\u00a0in\u00a0der\u00a0Europ\u00e4ischen\u00a0Union\u00a0zugelassenen\u00a0Arzneimittel\u00a0m it\u00a0einem\u00a0Orphan\u00a0\nDrug\u00a0 Status\u00a0 werden\u00a0 in\u00a0 der\u00a0 Krebstherapie\u00a0 eingesetzt,\u00a0 z.\u00a0B.\u00a0 Glivec\u00ae,\u00a0 Nexavar\u00ae,\u00a0\nSutent\u00ae.\u00a0Glivec\u00ae\u00a0ist\u00a0mittlerweile\u00a0nicht\u00a0nur\u00a0zugelassen\u00a0f\u00fcr\u00a0die\u00a0 chronische\u00a0myeloi\u2010\nsche\u00a0Leuk\u00e4mie,\u00a0sondern\u00a0auch\u00a0f\u00fcr\u00a0 andere\u00a0maligne\u00a0Erkrankungen.\u00a0\u00a0\nPreise\u00a0von\u00a0Biosimilars\u00a0\nBiosimilars\u00a0sind\u00a0die\u00a0Nachfolgepro dukte\u00a0biotechnologisch\u00a0hergest ellter\u00a0Originalpr\u00e4\u2010\nparate\u00a0(\u201eBiopharmazeutika\u201c),\u00a0we nn\u00a0deren\u00a0Patent\u00a0ausl\u00e4uft.\u00a0Ihr\u00a0Ma rkteintritt,\u00a0der\u00a0\nv e r m e h r t \u00a0f \u00fc r \u00a0di e \u00a0k o m m e n d e n\u00a0J a h r e \u00a0e r w a r t e t \u00a0w i r d , \u00a0h a t \u00a0z um i n d e s t \u00a0d \u00e4mpfende\u00a0\nAuswirkungen\u00a0auf\u00a0die\u00a0Ausgaben\u00a0und\u00a0kann\u00a0einen\u00a0Beitrag\u00a0zur\u00a0Kosten senkung\u00a0in\u00a0der\u00a0\nGKV\u00a0 leisten.\u00a0 Die\u00a0 Substituierbarkeit\u00a0 von\u00a0 biotechnologischen\u00a0 Orig inalprodukten\u00a0\ndurch\u00a0Biosimilars\u00a0wird\u00a0in\u00a0der\u00a0Medizin\u00a0allgemein\u00a0positiv\u00a0gesehen \u00a0und\u00a0in\u00a0Studien\u00a0\nbef\u00fcrwortet.\u00a0\u00a0\nBei\u00a0traditionellen\u00a0chemischen\u00a0Arzneimitteln\u00a0fallen\u00a0die\u00a0Preise\u00a0n ach\u00a0Ende\u00a0der\u00a0Pa\u2010\ntentlaufzeit\u00a0auf\u00a0das\u00a0Niveau\u00a0der\u00a0Generikapreise\u00a0bzw.\u00a0auf\u00a0die\u00a0Fes tbetr\u00e4ge.\u00a0Bei\u00a0bi\u2010 \n26\u00a0\n\u00a0opharmazeutischen\u00a0Arzneimitteln\u00a0ist\u00a0allerdings\u00a0ein\u00a0vergleichbar er\u00a0Preisverfall\u00a0nicht\u00a0\nzu\u00a0erwarten.\u00a0Die\u00a0Produktion\u00a0und\u00a0Herstellung\u00a0von\u00a0Biosimilars\u00a0ist \u00a0vom\u00a0Aufwand\u00a0her\u00a0\nnicht\u00a0gleichzusetzen\u00a0mit\u00a0der\u00a0Her stellung\u00a0von\u00a0Generika.\u00a0Herstell er\u00a0sind\u00a0mit\u00a0einem\u00a0\nweitaus\u00a0umfangreicheren\u00a0Entwickl ungsprozess\u00a0und\u00a0h\u00f6heren\u00a0Entwick lungskosten\u00a0\nkonfrontiert,\u00a0als\u00a0die\u00a0Herstellung \u00a0eines\u00a0Generikums\u00a0erfordert.\u00a0D ie\u00a0Entwicklungskos\u2010\nten\u00a0liegen\u00a0zwischen\u00a080\u00a0bis\u00a0120\u00a0Millionen\u00a0Euro\u00a0und\u00a0sind\u00a0damit\u00a010 \u2010fach\u00a0h\u00f6her\u00a0als\u00a0die\u00a0\nKosten\u00a0f\u00fcr\u00a0klassische\u00a0Generika.\u00a0Die\u00a0Zulassungsanforderungen\u00a0an\u00a0 ein\u00a0Biosimilar\u00a0sind\u00a0\nanspruchsvoller\u00a0als\u00a0die\u00a0Bio\u00e4quiva lenzpr\u00fcfungen\u00a0der\u00a0Generika.\u00a0Da \u00a0Biosimilars\u00a0sich\u00a0\nin\u00a0ihrer\u00a0biologischen\u00a0Wirkung,\u00a0in sbesondere\u00a0in\u00a0ihrer\u00a0Immunogeni t\u00e4t\u00a0und\u00a0bez\u00fcglich\u00a0\ndes\u00a0Auftretens\u00a0neutralisierender \u00a0Antik\u00f6rper\u00a0nicht\u00a0genau\u00a0wie\u00a0das \u00a0Referenzprodukt\u00a0\nverhalten,\u00a0werden\u00a0sie\u00a0vor\u00a0der\u00a0Zulassung\u00a0in\u00a0klinischen\u00a0Pr\u00fcfungen \u00a0getestet,\u00a0um\u00a0die\u00a0\nVergleichbarkeit\u00a0mit\u00a0dem\u00a0Referenz produkt\u00a0zu\u00a0belegen.\u00a0Nach\u00a0der\u00a0Z ulassung\u00a0sind\u00a0sie\u00a0\nBestandteil\u00a0von\u00a0Nachmarktkontrollen,\u00a0um\u00a0Arzneimittelrisiken\u00a0zu\u00a0 dokumentieren\u00a0\nund\u00a0abzuwehren.\u00a0\u00a0\nInsbesondere\u00a0ab\u00a0dem\u00a0Jahr\u00a02017\u00a0sind\u00a0vermehrt\u00a0Biosimilars\u00a0auf\u00a0dem \u00a0Markt\u00a0verf\u00fcg\u2010\nbar.\u00a0Die\u00a0Ausgaben\u00a0der\u00a0GKV\u00a0k\u00f6nnen\u00a0damit\u00a0um\u00a0mehr\u00a0als\u00a01\u00a0Milliarde\u00a0 Euro\u00a0pro\u00a0Jahr\u00a0\ngesenkt\u00a0werden.\u00a0Einsparungen\u00a0durch\u00a0Biosimilars\u00a0sind\u00a0also\u00a0zu\u00a0erw arten,\u00a0lassen\u00a0sich\u00a0\naber\u00a0erst\u00a0voll\u00a0aussch\u00f6pfen,\u00a0wenn\u00a0die\u00a0Akzeptanz\u00a0f\u00fcr\u00a0Biosimilars\u00a0 im\u00a0Vergleich\u00a0zu\u00a0\nOriginal\u2010Pr\u00e4paraten\u00a0ange messen\u00a0angestiegen\u00a0ist.\u00a0\nDer\u00a0Preis\u00a0f\u00fcr\u00a0Biosimilars\u00a0muss\u00a0den\u00a0Herstellern\u00a0erlauben,\u00a0ihre\u00a0G esamtkosten\u00a0zu\u00a0\ndecken.\u00a0Im\u00a0Gegensatz\u00a0zu\u00a0Original herstellern\u00a0profitieren\u00a0sie\u00a0nic ht\u00a0von\u00a0der\u00a0Marktex\u2010\nklusivit\u00e4t\u00a0ihres\u00a0Produktes,\u00a0sondern\u00a0m\u00fcssen\u00a0ihre\u00a0Entwicklungskos ten\u00a0unter\u00a0Wett\u2010\nbewerbsbedingungen\u00a0refinanzieren .\u00a0Durch\u00a0den\u00a0geringeren\u00a0Preisunt erschied\u00a0zwi\u2010\nschen\u00a0Biosimilars\u00a0und\u00a0den\u00a0Originalprodukten\u00a0im\u00a0Vergleich\u00a0zur\u00a0Ge nerikasparte\u00a0wird\u00a0\nder\u00a0Anreiz\u00a0zur\u00a0Substitution\u00a0vermindert.\u00a0Trotzdem\u00a0haben\u00a0sich\u00a0Bio similars\u00a0in\u00a0den\u00a0\njeweiligen\u00a0Indikationen\u00a0als\u00a0kosteneffektiver\u00a0als\u00a0die\u00a0Referenzpr \u00e4parate\u00a0erwiesen.\u00a0\u00a0\nMarkteintrittsbarrieren\u00a0und\u00a0missb r\u00e4uchliche\u00a0Preispolitiken\u00a0von\u00a0 Originalherstellern,\u00a0\ndie\u00a0die\u00a0Preise\u00a0der\u00a0Biosimilars\u00a0unterlaufen,\u00a0gef\u00e4hrden\u00a0allerding s\u00a0ihren\u00a0Umsatz.\u00a0Als\u00a0\nFolge\u00a0k\u00f6nnten\u00a0Hersteller\u00a0von\u00a0einer\u00a0Investition\u00a0in\u00a0Biosimilars\u00a0a bsehen.\u00a0Auch\u00a0die\u00a0\nM\u00f6glichkeit\u00a0von\u00a0Rabattvertr\u00e4gen\u00a0f \u00fcr\u00a0patentierte\u00a0Arzneimittel\u00a0zu m\u00a0Zweck\u00a0der\u00a0Ab\u2010\nsatzsicherung\u00a0nach\u00a0Ablauf\u00a0des\u00a0Patents\u00a0und\u00a0staatliche\u00a0Regularien ,\u00a0wie\u00a0Festbetr\u00e4ge,\u00a0\nstellen\u00a0Hindernisse\u00a0f\u00fcr\u00a0die\u00a0Markteinf\u00fchrung\u00a0von\u00a0Biosimilars\u00a0dar ,\u00a0da\u00a0sie\u00a0zum\u00a0An\u2010\ngleich\u00a0der\u00a0Preise\u00a0von\u00a0Originalpr\u00e4paraten\u00a0und\u00a0Biosimilars\u00a0f\u00fchren .\u00a0\u00a0\n1. Um\u00a0den\u00a0Markteintritt\u00a0von\u00a0Biosimilars\u00a0ordnungspolitisch\u00a0vorzuber ei\u2010\nten,\u00a0k\u00f6nnten\u00a0Anpassungen\u00a0stattfinden\u00a0wie\u00a0die\u00a0Markt\u00f6ffnung\u00a0f\u00fcr\u00a0B io\u2010\nsimilarhersteller\u00a0oder\u00a0die\u00a0Einf\u00fchrung\u00a0von\u00a0Wettbewerb\u00a0durch\u00a0Ausg e\u2010\nstaltung\u00a0von\u00a0Rabattvertr\u00e4gen,\u00a0die\u00a0die\u00a0Einf\u00fchrung\u00a0von\u00a0Biosimilar s\u00a0f\u00f6r\u2010\ndern.\u00a0\u00a0 \n27\u00a0\n\u00a02. Biosimilars\u00a0werden\u00a0\u00fcber\u00a0eine\u00a0bestimmte\u00a0Dauer\u00a0nicht\u00a0in\u00a0Regelunge n\u00a0\nzur\u00a0Bildung\u00a0von\u00a0Festbetr\u00e4gen\u00a0einbezogen.\u00a0\n3. Biosimilarhersteller\u00a0 k\u00f6nnen\u00a0 bei\u00a0 missbr\u00e4uchlicher\u00a0 Preisbildung\u00a0 u nd\u00a0\nMarkteintrittsbarrieren\u00a0die\u00a0Anwendung\u00a0des\u00a0Gesetzes\u00a0gegen\u00a0Wett\u2010bewerbsbeschr\u00e4nkungen\u00a0beim\u00a0Bundeskartellamt\u00a0einfordern.\u00a0\n4. Quoten\u00a0in\u00a0Arzneimittelvereinbarung ,\u00a0nach\u00a0denen\u00a0bei\u00a0der\u00a0Verf\u00fcgba r\u2010\nkeit\u00a0eines\u00a0Biosimilars\u00a0gefordert\u00a0wird,\u00a0dass\u00a0mindestens\u00a050\u00a0%\u00a0der \u00a0Ver\u2010\nordnungen\u00a0auf\u00a0die\u00a0kosteng\u00fcnstigere\u00a0Variante\u00a0entfallen\u00a0(\u00a7\u00a084\u00a0Abs .\u00a07,\u00a0\nSGB\u00a0V).\u00a0\nAusblick\u00a0\nZiel\u00a0sollte\u00a0es\u00a0sein,\u00a0die\u00a0Verha ndlungsm\u00f6glichkeiten\u00a0zwischen\u00a0Kas sen\u00a0und\u00a0Herstellern\u00a0\nzu\u00a0f\u00f6rdern,\u00a0innovative\u00a0Instrumen te\u00a0zur\u00a0Ausgabeneind\u00e4mmung\u00a0einzu f\u00fchren\u00a0und\u00a0\nauch\u00a0bei\u00a0Solisten\u00a0Strategien\u00a0zur\u00a0Preisbegrenzung\u00a0zu\u00a0finden.\u00a0Das \u00a0Risiko,\u00a0dass\u00a0phar\u2010\nmazeutische\u00a0Hersteller\u00a0auf\u00a0Grund\u00a0 solcher\u00a0enger\u00a0gesetzten\u00a0Rahmen bedingungen\u00a0\nden\u00a0deutschen\u00a0Markt\u00a0meiden\u00a0werden,\u00a0ist\u00a0als\u00a0gering\u00a0einzustufen.\u00a0 Der\u00a0deutsche\u00a0\nArzneimarkt\u00a0ist\u00a0der\u00a0weltweit\u00a0vie rtgr\u00f6\u00dfte\u00a0mit\u00a0einem\u00a0derzeit\u00a0noch \u00a0\u201egarantierten\u201c\u00a0\nAbnahmevolumen\u00a0f\u00fcr\u00a0potenziell\u00a073\u00a0Millionen\u00a0Versicherte\u00a0\u2013\u00a0ein\u00a0so lcher\u00a0Standort\u2010\nvorteil\u00a0f\u00fcr\u00a0die\u00a0Vermarktung\u00a0von\u00a0A rzneimitteln\u00a0ist\u00a0weltweit\u00a0kein \u00a0zweites\u00a0Mal\u00a0zu\u00a0\nfinden.\u00a0 Au\u00dferdem\u00a0 werden\u00a0 die\u00a0 pharm azeutischen\u00a0 Hersteller\u00a0 kaum\u00a0 ei ne\u00a0 L\u00f6sung\u00a0\nprovozieren\u00a0wollen,\u00a0die\u00a0zu\u00a0gro\u00dfen \u00a0Teilen\u00a0auf\u00a0Parallel\u2010\u00a0oder\u00a0Re\u2010 Importe\u00a0setzen.\u00a0Es\u00a0\nist\u00a0daher\u00a0notwendig,\u00a0Strategien\u00a0zu\u00a0entwerfen,\u00a0die\u00a0eine\u00a0langfris tige\u00a0Planbarkeit\u00a0auf\u00a0\nallen\u00a0Seiten\u00a0erm\u00f6glichen\u00a0\u2013\u00a0auf\u00a0Se iten\u00a0der\u00a0pharmazeutischen\u00a0Hers teller\u00a0ebenso\u00a0wie\u00a0\nauf\u00a0Seiten\u00a0der\u00a0Kassen.\u00a0Die\u00a0Vielzahl\u00a0der\u00a0bisherigen\u00a0Instrumente\u00a0 zur\u00a0Regulierung\u00a0im\u00a0\nGKV\u2010Arzneimittelmarkt\u00a0hat\u00a0sich\u00a0zumindest\u00a0als\u00a0nicht\u00a0zielf\u00fchrend\u00a0 bew\u00e4hrt.\u00a0\nLangfristig\u00a0sollte\u00a0auch\u00a0bedacht\u00a0 werden,\u00a0dass\u00a0f\u00fcr\u00a0global\u00a0agieren de\u00a0pharmazeutische\u00a0\nUnternehmer\u00a0eine\u00a0m\u00f6glichst\u00a0breite\u00a0gemeinsam\u00a0abgestimmte\u00a0Methodi k\u00a0der\u00a0Kos\u2010\nten\u2010Nutzen\u2010Bewertung\u00a0und\u00a0der\u00a0darauf\u00a0aufbauenden\u00a0Preisverhandlun gen\u00a0ein\u00a0Ziel\u00a0\nsein\u00a0sollte,\u00a0zumindest\u00a0f\u00fcr\u00a0den\u00a0Bereich\u00a0der\u00a0EU.\u00a0Dies\u00a0w\u00fcrde\u00a0die\u00a0N achfragemacht\u00a0\ndurch\u00a0eine\u00a0Vereinheitlichung\u00a0des\u00a0Prozedere\u00a0st\u00e4rken\u00a0und\u00a0die\u00a0nati onalen\u00a0Referenz\u2010\npreisdiskussionen\u00a0unn\u00f6tig\u00a0machen.\u00a0Insofern\u00a0sollte\u00a0dar\u00fcber\u00a0nachg edacht\u00a0werden,\u00a0\n\u00e4hnlich\u00a0wie\u00a0bei\u00a0der\u00a0Zulassung\u00a0der\u00a0meisten\u00a0Arzneimittel,\u00a0eine\u00a0eu rop\u00e4ische\u00a0Bewer\u2010\ntungsagentur\u00a0mit\u00a0der\u00a0Aufgabe\u00a0zu\u00a0betrauen,\u00a0Kosten\u2010Nutzen\u2010Studien \u00a0im\u00a0Rahmen\u00a0\neiner\u00a0Fr\u00fchbewertung\u00a0durchzuf\u00fchren\u00a0und\u00a0damit\u00a0eine\u00a0europ\u00e4ische\u00a0Ba sis\u00a0f\u00fcr\u00a0Preis\u2010\nverhandlungen\u00a0zu\u00a0schaffen.\u00a0Erste \u00a0Konzepte\u00a0zu\u00a0diesem\u00a0Thema\u00a0hat\u00a0d ie\u00a0AIM\u00a0vor\u00a0\nKurzem\u00a0erarbeitet\u00a0(siehe\u00a0Kapitel\u00a07).\u00a0\n\u00a0 \u00a0 \n28\u00a0\n\u00a0Quellen\u00a0\nCleary\u00a0EG,\u00a0Beierlein\u00a0JM,\u00a0Khanuja \u00a0NS,\u00a0McNamee\u00a0LM,\u00a0Ledley\u00a0FD\u00a0(201 8).\u00a0Contribution\u00a0of\u00a0NIH\u00a0funding\u00a0to\u00a0new\u00a0drug\u00a0approvals\u00a02010\u2010\n1016.\u00a0Proc\u00a0Natl\u00a0Acad\u00a0Sci\u00a0USA.\u00a0115\u00a0(10):2329\u20102334.\u00a0\nCour\u00a0des\u00a0Comptes\u00a0(2017).\u201cLa\u00a0fixati on\u00a0du\u00a0prix\u00a0des\u00a0m\u00e9dicaments:\u00a0d es\u00a0r\u00e9sultats\u00a0significatifs,\u00a0des\u00a0enjeux\u00a0toujours\u00a0majeurs\u00a0d\u2019effic ience\u00a0\net\u00a0de\u00a0soutenabilit\u00e9,\u00a0un\u00a0cadre\u00a0d\u2019action\u00a0\u00e0\u00a0fortement\u00a0r\u00e9\u00e9quilibrer \u201d\u00a0in\u00a0\u201cLa\u00a0S\u00e9curit\u00e9\u00a0Sociale.\u00a0Rapport\u00a0sur\u00a0l\u2019application\u00a0des\u00a0\nlois\u00a0de\u00a0financement\u00a0de\u00a0la\u00a0s\u00e9curit\u00e9\u00a0sociale\u201d:335\u2010395.\u00a0\nGesundheit\u00a0ad\u00a0hoc\u00a0(2021).\u00a0Arzneimittelkompass\u00a0diskutert\u00a0neue\u00a0Re geln\u00a0f\u00fcr\u00a0die\u00a0Preisregulierung\u00a0und\u00a0Patientensicherheit.\u00a0\n27.10.2021\u00a0\nGotham\u00a0D,\u00a0Redd\u00a0C,\u00a0Thaysen\u00a0M,\u00a0Tabitha\u00a0Ha,\u00a0Chow\u00a0H,\u00a0Athersuch\u00a0k\u00a0(2 017).Pills\u00a0and\u00a0profits.\u00a0How\u00a0drug \u00a0companies\u00a0make\u00a0a\u00a0killing\u00a0out\u00a0o f\u00a0\npublic\u00a0research.\u00a0Global\u00a0Just ice\u00a0Now\u00a0and\u00a0Stop\u00a0Aids.\u00a0\nKneller\u00a0R\u00a0(2010).\u00a0The\u00a0importance\u00a0of\u00a0new\u00a0companies\u00a0for\u00a0drug\u00a0disc overy:\u00a0origins\u00a0of\u00a0a\u00a0decade\u00a0of\u00a0new\u00a0drugs.\u00a0Nat\u00a0Rev\u00a0Drug\u00a0Discov.\u00a0 9:\u00a0\n867\u2010882.\u00a0\nOECD\u00a0\u2013\u00a0Organisation\u00a0for\u00a0Economic\u00a0Co\u2010operation\u00a0and\u00a0Development\u00a0( 2018).\u00a0Pharmaceutical\u00a0Innovat ion\u00a0and\u00a0Access\u00a0to\u00a0Medicines,\u00a0\nOECD\u00a0Health\u00a0Policy\u00a0Studies,\u00a0OECD \u00a0Publishing,\u00a0Paris.\u00a0www.oecd\u2010il ibrary.org/social\u2010issues\u2010migration\u2010\nhealth/pharmaceutical\u2010innovation\u2010and\u2010access\u2010to\u2010medicines_978926 4307391\u2010en\u00a0Pharma\u00a0Intelligence\u00a0\u201cScrip\u00a0100\u201d\u00a0:\u00a04\u2010\n9.\u00a0\nPrescrire\u00a0Editorial\u00a0Staff\u00a0(2019).\u00a0New\u00a0drugs:\u00a0the\u00a0key\u00a0role\u00a0of\u00a0pu blicly\u00a0\u2013\u00a0funded\u00a0research\u00a0in\u00a0the\u00a0United\u00a0States\u2010\u00a0Prescrire\u00a0Int;28 \u00a0(210):\u00a0\n306.\u00a0\nPrescrire\u00a0Editorial\u00a0Staff\u00a0(2020).\u00a0Zolgensma:\u00a0the\u00a0drug\u00a0of\u00a0extrem es.Prescrire\u00a0Int:\u00a029 \u00a0(214):\u00a0107.\u00a0\nSchipper\u00a0I,\u00a0\u00a0Cowan\u00a0R,\u00a0de\u00a0Haan\u00a0E\u00a0(2019).\u00a0Overpriced.\u00a0Drugs\u00a0devel oped\u00a0with\u00a0Dutch\u00a0public\u00a0funding.\u00a0SOMO\u00a0(Stichting\u00a0Onderzoek\u00a0\nMultinationale\u00a0Ondernemingen)\u00a0and\u00a0WEMOS\u00a0(Wemos\u00a0Foundation).\u00a0\nUN\u00a0\u2013\u00a0United\u00a0Nations\u00a0(2021).\u00a0United\u00a0Nations\u00a0Sustainable\u00a0Developm ent.\u00a0Goal\u00a03:\u00a0Ensure\u00a0healthy\u00a0lives\u00a0and\u00a0promote\u00a0well\u2010being\u00a0for\u00a0al l\u00a0\nat\u00a0all\u00a0ages.\u00a0Good\u00a0Health\u00a0and\u00a0Well\u00a0being.\u00a0www.un.org/sustainable development/health/,\u00a0letzter\u00a0Zugriff:\u00a030.11.21.\u00a0\nvan\u00a0Gils\u00a0B,\u00a0van\u00a0Hecke\u00a0M\u00a0(2019).\u00a0En\u00a0finir\u00a0avec\u00a0les\u00a0pilules\u00a0ch\u00e8re s.\u00a0Test\u00a0Sant\u00e9:\u00a0149:\u00a012\u201014.\u00a0\nvan\u00a0Hecke\u00a0M,\u00a0van\u00a0Gils\u00a0B\u00a0(2019).\u00a0M\u00e9dicaments.\u00a0Vous\u00a0les\u00a0payez\u00a0deu x\u00a0fois\u201d\u00a0Test\u00a0Sant\u00e9\u00a0149:\u00a08\u201011.\u00a0\nWHO\u00a0\u2013\u00a0World\u00a0Health\u00a0Organization\u00a0(2019) .\u00a0Improving\u00a0the\u00a0transparency\u00a0of\u00a0markets\u00a0for\u00a0medicines,\u00a0vaccines,\u00a0 and\u00a0other\u00a0health\u00a0\nproducts.\u00a0Seventy\u2010second\u00a0World\u00a0H ealth\u00a0Assembly,\u00a0resolution\u00a0WHA7 2.8.\u00a0\nPrescrire\u00a0Editorial\u00a0Staff\u00a0(2020).\u00a0Drug\u00a0prices:\u00a0European\u00a0countri es\u00a0join\u00a0forces\u201d\u00a0Prescrire\u00a0Int:\u00a02\u20109 \u00a0(216):\u00a0165.\u00a0\n\u00a0\n\u00a0 \u00a0 \n29\u00a0\n\u00a04 Welchen\u00a0therapeutischen\u00a0Fortschritt\u00a0bringen\u00a0neue\u00a0Wirkstoffe?\u00a0\u00a0\n Innovationskraft\u00a0 der\u00a0 pharmazeutischen\u00a0 Unternehmen\u00a0 im\u00a0 Spiegel\u00a04.1\nder\u00a0Innovationsreporte\u00a02013\u00a0bis\u00a02020 \u00a0\nDie\u00a0Tabelle\u00a04.1\u00a0listet\u00a0die\u00a0in\u00a0den\u00a0Innovationsreporten\u00a0der\u00a0Jahre \u00a02013\u00a0bis\u00a02020\u00a0be\u2010\nwerteten\u00a0 200\u00a0 Arzneimittel\u00a0 anhand\u00a0 des\u00a0 anatomisch\u2010therapeutisch\u2010c hemischen\u00a0\n(ATC)\u00a0Klassifikationssystems\u00a0der\u00a0 WHO\u00a0auf.\u00a0Es\u00a0f\u00e4llt\u00a0auf,\u00a0dass\u00a0di e\u00a0meisten\u00a0neuen\u00a0\nArzneimittel\u00a0 im\u00a0 Anwendungsgebiet\u00a0 der\u00a0 Onkologie\u00a0 bzw.\u00a0 immunmoduli erenden\u00a0\nMittel\u00a0(ATC\u2010Ebene\u00a01:\u00a0L;\u00a0n=79\u00a0bzw.\u00a039,5\u00a0%)\u00a0zugelassen\u00a0wurden,\u00a0ge folgt\u00a0von\u00a0Arznei\u2010\nmitteln\u00a0f\u00fcr\u00a0das\u00a0aliment\u00e4re\u00a0System\u00a0und\u00a0Stoffwechsel\u00a0(ATC\u2010Ebene\u00a01 :\u00a0A;\u00a0n=23\u00a0bzw.\u00a0\n11,5\u00a0%)\u00a0sowie\u00a0Antiinfektiva\u00a0zur\u00a0s ystemischen\u00a0Anwendung\u00a0(ATC\u2010Ebe ne\u00a01:\u00a0J;\u00a0n=21\u00a0\nbzw.\u00a010,5\u00a0%)\u00a0mit\u00a0Arzne imitteln\u00a0zur\u00a0Therapie\u00a0der\u00a0chronischen\u00a0Vir ushepatitis\u00a0C.\u00a0\nIn\u00a0der\u00a0Gruppe\u00a0der\u00a0antineoplastischen\u00a0und\u00a0immunmodulierenden\u00a0Mit tel,\u00a0d.\u00a0h.\u00a0ATC\u2010\nEbene\u00a01:\u00a0L,\u00a0gab\u00a0es\u00a0numerisch\u00a025\u00a0Zulassungen\u00a0zur\u00a0Therapie\u00a0selten er\u00a0Leiden,\u00a0soge\u2010\nnannte\u00a0Orphan\u2010Drugs ,\u00a0und\u00a054\u00a0 Non\u2010Orphan\u2010Drugs ,\u00a0was\u00a0bezogen\u00a0auf\u00a0die\u00a0 Orphan\u2010\nDrugs\u00a0einem\u00a0Anteil\u00a0von\u00a031,6\u00a0%\u00a0entspricht.\u00a0Im\u00a0aliment\u00e4ren\u00a0System\u00a0und\u00a0 bei\u00a0Stoff\u2010\nwechselerkrankungen\u00a0kam\u00a0es\u00a0zu\u00a0neun\u00a0 Orphan\u2010\u00a0und\u00a014\u00a0Non\u2010Orphan\u2010Zulassungen.\u00a0\nTabelle\u00a04.1:\u00a0Gesamtbewertungen\u00a0 der\u00a0Innovationsreporte\u00a02013\u00a0bis\u00a0 2020\u00a0auf\u00a0ATC\u2010\nEbene\u00a01\u00a0nach\u00a0 Orphan\u2010Drug \u2010Status\u00a0\nATC\u2010Bezeichnung\u00a0\u00a0 \u00a0\nAliment\u00e4res\u00a0System\u00a0und\u00a0Stoffwechsel\u00a0 11\u00a0(47,83\u00a0%)\u00a0 12\u00a0(52,17\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0\nNon\u2010Orphan\u00a0 9\u00a0(39,13\u00a0%)\u00a0 5\u00a0(21,74\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0\nOrphan\u00a0 2\u00a0(8,70\u00a0%)\u00a0 7\u00a0(30,43\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0\nBlut\u00a0und\u00a0blutbildende\u00a0Organe\u00a0 10\u00a0(76,92\u00a0%)\u00a0 1\u00a0(7,69\u00a0%)\u00a0 2\u00a0(15,38\u00a0%)\u00a0\nNon\u2010Orphan\u00a0 8\u00a0(61,54\u00a0%)\u00a0 1\u00a0(7,69\u00a0%)\u00a0 1\u00a0(7,69\u00a0%)\u00a0\nOrphan\u00a0 2\u00a0(15,38\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0 1\u00a0(7,69\u00a0%)\u00a0\nKardiovaskul\u00e4res\u00a0System\u00a0 10\u00a0(76,92\u00a0%)\u00a0 2\u00a0(15,38\u00a0%)\u00a0 1\u00a0(7,69\u00a0%)\u00a0\nNon\u2010Orphan\u00a0 8\u00a0(61,54\u00a0%)\u00a0 1\u00a0(7,69\u00a0%)\u00a0 1\u00a0(7,69\u00a0%)\u00a0\nOrphan\u00a0 2\u00a0(15,38\u00a0%)\u00a0 1\u00a0(7,69\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0\nDermatika\u00a0 3\u00a0(75,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0 1\u00a0(25,00\u00a0%)\u00a0\nNon\u2010Orphan\u00a0 3\u00a0(75,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0 1\u00a0(25,00\u00a0%)\u00a0\nOrphan\u00a0 0\u00a0(0,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0 \n30\u00a0\n\u00a0ATC\u2010Bezeichnung\u00a0\nUrogenitalsystem\u00a0und\u00a0Sexualhormone\u00a0 5\u00a0(100,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0\nNon\u2010Orphan\u00a0 5\u00a0(100,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0\nOrphan\u00a0 0\u00a0(0,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0\nSystemische\u00a0Hormonpr\u00e4parate,\u00a0exkl.\u00a0\nSexualhormone\u00a0und\u00a0Insuline\u00a01\u00a0(50,00\u00a0%)\u00a0 1\u00a0(50,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0\nNon\u2010Orphan\u00a0 1\u00a0(50,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0\nOrphan\u00a0 0\u00a0(0,00\u00a0%)\u00a0 1\u00a0(50,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0\nAntiinfektiva\u00a0zur\u00a0systemischen\u00a0\nAnwendung\u00a08\u00a0(38,10\u00a0%)\u00a0 12\u00a0(57,14\u00a0%)\u00a0 1\u00a0(4,76\u00a0%)\u00a0\nNon\u2010Orphan\u00a0 7\u00a0(33,33\u00a0%)\u00a0 10\u00a0(47,62\u00a0%)\u00a0 1\u00a0(4,76\u00a0%)\u00a0\nOrphan\u00a0 1\u00a0(4,76\u00a0%)\u00a0 2\u00a0(9,52\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0\nAntineoplastische\u00a0und\u00a0\nimmunmodulierende\u00a0Mittel\u00a023\u00a0(29,11\u00a0%)\u00a0 39\u00a0(49,37\u00a0%)\u00a0 17\u00a0(21,52\u00a0%)\u00a0\nNon\u2010Orphan\u00a0 14\u00a0(17,72\u00a0%)\u00a0 28\u00a0(35,44\u00a0%)\u00a0 12\u00a0(15,19\u00a0%)\u00a0\nOrphan\u00a0 9\u00a0(11,39\u00a0%)\u00a0 11\u00a0(13,92\u00a0%)\u00a0 5\u00a0(6,33\u00a0%)\u00a0\nMuskel\u00a0und\u00a0Skelettsystem\u00a0 2\u00a0(50,00\u00a0%)\u00a0 1\u00a0(25,00\u00a0%)\u00a0 1\u00a0(25,00\u00a0%)\u00a0\nNon\u2010Orphan\u00a0 2\u00a0(50,00\u00a0%)\u00a0 1\u00a0(25,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0\nOrphan\u00a0 0\u00a0(0,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0 1\u00a0(25,00\u00a0%)\u00a0\nNervensystem\u00a0 13\u00a0(81,25\u00a0%)\u00a0 2\u00a0(12,50\u00a0%)\u00a0 1\u00a0(6,25\u00a0%)\u00a0\nNon\u2010Orphan\u00a0 11\u00a0(68,75\u00a0%)\u00a0 2\u00a0(12,50\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0\nOrphan\u00a0 2\u00a0(12,50\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0 1\u00a0(6,25\u00a0%)\u00a0\nAntiparasit\u00e4re\u00a0Mittel,\u00a0Insektizide\u00a0und\u00a0\nRepellenzien\u00a01\u00a0(100,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0\nNon\u2010Orphan\u00a0 1\u00a0(100,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0\nOrphan\u00a0 0\u00a0(0,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0\nRespirationstrakt\u00a0 6\u00a0(54,55\u00a0%)\u00a0 3\u00a0(27,27\u00a0%)\u00a0 2\u00a0(18,18\u00a0%)\u00a0\nNon\u2010Orphan\u00a0 6\u00a0(54,55\u00a0%)\u00a0 2\u00a0(18,18\u00a0%)\u00a0 1\u00a0(9,09\u00a0%)\u00a0\nOrphan\u00a0 0\u00a0(0,00\u00a0%)\u00a0 1\u00a0(9,09\u00a0%)\u00a0 1\u00a0(9,09\u00a0%)\u00a0\n\u00a0\u00a0 \n31\u00a0\n\u00a0ATC\u2010Bezeichnung \u00a0\u00a0 \u00a0\nSinnesorgane\u00a0 3\u00a0(60,00\u00a0%)\u00a0 2\u00a0(40,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0\nNon\u2010Orphan\u00a0 2\u00a0(40,00\u00a0%)\u00a0 1\u00a0(20,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0\nOrphan\u00a0 1\u00a0(20,00\u00a0%)\u00a0 1\u00a0(20,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0\nVaria\u00a0 3\u00a0(100,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0\nNon\u2010Orphan\u00a0 3\u00a0(100,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0\nOrphan\u00a0 0\u00a0(0,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0 0\u00a0(0,00\u00a0%)\u00a0\nGesamt\u00a0(n=200)\u00a0 99\u00a0(49,50\u00a0%)\u00a0 75\u00a0(37,50\u00a0%)\u00a0 26\u00a0(13,00\u00a0%)\u00a0\nNon\u2010Orphan \u00a0(n=\u00a0148)\u00a0 80\u00a0(40,00\u00a0%)\u00a0 51\u00a0(25,00\u00a0%)\u00a0 17\u00a0(8,50\u00a0%)\u00a0\nOrphan\u00a0(n=52)\u00a0 19\u00a0(9,50\u00a0%)\u00a0 24\u00a0(12,00\u00a0%)\u00a0 9\u00a0(4,50\u00a0%)\u00a0\nDDD\u00a0 81.405.146\u00a0\u00a0 37.961.804,88\u00a0 11.403.091\u00a0\nDDD\u00a0Non\u2010Orphan \u00a0 80.881.170\u00a0 37.109.291\u00a0 10.820.015\u00a0\nDDD\u00a0Orphan\u00a0 523.976\u00a0 852.514\u00a0 583.076\u00a0\nKosten\u00a0 522.897.624\u00a0\u20ac\u00a0 815.291.375\u00a0\u20ac\u00a0 470.647.999\u00a0\u20ac\u00a0\nKosten\u00a0Non\u2010Orphan \u00a0 434.916.952\u00a0\u20ac\u00a0 620.820.884\u00a0\u20ac\u00a0 325.555.5534\u00a0\u20ac\u00a0\nKosten\u00a0Orphan\u00a0 87.980.672\u00a0\u20ac\u00a0 194.470.492\u00a0\u20ac\u00a0 145.092.446\u00a0\u20ac\u00a0\nF\u00fcr\u00a0Non\u2010Orphan \u2010Arzneimittel\u00a0fallen\u00a0in\u00a0der\u00a0realen\u00a0Versorgung\u00a0der\u00a0TK\u00a0von\u00a0Juli\u00a02 020\u00a0\nbis\u00a0Juni\u00a02021\u00a0durchschnittlich\u00a010,72\u00a0Euro\u00a0GKV\u00a0brutto\u00a0pro\u00a0DDD\u00a0an ,\u00a0f\u00fcr\u00a0Orphan\u2010\nArzneimittel\u00a0218,18\u00a0Euro\u00a0je\u00a0DDD,\u00a0d.\u00a0h.\u00a0mehr\u00a0als\u00a0das\u00a0Zwanzigfach e.\u00a0Aus\u00a0diesem\u00a0\nGrund\u00a0stehen\u00a0die\u00a0 Orphan\u2010Drug \u2010Bewertungen\u00a0des\u00a0G\u2010BA\u00a0in\u00a0d er\u00a0Kritik\u00a0der\u00a0bisherigen\u00a0\nInnovationsreporte\u00a0(Windt\u00a0et\u00a0al.,\u00a02013;\u00a0Windt\u00a0et\u00a0al.,\u00a02014;\u00a0Gla eske\u00a0et\u00a0al.,\u00a02015;\u00a0\nGlaeske\u00a0et\u00a0al.,\u00a02016;\u00a0Glaeske\u00a0&\u00a0Ludwig,\u00a02017;\u00a0Glaeske\u00a0&\u00a0Ludwig, \u00a02018;\u00a0Glaeske\u00a0&\u00a0\nLudwig,\u00a02019;\u00a0Glaeske,\u00a02020).\u00a0\nF\u00fcr\u00a0die\u00a0neuen\u00a0Behandlungsm\u00f6glichk eiten\u00a0von\u00a0seltenen\u00a0Krankheiten ,\u00a0an\u00a0denen\u00a0in\u00a0\nEuropa,\u00a0so\u00a0die\u00a0Definition,\u00a0weniger\u00a0als\u00a0f\u00fcnf\u00a0Einwohner\u00a0pro\u00a010.00 0\u00a0leiden,\u00a0ist\u00a0die\u00a0\nBereitschaft,\u00a0hohe\u00a0Preise\u00a0zu\u00a0akzeptieren\u00a0offenbar\u00a0besonders\u00a0aus gepr\u00e4gt,\u00a0ohne\u00a0\ndass\u00a0ein\u00a0Nutzen\u00a0in\u00a0jedem\u00a0Fall\u00a0ausreichend\u00a0nachgewiesen\u00a0w\u00e4re.\u00a0Sp itzenwerte\u00a0unter\u00a0\nden\u00a0Orphan\u2010Arzneimitteln\u00a0nehmen\u00a0Velaglucerase\u00a0alfa\u00a0mit\u00a01.748,91\u00a0Euro\u00a0je\u00a0D DD\u00a0\nzur\u00a0Therapie\u00a0des\u00a0Morbus\u00a0Gaucher,\u00a0Elosulfase\u00a0alfa\u00a0mit\u00a01.232,87\u00a0E uro\u00a0je\u00a0DDD\u00a0bei\u00a0\nMorbus\u00a0Morquio\u00a0Typ\u00a0A\u00a0sowie\u00a0Asfotase\u00a0alfa\u00a0mit\u00a01.182,48\u00a0Euro\u00a0je\u00a0D DD\u00a0bei\u00a0Hypo\u2010\nphosphatasie\u00a0ein,\u00a0allesamt\u00a0in\u00a0der\u00a0Gruppe\u00a0ATC\u2010Ebene\u00a01:\u00a0A\u00a0(Stoffw echsel).\u00a0Bei\u00a0den\u00a0\nNon\u2010Orphan \u2010Arzneimitteln\u00a0 f\u00fchren\u00a0 Ocriplasmin\u00a0 mit\u00a0 2.749,90\u00a0Euro\u00a0 pro\u00a0 DDD\u00a0 bei \u00a0 \n32\u00a0\n\u00a0vitreomakul\u00e4rer\u00a0Traktion,\u00a0das\u00a0a llerdings\u00a0nur\u00a0einmal\u00a0gegeben\u00a0wer den\u00a0muss,\u00a0gefolgt\u00a0\nvon\u00a0Conestat\u00a0alfa\u00a0mit\u00a02.043,25\u00a0E uro\u00a0je\u00a0DDD\u00a0bei\u00a0heredit\u00e4rem\u00a0Angi o\u00f6dem.\u00a0\nGerade\u00a0bei\u00a0Arzneimitteln\u00a0in\u00a0der\u00a0Onkologie\u00a0f\u00e4llt\u00a0als\u00a0Trend\u00a0auf,\u00a0 dass\u00a0pU\u00a0im\u00a0Rahmen\u00a0\nder\u00a0 Zulassung\u00a0 die\u00a0 Anwendungsgebi ete\u00a0 in\u00a0 therapeutische\u00a0 Subgruppe n\u00a0 bis\u00a0 zum\u00a0\nUnterschreiten\u00a0der\u00a0Schwelle\u00a0zur\u00a0A nerkennung\u00a0als\u00a0Arzneimittel\u00a0zu r\u00a0Therapie\u00a0selte\u2010\nner\u00a0Leiden\u00a0aufspalten.\u00a0F\u00fcr\u00a0sogenannte\u00a0 Orphan\u2010Arzneimittel\u00a0erhalten\u00a0pU\u00a0entspre\u2010\nchende\u00a0Verg\u00fcnstigungen\u00a0im\u00a0Rahmen \u00a0der\u00a0arzneimittelrechtlichen\u00a0Zu lassung\u00a0und\u00a0\nder\u00a0fr\u00fchen\u00a0Nutzenbewertung\u00a0(AMNOG \u2010Verfahren),\u00a0was\u00a0im\u00a0Innovation sreport\u00a02019\u00a0\nausf\u00fchrlich\u00a0erl\u00e4utert\u00a0wurde\u00a0(Glaeske\u00a0&\u00a0Ludwig,\u00a02019).\u00a0Bereits\u00a0i m\u00a0Innovationsre\u2010\nport\u00a02018\u00a0zeigte\u00a0sich\u00a0dieser\u00a0Trend\u00a0am\u00a0Beispiel\u00a0des\u00a0aufgrund\u00a0sei nes\u00a0Wirkungsme\u2010\nchanismus\u00a0 breit\u00a0 einsetzbaren\u00a0 Ang iogenesehemmers\u00a0 Ramucirumab\u00a0 (Cy ramza\u00ae),\u00a0\nder\u00a0zun\u00e4chst\u00a0als\u00a0 Orphan\u2010Drug\u00a0im\u00a0Anwendungsgebiet\u00a0Adenokarzinom\u00a0des\u00a0Magens\u00a0\nund\u00a0\u00f6sophagealen\u00a0\u00dcbergangs\u00a0auf\u00a0den\u00a0Markt\u00a0kam.\u00a0Hiernach\u00a0wurde\u00a0de r\u00a0Orphan\u2010\nDrug\u2010Status\u00a0zur\u00fcckgenommen\u00a0und\u00a0die\u00a0Zulassung\u00a0wurde\u00a0um\u00a0die\u00a0Zweitlini enthera\u2010\npie\u00a0des\u00a0metastasierten\u00a0Kolorekta lkarzinoms\u00a0sowie\u00a0nicht\u2010kleinzel liger\u00a0Lungenkrebs\u00a0\n(NSCLC)\u00a0erweitert\u00a0(Glaeske\u00a0&\u00a0Ludwig,\u00a02018).\u00a0\nAuch\u00a0der\u00a0Leiter\u00a0des\u00a0IQWiG,\u00a0J\u00fcrgen\u00a0Windeler,\u00a0das\u00a0im\u00a0Auftrag\u00a0des\u00a0 G\u2010BA\u00a0die\u00a0Bewer\u2010\ntung\u00a0von\u00a0Arzneimitteln\u00a0mit\u00a0neuen\u00a0Wirkstoffen\u00a0operativ\u00a0umsetzt,\u00a0 merkte\u00a0in\u00a0einer\u00a0\naktuellen\u00a0Pressemitteilung\u00a0an,\u00a0dass\u00a0das\u00a0Privileg\u00a0des\u00a0\u201efiktiven\u201c \u00a0Zusatznutzens\u00a0von\u00a0\nOrphan\u2010Drugs\u00a0nicht\u00a0gerechtfertigt\u00a0sei\u00a0und\u00a0diese\u00a0ein\u00a0regul\u00e4res\u00a0Nutzenbewertu ngs\u2010\nverfahren\u00a0durchlaufen\u00a0sollten.\u00a0Ei ne\u00a0Analyse\u00a0des\u00a0IQWiG\u00a0ergab,\u00a0da ss\u00a0bei\u00a022\u00a0(54\u00a0%)\u00a0\nvon\u00a041\u00a0als\u00a0 Orphan\u2010Drug\u00a0zugelassenen\u00a0Arzneimitteln\u00a0kein\u00a0Zusatznutzen\u00a0nachgewie\u2010\nsen\u00a0werden\u00a0konnte\u00a0(IQWiG,\u00a02022).\u00a0Daher\u00a0sollte\u00a0das\u00a0Verfahren\u00a0der \u00a0fr\u00fchen\u00a0Nutzen\u2010\nbewertung\u00a0mit\u00a0Fokus\u00a0auf\u00a0die\u00a0b isherigen\u00a0\u201ePrivilegien\u201c\u00a0f\u00fcr\u00a0 Orphan\u2010Drugs\u00a0novelliert\u00a0\nwerden,\u00a0um\u00a0auch\u00a0f\u00fcr\u00a0diese\u00a0einen\u00a0Zusatznutzen\u00a0in\u00a0regul\u00e4ren\u00a0Verfa hren\u00a0zur\u00a0Bedin\u2010\ngung\u00a0zu\u00a0machen.\u00a0Es\u00a0kann\u00a0schlie\u00dflich\u00a0nicht\u00a0sein,\u00a0dass\u00a0von\u00a0den\u00a0pU \u00a0letztlich\u00a0alles\u00a0als\u00a0\n\u201eselten\u201c\u00a0definiert\u00a0wird,\u00a0um\u00a0die\u00a0damit\u00a0verbundenen\u00a0Privilegien\u00a0a usnutzen\u00a0zu\u00a0k\u00f6n\u2010\nnen.\u00a0Ein\u00a0\u00f6konomischer\u00a0Nutzen\u00a0f\u00fcr\u00a0die\u00a0pharmazeutische\u00a0Industrie\u00a0 ist\u00a0eben\u00a0nicht\u00a0\nimmer\u00a0gleichzusetzen\u00a0mit\u00a0einem\u00a0B ehandlungsnutzen\u00a0f\u00fcr\u00a0die\u00a0Patien ten.\u00a0\nFast\u00a0die\u00a0H\u00e4lfte\u00a0der\u00a0neuen\u00a0Arznei mittel\u00a0(49,5\u00a0%)\u00a0erhielt\u00a0in\u00a0den\u00a0 Innovationsreporten\u00a0\n2013\u00a0bis\u00a02020\u00a0als\u00a0Gesamtbewertung\u00a0eine\u00a0rote\u00a0Ampel,\u00a0hierunter\u00a0fi elen\u00a019\u00a0Arznei\u2010\nmittel\u00a0mit\u00a0einer\u00a0 Orphan\u2010Zulassung\u00a0und\u00a080\u00a0regul\u00e4r\u00a0zugelassene\u00a0Arzneimittel.\u00a0\u00dcber\u00a0\nein\u00a0Drittel,\u00a0d.\u00a0h.\u00a037,5\u00a0%\u00a0bzw.\u00a024\u00a0als\u00a0 Orphan\u2010\u00a0sowie\u00a051\u00a0regul\u00e4r\u00a0zugelassene\u00a0Arznei\u2010\nmittel,\u00a0erhielt\u00a0eine\u00a0gelbe\u00a0Ampel\u00a0als\u00a0Gesamtbewertung,\u00a0was\u00a0die\u00a0U nsicherheit\u00a0und\u00a0\nden\u00a0Bedarf\u00a0an\u00a0weiterer\u00a0klinischer\u00a0Forschung\u00a0und\u00a0der\u00a0neuen\u00a0Verso rgungsforschung\u00a0\n\u201eam\u00a0 Krankenbett\u201c\u00a0 dokumentiert.\u00a0 Nur\u00a0 13\u00a0%\u00a0 der\u00a0 neuen\u00a0 Arzneimittel\u00a0 wurde\u00a0 mit\u00a0\neiner\u00a0gr\u00fcnen\u00a0Ampel\u00a0als\u00a0Gesamtbeur teilung\u00a0versehen,\u00a0hierunter\u00a0ne un\u00a0mit\u00a0Orphan\u2010\nZulassung\u00a0und\u00a017\u00a0im\u00a0regul\u00e4ren\u00a0Verfahren\u00a0(Tabelle\u00a04.1).\u00a0 \n33\u00a0\n\u00a0Zu\u00a0beachten\u00a0ist\u00a0hierbei,\u00a0dass\u00a0ei ne\u00a0arzneimittelrechtliche\u00a0Zulas sung\u00a0der\u00a0f\u00fchrenden\u00a0\nBeh\u00f6rden,\u00a0wie\u00a0der\u00a0FDA,\u00a0EMA,\u00a0BfArM\u00a0bzw.\u00a0PEI\u00a0sowie\u00a0MHRA,\u00a0keine\u00a0An gaben\u00a0zum\u00a0\ntherapeutischen\u00a0Fortschritt\u00a0im\u00a0Indikationsgebiet\u00a0beinhaltet,\u00a0de r\u00a0medical\u00a0need ,\u00a0der\u00a0\nobjektive\u00a0Bedarf\u00a0nach\u00a0neuen\u00a0Arzneimitteln,\u00a0ist\u00a0kein\u00a0Zulassungsk riterium.\u00a0Erst\u00a0im\u00a0\nVerfahren\u00a0der\u00a0fr\u00fchen\u00a0Nutzenbewert ung,\u00a0dem\u00a0sogenannten\u00a0AMNOG\u2010Ver fahren,\u00a0\ndes\u00a0Gemeinsamen\u00a0Bundesausschusses\u00a0(G\u2010BA)\u00a0werden\u00a0die\u00a0Arzneimitte l\u00a0mit\u00a0neuen\u00a0\nWirkstoffen\u00a0auf\u00a0Basis\u00a0des\u00a0\u00a7\u00a035a\u00a0bzw.\u00a0b\u00a0SGB\u00a0V\u00a0nach\u00a0den\u00a0Kriterien \u00a0einer\u00a0Reduktion\u00a0\nder\u00a0Mortalit\u00e4t\u00a0(lebensverl\u00e4nger nde\u00a0Wirkung),\u00a0Reduktion\u00a0der\u00a0Kran kheitsschwere\u00a0\n(Morbidit\u00e4t),\u00a0Verbesserung\u00a0der\u00a0Lebensqualit\u00e4t\u00a0(HRQoL)\u00a0sowie\u00a0bes serem\u00a0Schutz\u00a0\nder\u00a0Patienten\u00a0bzw.\u00a0niedrigeren\u00a0R aten\u00a0unerw\u00fcnschter\u00a0Arzneimittel wirkungen\u00a0unter\u00a0\nder\u00a0Therapie\u00a0(UAE)\u00a0im\u00a0Vergleich\u00a0der\u00a0im\u00a0klinischen\u00a0Alltag\u00a0verf\u00fcg baren\u00a0Therapieal\u2010\nternativen\u00a0 (zweckm\u00e4\u00dfige\u00a0 Vergleic hstherapie,\u00a0 zVT)\u00a0 bewertet.\u00a0 Aktu ell\u00a0 fehlt\u00a0 eine\u00a0\nsp\u00e4te\u00a0bzw.\u00a0besser\u00a0noch\u00a0kontinuierliche\u00a0Nutzenbewertung\u00a0neuer\u00a0Ar zneimittel\u00a0w\u00e4h\u2010\nrend\u00a0der\u00a0Laufzeit\u00a0des\u00a0Patentschutzes,\u00a0da\u00a0sich\u00a0der\u00a0Stellenwert\u00a0e iner\u00a0neuen\u00a0Thera\u2010\npieoption\u00a0 erst\u00a0 im\u00a0 klinischen\u00a0 Alltag\u00a0 herauskristallisiert,\u00a0 also\u00a0 unter\u00a0 \u201ereal\u2010life\u2010\nBedingungen\u201c.\u00a0Erst\u00a0damit\u00a0wird\u00a0eine\u00a0wirkliche\u00a0Nutzen\u2010Schaden\u2010Abw \u00e4gung\u00a0und\u00a0eine\u00a0\nfaire\u00a0Preisbeurteilung\u00a0erm\u00f6glicht ,\u00a0die\u00a0bei\u00a0der\u00a0Zulassung\u00a0wegen\u00a0 der\u00a0Intransparenz\u00a0\ngerade\u00a0in\u00a0diesem\u00a0Bereich\u00a0nicht\u00a0m\u00f6glich\u00a0war.\u00a0Zu\u00a0vielen\u00a0neuen\u00a0dir ekt\u00a0antiviralen\u00a0\nArzneimitteln\u00a0zur\u00a0Therapie\u00a0einer\u00a0chronischen\u00a0Hepatitis\u00a0C\u2010Virusi nfektion,\u00a0die\u00a0als\u00a0\nSp\u00e4tfolge\u00a0zu\u00a0Leberzirrhose,\u00a0Kar zinomen\u00a0und\u00a0der\u00a0Notwendigkeit\u00a0vo n\u00a0Lebertrans\u2010\nplantationen\u00a0 f\u00fchrt,\u00a0 wurden\u00a0 Rote\u2010H and\u2010Briefe\u00a0 publiziert\u00a0 (Janssen ,\u00a0 2013;\u00a0 Gilead\u00a0\nBMS,\u00a02015;\u00a0abbVie,\u00a02016).\u00a0Dies\u00a0erscheint\u00a0im\u00a0Hinblick\u00a0auf\u00a0die\u00a0Pr eisbildung\u00a0relevant,\u00a0\nda\u00a0in\u00a0den\u00a0klinischen\u00a0Studien\u00a0aufgrund\u00a0der\u00a0Einschlusskriterien\u00a0n icht\u00a0alle\u00a0Patienten,\u00a0\ndie\u00a0im\u00a0klinischen\u00a0Alltag\u00a0die\u00a0Arzneimittel\u00a0erhalten\u00a0haben,\u00a0abgeb ildet\u00a0werden\u00a0konn\u2010\nten.\u00a0Auch\u00a0erscheint\u00a0die\u00a0Preisbildung\u00a0mit\u00a0Orientierung\u00a0an\u00a0der\u00a0Ve rmeidung\u00a0der\u00a0\nKosten\u00a0der\u00a0Sp\u00e4tfolgen,\u00a0d.\u00a0h.\u00a0Lebertransplantation,\u00a0fragw\u00fcrdig,\u00a0 wenn\u00a0keine\u00a0Trans\u2010\nparenz\u00a0zu\u00a0Kosten\u00a0der\u00a0Forschung\u00a0und\u00a0Entwicklung\u00a0sowie\u00a0Produktion \u00a0gegeben\u00a0ist.\u00a0\nWeiterhin\u00a0f\u00e4llt\u00a0in\u00a0dieser\u00a0Indika tionsgruppe\u00a0 ein\u00a0kurzer\u00a0Produktl ebenszyklus\u00a0von\u00a0\nrund\u00a0f\u00fcnf\u00a0Jahren\u00a0und\u00a0weniger\u00a0auf\u00a0(Daclatasvir,\u00a0Boceprevir,\u00a0Telo previr\u00a0sowie\u00a0Om\u2010\nbitasvir\u00a0im\u00a0Kombinationspr\u00e4p arat).\u00a0Mit\u00a0dem\u00a0als\u00a0\u201e1.000\u2010 Dollar\u2010Pille\u201c\u00a0bezeichneten\u00a0\nArzneimittel\u00a0Sovaldi\u00ae\u00a0(Sofosbuvir)\u00a0hat\u00a0der\u00a0pU\u00a0Gilead\u00a0aufgrund\u00a0s einer\u00a0Preispolitik\u00a0\nmassive\u00a0Kritik\u00a0seitens\u00a0\u00c4rzten,\u00a0Patienten,\u00a0Kostentr\u00e4gern\u00a0und\u00a0Pol itik\u00a0hervorgerufen.\u00a0\nDas\u00a0Start\u2010up\u00a0Pharmasset\u00a0hatte\u00a062,4\u00a0Mio.\u00a0US\u00a0$\u00a0in\u00a0die\u00a0Entwicklung \u00a0von\u00a0Sofosbuvir\u00a0\ninvestiert,\u00a0f\u00fcr\u00a0Fehlschl\u00e4ge\u00a0weiterer\u00a0Entwicklungen\u00a0wurden\u00a0die\u00a0K osten\u00a0auf\u00a0271\u00a0Mi\u2010\no.\u00a0US\u00a0$\u00a0gesch\u00e4tzt,\u00a0in\u00a0Summe\u00a0also\u00a0333,4\u00a0Mio.\u00a0US\u00a0$.\u00a0Gilead\u00a0zahlte \u00a0f\u00fcr\u00a0die\u00a0\u00dcbernahme\u00a0\nseines\u00a0Konkurrenten\u00a0jedoch\u00a011\u00a0Mrd.\u00a0US\u00a0$,\u00a0die\u00a0vermutlich\u00a0beim\u00a0Ar zneimittel\u00a0Sofos\u2010\nbuvir\u00a0und\u00a0den\u00a0folgenden\u00a0Kombinationspr\u00e4paraten\u00a0eingepreist\u00a0wurd en\u00a0(a\u2010t,\u00a02015;\u00a0a\u2010t,\u00a0\n2016).\u00a0\u00a0\n\u00a0\n\u00a0 \u00a0 \n34\u00a0\n\u00a0Tabelle\u00a04.2:\u00a0Wirkstoffbewertungen\u00a0der\u00a0Innovationsreporte\u00a02013\u00a0b is\u00a02020\u00a0\nWirkstoff\u00a0\n(O=Orphan\u00a0Drug )\u00a0ATC\u00a0 Innov.\u00a0\nReport\u00a0Gesamtscore\u00a0 DDD\u00a07/2020\u2010\n6/2021\u00a0Bruttoausgaben\u00a0\n7/2020\u00a0\u2010\u00a06/2021\u00a0\nAmifampridin\u00a0(O)\u00a0 N07XX05\u00a0 2013\u00a0 7.525\u00a0 851.505\u00a0\nAsenapin\u00a0 N05AH05\u00a0 2013\u00a0 7.950\u00a0 69.392\u00a0\nBazedoxifen\u00a0 G03XC02\u00a0 2013\u00a0 \u00a0\u00a0 nicht\u00a0mehr\u00a0im\u00a0Handel\u00a0\nBilastin\u00a0 R06AX29\u00a0 2013\u00a0 13.700\u00a0 12.328\u00a0\nConestat\u00a0alfa\u00a0 B06AC04\u00a0 2013\u00a0 20\u00a0 40.456\u00a0\nCorifollitropin\u00a0alfa \u00a0 G03GA09\u00a0 2013\u00a0 284\u00a0 102.767\u00a0\nDenosumab\u00a0 M05BX04\u00a0 2013\u00a0 5.529.161\u00a0 26.478.193\u00a0\nDronedaron\u00a0 C01BD07\u00a0 2013\u00a0 514.065\u00a0 1.682.827\u00a0\nEltrombopag\u00a0(O)\u00a0 B02BX05\u00a0 2013\u00a0 121.152\u00a0 11.906.434\u00a0\nFebuxostat\u00a0 M04AA03\u00a0 2013\u00a0 3.996.661\u00a0 1.888.302\u00a0\nHistamindihydro\u2010\nchlorid\u00a0L03AX14\u00a0 2013\u00a0 \u00a0 \u00a0 nicht\u00a0mehr\u00a0im\u00a0Handel\u00a0\nIndacaterol\u00a0 R03AC18\u00a0 2013\u00a0 25.260\u00a0 14.878\u00a0\nMifamurtid\u00a0(O)\u00a0 L03AX15\u00a0 2013\u00a0 0\u00a0 0\u00a0\nOfatumumab\u00a0(O)\u00a0 L01XC10\u00a0 2013\u00a0 \u00a0 \u00a0\u00a0zu\u00a0der\u00a0Zeit\u00a0nicht\u00a0im\u00a0\nHandel\u00a0\nPazopanib\u00a0 L01EX03\u00a0 2013\u00a0 24.885\u00a0 3.906.757\u00a0\nPitavastatin\u00a0 C10AA08\u00a0 2013\u00a0 1.185\u00a0 695\u00a0\nPrucaloprid\u00a0 A06AX05\u00a0 2013\u00a0 354.774\u00a0 1.180.082\u00a0\nRoflumilast\u00a0 R03DX07\u00a0 2013\u00a0 574.718\u00a0 1.302.824\u00a0\nSilodosin\u00a0 G04CA04\u00a0 2013\u00a0 1.476.315\u00a0 510.873\u00a0\nTapentadol\u00a0 N02AX06\u00a0 2013\u00a0 1.323.068\u00a0 16.129.054\u00a0\nTicagrelor\u00a0 B01AC24\u00a0 2013\u00a0 2.028.016\u00a0 5.456.105\u00a0\nVelaglucerase\u00a0alfa\u00a0(O)\u00a0A16AB10\u00a0 2013\u00a0 \u00a0 2.316\u00a0 4.050.394\u00a0\nVernakalant\u00a0 C01BG11\u00a0 2013\u00a0 3\u00a0 510\u00a0 \n35\u00a0\n\u00a0Wirkstoff\u00a0\n(O=Orphan\u00a0Drug )\u00a0ATC\u00a0 Innov.\u00a0\nReport\u00a0Gesamtscore\u00a0 DDD\u00a07/2020\u2010\n6/2021\u00a0Bruttoausgaben\u00a0\n7/2020\u00a0\u2010\u00a06/2021\u00a0\nAbirateron\u00a0 L02BX03\u00a0 2014\u00a0 433.028\u00a0 53.715.324\u00a0\nApixaban\u00a0 B01AF02\u00a0 2014\u00a0 31.091.460\u00a0 93.988.387\u00a0\nBelatacept\u00a0 L04AA28\u00a0 2014\u00a0 39.998\u00a0 1.177.189\u00a0\nBelimumab\u00a0 L04AA26\u00a0 2014\u00a0 101.790\u00a0 3.420.263\u00a0\nBoceprevir\u00a0 J05AE12\u00a0 2014\u00a0 \u00a0\u00a0 nicht\u00a0mehr\u00a0im\u00a0Handel\u00a0\nCabazitaxel\u00a0 L01CD04\u00a0 2014\u00a0 32.085\u00a0 4.456.123\u00a0\nCollagenase\u00a0 M09AB02\u00a0 2014\u00a0 \u00a0\u00a0 nicht\u00a0mehr\u00a0im\u00a0Handel\u00a0\nDexamfetamin\u00a0 N06BA02\u00a0 2014\u00a0 136.201\u00a0 540.586\u00a0\nEribulin\u00a0 L01XX41\u00a0 2014\u00a0 17.951\u00a0 1.739.343\u00a0\nFampridin\u00a0 N07XX07\u00a0 2014\u00a0 788.690\u00a0 5.445.022\u00a0\nFingolimod\u00a0 L04AA27\u00a0 2014\u00a0 759.165\u00a0 45.475.935\u00a0\nIpilimumab\u00a0 L01XC11\u00a0 2014\u00a0 27.872\u00a0 13.256.915\u00a0\nLinagliptin\u00a0 A10BH05\u00a0 2014\u00a0 \u00a0\u00a0 nicht\u00a0mehr\u00a0im\u00a0Handel\u00a0\nNabiximols\u00a0 N02BG10\u00a0 2014\u00a0 364.388\u00a0 3.392.942\u00a0\nPirfenidon\u00a0(O)\u00a0 L04AX05\u00a0 2014\u00a0 47.320\u00a0 4.844.518\u00a0\nRetigabin\u00a0 N03AX21\u00a0 2014\u00a0 \u00a0\u00a0 nicht\u00a0mehr\u00a0im\u00a0Handel\u00a0\nTafamidis\u00a0(O)\u00a0 N07XX08\u00a0 2014\u00a0 42.180\u00a0 34.977.522\u00a0\nTelaprevir\u00a0 J05AE11\u00a0 2014\u00a0 \u00a0\u00a0 nicht\u00a0mehr\u00a0im\u00a0Handel\u00a0\nAclidiniumbromid\u00a0 R03BB05\u00a0 2015\u00a0 891.690\u00a0 1.206.359\u00a0\nAflibercept\u00a0 S01LA05\u00a0 2015\u00a0 3.264.169\u00a0 63.159.422\u00a0\nAxitinib\u00a0 L01XE17\u00a0 2015\u00a0 42.571\u00a0 5.320.177\u00a0\nAzilsartan\u2010\nmedoxomil\u00a0C09CA09\u00a0 2015\u00a0 \u00a0 48.979\u00a0 11.135\u00a0\nBrentuximab\u2010\nvedotin\u00a0(O)\u00a0L01XC12\u00a0 2015\u00a0 \u00a0 10.278\u00a0 4.170.410\u00a0\nCeftarolinfosamil\u00a0 J01DI02\u00a0 2015\u00a0 \u00a0\u00a0 nicht\u00a0mehr\u00a0im\u00a0Handel\u00a0\nCrizotinib\u00a0 L01ED01\u00a0 2015\u00a0 14.310\u00a0 2.556.614\u00a0 \n36\u00a0\n\u00a0Wirkstoff\u00a0\n(O=Orphan\u00a0Drug )\u00a0ATC\u00a0 Innov.\u00a0\nReport\u00a0Gesamtscore\u00a0 DDD\u00a07/2020\u2010\n6/2021\u00a0Bruttoausgaben\u00a0\n7/2020\u00a0\u2010\u00a06/2021\u00a0\nDapagliflozin\u00a0 A10BK01\u00a0 2015\u00a0 7.858.440\u00a0 12.934.182\u00a0\nDecitabin\u00a0(O)\u00a0 L01BC08\u00a0 2015\u00a0 18.381\u00a0 2.894.996\u00a0\nIvacaftor\u00a0(O)\u00a0 R07AX02\u00a0 2015\u00a0 75.565\u00a0 43.618.189\u00a0\nNomegestrolacetat\u00a0\n+\u00a0Estradiol\u00a0G03AA14\u00a0 2015\u00a0 \u00a0 587.356\u00a0 278.592\u00a0\nNomegestrol\u2010\nacetat\u00a0+\u00a0Estradiol\u00a0G04FB12\u00a0 2015\u00a0 \u00a0 \u00a0\u00a0 nicht\u00a0mehr\u00a0im\u00a0Handel\u00a0\nPasireotid\u00a0(O)\u00a0 H01CB05\u00a0 2015\u00a0 5.758\u00a0 662.419\u00a0\nPerampanel\u00a0 N03AX22\u00a0 2015\u00a0 285.821\u00a0 1.382.390\u00a0\nPixantron\u00a0 L01DB11\u00a0 2015\u00a0 48\u00a0 7.568\u00a0\nRilpivirin\u00a0 J05AG05\u00a0 2015\u00a0 25.170\u00a0 295.195\u00a0\nRuxolitinib\u00a0(O)\u00a0 L01EJ01\u00a0 2015\u00a0 261.968\u00a0 41.535.737\u00a0\nTegafur\u00a0+\u00a0\nGimeracil\u00a0+\u00a0\nOteracil\u00a0L01BC73\u00a0 2015\u00a0 \u00a0 961\u00a0 17.414\u00a0\nVandetanib\u00a0 L01EX04\u00a0 2015\u00a0 2.250\u00a0 388.288\u00a0\nVemurafenib\u00a0 L01EC01\u00a0 2015\u00a0 3.304\u00a0 693.228\u00a0\nAfatinib\u00a0 L01EB03\u00a0 2016\u00a0 14.567\u00a0 1.770.878\u00a0\nBosutinib\u00a0(O)\u00a0 L01EA04\u00a0 2016\u00a0 13.861\u00a0 1.432.873\u00a0\nClevidipin\u00a0 C08CA16\u00a0 2016\u00a0 \u00a0\u00a0 nicht\u00a0mehr\u00a0im\u00a0Handel\u00a0\nColestilan\u00a0 V03AE06\u00a0 2016\u00a0 \u00a0\u00a0 nicht\u00a0mehr\u00a0im\u00a0Handel\u00a0\nDabrafenib\u00a0 L01EC02\u00a0 2016\u00a0 57.860\u00a0 11.112.594\u00a0\nDihydroarte\u2010\u00a0\nmisinin\u00a0+\u00a0\nPiperaquintetra\u2010\nphosphat\u00a0P01BF05\u00a0 2016\u00a0\u00a0\u00a0\u00a0 nicht\u00a0mehr\u00a0im\u00a0Handel\u00a0\nElvitegravir\u00a0 J05AR09\u00a0 2016\u00a0 31.110\u00a0 927.118\u00a0\nEnzalutamid\u00a0 L02BB04\u00a0 2016\u00a0 389.676\u00a0 47.095.947\u00a0\nFidaxomicin\u00a0 A07AA12\u00a0 2016\u00a0 1.340\u00a0 238.478\u00a0 \n37\u00a0\n\u00a0Wirkstoff\u00a0\n(O=Orphan\u00a0Drug )\u00a0ATC\u00a0 Innov.\u00a0\nReport\u00a0Gesamtscore\u00a0 DDD\u00a07/2020\u2010\n6/2021\u00a0Bruttoausgaben\u00a0\n7/2020\u00a0\u2010\u00a06/2021\u00a0\nIngenolmebutat\u00a0 D06BX02\u00a0 2016\u00a0 \u00a0\u00a0 nicht\u00a0mehr\u00a0im\u00a0Handel\u00a0\nLinaclotid\u00a0 A06AX04\u00a0 2016\u00a0 12.208\u00a0 27.998\u00a0\nLipegfilgrastim\u00a0 L03AA14\u00a0 2016\u00a0 66.720\u00a0 5.104.426\u00a0\nLisdexamfetamin\u00a0 N06BA12\u00a0 2016\u00a0 2.913.150\u00a0 5.423.280\u00a0\nLixisenatid\u00a0 A10BX10\u00a0 2016\u00a0 \u00a0\u00a0 nicht\u00a0mehr\u00a0im\u00a0Handel\u00a0\nLomitapid\u00a0 C10AX12\u00a0 2016\u00a0 \u00a0 \u00a0 nicht\u00a0mehr\u00a0im\u00a0Handel\u00a0\nNepafenac\u00a0 S01BC10\u00a0 2016\u00a0 1.607.509\u00a0 963.233\u00a0\nOcriplasmin\u00a0 S01XA22\u00a0 2016\u00a0 58\u00a0 159.494\u00a0\nPertuzumab\u00a0 L01XC13\u00a0 2016\u00a0 345.087\u00a0 45.065.665\u00a0\nPomalidomid\u00a0(O)\u00a0 L04AX06\u00a0 2016\u00a0 30.630\u00a0 12.116.391\u00a0\nPonatinib\u00a0(O)\u00a0 L01EA05\u00a0 2016\u00a0 5.450\u00a0 1.464.629\u00a0\nRegorafenib\u00a0 L01XE21\u00a0 2016\u00a0 \u00a0\u00a0 nicht\u00a0mehr\u00a0im\u00a0Handel\u00a0\nTeriflunomid\u00a0 L04AA31\u00a0 2016\u00a0 680.288\u00a0 24.182.606\u00a0\nVismodegib\u00a0 L01XJ01\u00a0 2016\u00a0 3.024\u00a0 590.115\u00a0\nAlbiglutid\u00a0 A10BX13\u00a0 2017\u00a0 \u00a0\u00a0 nicht\u00a0mehr\u00a0im\u00a0Handel\u00a0\nAlipogentiparvovec\u00a0\n(O)\u00a0C10AX10\u00a0 2017\u00a0 \u00a0 \u00a0\u00a0 nicht\u00a0mehr\u00a0im\u00a0Handel\u00a0\nBedaquilin\u00a0(O)\u00a0 J04A K05\u00a0 2017\u00a0 3.098\u00a0 407.763\u00a0\nCabozantinib\u00a0(O)\u00a0 L01EX07\u00a0 2017\u00a0 33.394\u00a0 9.079.345\u00a0\nChols\u00e4ure\u00a0(O)\u00a0 A05AA03\u00a0 2017\u00a0 438\u00a0 198.032\u00a0\nCobicistat\u00a0 V03AX03\u00a0 2017\u00a0 12.180\u00a0 17.832\u00a0\nDaclatasvir\u00a0 J05AX14\u00a0 2017\u00a0 \u00a0 \u00a0 nicht\u00a0mehr\u00a0im\u00a0Handel\u00a0\nDelamanid\u00a0(O)\u00a0 J04AK06\u00a0 2017\u00a0 288\u00a0 43.202\u00a0\nDexlansoprazol\u00a0 A02BC06\u00a0 2017\u00a0 994\u00a0 377\u00a0\nDimethylfumarat\u00a0 L04AC07\u00a0 2017\u00a0 1.342.894\u00a0 43.494.870\u00a0\nDolutegravir\u00a0 J05AJ03\u00a0 2017\u00a0 278.958\u00a0 6.536.363\u00a0 \n38\u00a0\n\u00a0Wirkstoff\u00a0\n(O=Orphan\u00a0Drug )\u00a0ATC\u00a0 Innov.\u00a0\nReport\u00a0Gesamtscore\u00a0 DDD\u00a07/2020\u2010\n6/2021\u00a0Bruttoausgaben\u00a0\n7/2020\u00a0\u2010\u00a06/2021\u00a0\nElosulfase\u00a0alfa\u00a0(O)\u00a0 A16AB12\u00a0 2017\u00a0 6.516\u00a0 8.033.319\u00a0\nEmpagliflozin\u00a0 A10BK03\u00a0 2017\u00a0 11.139.829\u00a0 24.488.095\u00a0\nIbrutinib\u00a0(O)\u00a0 L01EL01\u00a0 2017\u00a0 222.079\u00a0 48.927.268\u00a0\nIdelalisib\u00a0 L01EM01\u00a0 2017\u00a0 3.960\u00a0 617.571\u00a0\nLedipasvir\u00a0+\u00a0\nSofosbuvir\u00a0J05AP51\u00a0 2017\u00a0 \u00a0 672\u00a0 356.101\u00a0\nMacitentan\u00a0(O)\u00a0 C02KX04\u00a0 2017\u00a0 107.220\u00a0 7.382.748\u00a0\nNalmefen\u00a0 N07BB05\u00a0 2017\u00a0 8.589\u00a0 42.645\u00a0\nObinutuzumab\u00a0(O)\u00a0 L01XC15\u00a0 2017\u00a0 53.373\u00a0 8.822.747\u00a0\nOlodaterol\u00a0 R03AC19\u00a0 2017\u00a0 19.110\u00a0 18.940\u00a0\nRiociguat\u00a0(O)\u00a0 C02KX05\u00a0 2017\u00a0 125.473\u00a0 7.724.235\u00a0\nSiltuximab\u00a0(O)\u00a0 L04AC11\u00a0 2017\u00a0 1.687\u00a0 388.818\u00a0\nSimeprevir\u00a0 J05AE14\u00a0 2017\u00a0 \u00a0\u00a0 nicht\u00a0mehr\u00a0im\u00a0Handel\u00a0\nSimoctocog\u00a0alfa\u00a0 B02BD17\u00a0 2017\u00a0 \u00a0\u00a0 \u00a0\u00a0\nSofosbuvir\u00a0 J05AP08\u00a0 2017\u00a0 56\u00a0 27.975\u00a0\nSucroferric\u00a0\nOxyhydroxid\u00a0V03AE05\u00a0 2017\u00a0 \u00a0 \u00a0\u00a0 \u00a0\u00a0\nTeduglutid\u00a0(O)\u00a0 A16AX08\u00a0 2017\u00a0 6.020\u00a0 4.130.524\u00a0\nTrastuzumab\u00a0\nEmtansin\u00a0L01XC14\u00a0 2017\u00a0\n\u00a0101.221\u00a0 23.805.048\u00a0\nTurocotocog\u00a0alfa\u00a0 B02BD16\u00a0 2017\u00a0 \u00a0\u00a0 \u00a0\u00a0\nUmeclidinium\u2010\nbromid\u00a0+\u00a0\nVilanterol\u00a0R03AL03\u00a0 2017\u00a0 \u00a01.806.990\u00a0 3.121.512\u00a0\nVedolizumab\u00a0 L04AA33\u00a0 2017\u00a0 1.218.207\u00a0 49.240.031\u00a0\nVilanterol\u00a0+\u00a0\nFluticasonfuroat\u00a0R03AK10\u00a0 2017\u00a0 \u00a06.980.040\u00a0 9.220.633\u00a0\nAlirocumab\u00a0 C10AX14\u00a0 2018\u00a0 21.000\u00a0 240.192\u00a0\nApremilast\u00a0 L04AA32\u00a0 2018\u00a0 241.862\u00a0 9.343.953\u00a0 \n39\u00a0\n\u00a0Wirkstoff\u00a0\n(O=Orphan\u00a0Drug )\u00a0ATC\u00a0 Innov.\u00a0\nReport\u00a0Gesamtscore\u00a0 DDD\u00a07/2020\u2010\n6/2021\u00a0Bruttoausgaben\u00a0\n7/2020\u00a0\u2010\u00a06/2021\u00a0\nAsfotase\u00a0alfa\u00a0(O)\u00a0 A16AB13\u00a0 2018\u00a0 5.742\u00a0 6.789.911\u00a0\nBlinatumomab\u00a0(O)\u00a0 L01XC19\u00a0 2018\u00a0 1.036\u00a0 1.193.694\u00a0\nCarfilzomib\u00a0(O)\u00a0 L01XG02\u00a0 2018\u00a0 41.579\u00a0 8.780.863\u00a0\nCeritinib\u00a0 L01ED02\u00a0 2018\u00a0 1.530\u00a0 276.971\u00a0\nCobimetinib\u00a0 L01EE02\u00a0 2018\u00a0 1.792\u00a0 366.615\u00a0\nDasabuvir\u00a0 L05AX16\u00a0 2018\u00a0 \u00a0\u00a0 nicht\u00a0mehr\u00a0im\u00a0Handel\u00a0\nDulaglutid\u00a0 A10BJ05\u00a0 2018\u00a0 6.752.294\u00a0 18.637.917\u00a0\nEdoxaban\u00a0 B01AF03\u00a0 2018\u00a0 12.339.000\u00a0 35.645.752\u00a0\nEliglustat\u00a0(O)\u00a0 A16AX10\u00a0 2018\u00a0 3.278\u00a0 2.921.051\u00a0\nEvolocumab\u00a0 C10AX13\u00a0 2018\u00a0 1.023.081\u00a0 17.056.589\u00a0\nIdebenon\u00a0(O)\u00a0 S01XA43\u00a0 2018\u00a0 13.710\u00a0 2.049.162\u00a0\nIsavuconazol\u00a0(O)\u00a0 J02AC05\u00a0 2018\u00a0 8.547\u00a0 1.119.995\u00a0\nIvermectin\u00a0 D11AX22\u00a0 2018\u00a0 2.214.720\u00a0 1.950.832\u00a0\nLenvatinib\u00a0 L01EX08\u00a0 2018\u00a0 22.374\u00a0 3.490.308\u00a0\nLumacaftor/\u00a0\nIvacaftor\u00a0(O)\u00a0R07AX30\u00a0 2018\u00a0\u00a033.348\u00a0 14.186.987\u00a0\nNaloxegol\u00a0 A06AH03\u00a0 2018\u00a0 138.230\u00a0 639.696\u00a0\nNetupitant/\u00a0\nPalonosetron\u00a0A04AA55\u00a0 2018\u00a0 \u00a0 17.726\u00a0 1.423.501\u00a0\nNintedanib\u00a0 L01EX09\u00a0 2018\u00a0 142.818\u00a0 15.755.005\u00a0\nNivolumab\u00a0 L01XC17\u00a0 2018\u00a0 240.514\u00a0 54.319.510\u00a0\nNonacog\u00a0gamma\u00a0 B02BD29\u00a0 2018\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOlaparib\u00a0(O)\u00a0 L01XK01\u00a0 2018\u00a0 121.194\u00a0 24.763.085\u00a0\nOmbitasvir\u00a0+\u00a0\nParitaprevir\u00a0+\u00a0\nRitonavir\u00a0J05AX67\u00a0 2018\u00a0 \u00a0 \u00a0\u00a0 \u00a0\u00a0\nPanobinostat\u00a0(O)\u00a0 L01XH03\u00a0 2018\u00a0 195\u00a0 45.622\u00a0\nPembrolizumab\u00a0 L01XC18\u00a0 2018\u00a0 422.808\u00a0 120.493.230\u00a0 \n40\u00a0\n\u00a0Wirkstoff\u00a0\n(O=Orphan\u00a0Drug )\u00a0ATC\u00a0 Innov.\u00a0\nReport\u00a0Gesamtscore\u00a0 DDD\u00a07/2020\u2010\n6/2021\u00a0Bruttoausgaben\u00a0\n7/2020\u00a0\u2010\u00a06/2021\u00a0\nRamucirumab\u00a0(O)\u00a0 L01XC21\u00a0 2018\u00a0 48.536\u00a0 8.242.747\u00a0\nSafinamid\u00a0 N04BD03\u00a0 2018\u00a0 623.793\u00a0 1.710.828\u00a0\nSebelipase\u00a0alfa\u00a0(O)\u00a0 A16AB14\u00a0 2018\u00a0 2.040\u00a0 1.441.611\u00a0\nSecukinumab\u00a0 L04AC10\u00a0 2018\u00a0 969.229\u00a0 55.051.654\u00a0\nTrametinib\u00a0 L01EE01\u00a0 2018\u00a0 61.317\u00a0 8.839.991\u00a0\nVortioxetin\u00a0 N06AX26\u00a0 2018\u00a0 196\u00a0 291\u00a0\nAlbutrepenonacog\u00a0\nalfa\u00a0(O)\u00a0B02BD33\u00a0 2019\u00a0 \u00a0 \u00a0\u00a0 \u00a0\u00a0\nBrivaracetam\u00a0 N03AX23\u00a0 2019\u00a0 934.574\u00a0 2.332.710\u00a0\nDaratumumab\u00a0(O)\u00a0 L01XC24\u00a0 2019\u00a0 331.246\u00a0 65.211.823\u00a0\nEfmoroctocog\u00a0alfa\u00a0 B02BD32\u00a0 2019\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEftrenonacog\u00a0alfa\u00a0\n(O)\u00a0B02BD34\u00a0 2019\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nElbasvir\u00a0+\u00a0\nGrazoprevir\u00a0J05AP54\u00a0 2019\u00a0 \u00a0 5.656\u00a0 1.725.315\u00a0\nElotuzumab\u00a0 L01XC23\u00a0 2019\u00a0 30.370\u00a0 5.843.581\u00a0\nHPV\u2010Impfstoff\u00a0 J07BM03\u00a0 2019\u00a0 12.029\u00a0 1.923.867\u00a0\nMepolizumab\u00a0 R03DX09\u00a0 2019\u00a0 176.665\u00a0 7.831.309\u00a0\nMigalastat\u00a0(O)\u00a0 A16AX14\u00a0 2019\u00a0 9.576\u00a0 6.337.008\u00a0\nOlaratumab\u00a0(O)\u00a0 L01XC27\u00a0 2019\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOpicapon\u00a0 N04BX04\u00a0 2019\u00a0 528.690\u00a0 1.809.690\u00a0\nOsimertinib\u00a0 L01EB04\u00a0 2019\u00a0 99.270\u00a0 21.876.253\u00a0\nPalbociclib\u00a0 L01EF01\u00a0 2019\u00a0 329.734\u00a0 33.129.235\u00a0\nPitolisant\u00a0(O)\u00a0 N07XX11\u00a0 2019\u00a0 61.553\u00a0 920.535\u00a0\nSacubitril\u00a0+\u00a0\nValsartan\u00a0C09DX04\u00a0 2019\u00a0 \u00a05.020.984\u00a0 28.390.567\u00a0\nSelexipag\u00a0 C02KX09\u00a0 2019\u00a0 18.749\u00a0 2.141.481\u00a0\n\u00a0\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \n41\u00a0\n\u00a0Wirkstoff\u00a0\n(O=Orphan\u00a0Drug )\u00a0ATC\u00a0 Innov.\u00a0\nReport\u00a0Gesamtscore\u00a0 DDD\u00a07/2020\u2010\n6/2021\u00a0Bruttoausgaben\u00a0\n7/2020\u00a0\u2010\u00a06/2021\u00a0\nSofosbuvir\u00a0+\u00a0\nVelpatasvir\u00a0J05AP55\u00a0 2019\u00a0 \u00a0 13.132\u00a0 4.631.755\u00a0\nTalimogen\u00a0\nlaherparepvec\u00a0L01XX51\u00a0 2019\u00a0 \u00a0 1.927\u00a0 390.285\u00a0\nTenofoviralafen\u2010\namid\u00a0J05AR18\u00a0\nJ05AR17\u00a0\nJ05AR19\u00a02019\u00a0 \u00a0 848.310\u00a0 24.269.123\u00a0\nTrifluridin\u00a0+\u00a0\nTipiracil\u00a0L01BC59\u00a0 2019\u00a0\n\u00a034.903\u00a0 4.042.346\u00a0\nAlectinib\u00a0 L01ED03\u00a0 2020\u00a0 40.236\u00a0 8.474.369\u00a0\nAtezolizumab\u00a0 L01XC32\u00a0 2020\u00a0 122.690\u00a0 25.072.481\u00a0\nAvelumab\u00a0(O)\u00a0 L01XC31\u00a0 2020\u00a0 12.887\u00a0 3.458.546\u00a0\nBaricitinib\u00a0 L04AA37\u00a0 2020\u00a0 475.447\u00a0 22.014.878\u00a0\nBrodalumab\u00a0 L04AC12\u00a0 2020\u00a0 89.276\u00a0 4.368.359\u00a0\nCenegermin\u00a0(O)\u00a0 S01XA24\u00a0 2020\u00a0 0\u00a0 0\u00a0\nCladribin\u00a0 L04AA40\u00a0 2020\u00a0 125.824\u00a0 8.465.484\u00a0\nDimethylfumarat\u00a0 D05BX02\u00a0 2020\u00a0 333.821\u00a0 2.937.283\u00a0\nDupilumab\u00a0 D11AH05\u00a0 2020\u00a0 860.183\u00a0 46.866.606\u00a0\nEtelcalcetid\u00a0 H05BX04\u00a0 2020\u00a0 267.813\u00a0 4.363.919\u00a0\nGlecaprevir\u00a0+\u00a0\nPibrentasvir\u00a0J05AP57\u00a0 2020\u00a0 \u00a0 15.764\u00a0 8.342.546\u00a0\nGuselkumab\u00a0 L04AC16\u00a0 2020\u00a0 338.660\u00a0 18.280.587\u00a0\nInotuzumab\u00a0\nOzogamicin\u00a0(O)\u00a0L01XC26\u00a0 2020\u00a0 \u00a0 500\u00a0 577.428\u00a0\nIxazomib\u00a0(O)\u00a0 L01XG03\u00a0 2020\u00a0 11.033\u00a0 2.836.177\u00a0\nIxekizumab\u00a0 L04AC13\u00a0 2020\u00a0 416.279\u00a0 20.742.623\u00a0\nLonoctocog\u00a0alfa\u00a0 B02BD35\u00a0 2020\u00a0 \u00a0\u00a0 \u00a0\u00a0\nMeningokokken\u2010B\u2010\nImpfstoff\u00a0J07AH09\u00a0 2020\u00a0 \u00a0 5.491\u00a0 585.478\u00a0\nMidostaurin\u00a0(O)\u00a0 L01EX10\u00a0 2020\u00a0 6.393\u00a0 4.177.808\u00a0 \n42\u00a0\n\u00a0Wirkstoff\u00a0\n(O=Orphan\u00a0Drug )\u00a0ATC\u00a0 Innov.\u00a0\nReport\u00a0Gesamtscore\u00a0 DDD\u00a07/2020\u2010\n6/2021\u00a0Bruttoausgaben\u00a0\n7/2020\u00a0\u2010\u00a06/2021\u00a0\nNabilon\u00a0 A04AD11\u00a0 2020\u00a0 1.783\u00a0 88.123\u00a0\nNiraparib\u00a0(O)\u00a0 L01XX54\u00a0 2020\u00a0 24.248\u00a0 6.680.036\u00a0\nNonacog\u00a0beta\u00a0\npegol\u00a0B02BD36\u00a0 2020\u00a0\n\u00a0\u00a0\u00a0 \u00a0\u00a0\nNusinersen\u00a0(O)\u00a0 M09AX07\u00a0 2020\u00a0 5.642\u00a0 4.079.885\u00a0\nObetichols\u00e4ure\u00a0(O)\u00a0 A05AA04\u00a0 2020\u00a0 15.315\u00a0 2.065.619\u00a0\nReslizumab\u00a0 R03SX08\u00a0 2020\u00a0 3.708\u00a0 154.830\u00a0\nRibociclib\u00a0 L01XE42\u00a0 2020\u00a0 107.576\u00a0 9.673.785\u00a0\nRolapitant\u00a0 A04AD14\u00a0 2020\u00a0 45\u00a0 2.178\u00a0\nSarilumab\u00a0 L04AC14\u00a0 2020\u00a0 91.133\u00a0 4.796.765\u00a0\nSofosbuvir\u00a0+\u00a0\nVelpatasvir\u00a0+\u00a0Voxilaprevir\u00a0J05AP56\u00a0 2020\u00a0 \u00a0 1.092\u00a0 761.314\u00a0\nTivozanib\u00a0 L01XE34\u00a0 2020\u00a0 1.985\u00a0 337.837\u00a0\nTofacitinib\u00a0 L04AA29\u00a0 2020\u00a0 417.031\u00a0 14.362.635\u00a0\nVenetoclax\u00a0 L01XX52\u00a0 2020\u00a0 81.305\u00a0 17.736.490\u00a0\nAmpelverteilung\u00a0\n\u00fcber\u00a0die\u00a0Jahre\u00a0\n(n=200)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0=\u00a099\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0=\u00a075\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0=\u00a026\u00a0\n\u00a0 \n43\u00a0\n\u00a0Im\u00a0Rahmen\u00a0der\u00a0\u201e Access\u00a0Campaign \u201c\u00a0hat\u00a0die\u00a0NGO\u00a0\u201e\u00c4rzte\u00a0ohne\u00a0Grenzen\u201c\u00a0die\u00a0Ausga\u2010\nben\u00a0der\u00a0pU\u00a0f\u00fcr\u00a0Marketing\u00a0denen\u00a0f\u00fcr\u00a0F&E\u00a0im\u00a0Mai\u00a02016\u00a0gegen\u00fcberges tellt\u00a0und\u00a0das\u00a0\nNarrativ\u00a0der\u00a0hohen\u00a0Entwicklungskosten\u00a0der\u00a0pU\u00a0kritisch\u00a0gew\u00fcrdigt .\u00a0Mit\u00a0Ausnahme\u00a0\ndes\u00a0pU\u00a0Roche\u00a0gaben\u00a0alle\u00a0pU\u00a0mehr\u00a0f\u00fcr\u00a0Marketing\u00a0als\u00a0f\u00fcr\u00a0F&E\u00a0aus,\u00a0 teils\u00a0sogar\u00a0mehr\u00a0\nals\u00a0das\u00a0Doppelte,\u00a0wie\u00a0beim\u00a0pU\u00a0Jo hnson\u00a0&\u00a0Johnson\u00a0(\u00c4rzte\u00a0ohne\u00a0Gre nzen,\u00a02018).\u00a0\nSomit\u00a0 w\u00e4re\u00a0 die\u00a0 Preisbildung\u00a0 neue r\u00a0 Arzneimittel\u00a0 im\u00a0 paneurop\u00e4isch en\u00a0 Kontext\u00a0\ntransparenter,\u00a0nachhaltiger\u00a0und\u00a0fairer\u00a0zu\u00a0gestalten\u00a0und\u00a0die\u00a0Pre isw\u00fcrdigkeit\u00a0konti\u2010\nnuierlich\u00a0zu\u00a0evaluieren.\u00a0\nAbb.\u00a04.3:\u00a0Ausgaben\u00a0f\u00fcr\u00a0Marketing \u00a0vs.\u00a0F&E\u00a0gro\u00dfer\u00a0pU\u00a0nach\u00a0US\u00a0$\u00a0\nQuelle:\u00a0\u00c4rzte\u00a0ohne\u00a0Grenzen,\u00a02018\u00a0\nUnd\u00a0das\u00a0kurze\u00a0Fazit\u00a0aus\u00a0den\u00a0Erge bnissen\u00a0der\u00a0Innovationsreporte\u00a0 2013\u00a0bis\u00a02020?\u00a0\n\uf0b7 Die\u00a0Innovationskraft\u00a0pharmazeutischer\u00a0Unternehmen\u00a0hat\u00a0sich\u00a0in\u00a0d en\u00a0\nvergangenen\u00a0acht\u00a0Jahren\u00a0als\u00a0eher\u00a0d\u00fcrftig\u00a0herausgestellt.\u00a0Nur\u00a013 \u00a0%\u00a0\nder\u00a0neu\u00a0eingef\u00fchrten\u00a0200\u00a0Arzneimittel,\u00a0die\u00a0haupts\u00e4chlich\u00a0im\u00a0amb u\u2010\nlanten\u00a0Bereich\u00a0angewendet\u00a0werden,\u00a0k\u00f6nnen\u00a0als\u00a0Innovation\u00a0einge\u2010\nstuft\u00a0werden\u00a0(gr\u00fcne\u00a0Ampel),\u00a0f\u00fcr\u00a0weitere\u00a038\u00a0%\u00a0m\u00fcssen\u00a0zus\u00e4tzliche \u00a0\nDaten\u00a0vorgelegt\u00a0werden,\u00a0um\u00a0entscheiden\u00a0zu\u00a0k\u00f6nnen,\u00a0ob\u00a0auch\u00a0sie\u00a0z u\u00a0\neinem\u00a0Gewinn\u00a0an\u00a0Patientennutzen\u00a0 beitragen.\u00a0Bei\u00a049\u00a0%\u00a0der\u00a0neuen\u00a0\n \n44\u00a0\n\u00a0Arzneimittel\u00a0gibt\u00a0es\u00a0aus\u00a0unserer\u00a0Sicht\u00a0diese\u00a0Notwendigkeit\u00a0\u2013\u00a0da her\u00a0\nmuss\u00a0ihre\u00a0Ampel\u00a0noch\u00a0auf\u00a0\u201erot\u201c\u00a0stehenbleiben.\u00a0Die\u00a0meisten\u00a0neuen \u00a0\nArzneimittel\u00a0kommen\u00a0aus\u00a0dem\u00a0onko logischen\u00a0Therapiebereich,\u00a0hier \u00a0\nscheint\u00a0sich\u00a0eine\u00a0neue\u00a0\u201e me\u2010too\u201c\u2010Strategie\u00a0zu\u00a0entwickeln\u00a0\u2013\u00a0alle\u00a0wol\u2010\nlen\u00a0an\u00a0diesem\u00a0lukrativen\u00a0Indikat ionsbereich\u00a0\u201emitverdienen\u201c.\u00a0\u201eDa s\u00a0\nLeiden\u00a0bestimmt\u00a0den\u00a0Preis\u201c,\u00a0so\u00a0die\u00a0Einstellung\u00a0vieler\u00a0pharmazeu ti\u2010\nscher\u00a0Unternehmen.\u00a0\n\uf0b7 Demgegen\u00fcber\u00a0\u201eimponieren\u201c\u00a0alle\u00a0neu en\u00a0Arzneimittel,\u00a0auch\u00a0die\u00a0mit \u00a0\neiner\u00a0roten\u00a0Ampel\u00a0versehenen,\u00a0davon\u00a0vor\u00a0allem\u00a0auch\u00a0die\u00a0 Orphan\u2010\nDrugs,\u00a0mit\u00a0extrem\u00a0hohen\u00a0Kosten.\u00a0Der\u00a0Nutzen\u00a0bleibt\u00a0oft\u00a0unbestimmt\u00a0\noder\u00a0marginal,\u00a0die\u00a0Preise\u00a0steigen\u00a0dagegen\u00a0exorbitant.\u00a0Die\u00a0geset zli\u2010\nchen\u00a0Krankenkassen\u00a0sind\u00a0dabei\u00a0auf\u00a0sich\u00a0gestellt,\u00a0wenn\u00a0es\u00a0um\u00a0die \u00a0\nAusgabend\u00e4mpfung\u00a0geht.\u00a0Wenn\u00a0nicht\u00a0Festbetr\u00e4ge,\u00a0Rabatte\u00a0aus\u00a0Ver\u2010\ntr\u00e4gen\u00a0 der\u00a0 Kassen\u00a0 mit\u00a0 einzelnen\u00a0 pU\u00a0 und\u00a0 die\u00a0 Rabatte\u00a0 aus\u00a0 dem\u00a0AMNOG\u2010Verfahren\u00a0zu\u00a0einer\u00a0Verring erung\u00a0der\u00a0Arzneimittelausgaben\u00a0\nbeitragen\u00a0w\u00fcrden,\u00a0m\u00fcsste\u00a0der\u00a0Beitragssatz\u00a0in\u00a0der\u00a0GKV\u00a0um\u00a0rund\u00a01\u00a0 %\u00a0\nangehoben\u00a0werden.\u00a0\n\uf0b7 Die\u00a0Politik\u00a0macht\u00a0in\u00a0diesem\u00a0Zus ammenhang\u00a0v\u00f6llig\u00a0 unzureichende\u00a0\nAngebote,\u00a0wenn\u00a0sie\u00a0meint,\u00a0durch\u00a0verk\u00fcrzte\u00a0Zeiten\u00a0von\u00a0der\u00a0Marktz u\u2010\nlassung\u00a0bis\u00a0zur\u00a0Festsetzung\u00a0des\u00a0Erstattungsbetrags\u00a0von\u00a013\u00a0auf\u00a0s ieben\u00a0\nMonate\u00a0eine\u00a0Entlastung\u00a0der\u00a0Kasse n\u00a0erreichen\u00a0zu\u00a0k\u00f6nnen.\u00a0Schlie\u00dfl ich\u00a0\nbehalten\u00a0die\u00a0pU\u00a0das\u00a0Privileg,\u00a0den\u00a0Einstandspreis\u00a0f\u00fcr\u00a0die\u00a0Preisv er\u2010\nhandlungen\u00a0wie\u00a0eh\u00a0und\u00a0je\u00a0intransparent\u00a0und\u00a0wenig\u00a0begr\u00fcndet\u00a0fest \u2010\nlegen\u00a0zu\u00a0k\u00f6nnen.\u00a0Und\u00a0diesem\u00a0erfahrungsgem\u00e4\u00df\u00a0\u00fcberh\u00f6ht\u00a0angesetz\u2010\nten\u00a0Preis\u00a0folgt\u00a0dann\u00a0auch\u00a0der\u00a0Erstattungsbetrag\u00a0\u2013\u00a0hohe\u00a0und\u00a0fair e\u00a0\nPreisreduzierungen\u00a0sind\u00a0da\u00a0auch\u00a0in\u00a0Zukunft\u00a0nicht\u00a0zu\u00a0erwarten.\u00a0\n\uf0b7 Warum\u00a0findet\u00a0die\u00a0Politik\u00a0nicht\u00a0den\u00a0Mut,\u00a0bei\u00a0der\u00a0Gruppe\u00a0der\u00a0neue n\u00a0\nund\u00a0besonders\u00a0teuren\u00a0Arzneimittel,\u00a0die\u00a0nur\u00a06\u00a0%\u00a0der\u00a0Verordnungen ,\u00a0\naber\u00a0knapp\u00a050\u00a0%\u00a0der\u00a0Arzneimittela usgaben\u00a0ausmachen,\u00a0die\u00a0Mehr\u2010\nwertsteuer\u00a0ganz\u00a0oder\u00a0zum\u00a0Teil\u00a0auszusetzen?\u00a0Dies\u00a0w\u00fcrde\u00a0im\u00a0Maxi\u2010\nmalfall\u00a0zu\u00a0rund\u00a0vier\u00a0Mrd.\u00a0Euro\u00a0Einsparungen\u00a0f\u00fchren.\u00a0Schlie\u00dflich \u00a0kann\u00a0\nes\u00a0nicht\u00a0sein,\u00a0dass\u00a0neben\u00a0der\u00a0\u00f6ffentlich\u00a0finanzierten\u00a0Forschung sf\u00f6r\u2010\nderung\u00a0in\u00a0Universit\u00e4ten\u00a0oder\u00a0durch\u00a0direkte\u00a0finanzielle\u00a0Zuwendun gen\u00a0\nvom\u00a0Staat\u00a0(siehe\u00a0CureVac\u00a0oder\u00a0BionTech),\u00a0die\u00a0bis\u00a0zu\u00a030\u00a0%\u00a0der\u00a0Fo r\u2010\nschungskosten\u00a0betragen\u00a0sollen,\u00a0extrem\u00a0hohe\u00a0Preise\u00a0und\u00a0zus\u00e4tzlic h\u00a0\nMehrwertsteuer\u00a0auf\u00a0Dauer\u00a0toleriert\u00a0werden.\u00a0\nWir\u00a0brauchen\u00a0dringend\u00a0eine\u00a0europ\u00e4ische\u00a0Preisagentur\u00a0f\u00fcr\u00a0Arzneim ittel\u00a0\u2013\u00a0pU\u00a0agie\u2010\nren\u00a0 global,\u00a0 ihnen\u00a0 muss\u00a0 auch\u00a0 ein\u00a0 globales\u00a0 Konzept\u00a0 gegen\u00fcbergeste llt\u00a0 werden.\u00a0\nPharmadialoge\u00a0zwischen\u00a0Politik\u00a0und\u00a0pU\u00a0als\u00a0\u201e closed\u00a0shop \u201c\u00a0m\u00fcssen\u00a0der\u00a0Vergangen\u2010\nheit\u00a0angeh\u00f6ren\u00a0\u2013\u00a0es\u00a0muss\u00a0nicht\u00a0nur\u00a0Transparenz\u00a0der\u00a0Zulassungsda ten,\u00a0der\u00a0For\u2010 \n45\u00a0\n\u00a0schungskosten\u00a0und\u00a0der\u00a0Nutzenbewertung\u00a0geben,\u00a0sondern\u00a0auch\u00a0im\u00a0fr \u00fchzeitigen\u00a0\nAustausch\u00a0\u00fcber\u00a0Forschungsschwerpunkte\u00a0und\u00a0\u00fcber\u00a0die\u00a0Preisgestalt ung.\u00a0Hier\u00a0ist\u00a0die\u00a0\nPolitik\u00a0gefordert,\u00a0Schrittmacherdienste\u00a0zu\u00a0leisten.\u00a0 \u00a0\nDass\u00a0neue\u00a0Wirkstoffe\u00a0nicht\u00a0automatisch\u00a0Vorteile\u00a0f\u00fcr\u00a0Patienten\u00a0b ieten,\u00a0hat\u00a0die\u00a0\nfr\u00fche\u00a0Nutzenbewertung\u00a0seit\u00a02011\u00a0de utlich\u00a0gezeigt.\u00a0Andererseits\u00a0 gab\u00a0es\u00a0in\u00a0den\u00a0\nletzten\u00a0Jahren\u00a0 durchaus\u00a0Indikationen,\u00a0in\u00a0denen\u00a0Neueinf\u00fchrungen\u00a0 die\u00a0Therapie\u00a0\ndeutlich\u00a0verbessert\u00a0haben\u00a0(Witte,\u00a02021).\u00a0Um\u00a0Neueinf\u00fchrungen\u00a0sac hgerecht\u00a0zu\u00a0\nbewerten,\u00a0ist\u00a0deshalb\u00a0eine\u00a0differenzierte\u00a0Betrachtung\u00a0n\u00f6tig.\u00a0Di e\u00a0folgende\u00a0Analyse\u00a0\nbeleuchtet\u00a0beispielhaft\u00a0zwei\u00a0Indikationen,\u00a0in\u00a0denen\u00a0in\u00a0den\u00a0letz ten\u00a0zehn\u00a0Jahren\u00a0\njeweils\u00a0eine\u00a0ganze\u00a0Reihe\u00a0von\u00a0Arzneistoffen\u00a0neu\u00a0auf\u00a0den\u00a0Markt\u00a0ka men:\u00a0das\u00a0fortge\u2010\nschrittene\u00a0maligne\u00a0Melanom\u00a0und\u00a0die\u00a0Immuntherapie\u00a0der\u00a0schubf\u00f6rmi g\u00a0remittie\u2010\nrenden\u00a0Multiplen\u00a0Sklerose.\u00a0\n Fortgeschrittenes\u00a0malignes\u00a0Melanom\u00a04.2\nEine\u00a0Analyse\u00a0der\u00a0Indikationen\u00a0\u201eFortgeschrittenes\u00a0malignes\u00a0Melan om\u201c\u00a0und\u00a0\u201eIm\u2010\nmuntherapie\u00a0der\u00a0schubf\u00f6rmig\u00a0remittierenden\u00a0Multiplen\u00a0Sklerose\u201c\u00a0 unter\u00a0Nutzung\u00a0\nder\u00a0Ergebnisse\u00a0in\u00a0den\u00a0bisher\u00a0publizierten\u00a0Innovationsreporten.\u00a0\nSeit\u00a0dem\u00a0Beginn\u00a0der\u00a0fr\u00fchen\u00a0Nutz enbewertung\u00a02011\u00a0bis\u00a0einschlie\u00dfl ich\u00a02020\u00a0sind\u00a0in\u00a0\nDeutschland\u00a0zehn\u00a0neue\u00a0Wirkstoffe \u00a0zur\u00a0Behandlung\u00a0des\u00a0malignen\u00a0Me lanoms\u00a0auf\u00a0\nden\u00a0Markt\u00a0gekommen.\u00a0Bei\u00a0allen\u00a0handelt\u00a0es\u00a0sich\u00a0um\u00a0Therapieoption en\u00a0f\u00fcr\u00a0das\u00a0\nfortgeschrittene\u00a0Melanom,\u00a0dessen\u00a0 Prognose\u00a0bislang\u00a0eher\u00a0schlecht \u00a0war\u00a0(Schaden\u2010\ndorf\u00a0et\u00a0al.,\u00a02015).\u00a0\nKrankheitsbild\u00a0\nDas\u00a0maligne\u00a0Melanom\u00a0entsteht\u00a0in\u00a0 den\u00a0pigmentbildenden\u00a0Melanozyte n.\u00a0Am\u00a0h\u00e4u\u2010\nfigsten\u00a0kommt\u00a0das\u00a0kutane\u00a0Melanom\u00a0vor,\u00a0deutlich\u00a0seltener\u00a0sind\u00a0an dere\u00a0Formen\u00a0des\u00a0\nMelanoms,\u00a0die\u00a0etwa\u00a0das\u00a0Auge,\u00a0die\u00a0Schleimh\u00e4ute\u00a0von\u00a0Mund\u00a0und\u00a0Geni talien\u00a0sowie\u00a0\ninnere\u00a0Organe\u00a0befallen\u00a0k\u00f6nnen.\u00a0\nAn\u00a0der\u00a0Entstehung\u00a0sind\u00a0genetische\u00a0Faktoren,\u00a0aber\u00a0auch\u00a0Umweltein fl\u00fcsse\u00a0beteiligt.\u00a0\nSo\u00a0sind\u00a0mehrere\u00a0Genotypen\u00a0bekannt,\u00a0bei\u00a0denen\u00a0ein\u00a0erh\u00f6htes\u00a0Risik o\u00a0f\u00fcr\u00a0ein\u00a0Mela\u2010\nnom\u00a0besteht.\u00a0Bei\u00a0etwa\u00a010\u00a0%\u00a0aller\u00a0Melanome\u00a0liegt\u00a0eine\u00a0famili\u00e4re\u00a0 Veranlagung\u00a0vor.\u00a0\nSporadisch\u00a0 treten\u00a0 Melanome\u00a0 besonders\u00a0 h\u00e4ufig\u00a0 bei\u00a0 Menschen\u00a0 mit\u00a0 he ller\u00a0 Haut\u00a0\nsowie\u00a0zahlreichen,\u00a0gro\u00dfen\u00a0bezie hungsweise\u00a0unregelm\u00e4\u00dfigen\u00a0Leberf lecken\u00a0(Naevi)\u00a0\nauf.\u00a0Als\u00a0wichtigster\u00a0exogener\u00a0Risikofaktor\u00a0gilt\u00a0die\u00a0Exposition\u00a0 gegen\u00fcber\u00a0ultraviolet\u2010\nter\u00a0Strahlung,\u00a0die\u00a0wahrscheinlic h\u00a0\u00fcber\u00a0mutagene\u00a0Prozesse\u00a0zur\u00a0Pa thogenese\u00a0von\u00a0\nMelanomen\u00a0beitr\u00e4gt.\u00a0Als\u00a0besonders\u00a0gef\u00e4hrlich\u00a0gilt\u00a0dabei\u00a0intensi ve\u00a0intermittierende\u00a0\nBestrahlung,\u00a0wie\u00a0etwa\u00a0im\u00a0Sommerurlaub,\u00a0sowie\u00a0die\u00a0Exposition\u00a0in\u00a0 Kindheit\u00a0und\u00a0 \n46\u00a0\n\u00a0Jugend.\u00a0Bei\u00a0etwa\u00a0der\u00a0H\u00e4lfte\u00a0der\u00a0prim\u00e4ren\u00a0Melanome\u00a0der\u00a0Haut\u00a0lieg t\u00a0eine\u00a0B\u2010RAF\u2010\nMutation\u00a0(RAF\u00a0ist\u00a0die\u00a0Abk\u00fcrzung\u00a0f\u00fcr\u00a0 Rapidly\u00a0growing\u00a0fibrosarcoma )\u00a0vor\u00a0(siehe\u00a0\nAbschnitt\u00a0Wirkungsmechanismen).\u00a0\nDas\u00a0maligne\u00a0Melanom\u00a0zeigt\u00a0sich\u00a0als\u00a0Hautver\u00e4nderung,\u00a0die\u00a0in\u00a0viel f\u00e4ltigen\u00a0Formen\u00a0\nauftreten\u00a0kann,\u00a0etwa\u00a0was\u00a0die\u00a0Ve rf\u00e4rbung,\u00a0Asymmetrie\u00a0oder\u00a0weiter e\u00a0Charakteristi\u2010\nka\u00a0wie\u00a0N\u00e4ssen\u00a0oder\u00a0Krustenbildung\u00a0angeht.\u00a0Nach\u00a0dem\u00a0Wachstumsmus ter\u00a0und\u00a0der\u00a0\nLokalisation\u00a0lassen\u00a0sich\u00a0vier\u00a0Haupttypen\u00a0unterscheiden.\u00a0Dazu\u00a0ge h\u00f6ren\u00a0das\u00a0Lentigo\u00a0\nmaligna\u2010Melanom\u00a0(etwa\u00a010\u00a0%\u00a0alle r\u00a0F\u00e4lle),\u00a0das\u00a0superfiziell\u00a0sprei tende\u00a0Melanom\u00a0\n(etwa\u00a060\u00a0%\u00a0aller\u00a0F\u00e4lle),\u00a0das\u00a0no dul\u00e4re\u00a0Melanom\u00a0(etwa\u00a020\u00a0%\u00a0aller\u00a0 F\u00e4lle)\u00a0sowie\u00a0das\u00a0\nakrolentigin\u00f6se\u00a0Melanom\u00a0(etwa\u00a05\u00a0%\u00a0aller\u00a0F\u00e4lle).\u00a0Daneben\u00a0sind\u00a0no ch\u00a0weitere\u00a0selte\u2010\nne\u00a0Melanom\u2010Arten\u00a0bekannt.\u00a0Als\u00a0aggressivste\u00a0dieser\u00a0Formen\u00a0mit\u00a0de r\u00a0ung\u00fcnstigsten\u00a0\nPrognose\u00a0gilt\u00a0das\u00a0nodul\u00e4re\u00a0maligne\u00a0Melanom.\u00a0Jedoch\u00a0h\u00e4ngt\u00a0die\u00a0Pr ognose\u00a0der\u00a0\nprim\u00e4ren\u00a0 Melanome\u00a0 und\u00a0 damit\u00a0 das\u00a0 Stadium\u00a0 haupts\u00e4chlich\u00a0 von\u00a0 ihrer \u00a0v e r t i k a l \u00a0\nmessbaren\u00a0Tumordicke\u00a0ab.\u00a0Die\u00a0meis ten\u00a0Melanome\u00a0der\u00a0Haut\u00a0werden\u00a0i n\u00a0Deutsch\u2010\nland\u00a0 in\u00a0 einem\u00a0 sehr\u00a0 fr\u00fchen\u00a0 Stadium\u00a0 entdeckt\u00a0 (Leitlinienprogramm\u00a0 Onkologie,\u00a0\n2020).\u00a0\nNach\u00a0Zahlen\u00a0des\u00a0Robert\u00a0Koch\u2010Instituts\u00a0erkrankten\u00a0im\u00a0Jahr\u00a02017\u00a0k napp\u00a023.000\u00a0\nMenschen\u00a0in\u00a0Deutschland\u00a0am\u00a0malignen\u00a0Melanom,\u00a0etwa\u00a02.800\u00a0starben \u00a0daran.\u00a0Die\u00a0\nstandardisierten\u00a0Sterberaten\u00a0lagen\u00a0bei\u00a02,4\u00a0beziehungsweise\u00a01,6, \u00a0jeweils\u00a0bezogen\u00a0\nauf\u00a0100.000\u00a0Einwohner\u00a0(RKI,\u00a02021).\u00a0\u00a0\nWirkungsmechanismen\u00a0\nDie\u00a0neu\u00a0verf\u00fcgbaren\u00a0Arzneistoffe\u00a0(Tabelle\u00a04.1)\u00a0lassen\u00a0sich\u00a0vers chiedenen\u00a0Wirkstoffklas\u2010\nsen\u00a0mit\u00a0unterschiedlichen\u00a0Wirkun gsmechanismen\u00a0zuordnen\u00a0(Schaden dorf\u00a0et\u00a0al,\u00a02015).\u00a0\u00a0\nTabelle\u00a04.3:\u00a0\u00dcbersicht\u00a0der\u00a0Wirkstoffklassen\u00a0von\u00a0neuen\u00a0Arzneisto ffen\u00a0zur\u00a0Behand\u2010\nlung\u00a0des\u00a0fortgeschrittenen\u00a0malignen\u00a0Melanoms\u00a0\nB\u2010RAF\u2010Inhibitoren\u00a0 MEK\u2010Inhibitoren\u00a0 Checkpoint\u2010Inhibitoren\u00a0 Sonstige\u00a0\nVemurafenib\u00a0(Zelboraf\u00ae,\u00a0\n2012)\u00a0Trametinib\u00a0\u00a0\n(Mekinist\u00ae,\u00a02014)\u00a0Ipilimumab\u00a0\u00a0\n(Yervoy\u00ae,\u00a02011)\u00a0Talimogen\u00a0\nlaherparepvec/T\u2010Vec\u00a0\n(Imlygic\u00ae,\u00a02015)\u00a0\nDabrafenib\u00a0\u00a0\n(Tafinlar\u00ae,\u00a02013)\u00a0Cobimetinib\u00a0\u00a0\n(Cotellic\u00ae,\u00a02015)\u00a0Pembrolizumab\u00a0\n(Keytruda\u00ae,\u00a02015)\u00a0\u00a0\nEncorafenib\u00a0\u00a0\n(Braftovi\u00ae,\u00a02018)\u00a0Binimetinib\u00a0\u00a0\n(Mektovi\u00ae,\u00a02018)\u00a0Nivolumab\u00a0\u00a0\n(Opdivo\u00ae,\u00a02015)\u00a0\u00a0\nIn\u00a0Klammern:\u00a0Handelsname,\u00a0Jahr\u00a0der\u00a0Erst\u2010Zulassung\u00a0 \n47\u00a0\n\u00a0Zu\u00a0 den\u00a0 zielgerichteten\u00a0 Therapien \u00a0 geh\u00f6ren\u00a0 B\u2010RAF\u2010Inhibitoren\u00a0 wie\u00a0 Vemurafenib\u00a0\noder\u00a0Dabrafenib\u00a0und\u00a0MEK\u2010Inhibitoren\u00a0wie\u00a0Trametinib\u00a0oder\u00a0Cobimet inib.\u00a0Sie\u00a0grei\u2010\nfen\u00a0an\u00a0verschiedenen\u00a0Stellen\u00a0des\u00a0MAPK\u2010Signalwegs\u00a0an,\u00a0der\u00a0bei\u00a0de r\u00a0Entstehung\u00a0des\u00a0\nmalignen\u00a0Melanoms\u00a0eine\u00a0w ichtige\u00a0Rolle\u00a0spielt.\u00a0\u00a0\nIm\u00a0 MAPK\u2010Signalweg\u00a0 akti viert\u00a0 die\u00a0 B\u2010RAF\u2010Protei nkinase\u00a0 die\u00a0 Mitogen \u2010aktivierten\u00a0\nSignal\u2010regulierten\u00a0Kinasen\u00a0(MEK)\u00a0und\u00a0diese\u00a0wiederum\u00a0die\u00a0extraze llul\u00e4ren\u00a0Signal\u2010\nregulierten\u00a0Kinase\u00a0ERK\u00a01\u00a0und\u00a0ERK\u00a02.\u00a0Im\u00a0normalen\u00a0MAPK\u2010Signalweg\u00a0 sind\u00a0Zellprolife\u2010\nration\u00a0und\u00a0Apoptose\u00a0balanciert.\u00a0 Allerdings\u00a0k\u00f6nnen\u00a0Mutationen\u00a0in \u00a0dem\u00a0Gen\u00a0auftre\u2010\nten,\u00a0das\u00a0f\u00fcr\u00a0die\u00a0B\u2010RAF\u2010Proteinkinase\u00a0codiert.\u00a0Bei\u00a0dieser\u00a0Varian te\u00a0ist\u00a0an\u00a0Position\u00a0600\u00a0\ndie\u00a0Aminos\u00e4ure\u00a0Valin\u00a0in\u00a0der\u00a0Regel\u00a0durch\u00a0Glutamins\u00e4ure\u00a0ersetzt,\u00a0 in\u00a0seltenen\u00a0F\u00e4llen\u00a0\nfindet\u00a0sich\u00a0auch\u00a0Lysin.\u00a0Dadurch\u00a0wird\u00a0der\u00a0MAPK\u2010Signalweg\u00a0\u00fcberakt iv,\u00a0was\u00a0zu\u00a0einer\u00a0\nerh\u00f6hten\u00a0Zellproliferation\u00a0f\u00fchrt.\u00a0\u00a0\nDie\u00a0zielgerichteten\u00a0Therapien\u00a0hemmen\u00a0die\u00a0\u00dcberaktivierung\u00a0und\u00a0da mit\u00a0auch\u00a0die\u00a0\nProliferation\u00a0der\u00a0Tumorzellen.\u00a0Sowohl\u00a0B\u2010RAF\u2010\u00a0als\u00a0auch\u00a0MEK\u2010Inhib itoren\u00a0sind\u00a0oral\u00a0\nverf\u00fcgbar.\u00a0\nNeben\u00a0 den\u00a0 zielgerichteten\u00a0 Therap ien\u00a0 wurden\u00a0 in\u00a0 den\u00a0 letzten\u00a0 Jahre n\u00a0 auch\u00a0 Arz\u2010\nneistoffe\u00a0auf\u00a0den\u00a0Markt\u00a0gebracht, \u00a0die\u00a0an\u00a0verschiedenen\u00a0Stellen\u00a0 des\u00a0Immunsystems\u00a0\nangreifen.\u00a0\nCheckpoint\u2010Inhibitoren\u00a0aktivieren\u00a0die\u00a0Tumorabwehr\u00a0des\u00a0Immunsyst ems.\u00a0\u201eCheck\u2010\npoints\u201c\u00a0sind\u00a0Stellen\u00a0in\u00a0Signalwegen\u00a0des\u00a0Immunsystems,\u00a0die\u00a0die\u00a0I mmunantwort\u00a0fein\u00a0\nregulieren\u00a0und\u00a0eine\u00a0Balance\u00a0zwi schen\u00a0wirksamer\u00a0Abwehr\u00a0und\u00a0\u00fcbers chie\u00dfender\u00a0\nImmunantwort\u00a0erm\u00f6glichen.\u00a0Melan omzellen\u00a0k\u00f6nnen\u00a0Mechanismen\u00a0nutz en,\u00a0um\u00a0\nder\u00a0Tumorabwehr\u00a0zu\u00a0entkommen.\u00a0Da zu\u00a0geh\u00f6rt\u00a0die\u00a0Expression\u00a0von\u00a0PD \u2010Liganden\u00a0\n(PD\u00a0steht\u00a0f\u00fcr\u00a0 programmed\u00a0cell\u00a0death\u00a0protein ),\u00a0die\u00a0an\u00a0den\u00a0PD\u2010Oberfl\u00e4chenrezeptor\u00a0\nauf\u00a0zytotoxischen\u00a0T\u2010Zellen\u00a0binden \u00a0und\u00a0deren\u00a0Aktivit\u00e4t\u00a0herunterr egulieren.\u00a0PD1\u2010\nAntik\u00f6rper\u00a0wie\u00a0Nivolumab\u00a0und\u00a0Pembrolizumab\u00a0unterbrechen\u00a0diesen\u00a0 Vorgang\u00a0und\u00a0\nsorgen\u00a0daf\u00fcr,\u00a0dass\u00a0T\u2010Zellen\u00a0akti viert\u00a0werden,\u00a0proliferieren\u00a0und \u00a0Tumorzellen\u00a0zerst\u00f6\u2010\nren\u00a0k\u00f6nnen.\u00a0\nEin\u00a0 weiterer\u00a0 \u201eCheckpoint\u201c\u00a0 ist\u00a0 der\u00a0 CTLA\u20104\u2010Rezeptor\u00a0 (Cytotoxic\u00a0 T\u2010Lymphocyte\u2010\nassociated\u00a0antigen\u20104) , \u00a0der\u00a0auf \u00a0T\u2010 Zell en\u00a0expri m i ert\u00a0wi rd\u00a0und\u00a0di ese\u00a0ausbrem sen\u00a0\nkann,\u00a0wenn\u00a0Liganden\u00a0an\u00a0den\u00a0Rezeptor\u00a0binden.\u00a0Der\u00a0CTLA\u20104\u2010Antik\u00f6rp er\u00a0Ipilimumab\u00a0\nverhindert\u00a0 die\u00a0 Ligandenbindung\u00a0 und\u00a0 verst\u00e4rkt\u00a0 so\u00a0 die\u00a0 Immunabwehr \u00a0d u r c h \u00a0T \u2010\nZellen.\u00a0\u00a0\nDie\u00a0Checkpoint\u2010Inhibitoren\u00a0werden\u00a0als\u00a0Infusion\u00a0verabreicht.\u00a0 \n48\u00a0\n\u00a0Talimogen\u00a0laherparepvec\u00a0(T\u2010Vec)\u00a0ist\u00a0eine\u00a0onkolytische\u00a0Immunther apie.\u00a0Es\u00a0handelt\u00a0\nsich\u00a0um\u00a0ein\u00a0gentechnologisch\u00a0ver\u00e4ndertes,\u00a0abgeschw\u00e4chtes\u00a0Herpes \u2010simplex\u2010Virus\u00a0\nTyp\u00a01,\u00a0in\u00a0dessen\u00a0Genom\u00a0die\u00a0codierende\u00a0Sequenz\u00a0f\u00fcr\u00a0den\u00a0humanen\u00a0G ranulozyten\u2010\u00a0\nund\u00a0Makrophagen\u2010koloniestimuliere nden\u00a0Faktor\u00a0(GM\u2010CSF)\u00a0eingef\u00fcgt \u00a0wurde.\u00a0Der\u00a0\nWirkstoff\u00a0wird\u00a0in\u00a0die\u00a0betroffenen\u00a0Hautl\u00e4sionen\u00a0injiziert.\u00a0Vermu tlich\u00a0wirkt\u00a0T\u2010Vec\u00a0\n\u00fcber\u00a0mehrere\u00a0Mechanismen.\u00a0Dazu\u00a0geh\u00f6ren\u00a0ein\u00a0lokale\u00a0Lyse\u00a0von\u00a0Tumo rzellen,\u00a0aber\u00a0\nauch\u00a0eine\u00a0Verst\u00e4rkung\u00a0der\u00a0Immunantwort\u00a0durch\u00a0die\u00a0vermehrte\u00a0Frei setzung\u00a0von\u00a0\nTumorantigenen.\u00a0Die\u00a0Expression\u00a0von\u00a0GM\u2010CSF\u00a0soll\u00a0au\u00dferdem\u00a0die\u00a0Rei fung\u00a0von\u00a0dend\u2010\nritischen\u00a0 Zellen\u00a0 sowie\u00a0 die\u00a0 Immuninfiltration\u00a0 des\u00a0 Tumorgewebes\u00a0 m it\u00a0 CD8\u2010\nLymphozyten\u00a0induzieren.\u00a0\nZulassung\u00a0\nDie\u00a0Mehrheit\u00a0der\u00a0Wirkstoffe\u00a0ist\u00a0f\u00fcr\u00a0die\u00a0Behandlung\u00a0des\u00a0fortgesc hrittenen,\u00a0nicht\u00a0\nresezierbaren\u00a0 oder\u00a0 metastasierten\u00a0 Melanoms\u00a0 bei\u00a0 Erwachsenen\u00a0 zuge lassen.\u00a0 I\u2010\npilimumab\u00a0kann\u00a0au\u00dferdem\u00a0bei\u00a0Juge ndlichen\u00a0ab\u00a012\u00a0Jahren\u00a0eingesetz t\u00a0werden.\u00a0Die\u00a0\nAnwendung\u00a0 von\u00a0 T\u2010Vec\u00a0 ist\u00a0 auf\u00a0 die\u00a0 Behandlung\u00a0 von\u00a0 Erwachsenen\u00a0 mit\u00a0 nicht\u2010\nresezierbarem\u00a0Melanom\u00a0in\u00a0den\u00a0Stadien\u00a0IIIB,\u00a0IIIC\u00a0und\u00a0IVM1a\u00a0mit\u00a0r egionalen\u00a0oder\u00a0\nFernmetastasen\u00a0beschr\u00e4nkt,\u00a0die\u00a0nicht\u00a0das\u00a0Gehirn,\u00a0die\u00a0Knochen,\u00a0d ie\u00a0Lunge\u00a0oder\u00a0die\u00a0\nEingeweide\u00a0betreffen.\u00a0Die\u00a0B\u2010RAF\u2010\u00a0 und\u00a0MEK\u2010Inhibitoren\u00a0sind\u00a0nur\u00a0b ei\u00a0B\u2010RAF\u2010V600\u2010\nMutation\u00a0zugelassen.\u00a0\nAlle\u00a0Wirkstoffe\u00a0k\u00f6nnen\u00a0unter\u00a0ande rem\u00a0als\u00a0Erstlinientherapie\u00a0ein gesetzt\u00a0werden.\u00a0\nIpilimumab\u00a0war\u00a0zun\u00e4chst\u00a0nur\u00a0f\u00fcr\u00a0die\u00a0Zweitlinientherapie\u00a0zugelas sen,\u00a0inzwischen\u00a0\nwurde\u00a0die\u00a0Zulassung\u00a0erweitert.\u00a0Die\u00a0Fachinformation\u00a0von\u00a0Trametin ib\u00a0weist\u00a0darauf\u00a0\nhin,\u00a0dass\u00a0eine\u00a0Monotherapie\u00a0mit\u00a0Trametinib\u00a0keinen\u00a0Vorteil\u00a0f\u00fcr\u00a0P atienten\u00a0bietet,\u00a0\nderen\u00a0 Erkrankung\u00a0 unter\u00a0 einer\u00a0 vorhergehenden\u00a0 Behandlung\u00a0 mit\u00a0 eine m\u00a0 B\u2010RAF\u2010\nInhibitor\u00a0weiter\u00a0fortgeschritten\u00a0ist.\u00a0Eine\u00a0adjuvante\u00a0Therapie\u00a0i st\u00a0gem\u00e4\u00df\u00a0Zulassung\u00a0\nmit\u00a0 Nivolumab,\u00a0 Pembrolizumab\u00a0 sowie\u00a0 der\u00a0 Kombination\u00a0 von\u00a0 Dabrafen ib\u00a0 und\u00a0\nTrametinib\u00a0m\u00f6glich.\u00a0\nEinige\u00a0der\u00a0Wirkstoffe\u00a0sind\u00a0sowohl\u00a0als\u00a0Monotherapie\u00a0als\u00a0auch\u00a0in\u00a0 Kombination\u00a0zuge\u2010\nlassen,\u00a0andere\u00a0dagegen\u00a0k\u00f6nnen\u00a0zulassungskonform\u00a0nur\u00a0als\u00a0Monothe rapie\u00a0bzw.\u00a0nur\u00a0\nals\u00a0Kombinationstherapie\u00a0eingesetzt\u00a0werden\u00a0(Tabelle\u00a04.4).\u00a0\n\u00a0 \u00a0 \n49\u00a0\n\u00a0Tabelle\u00a04.4:\u00a0Zulassung\u00a0der\u00a0Wirkstoffe\u00a0als\u00a0Mono\u2010\u00a0bzw.\u00a0Kombinatio nstherapie\u00a0\u00a0\nMonotherapie\u00a0 Kombinationstherapie\u00a0\nIpilimumab\u00a0 Ipilimumab\u00a0+\u00a0Nivolumab\u00a0\nVemurafenib\u00a0 Dabrafenib\u00a0+\u00a0Trametinib\u00a0\nDabrafenib\u00a0 Cobimetinib\u00a0+\u00a0Vemurafenib\u00a0\nTrametinib\u00a0 Binimetinib\u00a0+\u00a0Encorafenib\u00a0\nPembrolizumab\u00a0 \u00a0\nNivolumab\u00a0 \u00a0\nTalimogen\u00a0laherparepvec\u00a0 \u00a0\nErgebnisse\u00a0der\u00a0fr\u00fchen\u00a0Nutzenbewertung\u00a0\nSechs\u00a0der\u00a0zehn\u00a0Wirkstoffe\u00a0haben\u00a0bei\u00a0der\u00a0fr\u00fchen\u00a0Nutzenbewertung\u00a0 mehrere\u00a0Ver\u2010\nfahren\u00a0durchlaufen.\u00a0Diese\u00a0ergaben\u00a0sich\u00a0teils\u00a0durch\u00a0Zulassungser weiterungen,\u00a0etwa\u00a0\ndurch\u00a0Kombinationstherapien\u00a0oder\u00a0weitere\u00a0Indikationen\u00a0wie\u00a0etwa\u00a0 die\u00a0adjuvante\u00a0\nBehandlung.\u00a0In\u00a0anderen\u00a0F\u00e4llen\u00a0ware n\u00a0die\u00a0urspr\u00fcnglichen\u00a0Bewertun gen\u00a0befristet.\u00a0\nF\u00fcr\u00a0die\u00a0Nutzenbewertung\u00a0wurden\u00a0je\u00a0nach\u00a0Wirkstoff\u00a0und\u00a0Zulassung\u00a0 teilweise\u00a0meh\u2010\nrere\u00a0Subgruppen\u00a0gebildet.\u00a0Dabei\u00a0wurde\u00a0in\u00a0der\u00a0Regel\u00a0unterschiede n,\u00a0ob\u00a0bei\u00a0den\u00a0\nPatienten\u00a0eine\u00a0B\u2010RAF\u2010V600\u2010Muta tion\u00a0vorliegt\u00a0(wenn\u00a0die\u00a0Zulassung \u00a0Mutation\u00a0und\u00a0\nWildtyp\u00a0umfasst)\u00a0und\u00a0ob\u00a0es\u00a0sich\u00a0um\u00a0Erstlinien\u2010\u00a0oder\u00a0Zweitlinien therapie\u00a0handelt.\u00a0\nMono\u2010\u00a0und\u00a0Kombinationstherapien\u00a0wurden\u00a0separat\u00a0bewertet.\u00a0F\u00fcr\u00a0di e\u00a0Subgruppen\u00a0\ngalten\u00a0unterschiedliche\u00a0zweckm\u00e4\u00dfi ge\u00a0Vergleichstherapien\u00a0(zVT).\u00a0\nBei\u00a0drei\u00a0der\u00a0zehn\u00a0Wirkstoffe\u00a0(T\u2010Vec,\u00a0Binimetinib,\u00a0Encorafenib)\u00a0 lie\u00df\u00a0sich\u00a0in\u00a0keiner\u00a0\nSubgruppe\u00a0oder\u00a0Indikation\u00a0ein\u00a0Z usatznutzen\u00a0gegen\u00fcber\u00a0der\u00a0zVT\u00a0na chweisen.\u00a0\u00a0\nWenn\u00a0kein\u00a0Zusatznutzen\u00a0zuerkannt\u00a0wurde,\u00a0war\u00a0der\u00a0Grund\u00a0daf\u00fcr\u00a0in\u00a0 der\u00a0Regel,\u00a0dass\u00a0\nder\u00a0pharmazeutische\u00a0Unternehmer\u00a0keine\u00a0geeignete\u00a0Studie\u00a0durchgef \u00fchrt\u00a0hatte,\u00a0die\u00a0\ndie\u00a0zVT\u00a0ausreichend\u00a0abbildete,\u00a0oder\u00a0dass\u00a0die\u00a0vorgelegten\u00a0Daten\u00a0 methodisch\u00a0nicht\u00a0\ngeeignet\u00a0waren,\u00a0etwa\u00a0bei\u00a0unzurei chend\u00a0adjustierten\u00a0indirekten\u00a0V ergleichen.\u00a0\u00a0\nDass\u00a0neue\u00a0Wirkstoffe\u00a0differenziert\u00a0betrachtet\u00a0werden\u00a0m\u00fcssen,\u00a0ze igt\u00a0das\u00a0Beispiel\u00a0\nMelanom\u00a0eindr\u00fccklich:\u00a0So\u00a0wurde\u00a0keinem\u00a0Wirkstoff\u00a0in\u00a0allen\u00a0Subgru ppen\u00a0und\u00a0Indi\u2010\nkationen\u00a0ein\u00a0Zusatznutzen\u00a0anerkannt\u00a0(Tabelle\u00a04.3).\u00a0Hinweise\u00a0ode r\u00a0Anhaltspunkte\u00a0\nf\u00fcr\u00a0einen\u00a0betr\u00e4chtlichen\u00a0Zusatznutzen\u00a0gab\u00a0es\u00a0f\u00fcr\u00a0sechs\u00a0Wirkstof fe\u00a0bzw.\u00a0Wirkstoff\u2010\nKombinationen,\u00a0 aber\u00a0 nur\u00a0 in\u00a0 ausgew\u00e4hlten\u00a0 Subgruppen.\u00a0 Beispiele\u00a0 s ind\u00a0 etwa\u00a0\nVemurafenib\u00a0 plus\u00a0 Cobimetinib\u00a0 oder\u00a0 Dabrafenib\u00a0 plus\u00a0 Trametinib\u00a0 je weils\u00a0 in\u00a0 der\u00a0\nErstlinientherapie\u00a0bei\u00a0B\u2010RAF\u2010Mutation.\u00a0Pembrolizumab\u00a0wurde\u00a0ein\u00a0 betr\u00e4chtlicher\u00a0 \n50\u00a0\n\u00a0Zusatznutzen\u00a0nur\u00a0in\u00a0der\u00a0Zweitlinientherapie\u00a0sowie\u00a0bei\u00a0BRAF\u2010Wild typ\u00a0in\u00a0der\u00a0Erstli\u2010\nnientherapie\u00a0zuerkannt.\u00a0\nUnterschiede\u00a0im\u00a0Ausma\u00df\u00a0des\u00a0Zusatznutzens\u00a0zeigten\u00a0sich\u00a0in\u00a0der\u00a0ad juvanten\u00a0Thera\u2010\npie:\u00a0 So\u00a0 wurde\u00a0 f\u00fcr\u00a0 Dabrafenib\u00a0 und\u00a0 Trametinib\u00a0 ein\u00a0 betr\u00e4chtlicher\u00a0 Zusatznutzen\u00a0\nfestgestellt,\u00a0f\u00fcr\u00a0Pembrolizumab\u00a0 und\u00a0Nivolumab\u00a0war\u00a0er\u00a0nicht\u00a0quan tifizierbar.\u00a0\nDass\u00a0manchmal\u00a0neue\u00a0Therapien\u00a0\u00e4lteren\u00a0auch\u00a0unterlegen\u00a0sein\u00a0k\u00f6nne n,\u00a0wird\u00a0am\u00a0\nBeispiel\u00a0der\u00a0Kombination\u00a0von\u00a0Ip ilimumab\u00a0und\u00a0Nivolumab\u00a0deutlich: \u00a0Hier\u00a0wurde\u00a0in\u00a0\nder\u00a0Erstlinientherapie\u00a0beim\u00a0B\u2010RA F\u2010Wildtyp\u00a0sogar\u00a0ein\u00a0geringerer\u00a0 Nutzen\u00a0als\u00a0f\u00fcr\u00a0die\u00a0\nzVT\u00a0 Nivolumab\u2010Monotherapie\u00a0 festg estellt.\u00a0 Tragende\u00a0 Gr\u00fcnde\u00a0 waren\u00a0 das\u00a0 ausge\u2010\npr\u00e4gte\u00a0Nebenwirkungspotenzial,\u00a0w\u00e4 hrend\u00a0gleichzeitig\u00a0positive\u00a0Ef fekte\u00a0fehlten.\u00a0\n\u00a0 \u00a0 \n51\u00a0\n\u00a0Tabelle\u00a04.5:\u00a0\u00dcbersicht\u00a0der\u00a0Nutzenbewertungen\u00a0zum\u00a0malignen\u00a0Melan om\u00a0\nWirkstoff(\u2010kombination)\u00a0 Beschlussdatum\u00a0\n(ggf.\u00a0Teil\u2010Indikation)\u00a0\u00a0Zusatznutzen\u00a0\nbei\u00a0B\u2010RAF\u2010V600\u2010\nMutation\u00a0bei\u00a0B\u2010RAF\u2010V600\u2010Wildtyp\u00a0\nIpilimumab\u00a0 2011\u00a0(Zweitlinie)\u00a0 betr\u00e4chtlich\u00a0(Hinweis)***\u00a0\n\u00a0 2013\u00a0(Erstlinie)\u00a0 nicht\u00a0belegt\u00a0 nicht\u00a0belegt\u00a0\n\u00a0 2018\u00a0(ab\u00a012\u00a0Jahre)\u00a0\u00a0 nicht\u00a0belegt***\u00a0\nIpilimumab\u00a0plus\u00a0\nNivolumab\u00a0\u00a02018\u00a0(Erstlinie)\u00a0\u00a0 nicht\u00a0belegt\u00a0 geringer\u00a0Nutzen\u00a0(Hinweis)\u00a0\n\u00a0 2018\u00a0(Zweitlinie)\u00a0 nicht\u00a0belegt***\u00a0\nNivolumab\u00a0\u00a0 2015\u00a0(Erstlinie)\u00a0 nicht\u00a0belegt\u00a0 betr\u00e4chtlich\u00a0(Hinweis)\u00a0\n\u00a0 2019\u00a0(adjuvant)*\u00a0 nicht\u00a0quantifizierbar\u00a0(Anhaltspunkt)***\u00a0\nVemurafenib\u00a0\u00a0 2014\u00a0 betr\u00e4chtlich\u00a0(Hinweis)\u00a0 n.z.\u00a0\nVemurafenib\u00a0plus\u00a0\nCobimetinib\u00a02015\u00a0 betr\u00e4chtlich\u00a0(Hinweis)\u00a0 n.z.\u00a0\nDabrafenib\u00a0 2013\u00a0 nicht\u00a0belegt\u00a0 n.z.\u00a0\nDabrafenib\u00a0plus\u00a0\nTrametinib\u00a02015\u00a0 betr\u00e4chtlich\u00a0(Hinweis)\u00a0 n.z.\u00a0\n\u00a0 2018\u00a0(adjuvant)**\u00a0 betr\u00e4chtlich\u00a0(Hinweis)\u00a0 n.z.\u00a0\nTrametinib\u00a0 2015\u00a0 nicht\u00a0belegt\u00a0 n.z.\u00a0\nPembrolizumab\u00a0 2016\u00a0(Erstlinie)\u00a0 nicht\u00a0belegt\u00a0 betr\u00e4chtlich\u00a0(Anhaltspunkt)\u00a0\n\u00a0 2016\u00a0(Zweitlinie)\u00a0 betr\u00e4chtlich\u00a0(Hinweis)***\u00a0\n\u00a0 2019\u00a0(adjuvant)**\u00a0 nicht\u00a0quantifizierbar\u00a0(Hinweis)***\u00a0\nTalimogen\u00a0laherparepvec\u00a0 2016\u00a0(Ers tlinie)\u00a0 nicht\u00a0belegt\u00a0 nicht\u00a0bel egt\u00a0\n\u00a0 2016\u00a0(Zweitlinie)\u00a0 nicht\u00a0belegt***\u00a0\nBinimetinib\u00a0plus\u00a0\nEncorafenib\u00a02019\u00a0(Erstlinie)\u00a0 nicht\u00a0belegt\u00a0 n.z.\u00a0\n\u00a0 2019\u00a0(Zweitlinie)\u00a0 nicht\u00a0belegt\u00a0 n.z.\u00a0\n*\u00a0befristet\u00a0bis\u00a0April\u00a02021,\u00a0neue\u00a0Beschlussfassung\u00a0Mitte\u00a0Septemb er\u00a02021\u00a0geplant\u00a0**\u00a0befristet\u00a0bis\u00a0April\u00a02024\u00a0***\u00a0nur\u00a0eine\u00a0Bewert ung\u00a0\nn.z.:\u00a0nicht\u00a0zugelassen.\u00a0Nutzenbewertungen\u00a0f\u00fcr\u00a0Erwachsene,\u00a0wenn\u00a0 nicht\u00a0anders\u00a0benannt.\u00a0Ergebnisse\u00a0von\u00a0aufgehobenen\u00a0Beschl\u00fcs\u2010\nsen\u00a0sind\u00a0nicht\u00a0aufgef\u00fchrt,\u00a0bei\u00a0Neubewertungen\u00a0nach\u00a0Fristablauf\u00a0 nur\u00a0der\u00a0jeweils\u00a0letzte\u00a0Stand.\u00a0\u00a0 \n52\u00a0\n\u00a0Tabelle\u00a04.6:\u00a0Bewertungen\u00a0und\u00a0Preise\u00a0neuer\u00a0Arzneimittel\u00a0mit\u00a0Indi kation\u00a0malignes\u00a0Melanom\u00a0\nWirkstoff\u00a0\u00a0\n(Pr\u00e4parat)\u00a0\n[pU]\u00a0Markt\u2010\u00a0\nEintritt\u00a0GKV\u00a0netto\u00a0je\u00a0DDD\u00a0\n[\u20ac]\u00a02020\u00a0real\u2010life\u00a0ApoVK\u00a0bei\u00a0\nMarkteintritt\u00a0Preis\u2010\u00a0\nReduktion\u00a0durch\u00a0\u00a0\nErstattungs\u2010\u00a0\nbetrag\u00a0Jahresthera\u2010\npiekosten\u00a0im\u00a0\nG\u2010BA\u2010\nBeschluss\u00a0Bewertung \u00a0\nVerf\u00fcgbare\u00a0\nTherapien\u00a0(Zusatz\u2010)\u00a0\nNutzen\u00a0Kosten\u00a0 Gesamtscore\u00a0\nB\u2010RAF\u2010Inhibitoren \u00a0\nVemurafenib\u00a0\n(Zelboraf\u00ae)\u00a0[Roche]\u00a02012\u00a0 198,86\u00a0\u20ac\u00a0 2.888,20\u00a0\u20ac\u00a0 49\u00a0%\u00a094.069,36\u00a0\u20ac\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\nDabrafenib\u00a0\n(Tafinlar\u00ae)\u00a0\u00a0\n[Novartis] \u00a02013\u00a0 191,90\u00a0\u20ac\u00a0 8.551,42\u00a0\u20ac\u00a0 32\u00a0%\u00a098.118,33\u00a0\u00a0bis\u00a0\n132.634,71\u00a0\u20ac\u00a0 \u00a0 \u00a0 \u00a0 \u00a0\nEncorafenib\u00a0\n(Braftovi\u00ae)\u00a0[Pierre\u2010Fabre]\u00a02018\u00a0 230,96\u00a0\u20ac\u00a0 2.024,17\u00a0\u20ac\u00a0 9\u00a0%\u00a0Kombi\u00a0+\u00a0\nBinimetinib\u00a0\n173.798,40\u00a0\u20ac\u00a0Aufgrund\u00a0des\u00a0sp\u00e4ten\u00a0Markteintritts\u00a0noch\u00a0nicht\u00a0in\u00a0den\u00a0\nInnovationsreporten\u00a0bewertet\u00a0\nGentherapie\u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0\u00a0\nTalimogen\u00a0laher\u2010parepvec/T\u2010Vec.\u00a0(Imlygic\u00ae)\u00a0[Amgen\u00a0Europe]\u00a02016\u00a0 187,22\u00a0\u20ac\u00a0 2.949,97\u00a0\u20ac\u00a0 49\u00a0%\u00a072.287,80\u00a0bis\u00a0\n289.151,20\u00a0\u20ac\u00a0\u00a0\u00a0\u00a0\u00a0\nMEK\u2010Inhibitoren\u00a0 \u00a0\nTrametinib\u00a0\n(Mekinist\u00ae)\u00a0[Novartis)\u00a02014\u00a0 144,02\u00a0\u20ac\u00a0 9.156,63\u00a0\u20ac\u00a0 53\u00a0%\u00a0105.061,60\u00a0\u20ac\u00a0\nKombi\u00a0+\u00a0\nDabrafenib\u00a0\n196.129,59\u00a0\u20ac\u00a0\u00a0\u00a0\u00a0\u00a0\nCobimetinib\u00a0\n(Cotellic\u00ae)\u00a0\n[Roche]\u00a02015\u00a0 193,69\u00a0\u20ac\u00a0 7.164,93\u00a0\u20ac\u00a0 19\u00a0%\u00a0 Kombi\u00a0+\u00a0\nVemurafenib\u00a0\n180.952,49\u00a0\u20ac\u00a0\u00a0 \u00a0 \u00a0 \u00a0 \n53\u00a0\n\u00a0Wirkstoff\u00a0\u00a0\n(Pr\u00e4parat)\u00a0\n[pU]\u00a0Markt\u2010\u00a0\nEintritt\u00a0GKV\u00a0netto\u00a0je\u00a0DDD\u00a0\n[\u20ac]\u00a02020\u00a0real\u2010life\u00a0ApoVK\u00a0bei\u00a0\nMarkteintritt\u00a0Preis\u2010\u00a0\nReduktion\u00a0durch\u00a0\u00a0\nErstattungs\u2010\u00a0\nbetrag\u00a0Jahresthera\u2010\npiekosten\u00a0im\u00a0\nG\u2010BA\u2010\nBeschluss\u00a0Bewertung \u00a0\nVerf\u00fcgbare\u00a0\nTherapien\u00a0(Zusatz\u2010)\u00a0\nNutzen\u00a0Kosten\u00a0 Gesamtscore\u00a0\nBinimetinib\u00a0\n(Mektovi\u00ae)\u00a0[Pierre\u2010Fabre]\u00a02018\u00a0 103,92\u00a0\u20ac\u00a0 3.803,68\u00a0\u20ac\u00a0 2\u00a0%\u00a0Kombi\u00a0+\nEncorafenib\u00a0\n173.798,40\u00a0\u20ac\u00a0Aufgrund\u00a0des\u00a0sp\u00e4ten\u00a0Markteintritts\u00a0noch\u00a0nicht\u00a0in\u00a0den\u00a0\nInnovationsreporten\u00a0bewertet\u00a0\nCheckpoint\u2010Inhibitoren\u00a0(PD1\u2010Hemmer) \u00a0\nIpilimumab\u00a0\n(Yervoy\u00ae)\u00a0\n[Bristol\u2010Myers\u2010\nSquibb]\u00a02011\u00a0 428,31\u00a0\u20ac\u00a0 20.757,68\u00a0\u20ac\u00a0 27\u00a0%\u00a0 82.461,56\u00a0bis\u00a0\n91.022,76\u00a0\u20ac;\u00a0in\u00a0\nKombi\u00a0+\u00a0\nNivolumab\u00a0\n136.540,64\u00a0\u20ac\u00a0\u00a0 \u00a0 \u00a0 \u00a0\nPembrolizumab\u00a0\n(Keytruda\u00ae)\u00a0[Merck\u00a0Sharp\u00a0&\u00a0Dohme\u00a02015\u00a0 263,73\u00a0\u20ac\u00a0 1.785,00\u00a0\u20ac\u00a0 32\u00a0%\u00a0 103.757,46\u00a0bis\u00a0\n144.056,64\u00a0\u20ac\u00a0\u00a0\u00a0\n\u00a0\u00a0\nNivolumab\u00a0\n(Opdivo\u00ae)\u00a0\n[Bristol\u2010Myers\u2010\nSquibb]\u00a02015\u00a0 206,56\u00a0\u20ac\u00a0 1.803,94\u00a0\u20ac\u00a0 26\u00a0%\u00a079.308,84\u00a0bis\u00a0\n106.465,3\u00a0\u20ac;\u00a0\nKombi\u00a0+\u00a0\nIpilimumab\u00a0\n155.133,04\u00a0\u20ac\u00a0\u00a0 \u00a0 \u00a0 \u00a0\n\u00a0\n\u00a0 \n54\u00a0\n\u00a0Die\u00a0Fortschritte\u00a0beim\u00a0therapeuti schen\u00a0Nutzen\u00a0schlagen\u00a0sich\u00a0auch \u00a0in\u00a0Ver\u00e4nderun\u2010\ngen\u00a0der\u00a0zVT\u00a0im\u00a0Verlauf\u00a0der\u00a0Jahre\u00a0nieder.\u00a0Wurde\u00a0f\u00fcr\u00a0die\u00a0Nutzenbe wertung\u00a0in\u00a0der\u00a0\nErstlinientherapie\u00a0 als\u00a0 zVT\u00a0 zu\u00a0 Beginn\u00a0 noch\u00a0 Dacarbazin\u00a0 unabh\u00e4ngig \u00a0v o m \u00a0B \u2010 R A F \u2010\nStatus\u00a0herangezogen,\u00a0differenzie rte\u00a0sie\u00a0sich\u00a0nachfolgend\u00a0weiter \u00a0auf:\u00a0\u00a0\nZun\u00e4chst\u00a0wurde\u00a0Ipilimumab\u00a0als\u00a0zVT\u00a0beim\u00a0B\u2010RAF\u2010Wildtyp\u00a0festgelegt ,\u00a0inzwischen\u00a0ist\u00a0\nes\u00a0Pembrolizumab\u00a0oder\u00a0Nivolumab.\u00a0Bei\u00a0B\u2010RAF\u2010V600\u2010Mutation\u00a0etabli erte\u00a0sich\u00a0zu\u2010\nn\u00e4chst\u00a0Vemurafenib\u00a0als\u00a0zVT,\u00a0inzwischen\u00a0sind\u00a0es\u00a0die\u00a0Kombinatione n\u00a0Vemurafenib\u00a0+\u00a0\nCobimetinib\u00a0oder\u00a0Dabrafenib\u00a0+\u00a0Tr ametinib.\u00a0Die\u00a0neueren\u00a0Therapien \u00a0hatten\u00a0in\u00a0den\u00a0\nNutzenbewertungsverfahren\u00a0allesamt\u00a0einen\u00a0Zusatznutzen\u00a0f\u00fcr\u00a0die\u00a0j eweilige\u00a0Sub\u2010\ngruppe\u00a0gegen\u00fcber\u00a0der\u00a0damals\u00a0festge legten\u00a0zVT\u00a0zuerkannt\u00a0bekommen .\u00a0\nErkenntnisse\u00a0zur\u00a0Sicherheit\u00a0nach\u00a0der\u00a0Zulassung\u00a0\nSeit\u00a0der\u00a0Zulassung\u00a0ergaben\u00a0sich\u00a0f\u00fcr\u00a0viele\u00a0der\u00a0neuen\u00a0Wirkstoffe\u00a0 beziehungsweise\u00a0\nderen\u00a0Kombinationen\u00a0neue\u00a0Erk enntnisse\u00a0zur\u00a0Sicherheit.\u00a0\nRote\u2010Hand\u2010Briefe\u00a0wurden\u00a0f\u00fcr\u00a0zwei \u00a0Wirkstoffe\u00a0versandt:\u00a0F\u00fcr\u00a0Vemur afenib\u00a0im\u00a0Au\u2010\ngust\u00a02013\u00a0wegen\u00a0des\u00a0Risikos\u00a0f\u00fcr\u00a0eine\u00a0Progression\u00a0maligner\u00a0Erkra nkungen\u00a0und\u00a0\nArzneimittelausschlag\u00a0 mit\u00a0 Eosinophilie\u00a0 und\u00a0 systemischen\u00a0 Symptom en\u00a0 (DRESS\u2010\nSyndrom)\u00a0sowie\u00a0f\u00fcr\u00a0Cobimetinib\u00a0im\u00a0April\u00a02017\u00a0wegen\u00a0des\u00a0Risikos\u00a0 von\u00a0schweren\u00a0\nBlutungsereignissen\u00a0und\u00a0Rhabdomyolyse.\u00a0\nDie\u00a0Arzneimittelkommission\u00a0der\u00a0deutschen\u00a0\u00c4rzteschaft\u00a0versandte\u00a0 dar\u00fcber\u00a0hinaus\u00a0\nweitere\u00a0Drug\u00a0Safety\u00a0Mails,\u00a0die\u00a0vier\u00a0der\u00a0zehn\u00a0Wirkstoffe\u00a0betrafe n.\u00a0In\u00a0vielen\u00a0dieser\u00a0\nF\u00e4lle\u00a0waren\u00a0die\u00a0Fachinformationen\u00a0um\u00a0entsprechende\u00a0Warnhinweise \u00a0oder\u00a0Ne\u2010\nbenwirkungen\u00a0erg\u00e4nzt\u00a0worden.\u00a0Eine\u00a0Drug\u00a0Safety\u00a0Mail\u00a0thematisiert e\u00a0eine\u00a0Reihe\u00a0\nneuer\u00a0 Risikosignale\u00a0 als\u00a0 Klassene ffekt\u00a0 der\u00a0 Checkpoint\u2010Inhibitore n\u00a0 Nivolumab,\u00a0\nPembrolizumab\u00a0und\u00a0Ipilimumab.\u00a0\nF\u00fcr\u00a0Vemurafenib,\u00a0Pembrolizumab\u00a0und\u00a0Nivolumab\u00a0wurden\u00a0jeweils\u00a0meh r\u00a0als\u00a0eine\u00a0\nDrug\u00a0Safety\u00a0Mail\u00a0versandt.\u00a0\nBewertungen\u00a0in\u00a0fr\u00fcheren\u00a0Innovationsreporten\u00a0\nAcht\u00a0der\u00a0zehn\u00a0Wirkstoffe\u00a0wurden\u00a0in\u00a0fr\u00fcheren\u00a0Innovationsreporten \u00a0bewertet.\u00a0F\u00fcr\u00a0\nBinimetinib\u00a0und\u00a0Encorafenib\u00a0lieg en\u00a0aufgrund\u00a0des\u00a0sp\u00e4ten\u00a0Marktein tritts\u00a0noch\u00a0keine\u00a0\nBewertungen\u00a0vor.\u00a0\nHinsichtlich\u00a0der\u00a0verf\u00fcgbaren\u00a0Ther apien\u00a0erhielten\u00a0zwei\u00a0Wirkstoff e\u00a0(Trametinib\u00a0und\u00a0\nT\u2010Vec)\u00a0als\u00a0neuartige\u00a0Therapieoptionen\u00a0eine\u00a0gr\u00fcne\u00a0Ampel,\u00a0zwei\u00a0we itere\u00a0(Ipilimum\u2010\nab\u00a0und\u00a0Dabrafenib)\u00a0eine\u00a0rote\u00a0Ampel,\u00a0die\u00a0restlichen\u00a0Wirkstoffe\u00a0w urden\u00a0mit\u00a0einer\u00a0\ngelben\u00a0Ampel\u00a0bewertet.\u00a0 \n55\u00a0\n\u00a0In\u00a0der\u00a0Bewertung\u00a0des\u00a0Nutzens\u00a0wurde\u00a0zwei\u00a0Wirkstoffen\u00a0(Vemurafeni b,\u00a0Cobimeti\u2010\nnib)\u00a0eine\u00a0gr\u00fcne\u00a0Ampel\u00a0zuerkannt,\u00a0ein\u00a0Wirkstoff\u00a0(T\u2010Vec)\u00a0mit\u00a0eine r\u00a0roten\u00a0Ampel\u00a0und\u00a0\ndie\u00a0restlichen\u00a0Wirkstoffe\u00a0mit\u00a0einer\u00a0gelben\u00a0Ampel\u00a0bewertet.\u00a0\nEinschr\u00e4nkend\u00a0ist\u00a0zu\u00a0bemerken,\u00a0dass\u00a0einige\u00a0Wirkstoffe\u00a0nicht\u00a0aus schlie\u00dflich\u00a0f\u00fcr\u00a0das\u00a0\nmaligne\u00a0Melanom,\u00a0sondern\u00a0auch\u00a0 f\u00fcr\u00a0die\u00a0Behandlung\u00a0anderer\u00a0Krebsa rten\u00a0zugelas\u2010\nsen\u00a0sind\u00a0und\u00a0die\u00a0Bewertung\u00a0teils\u00a0\u00fcber\u00a0mehrere\u00a0Indikationen\u00a0hinw eg\u00a0erfolgte.\u00a0\nHinsichtlich\u00a0der\u00a0verf\u00fcgbaren\u00a0Therapien\u00a0wurde\u00a0in\u00a0der\u00a0Regel\u00a0wirks toffbezogen\u00a0be\u2010\nwertet,\u00a0auch\u00a0wenn\u00a0der\u00a0Wirkstoff\u00a0 in\u00a0Kombination\u00a0mit\u00a0anderen\u00a0eing esetzt\u00a0wird.\u00a0\nBewertungen\u00a0von\u00a0unabh\u00e4ngigen\u00a0Arzneimittelzeitschriften\u00a0\nIn\u00a0der\u00a0arznei\u2010telegramm\u00a0Datenbank\u00a0werden\u00a0zur\u00a0Behandlung\u00a0des\u00a0mal ignen\u00a0Mela\u2010\nnoms\u00a0bei\u00a0den\u00a0B\u2010RAF\u2010/MEK\u2010Inhibitor\u2010Kombinationen\u00a0Dabrafenib\u00a0und\u00a0 Trametinib\u00a0als\u00a0\nMittel\u00a0 der\u00a0 Wahl\u00a0 eingestuft,\u00a0 Vemurafenib/Cobimetinib\u00a0 sowie\u00a0 Binim eti\u2010\nnib/Encorafenib\u00a0als\u00a0Varianten\u00a0o hne\u00a0besonderen\u00a0Stellenwert.\u00a0F\u00fcr\u00a0 Nivolumab\u00a0und\u00a0\nPembrolizumab\u00a0werden\u00a0Hinweise\u00a0f\u00fcr\u00a0eine\u00a0Lebensverl\u00e4ngerung\u00a0im\u00a0Ve rgleich\u00a0zu\u00a0\n\u00e4lteren\u00a0Standards\u00a0anerkannt.\u00a0T\u2010Vec\u00a0und\u00a0Ipilimumab\u00a0werden\u00a0als\u00a0um strittenes\u00a0The\u2010\nrapieprinzip\u00a0eingestuft.\u00a0\u00a0\nDie\u00a0Zeitschrift\u00a0Prescrire\u00a0stufte\u00a02020\u00a0die\u00a0Kombination\u00a0aus\u00a0Dabra fenib\u00a0und\u00a0Trameti\u2010\nnib\u00a0als\u00a0\u201epossibly\u00a0helpful \u201c\u00a0ein,\u00a0nachdem\u00a0sie\u00a02016\u00a0f\u00fcr\u00a0die\u00a0Kombination\u00a0Cobimetinib\u00a0+\u00a0\nVemurafenib\u00a0das\u00a0Urteil\u00a0\u201e nothing\u00a0new \u201c\u00a0gef\u00e4llt\u00a0hatte.\u00a0\u00a0\nBei\u00a0den\u00a0Checkpoint\u2010Inhibitoren\u00a0wurde\u00a0Nivolumab\u00a02016\u00a0als\u00a0\u201e a\u00a0real\u00a0advance \u201c\u00a0be\u2010\nwertet,\u00a0Ipilimumab\u00a02015\u00a0als\u00a0\u201e possibly\u00a0helpful \u201c.\u00a02018\u00a0wurde\u00a0aber\u00a0eine\u00a0Warnung\u00a0vor\u00a0\nder\u00a0Kombination\u00a0beider\u00a0Wirkstoffe\u00a0ausgesprochen.\u00a0Pembrolizumab\u00a0 erhielt\u00a02017\u00a0\ndie\u00a0Einstufung\u00a0\u201e nothing\u00a0new \u201c.\u00a0Als\u00a0adjuvante\u00a0Therapie\u00a0wurden\u00a0Nivolumab\u00a0und\u00a0\nPembrolizumab\u00a0in\u00a0Prescrire\u00a0noch\u00a0nicht\u00a0abschlie\u00dfend\u00a0bewertet\u00a0(\u201e judgment\u00a0reser\u2010\nved\u201c).\u00a0\nBinimetinib\u00a0und\u00a0Encora fenib\u00a0sowie\u00a0T\u2010Vec\u00a0wurden\u00a0in\u00a0Prescrire\u00a0bis her\u00a0nicht\u00a0bewertet.\u00a0\nStellenwert\u00a0in\u00a0der\u00a0Therapie\u00a0\nDass\u00a0einige\u00a0der\u00a0neuen\u00a0Wirkstoffe\u00a0b zw.\u00a0Wirkstoff\u2010Kombinationen\u00a0e inen\u00a0therapeuti\u2010\nschen\u00a0 Fortschritt\u00a0 darstellen,\u00a0 spiegelt\u00a0 sich\u00a0 auch\u00a0 in\u00a0 aktuellen\u00a0 L eitlinien\u2010\nEmpfehlungen\u00a0wider.\u00a0In\u00a0den\u00a0Deta ils\u00a0gibt\u00a0es\u00a0jedoch\u00a0kleinere\u00a0Unte rschiede.\u00a0\nDie\u00a0deutsche\u00a0onkologische\u00a0Leitlinie\u00a0zum\u00a0Melanom\u00a0(Leitlinienprog ramm\u00a0Onkologie,\u00a0\n2020)\u00a0empfiehlt\u00a0f\u00fcr\u00a0die\u00a0adjuvante\u00a0Therapie\u00a0in\u00a0den\u00a0Stadien\u00a0III\u00a0A \u2010D\u00a0sowie\u00a0IV\u00a0mit\u00a0\nvollst\u00e4ndiger\u00a0Resektion\u00a0PD1\u2010Anti k\u00f6rper,\u00a0bei\u00a0B\u2010RAF\u2010V600\u2010Mutation \u00a0alternativ\u00a0die\u00a0 \n56\u00a0\n\u00a0Kombination\u00a0 aus\u00a0 einem\u00a0 B\u2010RAF\u2010\u00a0 und\u00a0 MEK\u2010Inhibitor.\u00a0 T\u2010Vec\u00a0 erh\u00e4lt\u00a0 ei ne\u00a0 Kann\u2010\nEmpfehlung\u00a0als\u00a0weitere\u00a0Therapieo ption\u00a0bei\u00a0lokoregionalen\u00a0Metast asen.\u00a0\nF\u00fcr\u00a0die\u00a0systemische\u00a0medikament\u00f6se\u00a0Therapie\u00a0in\u00a0Stadium\u00a0IV\u00a0wird\u00a0b ei\u00a0einer\u00a0B\u2010RAF\u2010\nV600\u2010Mutation\u00a0die\u00a0Kombination\u00a0eines\u00a0B\u2010RAF\u2010\u00a0mit\u00a0einem\u00a0MEK\u2010Inhibi tor\u00a0oder\u00a0eine\u00a0\nCheckpoint\u2010Inhibitor\u2010Therapie\u00a0 (PD1\u2010Antik\u00f6rper\u2010Monotherapie\u00a0 oder \u00a0 Kombination\u00a0\naus\u00a0 PD1\u2010Antik\u00f6rper+CTLA\u20104\u2010Antik\u00f6 rper)\u00a0 empfohlen.\u00a0 Die\u00a0 Leitlinie\u00a0 gibt\u00a0 an,\u00a0 dass\u00a0\naktuell\u00a0keine\u00a0Daten\u00a0zur\u00a0besten\u00a0s equentiellen\u00a0Therapie\u00a0von\u00a0B\u2010RAF /MEK\u2010Inhibitoren\u00a0\nund\u00a0Checkpoint\u2010Inhibitoren\u00a0vorliegen.\u00a0Bei\u00a0nicht\u2010resezierbaren\u00a0M etasen\u00a0soll\u00a0die\u00a0\nOption\u00a0einer\u00a0Immuntherapie\u00a0mit\u00a0Checkpoint\u2010Inhibitoren\u00a0gepr\u00fcft\u00a0w erden.\u00a0Dabei\u00a0\nwerden\u00a0PD\u20101\u2010Antik\u00f6rper\u00a0oder\u00a0deren\u00a0Kombination\u00a0mit\u00a0Ipilimumab\u00a0ei ner\u00a0Monothe\u2010\nrapie\u00a0mit\u00a0Ipilimumab\u00a0vorgezogen.\u00a0\nDar\u00fcber\u00a0hinaus\u00a0werden\u00a0Pr\u00e4ferenzen\u00a0f\u00fcr\u00a0bestimmte\u00a0Wirkstoffe\u00a0in\u00a0d en\u00a0aufgef\u00fchrten\u00a0Wirk\u2010\nstoffklassen\u00a0in\u00a0der\u00a0deutschen\u00a0onk ologischen\u00a0Leitlinie\u00a0zum\u00a0Melan om\u00a0nicht\u00a0formuliert.\u00a0\nIn\u00a0 der\u00a0 europ\u00e4ischen\u00a0 Leitlini e,\u00a0 herausgegeben\u00a0 durch\u00a0 das\u00a0 European\u00a0 Dermatology\u00a0\nForum\u00a0(EDF),\u00a0die\u00a0 European\u00a0Association\u00a0of\u00a0Dermato\u2010Oncology \u00a0(EADO)\u00a0und\u00a0die\u00a0 Euro\u2010\npean\u00a0Organization\u00a0of\u00a0Research\u00a0and\u00a0Treatment\u00a0of\u00a0Cancer \u00a0(EORTC)\u00a0(Garbe\u00a0et\u00a0al.,\u00a02020)\u00a0\nwird\u00a0f\u00fcr\u00a0die\u00a0adjuvante\u00a0Therapie\u00a0in\u00a0den\u00a0Stadien\u00a0IIIA\u2010D\u00a0und\u00a0Stadi um\u00a0IV\u00a0nach\u00a0vollst\u00e4ndi\u2010\nger\u00a0Resektion\u00a0eine\u00a0PD1\u2010Antik\u00f6rper\u2010Therapie\u00a0empfohlen,\u00a0unabh\u00e4ngi g\u00a0davon,\u00a0ob\u00a0eine\u00a0\nB\u2010RAF\u2010V600\u2010Mutation\u00a0vorliegt.\u00a0In\u00a0den\u00a0Stadien\u00a0IIIA\u2010D\u00a0kann\u00a0bei\u00a0Vo rliegen\u00a0der\u00a0Mutation\u00a0\nauch\u00a0eine\u00a0Kombination\u00a0von\u00a0B\u2010RAF\u2010 \u00a0und\u00a0MEK\u2010Inhibitor\u00a0eingesetzt\u00a0w erden.\u00a0\nF\u00fcr\u00a0 die\u00a0 systemische\u00a0 Behandlung\u00a0 in\u00a0 Stadium\u00a0 IV\u00a0 wird\u00a0 eine\u00a0 Immunthe rapie\u00a0 mit\u00a0\nCheckpoint\u2010Inhibitoren\u00a0 als\u00a0 Erstlinientherapie\u00a0 empfohlen:\u00a0 entwed er\u00a0 eine\u00a0 PD1\u2010\nAntik\u00f6rper\u2010Monotherapie\u00a0oder\u00a0die \u00a0Kombination\u00a0mit\u00a0Ipilimumab.\u00a0Be i\u00a0Patienten\u00a0mit\u00a0\nB\u2010RAF\u2010V600\u2010Mutation\u00a0 kann\u00a0 in\u00a0 besti mmten\u00a0 F\u00e4llen,\u00a0 etwa\u00a0 bei\u00a0 einem\u00a0 a ggressiven\u00a0\nKrankheitsverlauf,\u00a0alternativ\u00a0zu\u00a0 den\u00a0Checkpoint\u2010Inhibitoren\u00a0auc h\u00a0die\u00a0Kombination\u00a0\naus\u00a0B\u2010RAF\u2010\u00a0und\u00a0MEK\u2010Inhibitor\u00a0als\u00a0Erstlinientherapie\u00a0angeboten\u00a0w erden.\u00a0Als\u00a0Zweit\u2010\nlinientherapie\u00a0wird\u00a0die\u00a0Kombination\u00a0aus\u00a0B\u2010RAF\u2010\u00a0und\u00a0MEK\u2010Inhibito r\u00a0empfohlen,\u00a0\nwenn\u00a0die\u00a0Erkrankung\u00a0auf\u00a0eine\u00a0Immuntherapie\u00a0nicht\u00a0anspricht.\u00a0Die \u00a0Leitlinie\u00a0weist\u00a0\ndarauf\u00a0 hin,\u00a0 dass\u00a0 die\u00a0 optimale\u00a0 Abfolge\u00a0 von\u00a0 Immuntherapie\u00a0 und\u00a0 B\u2010R AF\u2010/MEK\u2010\nInhibitoren\u00a0 bei\u00a0 B\u2010RAF\u2010V600\u2010Mutat ion\u00a0 derzeit\u00a0 noch\u00a0 in\u00a0 Studien\u00a0unt ersucht\u00a0 wird.\u00a0\nPr\u00e4ferenzen\u00a0f\u00fcr\u00a0bestimmte\u00a0Wirkst offe\u00a0in\u00a0den\u00a0aufgef\u00fchrten\u00a0Wirkst offklassen\u00a0wer\u2010\nden\u00a0nicht\u00a0formuliert.\u00a0\nT\u2010Vec\u00a0wird\u00a0als\u00a0eine\u00a0von\u00a0mehreren \u00a0Therapieoptionen\u00a0bei\u00a0Hautmetas tasen\u00a0genannt,\u00a0\nje\u00a0nach\u00a0Anzahl,\u00a0Gr\u00f6\u00dfe\u00a0und\u00a0Lokalisation.\u00a0\nDie\u00a0Clinical\u00a0Practice\u00a0Guideline \u00a0der\u00a0ESMO\u00a0(Michielin\u00a0et\u00a0al.,\u00a02019)\u00a0f\u00fcr\u00a0das\u00a0kutane\u00a0\nMelanom\u00a0empfiehlt\u00a0f\u00fcr\u00a0die\u00a0adjuvante\u00a0Therapie\u00a0die\u00a0PD1\u2010Antik\u00f6rper \u00a0Niv o lum ab\u00a0 \n57\u00a0\n\u00a0oder\u00a0Pembrolizumab,\u00a0weist\u00a0aber\u00a0auf\u00a0fehlende\u00a0Daten\u00a0zum\u00a0Gesamt\u00fcbe rleben\u00a0hin.\u00a0\nAls\u00a0 gleichwertige\u00a0 Alternative\u00a0 kann\u00a0 laut\u00a0 Leitlinie\u00a0 bei\u00a0 B\u2010RAF\u2010V60 0\u2010Mutation\u00a0 die\u00a0\nKombination\u00a0aus\u00a0Dabrafenib\u00a0und\u00a0Trametinib\u00a0eingesetzt\u00a0werden.\u00a0Da \u00a0direkt\u00a0verglei\u2010\nchende\u00a0Daten\u00a0fehlen,\u00a0empfiehlt\u00a0d ie\u00a0Leitlinie\u00a0beim\u00a0B\u2010RAF\u2010mutiert en\u00a0Melanom\u00a0eine\u00a0\nindividuelle\u00a0Behandlungsentscheidung\u00a0unter\u00a0Ber\u00fccksichtigung\u00a0des \u00a0Toxizit\u00e4tspro\u2010\nfils.\u00a0\nBeim\u00a0nicht\u2010resezierbaren\u00a0Melanom\u00a0in\u00a0Stadium\u00a0III\u00a0oder\u00a0IV\u00a0werden\u00a0 als\u00a0Erstlinienthe\u2010\nrapie\u00a0die\u00a0Monotherapie\u00a0mit\u00a0Nivolumab\u00a0oder\u00a0Pembrolizumab,\u00a0die\u00a0Ko mbination\u00a0von\u00a0\nNivolumab\u00a0und\u00a0Ipilimumab\u00a0oder\u00a0bei\u00a0B\u2010RAF\u2010V600\u2010Mutation\u00a0die\u00a0Kombi nation\u00a0aus\u00a0\neinem\u00a0B\u2010RAF\u2010\u00a0und\u00a0einem\u00a0MEK\u2010Inhibitor\u00a0genannt.\u00a0F\u00fcr\u00a0die\u00a0Kombinati on\u00a0aus\u00a0B\u2010RAF\u2010\n/MEK\u2010Inhibitor\u00a0wird\u00a0keine\u00a0Pr\u00e4fere nz\u00a0f\u00fcr\u00a0bestimmte\u00a0Wirkstoffe\u00a0fo rmuliert.\u00a0\nT\u2010Vec\u00a0wird\u00a0als\u00a0Therapieoption\u00a0be i\u00a0nicht\u2010resezierbarem\u00a0Melanom\u00a0i m\u00a0Stadium\u00a0IIIB/C\u00a0\nbzw.\u00a0IVM1a\u00a0genannt.\u00a0\n Immuntherapien\u00a0f\u00fcr\u00a0die\u00a0schubf\u00f6rmi g\u00a0remittierende\u00a0multiple\u00a0Skler ose\u00a0 4.3\nSeit\u00a0dem\u00a0Beginn\u00a0der\u00a0fr\u00fchen\u00a0Nutz enbewertung\u00a02011\u00a0bis\u00a0einschlie\u00dfl ich\u00a02020\u00a0sind\u00a0in\u00a0\nDeutschland\u00a0mehrere\u00a0neue\u00a0Wirkstoffe\u00a0als\u00a0Immuntherapien\u00a0f\u00fcr\u00a0die\u00a0 Behandlung\u00a0der\u00a0\nschubf\u00f6rmig\u00a0remittierenden\u00a0multiplen\u00a0Sklerose\u00a0(RRMS)\u00a0auf\u00a0den\u00a0Ma rkt\u00a0gekommen.\u00a0\nHier\u00a0sollen\u00a0allerdings\u00a0nur\u00a0sechs\u00a0davon\u00a0betrachtet\u00a0werden,\u00a0f\u00fcr\u00a0d ie\u00a0auch\u00a0fr\u00fche\u00a0Nut\u2010\nzenbewertungen\u00a0vorliegen:\u00a0Fingolim od\u00a0(Gilenya\u00ae),\u00a0Dimethylfumara t\u00a0(Tecfidera\u00ae),\u00a0\nTeriflunomid\u00a0 (Aubagio\u00ae),\u00a0 Cladribin\u00a0 (Mavenclad\u00ae),\u00a0 Ocrelizumab\u00a0 (O crevus\u00ae)\u00a0 und\u00a0\nOzanimod\u00a0(Zeposia\u00ae).\u00a0\nDer\u00a02013\u00a0f\u00fcr\u00a0die\u00a0Behandlung\u00a0der\u00a0RRMS\u00a0zugelassene\u00a0Wirkstoff\u00a0Alem tuzumab\u00a0muss\u2010\nte\u00a0sich\u00a0nicht\u00a0der\u00a0fr\u00fchen\u00a0Nutzenbewertung\u00a0unterziehen,\u00a0da\u00a0er\u00a0ber eits\u00a0zuvor\u00a0f\u00fcr\u00a0eine\u00a0\nandere\u00a0Indikation\u00a0zugelassen\u00a0war. \u00a0Gleiches\u00a0gilt\u00a0auch\u00a0f\u00fcr\u00a0Dacliz umab,\u00a0das\u00a0ab\u00a02016\u00a0\nf\u00fcr\u00a0MS\u00a0zugelassen\u00a0war,\u00a0dessen\u00a0Zulassung\u00a0aber\u00a02018\u00a0wegen\u00a0Sicherh eitsbedenken\u00a0\nwiderrufen\u00a0wurde.\u00a0\nTeilweise\u00a0sind\u00a0die\u00a0besprochenen\u00a0Wirkstoffe\u00a0auch\u00a0f\u00fcr\u00a0andere\u00a0MS\u2010F ormen\u00a0zugelas\u2010\nsen.\u00a0Die\u00a0folgenden\u00a0Betrachtungen\u00a0beschr\u00e4nken\u00a0sich\u00a0jedoch\u00a0auf\u00a0di e\u00a0Therapie\u00a0der\u00a0\nRRMS.\u00a0Wirkstoffe,\u00a0die\u00a0ausschlie\u00dflich\u00a0f\u00fcr\u00a0die\u00a0sekund\u00e4r\u00a0progredie nte\u00a0multiple\u00a0Skle\u2010\nrose\u00a0zugelassen\u00a0sind,\u00a0werden\u00a0hier \u00a0ebenfalls\u00a0nicht\u00a0besprochen.\u00a0\nKrankheitsbild\u00a0\nMultiple\u00a0Sklerose\u00a0(MS)\u00a0ist\u00a0eine\u00a0chronische\u00a0Autoimmunerkrankung, \u00a0die\u00a0sich\u00a0in\u00a0Ent\u2010\nz\u00fcndungen\u00a0und\u00a0Demyelinisierungen\u00a0des\u00a0zentralen\u00a0Nervensystems\u00a0(Z NS)\u00a0zeigt.\u00a0Je\u00a0\nnachdem\u00a0welches\u00a0Areal\u00a0des\u00a0ZNS\u00a0betroffen\u00a0ist,\u00a0kann\u00a0die\u00a0Erkrankun g\u00a0zu\u00a0unterschied\u2010 \n58\u00a0\n\u00a0lichen\u00a0 neurologischen\u00a0 Symptomen\u00a0 f\u00fchren.\u00a0 Dazu\u00a0 geh\u00f6ren\u00a0 etwa\u00a0 Sehst \u00f6rungen,\u00a0\nMuskelschw\u00e4che\u00a0in\u00a0den\u00a0Gliedma\u00dfen,\u00a0Empfindungsst\u00f6rungen\u00a0und\u00a0St\u00f6r ungen\u00a0der\u00a0\nBewegungskoordination.\u00a0\nDie\u00a0Pr\u00e4valenz\u00a0liegt\u00a0bei\u00a0rund\u00a050\u00a0bis\u00a0300\u00a0Erkrankten\u00a0pro\u00a0100.000, \u00a0Frauen\u00a0sind\u00a0h\u00e4ufi\u2010\nger\u00a0betroffen\u00a0als\u00a0M\u00e4nner.\u00a0Die\u00a0Erk rankung\u00a0manifestiert\u00a0sich\u00a0in\u00a0d er\u00a0Regel\u00a0im\u00a0fr\u00fchen\u00a0\nErwachsenenalter.\u00a0Die\u00a0Erkrankung\u00a0\u00e4u\u00dfert\u00a0sich\u00a0zu\u00a0Beginn\u00a0in\u00a0der\u00a0R egel\u00a0mit\u00a0einer\u00a0\neinzelnen\u00a0 Krankheitsepisode\u00a0 (klin i s c h \u00a0i s o l i e r t e s \u00a0S y n d r o m ) . \u00a0T r e t en\u00a0 im\u00a0 weiteren\u00a0\nVerlauf\u00a0weitere\u00a0Sch\u00fcbe\u00a0auf,\u00a0bezeichnet\u00a0man\u00a0diese\u00a0Form\u00a0als\u00a0schub f\u00f6rmig\u00a0remittie\u2010\nrende\u00a0MS\u00a0( relapsing\u00a0remitting\u00a0multiple\u00a0sclerosis ,\u00a0RRMS).\u00a0Die\u00a0RRMS\u00a0ist\u00a0die\u00a0h\u00e4ufigste\u00a0\nForm\u00a0der\u00a0MS\u00a0und\u00a0tritt\u00a0bei\u00a0etwa\u00a085\u00a0%\u00a0der\u00a0MS\u2010Patienten\u00a0auf.\u00a0Im\u00a0sp \u00e4teren\u00a0Krank\u2010\nheitsverlauf\u00a0kann\u00a0sich\u00a0daraus\u00a0das\u00a0sich\u00a0zunehmend\u00a0verschlechtern de\u00a0Krankheitsbild\u00a0\nder\u00a0sekund\u00e4r\u00a0progredienten\u00a0MS\u00a0( secondary\u00a0progressive\u00a0multiple\u00a0sclerosis ,\u00a0SPMS)\u00a0\nentwickeln.\u00a0Bei\u00a0etwa\u00a015\u00a0%\u00a0der\u00a0an\u00a0MS\u00a0Erkrankten\u00a0schreitet\u00a0die\u00a0Er krankung\u00a0von\u00a0\nAnfang\u00a0an\u00a0kontinuierlich\u00a0fort.\u00a0Das\u00a0wird\u00a0auch\u00a0als\u00a0prim\u00e4r\u00a0progred iente\u00a0MS\u00a0( primary\u00a0\nprogressive\u00a0multiple\u00a0sclerosis ,\u00a0PPMS)\u00a0bezeichnet.\u00a0\nDie\u00a0schubf\u00f6rmige\u00a0Multiple\u00a0Sklerose\u00a0(RMS)\u00a0kann\u00a0in\u00a0die\u00a0beiden\u00a0Unt erformen\u00a0schub\u2010\nf\u00f6rmig\u00a0remittierende\u00a0Multiple\u00a0Sklerose\u00a0(RRMS)\u00a0und\u00a0sekund\u00e4r\u00a0prog rediente\u00a0Multip\u2010\nle\u00a0Sklerose\u00a0mit\u00a0aufgesetzten\u00a0Sch\u00fcben\u00a0(rSPMS)\u00a0eingeteilt\u00a0werden. \u00a0\nWie\u00a0die\u00a0Erkrankung\u00a0genau\u00a0entsteht,\u00a0ist\u00a0bisher\u00a0noch\u00a0nicht\u00a0vollst \u00e4ndig\u00a0gekl\u00e4rt.\u00a0So\u2010\nwohl\u00a0Umwelteinfl\u00fcsse,\u00a0als\u00a0auch\u00a0g enetische\u00a0und\u00a0epigenetische\u00a0Fak toren\u00a0scheinen\u00a0\neine\u00a0Rolle\u00a0zu\u00a0spielen.\u00a0In\u00a0der\u00a0Pathogenese\u00a0kommt\u00a0vermutlich\u00a0dem\u00a0 adaptiven\u00a0Im\u2010\nmunsystem\u00a0mit\u00a0T\u2010\u00a0und\u00a0B\u2010Lymphozyte n\u00a0eine\u00a0Schl\u00fcsselposition\u00a0zu,\u00a0a ber\u00a0auch\u00a0Reak\u2010\ntionen\u00a0des\u00a0angeborenen\u00a0Immunsystems\u00a0tragen\u00a0zur\u00a0 Entstehung\u00a0und\u00a0z um\u00a0Fort\u2010\nschreiten\u00a0der\u00a0Erkrankung\u00a0bei.\u00a0Die\u00a0Immunzellen\u00a0l\u00f6sen\u00a0Entz\u00fcndungs prozesse\u00a0aus,\u00a0\ndurch\u00a0die\u00a0die\u00a0Myelinscheiden\u00a0der\u00a0Nervenfasern\u00a0gesch\u00e4digt\u00a0werden .\u00a0Aktivierte\u00a0T\u2010\nLymphozyten\u00a0k\u00f6nnen\u00a0die\u00a0Blut\u2010Hirn\u2010Schranke\u00a0\u00fcberwinden,\u00a0so\u00a0dass\u00a0d ie\u00a0Pathome\u2010\nchanismen\u00a0 nicht\u00a0 die\u00a0 Peripherie,\u00a0 s ondern\u00a0 das\u00a0 zentrale\u00a0 Nervensyst em\u00a0 betreffen\u00a0\n(Thompson\u00a0et\u00a0al.,\u00a02018,\u00a0Reich\u00a0et\u00a0al.,\u00a02018).\u00a0\nWirkungsmechanismen\u00a0\nDie\u00a0neu\u00a0verf\u00fcgbaren\u00a0Immuntherapien\u00a0weisen\u00a0sehr\u00a0unterschiedliche \u00a0Wirkungsme\u2010\nchanismen\u00a0auf,\u00a0die\u00a0in\u00a0einigen\u00a0F\u00e4 llen\u00a0noch\u00a0nicht\u00a0vollst\u00e4ndig\u00a0gek l\u00e4rt\u00a0sind\u00a0(Thompson\u00a0\net\u00a0al.,\u00a02018,\u00a0DGN,\u00a02021).\u00a0\nFingolimod\u00a0und\u00a0Ozanimod\u00a0sind\u00a0Modu latoren\u00a0des\u00a0Sphingosin\u20101\u2010Phosp hat\u00a0(S1P)\u2010\nRezeptors,\u00a0der\u00a0sich\u00a0auf\u00a0Lymphozyten\u00a0findet.\u00a0Die\u00a0Wirkstoffe\u00a0verh indern\u00a0die\u00a0Bindung\u00a0\nvon\u00a0S1P\u00a0an\u00a0den\u00a0Rezeptor\u00a0und\u00a0bloc kieren\u00a0so\u00a0die\u00a0Migration\u00a0der\u00a0Lym phozyten\u00a0aus\u00a0\nden\u00a0Lymphknoten.\u00a0Damit\u00a0soll\u00a0verh indert\u00a0werden,\u00a0dass\u00a0die\u00a0Lymphoz yten\u00a0Sch\u00e4den\u00a0 \n59\u00a0\n\u00a0in\u00a0Gehirn\u00a0und\u00a0R\u00fcckenmark\u00a0anrichten.\u00a0Fingolimod\u00a0bindet\u00a0nach\u00a0Phos phorylierung\u00a0an\u00a0\nvier\u00a0der\u00a0f\u00fcnf\u00a0S1P\u2010Rezeptor\u2010Subtypen\u00a0(au\u00dfer\u00a0an\u00a0S1P2),\u00a0w\u00e4hrend\u00a0Oz animod\u00a0selektiv\u00a0\nauf\u00a0S1P1\u00a0und\u00a0S1P5\u00a0wirkt.\u00a0\nTeriflunomid\u00a0hemmt\u00a0das\u00a0Enzym\u00a0Dihydroorotat\u2010Dehydrogenase,\u00a0das\u00a0i n\u00a0Mitochond\u2010\nrien\u00a0 vorkommt\u00a0 und\u00a0 eine\u00a0 wichtige\u00a0 Rolle\u00a0 bei\u00a0 der\u00a0 Synthese\u00a0 von\u00a0 Pyri midin\u2010\nNukleotiden\u00a0spielt.\u00a0Dadurch\u00a0werden\u00a0die\u00a0Proliferation\u00a0von\u00a0autore aktiven\u00a0T\u2010\u00a0und\u00a0B\u2010\nLymphozyten\u00a0und\u00a0nachfolgend\u00a0infl ammatorische\u00a0Prozesse\u00a0gehemmt.\u00a0\nDimethylfumarat\u00a0reduziert\u00a0die\u00a0Fre isetzung\u00a0von\u00a0inflammatorischen \u00a0Zytokinen\u00a0und\u00a0\naktiviert\u00a0 vermutlich\u00a0 \u00fcber\u00a0 den\u00a0 Transkriptionsfaktor\u00a0 Nuclear\u00a0 factor\u00a0 (erythroid\u2010\nderived\u00a02)\u2010like\u00a02 \u00a0(Nrf2)\u00a0antioxidative\u00a0Signalwege.\u00a0\u00a0\nCladribin\u00a0ist\u00a0ein\u00a0Nukleosid\u2010Analogon\u00a0des\u00a0Desoxyadenosin.\u00a0Als\u00a0Pr odrug\u00a0wird\u00a0es\u00a0\nintrazellul\u00e4r\u00a0aktiviert\u00a0und\u00a0induziert\u00a0selektiv\u00a0bei\u00a0Lymphozyten\u00a0 eine\u00a0Apoptose.\u00a0So\u00a0\nwird\u00a0die\u00a0Progression\u00a0der\u00a0MS\u00a0gehemmt.\u00a0\nOcrelizumab\u00a0ist\u00a0ein\u00a0humanisierter\u00a0monoklonaler\u00a0Antik\u00f6rper,\u00a0der\u00a0 sich\u00a0gegen\u00a0das\u00a0\nCD20\u2010Antigen\u00a0auf\u00a0der\u00a0Oberfl\u00e4che\u00a0vor\u00a0allem\u00a0von\u00a0B\u2010Zellen\u00a0richtet. \u00a0Dadurch\u00a0zirkulie\u2010\nren\u00a0im\u00a0peripheren\u00a0Blut\u00a0weniger\u00a0aktivierte\u00a0B\u2010Zellen,\u00a0was\u00a0den\u00a0Ang riff\u00a0auf\u00a0die\u00a0Myelin\u2010\nscheiden\u00a0reduziert.\u00a0\nFingolimod,\u00a0 Ozanimod,\u00a0 Teriflunomid,\u00a0 Dimethylfumarat\u00a0 und\u00a0 Cladrib in\u00a0 sind\u00a0 oral\u00a0\nverf\u00fcgbar,\u00a0w\u00e4hrend\u00a0Ocrelizumab\u00a0a ls\u00a0Infusion\u00a0verabreicht\u00a0wird.\u00a0\nZulassung\u00a0\nBei\u00a0Fingolimod,\u00a0Teriflunomid,\u00a0Ocr elizumab\u00a0und\u00a0Ozanimod\u00a0handelt\u00a0 es\u00a0sich\u00a0um\u00a0neue\u00a0\nWirkstoffe,\u00a0Dimethylfumarat\u00a0und\u00a0Cladribin\u00a0waren\u00a0zuvor\u00a0bereits\u00a0f \u00fcr\u00a0andere\u00a0Indika\u2010\ntionen\u00a0 zugelassen\u00a0 (Psoriasis\u00a0 bez iehungsweise\u00a0 Haarzell\u2010Leuk\u00e4mie) .\u00a0 Den\u00a0 ersten\u00a0\nAntrag\u00a0auf\u00a0Zulassung\u00a0von\u00a0Cladribin\u00a0bei\u00a0Multipler\u00a0Sklerose\u00a0hatte \u00a0die\u00a0EMA\u00a02011\u00a0aus\u00a0\nSicherheitsgr\u00fcnd en\u00a0abgelehnt.\u00a0\nBis\u00a0auf\u00a0Fingolimod\u00a0und\u00a0Teriflunomid\u00a0sind\u00a0alle\u00a0der\u00a0hier\u00a0diskutie rten\u00a0Immunthera\u2010\npien\u00a0nur\u00a0f\u00fcr\u00a0Erwachsene\u00a0zugelassen.\u00a0Die\u00a0Zulassung\u00a0von\u00a0Fingolimo d\u00a0erstreckt\u00a0sich\u00a0\nauf\u00a0Patienten\u00a0ab\u00a0zehn\u00a0Jahren.\u00a0\u00a0\nDie\u00a0Indikation\u00a0von\u00a0Ocrelizumab\u00a0und\u00a0Ozanimod\u00a0ist\u00a0auf\u00a0aktive\u00a0RRMS \u00a0festgelegt,\u00a0\nw\u00e4hrend\u00a0Cladribin\u00a0nur\u00a0bei\u00a0hochaktiver\u00a0Erkrankung\u00a0einsetzbar\u00a0ist .\u00a0Fingolimod\u00a0ist\u00a0als\u00a0\nZweitlinientherapie\u00a0zugelassen,\u00a0a ls\u00a0Erstlinientherapie\u00a0nur\u00a0bei\u00a0 rasch\u00a0fortschreiten\u2010\nder\u00a0schwerwiegender\u00a0Erkrankung.\u00a0\n\u00a0 \u00a0 \n60\u00a0\n\u00a0Ergebnisse\u00a0der\u00a0fr\u00fchen\u00a0Nutzenbewertung\u00a0\nVon\u00a0den\u00a0hier\u00a0betrachteten\u00a0sechs\u00a0Wirkstoffen\u00a0haben\u00a0nur\u00a0Fingolimo d\u00a0und\u00a0Terif\u2010\nlunomid\u00a0mehrere\u00a0Verfahren\u00a0zur\u00a0fr\u00fchen\u00a0Nutzenbewertung\u00a0durchlaufe n.\u00a0Grund\u00a0f\u00fcr\u00a0\ndie\u00a0insgesamt\u00a0f\u00fcnf\u00a0bzw.\u00a0zwei\u00a0Verfahren\u00a0zwischen\u00a02011\u00a0und\u00a02021\u00a0w aren\u00a0teils\u00a0Neu\u2010\nbewertungen\u00a0nach\u00a0Fristablauf,\u00a0te ils\u00a0Indikationserweiterungen\u00a0wi e\u00a0die\u00a0Zulassung\u00a0\nf\u00fcr\u00a0Kinder\u00a0ab\u00a0zehn\u00a0Lebensjahren.\u00a0In\u00a0der\u00a0Nutzenbewertung\u00a0\u00e4nderte \u00a0sich\u00a0teilweise\u00a0\nauch\u00a0der\u00a0Zuschnitt\u00a0der\u00a0Subgruppen.\u00a0(Tabelle\u00a04.5).\u00a0\u00a0\nBis\u00a0auf\u00a0Teriflunomid\u00a0und\u00a0Dimethylfumarat\u00a0wurden\u00a0f\u00fcr\u00a0die\u00a0Nutzenb ewertungen\u00a0\nmehrere\u00a0Subgruppen\u00a0gebildet,\u00a0f\u00fcr\u00a0die\u00a0vor\u00a0allem\u00a0die\u00a0Vorbehandlun g,\u00a0teilweise\u00a0auch\u00a0\nder\u00a0Grad\u00a0der\u00a0Krankheitsaktivit\u00e4t\u00a0eine\u00a0Rolle\u00a0spielte.\u00a0Bei\u00a0Fingol imod\u00a0und\u00a0Terifluno\u2010\nmid\u00a0wurde\u00a0die\u00a0p\u00e4diatrische\u00a0Indikation\u00a0getrennt\u00a0bewertet.\u00a0\u00a0\nF\u00fcr\u00a0 die\u00a0 Subgruppen\u00a0 wurden\u00a0 untersc hiedliche\u00a0 zweckm \u00e4\u00dfige\u00a0 Vergleic hstherapien\u00a0\nfestgelegt.\u00a0F\u00fcr\u00a0nicht\u00a0vorbehandelte\u00a0Patienten\u00a0bei\u00a0nicht\u2010hochakt iver\u00a0Erkrankung\u00a0war\u00a0\ndie\u00a0zVT\u00a0Glatirameracetat\u00a0oder\u00a0Be tainterferon\u00a01a\u00a0oder\u00a01b.\u00a0Bei\u00a0ak tiver,\u00a0aber\u00a0nicht\u00a0\nhoch\u2010aktiver\u00a0Erkrankung\u00a0wurde\u00a0im\u00a0Nutzenbewertungsverfahren\u00a0f\u00fcr\u00a0 Ozanimod\u00a0in\u00a0der\u00a0\nErstlinientherapie\u00a0auch\u00a0das\u00a0inzwischen\u00a0verf\u00fcgbare\u00a0Ocrelizumab\u00a0a ls\u00a0zVT\u00a0betrachtet.\u00a0\u00a0\nBei\u00a0vorbehandelten\u00a0Patienten\u00a0mit\u00a0hochaktiver\u00a0Erkrankung\u00a0galten\u00a0 bis\u00a0zur\u00a0Nutzen\u2010\nbewertung\u00a0von\u00a0Ocrelizumab\u00a02018\u00a0Alemtuzumab,\u00a0Fingolimod,\u00a0Nataliz umab\u00a0oder\u00a0\nein\u00a0Wechsel\u00a0der\u00a0Basistherapie\u00a0al s\u00a0zweckm\u00e4\u00dfige\u00a0Vergleichstherapi en.\u00a0Bei\u00a0der\u00a0Nut\u2010\nzenbewertung\u00a0von\u00a0Ozanimod\u00a0wurde\u00a0w\u00e4hrend\u00a0des\u00a0Verfahrens\u00a0die\u00a0zwec km\u00e4\u00dfige\u00a0\nVergleichstherapie\u00a0ge\u00e4ndert,\u00a0da\u00a0der\u00a0Wechsel\u00a0der\u00a0Basistherapie\u00a0n icht\u00a0mehr\u00a0als\u00a0\nStand\u00a0der\u00a0medizinischen\u00a0Wissenschaft\u00a0gilt.\u00a0Das\u00a0pharmazeutische\u00a0 Unternehmen\u00a0\nhatte\u00a0die\u00a0Gelegenheit,\u00a0ein\u00a0neues\u00a0 Dossier\u00a0einzureichen,\u00a0verzicht ete\u00a0aber\u00a0darauf.\u00a0\nEine\u00a0patientenindividuelle\u00a0Therapie,\u00a0teils\u00a0unter\u00a0Ber\u00fccksichtigu ng\u00a0der\u00a0Vortherapie\u00a0\nund\u00a0der\u00a0Zulassung\u00a0wurde\u00a0bei\u00a0mehreren\u00a0Subgruppen\u00a0im\u00a0Rahmen\u00a0der\u00a0N utzenbewer\u2010\ntung\u00a0von\u00a0Fingolimod\u00a0als\u00a0zweckm\u00e4\u00df ige\u00a0Vergleichstherapie\u00a0herangez ogen.\u00a0\nVon\u00a0den\u00a0hier\u00a0betrachteten\u00a0neuen\u00a0 Wirkstoffen\u00a0wurden\u00a0nur\u00a0Fingolim od\u00a0und\u00a0Ocreli\u2010\nzumab\u00a0im\u00a0Laufe\u00a0des\u00a0ausgewerteten\u00a0Zeitraums\u00a0f\u00fcr\u00a0bestimmte\u00a0Subgru ppen\u00a0als\u00a0je\u2010\nweils\u00a0eine\u00a0von\u00a0mehreren\u00a0Optionen\u00a0der\u00a0zVT\u00a0eingestuft.\u00a0Das\u00a0entspr icht\u00a0dem\u00a0Ergeb\u2010\nnis\u00a0der\u00a0jeweiligen\u00a0Nutzenbewertungsverfahren.\u00a0Inwieweit\u00a0Ozanimo d\u00a0als\u00a0zuletzt\u00a0\nbewerteter\u00a0Wirkstoff,\u00a0dem\u00a0in\u00a0einer\u00a0Subgruppe\u00a0ein\u00a0Zusatznutzen\u00a0z uerkannt\u00a0wurde,\u00a0\nbei\u00a0k\u00fcnftigen\u00a0Nutzenbewertungen\u00a0 in\u00a0dieser\u00a0Indikation\u00a0ebenfalls\u00a0 als\u00a0zVT\u00a0eingestuft\u00a0\nwird,\u00a0ist\u00a0derzeit\u00a0offen.\u00a0\n\u00a0 \u00a0 \n61\u00a0\n\u00a0Tabelle\u00a04.7:\u00a0\u00dcbersicht\u00a0der\u00a0Nutzenbewertungen\u00a0zu\u00a0RRMS\u00a0\u00a0\nWirkstoff\u00a0 Beschlussdatum\u00a0 Indikation\u00a0bzw.\u00a0Subgruppe\u00a0 Ergebnis\u00a0Zusatznutzen\u00a0\nFingolimod\u00a0 2015/2016\u00a0 hohe\u00a0Krankheitsaktivit\u00e4t\u00a0trotz\u00a0\nVorbehandlung:\u00a0Umstellung\u00a0\noder\u00a0Anpassung\u00a0der\u00a0vorherigen\u00a0\nTherapie\u00a0nicht\u00a0belegt\u00a0\n\u00a0 \u00a0 hohe\u00a0Krankheitsaktivit\u00e4t\u00a0trotz\u00a0\nVorbehandlung:\u00a0\u00a0\nTherapieeskalation\u00a0nicht\u00a0belegt\u00a0\n\u00a0 \u00a0 rasch\u00a0fortschreitende,\u00a0schwere\u00a0\nRRMS\u00a0gering\u00a0(Hinweis)\u00a0\n\u00a0 2019\u00a0 p\u00e4diatrisch*,\u00a0hohe\u00a0\nKrankheitsaktivit\u00e4t\u00a0trotz\u00a0\nVorbehandlung:\u00a0\nTherapieeskalation\u00a0nicht\u00a0belegt\u00a0\n\u00a0 \u00a0 p\u00e4diatrisch*,\u00a0hohe\u00a0\nKrankheitsaktivit\u00e4t\u00a0trotz\u00a0\nVorbehandlung:\u00a0Wechsel\u00a0\ninnerhalb\u00a0der\u00a0Basis\u2010Therapie\u00a0nicht\u00a0quantifizierbar\u00a0\n(Anhaltspunkt)\u00a0\n\u00a0 \u00a0 p\u00e4diatrisch*,\u00a0rasch\u00a0\nfortschreitende,\u00a0schwere\u00a0\nRRMS,\u00a0therapienaiv\u00a0\u00a0nicht\u00a0quantifizierbar\u00a0\n(Anhaltspunkt)\u00a0\n\u00a0 \u00a0 p\u00e4diatrisch*,\u00a0rasch\u00a0\nfortschreitende,\u00a0schwere\u00a0\nRRMS,\u00a0vorbehandelt\u00a0\u00a0nicht\u00a0belegt\u00a0\nTeriflunomid\u00a0 2014\u00a0\n2022\u00a0\u00a0RRMS\u00a0\u00a0\nRRMS\u00a0P\u00e4diatrie\u00a010\u201017\u00a0nicht\u00a0belegt\u00a0\nnicht\u00a0belegt\u00a0\nDimethylfumarat\u00a0 2014\u00a0 RRMS\u00a0 nicht\u00a0belegt\u00a0\nCladribin\u00a0\u00a0 2018\u00a0 nicht\u00a0vorbehandelt\u00a0 nicht\u00a0belegt\u00a0\n\u00a0 \u00a0 hohe\u00a0Krankheitsaktivit\u00e4t\u00a0trotz\u00a0\nVorbehandlung\u00a0nicht\u00a0belegt\u00a0\nOcrelizumab\u00a0 2018\u00a0 aktive\u00a0Erkrankung\u00a0ohne\u00a0\nVorbehandlung\u00a0oder\u00a0mit\u00a0\nVorbehandlung,\u00a0wenn\u00a0kein\u00a0hochaktiver\u00a0Verlauf\u00a0\u00a0gering\u00a0(Beleg)\u00a0\n\u00a0 \u00a0 hohe\u00a0Krankheitsaktivit\u00e4t\u00a0trotz\u00a0\nVorbehandlung\u00a0nicht\u00a0belegt\u00a0\nOzanimod\u00a0 2021\u00a0 aktive\u00a0Erkrankung\u00a0ohne\u00a0\nVorbehandlung\u00a0oder\u00a0mit\u00a0Vorbehandlung,\u00a0wenn\u00a0kein\u00a0\nhochaktiver\u00a0Verlauf\u00a0gering\u00a0(Hinweis)\u00a0\n\u00a0 \u00a0 hohe\u00a0Krankheitsaktivit\u00e4t\u00a0trotz\u00a0\nVorbehandlung\u00a0nicht\u00a0belegt\u00a0\n*Kinder\u00a0und\u00a0Jugendliche\u00a010\u00a0bis\u00a0unter\u00a018\u00a0Jahre\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nNutzenbewertungen\u00a0f\u00fcr\u00a0Erwachsene,\u00a0wenn\u00a0nicht\u00a0anders\u00a0benannt.\u00a0Er gebnisse\u00a0von\u00a0aufgehobenen\u00a0Beschl\u00fcssen\u00a0oder\u00a0zu\u00a0anderen\u00a0\nIndikation\u00a0au\u00dfer\u00a0RRMS\u00a0sind\u00a0nicht\u00a0aufgef\u00fchrt,\u00a0bei\u00a0Neubewertungen \u00a0nach\u00a0Fristablauf\u00a0nur\u00a0der\u00a0jeweils\u00a0letzte\u00a0Stand.\u00a0 \n62\u00a0\n\u00a0Tabelle\u00a04.8:\u00a0Arzneimittel\u00a0zur\u00a0Therapie\u00a0der\u00a0schubf\u00f6rmig\u00a0remittie renden\u00a0multiplen\u00a0Sklerose\u00a0(RRMS)\u00a0\nWirkstoff\u00a0\u00a0\n(Pr\u00e4parat)\u00a0\n[pU]\u00a0Markt\u2010\u00a0\nEintritt\u00a0GKV\u00a0netto\u00a0je\u00a0DDD\u00a0\n[\u20ac]\u00a02020\u00a0real\u2010life\u00a0ApoVK\u00a0bei\u00a0\nMarkteintritt\u00a0Preis\u2010\u00a0\nReduktion\u00a0durch\u00a0\u00a0\nErstattungs\u2010\u00a0\nbetrag\u00a0Jahresthera\u2010\npiekosten\u00a0im\u00a0\nG\u2010BA\u2010\nBeschluss\u00a0Bewertung \u00a0\nVerf\u00fcgbare\u00a0\nTherapien\u00a0(Zusatz\u2010)\u00a0\nNutzen\u00a0Kosten\u00a0 Gesamtscore\u00a0\nDimethylfumarat\u00a0\n(Tecfidera\u00ae)\u00a0\n[Biogen]\u00a02014\u00a0 30,53\u00a0\u20ac\u00a0 2.171,65\u00a0\u20ac\u00a0 57\u00a0%\u00a026.711,48\u00a0\u20ac\u00a0\n\u00a0\u00a0 \u00a0 \u00a0\nDihydroootat\u2010Dehydrogenase\u2010Hemmer \u00a0\nTeriflunomid\u00a0\n(Aubagio\u00ae)\u00a0[Sanofi\u2010Aventis]\u00a02013\u00a0 34,10\u00a0\u20ac\u00a0 1.890,83\u00a0\u20ac\u00a0 46\u00a0%\u00a022.972,40\u00a0\u20ac\u00a0\n\u00a0\u00a0 \u00a0 \u00a0\nNukleosid\u2010Analogon\u00a0 \u00a0 \u00a0\nCladribin\u00a0\n(Mavenclad\u00ae)\u00a0[Merck]\u00a02017\u00a0 63,75\u00a0\u20ac\u00a0 15.692,35\u00a0\u20ac\u00a0 24\u00a0%\u00a0 34.620,46\u00a0\u20ac\u00a0\u00a0\n(1.\u00a0Jahr)\u00a034.620,46\u00a0\u20ac\u00a0\u00a0(2.\u00a0Jahr)\u00a0\u00a0\u00a0 \u00a0\u00a0\nSphingosin\u20101\u2010Phosphat\u00a0(S1P)\u2010Rezeptor\u2010Modulatoren\u00a0\nFingolimod\u00a0\n(Gilenya\u00ae)\u00a0\n[Novartis]\u00a02011\u00a0 59,93\u00a0\u20ac\u00a0 2.346,16\u00a0\u20ac\u00a0 26\u00a0%\u00a0 11.454,22\u00a0\u20ac\u00a0bis\u00a0\n22.142,50\u00a0\u20ac\u00a0\u00a0 \u00a0 \u00a0 \u00a0\nOzanimod\u00a0\n(Zeposia\u00ae)\u00a0[Bristol\u2010Myers\u2010Squibb]\u00a0\u00a0\u00a0\u00a0\u00a0\u00a02020\u00a0 69,69\u00a0\u20ac\u00a0 6.954,77\u00a0\u20ac\u00a0 12\u00a0%\u00a024.391,01\u00a0\u20ac\u00a0Aufgrund\u00a0des\u00a0sp\u00e4ten\u00a0Markteintritts\u00a0noch\u00a0nicht\u00a0in\u00a0den\u00a0\nInnovationsreporten\u00a0bewertet.\u00a0 \n63\u00a0\n\u00a0Wirkstoff\u00a0\u00a0\n(Pr\u00e4parat)\u00a0\n[pU]\u00a0Markt\u2010\u00a0\nEintritt\u00a0GKV\u00a0netto\u00a0je\u00a0DDD\u00a0\n[\u20ac]\u00a02020\u00a0real\u2010life\u00a0ApoVK\u00a0bei\u00a0\nMarkteintritt\u00a0Preis\u2010\u00a0\nReduktion\u00a0durch\u00a0\u00a0\nErstattungs\u2010\u00a0\nbetrag\u00a0Jahresthera\u2010\npiekosten\u00a0im\u00a0\nG\u2010BA\u2010\nBeschluss\u00a0Bewertung \u00a0\nVerf\u00fcgbare\u00a0\nTherapien\u00a0(Zusatz\u2010)\u00a0\nNutzen\u00a0Kosten\u00a0 Gesamtscore\u00a0\n\u00a0\n\u00a0\nHumanisierte\u00a0monoklonale\u00a0Antik\u00f6rper\u00a0\nAlemtuzumab\u00a0\n(Lemtrada\u00ae)\u00a0[Sanofi]\u00a02013\u00a0 90,17\u00a0\u20ac\u00a0 10.653,50\u00a0\u20ac\u00a0 keine\u00a053.268,00\u00a0\u20ac\u00a0\n(1.Jahr)\u00a0\n31.961,00\u00a0\u20ac\u00a0\n(2.\u00a0Jahr)\u00a0Aufgrund\u00a0des\u00a0sp\u00e4ten\u00a0Markteintritts\u00a0noch\u00a0nicht\u00a0in\u00a0den\u00a0\nInnovationsreporten\u00a0bewertet.\u00a0\nDaclizumab\u00a0\n(Zinbryta\u00ae)\u00a0\n[Biogen]\u00a02016\u00a0 66,24\u00a0\u20ac\u00a0 6.301,04\u00a0\u20ac\u00a0 0\u00a0%\u00a0 Marktr\u00fcck\u2010\nnahme\u00a0\n03/2018\u00a0Aufgrund\u00a0der\u00a0Marktr\u00fccknahme\u00a0nicht\u00a0in\u00a0den\u00a0Innovationsre\u2010\nporten\u00a0bewertet.\u00a0\nOcrelizumab\u00a0(Ocrevus\u00ae)\u00a0[Roche]\u00a02018\u00a0 65,44\u00a0\u20ac\u00a0 8.330,80\u00a0\u20ac\u00a0 24\u00a0%\u00a031.426,12\u20ac\u00a0Aufgrund\u00a0des\u00a0sp\u00e4ten\u00a0Markteintritts\u00a0noch\u00a0nicht\u00a0in\u00a0den\u00a0\nInnovationsreporten\u00a0bewertet.\u00a0\n\u00a0\n\u00a0 \n64\u00a0\n\u00a0F\u00fcr\u00a0die\u00a0Wirkstoffe\u00a0Fingolimod,\u00a0Ocrelizumab\u00a0und\u00a0Ozanimod\u00a0wurde\u00a0i n\u00a0mindestens\u00a0\neiner\u00a0Subgruppe\u00a0ein\u00a0Zusatznutzen\u00a0 festgestellt.\u00a0Allerdings\u00a0wurde \u00a0bei\u00a0keinem\u00a0dieser\u00a0\nWirkstoffe\u00a0f\u00fcr\u00a0alle\u00a0Subgruppen\u00a0ein\u00a0Zusatznutzen\u00a0anerkannt.\u00a0In\u00a0d rei\u00a0F\u00e4llen\u00a0wurde\u00a0\ndas\u00a0Ausma\u00df\u00a0des\u00a0Zusatznutzens\u00a0als\u00a0gering\u00a0eingestuft,\u00a0in\u00a0zwei\u00a0F\u00e4l len\u00a0war\u00a0es\u00a0nicht\u00a0\nquantifizierbar.\u00a0\nWenn\u00a0kein\u00a0Zusatznutzen\u00a0zuerkannt\u00a0wurde,\u00a0lag\u00a0das\u00a0zum\u00a0Teil\u00a0daran, \u00a0dass\u00a0keine\u00a0\nDaten\u00a0vorgelegt\u00a0wurden\u00a0oder\u00a0in\u00a0d en\u00a0vorgelegten\u00a0Studien\u00a0die\u00a0zVT\u00a0 nicht\u00a0umgesetzt\u00a0\nworden\u00a0ist.\u00a0Allerdings\u00a0fand\u00a0sich\u00a0f\u00fcr\u00a0viele\u00a0Subgruppen\u00a0auch\u00a0in\u00a0g eeigneten\u00a0direkten\u00a0\nVergleichen\u00a0mit\u00a0der\u00a0zV T\u00a0kein\u00a0Zusatznutzen.\u00a0\nErkenntnisse\u00a0zur\u00a0Sicherheit\u00a0nach\u00a0der\u00a0Zulassung\u00a0\nSeit\u00a0der\u00a0Zulassung\u00a0wurden\u00a0im\u00a0betrachteten\u00a0Zeitraum\u00a02011\u00a0bis\u00a0202 0\u00a0f\u00fcr\u00a0zwei\u00a0der\u00a0\nsechs\u00a0Immuntherapeutika\u00a0Rote\u2010Hand\u2010Briefe\u00a0verschickt.\u00a0\nDie\u00a0neun\u00a0Rote\u2010Hand\u2010Briefe\u00a0zu\u00a0Fingolimod\u00a0bezogen\u00a0sich\u00a0auf\u00a0versch iedene\u00a0Risiken\u00a0\nbeziehungsweise\u00a0Risikosignale:\u00a0vier\u00a0zu\u00a0kardialen\u00a0Risiken,\u00a0in\u00a0de nen\u00a0auf\u00a0neue\u00a0Kontra\u2010\nindikationen\u00a0und\u00a0Empfehlungen\u00a0zur\u00a0\u00dcberwachung\u00a0hingewiesen\u00a0wurde .\u00a0Die\u00a0Emp\u2010\nfehlungen\u00a0zur\u00a0kardialen\u00a0\u00dcberwac hung\u00a0wurden\u00a0mehrmals\u00a0aktualisier t\u00a0und\u00a0\u00fcberar\u2010\nbeitet.\u00a0Weitere\u00a0Rote\u2010Hand\u2010Briefe \u00a0thematisierten\u00a0Empfehlungen\u00a0zu r\u00a0Reduktion\u00a0des\u00a0\nRisikos\u00a0f\u00fcr\u00a0arzneimittelinduzier te\u00a0Lebersch\u00e4den\u00a0und\u00a0wiesen\u00a0auf\u00a0 Risiken\u00a0der\u00a0im\u2010\nmunsuppressiven\u00a0Effekte\u00a0hin.\u00a0Berichtet\u00a0wurde\u00a0au\u00dferdem\u00a0\u00fcber\u00a0aufg etretene\u00a0F\u00e4lle\u00a0\nmit\u00a0h\u00e4mophagozytischem\u00a0Syndrom\u00a0be ziehungsweise\u00a0mit\u00a0progressiver \u00a0multifokaler\u00a0\nLeukenzephalopathie\u00a0(PML).\u00a0Des\u00a0We iteren\u00a0informierte\u00a0ein\u00a0Rote\u2010Ha nd\u2010Brief\u00a0\u00fcber\u00a0\neine\u00a0neue\u00a0Kontraindikation.\u00a0Sie\u00a0 umfasst\u00a0Schwangere\u00a0sowie\u00a0Frauen \u00a0im\u00a0geb\u00e4rf\u00e4hi\u2010\ngen\u00a0Alter,\u00a0die\u00a0keine\u00a0wirksame\u00a0Ko ntrazeptionsmethode\u00a0verwenden.\u00a0\nZu\u00a0Dimethylfumarat\u00a0wurden\u00a0drei\u00a0Rote\u2010Hand\u2010Briefe\u00a0versandt,\u00a0die\u00a0\u00fc ber\u00a0aufgetrete\u2010\nne\u00a0F\u00e4lle\u00a0mit\u00a0progressiver\u00a0multifokaler\u00a0Leukenzephalopathie\u00a0(PML )\u00a0informierten\u00a0\nsowie\u00a0Empfehlungen\u00a0zur\u00a0Risikoreduktion\u00a0enthielten.\u00a0\nDie\u00a0Zulassung\u00a0von\u00a0Daclizumab\u00a0ruht\u00a0seit\u00a0M\u00e4rz\u00a02018\u00a0in\u00a0Folge\u00a0eines \u00a0Pharmakovi\u2010\ngilanzverfahrens\u00a0der\u00a0EMA\u00a0aufgrund\u00a0einer\u00a0negativen\u00a0Nutzen\u2010Risiko \u2010Bilanz.\u00a0Mittels\u00a0\nRote\u2010Hand\u2010Brief\u00a0erfolgte\u00a0ein\u00a0R\u00fcckruf\u00a0des\u00a0Arzneimittels.\u00a0\n\u00a0\u00a0 \n65\u00a0\n\u00a0Bewertungen\u00a0in\u00a0fr\u00fcheren\u00a0Innovationsreporten\u00a0\nVier\u00a0der\u00a0sechs\u00a0Wirkstoffe\u00a0wurden\u00a0in\u00a0fr\u00fcheren\u00a0Innovationsreporte n\u00a0bewertet.\u00a0Auf\u2010\ngrund\u00a0des\u00a0sp\u00e4teren\u00a0Markteintrittes\u00a0liegen\u00a0f\u00fcr\u00a0Ocrelizumab\u00a0und\u00a0O zanimod\u00a0keine\u00a0\nBewertungen\u00a0vor.\u00a0\nHinsichtlich\u00a0der\u00a0verf\u00fcgbaren\u00a0Ther apien\u00a0erhielt\u00a0kein\u00a0Wirkstoff\u00a0e ine\u00a0gr\u00fcne\u00a0Ampel,\u00a0\ngleiches\u00a0gilt\u00a0auch\u00a0f\u00fcr\u00a0die\u00a0Bewertung\u00a0des\u00a0Nutzens.\u00a0Teriflunomid\u00a0 und\u00a0Cladribin\u00a0wur\u2010\nden\u00a0in\u00a0beiden\u00a0Aspekten\u00a0mit\u00a0einer\u00a0roten\u00a0Ampel\u00a0bewertet,\u00a0gleiches \u00a0gilt\u00a0auch\u00a0f\u00fcr\u00a0\nFingolimod\u00a0in\u00a0der\u00a0Kategorie\u00a0\u201eVer f\u00fcgbare\u00a0Therapien\u201c.\u00a0In\u00a0allen\u00a0an deren\u00a0F\u00e4llen\u00a0wur\u2010\nden\u00a0gelbe\u00a0Ampeln\u00a0vergeben.\u00a0\nDabei\u00a0ist\u00a0allerdings\u00a0zu\u00a0beachten ,\u00a0dass\u00a0Fingolimod\u00a0zum\u00a0Zeitpunkt \u00a0der\u00a0Bewertung\u00a0\nnoch\u00a0nicht\u00a0f\u00fcr\u00a0die\u00a0p\u00e4diatrische\u00a0Indikation\u00a0zugelassen\u00a0war.\u00a0\nBewertungen\u00a0von\u00a0unabh\u00e4ngigen\u00a0Arzneimittelzeitschriften\u00a0\nEher\u00a0zur\u00fcckhaltend\u00a0fallen\u00a0die\u00a0Bewertungen\u00a0der\u00a0arznei\u2010telegramm\u00a0 Datenbank\u00a0aus:\u00a0\nFingolimod,\u00a0Dimethylfumarat\u00a0und\u00a0 Ocrelizumab\u00a0werden\u00a0als\u00a0\u201eMittel\u00a0 der\u00a0Reserve\u201c\u00a0\neingestuft,\u00a0Teriflunomid,\u00a0Cladribin\u00a0und\u00a0Ozanimod\u00a0als\u00a0\u201ezweifelha ftes\u201c\u00a0oder\u00a0\u201eum\u2010\nstrittenes\u201c\u00a0Therapieprinzip.\u00a0\nDie\u00a0Zeitschrift\u00a0Prescrire\u00a0wertete\u00a0Fingolimod\u00a02011\u00a0f\u00fcr\u00a0die\u00a0Anwen dung\u00a0bei\u00a0Erwach\u2010\nsenen\u00a0und\u00a02019\u00a0f\u00fcr\u00a0die\u00a0p\u00e4diatrisc hen\u00a0Altersgruppen,\u00a0Dimethylfum arat\u00a02015\u00a0und\u00a0\nOcrelizumab\u00a02019\u00a0als\u00a0\u201enothing\u00a0new\u201c.\u00a0Die\u00a0Klassifizierung\u00a0\u201enot\u00a0ac ceptable\u201c\u00a0wurde\u00a0\n2015\u00a0f\u00fcr\u00a0Teriflunomid\u00a0und\u00a02019\u00a0f\u00fcr\u00a0 Cladribin\u00a0vergeben.\u00a0Ozanimod \u00a0wurde\u00a0bislang\u00a0\nnicht\u00a0bewertet.\u00a0\nStellenwert\u00a0in\u00a0der\u00a0Therapie\u00a0\nIn\u00a0der\u00a0aktuellen\u00a0S2k\u2010Leitlinie\u00a0der\u00a0Deutschen\u00a0Gesellschaft\u00a0f\u00fcr\u00a0N eurologie\u00a0(DGN,\u00a0\n2021)\u00a0werden\u00a0die\u00a0Immuntherapeutika\u00a0in\u00a0drei\u00a0Wirksamkeitskategori en\u00a0eingeteilt.\u00a0\nDie\u00a0Einteilung\u00a0beruht\u00a0auf\u00a0dem\u00a0Ausma\u00df,\u00a0mit\u00a0dem\u00a0die\u00a0Wirkstoffe\u00a0in \u00a0Studien\u00a0die\u00a0\nSchubraten\u00a0reduzierten.\u00a0Die\u00a0Wirksamkeitskategorie\u00a01\u00a0entspricht\u00a0 dabei\u00a0einer\u00a0eher\u00a0\nniedrigen\u00a0Reduktion,\u00a0Kategorie\u00a03\u00a0einer\u00a0eher\u00a0hohen.\u00a0F\u00fcr\u00a0die\u00a0Eint eilung\u00a0in\u00a0die\u00a0Kate\u2010\ngorien\u00a01\u00a0und\u00a02\u00a0werden\u00a0Placebo\u2010Ver gleiche\u00a0herangezogen,\u00a0f\u00fcr\u00a0die\u00a0 Kategorie\u00a03\u00a0zu\u2010\ns\u00e4tzlich\u00a0auch\u00a0Vergleiche\u00a0mit\u00a0Substanzen\u00a0aus\u00a0der\u00a0Kategorie\u00a01.\u00a0Ko ntrollierte\u00a0Ver\u2010\ngleichsstudien\u00a0zwischen\u00a0allen\u00a0Wirk stoffen\u00a0fehlen\u00a0derzeit\u00a0jedoch .\u00a0Die\u00a0Leitlinie\u00a0weist\u00a0\ndarauf\u00a0hin,\u00a0dass\u00a0das\u00a0Risiko\u00a0f\u00fcr\u00a0schwere\u00a0Nebenwirkungen\u00a0bei\u00a0den\u00a0 Wirkstoffen\u00a0in\u00a0\nKategorie\u00a01\u00a0in\u00a0der\u00a0Regel\u00a0niedriger\u00a0ist\u00a0als\u00a0in\u00a0den\u00a0Kategorien\u00a02\u00a0 oder\u00a03.\u00a0Die\u00a0Vertr\u00e4g\u2010\nlichkeit\u00a0im\u00a0Alltag\u00a0l\u00e4sst\u00a0sich\u00a0aus\u00a0 der\u00a0Kategorieneinteilung\u00a0jedo ch\u00a0nicht\u00a0ableiten.\u00a0 \n66\u00a0\n\u00a0Von\u00a0den\u00a0hier\u00a0betrachteten\u00a0Wirkstoffen\u00a0werden\u00a0Teriflunomid\u00a0und\u00a0D imethylfumarat\u00a0\nder\u00a0Wirksamkeitskategorie\u00a01\u00a0zuge ordnet\u00a0(neben\u00a0Beta\u2010Interferonen \u00a0und\u00a0Glatirame\u2010\nroiden),\u00a0Cladribin,\u00a0Fingolimod\u00a0 und\u00a0Ozanimod\u00a0der\u00a0Wirksamkeitskat egorie\u00a02,\u00a0Ocreli\u2010\nzumab\u00a0der\u00a0Wirksamkeitskategorie\u00a03\u00a0(neben\u00a0Alemtuzumab\u00a0und\u00a0Natali zumab).\u00a0Die\u00a0\nLeitlinie\u00a0benennt\u00a0auch\u00a0den\u00a0 off\u2010label\u00a0use \u00a0von\u00a0Rituximab,\u00a0das\u00a0chemisch\u00a0eng\u00a0mit\u00a0\nOcrelizumab\u00a0verwandt\u00a0ist,\u00a0als\u00a0Ther apieoption\u00a0in\u00a0Wirksamkeitskat egorie\u00a03.\u00a0Ocreli\u2010\nzumab\u00a0und\u00a0Rituximab\u00a0werden\u00a0in\u00a0den\u00a0Empfehlungen\u00a0als\u00a0CD20\u2010Antik\u00f6r per\u00a0gemein\u2010\nsam\u00a0betrachtet.\u00a0\nDie\u00a0Leitlinie\u00a0weist\u00a0explizit\u00a0darauf\u00a0hin,\u00a0dass\u00a0bei\u00a0der\u00a0Auswahl\u00a0d er\u00a0Immuntherapeutika\u00a0\nin\u00a0allen\u00a0F\u00e4llen\u00a0patientenindividuell\u00a0nicht\u00a0nur\u00a0die\u00a0zu\u00a0erwartend en\u00a0Therapieeffekte,\u00a0\nsondern\u00a0auch\u00a0Vertr\u00e4glichkeit\u00a0und\u00a0schwerwiegende\u00a0Nebenwirkungen\u00a0 sowie\u00a0even\u2010\ntuelle\u00a0Komorbidit\u00e4ten\u00a0zu\u00a0beachten\u00a0sind.\u00a0Im\u00a0Aufkl\u00e4rungsgespr\u00e4ch\u00a0 sollen\u00a0Patienten\u00a0\nin\u00a0die\u00a0Lage\u00a0versetzt\u00a0werden,\u00a0nach\u00a0einer\u00a0individuellen\u00a0Nutzen\u2010Ri siko\u2010Abw\u00e4gung\u00a0\neine\u00a0informierte\u00a0Entscheidung\u00a0gem \u00e4\u00df\u00a0ihren\u00a0pers\u00f6nlichen\u00a0Pr\u00e4feren zen\u00a0zu\u00a0treffen.\u00a0\nBei\u00a0nicht\u00a0vorbehandelten\u00a0Patienten\u00a0k\u00f6nnen\u00a0Substanzen\u00a0der\u00a0Katego rie\u00a01\u00a0zum\u00a0Ein\u2010\nsatz\u00a0kommen,\u00a0wenn\u00a0kein\u00a0hochaktiver\u00a0Verlauf\u00a0vorliegt.\u00a0Bei\u00a0Patien ten\u00a0mit\u00a0Kinder\u2010\nwunsch\u00a0wird\u00a0Teriflunomid\u00a0wegen\u00a0seines\u00a0teratogenen\u00a0Potenzials\u00a0un d\u00a0der\u00a0vorhan\u2010\ndenen\u00a0ausreichend\u00a0sicheren\u00a0Alternativen\u00a0nicht\u00a0als\u00a0Mittel\u00a0der\u00a0er sten\u00a0Wahl\u00a0in\u00a0Kate\u2010\ngorie\u00a01\u00a0betrachtet.\u00a0Bei\u00a0wahrscheinlich\u00a0hochaktivem\u00a0Verlauf\u00a0k\u00f6nn en\u00a0Wirkstoffe\u00a0aus\u00a0\nden\u00a0Kategorien\u00a02\u00a0und\u00a03\u00a0 verordnet\u00a0werden.\u00a0\u00a0\nEntwickelt\u00a0sich\u00a0w\u00e4hrend\u00a0einer\u00a0Be handlung\u00a0mit\u00a0einem\u00a0Wirkstoff\u00a0au s\u00a0Kategorie\u00a01\u00a0ein\u00a0\nentz\u00fcndlich\u00a0 aktiver\u00a0 Verlauf,\u00a0 wird\u00a0 je\u00a0 nach\u00a0 Ausma\u00df\u00a0 der\u00a0 Krankheits aktivit\u00e4t\u00a0 ein\u00a0\nWechsel\u00a0auf\u00a0einen\u00a0Wirkstoff\u00a0aus\u00a0den\u00a0Kategorien\u00a02\u00a0oder\u00a03\u00a0empfohl en.\u00a0Ein\u00a0Wechsel\u00a0\ninnerhalb\u00a0der\u00a0Kategorie\u00a01\u00a0sollte\u00a0nur\u00a0erwogen\u00a0werden,\u00a0wenn\u00a0patie ntenindividuelle\u00a0\nGr\u00fcnde\u00a0gegen\u00a0Wirkstoffe\u00a0aus\u00a0den\u00a0Kategorien\u00a02\u00a0oder\u00a03\u00a0sprechen.\u00a0W ird\u00a0eine\u00a0Be\u2010\nhandlung\u00a0mit\u00a0einem\u00a0Wirkstoff\u00a0aus\u00a0Kategorie\u00a03\u00a0n\u00f6tig,\u00a0stuft\u00a0die\u00a0L eitlinie\u00a0bei\u00a0JCV\u2010\nAntik\u00f6rper\u2010positiven\u00a0Patienten\u00a0C D20\u2010Antik\u00f6rper\u00a0als\u00a0Therapie\u00a0der \u00a0ersten\u00a0Wahl\u00a0ein.\u00a0\nBegr\u00fcndet\u00a0wird\u00a0das\u00a0vor\u00a0allem\u00a0durch\u00a0ein\u00a0besseres\u00a0Sicherheitsprof il\u00a0im\u00a0Vergleich\u00a0zu\u00a0\nAlemtuzumab\u00a0und\u00a0Natalizumab.\u00a0Alemtuzumab\u00a0sollte\u00a0in\u00a0Kategorie\u00a03\u00a0 nur\u00a0eingesetzt\u00a0\nwerden,\u00a0wenn\u00a0eine\u00a0Therapie\u00a0mit\u00a0Natalizumab\u00a0oder\u00a0CD20\u2010Antik\u00f6rper n\u00a0nicht\u00a0m\u00f6g\u2010\nlich\u00a0ist,\u00a0die\u00a0Patienten\u00a0nicht\u00a0darauf\u00a0ansprechen\u00a0oder\u00a0die\u00a0Behand lung\u00a0nicht\u00a0vertra\u2010\ngen.\u00a0\u00a0\nDie\u00a0Empfehlungen\u00a0der\u00a0deutschen\u00a0L eitlinie\u00a0entsprechen\u00a0in\u00a0wesentl ichen\u00a0Punkten\u00a0\nder\u00a0 europ\u00e4ischen\u00a0 Leitlinie,\u00a0 herausgegeben\u00a0 durch\u00a0 das\u00a0 European\u00a0 Committee\u00a0 of\u00a0\nTreatment\u00a0 and\u00a0 Research\u00a0 in\u00a0 Multiple\u00a0 Sclerosis \u00a0 (ECTRIMS)\u00a0 und\u00a0 die\u00a0 European\u00a0\nAcademy\u00a0of\u00a0Neurology \u00a0(EAN)\u00a0(Montalban\u00a0et\u00a0al.,\u00a02018),\u00a0sind\u00a0aber\u00a0wesentlich\u00a0detail\u2010\nlierter.\u00a0 \n67\u00a0\n\u00a0 Diskussion\u00a04.4\nIn\u00a0den\u00a0Jahren\u00a02011\u00a0bis\u00a02020\u00a0finden\u00a0sich\u00a0unter\u00a0den\u00a0neuen\u00a0Wirksto ffen\u00a0f\u00fcr\u00a0die\u00a0Be\u2010\nhandlung\u00a0des\u00a0fortgeschrittenen\u00a0ma lignen\u00a0Melanoms\u00a0eine\u00a0Reihe\u00a0von \u00a0Beispielen\u00a0f\u00fcr\u00a0\ntherapeutischen\u00a0Fortschritt,\u00a0dem\u00a0die\u00a0fr\u00fche\u00a0Nutzenbewertung\u00a0in\u00a0e inigen\u00a0F\u00e4llen\u00a0ein\u00a0\nbetr\u00e4chtliches\u00a0Ausma\u00df\u00a0attestiert .\u00a0Unter\u00a0den\u00a0Neueinf\u00fchrungen\u00a0in\u00a0 der\u00a0Immunthera\u2010\npie\u00a0der\u00a0RRMS\u00a0finden\u00a0sich\u00a0zwar\u00a0einige\u00a0neue\u00a0Wirkungsmechanismen,\u00a0 der\u00a0Mehrwert\u00a0\nder\u00a0neuen\u00a0Therapieoptionen\u00a0im\u00a0Ve rgleich\u00a0zu\u00a0bisherigen\u00a0Behandlun gsm\u00f6glichkei\u2010\nten\u00a0bleibt\u00a0jedoch\u00a0oft\u00a0unklar.\u00a0Wenn\u00a0ein\u00a0Zusatznutzen\u00a0\u00fcberhaupt\u00a0a nerkannt\u00a0wurde,\u00a0\nwar\u00a0er\u00a0gering\u00a0oder\u00a0nicht\u00a0quantifizierbar\u00a0(Tabellen\u00a04.3\u00a0und\u00a04.4) .\u00a0Das\u00a0belegt,\u00a0dass\u00a0\nsich\u00a0 anhand\u00a0 von\u00a0 Bewertungskriterien,\u00a0 die\u00a0 ausschlie\u00dflich\u00a0 auf\u00a0 pha rmakologische\u00a0\nAspekte\u00a0 fokussieren,\u00a0 etwa\u00a0 ob\u00a0 es\u00a0 sich\u00a0 um\u00a0 einen\u00a0 neuen\u00a0 Wirkungsmec hanismus\u00a0\nhandelt\u00a0beziehungsweise\u00a0den\u00a0erste n\u00a0Vertreter\u00a0einer\u00a0neuen\u00a0Wirkst offklasse,\u00a0der\u00a0\npatientenrelevante\u00a0Nutzen\u00a0eines\u00a0neuen\u00a0Wirkstoffs\u00a0nicht\u00a0umfassen d\u00a0absch\u00e4tzen\u00a0\nl\u00e4sst.\u00a0\nIn\u00a0den\u00a0Verfahren\u00a0zur\u00a0fr\u00fchen\u00a0Nutzenbewertung\u00a0f\u00e4llt\u00a0f\u00fcr\u00a0die\u00a0beide n\u00a0betrachteten\u00a0\nIndikationen\u00a0 auf,\u00a0 dass\u00a0 immer\u00a0 wied er\u00a0 direkte\u00a0 vergleichende\u00a0 Studi e n \u00a0m i t \u00a0d e r \u00a0\nzweckm\u00e4\u00dfigen\u00a0Vergleichstherapie\u00a0 fehlen.\u00a0In\u00a0einigen\u00a0F\u00e4llen\u00a0wurde n\u00a0deshalb\u00a0indi\u2010\nrekte\u00a0Vergleiche\u00a0herangezogen,\u00a0v on\u00a0denen\u00a0aber\u00a0bei\u00a0weitem\u00a0nicht\u00a0 alle\u00a0als\u00a0metho\u2010\ndisch\u00a0geeignet\u00a0eingestuft\u00a0wurden.\u00a0Wenn\u00a0ein\u00a0Zusatznutzen\u00a0zuerkan nt\u00a0wurde,\u00a0wur\u2010\nde\u00a0die\u00a0Wahrscheinlichkeit\u00a0nur\u00a0selten\u00a0als\u00a0Beleg\u00a0eingestuft,\u00a0meis t\u00a0nur\u00a0als\u00a0Hinweis\u00a0\noder\u00a0als\u00a0Anhaltspunkt.\u00a0\u00a0\nDiese\u00a0Beobachtungen\u00a0decken\u00a0sich\u00a0mit\u00a0denen\u00a0f\u00fcr\u00a0die\u00a0fr\u00fche\u00a0Nutzenb ewertung\u00a0ins\u2010\ngesamt,\u00a0bezogen\u00a0auf\u00a0die\u00a0Jahre\u00a02011\u00a0bis\u00a02020:\u00a0Das\u00a0Urteil\u00a0\u201eZusatz nutzen\u00a0nicht\u00a0be\u2010\nlegt\u201c\u00a0ist\u00a0in\u00a0der\u00a0Mehrheit\u00a0der\u00a0F\u00e4 lle\u00a0darauf\u00a0zur\u00fcckzuf\u00fchren,\u00a0dass \u00a0keine\u00a0entsprechen\u2010\nde\u00a0Evidenz\u00a0verf\u00fcgbar\u00a0oder\u00a0aus\u00a0Sicht\u00a0des\u00a0gemeinsamen\u00a0Bundesaussc husses\u00a0(G\u2010BA)\u00a0\ndie\u00a0 vorgelegte\u00a0 Evidenz\u00a0 nicht\u00a0 geeignet\u00a0 war.\u00a0 Wenn\u00a0 ein\u00a0 Zusatznutze n\u00a0 zuerkannt\u00a0\nwurde,\u00a0wurde\u00a0die\u00a0Erkenntnissicherheit\u00a0f\u00fcr\u00a0knapp\u00a0zwei\u00a0Drittel\u00a0al ler\u00a0Fragestellungen\u00a0\nnur\u00a0als\u00a0Hinweis\u00a0oder\u00a0Anhaltspunkt\u00a0eingestuft.\u00a0(Witte,\u00a02021).\u00a0\nDie\u00a0Ursachen\u00a0f\u00fcr\u00a0dieses\u00a0Ph\u00e4nomen\u00a0werden\u00a0seit\u00a0vielen\u00a0Jahren\u00a0disk utiert:\u00a0Zum\u00a0Zeit\u2010\npunkt\u00a0der\u00a0Zulassung\u00a0(und\u00a0damit\u00a0auch\u00a0in\u00a0der\u00a0Regel\u00a0zum\u00a0Zeitpunkt\u00a0 der\u00a0fr\u00fchen\u00a0Nut\u2010\nzenbewertung)\u00a0liegen\u00a0oftmals\u00a0keine\u00a0Studien\u00a0vor,\u00a0die\u00a0relevante\u00a0T herapieoptionen\u00a0\nmiteinander\u00a0vergleichen.\u00a0Gleiche s\u00a0gilt\u00a0auch\u00a0f\u00fcr\u00a0Studien,\u00a0die\u00a0na ch\u00a0der\u00a0Zulassung\u00a0\ndurchgef\u00fchrt\u00a0werden.\u00a0Diese\u00a0dienen\u00a0oft\u00a0eher\u00a0der\u00a0Erweiterung\u00a0von\u00a0 Indikationen\u00a0als\u00a0\nder\u00a0Schaffung\u00a0vergleichender\u00a0Evidenz.\u00a0Fachleute\u00a0fordern\u00a0deshalb \u00a0von\u00a0den\u00a0Zulas\u2010\nsungsbeh\u00f6rden,\u00a0entsprechende\u00a0Anreize\u00a0zu\u00a0schaffen,\u00a0damit\u00a0die\u00a0pha rmazeutischen\u00a0\nUnternehmen\u00a0aussagekr\u00e4ftige\u00a0vergleichende\u00a0Evidenz\u00a0vor\u00a0und\u00a0nach\u00a0 der\u00a0Zulassung\u00a0\ngenerieren,\u00a0und\u00a0die\u00a0Anforderungen\u00a0an\u00a0die\u00a0Studien\u00a0in\u00a0Zusammenarb eit\u00a0mit\u00a0Institu\u2010 \n68\u00a0\n\u00a0tionen\u00a0f\u00fcr\u00a0die\u00a0Nutzenbewertung\u00a0fe stzulegen\u00a0(Naci\u00a0et\u00a0al.,\u00a02020,\u00a0 Cipriani\u00a0et\u00a0al.,\u00a02020,\u00a0\nWieseler\u00a0et\u00a0al.,\u00a02019).\u00a0\nWie\u00a0n\u00f6tig\u00a0das\u00a0ist,\u00a0zeigt\u00a0das\u00a0Beispiel\u00a0Multiple\u00a0Sklerose:\u00a0Einer\u00a0 Auswertung\u00a0der\u00a0Zeit\u2010\nschrift\u00a0Prescrire\u00a0aus\u00a0dem\u00a0Jahr\u00a02019\u00a0zufolge\u00a0basierte\u00a0die\u00a0Zulass ung\u00a0von\u00a0acht\u00a0neuen\u00a0\nWirkstoffen\u00a0f\u00fcr\u00a0diese\u00a0Indikation\u00a0in\u00a0den\u00a0letzten\u00a015\u00a0Jahren\u00a0auf\u00a01 6\u00a0klinischen\u00a0Studien,\u00a0\nvon\u00a0denen\u00a0lediglich\u00a0f\u00fcnf\u00a0das\u00a0neue\u00a0Arzneimittel\u00a0mit\u00a0einem\u00a0aktive n\u00a0Komparator\u00a0vergli\u2010\nchen.\u00a0Die\u00a0anderen\u00a0elf\u00a0Studien\u00a0war en\u00a0lediglich\u00a0placebokontrollie rt.\u00a0Nach\u00a0der\u00a0Zulas\u2010\nsung\u00a0wurden\u00a052\u00a0weitere\u00a0randomisierte\u00a0kontrollierte\u00a0Studien\u00a0durc hgef\u00fchrt,\u00a0von\u00a0de\u2010\nnen\u00a0zwei\u00a0Drittel\u00a0ebenfalls\u00a0ledig lich\u00a0mit\u00a0Placebo\u00a0verglichen\u00a0(Pr escrire\u00a0Int,\u00a02019).\u00a0\nFehlt\u00a0solche\u00a0vergleichende\u00a0Evidenz,\u00a0beeintr\u00e4chtigt\u00a0das\u00a0die\u00a0klin ische\u00a0Entscheidungs\u2010\nfindung\u00a0empfindlich.\u00a0Das\u00a0spiegelt\u00a0sich\u00a0teilweise\u00a0auch\u00a0in\u00a0Leitli nienempfehlungen\u00a0\nwider,\u00a0wenn\u00a0mangels\u00a0vergleichender\u00a0Daten\u00a0keine\u00a0Priorisierung\u00a0ei nzelner\u00a0Wirkstof\u2010\nfe\u00a0m\u00f6glich\u00a0ist.\u00a0Neue\u00a0vergleichende\u00a0Erkenntnisse\u00a0zur\u00a0Immuntherap ie\u00a0der\u00a0RRMS\u00a0sind\u00a0\nf\u00fcr\u00a0Mitte\u00a02022\u00a0zu\u00a0erwarten:\u00a0Der\u00a0G\u2010BA\u00a0hat\u00a0das\u00a0Institut\u00a0f\u00fcr\u00a0Quali t\u00e4t\u00a0und\u00a0Wirtschaft\u2010\nlichkeit\u00a0im\u00a0Gesundheitswesen\u00a0(IQWiG)\u00a0beauftragt,\u00a0f\u00fcr\u00a0Alemtuzuma b,\u00a0Natalizumab,\u00a0\nFingolimod,\u00a0Ocrelizumab,\u00a0Cladribi n,\u00a0Teriflunomid\u00a0und\u00a0Dimethylfu marat\u00a0ein\u00a0Gut\u2010\nachten\u00a0f\u00fcr\u00a0eine\u00a0Nutzenbewertung\u00a0zu\u00a0erstellen,\u00a0die\u00a0die\u00a0Wirkstoff e\u00a0bei\u00a0der\u00a0Behand\u2010\nlung\u00a0 von\u00a0 Erwachsenen\u00a0 mit\u00a0 hochaktiver\u00a0 schubf\u00f6rmig\u2010remittierender \u00a0M u l t i p l e r \u00a0\nSklerose\u00a0trotz\u00a0vollst\u00e4ndiger\u00a0und \u00a0angemessener\u00a0Behandlung\u00a0mit\u00a0mi ndestens\u00a0einer\u00a0\nkrankheitsmodifizierenden\u00a0Therapie\u00a0vergleicht\u00a0(G\u2010BA,\u00a02020).\u00a0\nWie\u00a0lange\u00a0es\u00a0mitunter\u00a0nach\u00a0der\u00a0Zulassung\u00a0dauern\u00a0kann,\u00a0bis\u00a0aussa gekr\u00e4ftige\u00a0Daten\u00a0\nzu\u00a0 bestimmten\u00a0 patientenrelevante n\u00a0 Endpunkten\u00a0 vorliegen,\u00a0 zeigt\u00a0 d as\u00a0 Beispiel\u00a0\nPembrolizumab:\u00a0F\u00fcr\u00a0die\u00a0adjuvante\u00a0 Therapie\u00a0beim\u00a0malignen\u00a0Melanom \u00a0wurde\u00a0der\u00a0\nWirkstoff\u00a0im\u00a0Dezember\u00a02018\u00a0zuge lassen.\u00a0Zu\u00a0diesem\u00a0Zeitpunkt\u00a0lage n\u00a0noch\u00a0keine\u00a0\nDaten\u00a0zum\u00a0Gesamt\u00fcberleben\u00a0vor.\u00a0Auch\u00a0f\u00fcr\u00a0eine\u00a0sichere\u00a0Einsch\u00e4tzu ng\u00a0zum\u00a0Auftre\u2010\nten\u00a0von\u00a0Rezidiven\u00a0und\u00a0des\u00a0rezidivf reien\u00a0\u00dcberlebens\u00a0waren\u00a0die\u00a0In formationen\u00a0f\u00fcr\u00a0\ndie\u00a0Nutzenbewertung\u00a0noch\u00a0nicht\u00a0ausreichend.\u00a0Der\u00a0pharmazeutische \u00a0Unternehmer\u00a0\nmuss\u00a0der\u00a0europ\u00e4ischen\u00a0Zulassungsbeh\u00f6rde\u00a0weitere\u00a0Daten\u00a0vorlegen, \u00a0allerdings\u00a0erst\u00a0\nim\u00a04.\u00a0Quartal\u00a02023.\u00a0Zum\u00a0Zeitpunkt\u00a0der\u00a0ersten\u00a0fr\u00fchen\u00a0Nutzenbewer tung\u00a0konnte\u00a0der\u00a0\nG\u2010BA\u00a0deshalb\u00a0nur\u00a0ein\u00a0Hinweis\u00a0auf\u00a0einen\u00a0nicht\u00a0quantifizierbaren\u00a0 Zusatznutzen\u00a0fest\u2010\nstellen.\u00a0Der\u00a0Beschluss\u00a0wurde\u00a0befristet,\u00a0eine\u00a0Neubewertung\u00a0begin nt\u00a0voraussichtlich\u00a0\nim\u00a0April\u00a02024.\u00a0\u00a0\nOb\u00a0neue\u00a0Wirkstoffe\u00a0einen\u00a0therapeutischen\u00a0Fortschritt\u00a0darstellen ,\u00a0h\u00e4ngt\u00a0oft\u00a0auch\u00a0\ndavon\u00a0ab,\u00a0welche\u00a0Patientengruppe\u00a0betrachtet\u00a0wird.\u00a0Das\u00a0verdeutli cht\u00a0die\u00a0Notwen\u2010\ndigkeit\u00a0 differenzierter\u00a0 Betrachtungen.\u00a0 Beim\u00a0 malignen\u00a0 Melanom\u00a0 wu rde\u00a0 etwa\u00a0\nPembrolizumab\u00a0bei\u00a0der\u00a0Behandlung\u00a0von\u00a0Patienten\u00a0mit\u00a0B\u2010RAF\u2010V600\u2010W ildtyp\u00a0in\u00a0der\u00a0\nErstlinientherapie\u00a0ein\u00a0betr\u00e4chtlicher\u00a0Zusatznutzen\u00a0zuerkannt,\u00a0w \u00e4hrend\u00a0er\u00a0bei\u00a0Tu\u2010\nmoren\u00a0 mit\u00a0 B\u2010RAF\u2010V600\u2010Mutation\u00a0 nicht\u00a0 belegt\u00a0 ist.\u00a0 Bei\u00a0 der\u00a0 Kombina tion\u00a0 von\u00a0 I\u2010 \n69\u00a0\n\u00a0pilimumab\u00a0und\u00a0Nivolumab\u00a0in\u00a0der\u00a0Er stlinientherapie\u00a0fand\u00a0sich\u00a0bei \u00a0B\u2010RAF\u2010V600\u2010\nWildtyp\u00a0sogar\u00a0ein\u00a0Hinweis\u00a0auf\u00a0einen\u00a0geringeren\u00a0Nutzen.\u00a0Hier\u00a0feh lten\u00a0nicht\u00a0nur\u00a0\npositive\u00a0Effekte,\u00a0wie\u00a0es\u00a0auch\u00a0bei\u00a0Vorliegen\u00a0einer\u00a0B\u2010RAF\u2010V600\u2010Mu tation\u00a0konstatiert\u00a0\nwurde,\u00a0sondern\u00a0es\u00a0fanden\u00a0sich\u00a0dar\u00fcber\u00a0hinaus\u00a0auch\u00a0noch\u00a0Hinweise \u00a0f\u00fcr\u00a0ein\u00a0ausge\u2010\npr\u00e4gtes\u00a0Nebenwirkungspotenzial.\u00a0\nDie\u00a0beiden\u00a0betrachteten\u00a0Indikationen\u00a0illustrieren,\u00a0dass\u00a0sich\u00a0na ch\u00a0der\u00a0Zulassung\u00a0\nund\u00a0der\u00a0fr\u00fchen\u00a0Nutzenbewertung\u00a0nicht\u00a0nur\u00a0neue\u00a0Daten\u00a0zum\u00a0Nutzen, \u00a0sondern\u00a0auch\u00a0\nwichtige\u00a0Erkenntnisse\u00a0zur\u00a0Sicherheit\u00a0ergeben\u00a0k\u00f6nnen.\u00a0Das\u00a0unters treicht\u00a0die\u00a0Forde\u2010\nrung,\u00a0die\u00a0fr\u00fche\u00a0Nutzenbewertung\u00a0regelhaft\u00a0durch\u00a0eine\u00a0sp\u00e4tere\u00a0Be wertung\u00a0einige\u00a0\nJahre\u00a0sp\u00e4ter\u00a0zu\u00a0erg\u00e4nzen\u00a0(Glaeske\u00a0et\u00a0al,\u00a02017).\u00a0Zum\u00a0Teil\u00a0passie rt\u00a0das\u00a0auch\u00a0schon\u00a0im\u00a0\nAMNOG\u2010Verfahren.\u00a0So\u00a0hat\u00a0der\u00a0G\u2010BA\u00a0im\u00a0M\u00e4rz\u00a02021\u00a0f\u00fcr\u00a0den\u00a0Wirkstoff \u00a0Tofacitinib\u00a0im\u00a0\nAnwendungsgebiet\u00a0Rheumatoide\u00a0Art hritis\u00a0unter\u00a0anderem\u00a0wegen\u00a0neue r\u00a0Daten\u00a0zur\u00a0\nLangzeitsicherheit\u00a0eine\u00a0erneute\u00a0Nutzenbewertung\u00a0veranlasst\u00a0(G\u2010B A,\u00a02021).\u00a0\u00a0\nQuellen\u00a0\nDen\u00a0Beschreibungen\u00a0der\u00a0Zulassungsstatus\u00a0liegt\u00a0die\u00a0jeweils\u00a0aktue llste\u00a0Fachinformation\u00a0des\u00a0jeweilig en\u00a0Pr\u00e4parats\u00a0auf\u00a0der\u00a0Website\u00a0 der\u00a0\nEMA\u00a0https://www.ema.europa.eu/\u00a0zugrunde.\u00a0Letzter\u00a0Zugriff:\u00a014.06 .2021.\u00a0\nDie\u00a0arznei\u2010telegramm\u00a0Datenbank\u00a0https://www.arznei\u2010telegramm.de/ \u00a0und\u00a0die\u00a0Bewertungen\u00a0in\u00a0Prescrire\u00a0(genannt\u00a0ist\u00a0jeweils\u00a0das\u00a0\nVer\u00f6ffentlichungsdatum\u00a0in\u00a0der\u00a0englischsprachigen\u00a0Ausgabe)\u00a0https ://english.prescrire.org/\u00a0wurden\u00a0zuletzt\u00a0am\u00a014.06.2021\u00a0\n\u00fcberpr\u00fcft,\u00a0ebenso\u00a0die\u00a0Ergebnisse\u00a0der\u00a0fr\u00fchen\u00a0Nutzenbewertung\u00a0des \u00a0G\u2010BA\u00a0unter\u00a0https://www.g\u2010\nba.de/bewertungsverfahren/nutzenbewertung/\u00a0\nDie\u00a0Website\u00a0der\u00a0Arzneimittelkommission\u00a0der\u00a0deutschen\u00a0\u00c4rzteschaf t\u00a0(Akd\u00c4)\u00a0https://akdae.de/Arzneimittelsicherheit/index.html\u00a0\nwurde\u00a0zuletzt\u00a0am\u00a014.06.2021\u00a0auf\u00a0Rote\u2010Hand\u2010Briefe\u00a0und\u00a0Drug\u00a0Safet y\u00a0Mails\u00a0zu\u00a0den\u00a0besprochenen\u00a0Wirkstoffen\u00a0gepr\u00fcft.\u00a0\nDie\u00a0Bewertungen\u00a0der\u00a0bisherigen\u00a0Innovationsreporte\u00a0wurden\u00a0jeweil s\u00a0den\u00a0Langfassungen\u00a0entnommen.\u00a0https://www.socium.uni\u2010\nbremen.de/ueber\u2010das\u2010socium/mitglieder/gerd\u2010glaeske/projekte/inn ovationsreport/archiv\u2010innovationsreporte\u20102013\u2010\u20102020/,\u00a0letzter\u00a0\nZugriff\u00a014.06.2021.\u00a0\nabbVie\u00a0(2016).\u00a0Wichtige\u00a0Informationen\u00a0\u2010\u00a0Rote\u00a0Hand\u00a0Brief.\u00a0\nhttps://www.akdae.de/Arzneimittelsicherheit/RHB/Archiv/2016/201 60104.pdf,\u00a0letzter\u00a0Zugriff:\u00a010.02.2022.\u00a0\n\u00c4rzte\u00a0ohne\u00a0Grenzen\u00a0(2018).\u00a0Ein\u00a0System\u00a0verfehlt\u00a0sein\u00a0Ziel.\u00a0https ://www.aerzte\u2010ohne\u2010\ngrenzen.de/sites/default/files/ei n_system_verfehlt_medikamenten kampagne_rz01_20180606_web.pdf,\u00a0letzter\u00a0\nZugriff:\u00a010.02.2022.\u00a0\na\u2010t\u00a0(2015).\u00a0Weiterhin\u00a0Mondpreise\u00a0f\u00fcr\u00a0Hepatitis\u2010C\u2010Mittel\u00a0Sofosbu vir\u00a0(SOVALDI).\u00a0https://www.arznei\u2010\ntelegramm.de/html/2015_02/1502017_01.html,\u00a0letzter\u00a0Zugriff:\u00a010. 02.2022.\u00a0\na\u2010t\u00a0(2016).\u00a0Finanzielle\u00a0Spekulationen\u00a0behindern\u00a0Versorgung\u00a0mit\u00a0 Arzneimitteln.\u00a0https://www.arznei\u2010\ntelegramm.de/html/2016_09/1609079_02.html,\u00a0letzter\u00a0Zugriff:\u00a010. 02.2022.\u00a0\nCipriani\u00a0A,\u00a0Ioannidis\u00a0J,\u00a0Rothwell\u00a0P,\u00a0Glasziou\u00a0P,\u00a0Li\u00a0T,\u00a0Hernande z\u00a0A\u00a0et\u00a0al.\u00a0(2020).\u00a0Generating\u00a0comparative\u00a0evidence\u00a0on\u00a0new\u00a0drugs \u00a0and\u00a0\ndevices\u00a0after\u00a0approval.\u00a0Lancet\u00a0395(10228):\u00a0998\u20101010.\u00a0\nDGN\u00a0\u00a0Deutsche\u00a0Gesellschaft\u00a0f\u00fcr\u00a0Neurologie\u00a0(2021).\u00a0S2k\u2010Leitlinie \u00a0Diagnose\u00a0und\u00a0Therapie\u00a0der\u00a0Multiplen\u00a0Sklerose,\u00a0Neuromyelitis\u2010\noptica\u2010Spektrum\u2010Erkrankungen\u00a0und\u00a0MOG\u2010IgG\u2010assoziierten\u00a0Erkrankun gen.\u00a0https://dgn.org/leitlinien/ll\u2010030\u2010050\u2010 \n70\u00a0\n\u00a0diagnose\u2010und\u2010therapie\u2010der\u2010multiplen\u2010sklerose\u2010neuromyelitis\u2010opti ca\u2010spektrum\u2010erkrankungen\u2010und\u2010mog\u2010igg\u2010\nassoziierten\u2010erkrankungen/,\u00a0letzter\u00a0Zugriff\u00a014.06.2021.\u00a0\nFricke\u00a0U,\u00a0G\u00fcnther\u00a0J,\u00a0Niepraschk\u00a0 von\u00a0Dollen\u00a0K,\u00a0Zawinell\u00a0A\u00a0(2022) .\u00a0Methodik\u00a0der\u00a0ATC\u2010Klassifikation\u00a0und\u00a0DDD\u2010Festlegung\u00a0f\u00fcr\u00a0den\u00a0\ndeutschen\u00a0Arzneimittelmarkt.\u00a0\nhttps://www.wido.de/fileadmin/Dateien/Dokumente/Publikationen_P rodukte/Arzneimittel\u2010\nKlassifikation/ATC_2021/atc_gkv\u2010a i_2021.zip,\u00a0letzter\u00a0Zugriff:\u00a01 0.02.2022.\u00a0\nGarbe\u00a0C,\u00a0Amaral\u00a0T,\u00a0Peris\u00a0K,\u00a0Hauschild\u00a0A,\u00a0Arenberger\u00a0P,\u00a0Bastholt \u00a0L\u00a0et\u00a0al.\u00a0(2020).\u00a0European\u00a0consensus\u2010based\u00a0interdisciplinary\u00a0\nguideline\u00a0for\u00a0melanoma.\u00a0Part\u00a02:\u00a0 Treatment.\u00a0Update\u00a02019.\u00a0Eur\u00a0J\u00a0C ancer\u00a0126:\u00a0159\u2010177.\u00a0\nG\u2010BA\u00a0(2020).\u00a0Beauftragung\u00a0IQWiG:\u00a0Nutzenbewertung\u00a0von\u00a0Alemtuzuma b,\u00a0Cladribin,\u00a0Dimethylfumarat,\u00a0Fingolimod,\u00a0Natalizumab,\u00a0\nOcrelizumab\u00a0und\u00a0Teriflunomid\u00a0zur\u00a0Behandlung\u00a0der\u00a0Multiplen\u00a0Skler ose.\u00a0https://www.g\u2010ba.de/beschluesse/4386/,\u00a0\nletzter\u00a0Zugriff\u00a016.06.2021.\u00a0\nG\u2010BA\u00a0(2021).\u00a0Veranlassung\u00a0einer\u00a0erneuten\u00a0Nutzenbewertung:\u00a0Tofac itinib\u00a0(rheumatoide\u00a0Arthritis).\u00a0https://www.g\u2010\nba.de/beschluesse/4740/,\u00a0letzter\u00a0Zugriff\u00a016.06.2021.\u00a0\nGilead,\u00a0BMS\u00a0(2015).\u00a0Wichtige\u00a0Inf ormation\u00a0zu\u00a0Harvoni,\u00a0Sovaldi\u00a0un d\u00a0Daklinza\u00a0\u2013\u00a0Rote\u2010Hand\u2010Briefe.\u00a0\nhttps://www.akdae.de/Arzneimittelsicherheit/RHB/Archiv/2015/201 50512.pdf,\u00a0letzter\u00a0Zugriff:\u00a010.02.2022.\u00a0\nGlaeske\u00a0G\u00a0(Hg.)\u00a0(2020).\u00a0Innovationsreport\u00a02020.\u00a0Bremen,\u00a0SOCIUM. \u00a0\nGlaeske\u00a0G,\u00a0Ludwig\u00a0W\u2010D,\u00a0Wei\u00dfbach\u00a0 L\u00a0(2017).\u00a0AMNOG:\u00a0Pflicht\u00a0zur\u00a0sp \u00e4ten\u00a0Nutzenbewertung.\u00a0Dtsch\u00a0\u00c4rztebl\u00a0114(45):\u00a0A\u20102086/B\u2010\n1758/C\u20101716.\u00a0\nGlaeske\u00a0G,\u00a0Ludwig\u00a0W\u2010D\u00a0(Hg.)\u00a0(2017).\u00a0Innovationsreport\u00a02017.\u00a0Bre men,\u00a0SOCIUM.\u00a0\nGlaeske\u00a0G,\u00a0Ludwig\u00a0W\u2010D\u00a0(Hg.)\u00a0(2018).\u00a0Innovationsreport\u00a02018.\u00a0Bre men,\u00a0SOCIUM.\u00a0\nGlaeske\u00a0G,\u00a0Ludwig\u00a0W\u2010D\u00a0(Hg.)\u00a0(2019).\u00a0Innovationsreport\u00a02019.\u00a0Bre men,\u00a0SOCIUM.\u00a0\nGlaeske\u00a0G,\u00a0Ludwig\u00a0W\u2010D,\u00a0Th\u00fcrmann\u00a0P\u00a0(Hg.)\u00a0(2016).\u00a0Innovationsrepo rt\u00a02016.\u00a0Bremen,\u00a0\u00a0\nGlaeske\u00a0G,\u00a0Ludwig\u00a0W\u2010D,\u00a0Th\u00fcrmann\u00a0P\u00a0(Hg.)(2015).\u00a0Innovationsrepor t\u00a02015.\u00a0Bremen,\u00a0SOCIUM.\u00a0\nIQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0im\u00a0Gesundh eitswesen\u00a0(2022).\u00a0Orphan\u00a0Drugs:\u00a0Privileg\u00a0des\u00a0\u201efiktiven\u201c\u00a0\nZusatznutzens\u00a0nicht\u00a0gerechtfertigt.\u00a0https://www.iqwig.de/presse /pressemitteilungen/pressemitteilungen\u2010\ndetailseite_58496.html,\u00a0letzter\u00a0Zugriff:\u00a010.02.2022.\u00a0\nJanssen\u00a0(2013).\u00a0Wichtige\u00a0Arzneimittelinformation\u00a0\u2013\u00a0Rote\u2010Hand\u2010Br ief.\u00a02013.\u00a0\nhttps://www.akdae.de/Arzneimittelsicherheit/RHB/Archiv/2013/201 30409.pdf,\u00a0letzter\u00a0Zugriff:\u00a010.02.2022.\u00a0\nLeitlinienprogramm\u00a0Onkologie\u00a0(2020).\u00a0S3\u2010Leitlinie\u00a0Diagnostik,\u00a0T herapie\u00a0und\u00a0Nachsorge\u00a0des\u00a0Melanoms,\u00a0Version\u00a03.3.\u00a0\nhttps://www.leitlinienprogramm\u2010onkologie.de/leitlinien/melanom/ ,\u00a0letzter\u00a0Zugriff\u00a014.06.2021.\u00a0\nMichielin\u00a0O,\u00a0van\u00a0Akkooi\u00a0A,\u00a0Ascierto\u00a0P,\u00a0Dummer\u00a0R,\u00a0Keilholz\u00a0U\u00a0(20 19).\u00a0Cutaneous\u00a0melanoma:\u00a0ESMO\u00a0C linical\u00a0Practice\u00a0Guidelines\u00a0for\u00a0\ndiagnosis,\u00a0treatment\u00a0and\u00a0follow\u2010up.\u00a0Annals\u00a0Oncol\u00a030(12):\u00a01884\u20101 901.\u00a0\nMontalban\u00a0X,\u00a0Gold\u00a0R,\u00a0Thompson\u00a0A,\u00a0Otero\u2010Romeros\u00a0S,\u00a0Amato\u00a0M,\u00a0Chan draratna\u00a0D\u00a0et\u00a0al.\u00a0(2018).\u00a0EC TRIMS/EAN\u00a0Guideline\u00a0on\u00a0the\u00a0\npharmacological\u00a0treatment\u00a0of\u00a0peop le\u00a0with\u00a0multiple\u00a0sclerosis.\u00a0Eu r\u00a0J\u00a0Neurol\u00a025(2):\u00a0215\u2010237.\u00a0\nNaci\u00a0H,\u00a0Salcher\u2010Konrad\u00a0M,\u00a0Kesselh eim\u00a0A,\u00a0Wieseler\u00a0B,\u00a0Rochaix\u00a0L,\u00a0 Redberg\u00a0R\u00a0et\u00a0al.\u00a0(2020).\u00a0Generating\u00a0comparative\u00a0evidence\u00a0on\u00a0new \u00a0\ndrugs\u00a0and\u00a0devices\u00a0before\u00a0approval.\u00a0Lancet\u00a0395(10228):\u00a0986\u2010997.\u00a0 \n71\u00a0\n\u00a0Prescrire\u00a0International\u00a0(2019).\u00a0Multiple\u00a0sclerosis:\u00a0wasted\u00a0oppo rtunities.\u00a0Prescrire\u00a0Int\u00a028(203):\u00a087.\u00a0\nReich\u00a0D,\u00a0Lucchinetti\u00a0C,\u00a0Calabresi\u00a0P.\u00a0Multiple\u00a0sclerosis\u00a0(2018). \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a0378(2):\u00a0169\u2010180.\u00a0\nRKI\u00a0(2021).\u00a0Malignes\u00a0Melanom\u00a0der\u00a0Haut.\u00a0https://www.krebsdaten.d e/melanom,\u00a0letzter\u00a0Zugriff\u00a014.06.2021.\u00a0\nSchadendorf\u00a0D,\u00a0Fisher,\u00a0D,\u00a0Garbe\u00a0C,\u00a0Gershenwald\u00a0J,\u00a0Grob\u00a0J,\u00a0Halpe rn\u00a0A\u00a0et\u00a0al.\u00a0(2015).\u00a0Melanoma.\u00a0Nature\u00a0Rev\u00a0Dis\u00a0Prim\u00a01:\u00a0150\u2010203.\u00a0\nThompson\u00a0A,\u00a0Baranzini\u00a0S,\u00a0Geurts\u00a0 J,\u00a0Hemmer\u00a0B,\u00a0Ciccarelli\u00a0O\u00a0(2018 ).\u00a0Multiple\u00a0sclerosis.\u00a0Lancet\u00a0391(10130):\u00a01622\u20101636.\u00a0\nWieseler\u00a0B,\u00a0McGauran\u00a0N,\u00a0Kaiser\u00a0T\u00a0(2019).\u00a0New\u00a0drugs:\u00a0where\u00a0did\u00a0w e\u00a0go\u00a0wrong\u00a0and\u00a0what\u00a0can\u00a0we\u00a0do\u00a0better?\u00a0BMJ\u00a0366:\u00a0l4340.\u00a0\nWindt\u00a0R,\u00a0Boeschen\u00a0D,\u00a0Glaeske\u00a0G\u00a0(2013).\u00a0Innovationsreport\u00a02013.\u00a0 Bremen,\u00a0SOCIUM.\u00a0\nWindt\u00a0R,\u00a0Boeschen\u00a0D,\u00a0Glaeske\u00a0G\u00a0(2014).\u00a0Innovationsreport\u00a02014.\u00a0 Bremen,\u00a0SOCIUM.\u00a0\nWitte\u00a0J\u00a0(2021)\u00a0Zahlen,\u00a0Daten,\u00a0Fakten.\u00a0Oder:\u00a0Was\u00a0wir\u00a0\u00fcber\u00a0die\u00a0fr \u00fche\u00a0Nutzenbewertung\u00a0wissen\u00a0und\u00a0was\u00a0nicht.\u00a0Vortrag\u00a0bei\u00a0der\u00a0G\u2010BA\u2010\nOnline\u2010Veranstaltung\u00a0\u201e10\u00a0Jahre\u00a0AMNOG\u00a0\u2010\u00a0Zehn\u00a0Jahre\u00a0Lernen\u00a0und\u00a0We iterdenken\u00a0in\u00a0der\u00a0fr\u00fchen\u00a0Nutzenbewertung\u201c\u00a0\nam\u00a019.03.2021\u00a0https://www.g\u2010ba.de/service/veranstaltungen/10\u2010ja hre\u2010amnog/,\u00a0letzter\u00a0Zugriff\u00a016.06.2021.\u00a0\n\u00a0 \u00a0 \n72\u00a0\n\u00a0\u00a0 \u00a0 \n73\u00a0\n\u00a05 Schw\u00e4chen\u00a0des\u00a0AMNOG\u00a0\u2013\u00a0\u201eBl\u00fctenlese\u201c\u00a0aus\u00a0acht\u00a0Jahren\u00a0Innovations\u2010\nreport\u00a0\nIn\u00a0diesem\u00a0Kapitel\u00a0soll\u00a0auf\u00a0einige\u00a0Erfolge,\u00a0aber\u00a0auch\u00a0auf\u00a0Schw\u00e4c hen\u00a0des\u00a0AMNOG\u00a0\nhingewiesen\u00a0werden,\u00a0das\u00a0am\u00a01.1.2011\u00a0in\u00a0Kraft\u00a0trat.\u00a0Dabei\u00a0wird\u00a0B ezug\u00a0genommen\u00a0\nauf\u00a0die\u00a0Ergebnisse\u00a0der\u00a0bisher\u00a0publizierten\u00a0acht\u00a0Innovationsrepo rte\u00a0(2013\u00a0bis\u00a02020),\u00a0\nin\u00a0denen\u00a0jeweils\u00a0die\u00a0neuen\u00a0paten tgesch\u00fctzten\u00a0Arzneimittel\u00a0nach\u00a0 einem\u00a0eigenen\u00a0\nBewertungsschema\u00a0beurteilt\u00a0wurden, \u00a0die\u00a0zwei\u00a0Jahre\u00a0vor\u00a0der\u00a0jewei ligen\u00a0Publikation\u00a0\nim\u00a0Markt\u00a0erstmals\u00a0angeboten\u00a0wurden.\u00a0Das\u00a0hat\u00a0den\u00a0Vorteil,\u00a0dass\u00a0n eben\u00a0den\u00a0Daten\u00a0\naus\u00a0den\u00a0Zulassungsstudien\u00a0weitere\u00a0Daten\u00a0aus\u00a0der\u00a0realen\u00a0Versorgu ng\u00a0einflie\u00dfen\u00a0\nund\u00a0Aspekte\u00a0wie\u00a0bisher\u00a0unbekannte\u00a0unerw\u00fcnschte\u00a0Wirkungen,\u00a0die\u00a0z u\u00a0Rote\u2010Hand\u2010\nBriefen\u00a0f\u00fchrten,\u00a0oder\u00a0die\u00a0oft\u00a0 \u00fcberraschend\u00a0schnell\u00a0entschiedene \u00a0Aufnahme\u00a0in\u00a0\nLeitlinien\u00a0ber\u00fccksichtigt\u00a0werden\u00a0konnten.\u00a0Grunds\u00e4tzlich\u00a0ist\u00a0auc h\u00a0zu\u00a0konstatieren,\u00a0\ndass\u00a0die\u00a0von\u00a0den\u00a0pharmazeutischen\u00a0Unternehmen\u00a0vorgelegten\u00a0Daten ,\u00a0Studien\u00a0und\u00a0\nDossiers\u00a0im\u00a0Laufe\u00a0der\u00a0letzten\u00a0Jahre\u00a0an\u00a0Aussagekraft\u00a0und\u00a0methodi scher\u00a0Belastbar\u2010\nkeit\u00a0gewonnen\u00a0haben,\u00a0wenn\u00a0auch\u00a0noch\u00a0nicht\u00a0alle\u00a0gesetzlichen\u00a0Anf orderungen\u00a0an\u00a0\nden\u00a0 Nachweis\u00a0 des\u00a0 Patientennutzens\u00a0 ausreichend\u00a0 ber\u00fccksichtig\u00a0 wer den:\u00a0 Der\u00a0\n\u00a7\u00a035\u00a0b\u00a0SGB\u00a0V\u00a0sieht\u00a0n\u00e4mlich\u00a0diesen\u00a0Nachweis\u00a0erst\u00a0dann\u00a0als\u00a0erbrac ht\u00a0an,\u00a0wenn\u00a0die\u00a0\nStudien\u00a0eine\u00a0verl\u00e4ngerte\u00a0Lebenszeit,\u00a0eine\u00a0Verringerung\u00a0der\u00a0Kran kheitslast\u00a0und\u00a0der\u00a0\nunerw\u00fcnschten\u00a0Begleiterscheinungen\u00a0und\u00a0eine\u00a0Verbesserung\u00a0der\u00a0Le bensqualit\u00e4t\u00a0\nzeigen.\u00a0Dies\u00a0ist\u00a0aber\u00a0bisher\u00a0nur \u00a0bedingt\u00a0der\u00a0Fall,\u00a0hier\u00a0gibt\u00a0es \u00a0Nachholbedarf.\u00a0\nGrunds\u00e4tzlich\u00a0ist\u00a0das\u00a0AMNOG\u00a0insofern\u00a0ein\u00a0Fortschritt\u00a0in\u00a0der\u00a0GKV \u2010Arzneimittel\u2010\nversorgung,\u00a0als\u00a0dadurch\u00a0eine\u00a0Kosten\u2010Nutzen\u2010Bewertung\u00a0vorgesehen \u00a0i st, \u00a0di e\u00a0zu\u00a0\nerheblichen\u00a0Einsparungen\u00a0auf\u00a0Grund\u00a0der\u00a0Verhandlungen\u00a0\u00fcber\u00a0einen \u00a0Erstattungs\u2010\nbetrag\u00a0zwischen\u00a0dem\u00a0GKV\u2010Spitze nverband\u00a0und\u00a0dem\u00a0jeweiligen\u00a0pharm azeutischen\u00a0\nUnternehmer\u00a0als\u00a0Anbieter\u00a0eines\u00a0neuen\u00a0patentgesch\u00fctzten\u00a0Arzneimi ttels\u00a0f\u00fchren\u00a0\nsollte:\u00a0zwei\u00a0Mrd.\u00a0Euro\u00a0wurden\u00a0bei\u00a0der\u00a0Gesetzeseinf\u00fchrung\u00a0progno stiziert.\u00a0In\u00a0der\u00a0\nRealit\u00e4t\u00a0wurde\u00a0dieser\u00a0Betrag\u00a0allerdings\u00a0erst\u00a0im\u00a0achten\u00a0Jahr\u00a0nac h\u00a0Inkrafttreten\u00a0des\u00a0\nAMNOG\u00a0erreicht\u00a0(im\u00a0Jahre\u00a02018\u00a0ware n\u00a0es\u00a0nach\u00a0den\u00a0Angaben\u00a0im\u00a0Arzn eiverord\u2010\nnungs\u2010Report\u00a02,65\u00a0Mrd.\u00a0Euro),\u00a0der\u00a0Preisanstieg\u00a0bei\u00a0neuen\u00a0patent gesch\u00fctzten\u00a0Mit\u2010\nteln\u00a0pro\u00a0Packung\u00a0konnte\u00a0nicht\u00a0gebremst\u00a0werden\u00a0(IMS,\u00a02021).\u00a0Nebe n\u00a0den\u00a0noch\u00a0\nkeineswegs\u00a0ausreichenden\u00a0Erfolgen\u00a0gibt\u00a0es\u00a0aber\u00a0auch\u00a0Hinweise\u00a0au f\u00a0Schw\u00e4chen\u00a0des\u00a0\nAMNOG\u2010Prozesses,\u00a0der\u00a0sich\u00a0letztlich\u00a0negativ\u00a0auf\u00a0das\u00a0Preisniveau \u00a0der\u00a0neuen\u00a0Arz\u2010\nneimittel\u00a0auswirkt\u00a0und\u00a0damit\u00a0die\u00a0Ausgaben\u00a0der\u00a0GKV\u00a0f\u00fcr\u00a0neue\u00a0pate ntgesch\u00fctzte\u00a0\nArzneimittel\u00a0deutlich\u00a0erh\u00f6ht.\u00a0Auf\u00a0solche\u00a0erkennbaren\u00a0Schw\u00e4chen\u00a0 soll\u00a0im\u00a0Folgen\u2010\nden\u00a0hingewiesen\u00a0werden.\u00a0\n\u00a0 \n74\u00a0\n\u00a0 Analyse\u00a05.1\nFreie\u00a0Preisbildung\u00a0der\u00a0pharmazeutischen\u00a0Unternehmen\u00a0im\u00a0ersten\u00a0V ermarktungs\u2010\njahr\u00a0\nEs\u00a0ist\u00a0ohne\u00a0Frage\u00a0ein\u00a0\u201eSystemfehler\u201c\u00a0im\u00a0Gesetz,\u00a0dass\u00a0die\u00a0pharma zeutischen\u00a0Unter\u2010\nnehmen\u00a0im\u00a0ersten\u00a0Jahr\u00a0der\u00a0Vermarktung\u00a0den\u00a0Listenpreis\u00a0noch\u00a0imme r\u00a0selbst\u00a0be\u2010\nstimmen\u00a0k\u00f6nnen,\u00a0w\u00e4hrend\u00a0der\u00a0verhandelte\u00a0Erstattungsbetrag\u00a0erst\u00a0 ab\u00a0dem\u00a0zweiten\u00a0\nVermarktungsjahr,\u00a0also\u00a0ab\u00a0Monat\u00a013\u00a0in\u00a0Kraft\u00a0tritt.\u00a0Wenn\u00a0aber\u00a0sc hon\u00a0f\u00fcr\u00a0das\u00a0erste\u00a0\nJahr\u00a0ein\u00a0Preis\u00a0gilt,\u00a0den\u00a0die\u00a0pharmazeutischen\u00a0Unternehmen\u00a0selbe r\u00a0bestimmen\u00a0\nk\u00f6nnen,\u00a0ist\u00a0die\u00a0Preisrichtung\u00a0bereits\u00a0vorgezeichnet.\u00a0Die\u00a0Verhan dlungen\u00a0\u00fcber\u00a0den\u00a0\nErstattungsbetrag\u00a0sind\u00a0dann\u00a0bere its\u00a0stark\u00a0beeinflusst\u00a0von\u00a0dem\u00a0b isherigen\u00a0Listen\u2010\npreis\u00a0im\u00a0ersten\u00a0Vermarktungsjahr\u00a0und\u00a0werden\u00a0dann\u00a0sicherlich\u00a0kau m\u00a0die\u00a0kosten\u2010\nd\u00e4mpfende\u00a0Wirkung\u00a0erreichen\u00a0k\u00f6nnen,\u00a0die\u00a0ohne\u00a0ein\u00a0von\u00a0den\u00a0pharma zeutischen\u00a0\nUnternehmen\u00a0bereits\u00a0vorgegebenes \u00a0Preisniveau\u00a0erzielbar\u00a0w\u00e4re.\u00a0\nWertbestimmung\u00a0\u00fcber\u00a0Vergleichstherapien\u00a0\nEs\u00a0gibt\u00a0eine\u00a0zweite\u00a0Schw\u00e4che\u00a0im\u00a0AMNOG,\u00a0die\u00a0mit\u00a0der\u00a0Preisorienti erung\u00a0an\u00a0einer\u00a0\nVergleichstherapie\u00a0zu\u00a0tun\u00a0hat.\u00a0Dies\u00a0l\u00e4sst\u00a0sich\u00a0gut\u00a0am\u00a0Beispiel\u00a0 der\u00a0Therapie\u00a0der\u00a0\nspinalen\u00a0Muskelatrophie\u00a0zeigen,\u00a0einer\u00a0Erkrankung\u00a0bei\u00a0Kindern,\u00a0d ie\u00a0unbehandelt\u00a0\nzumeist\u00a0in\u00a0den\u00a0ersten\u00a0beiden\u00a0Lebensjahren\u00a0der\u00a0betroffenen\u00a0Kinde r\u00a0zum\u00a0 Tode\u00a0\nf\u00fchrt.\u00a0Insofern\u00a0ist\u00a0die\u00a0ab\u00a0dem\u00a0Jahr\u00a02017\u00a0mit\u00a0dem\u00a0Arzneimittel\u00a0S pinraza\u00ae\u00a0(Nusiner\u2010\nsen)\u00a0m\u00f6gliche\u00a0Therapie,\u00a0die\u00a02019\u00a0mit\u00a0dem\u00a0Arzneimittel\u00a0Zolgensma \u00ae\u00a0eine\u00a0weitere\u00a0\nOption\u00a0erhielt,\u00a0ohne\u00a0Frage\u00a0ein\u00a0therapeutischer\u00a0Fortschritt.\u00a0F\u00fcr \u00a0Spinraza\u00ae\u00a0hatte\u00a0der\u00a0\nHersteller\u00a0Biogen\u00a0einen\u00a0Preis\u00a0aufgerufen,\u00a0der\u00a0bei\u00a0Markteinf\u00fchru ng\u00a0zu\u00a0Jahresthera\u2010\npiekosten\u00a0von\u00a0621.354,48\u00a0Euro\u00a0im\u00a0ersten\u00a0Jahr\u00a0der\u00a0Therapie\u00a0und\u00a03 10.677,24\u00a0Euro\u00a0in\u00a0\njedem\u00a0weiteren\u00a0Jahr\u00a0f\u00fchrte\u00a0(G\u2010BA,\u00a02021).\u00a0Nach\u00a0der\u00a0Verhandlung\u00a0d es\u00a0Erstattungs\u2010\nbetrags\u00a0ab\u00a0dem\u00a0zweiten\u00a0Jahr\u00a0der\u00a0Vermarktung\u00a0beliefen\u00a0sich\u00a0die\u00a0J ahrestherapiekos\u2010\nten\u00a0immer\u00a0noch\u00a0auf\u00a0566.745,01\u00a0Euro\u00a0im\u00a0ersten\u00a0Jahr\u00a0sowie\u00a0auf\u00a0261 .574,62\u00a0Euro\u00a0f\u00fcr\u00a0\njedes\u00a0weitere\u00a0Jahr\u00a0der\u00a0Therapie\u00a0(G\u2010BA\u00a02020).\u00a0Betrachtet\u00a0man\u00a0nun \u00a0die\u00a0vermuteten\u00a0\nForschungskosten\u00a0f\u00fcr\u00a0Spinraza\u00ae,\u00a0so\u00a0wird\u00a0ein\u00a0Betrag\u00a0von\u00a0rund\u00a035\u00a0 Mio.\u00a0US\u2010$\u00a0ange\u2010\ngeben.\u00a0Der\u00a0Gewinn\u00a0f\u00fcr\u00a0die\u00a0Firma\u00a0Biogen\u00a0betrug\u00a0in\u00a0den\u00a0Jahren\u00a0201 7\u00a0bis\u00a02019\u00a0insge\u2010\nsamt\u00a04.061,5\u00a0Mio.\u00a0US\u2010$.\u00a0L\u00e4sst\u00a0sich\u00a0irgendeine\u00a0Rationale\u00a0f\u00fcr\u00a0den \u00a0Preis\u00a0von\u00a0Spin\u2010\nraza\u00ae\u00a0finden?\u00a0Die\u00a0Konsequenz\u00a0die ses\u00a0extrem\u00a0hohen\u00a0Preises\u00a0und\u00a0le tztlich\u00a0auch\u00a0des\u00a0\nverhandelten\u00a0Erstattungsbetrages\u00a0ist\u00a0aber,\u00a0dass\u00a0diese\u00a0finanziel len\u00a0Gr\u00f6\u00dfenordnun\u2010\ngen\u00a0nun\u00a0auch\u00a0den\u00a0Preisanker\u00a0f\u00fcr\u00a0weitere\u00a0Pr\u00e4parate\u00a0in\u00a0der\u00a0Indika tion\u00a0spinale\u00a0Mus\u2010\nkelatrophie\u00a0bei\u00a0Kindern\u00a0bildet.\u00a0De r\u00a0Preis\u00a0f\u00fcr\u00a0Zolgensma\u00ae\u00a0von\u00a0de r\u00a0Firma\u00a0Novartis,\u00a0\ndas\u00a0gegen\u00fcber\u00a0der\u00a0lebenslangen\u00a0T herapie\u00a0mit\u00a0Spinraza\u00ae\u00a0nur\u00a0einma l\u00a0injiziert\u00a0wer\u2010\nden\u00a0muss,\u00a0bezieht\u00a0sich\u00a0daher\u00a0auch\u00a0auf\u00a0den\u00a0Spinraza\u00ae\u2010Preis\u00a0und\u00a0l \u00e4sst\u00a0sich\u00a0die\u00a0ein\u2010\nmalige\u00a0Gabe\u00a0mit\u00a0einem\u00a0extrem\u00a0hoh en\u00a0Preis\u00a0von\u00a0zwei\u00a0Mio.\u00a0Euro\u00a0bez ahlen.\u00a0Eine\u00a0\nRelation\u00a0Forschungskosten\u00a0und\u00a0Gewinn\u00a0wird\u00a0auch\u00a0in\u00a0diesem\u00a0Fall\u00a0z ugunsten\u00a0des\u00a0 \n75\u00a0\n\u00a0pharmazeutischen\u00a0Unternehmens\u00a0ausfallen.\u00a0Auch\u00a0hier\u00a0spielt\u00a0wiede rum\u00a0der\u00a0\u201eLu\u2010\nxus\u201c\u00a0in\u00a0unserem\u00a0System\u00a0eine\u00a0Rolle,\u00a0der\u00a0es\u00a0den\u00a0pharmazeutischen\u00a0 Unternehmen\u00a0\nerm\u00f6glicht,\u00a0im\u00a0ersten\u00a0Vermarktungsjahr\u00a0nach\u00a0der\u00a0Zulassung\u00a0einen \u00a0allein\u00a0von\u00a0ihm\u00a0\nkalkulierten\u00a0Preis\u00a0zu\u00a0verlangen,\u00a0der\u00a0weder\u00a0begr\u00fcndet\u00a0noch\u00a0trans parent\u00a0erl\u00e4utert\u00a0\nwerden\u00a0kann.\u00a0\u00a0\nHohe\u00a0Preise\u00a0bleiben\u00a0aufgrund\u00a0der\u00a0Vergleichstherapie\u00a0in\u00a0der\u00a0jewe iligen\u00a0Indikation\u00a0\nbestehen\u00a0\nDas\u00a0Beispiel\u00a0der\u00a0Hepatitis\u2010C\u2010The rapie\u00a0mit\u00a0Arzneimitteln,\u00a0die\u00a0zw ischen\u00a02014\u00a0und\u00a0\n2017\u00a0als\u00a0neue\u00a0und\u00a0patengesch\u00fctzte\u00a0Mittel\u00a0auf\u00a0den\u00a0Markt\u00a0kamen,\u00a0m acht\u00a0die\u00a0schon\u00a0\noben\u00a0formulierte\u00a0Kritik\u00a0der\u00a0Prei ssetzung\u00a0\u00fcber\u00a0eine\u00a0Vergleichsth erapie\u00a0deutlich.\u00a0Das\u00a0\nerste\u00a0zugelassene\u00a0und\u00a0bewertete\u00a0Mittel\u00a0setzt\u00a0den\u00a0Preisanker,\u00a0di e\u00a0Preise\u00a0der\u00a0da\u2010\nnach\u00a0angebotenen\u00a0Mittel\u00a0sind\u00a0zwa r\u00a0z.\u00a0T.\u00a0niedriger,\u00a0bewegen\u00a0sich \u00a0aber\u00a0dennoch\u00a0in\u00a0\neinem\u00a0Bereich,\u00a0der\u00a0durch\u00a0das\u00a0erste\u00a0Mittel,\u00a0in\u00a0diesem\u00a0Fall\u00a0Soval di\u00ae\u00a0(Sofosbuvir),\u00a0\nbeansprucht\u00a0wurde.\u00a0Die\u00a0Konkurrenz \u00a0verschiedener\u00a0pharmazeutische r\u00a0Unterneh\u2010\nmen,\u00a0die\u00a0Pr\u00e4parate\u00a0zur\u00a0Behandlung\u00a0von\u00a0Hepatitis\u2010C\u00a0anbieten,\u00a0f\u00fch rt\u00a0also\u00a0nur\u00a0be\u2010\ndingt\u00a0zu\u00a0einer\u00a0sonst\u00a0erwartbaren\u00a0und\u00a0auch\u00a0\u00fcblichen\u00a0marktwirtsch aftlichen\u00a0Preisre\u2010\ngulierung.\u00a0Der\u00a0gesetzliche\u00a0Rahmen\u00a0f\u00fcr\u00a0den\u00a0G\u2010BA\u00a0einerseits\u00a0und\u00a0d ie\u00a0hiernach\u00a0erfol\u2010\ngende\u00a0 Verhandlung\u00a0 des\u00a0 Erstattungsb etrags\u00a0 seitens\u00a0 des\u00a0 GKV\u2010Spitze nverbandes\u00a0\nandereseits\u00a0scheint\u00a0nicht\u00a0ausreichend,\u00a0um\u00a0den\u00a0Erfordernissen\u00a0ei ner\u00a0transparenten\u00a0\nBildung\u00a0eines\u00a0fairen\u00a0Preises\u00a0zu\u00a0gen\u00fcgen,\u00a0indem\u00a0biotechnologisch \u00a0produzierte\u00a0Arz\u2010\nneimittel\u00a0regelhaft\u00a0exorbitante\u00a0 Jahrestherapiekosten\u00a0bedingen.\u00a0 Im\u00a0Ergebnis\u00a0bleibt\u00a0\nfestzuhalten,\u00a0dass\u00a0der\u00a0Gemeinsame\u00a0Bundesausschuss\u00a0(G\u2010BA)\u00a0mit\u00a0de r\u00a0Wahl\u00a0der\u00a0zVT\u00a0\neinerseits\u00a0 und\u00a0 die\u00a0 jeweiligen\u00a0 Verhandlungsgruppen\u00a0 beim\u00a0 GKV\u2010Spit zenverband\u00a0\ndurch\u00a0ihr\u00a0Geschick\u00a0bei\u00a0der\u00a0Verhandlung\u00a0eines\u00a0Erstattungsbetrage s\u00a0andererseits\u00a0die\u00a0\nKosten\u00a0 eines\u00a0 neuen\u00a0 Arzneimittels \u00a0 definieren,\u00a0 jedoch\u00a0 hierbei\u00a0 vom \u00a0 Gesetzgeber\u00a0\nunn\u00f6tige\u00a0Grenzen\u00a0gesetzt\u00a0wurden\u00a0(G\u2010BA,\u00a02018). \u00a0Dies\u00a0wird\u00a0besonders\u00a0deutlich\u00a0an\u00a0\ndem\u00a0 Beispiel\u00a0 Dupixent\u00ae,\u00a0 einem\u00a0 neu en\u00a0 patentgesch\u00fctzten\u00a0 Biologiku m , \u00a0d a s \u00a0z u r \u00a0\nBehandlung\u00a0 der\u00a0 Neurodermitis\u00a0 zuge lassen\u00a0 ist\u00a0 \u2013\u00a0 bei\u00a0 Markteinf\u00fchru n g \u00a0h a t \u00a0d a s \u00a0\npharmazeutische\u00a0Unternehmen\u00a0Jahrestherapiekosten\u00a0von\u00a021.390,03\u00a0 Euro\u00a0verlangt\u00a0\n(G\u2010BA,\u00a02018),\u00a0sie\u00a0sanken\u00a0nach\u00a0der\u00a0Verhandlung\u00a0um\u00a08\u00a0%.\u00a0Die\u00a0Jahre stherapiekosten\u00a0\nder\u00a0zweckm\u00e4\u00dfigen\u00a0Vergleichsthera pie\u00a0mit\u00a0topischen\u00a0Kortikosteroi den\u00a0oder\u00a0syste\u2010\nmisch\u00a0angewendeten\u00a0Ciclosoprin\u00a0liegen\u00a0bei\u00a0ca.\u00a01.000\u00a0bis\u00a03.000\u00a0E uro.\u00a0Da\u00a0aber\u00a0f\u00fcr\u00a0\nBiologika\u00a0durchg\u00e4ngig\u00a0f\u00fcnfstelli ge\u00a0Jahrestherapiekosten\u00a0\u00fcblich\u00a0 sind,\u00a0f\u00fchrte\u00a0dieser\u00a0\nextreme\u00a0Unterschied\u00a0in\u00a0den\u00a0Jahrestherapiekosten\u00a0nicht\u00a0einmal\u00a0zu \u00a0ausf\u00fchrlichen\u00a0\nDiskussionen\u00a0\u2013\u00a0der\u00a0Preisanker\u00a0\u201eBiologika\u201c\u00a0hat\u00a0offenbar\u00a0letztlic h\u00a0den\u00a0Ausschlag\u00a0f\u00fcr\u00a0\ndie\u00a0Festsetzung\u00a0des\u00a0Erstattungsbetrages\u00a0gegeben.\u00a0\n\u00a0\n\u00a0 \n76\u00a0\n\u00a0Orphan\u00a0Drugs \u00a0ohne\u00a0Preisanker\u00a0\nOrphan\u00a0Drugs ,\u00a0also\u00a0Arzneimittel\u00a0f\u00fcr\u00a0Patiente n,\u00a0die\u00a0unter\u00a0Krankheiten\u00a0leiden ,\u00a0die\u00a0in\u00a0\nEuropa\u00a0maximal\u00a0bei\u00a0f\u00fcnf\u00a0von\u00a010.000\u00a0Einwohnern\u00a0vorkommen,\u00a0werden \u00a0im\u00a0Zulas\u2010\nsungsprozess\u00a0wie\u00a0im\u00a0AMNOG\u00a0bevorzu gt\u00a0behandelt.\u00a0Die\u00a0Zulassung\u00a0is t\u00a0erleichtert,\u00a0in\u00a0\nEuropa\u00a0kommt\u00a0es\u00a0auch\u00a0zu\u00a0sukzessiven\u00a0Erweiterungen\u00a0der\u00a0Zulassung \u00a0f\u00fcr\u00a0kleinere\u00a0\nPatientengruppen,\u00a0die\u00a0\u00fcblicherweise\u00a0nicht\u00a0zu\u00a0den\u00a0typischen\u00a0gene tisch\u00a0bedingten\u00a0\nOrphan\u00a0Diseases \u00a0geh\u00f6ren\u00a0(diese\u00a0strategische\u00a0Verkleinerung\u00a0der\u00a0Patientengruppen \u00a0\nwird\u00a0auch\u00a0als\u00a0 \u201eSlicing\u201c\u00a0bezeichnet,\u00a0was\u00a0nichts\u00a0anderes\u00a0bedeutet,\u00a0als\u00a0dass\u00a0gr\u00f6\u00dfere\u00a0\nPatientenkollektive\u00a0in\u00a0kleine\u00a0Gr uppen\u00a0gem\u00e4\u00df\u00a0der\u00a0Definition\u00a0selt ener\u00a0Krankheiten\u00a0\naufgeteilt\u00a0werden,\u00a0damit\u00a0die\u00a0pharmazeutischen\u00a0Unternehmen\u00a0die\u00a0V orteile\u00a0der\u00a0\nOrphan\u00a0Drugs \u00a0in\u00a0der\u00a0Zulassung\u00a0nutzen\u00a0k\u00f6nnen).\u00a0In\u00a0Deutschland\u00a0gilt\u00a0im\u00a0AMNOG\u2010\nProzess\u00a0der\u00a0Zusatznutzen\u00a0f\u00fcr\u00a0alle\u00a0 Orphan\u00a0Drugs \u00a0als\u00a0belegt,\u00a0es\u00a0wird\u00a0lediglich\u00a0eine\u00a0\nQuantifizierung\u00a0des\u00a0Zusatznutzens\u00a0ausgesprochen,\u00a0eine\u00a0zweckm\u00e4\u00dfi ge\u00a0Vergleichs\u2010\ntherapie\u00a0wird\u00a0nicht\u00a0bestimmt,\u00a0was\u00a0zur\u00a0Folge\u00a0hat,\u00a0dass\u00a0es\u00a0auch\u00a0k einen\u00a0Bezug\u00a0auf\u00a0\neinen\u00a0Preisanker\u00a0gibt.\u00a0In\u00a0den\u00a0bisher\u00a0publizierten\u00a0acht\u00a0Innovati onsreporten\u00a0(2013\u00a0\nbis\u00a02020)\u00a0wurden\u00a0insgesamt\u00a092\u00a0 Orphan\u00a0Drugs \u00a0bewertet,\u00a0ein\u00a0Zusat znutzen\u00a0wurde\u00a0in\u00a0\n14\u00a0von\u00a026\u00a0Subgruppen\u00a0bei\u00a0Patienten\u00a0erkannt.\u00a0Eine\u00a0\u00fcbliche\u00a0AMNOG\u2010 Bewertung\u00a0\nmuss\u00a0erst\u00a0stattfinden,\u00a0wenn\u00a0f\u00fcr\u00a0ein\u00a0 Orphan\u00a0Drug \u00a0die\u00a0Umsatzschwelle\u00a0von\u00a050\u00a0Mio.\u00a0\nEuro\u00a0\u00fcberschritten\u00a0ist,\u00a0die\u00a0zur\u00a0Aufhebung\u00a0des\u00a0 Orphan\u2010Drugs\u2010Status \u00a0f\u00fchrt.\u00a0Dies\u00a0ist\u00a0\nbisher\u00a0bei\u00a0sechs\u00a0Pr\u00e4paraten\u00a0erfolgt,\u00a0die\u00a0allesamt\u00a0zur\u00a0Gruppe\u00a0de r\u00a0Onkologika\u00a0geh\u00f6\u2010\nren.\u00a0Seit\u00a0August\u00a02019\u00a0m\u00fcssen\u00a0in\u00a0diesem\u00a0Umsatz\u00a0auch\u00a0die\u00a0station\u00e4 ren\u00a0Kosten\u00a0be\u2010\nr\u00fccksichtigt\u00a0werden.\u00a0Die\u00a0Ermittlung\u00a0dieser\u00a0Kosten\u00a0ist\u00a0aber\u00a0ausg esprochen\u00a0schwie\u2010\nrig,\u00a0da\u00a0die\u00a0Ausgaben\u00a0f\u00fcr\u00a0Arzneim ittel\u00a0in\u00a0der\u00a0station\u00e4ren\u00a0Versor gung\u00a0kaum\u00a0ermit\u2010\ntelbar\u00a0sind,\u00a0sondern\u00a0undifferenz iert\u00a0in\u00a0den\u00a0Gesamtbehandlungsko sten\u00a0aufgehen.\u00a0\nWegen\u00a0der\u00a0erleichterten\u00a0Zulassung\u00a0und\u00a0des\u00a0Sonderstatus\u00a0im\u00a0AMNOG \u2010Verfahren\u00a0\nhaben\u00a0sich\u00a0die\u00a0 Orphan\u00a0Drugs \u00a0zu\u00a0einer\u00a0begehrten\u00a0Arzneimittelgruppe\u00a0aus\u00a0Sicht\u00a0der\u00a0\npharmazeutischen\u00a0Unternehmen\u00a0entwickelt.\u00a0Dass\u00a0in\u00a0diesem\u00a0Zusamme nhang\u00a0aller\u2010\ndings\u00a0auch\u00a0bestimmte\u00a0seltene\u00a0Erkrankungen\u00a0erstmals\u00a0behandelt\u00a0we rden\u00a0k\u00f6nnen,\u00a0\nist\u00a0sicherlich\u00a0ein\u00a0therapeutischer\u00a0Fortschritt\u00a0f\u00fcr\u00a0vielen\u00a0Patie ntinnen\u00a0und\u00a0Patienten\u00a0\n(z.\u00a0B.\u00a0die\u00a0Therapie\u00a0bei\u00a0spinaler \u00a0Muskelatrophie\u00a0bei\u00a0Kindern,\u00a0si ehe\u00a0Kapitel\u00a06).\u00a0\nKeine\u00a0Addition\u00a0der\u00a0Kosten\u00a0bei\u00a0Kombinationstherapien,\u00a0v.a.\u00a0in\u00a0de r\u00a0Onkologie\u00a0\nSeit\u00a0Jahren\u00a0ist\u00a0es\u00a0z.\u00a0B.\u00a0in\u00a0der\u00a0Onkologie\u00a0\u00fcblich,\u00a0mehrere\u00a0Wirks toffe\u00a0gleichzeitig\u00a0\neinzusetzen,\u00a0um\u00a0auf\u00a0diese\u00a0Weise\u00a0den\u00a0Behandlungsverlauf\u00a0wirksame r\u00a0zu\u00a0gestalten.\u00a0\nDiese\u00a0bekannten\u00a0Kombinationsstrategien\u00a0spielen\u00a0in\u00a0den\u00a0AMNOG\u2010Ver fahren\u00a0jedoch\u00a0\nim\u00a0Hinblick\u00a0auf\u00a0die\u00a0Addition\u00a0der \u00a0Kosten\u00a0keine\u00a0erkennbare\u00a0Rolle. \u00a0So\u00a0wurde\u00a0z.\u00a0B.\u00a0das\u00a0\nMittel\u00a0Yervoy\u00ae\u00a0mit\u00a0Jahrestherapie kosten\u00a0in\u00a0H\u00f6he\u00a0von\u00a091.022,76\u00a0E uro\u00a0im\u00a0AMNOG\u2010 \n77\u00a0\n\u00a0Verfahren1\u00a0als\u00a0Mittel\u00a0mit\u00a0betr\u00e4chtliche m\u00a0Zusatznutzen\u00a0gegen\u00fcber\u00a0einer\u00a0 Best\u00a0Sup\u2010\nportive\u00a0Care\u00a0(BSC) \u00a0im\u00a0Rahmen\u00a0einer\u00a0Zweitlinienther apie\u00a0bewertet,\u00a0w\u00e4hrend\u00a0in\u00a0der\u00a0\nErstlinientherapie\u00a0 kein\u00a0 Zusatznut zen\u00a0 gesehen\u00a0 wurde.\u00a0 Dem\u00a0 Mittel\u00a0 Opdivo\u00ae\u00a0 mit\u00a0\nKosten\u00a0in\u00a0H\u00f6he\u00a0von\u00a0106.465,32\u00a0Euro2\u00a0wurde\u00a0ein\u00a0betr\u00e4chtlicher\u00a0Nutzen\u00a0gegen\u00fcber\u00a0\nder\u00a0 Therapie\u00a0 mit\u00a0 Dacarbazin/Ipilimumab\u00a0 zuerkannt.\u00a0 Der\u00a0 Kombinati onstherapie\u00a0\nvon\u00a0Yervoy\u00ae\u00a073.997,52\u00a0Euro\u00a0plus\u00a0Opdivo\u00ae\u00a062.543,12\u00a0Euro\u00a0mit\u00a0Jahr estherapiekos\u2010\nten\u00a0von\u00a0\u00a0136.540,64\u00a0Euro\u00a0in\u00a0Kombination3\u00a0wurde\u00a0aber\u00a0nur\u00a0ein\u00a0geringer\u00a0Zusatznut\u2010\nzen\u00a0gegen\u00fcber\u00a0Nivolumab/Pembroliz umab\u00a0zugesprochen.\u00a0Im\u00a0AMNOG\u2010Ve rfahren\u00a0\nwerden\u00a0also\u00a0nur\u00a0einzelne\u00a0Arzneimittelpreise\u00a0statt\u00a0eines\u00a0leitlin ienorientierten\u00a0Thera\u2010\npiepreises\u00a0verhandelt,\u00a0was\u00a0vor\u00a0allem\u00a0in\u00a0der\u00a0Onkologie\u00a0die\u00a0Ausga benbelastungen\u00a0f\u00fcr\u00a0\ndie\u00a0GKV\u00a0in\u00a0die\u00a0H\u00f6he\u00a0treibt.\u00a0Hier\u00a0sollte\u00a0dringend\u00a0nachgebessert\u00a0 werden.\u00a0\nDas\u00a0Problem\u00a0der\u00a0Mischpreise\u00a0bei\u00a0Arzneimitteln\u00a0mit\u00a0unterschiedli ch\u00a0bewerteten\u00a0\nIndikationen\u00a0und\u00a0Subgruppen\u00a0\nIm\u00a0Arzneimittelmarkt\u00a0werden\u00a0in\u00a0der\u00a0Zwischenzeit\u00a0auff\u00e4llig\u00a0viele \u00a0neue\u00a0Arzneimittel\u00a0\nangeboten,\u00a0die\u00a0biotechnologisch\u00a0produziert\u00a0werden.\u00a0Im\u00a0Einzelnen \u00a0handelt\u00a0es\u00a0sich\u00a0um\u00a0\nBlutgerinnungsfaktoren,\u00a0Insulinanaloga\u00a0mit\u00a0modifizierter\u00a0Wirkda uer,\u00a0Enzymersatz\u2010\npr\u00e4parate\u00a0oder\u00a0MAK,\u00a0d.\u00a0h.\u00a0Biologika\u00a0bzw.\u00a0deren\u00a0Biosimilars.\u00a0Die se\u00a0MAK\u00a0werden\u00a0vor\u00a0\nallem\u00a0in\u00a0den\u00a0Indikationsbereichen\u00a0Onkologie,\u00a0Rheumatoide\u00a0Arthri tis,\u00a0Multiple\u00a0Skle\u2010\nrose\u00a0oder\u00a0Psoriasis\u00a0angewendet.\u00a0F\u00fcr\u00a0MAK\u00a0fallen\u00a0z.\u00a0T.\u00a0extrem\u00a0hoh e\u00a0Jahrestherapie\u2010\nkosten\u00a0von\u00a060.000\u00a0Euro\u00a0und\u00a0mehr\u00a0an.\u00a0So\u00a0entfielen\u00a0z.\u00a0B.\u00a0von\u00a0den\u00a0 31\u00a0neuen\u00a0Mitteln\u00a0im\u00a0\nJahre\u00a02017\u00a0mit\u00a0elf\u00a0Wirkstoffen\u00a0rund\u00a0ein\u00a0Drittel\u00a0der\u00a0neu\u00a0zugelas senen\u00a0Arzneimittel\u00a0auf\u00a0\ndie\u00a0Behandlung\u00a0verschiedener\u00a0Kre bserkrankungen,\u00a0zehn\u00a0weitere\u00a0di enen\u00a0der\u00a0Behand\u2010\nlung\u00a0von\u00a0Entz\u00fcndungskrankheiten\u00a0\u2013\u00a0d.\u00a0h.\u00a0Krankheiten,\u00a0denen\u00a0eine \u00a0Fehlsteuerung\u00a0des\u00a0\nImmunsystems\u00a0zugrunde\u00a0liegt.\u00a0Rheumatoide\u00a0Arthritis\u00a0und\u00a0Asthma\u00a0z \u00e4hlen\u00a0dazu,\u00a0aber\u00a0\nauch\u00a0Schuppenflechte\u00a0und\u00a0atopische\u00a0Dermatitis\u00a0(auch\u00a0Neurodermit is\u00a0genannt).\u00a0Im\u00a0\nFokus\u00a0der\u00a0Diskussionen\u00a0stehen\u00a0ab er\u00a0insbesondere\u00a0die\u00a0Preise\u00a0f\u00fcr\u00a0 die\u00a0jeweiligen\u00a0Arz\u2010\nneimittel,\u00a0 weil\u00a0 die\u00a0 Wirtschaftli c h k e i t \u00a0d e r \u00a0V e r o r d n u n g \u00a0m i t \u00a0A M N O G \u2010Arzneimitteln\u00a0\nhinterfragt\u00a0wird,\u00a0wenn\u00a0der\u00a0Zusatznutzen\u00a0eines\u00a0Arzneimittels\u00a0bez \u00fcglich\u00a0des\u00a0zugelas\u2010\nsenen\u00a0Indikationsgebietes\u00a0auf\u00a0der\u00a0Basis\u00a0von\u00a0verschiedenen\u00a0Patie ntengruppen\u00a0(Sub\u2010\npopulationen)\u00a0bestimmt\u00a0wurde.\u00a0Dies\u00a0ist\u00a0immer\u00a0dann\u00a0zwingend,\u00a0wen n\u00a0f\u00fcr\u00a0die\u00a0ver\u2010\nschiedenen,\u00a0in\u00a0die\u00a0Zulassungsstudien\u00a0einbezogenen\u00a0Patientengrup pen\u00a0ein\u00a0differen\u2010\nzierter\u00a0Behandlungsstandard\u00a0existiert.\u00a0Diese\u00a0Differenzierung\u00a0wi rd\u00a0schon\u00a0seit\u00a0vielen\u00a0\nJahren\u00a0angewendet\u00a0und\u00a0wurde\u00a0auch\u00a0durch\u00a0die\u00a0Regelungen\u00a0des\u00a0AMNOG \u00a0nicht\u00a0ver\u00e4n\u2010\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n1\u00a0https://www.g\u2010ba.de/downloads/ 91\u20101385\u201016/2016\u2010 04\u201007_Geltende\u2010F assung_Ipilimumab_D\u2010\n014.pdf\u00a02\u00a0https://www.g\u2010ba.de/downloads/91\u2010 1385\u2010179/2016\u201012 \u201015_Geltende\u2010 Fassung_Nivolumab_D\u2010\n176.pdf\u00a0\n3\u00a0https://www.g\u2010ba.de/downloads/91\u2010 1385\u2010372/2018\u201012 \u201020_Geltende\u2010 Fassung_Nivolumab_D\u2010\n370.pdf\u00a0 \n78\u00a0\n\u00a0dert.\u00a0Als\u00a0Beispiel\u00a0sei\u00a0hier\u00a0die\u00a0Nutzenbewertung\u00a0von\u00a0Clopidogrel \u00a0(Plavix\u00ae,\u00a0Iscover\u00ae)\u00a0\naus\u00a0dem\u00a0Jahre\u00a02006\u00a0in\u00a0die\u00a0AMNOG\u2010Systematik\u00a0\u00fcbertragen:\u00a0\nTabelle\u00a05.1:\u00a0Nutzenbewertung\u00a02006\u00a0\u00fcbersetzt\u00a0in\u00a0fiktives\u00a0Verfahr en\u00a0nach\u00a0AMNOG\u00a0\u00a0\nNeuer\u00a0Wirkstoff\u00a0 Clopidogrel\u00a0(Plavix\u00ae,\u00a0Iscover\u00ae)\u00a0\nZugelassenes\u00a0\nAnwendungsgebiet\u00a0Sekund\u00e4rprophylaxe\u00a0vaskul\u00e4rer\u00a0Erkrankungen\u00a0\nZweckm\u00e4\u00dfige\u00a0\nVergleichstherapie\u00a0(zVT)\u00a0Acetylsalicyls\u00e4ure\u00a0\nZusatznutzen\u00a0im\u00a0\nVerh\u00e4ltnis\u00a0zur\u00a0zVT\u00a0Subpopulation\u00a0A\u00a0Patienten\u00a0mit\u00a0symptomatischer\u00a0pAVK\u00a0\u2013\u00a0Zusatznutzen\u00a0\nbelegt\u00a0\nSubpopulation\u00a0B\u00a0Patienten\u00a0mit\u00a0ZVK\u00a0und\u00a0KHK\u00a0\u2013\u00a0Zusatznutzen\u00a0nicht\u00a0\nnachgewiesen\u00a0\nQuelle:\u00a0Kaesbach,\u00a02018,\u00a0S.\u00a027\u00a0\nDas\u00a0Problem\u00a0liegt\u00a0nun\u00a0darin,\u00a0dass\u00a0trotz\u00a0der\u00a0unterschiedlichen\u00a0E rgebnisse\u00a0f\u00fcr\u00a0den\u00a0\nZusatznutzen\u00a0in\u00a0solchen\u00a0F\u00e4llen\u00a0nahezu\u00a0regelhaft\u00a0ein\u00a0Mischpreis\u00a0 als\u00a0Erstattungsbe\u2010\ntrag\u00a0im\u00a0AMNOG\u2010Prozess\u00a0vereinbart\u00a0wird,\u00a0der\u00a0die\u00a0Unterschiede\u00a0im\u00a0 Zusatznutzen\u00a0\nnicht\u00a0 mehr\u00a0 widerspiegelt.\u00a0 Dabei\u00a0 sollte\u00a0 f\u00fcr\u00a0 Arzneimittel\u00a0 ohne\u00a0 Zu satznutzen\u00a0 ein\u00a0\nErstattungsbetrag\u00a0vereinbart\u00a0wer den,\u00a0der\u00a0die\u00a0Jahrestherapiekost en\u00a0der\u00a0zweckm\u00e4\u2010\n\u00dfigen\u00a0Vergleichstherapie\u00a0nicht\u00a0 \u00fcbersteigt.\u00a0Wenn\u00a0dagegen\u00a0ein\u00a0Zus atznutzen\u00a0gar\u00a0\nnicht\u00a0belegt\u00a0ist,\u00a0sollten\u00a0die\u00a0Jahrestherapiekosten\u00a0f\u00fcr\u00a0das\u00a0neue \u00a0Arzneimittel\u00a0gerin\u2010\nger\u00a0ausfallen\u00a0als\u00a0die\u00a0Kosten\u00a0f\u00fcr \u00a0die\u00a0zweckm\u00e4\u00dfige\u00a0Vergleichsther apie.\u00a0\u00a0\nEin\u00a0Mischpreis\u00a0verdeckt\u00a0also\u00a0letztlich\u00a0die\u00a0vorhandenen\u00a0Untersch iede\u00a0im\u00a0Zusatznut\u2010\nzen.\u00a0Gleichg\u00fcltig,\u00a0bei\u00a0welcher\u00a0Indikation\u00a0das\u00a0Mittel\u00a0eingesetzt \u00a0wird,\u00a0kommt\u00a0es\u00a0zur\u00a0\nAbrechnung\u00a0des\u00a0gleichen\u00a0Erstattungsbetrags,\u00a0der\u00a0als\u00a0Verhandlung sergebnis\u00a0zwi\u2010\nschen\u00a0dem\u00a0pharmazeutischen\u00a0Unternehmer\u00a0und\u00a0dem\u00a0GKV\u2010Spitzenverba nd\u00a0verein\u2010\nbart\u00a0worden\u00a0ist.\u00a0Im\u00a0Ergebnis\u00a0bede utet\u00a0dies\u00a0aber,\u00a0schematisch\u00a0au sgedr\u00fcckt,\u00a0dass\u00a0\nder\u00a0 neue\u00a0 Wirkstoff\u00a0 im\u00a0 Indikationsbereich\u00a0 des\u00a0 nachgewiesenen\u00a0 Zus atznutzens\u00a0\nm\u00f6glicherweise\u00a0einen\u00a0zu\u00a0geringen\u00a0Preis\u00a0erzielt,\u00a0w\u00e4hrend\u00a0er\u00a0im\u00a0I ndikationsbereich\u00a0\nohne\u00a0Zusatznutzen\u00a0zu\u00a0teuer\u00a0ist.\u00a0Es\u00a0sei\u00a0denn,\u00a0man\u00a0k\u00f6nnte\u00a0von\u00a0ein em\u00a0\u201eNullsummen\u2010\nspiel\u201c\u00a0ausgehen,\u00a0wenn\u00a0man\u00a0die\u00a0Ausgaben\u00a0f\u00fcr\u00a0die\u00a0Verordnungen\u00a0mit \u00a0und\u00a0ohne\u00a0\nnachgewiesenen\u00a0Zusatznutzen\u00a0mittelt.\u00a0Aber\u00a0selbst\u00a0wenn\u00a0dies\u00a0denk bar\u00a0ist,\u00a0so\u00a0w\u00fcr\u2010\nde\u00a0es\u00a0aber\u00a0bedeuten,\u00a0dass\u00a0der\u00a0Zusatznutzen\u00a0nicht\u00a0zum\u00a0Steuerungs \u2010,\u00a0Differenzie\u2010\nrungs\u2010\u00a0und\u00a0damit\u00a0Wettbewerbsinstrument\u00a0wird,\u00a0weil\u00a0in\u00a0vielen\u00a0F\u00e4l len\u00a0das\u00a0Preissig\u2010\nnal\u00a0gegen\u00fcber\u00a0der\u00a0zweckm\u00e4\u00dfigen\u00a0V ergleichstherapie\u00a0entf\u00e4llt\u00a0und\u00a0 eben\u00a0nicht\u00a0deut\u2010\nlich\u00a0wird,\u00a0dass\u00a0unter\u00a0diesen\u00a0Bedingungen\u00a0die\u00a0Anwendung\u00a0der\u00a0beka nnten\u00a0zweck\u2010\nm\u00e4\u00dfigen\u00a0 Vergleichstherapie\u00a0 (bisheriger\u00a0 \u201eStandard\u201c)\u00a0 als\u00a0 bew\u00e4hrte \u00a0 Therapie\u00a0 die\u00a0\nbessere\u00a0Wahl\u00a0w\u00e4re.\u00a0Die\u00a0Anwendung\u00a0eines\u00a0neuen\u00a0Mittels\u00a0ohne\u00a0Zusat znutzen\u00a0w\u00fcr\u2010\nde\u00a0zwar\u00a0die\u00a0bisherige\u00a0Therapie\u00a0n icht\u00a0verteuern,\u00a0ist\u00a0aber\u00a0immer\u00a0 noch\u00a0mit\u00a0Unw\u00e4g\u2010\nbarkeiten\u00a0bez\u00fcglich\u00a0der\u00a0Vertr\u00e4glichkeit\u00a0und\u00a0der\u00a0Anwendung\u00a0in\u00a0br eiteren\u00a0Patien\u2010\ntenpopulationen\u00a0verbunden.\u00a0Zu\u00a0bedenken\u00a0ist\u00a0aber\u00a0auch,\u00a0ob\u00a0Mischp reise\u00a0nicht\u00a0die\u00a0 \n79\u00a0\n\u00a0gesamte\u00a0Versorgung\u00a0unn\u00f6tig\u00a0verte uern\u00a0k\u00f6nnen,\u00a0wenn\u00a0gr\u00f6\u00dfere\u00a0Veror dnungsantei\u2010\nle\u00a0des\u00a0neuen\u00a0Wirkstoffs\u00a0auf\u00a0solche\u00a0Subpopulationen\u00a0entfallen,\u00a0i n\u00a0denen\u00a0kein\u00a0Zu\u2010\nsatznutzen\u00a0festgestellt\u00a0wurde\u00a0 und\u00a0daher\u00a0nur\u00a0Kosten\u00a0wie\u00a0die\u00a0der\u00a0 zweckm\u00e4\u00dfigen\u00a0\nVergleichstherapie\u00a0gerechtfertigt\u00a0w\u00e4ren.\u00a0\nIndividuell\u00a0ad\u00e4quate\u00a0Preise\u00a0h\u00e4tt en\u00a0die\u00a0Marketingaktivit\u00e4ten\u00a0der \u00a0pharmazeutischen\u00a0\nUnternehmen\u00a0stoppen\u00a0k\u00f6nnen,\u00a0die\u00a0auch\u00a0Mittel\u00a0ohne\u00a0nachgewiesenen \u00a0Zusatznutzen\u00a0\nund\u00a0damit\u00a0ohne\u00a0Vorteil\u00a0f\u00fcr\u00a0die\u00a0Patienten\u00a0in\u00a0den\u00a0Arztpraxen\u00a0prop agieren,\u00a0ein\u00a0Misch\u2010\npreis\u00a0nivelliert\u00a0n\u00e4mlich\u00a0die\u00a0notwendige\u00a0Differenzierung\u00a0bez\u00fcgli ch\u00a0der\u00a0Unterschiede\u00a0\nim\u00a0Zusatznutzen\u00a0\u2013\u00a0ein\u00a0Gewinn\u00a0f\u00fcr\u00a0die\u00a0Pharmaindustrie,\u00a0nicht\u00a0abe r\u00a0f\u00fcr\u00a0die\u00a0Patienten\u00a0\noder\u00a0die\u00a0Krankenkassen.\u00a0Die\u00a0Chance\u00a0f\u00fcr\u00a0mehr\u00a0Transparenz\u00a0und\u00a0den \u00a0schon\u00a0am\u00a0Preis\u00a0\nerkennbaren\u00a0Unterschied\u00a0zwischen\u00a0Indikationen\u00a0mit\u00a0und\u00a0ohne\u00a0Zusa tznutzen\u00a0wurde\u00a0\ndaher\u00a0leider\u00a0vom\u00a0Bundessozialgericht\u00a0nicht\u00a0genutzt,\u00a0das\u00a0am\u00a04.\u00a0J uli\u00a02018\u00a0entschieden\u00a0\n(BSG,\u00a004.07.2018\u00a0\u2010\u00a0B\u00a03\u00a0KR\u00a020/17\u00a0R)\u00a0und\u00a0ausgef\u00fchrt\u00a0hat,\u00a0dass\u00a0es\u00a0 auch\u00a0weiterhin\u00a0nur\u00a0\neinen\u00a0 Preis\u00a0 f\u00fcr\u00a0 verschreibungspflichtige\u00a0 Arzneimittel\u00a0 geben\u00a0 sol l.\u00a0Der\u00a0sogenannte\u00a0\nMischpreis\u00a0bei\u00a0neuen\u00a0Arzneimitteln\u00a0wird\u00a0daher\u00a0Realit\u00e4t\u00a0bleiben, \u00a0trotz\u00a0der\u00a0nachvoll\u2010\nziehbaren\u00a0Argumente\u00a0f\u00fcr\u00a0eine\u00a0dif ferenzierte\u00a0Festlegung\u00a0der\u00a0Erst attungsbetr\u00e4ge\u00a0nach\u00a0\ndem\u00a0Ausma\u00df\u00a0des\u00a0Zusatznutzens\u00a0gegen\u00fcber\u00a0einer\u00a0zweckm\u00e4\u00dfigen\u00a0Vergl eichstherapie.\u00a0\nOpt\u2010out\u00a0und\u00a0Marktr\u00fccknahmen\u00a0als\u00a0Druckmittel\u00a0der\u00a0pharmazeutischen\u00a0Unter nehmen\u00a0\nEine\u00a0der\u00a0unmittelbaren\u00a0Auswirkungen\u00a0der\u00a0Zusatznutzenbewertung\u00a0a uf\u00a0die\u00a0Versor\u2010\ngung\u00a0kann\u00a0die\u00a0Entscheidung\u00a0f\u00fcr\u00a0ein\u00a0 Opt\u2010out\u00a0bzw.\u00a0die\u00a0Einstellung\u00a0des\u00a0Vertriebs\u00a0sein.\u00a0\nAls\u00a0\u201eechtes\u201c\u00a0 Opt\u2010out\u00a0wird\u00a0dabei\u00a0definiert,\u00a0dass\u00a0der\u00a0pharmazeutische\u00a0Unternehmer\u00a0\nden\u00a0 Vertrieb\u00a0 f\u00fcr\u00a0 sein\u00a0 Produkt\u00a0 innerhalb\u00a0 von\u00a0 vier\u00a0 Wochen\u00a0 nach\u00a0 de m\u00a0 G\u2010BA\u2010\nBeschluss\u00a0 einstellt\u00a0 (\u00a7\u00a04\u00a0Abs.\u00a07\u00a0 Rahmenvereinbarung\u00a0 nach\u00a0 \u00a7\u00a0130b\u00a0 Abs.\u00a09\u00a0SGB\u00a0V).\u00a0\nWenn\u00a0f\u00fcr\u00a0ein\u00a0Arzneimittel\u00a0in\u00a0der\u00a0Nutzenbewertung\u00a0kein\u00a0Zusatznut zen\u00a0im\u00a0Vergleich\u00a0\nzur\u00a0zweckm\u00e4\u00dfigen\u00a0Vergleichsthera pie\u00a0belegt\u00a0werden\u00a0kann,\u00a0d\u00fcrfen\u00a0 \u2013\u00a0gem\u00e4\u00df\u00a0den\u00a0\ngesetzlichen\u00a0Vorgaben\u00a0\u2013\u00a0die\u00a0von\u00a0der\u00a0GKV\u00a0erstatteten\u00a0Kosten\u00a0in\u00a0d er\u00a0Regel\u00a0nicht\u00a0\nh\u00f6her\u00a0als\u00a0die\u00a0Jahrestherapiekost en\u00a0der\u00a0zweckm\u00e4\u00dfigen\u00a0Vergleichst herapie\u00a0sein.\u00a0Das\u00a0\nkann\u00a0theoretisch\u00a0bedeuten,\u00a0dass\u00a0die\u00a0erstatteten\u00a0Kosten\u00a0nicht\u00a0h\u00f6 her\u00a0sein\u00a0d\u00fcrfen\u00a0als\u00a0\nf\u00fcr\u00a0eine\u00a0generische\u00a0Vergleichstherapie.\u00a0F\u00fcr\u00a0ein\u00a0pharmazeutische s\u00a0Unternehmen\u00a0ist\u00a0\nes\u00a0dann\u00a0offenbar\u00a0aus\u00a0wirtschaft lichen\u00a0Gr\u00fcnden\u00a0sinnvoller,\u00a0auf\u00a0d en\u00a0Vertrieb\u00a0des\u00a0\nArzneimittels\u00a0in\u00a0Deutschland\u00a0zu\u00a0v erzichten.\u00a0Seit\u00a0Inkrafttreten\u00a0 des\u00a0AMVSG\u00a0(Gesetz\u00a0\nzur\u00a0St\u00e4rkung\u00a0der\u00a0Arzneimittelversorgung\u00a0in\u00a0der\u00a0GKV)\u00a0am\u00a013.\u00a0Mai\u00a0 2017\u00a0gilt\u00a0jedoch,\u00a0\ndass\u00a0in\u00a0begr\u00fcndeten\u00a0Einzelf\u00e4llen\u00a0anders\u00a0entschieden\u00a0werden\u00a0kann ,\u00a0wenn\u00a0es\u00a0sich\u00a0\nz.\u00a0B.\u00a0bei\u00a0dem\u00a0bewerteten\u00a0Arzneimittel\u00a0um\u00a0eine\u00a0wichtige\u00a0Therapie option\u00a0handelt\u00a0\n(Beispiele\u00a0f\u00fcr\u00a0 Opt\u2010out:\u00a0Aliskiren/Amlodipin,\u00a0Canagliflozin,\u00a0Canagliflozin/Metformin,\u00a0\nCollagenase\u00a0Clostridium\u00a0histolyticum,\u00a0Empagliflozin/Metformin,\u00a0 Gaxilose,\u00a0Linaglip\u2010\ntin,\u00a0Lomitamid,\u00a0Lurasidon,\u00a0Ospemifen,\u00a0Retigabin).\u00a0 \n80\u00a0\n\u00a0Marktr\u00fccknahmen\u00a0aus\u00a0wirtschaftlichen\u00a0Gr\u00fcnden\u00a0gibt\u00a0es\u00a0jedoch\u00a0nic ht\u00a0erst\u00a0seit\u00a0oder\u00a0\nwegen\u00a0des\u00a0AMNOG\u2010Verfahrens.\u00a0Ein\u00a0prominentes\u00a0Beispiel\u00a0ist\u00a0das\u00a0Fe rtigarzneimittel\u00a0\nMabCampath\u00ae\u00a0mit\u00a0dem\u00a0Wirkstoff\u00a0Alemtuzumab.\u00a0Es\u00a0wurde\u00a02001\u00a0in\u00a0der \u00a0Indikation\u00a0\nder\u00a0 chronisch\u00a0 lymphatischen\u00a0 Leuk\u00e4mie\u00a0 vom\u00a0 B\u2010Zell\u2010Typ\u00a0 (B\u2010CLL)\u00a0 zug elassen\u00a0 und\u00a0\ndurch\u00a0den\u00a0Zulassungsinhaber\u00a0im\u00a0Jahr\u00a02012\u00a0vom\u00a0Markt\u00a0genommen,\u00a0um \u00a0es\u00a0sp\u00e4ter\u00a0\n(2013)\u00a0zu\u00a0einem\u00a0deutlich\u00a0h\u00f6heren\u00a0Preis\u00a0f\u00fcr\u00a0die\u00a0Behandlung\u00a0der\u00a0M ultiplen\u00a0Sklerose\u00a0\n(als\u00a0Lemtrada\u00ae)\u00a0vertreiben\u00a0zu\u00a0k\u00f6nnen,\u00a0konkret\u00a0lag\u00a0der\u00a0Preis\u00a0je\u00a0 mg\u00a0f\u00fcr\u00a0MabCam\u2010\npath\u00ae\u00a0bei\u00a021,00\u00a0Euro,\u00a0f\u00fcr\u00a0Lemtra da\u00ae\u00a0bei\u00a0887,00\u00a0Euro\u00a0(siehe\u00a0Tabe lle\u00a04.6).\u00a0Den\u00a0Pati\u2010\nenten\u00a0mit\u00a0B\u2010CLL\u00a0wurde\u00a0so\u00a0eine\u00a0wi chtige\u00a0Behandlungsoption\u00a0genomm en.\u00a0\nIn\u00a0der\u00a0Vergangenheit\u00a0haben\u00a0zudem\u00a0sowohl\u00a0die\u00a0seit\u00a02004\u00a0bestehend e\u00a0Festbetragsre\u2010\ngelung\u00a0f\u00fcr\u00a0patentgesch\u00fctzte\u00a0Arzneimittel,\u00a0als\u00a0auch\u00a0die\u00a0Notwendi gkeit,\u00a0f\u00fcr\u00a0sogenann\u2010\nte\u00a0 Altzulassungen\u00a0 umfangreiche\u00a0 klinische\u00a0 Studien\u00a0 einzureichen,\u00a0 h\u00e4ufiger\u00a0 Anlass\u00a0\ngegeben,\u00a0Arzneimittel\u00a0auch\u00a0aus\u00a0wirtschaftlichen\u00a0Gr\u00fcnden\u00a0vom\u00a0Mar kt\u00a0zu\u00a0nehmen.\u00a0\nAuch\u00a0 unabh\u00e4ngig\u00a0 vom\u00a0 AMNOG\u2010Verfahren\u00a0 wurden\u00a0 und\u00a0 werden\u00a0 Arzneimit tel\u00a0 vom\u00a0\nHersteller\u00a0aus\u00a0wirtschaftlichen \u00a0Gr\u00fcnden\u00a0aus\u00a0dem\u00a0Handel\u00a0genommen .\u00a0Marktr\u00fccknah\u2010\nmen\u00a0im\u00a0Rahmen\u00a0des\u00a0AMNOG\u2010Verfahrens\u00a0scheinen\u00a0h\u00e4ufig\u00a0der\u00a0Verhinde rung\u00a0einer\u00a0\nPreisfestsetzung\u00a0von\u00a0Arzneimitte ln\u00a0zu\u00a0dienen,\u00a0die\u00a0keinen\u00a0belegt en\u00a0Zusatznutzen\u00a0haben.\u00a0\nIn\u00a0bestimmten\u00a0Situationen\u00a0k\u00f6nnen\u00a0allerdings\u00a0auch\u00a0Arzneimittel\u00a0o hne\u00a0\u00fcberlegene\u00a0Wirk\u2010\nsamkeit\u00a0eine\u00a0relevante\u00a0Erweiter ung\u00a0der\u00a0Therapieoptionen\u00a0darstel len.\u00a0Bisher\u00a0wurden\u00a0\nnach\u00a0den\u00a0Daten\u00a0der\u00a0publizi erten\u00a0Innov ationsreporte\u00a011\u00a0%\u00a0al ler\u00a0n utzenbewerteten\u00a0\nArzneimittel\u00a0 vom\u00a0 Markt\u00a0 genommen\u00a0 (z.\u00a0B.\u00a0 Albiglutid,\u00a0 Dapagliflozi n,\u00a0 Dapagliflo\u2010\nzin/Metformin,\u00a0Insulin\u00a0degludec,\u00a0M irabegron,\u00a0Perampanel,\u00a0Regora fenib).\u00a0\nFehlende\u00a0Nutzenbewertung\u00a0bei\u00a0neue n\u00a0Indikationen\u00a0von\u00a0pr\u00e4\u2010AMNOG\u2010W irkstoffen\u00a0\nWie\u00a0schon\u00a0angesprochen\u00a0gibt\u00a0es\u00a0auch\u00a0Marktr\u00fccknahmen\u00a0von\u00a0Mitteln \u00a0aus\u00a0vor\u2010\nAMNOG\u2010Zeiten,\u00a0f\u00fcr\u00a0die\u00a0das\u00a0jeweilige\u00a0pharmazeutische\u00a0Unternehmen \u00a0den\u00a0Antrag\u00a0\nauf\u00a0Entzug\u00a0der\u00a0bisherigen\u00a0Zulassung\u00a0beantragt,\u00a0um\u00a0dasselbe\u00a0Mitt el\u00a0dann\u00a0in\u00a0einer\u00a0\nanderen\u00a0und\u00a0profitableren\u00a0Indikation\u00a0zuzulassen.\u00a0Bei\u00a0einem\u00a0solc hen\u00a0Indikations\u2010\nwechsel\u00a0entf\u00e4llt\u00a0dann\u00a0der\u00a0AMNOG\u2010 Prozess\u00a0mit\u00a0der\u00a0Feststellung\u00a0de s\u00a0Zusatznutzens\u00a0\nund\u00a0ebenso\u00a0die\u00a0Preisverhandlungen\u00a0\u00fcber\u00a0den\u00a0Erstattungsbetrag.\u00a0D iese\u00a0Strategie\u00a0\nhat\u00a0 der\u00a0 pharmazeutische\u00a0 Unternehmer\u00a0 Sanofi\u2010Aventis\u00a0 genutzt,\u00a0 um\u00a0 f\u00fcr\u00a0 seinen\u00a0\nWirkstoff\u00a0Alemtuzumab,\u00a0f\u00fcr\u00a0den\u00a0am\u00a06.7.2001\u00a0eine\u00a0EU\u2010Zulassung\u00a0zu r\u00a0Behandlung\u00a0\nder\u00a0Leuk\u00e4mie\u00a0ergangen\u00a0war,\u00a0am\u00a08.8.2012\u00a0den\u00a0Antrag\u00a0auf\u00a0Entzug\u00a0de r\u00a0Zulassung\u00a0zu\u00a0\nbeantragen\u00a0und\u00a0dann\u00a0am\u00a012.9.2013\u00a0eine\u00a0EU\u2010Zulassung\u00a0zur\u00a0Behandlu ng\u00a0bei\u00a0Multip\u2010\nler\u00a0Sklerose\u00a0(MS)\u00a0zu\u00a0erreichen.\u00a0Der\u00a0f\u00fcr\u00a0den\u00a0pharmazeutischen\u00a0He rsteller\u00a0finanzielle\u00a0\nNutzen\u00a0dieser\u00a0\u201eTransaktion\u201c\u00a0is t\u00a0un\u00fcbersehbar:\u00a0In\u00a0der\u00a0Leuk\u00e4mie\u2010I ndikation\u00a0wurde\u00a0\ndas\u00a0Mittel\u00a0f\u00fcr\u00a0wenige\u00a0tausend\u00a0Patienten\u00a0eingesetzt\u00a0\u2013\u00a0der\u00a0Millig ramm\u2010Preis\u00a0in\u00a0die\u2010\nsem\u00a0Anwendungsbereich\u00a0betrug\u00a021,00\u00a0Euro,\u00a0in\u00a0der\u00a0MS\u2010Indikation\u00a0g eht\u00a0es\u00a0um\u00a0die\u00a0\nBehandlung\u00a0von\u00a0mehreren\u00a0100.000\u00a0Patienten,\u00a0nun\u00a0zu\u00a0einem\u00a0Milligr ammpreis\u00a0von\u00a0\n887,00\u00a0Euro,\u00a0also\u00a0dem\u00a042\u2010fachen\u00a0des\u00a0urspr\u00fcnglichen\u00a0Preises.\u00a0Die \u00a0Schw\u00e4che\u00a0des\u00a0 \n81\u00a0\n\u00a0AMNOG\u00a0ist\u00a0in\u00a0Bezug\u00a0auf\u00a0diesen\u00a0Zusammenhang\u00a0schnell\u00a0beschrieben: \u00a0Auch\u00a0bei\u00a0\neiner\u00a0Indikations\u00e4nderung\u00a0eines\u00a0M ittels\u00a0aus\u00a0der\u00a0vor\u2010AMNOG\u2010Zeit\u00a0 darf\u00a0dies\u00a0kein\u00a0\nGrund\u00a0sein,\u00a0die\u00a0Nutzenbewertung\u00a0und\u00a0die\u00a0Verhandlung\u00a0um\u00a0den\u00a0Erst attungsbetrag\u00a0\nauszusetzen,\u00a0ansonsten\u00a0wird\u00a0diese\u00a0Strategie\u00a0sicherlich\u00a0immer\u00a0wi eder\u00a0Nachahmer\u00a0\nfinden.\u00a0Bei\u00a0dem\u00a0Wirkstoff\u00a0Ofatumumab\u00a0ist\u00a0eine\u00a0\u00e4hnliche\u00a0Entwickl ung\u00a0im\u00a0Gange:\u00a0\nAuch\u00a0dieses\u00a0Mittel\u00a0wurde\u00a0zun\u00e4chst\u00a0zur\u00a0Behandlung\u00a0der\u00a0Leuk\u00e4mie\u00a0e ingesetzt\u00a0(EU\u2010\nZulassung\u00a0 am\u00a0 19.4.2010\u00a0 unter\u00a0 dem\u00a0 Handelsnamen\u00a0 Arzerra\u00ae),\u00a0 dann\u00a0 f olgte\u00a0 der\u00a0\nAntrag\u00a0auf\u00a0Entzug\u00a0dieser\u00a0Zulassung\u00a0am\u00a08.11.2016,\u00a0im\u00a0Februar\u00a0wur de\u00a0die\u00a0Zulassung\u00a0\nbei\u00a0 MS\u00a0 beantragt\u00a0 und\u00a0 liegt\u00a0 seit\u00a0 dem\u00a0 26.3.2021\u00a0 unter\u00a0 dem\u00a0 Handels namen\u00a0\nKesimpta\u00ae\u00a0vor.\u00a0Der\u00a0Apothekenverkaufspreis\u00a0von\u00a0Arzerra\u00ae\u00a0lag\u00a0zule tzt\u00a0bei\u00a03,20\u00a0Euro\u00a0\nje\u00a0mg,\u00a0nach\u00a0Relaunch\u00a0als\u00a0Kesimpta\u00ae\u00a0bei\u00a074,80\u00a0bis\u00a076,72\u00a0Euro\u00a0pro \u00a0mg\u00a0je\u00a0nach\u00a0Pa\u2010\nckungsgr\u00f6\u00dfe,\u00a0d.\u00a0h.\u00a0um\u00a0den\u00a0Faktor\u00a023\u00a0bis\u00a024\u00a0h\u00f6her.\u00a0\nProblematische\u00a0freie\u00a0Preisbildung\u00a0im\u00a0ersten\u00a0Jahr\u00a0bei\u00a0Einmalther apien\u00a0\nDie\u00a0Pr\u00e4parate\u00a0Yescarta\u00ae\u00a0und\u00a0Kymriah\u00ae\u00a0werden\u00a0beim\u00a0B\u2010Zell\u2010Lymphom \u00a0eingesetzt.\u00a0\nDer\u00a0 vom\u00a0 pharmazeutischen\u00a0 Unternehmer\u00a0 verlangte\u00a0 Preis\u00a0 bei\u00a0 Markte inf\u00fchrung\u00a0\nbetrug\u00a0f\u00fcr\u00a0Yescarta\u00ae\u00a0327.000\u00a0Euro,\u00a0f\u00fcr\u00a0Kymriah\u00ae\u00a0320.000\u00a0Euro,\u00a0d er\u00a0verhandelt\u00a0\nErstattungsbetrag\u00a0lag\u00a0bei\u00a0282.000\u00a0resp.\u00a0275.000\u00a0Euro.\u00a0Da\u00a0die\u00a0Mi ttel\u00a0jeweils\u00a0aber\u00a0\nnur\u00a0einmal\u00a0verabreicht\u00a0werden\u00a0m\u00fcssen,\u00a0f\u00e4llt\u00a0im\u00a0ersten\u00a0Jahr\u00a0imme r\u00a0der\u00a0vom\u00a0phar\u2010\nmazeutischen\u00a0Unternehmer\u00a0festgesetzte\u00a0Preis\u00a0an.\u00a0Erst\u00a0ab\u00a0dem\u00a0zwe iten\u00a0Jahr\u00a0wird\u00a0\nder\u00a0Erstattungsbetrag\u00a0g\u00fcltig.\u00a0Mit\u00a0anderen\u00a0Worten:\u00a0Bei\u00a0solchen\u00a0M itteln\u00a0mit\u00a0einma\u2010\nliger\u00a0Anwendung\u00a0sollte\u00a0eine\u00a0Behandlung\u00a0erst\u00a0dann\u00a0erlaubt\u00a0werden ,\u00a0wenn\u00a0\u00fcber\u00a0den\u00a0\nErstattungsbetrag\u00a0entschieden\u00a0wurde.\u00a0\nL\u00fcckenhafte\u00a0Regularien\u00a0f\u00fcr\u00a0die\u00a0Anwendung\u00a0im\u00a0station\u00e4ren\u00a0Sektor\u00a0\nF\u00fcr\u00a0das\u00a0Arzneimittel\u00a0Glybera\u00ae,\u00a0das\u00a0bei\u00a0famili\u00e4rer\u00a0Lipoproteinli pasedefizienz\u00a0(LPLD)\u00a0\neingesetzt\u00a0wird,\u00a0wurde\u00a0bei\u00a0der\u00a0Markteinf\u00fchrung\u00a0ein\u00a0Preis\u00a0von\u00a043 .870\u00a0Euro\u00a0vom\u00a0\npharmazeutischen\u00a0Unternehmer\u00a0fest gelegt.\u00a0Da\u00a0sich\u00a0die\u00a0Vertragspa rtner\u00a0 darauf\u00a0\nverst\u00e4ndigten,\u00a0dass\u00a0dieses\u00a0Mitte l\u00a0nur\u00a0im\u00a0station\u00e4ren\u00a0Bereich\u00a0an gewendet\u00a0wird,\u00a0\nsollte\u00a0der\u00a0Erstattungsbetrag\u00a0nach\u00a0dem\u00a0AMVSG\u00a0von\u00a013.5.2017\u00a0auch\u00a0 im\u00a0station\u00e4ren\u00a0\nSektor\u00a0als\u00a0Obergrenze\u00a0gelten.\u00a0Bisher\u00a0wurde\u00a0auch\u00a0kein\u00a0Erstattung sbetrag\u00a0verein\u2010\nbart.\u00a0Zudem\u00a0ist\u00a0die\u00a0praktische\u00a0U msetzung\u00a0dieser\u00a0Regelung\u00a0ohnehi n\u00a0unklar,\u00a0da\u00a0die\u00a0\nstation\u00e4r\u00a0anfallenden\u00a0Arzneimitte lkosten\u00a0im\u00a0DRG\u2010\u00a0oder\u00a0NUB\u2010Syste m\u00a0nur\u00a0schwer\u2010\nlich\u00a0herauszurechnen\u00a0sind\u00a0und\u00a0dahe r\u00a0eher\u00a0untergehen.\u00a0F\u00fcr\u00a0diese\u00a0 Fallkonstellation\u00a0\nmuss\u00a0dringend\u00a0eine\u00a0klare\u00a0Reg elung\u00a0geschaffen\u00a0werden.\u00a0\u00a0\nInsgesamt\u00a0 sind\u00a0 es\u00a0 die\u00a0 folgenden\u00a0 Aspekte,\u00a0 die\u00a0 als\u00a0 Schw\u00e4che\u00a0 des\u00a0 A MNOG\u2010\nVerfahrens\u00a0angesprochen\u00a0und\u00a0f\u00fcr\u00a0d ie\u00a0L\u00f6sungen\u00a0in\u00a0diesem\u00a0sog.\u00a0ler nenden\u00a0System\u00a0\ngefunden\u00a0werden\u00a0m\u00fcssen:\u00a0 \n82\u00a0\n\u00a0\uf0b7 Die\u00a0Preisfindung\u00a0\u00fcber\u00a0 eine\u00a0Vergleichstherapie\u00a0ist\u00a0(zumeist)\u00a0ung eeignet.\u00a0\n\uf0b7 Die\u00a0Bevorzugung\u00a0von\u00a0 Orphan\u00a0Drugs \u00a0muss\u00a0\u00fcberdacht\u00a0werden.\u00a0\n\uf0b7 Es\u00a0muss\u00a0auch\u00a0f\u00fcr\u00a0\u00e4ltere\u00a0Mittel\u00a0in\u00a0neuen\u00a0Indikationen\u00a0eine\u00a0oblig atori\u2010\nsche\u00a0Neubewertung\u00a0geben.\u00a0\n\uf0b7 Die\u00a0Mischpreisregelung\u00a0sollte\u00a0erneut\u00a0\u00fcberdacht\u00a0werden.\u00a0\n\uf0b7 Es\u00a0fehlt\u00a0eine\u00a0L\u00f6sung\u00a0f\u00fcr\u00a0die\u00a0Kosteneind\u00e4mmung\u00a0bei\u00a0Kombinations\u2010\ntherapien.\u00a0\n\uf0b7 Die\u00a0freie\u00a0Preisbildung\u00a0im\u00a0ersten\u00a0Jahr\u00a0muss\u00a0grunds\u00e4tzlich,\u00a0aber\u00a0 spezi\u2010\nell\u00a0bei\u00a0Einmaltherapien\u00a0abgeschafft\u00a0werden.\u00a0\n\uf0b7 Die\u00a0 AMNOG\u2010Ergebnisse\u00a0 sind\u00a0 im\u00a0 station\u00e4ren\u00a0 Sektor\u00a0 schlecht\u00a0 an\u2010\nwendbar,\u00a0hier\u00a0m\u00fcssen\u00a0praktikable\u00a0L\u00f6sungen\u00a0gefunden\u00a0werden.\u00a0\n\uf0b7 Der\u00a0Marktr\u00fccknahme\u00a0als\u00a0Druckmitte l\u00a0der\u00a0Industrie\u00a0steht\u00a0kein\u00a0\u00c4qu i\u2010\nvalent\u00a0auf\u00a0Seiten\u00a0der\u00a0GKV\u00a0gegen\u00fcber.\u00a0\n Kernprobleme\u00a0und\u00a0Forderungen\u00a0aus\u00a0der\u00a0AMNOG\u2010Analyse\u00a05.2\nEfficacy\u00a0und\u00a0effectiveness \u00a0\nSowohl\u00a0in\u00a0den\u00a0USA\u00a0als\u00a0auch\u00a0in\u00a0Europa\u00a0haben\u00a0die\u00a0zust\u00e4ndigen\u00a0regu latorischen\u00a0Be\u2010\nh\u00f6rden\u00a0in\u00a0den\u00a0letzten\u00a0Jahren\u00a0verschiedene\u00a0Verfahren\u00a0eingef\u00fchrt, \u00a0die\u00a0eine\u00a0Be\u2010\nschleunigung\u00a0der\u00a0Zulassung\u00a0neuer\u00a0Arzneimittel\u00a0erlauben,\u00a0um\u00a0Pati enten\u00a0mit\u00a0schwe\u2010\nren\u00a0oder\u00a0seltenen\u00a0Erkrankungen\u00a0(z.\u00a0B.\u00a0in\u00a0der\u00a0Onkologie)\u00a0einen\u00a0r ascheren\u00a0Zugang\u00a0zu\u00a0\nneuen\u00a0Arzneimitteln\u00a0zu\u00a0erm\u00f6gliche n,\u00a0so\u00a0jedenfalls\u00a0die\u00a0h\u00e4ufig\u00a0of fizielle\u00a0Lesart\u00a0dieser\u00a0\nStrategie.\u00a0Ein\u00a0Ergebnis\u00a0solcher\u00a0 beschleunigten\u00a0Zulassungsverfah ren\u00a0sind\u00a0letztlich\u00a0\naber\u00a0 auch\u00a0 die\u00a0 un\u00fcbersehbar\u00a0 gro\u00dfe\u00a0 Anzahl\u00a0 von\u00a0 neuen\u00a0 Arzneimitteln ,\u00a0 die\u00a0 den\u00a0\nAMNOG\u2010Prozess\u00a0ohne\u00a0belegten\u00a0Zusatznutzen\u00a0beenden\u00a0\u2013\u00a0es\u00a0sind\u00a0seit \u00a0der\u00a0Einf\u00fch\u2010\nrung\u00a0des\u00a0AMNOG\u00a0im\u00a0Jahre\u00a02011\u00a0mit\u00a0216\u00a0neuen\u00a0Mitteln\u00a0\u00fcber\u00a0die\u00a0H\u00e4l fte\u00a0aller\u00a0seit\u2010\ndem\u00a0bewerteten\u00a0Medikamente.\u00a0Ein\u00a0Grund\u00a0f\u00fcr\u00a0dieses\u00a0eher\u00a0verst\u00f6ren de,\u00a0ja\u00a0desas\u2010\ntr\u00f6se\u00a0Ergebnis\u00a0k\u00f6nnte\u00a0durch\u00a0die\u00a0Gegen\u00fcberstellung\u00a0des\u00a0im\u00a0Arznei mittelrecht\u00a0ver\u2010\nankerten\u00a0Begriffs\u00a0 efficacy\u00a0\u2013\u00a0der\u00a0unter\u00a0Idealbedingungen\u00a0in\u00a0einer\u00a0Zulassungsstudie\u00a0\nerreichbaren\u00a0Wirksamkeit\u00a0\u2013\u00a0und\u00a0der\u00a0 effectiveness \u00a0\u2013\u00a0der\u00a0unter\u00a0den\u00a0Alltagsbedin\u2010\ngungen\u00a0 im\u00a0 Rahmen\u00a0 unterschiedlicher\u00a0 \u00e4rztlicher\u00a0 Behandlungskompet enzen\u00a0 und\u00a0\nsystemisch\u00a0gesetzter\u00a0Rahmenbedin gungen\u00a0(Honorierung,\u00a0Leitlinien \u00a0usw.)\u00a0erreich\u2010\nbaren\u00a0Wirksamkeit\u00a0f\u00fcr\u00a0die\u00a0nicht\u00a0mehr\u00a0selektierten\u00a0Patienten\u00a0\u2013\u00a0a nalysiert\u00a0werden.\u00a0\nDazu\u00a0sollen\u00a0die\u00a0folgenden\u00a0\u00dcberle gungen\u00a0einen\u00a0Beitrag\u00a0und\u00a0Diskus sionsanreiz\u00a0bie\u2010\nten\u00a0(Windeler\u00a0&\u00a0Antes\u00a02001;\u00a0Gla eske,\u00a02012;\u00a0Glaeske\u00a0et\u00a0al.,\u00a02017 ).\u00a0\nVom\u00a0Wert\u00a0einer\u00a0Arzneimitteltherapie\u00a0\u2013\u00a0Wirksamkeit\u00a0ist\u00a0nicht\u00a0gle ich\u00a0Wirksamkeit\u00a0 \n83\u00a0\n\u00a0Die\u00a0Zulassung\u00a0eines\u00a0Arzneimittels\u00a0sagt\u00a0noch\u00a0nichts\u00a0\u00fcber\u00a0dessen\u00a0 gesundheitlichen\u00a0\noder\u00a0\u00f6konomischen\u00a0(Netto\u2010)Nutzen\u00a0aus.\u00a0Vielmehr\u00a0muss\u00a0sich\u00a0das\u00a0Mi ttel\u00a0in\u00a0der\u00a0\nallt\u00e4glichen\u00a0medizinischen\u00a0Versorgung\u00a0beweisen\u00a0und\u00a0zeigen,\u00a0dass \u00a0es\u00a0bezogen\u00a0auf\u00a0\nklinisch\u00a0relevante\u00a0Endpunkte\u00a0in\u00a0der\u00a0Langzeitanwendung\u00a0bzw.\u00a0in\u00a0d er\u00a0Anwendung\u00a0in\u00a0\nnicht\u00a0mehr\u00a0selektierten\u00a0Patien tenpopulationen\u00a0Vorteile\u00a0gegen\u00fcbe r\u00a0bereits\u00a0ange\u2010\nbotenen\u00a0 Arzneimitteln\u00a0 oder\u00a0 andere n\u00a0 medizinischen\u00a0 Interventionen \u00a0h a t . \u00a0D i e s e \u00a0\nVorteile\u00a0k\u00f6nnen\u00a0in\u00a0der\u00a0Verbesserung\u00a0des\u00a0Therapieergebnisses\u00a0ode r\u00a0des\u00a0Risiko\u2010\nNutzen\u2010Verh\u00e4ltnisses\u00a0und\u00a0damit\u00a0in\u00a0einer\u00a0Optimierung\u00a0des\u00a0Patient ennutzens\u00a0liegen.\u00a0\nDie\u00a0Hoffnungen\u00a0vieler\u00a0an\u00a0schwerwiegenden\u00a0bisher\u00a0nur\u00a0symptomatis ch\u00a0behandel\u2010\nbaren\u00a0Krankheiten\u00a0leidender\u00a0Patienten\u00a0richten\u00a0sich\u00a0auf\u00a0die\u00a0Entw icklung\u00a0 neuer\u00a0\nMedikamente.\u00a0So\u00a0bieten\u00a0therapeut ische\u00a0Innovationen\u00a0in\u00a0der\u00a0Zwisc henzeit\u00a0wirksa\u2010\nme\u00a0Therapien\u00a0auch\u00a0z.\u00a0B.\u00a0bei\u00a0der\u00a0 Behandlung\u00a0von\u00a0Virusinfektionen \u00a0wie\u00a0HIV/AIDS\u00a0\noder\u00a0Hepatitis\u00a0C\u00a0an.\u00a0Gleiches\u00a0gilt\u00a0f\u00fcr\u00a0die\u00a0Behandlung\u00a0von\u00a0Autoi mmunerkrankungen\u00a0\nwie\u00a0Rheumatoide\u00a0Arthritis,\u00a0Psoriasis\u00a0oder\u00a0chronisch\u00a0entz\u00fcndlich e\u00a0Darmerkrankun\u2010\ngen\u00a0wie\u00a0Morbus\u00a0Crohn\u00a0und\u00a0Colitis\u00a0ulcerosa.\u00a0Einige\u00a0Verbesserunge n\u00a0haben\u00a0sich\u00a0\nauch\u00a0bei\u00a0der\u00a0Behandlung\u00a0von\u00a0Krebs erkrankungen\u00a0wie\u00a0z.\u00a0B.\u00a0beim\u00a0ma lignen\u00a0Mela\u2010\nnom\u00a0durch\u00a0die\u00a0Anwendung\u00a0von\u00a0Immuntherapeutika\u00a0ergeben.\u00a0Manche\u00a0H offnungen\u00a0\nwurden\u00a0allerdings\u00a0bislang\u00a0auch\u00a0entt\u00e4uscht:\u00a0So\u00a0ist\u00a0noch\u00a0immer\u00a0ke in\u00a0Arzneimittel\u00a0auf\u00a0\ndem\u00a0Markt,\u00a0mit\u00a0dem\u00a0das\u00a0Fortschreiten\u00a0einer\u00a0Alzheimerdemenz\u00a0gest oppt\u00a0werden\u00a0\nk\u00f6nnte;\u00a0ein\u00a0Ziel,\u00a0das\u00a0gerade\u00a0in\u00a0Gesellschaften\u00a0l\u00e4ngeren\u00a0Lebens\u00a0 wie\u00a0der\u00a0unsrigen\u00a0\nund\u00a0anderer\u00a0entwickelter\u00a0Industriestaaten\u00a0bei\u00a0dieser\u00a0altersbedi ngten\u00a0Erkrankung\u00a0\ndringend\u00a0erreicht\u00a0werden\u00a0sollte,\u00a0um\u00a0die\u00a0derzeit\u00a0bereits\u00a0\u00fcberlas tete\u00a0pflegerische\u00a0\nBetreuung\u00a0der\u00a0betroffenen\u00a0\u00e4lteren\u00a0Menschen\u00a0zu\u00a0entlasten.\u00a0Welche \u00a0Dimension\u00a0\nallein\u00a0dieser\u00a0Krankheitsbereich\u00a0f\u00fcr\u00a0unser\u00a0Gesundheitswesen\u00a0bede utet,\u00a0l\u00e4sst\u00a0sich\u00a0\nbereits\u00a0aus\u00a0den\u00a0epidemiologische n\u00a0Gegebenheiten\u00a0ableiten:\u00a0Im\u00a0Al ter\u00a0von\u00a060\u00a0Jah\u2010\nren\u00a0liegt\u00a0die\u00a0Pr\u00e4valenz\u00a0der\u00a0Alzheimerdemenz\u00a0bei\u00a00,6\u00a0%,\u00a0im\u00a0Alter \u00a0von\u00a090\u00a0Jahren\u00a0bei\u00a0\n32\u00a0%.\u00a0Dieser\u00a0lineare\u00a0Anstieg\u00a0ist\u00a0deshalb\u00a0im\u00a0Rahmen\u00a0der\u00a0demograp hischen\u00a0Ver\u00e4n\u2010\nderung\u00a0in\u00a0unserer\u00a0Gesellschaft\u00a0von\u00a0besonderer\u00a0Bedeutung,\u00a0weil\u00a0d erzeit\u00a0etwa\u00a0f\u00fcnf\u00a0\nMio.\u00a0Menschen\u00a0im\u00a0Alter\u00a0\u00fcber\u00a080\u00a0J ahre\u00a0in\u00a0unserer\u00a0Bev\u00f6lkerung\u00a0leb en.\u00a02050\u00a0werden\u00a0\nes\u00a0aber\u00a0bereits\u00a011\u00a0Mio.\u00a0sein\u00a0\u2013\u00a0es\u00a0ist\u00a0daher\u00a0klar\u00a0erkennbar,\u00a0das s\u00a0mit\u00a0diesem\u00a0Anstieg\u00a0\nauch\u00a0der\u00a0Anteil\u00a0der\u00a0Menschen\u00a0mit \u00a0einer\u00a0Alzheimerdemenz\u00a0dramatis ch\u00a0ansteigen\u00a0\nwird\u00a0\u2013\u00a0von\u00a0heute\u00a0etwa\u00a01,2\u00a0Mio.\u00a0auf\u00a0etwa\u00a0drei\u00a0Mio.\u00a0Menschen\u00a0im\u00a0J ahr\u00a02050.\u00a0Eine\u00a0\nad\u00e4quate\u00a0Arzneimitteltherapie\u00a0zur\u00a0Verringerung\u00a0der\u00a0H\u00e4ufigkeit\u00a0e iner\u00a0Alzheimer\u2010\ndemenz\u00a0w\u00e4re\u00a0daher\u00a0von\u00a0gro\u00dfem\u00a0Nutzen\u00a0f\u00fcr\u00a0die\u00a0Patienten,\u00a0aber\u00a0auc h\u00a0f\u00fcr\u00a0unser\u00a0\ngesamtes\u00a0Gesundheitswesen,\u00a0weil\u00a0dadurch\u00a0die\u00a0Ausgaben\u00a0f\u00fcr\u00a0die\u00a0pf legerischen\u00a0\nLeistungen\u00a0deutlich\u00a0gesenkt\u00a0werden\u00a0k\u00f6nnten\u00a0(Glaeske\u00a0&\u00a0Berlit,\u00a02 018).\u00a0\nSeit\u00a0jeher\u00a0bewegt\u00a0sich\u00a0der\u00a0Einsatz\u00a0von\u00a0Pharmaka\u00a0in\u00a0der\u00a0medizini schen\u00a0Versorgung\u00a0\nauch\u00a0im\u00a0Spannungsfeld\u00a0der\u00a0Problemfelder\u00a0Wirksamkeit,\u00a0patienteno rientierter\u00a0Nut\u2010\nzen,\u00a0gesellschaftliche\u00a0Wohlfahrt\u00a0und\u00a0Kosten.\u00a0Dieses\u00a0Spannungsfe ld\u00a0ist\u00a0in\u00a0den\u00a0letzten\u00a0\nJahren\u00a0auch\u00a0deshalb\u00a0besonders\u00a0in\u00a0den\u00a0Mittelpunkt\u00a0der\u00a0Diskussion en\u00a0ger\u00fcckt,\u00a0weil\u00a0die\u00a0 \n84\u00a0\n\u00a0Ausgaben\u00a0f\u00fcr\u00a0die\u00a0Arzneimitteltherapie\u00a0bei\u00a0den\u00a0schon\u00a0erw\u00e4hnten\u00a0t herapeutischen\u00a0\nInnovationen\u00a0deutlich\u00a0angestiegen\u00a0sind.\u00a0Gegen\u00fcber\u00a0der\u00a0 Old\u00a0Pharmaceutical\u00a0Rese\u2010\narch,\u00a0die\u00a0auf\u00a0neue\u00a0und\u00a0dann\u00a0patentgesch\u00fctzte\u00a0chemisch\u00a0synthetisiert e\u00a0Wirkstoffe\u00a0\nsetzte,\u00a0dominieren\u00a0seit\u00a0etwa\u00a020\u00a0 Jahren\u00a0Wirkstoffe\u00a0aus\u00a0dem\u00a0Berei ch\u00a0der\u00a0New\u00a0Phar\u2010\nmaceutical\u00a0Research .\u00a0Dies\u00a0sind\u00a0neue\u00a0Forschungsstrategien,\u00a0die\u00a0gentechnisch\u00a0oder\u00a0\nbiologisch\u00a0hergestellte\u00a0Medikame nte\u00a0(erstangebotene\u00a0Biologicals \u00a0und\u00a0Biosimilars\u00a0als\u00a0\nkosteng\u00fcnstigere\u00a0 Nachahmerprodukte)\u00a0 zur\u00a0 Behandlung\u00a0 von\u00a0 z.\u00a0B.\u00a0 Rh eumatoider\u00a0\nArthritis,\u00a0Psoriasis,\u00a0Morbus\u00a0Crohn,\u00a0Colitis\u00a0ulcerosa\u00a0oder\u00a0Krebs erkrankungen\u00a0in\u00a0den\u00a0\nMittelpunkt\u00a0stellen.\u00a0Einige\u00a0solcher\u00a0Mittel\u00a0geh\u00f6ren\u00a0schon\u00a0viele\u00a0 Jahre\u00a0zum\u00a0Repertoire\u00a0\neiner\u00a0Behandlung,\u00a0die\u00a0auch\u00a0tats\u00e4chlich\u00a0f\u00fcr\u00a0viele\u00a0Patienten\u00a0eine n\u00a0therapeutischen\u00a0\nFortschritt\u00a0bieten.\u00a0Das\u00a0Gleiche\u00a0gilt\u00a0f\u00fcr\u00a0neue\u00a0Medikamente\u00a0zur\u00a0B ehandlung\u00a0von\u00a0Hepa\u2010\ntitis\u00a0C\u00a0oder\u00a0Multipler\u00a0Sklerose.\u00a0Daneben\u00a0ist\u00a0aber\u00a0auch\u00a0offensic htlich,\u00a0dass\u00a0in\u00a0der\u00a0\nVersorgung\u00a0mit\u00a0Antibiotika\u00a0oder\u00a0bei\u00a0den\u00a0meisten\u00a0weiteren\u00a0neurol ogischen\u00a0Erkran\u2010\nkungen\u00a0und\u00a0psychischen\u00a0St\u00f6rungen\u00a0(z.\u00a0B.\u00a0Depressionen),\u00a0kaum\u00a0neu e\u00a0Arzneimittel\u00a0auf\u00a0\ndem\u00a0Markt\u00a0angeboten\u00a0wurden\u00a0und\u00a0werden.\u00a0Neue\u00a0Arzneimittel\u00a0werden \u00a0stattdessen\u00a0\nvor\u00a0allem\u00a0in\u00a0solchen\u00a0Indikationsb ereichen\u00a0angeboten,\u00a0in\u00a0denen\u00a0h ohe\u00a0Preise,\u00a0oft\u00a0auch\u00a0\nals\u00a0\u201eMondpreise\u201c\u00a0charakterisiert,\u00a0verlangt\u00a0werden\u00a0k\u00f6nnen.\u00a0Die\u00a0O nkologie\u00a0oder\u00a0Arz\u2010\nneimittel\u00a0bei\u00a0seltenen\u00a0Erkrankungen\u00a0 (Orphan\u00a0Diseases) \u00a0haben\u00a0sich\u00a0in\u00a0diesem\u00a0Zu\u2010\nsammenhang\u00a0als\u00a0besonders\u00a0lukrativ\u00a0f\u00fcr\u00a0die\u00a0pU\u00a0herausgestellt,\u00a0we il\u00a0in\u00a0diesen\u00a0Behand\u2010\nlungsfeldern\u00a0kaum\u00a0\u00fcber \u00a0hohe\u00a0Preise\u00a0diskutier t\u00a0wird:\u00a0Schlie\u00dflich \u00a0sollen\u00a0die\u00a0jeweiligen\u00a0\nPatienten\u00a0m\u00f6glichst\u00a0alle\u00a0Optionen\u00a0f\u00fcr\u00a0eine\u00a0Behandlung\u00a0und\u00a0eine\u00a0 m\u00f6gliche\u00a0Lebens\u2010\nverl\u00e4ngerung\u00a0in\u00a0Anspruch\u00a0nehmen\u00a0d\u00fcrfen,\u00a0auch\u00a0wenn\u00a0die\u00a0Therapiek osten\u00a0pro\u00a0Jahr\u00a0\noftmals\u00a0100.000\u00a0Euro\u00a0und\u00a0mehr\u00a0betragen.\u00a0Dabei\u00a0sind\u00a0die\u00a0Daten\u00a0zu r\u00a0Lebenszeitver\u2010\nl\u00e4ngerung\u00a0sowie\u00a0zur\u00a0Verbesserung\u00a0der\u00a0Lebensqualit\u00e4t\u00a0oft\u00a0nur\u00a0wen ig\u00a0\u00fcberzeugend\u00a0\n(Glaeske\u00a0et\u00a0al.,\u00a02017).\u00a0Die\u00a0folgende\u00a0Tabelle\u00a05.2\u00a0zeigt\u00a0die\u00a0Indu strieums\u00e4tze\u00a0der\u00a020\u00a0\numsatzst\u00e4rksten\u00a0Arzneimittel\u00a0im\u00a0Jahre\u00a02020/21,\u00a0die\u00a0nahezu\u00a0alles amt\u00a0zu\u00a0den\u00a0biolo\u2010\ngisch\u00a0oder\u00a0gentechnologisch\u00a0herg estellten\u00a0Mitteln\u00a0geh\u00f6ren.\u00a0Und\u00a0 obwohl\u00a0der\u00a0Ver\u2010\nordnungsanteil\u00a0f\u00fcr\u00a0solche\u00a0patentgesch\u00fctzten\u00a0AM\u00a0innerhalb\u00a0der\u00a0GK V\u00a0nur\u00a06,4\u00a0%\u00a0am\u00a0\nDDD\u00a0Gesamtvolumen\u00a0betr\u00e4gt,\u00a0f\u00fchren\u00a0diese\u00a0Mittel\u00a0zu\u00a046,3\u00a0%\u00a0der\u00a0Au sgaben,\u00a0n\u00e4mlich\u00a0\nzu\u00a021,6\u00a0Mrd.\u00a0Euro\u00a0von\u00a0insgesamt\u00a043,4\u00a0Mrd.\u00a0Euro\u00a0(plus\u00a05,3\u00a0%\u00a0zum\u00a0 Vorjahr).\u00a0Damit\u00a0\nergeben\u00a0sich\u00a0um\u00a0den\u00a0Faktor\u00a07\u00a0h\u00f6h ere\u00a0Therapiekosten\u00a0im\u00a0Vergleich \u00a0zum\u00a0patentfreien\u00a0\nBereich.\u00a0Aber\u00a0nicht\u00a0immer\u00a0zeigen\u00a0neue\u00a0Therapien\u00a0auch\u00a0einen\u00a0klar en\u00a0Nutzen\u00a0f\u00fcr\u00a0die\u00a0\nPatienten.\u00a0Vielmehr\u00a0entsteht\u00a0oftmals\u00a0nach\u00a0kritischer\u00a0Bewertung\u00a0 der\u00a0vorliegenden\u00a0\nStudien\u00a0aus\u00a0der\u00a0Versorgung\u00a0der\u00a0Eindruck,\u00a0dass\u00a0die\u00a0Kosten\u00a0f\u00fcr\u00a0di e\u00a0Therapien\u00a0deutlich\u00a0\nschneller\u00a0als\u00a0der\u00a0Nutzen\u00a0in\u00a0der\u00a0Behandlung\u00a0ansteigen.\u00a0Die\u00a0Bewer tung\u00a0der\u00a0neuen\u00a0\nMittel\u00a0f\u00e4llt\u00a0daher\u00a0nach\u00a0einigen\u00a0Jahren\u00a0Therapieerfahrung\u00a0oftmal s\u00a0eher\u00a0entt\u00e4uschend\u00a0\naus\u00a0(Glaeske\u00a0et\u00a0al.,\u00a02017).\u00a0\nIn\u00a0der\u00a0Aufstellung\u00a0nach\u00a0Industrieumsatz\u00a0(Tabelle\u00a05.2)\u00a0sind\u00a0Kreb sarzneimittel\u00a0mit\u00a0\nsechs\u00a0Nennungen\u00a0vertreten\u00a0und\u00a0bilden\u00a0somit\u00a0die\u00a0gr\u00f6\u00dfte\u00a0Gruppe.\u00a0D ie\u00a0beiden\u00a0Mittel\u00a0\nzur\u00a0Behandlung\u00a0von\u00a0Multipler\u00a0Sklerose\u00a0(MS)\u00a0und\u00a0die\u00a0beiden\u00a0Mitte l\u00a0zur\u00a0Behandlung\u00a0 \n85\u00a0\n\u00a0der\u00a0Psoriasis\u00a0repr\u00e4sentieren\u00a0ebenfalls\u00a0umsatzstarke\u00a0Indikatione n.\u00a0In\u00a0der\u00a0GKV\u00a0ist\u00a0die\u00a0\nRangfolge\u00a0der\u00a0f\u00fchrenden\u00a0Arzneimi ttel\u00a0identisch\u00a0mit\u00a0dem\u00a0hier\u00a0gez eigten\u00a0Ranking.\u00a0\nTabelle\u00a05.2:\u00a0Die\u00a020\u00a0f\u00fchrenden\u00a0Pr\u00e4parate\u00a0nach\u00a0Industrieumsatz\u00a0im \u00a0Jahreszeitraum\u00a0\nJuli\u00a02020\u00a0bis\u00a0Juni\u00a02021\u00a0\nRang\u00a0Pr\u00e4parat\u00a0(Hersteller)\u00a0\u00a0\n(Wirkstoff)\u00a0Anwendungsgebiet\u00a0Umsatz\u00a0\n2020/2021\u00a0\nin\u00a0Mio.\u00a0\u20ac\u00a0Gegen\u00fcber\u00a0\u00a0\n2019\u00a0\u00a0\nin\u00a0%\u00a0\n1\u00a0Eliquis\u00ae\u00a0(Bristol\u2010Myers\u00a0Squibb/Pfizer)\u00a0\n(Apixaban)\u00a0\u00a0Antikoagulanzien\u00a0\u00a0 844,6\u00a0 +12,6\u00a0\n2\u00a0Revlimid\u00ae\u00a0(Celgene\u00a0Europe)\u00a0\u00a0\n(Lenalidomid)\u00a0z.\u00a0B.\u00a0Myelom\u00a0 617,4\u00a0 +18,0\u00a0\n3\u00a0Xarelto\u00ae\u00a0(Bayer)\u00a0\u00a0\n(Rivaroxaban)\u00a0Antikoagulanzien\u00a0 456,5\u00a0 +30,6\u00a0\n4\u00a0Stelara\u00ae\u00a0(Janssen\u2010Cilag)\u00a0\n(Ustekinumab)\u00a0entz\u00fcndliche\u00a0Erkrankungen,\u00a0\nz.\u00a0B.\u00a0Plaque\u2010Psoriasis\u00a0419,1\u00a0 +34,1\u00a0\n5\u00a0Imbruvica\u00ae\u00a0(Janssen\u2010Cilag)\u00a0\n(Ibrutinib)\u00a0Blutkrebs\u00a0 376,1\u00a0 +12,3\u00a0\n6\u00a0Zytiga\u00ae\u00a0(Janssen\u2010Cilag)\u00a0\u00a0\n(Abirateronacetat)\u00a0Prostatakrebs\u00a0 371,0\u00a0 +0,9\u00a0\n7\u00a0Xtandi\u00ae\u00a0(Astellas)\u00a0\n(Enzalutamid)\u00a0Prostatakrebs\u00a0 336,2\u00a0 +12,5\u00a0\n8\u00a0Lixiana\u00ae\u00a0(Daiichi\u00a0Sankyo\u00a0Europe)\u00a0\u00a0\n(Endoxaban)\u00a0Antikoagulanzien\u00a0 333,7\u00a0 +16,8\u00a0\n9\u00a0Cosentyx\u00ae\u00a0(Novartis)\u00a0\u00a0\n(Secukinumab)\u00a0z.\u00a0B.\u00a0Schuppenflechte\u00a0 303,5\u00a0 +4,9\u00a0\n10\u00a0Entresto\u00ae(Novartis)\u00a0(Sacubitril,\u00a0\nValsartan)\u00a0Herzinsuffizienz\u00a0 279,1\u00a0 +32,6\u00a0\n11\u00a0Eylea\u00ae\u00a0(Bayer)\u00a0\u00a0\n(Aflibercept)\u00a0Makuladegeneration\u00a0 276,9\u00a0 \u20100,9\u00a0\n12\u00a0Ibrance\u00ae\u00a0(Pfizer)\u00a0\u00a0\n(Palbociclib)\u00a0Brustkrebs\u00a0 271,1\u00a0 +8,1\u00a0\n13\u00a0Jakavi\u00ae\u00a0(Novartis)\u00a0\u00a0\n(Ruxolitinib)\u00a0Blutkrebs\u00a0 269,1\u00a0 +12,1\u00a0\n14\u00a0Lucentis\u00ae\u00a0(Novartis)\u00a0\u00a0\n(Ranibizumab)\u00a0Makuladegeneration\u00a0 265,9\u00a0 \u20100,9\u00a0\n15\u00a0Gilenya\u00ae\u00a0(Novartis)\u00a0\u00a0\n(Fingolimod)\u00a0MS\u00a0 245,8\u00a0 \u20107,0\u00a0\n16\u00a0Jardiance\u00ae\u00a0(Boehringer\u00a0Ingelheim)\u00a0\n(Empagliflozin)\u00a0Diabetes\u00a0mellitus\u00a0\nHerzinsuffizienz\u00a0230,8\u00a0 +18,9\u00a0\n17\u00a0Vyndaqel\u00ae\u00a0(Pfizer)\u00a0(Tafamidis)\u00a0Transthyretin\u2010Amyloidose\u00a0 228,7\u00a0 +311,3\u00a0\n18\u00a0Dupixent\u00ae\u00a0(Sanofi\u2010Aventis)\u00a0(Dupi\u2010\nlumab)\u00a0Dermatitis\u00a0 218,9\u00a0 +76,5\u00a0\n19\u00a0Tecfidera\u00ae\u00a0(Biogen)\u00a0\u00a0\n(Dimethylfumarat)\u00a0MS\u00a0 213,2\u00a0 +3,4\u00a0\n20\u00a0Humira\u00ae\u00a0(Abbott/Abbvie)\u00a0\u00a0\n(Adalimumab)z.\u00a0B.\u00a0Rheumatische\u00a0Arthritis\u00a0 202,1\u00a0 \u201043,0\u00a0\n\u00a0Gesamtmarkt\u00a0 \u00a0 38.217,07\u00a0 +4,4\u00a0\nQuelle:\u00a0nach\u00a0IMS\u00a0Health,\u00a02021\u00a0 \u00a0 \u00a0 \n86\u00a0\n\u00a0Vor\u00a0der\u00a0Vermarktung\u00a0eines\u00a0Arzne imittels\u00a0steht\u00a0die\u00a0Zulassung\u00a0\nNahezu\u00a0alle\u00a0Arzneimittel,\u00a0die\u00a0in\u00a0 Deutschland\u00a0verordnet\u00a0werden\u00a0( Ausnahme\u00a0z.\u00a0B.\u00a0\nHom\u00f6opathische\u00a0Arzneimittel\u00a0mit\u00a0 Indikationsanspruch),\u00a0bed\u00fcrfen\u00a0 einer\u00a0Zulassung\u00a0\nauf\u00a0der\u00a0Basis\u00a0von\u00a0methodisch\u00a0a d\u00e4quaten\u00a0Studien\u00a0an\u00a0gesunden\u00a0Prob anden\u00a0(Phase\u00a0I)\u00a0\nsowie\u00a0an\u00a0Patienten,\u00a0die\u00a0unter\u00a0den\u00a0Symptomen\u00a0oder\u00a0Krankheiten\u00a0le iden\u00a0(Phasen\u00a0II\u00a0\nund\u00a0III),\u00a0f\u00fcr\u00a0die\u00a0der\u00a0pharmazeutische\u00a0Unternehmer\u00a0(pU)\u00a0die\u00a0Mitt el\u00a0auf\u00a0dem\u00a0Markt\u00a0\nanbieten\u00a0 m\u00f6chte\u00a0 (siehe\u00a0 \u00a7\u00a021\u00a0 in\u00a0 Verbindung\u00a0 mit\u00a0 \u00a7\u00a025\u00a0 des\u00a0 Arzneimi ttelgesetzes\u00a0\nAMG).\u00a0Insofern\u00a0bestimmt\u00a0der\u00a0pU\u00a0den\u00a0Indikationsanspruch\u00a0f\u00fcr\u00a0sein \u00a0Arzneimittel,\u00a0\ndas\u00a0m\u00f6glicherweise\u00a0auch\u00a0f\u00fcr\u00a0di e\u00a0Behandlung\u00a0anderer\u00a0Krankheiten\u00a0 eingesetzt\u00a0wer\u2010\nden\u00a0k\u00f6nnte,\u00a0dort\u00a0aber\u00a0weniger\u00a0\u00f6konomischen\u00a0Erfolg\u00a0und\u00a0damit\u00a0wen iger\u00a0Profit\u00a0\nverspricht.\u00a0Er\u00a0w\u00e4hlt\u00a0letztlich\u00a0auch\u00a0die\u00a0Patienten\u00a0aus,\u00a0die\u00a0in\u00a0s olche\u00a0Zulassungsstu\u2010\ndien\u00a0einbezogen\u00a0werden\u00a0\u2013\u00a0eine\u00a0Se lektion,\u00a0die\u00a0in\u00a0den\u00a0meisten\u00a0F\u00e4l len\u00a0nicht\u00a0das\u00a0Pati\u2010\nentenklientel\u00a0widerspiegelt,\u00a0das\u00a0sp\u00e4ter\u00a0nach\u00a0der\u00a0Zulassung\u00a0mit\u00a0 dem\u00a0neuen\u00a0Mittel\u00a0\nbehandelt\u00a0wird:\u00a0Meist\u00a0werden\u00a0mehr\u00a0M\u00e4nner\u00a0als\u00a0Frauen\u00a0in\u00a0die\u00a0Stud ien\u00a0eingeschlos\u2010\nsen\u00a0(bei\u00a0Frauen\u00a0k\u00f6nnten\u00a0hormonelle\u00a0Schwankungen\u00a0die\u00a0Studienerge bnisse\u00a0verzer\u2010\nren\u00a0und\u00a0eine\u00a0evtl.\u00a0sp\u00e4ter\u00a0eintretende\u00a0Schwangerschaft\u00a0unter\u00a0den \u00a0Folgen\u00a0der\u00a0Ein\u2010\nnahme\u00a0des\u00a0zu\u00a0pr\u00fcfenden\u00a0Mittels\u00a0Sch\u00e4den\u00a0beim\u00a0Neugeborenen\u00a0nach\u00a0s ich\u00a0ziehen),\u00a0\ndie\u00a0Patienten\u00a0sollten\u00a0m\u00f6glichst\u00a0nur\u00a0unter\u00a0der\u00a0zu\u00a0behandelnden\u00a0E rkrankung\u00a0leiden\u00a0\nund\u00a0keine\u00a0anderen\u00a0Arzneimittel\u00a0einnehmen.\u00a0Wesentlich\u00a0f\u00fcr\u00a0einen\u00a0 \u201eungest\u00f6rten\u201c\u00a0\nNachweis\u00a0einer\u00a0(idealen)\u00a0Wirksamkeit\u00a0ist\u00a0auch,\u00a0dass\u00a0die\u00a0Studien teilnehmer\u00a0von\u00a0\nspeziell\u00a0geschulten\u00a0Studien\u00e4rzten\u00a0und\u00a0\u2013schwestern\u00a0\u00fcber\u00a0die\u00a0Wirk ungen\u00a0und\u00a0uner\u2010\nw\u00fcnschten\u00a0Wirkungen\u00a0aufgekl\u00e4rt\u00a0und \u00a0begleitet\u00a0werden,\u00a0sodass\u00a0auc h\u00a0die\u00a0Adh\u00e4renz,\u00a0\nalso\u00a0die\u00a0bestimmungsgem\u00e4\u00dfe\u00a0Anwendu ng\u00a0unter\u00a0dauernder\u00a0Kontrolle\u00a0 steht.\u00a0Im\u00a0\nPrinzip\u00a0sind\u00a0die\u00a0Studien\u00a0so\u00a0aufgebaut,\u00a0dass\u00a0die\u00a0individuellen\u00a0C harakteristika\u00a0der\u00a0\neingeschlossenen\u00a0Patienten\u00a0m\u00f6glic hst\u00a0wenig\u00a0zu\u00a0Verzerrungen\u00a0f\u00fchr en,\u00a0um\u00a0damit\u00a0\nein\u00a0ungest\u00f6rtes\u00a0Bild\u00a0und\u00a0Ergebnis\u00a0bez\u00fcglich\u00a0der\u00a0Wirksamkeit\u00a0des \u00a0eingesetzten\u00a0\nneuen\u00a0Wirkstoffes\u00a0zu\u00a0erreichen.\u00a0Im\u00a0Vergleich\u00a0zur\u00a0sp\u00e4teren\u00a0Verso rgung\u00a0sind\u00a0es\u00a0\ndaher\u00a0eher\u00a0\u201eartifizielle\u201c\u00a0Patien ten,\u00a0an\u00a0denen\u00a0die\u00a0Anforderungen \u00a0des\u00a0derzeit\u00a0g\u00fclti\u2010\ngen\u00a0Arzneimittelgesetzes\u00a0(AMG\u00a076),\u00a0das\u00a01976\u00a0verabschiedet\u00a0und\u00a01 978\u00a0in\u00a0Kraft\u00a0trat,\u00a0\nn\u00e4mlich\u00a0neben\u00a0der\u00a0Wirksamkeit\u00a0auch\u00a0die\u00a0Unbedenklichkeit\u00a0und\u00a0die \u00a0pharmazeuti\u2010\nsche\u00a0Qualit\u00e4t\u00a0untersucht\u00a0und\u00a0nachgewiesen\u00a0werden\u00a0m\u00fcssen.\u00a0Diese\u00a0 Ergebnisse\u00a0\nwerden\u00a0dann\u00a0einer\u00a0Zulassungsbeh\u00f6rde,\u00a0derzeit\u00a0zumeist\u00a0der\u00a0Europe an\u00a0Medicines\u00a0\nAgency\u00a0(EMA)\u00a0oder,\u00a0z.\u00a0B.\u00a0bei\u00a0pfl anzlichen\u00a0Mitteln,\u00a0dem\u00a0Bundesin stitut\u00a0f\u00fcr\u00a0Arznei\u2010\nmittel\u00a0und\u00a0Medizinprodukte\u00a0(BfArM)\u00a0vorgelegt.\u00a0An\u00a0Hand\u00a0der\u00a0einge reichten\u00a0Unter\u2010\nlagen\u00a0wird\u00a0dann\u00a0gepr\u00fcft,\u00a0ob\u00a0dem\u00a0 Zulassungsantrag\u00a0des\u00a0Hersteller s\u00a0stattgegeben\u00a0\nwerden\u00a0kann\u00a0oder\u00a0widersprochen\u00a0w erden\u00a0muss.\u00a0Bei\u00a0einer\u00a0positiven \u00a0Pr\u00fcfung\u00a0wird\u00a0\ndas\u00a0Mittel\u00a0zugelassen\u00a0und\u00a0kann\u00a0dann\u00a0auch,\u00a0beginnend\u00a0mit\u00a0dem\u00a0ers ten\u00a0Tag\u00a0der\u00a0\nZulassung,\u00a0je\u00a0nach\u00a0dem\u00a0Status\u00a0\u201ere zeptpflichtig\u00a0(Rx)\u201c\u00a0oder\u00a0\u201enich t\u2010rezeptpflichtig\u00a0\n(non\u2010Rx)\u201c\u00a0von\u00a0\u00c4rzten\u00a0verordnet\u00a0od er\u00a0von\u00a0Apothekern\u00a0verkauft\u00a0wer den.\u00a0 \n87\u00a0\n\u00a0Die\u00a0Zulassung\u00a0eines\u00a0Medikamentes\u00a0 erfolgt\u00a0in\u00a0der\u00a0Regel\u00a0ohne\u00a0Beac htung\u00a0der\u00a0be\u2010\nreits\u00a0auf\u00a0dem\u00a0Markt\u00a0befindlichen\u00a0 Mittel.\u00a0Eine\u00a0Rangfolge\u00a0bezogen \u00a0auf\u00a0die\u00a0relative\u00a0\ntherapeutische\u00a0Wirksamkeit\u00a0im\u00a0Ve rgleich\u00a0zu\u00a0anderen\u00a0Arzneimittel n\u00a0im\u00a0Sinne\u00a0einer\u00a0\nKlassifikation\u00a0als\u00a0erste\u00a0oder\u00a0le tzte\u00a0Wahl\u00a0ist\u00a0aus\u00a0der\u00a0Zulassung sentscheidung\u00a0nicht\u00a0\nableitbar.\u00a0Generell\u00a0sieht\u00a0die\u00a0klinische\u00a0Pr\u00fcfung\u00a0(Nachweis\u00a0der\u00a0 efficacy,\u00a0sprich\u00a0der\u00a0\nWirksamkeit\u00a0f\u00fcr\u00a0Patienten\u00a0unter\u00a0Idealbedingungen)\u00a0nur\u00a0den\u00a0Vergl eich\u00a0des\u00a0Wirk\u2010\nstoffs\u00a0mit\u00a0einem\u00a0Placebo,\u00a0nicht\u00a0jedoch\u00a0mit\u00a0einem\u00a0bereits\u00a0zugela ssenen\u00a0und\u00a0sp\u00e4ter\u00a0\nevtl.\u00a0konkurrierenden\u00a0Wirkstoff\u00a0vor.\u00a0Die\u00a0Erteilung\u00a0der\u00a0Zulassun g\u00a0sagt\u00a0auch\u00a0nichts\u00a0\ndar\u00fcber\u00a0aus,\u00a0ob\u00a0ein\u00a0objektivierb arer\u00a0Bedarf\u00a0f\u00fcr\u00a0dieses\u00a0pharmaze utische\u00a0Produkt\u00a0\nbesteht.\u00a0Gleichwohl\u00a0stellt\u00a0die\u00a0Zulassung\u00a0eines\u00a0Medikamentes\u00a0in\u00a0 der\u00a0Wahrnehmung\u00a0\nder\u00a0verordnenden\u00a0\u00c4rzte\u00a0und\u00a0der\u00a0Verbraucher\u00a0h\u00e4ufig\u00a0einen\u00a0Qualit\u00e4 ts\u2010\u00a0und\u00a0in\u00a0gewis\u2010\nser\u00a0Weise\u00a0auch\u00a0einen\u00a0Bedarfsnachweis\u00a0dar.\u00a0So\u00a0wurde\u00a0im\u00a0Zuge\u00a0der\u00a0 R\u00fccknahme\u00a0des\u00a0\nRheumamedikaments\u00a0Vioxx\u00ae\u00a0(Rofecoxib)\u00a0im\u00a0September\u00a02004\u00a0auch\u00a0Kri tik\u00a0an\u00a0der\u00a0\n\u00c4rzteschaft\u00a0laut.\u00a0Das\u00a0bei\u00a0l\u00e4ngerer\u00a0Einnahme\u00a0des\u00a0Medikaments\u00a0deu tlich\u00a0erh\u00f6hte\u00a0\nRisiko\u00a0f\u00fcr\u00a0Herzinfarkt\u00a0und\u00a0Schlaganfall,\u00a0welches\u00a0in\u00a0Anwendungss tudien\u00a0nachgewie\u2010\nsen\u00a0wurde,\u00a0war\u00a0bereits\u00a0\u00fcber\u00a0Beipackzettel\u00a0und\u00a0Fachinformation\u00a0b ekannt.\u00a0Behan\u2010\ndelnde\u00a0\u00c4rzte\u00a0h\u00e4tten\u00a0diese\u00a0Inform ation\u00a0bei\u00a0der\u00a0Therapie\u00a0von\u00a0Risi kopatienten\u00a0daher\u00a0\nber\u00fccksichtigen\u00a0k\u00f6nnen,\u00a0sogar\u00a0m\u00fcssen\u00a0und\u00a0keineswegs\u00a0die\u00a0grunds\u00e4 tzliche\u00a0Verf\u00fcg\u2010\nbarkeit\u00a0des\u00a0Mittels\u00a0und\u00a0dessen\u00a0Zulassung\u00a0mit\u00a0dem\u00a0Nachweis\u00a0eines \u00a0allgemeinen\u00a0\nund\u00a0uneingeschr\u00e4nkten\u00a0Nutzens\u00a0f\u00fcr \u00a0alle\u00a0Patienten\u00a0gleichsetzen\u00a0d \u00fcrfen.\u00a0\nZur\u00a0Dichotomie\u00a0von\u00a0 Efficacy\u00a0und\u00a0Effectiveness \u00a0\nDie\u00a0Zulassung\u00a0eines\u00a0Arzneimittels\u00a0aufgrund\u00a0des\u00a0Nachweises\u00a0der\u00a0 efficacy,\u00a0also\u00a0der\u00a0\nWirksamkeit\u00a0unter\u00a0streng\u00a0kontrol lierten\u00a0Studienbedingungen\u00a0sagt \u00a0daher\u00a0nur\u00a0be\u2010\ndingt\u00a0etwas\u00a0\u00fcber\u00a0dessen\u00a0gesundheitlichen\u00a0oder\u00a0\u00f6konomischen\u00a0(Net to\u2010)Nutzen\u00a0aus.\u00a0\nVielmehr\u00a0muss\u00a0sich\u00a0das\u00a0Mittel\u00a0in\u00a0der\u00a0allt\u00e4glichen\u00a0medizinischen \u00a0Versorgung\u00a0bewei\u2010\nsen.\u00a0Es\u00a0muss\u00a0zeigen,\u00a0dass\u00a0es\u00a0bezogen\u00a0auf\u00a0klinisch\u00a0relevante\u00a0End punkte\u00a0in\u00a0der\u00a0Lang\u2010\nzeitanwendung\u00a0bzw.\u00a0in\u00a0der\u00a0Anwendung\u00a0in\u00a0nicht\u00a0mehr\u00a0selektierten\u00a0 Patientenpopu\u2010\nlationen\u00a0 Vorteile\u00a0 gegen\u00fcber\u00a0 bere its\u00a0 angebotenen\u00a0 Arzneimitteln\u00a0 o der\u00a0 anderen\u00a0\nmedizinischen\u00a0Interventionen\u00a0hat\u00a0\u2013\u00a0Nachweis\u00a0der\u00a0 effectiveness ,\u00a0der\u00a0Wirksamkeit\u00a0\nf\u00fcr\u00a0Patienten\u00a0unter\u00a0Alltagsbedin gungen.\u00a0Diese\u00a0Vorteile\u00a0k\u00f6nnen\u00a0i n\u00a0der\u00a0Verbesse\u2010\nrung\u00a0des\u00a0Therapieergebnisses\u00a0oder \u00a0des\u00a0Risiko\u2010Nutzen\u2010Verh\u00e4ltniss es\u00a0oder\u00a0in\u00a0der\u00a0\nSenkung\u00a0der\u00a0direkten\u00a0oder\u00a0transsektoralen\u00a0Kosten\u00a0liegen\u00a0\u2013\u00a0festz ustellen\u00a0ist\u00a0aller\u2010\ndings,\u00a0dass\u00a0zwischen\u00a0 efficacy\u00a0und\u00a0effectiveness \u00a0aber\u00a0h\u00e4ufig\u00a0eine\u00a0Evidenz\u2010L\u00fccke\u00a0\nklafft,\u00a0die\u00a0auf\u00a0den\u00a0Selektionsbias\u00a0in\u00a0den\u00a0klinischen\u00a0Studien\u00a0zu r\u00fcckzuf\u00fchren\u00a0ist:\u00a0Die\u00a0\nsp\u00e4teren\u00a0Patienten\u00a0sind\u00a0eben\u00a0nur \u00a0bedingt\u00a0mit\u00a0den\u00a0Studienpatient en\u00a0vergleichbar:\u00a0\nEin\u00a0anderes\u00a0Alter\u00a0kann\u00a0z.\u00a0B.\u00a0di e\u00a0Abbau\u2010\u00a0und\u00a0Verstoffwechselungs geschwindigkei\u2010\nten\u00a0beeinflussen,\u00a0weil\u00a0Nieren\u00a0und\u00a0Leber\u00a0im\u00a0h\u00f6heren\u00a0Alter\u00a0oftmal s\u00a0weniger\u00a0gut\u00a0\nfunktionieren.\u00a0Die\u00a0Patienten\u00a0lei den\u00a0m\u00f6glicherweise\u00a0unter\u00a0mehrer en\u00a0Erkrankungen,\u00a0\ndie\u00a0sich\u00a0gegenseitig\u00a0und\u00a0vor\u00a0allem\u00a0auch\u00a0die\u00a0Wirksamkeit\u00a0des\u00a0neu en\u00a0Mittels\u00a0beein\u2010 \n88\u00a0\n\u00a0flussen\u00a0k\u00f6nnen\u00a0(Multimorbidit\u00e4t).\u00a0Das\u00a0Gleiche\u00a0gilt\u00a0dann,\u00a0wenn\u00a0b ei\u00a0mehreren\u00a0Er\u2010\nkrankungen\u00a0eine\u00a0Vielzahl\u00a0von\u00a0Arzneimitteln\u00a0eingenommen\u00a0werden\u00a0m \u00fcssen\u00a0(Poly\u2010\npharmazie),\u00a0 die\u00a0 zu\u00a0 Interaktionen\u00a0 mit\u00a0 dem\u00a0 neuen\u00a0 Arzneimittel\u00a0 f\u00fch ren\u00a0 k\u00f6nnen.\u00a0\nZudem\u00a0ist\u00a0die\u00a0Adh\u00e4renz\u00a0oftmals\u00a0gest\u00f6rt,\u00a0weil\u00a0nicht\u00a0alle\u00a0Patient en\u00a0ihre\u00a0Arzneimittel\u00a0\nregelm\u00e4\u00dfig\u00a0einnehmen,\u00a0was\u00a0in\u00a0den\u00a0Studien\u00a0z.\u00a0B.\u00a0durch\u00a0Studiensch western\u00a0kontrol\u2010\nliert\u00a0wurde.\u00a0Mit\u00a0anderen\u00a0Worten:\u00a0 Es\u00a0kann\u00a0zu\u00a0Effektivit\u00e4tsverlus ten\u00a0in\u00a0der\u00a0nicht\u00a0\nmehr\u00a0 durch\u00a0 Studienanforderungen\u00a0 definierten\u00a0 und\u00a0 protokollgeleit eten\u00a0 Anwen\u2010\ndung\u00a0von\u00a0Arzneimitteln\u00a0in\u00a0der\u00a0\u00fcblichen\u00a0Versorgung\u00a0kommen\u00a0\u2013\u00a0ob\u00a0a mbulant\u00a0oder\u00a0\nstation\u00e4r.\u00a0\nAbb.\u00a05.1:\u00a0Reduzierung\u00a0des\u00a0pharmakotherapeutischen\u00a0Potenzials\u00a0du rch\u00a0Trans\u2010\nfer,\u00a0Implementierung\u00a0und\u00a0Umsetzung\u00a0\n\u00a0\nAnders\u00a0als\u00a0nach\u00a0den\u00a0definierten\u00a0Protokollen\u00a0des\u00a0pU\u00a0in\u00a0Zulassung sstudien,\u00a0die\u00a0einer\u00a0\nstrengen\u00a0 Methodik\u00a0 folgen,\u00a0 um\u00a0 e inen\u00a0 m\u00f6glichst\u00a0 ungest\u00f6rten\u00a0 und\u00a0 un verzerrten\u00a0\nWirksamkeitsnachweis\u00a0als\u00a0Anforderung\u00a0f\u00fcr\u00a0eine\u00a0Zulassung\u00a0erreich en\u00a0zu\u00a0k\u00f6nnen\u00a0(in\u00a0\nder\u00a0Abbildung\u00a0\u201amaximale\u00a0Effekt ivit\u00e4t\u2018),\u00a0sind\u00a0die\u00a0Entscheidungen \u00a0der\u00a0behandelnden\u00a0\n\u00c4rzte\u00a0f\u00fcr\u00a0oder\u00a0gegen\u00a0eine\u00a0Anwendung\u00a0eines\u00a0Arzneimittels\u00a0als\u00a0kom plexe,\u00a0oft\u00a0auch\u00a0\nschwer\u00a0durchschaubare\u00a0Intervention\u00a0zu\u00a0bewerten.\u00a0Das\u00a0Rezeptieren \u00a0eines\u00a0Arznei\u2010\nmittels\u00a0ist\u00a0einerseits\u00a0eine\u00a0rational\u00a0begr\u00fcndbare\u00a0\u00e4rztliche\u00a0Hand lung,\u00a0andererseits\u00a0\nein\u00a0sozialer\u00a0Akt\u00a0mit\u00a0rituell\u2010symbolischem\u00a0Charakter.\u00a0Die\u00a0Verord nung\u00a0eines\u00a0Medi\u2010\nkamentes\u00a0zielt\u00a0nicht\u00a0zwangsl\u00e4ufig\u00a0allein\u00a0auf\u00a0die\u00a0Vorbeugung,\u00a0He ilung\u00a0oder\u00a0Linde\u2010\nrung\u00a0von\u00a0Krankheit.\u00a0Beispielsweise\u00a0ist\u00a0der\u00a0Griff\u00a0zum\u00a0Rezeptbloc k\u00a0\u2013\u00a0auch\u00a0in\u00a0seiner\u00a0\nmodernen\u00a0Form\u00a0als\u00a0Eingabe\u00a0von\u00a0Computerbefehlen\u00a0\u2013\u00a0eine\u00a0tradition elle\u00a0Geste,\u00a0die\u00a0Reduzierte\nEffektivit\u00e4tTransfer- undImplementierungs-verlusteTransfer- undImplementierungs-verluste\nUmsetzungs-\nverluste\nResteffektivit\u00e4tMaximale\nEffektivit\u00e4t\nReduzierte\nEffektivit\u00e4tTransfer- undImplementierungs-verlusteTransfer- undImplementierungs-verluste\nUmsetzungs-\nverluste\nResteffektivit\u00e4tMaximale\nEffektivit\u00e4t \n89\u00a0\n\u00a0z.\u00a0B.\u00a0auch\u00a0darauf\u00a0hinweist,\u00a0dass\u00a0eine\u00a0Konsultation\u00a0nun\u00a0beendet\u00a0 ist.\u00a0\u00c4rzte\u00a0selbst\u00a0\nnennen\u00a0in\u00a0Studien\u00a0u.\u00a0a.\u00a0folgende\u00a0Aspekte\u00a0als\u00a0entscheidungsleite nd\u00a0f\u00fcr\u00a0die\u00a0Arznei\u2010\nmittelverordnung\u00a0 (vgl.\u00a0 Bradley,\u00a0 1991),\u00a0 die\u00a0 letztlich\u00a0 alle\u00a0 in\u00a0 ei ner\u00a0Effectiveness \u2010\nForschung\u00a0ber\u00fccksichtigt\u00a0werden\u00a0m\u00fcssen,\u00a0da\u00a0es\u00a0sich\u00a0um\u00a0eine\u00a0komp lexe\u00a0Interventi\u2010\non\u00a0handelt:\u00a0\n\uf0b7 (Wahrscheinlichkeit\u00a0der)\u00a0Wirksamkeit\u00a0(i.d.R.\u00a0 efficacy)\u00a0bzw.\u00a0Nutzen\u00a0\nf\u00fcr\u00a0den\u00a0individuellen\u00a0Patienten,\u00a0\n\uf0b7 Sicherheit\u00a0der\u00a0Anwendung\u00a0bzw.\u00a0Profil\u00a0der\u00a0unerw\u00fcnschten\u00a0Wirkun\u2010\ngen\u00a0und\u00a0Kontraindikationen,\u00a0\n\uf0b7 Kosten\u00a0des\u00a0Medikamentes\u00a0an\u00a0sich\u00a0und\u00a0H\u00f6he\u00a0der\u00a0von\u00a0den\u00a0Patienten\u00a0\nzu\u00a0tragenden\u00a0Kosten,\u00a0\n\uf0b7 Art\u00a0und\u00a0Schwere\u00a0der\u00a0Erkrankung\u00a0sowie\u00a0Grad\u00a0der\u00a0erzielten\u00a0Kontrol le\u00a0\n\u00fcber\u00a0die\u00a0Krankheit,\u00a0\n\uf0b7 eigene\u00a0klinische\u00a0Erfahrung,\u00a0ei ndrucksvolle\u00a0schwerwiegende\u00a0Negat i\u2010\nverfahrungen\u00a0in\u00a0der\u00a0Vergangenheit \u00a0(auch\u00a0lange\u00a0zur\u00fcckliegende\u00a0od er\u00a0\nanderer\u00a0Personen),\u00a0\n\uf0b7 W\u00fcnsche,\u00a0Erwartungen\u00a0und\u00a0Forderungen\u00a0der\u00a0Patienten\u00a0\n\uf0b7 Einstellung\u00a0und\u00a0Kritik\u00a0der\u00a0Kollegen\u00a0\n\uf0b7 eigene\u00a0Einstellungen,\u00a0Erwartungen\u00a0und\u00a0Konzepte\u00a0sowie\u00a0\n\uf0b7 Einfl\u00fcsse\u00a0von\u00a0pharmazeutischen\u00a0Unternehmen\u00a0und\u00a0deren\u00a0pharma\u2010\nzeutischen\u00a0Referenten\u00a0sowie\u00a0Mult iplikatoren\u00a0auf\u00a0Kongressen\u00a0oder \u00a0\nDarstellungen\u00a0in\u00a0\u201eHochglanzbrosch\u00fcren\u201c\u00a0oder\u00a0sonstigem\u00a0Werbema\u2010\nterial\u00a0der\u00a0jeweiligen\u00a0pharmazeutischen\u00a0Firmen\u00a0\nBislang\u00a0ist\u00a0es\u00a0jedoch\u00a0noch\u00a0nicht\u00a0ausreichend\u00a0gelungen,\u00a0\u00e4rztlich es\u00a0Arzneiverord\u2010\nnungsverhalten\u00a0in\u00a0einem\u00a0Modell\u00a0befriedigend\u00a0abzubilden.\u00a0Der\u00a0Ent scheidungspro\u2010\nzess\u00a0l\u00e4sst\u00a0sich\u00a0nur\u00a0unzureichend\u00a0als\u00a0 reasoned\u00a0action ,\u00a0als\u00a0Ergebnis\u00a0einer\u00a0Abw\u00e4gung\u00a0\nzwischen\u00a0 Pro\u2010\u00a0 und\u00a0 Kontra\u2010Argumenten,\u00a0 darstellen.\u00a0 Eine\u00a0 Medikamen tenverord\u2010\nnung\u00a0ist\u00a0das\u00a0Produkt\u00a0eines\u00a0Interaktionsprozesses\u00a0zwischen\u00a0Arzt\u00a0 und\u00a0Patient\u00a0\u2013\u00a0arzt\u2010\nseitige\u00a0 Faktoren\u00a0 wirken\u00a0 sich\u00a0 a us\u00a0 und\u00a0 bedingen\u00a0 die\u00a0 individuelle\u00a0 Entscheidung.\u00a0\nDadurch\u00a0kann\u00a0zwischen\u00a0dem\u00a0pharmakotherapeutischen\u00a0Potenzial\u00a0ein es\u00a0Arzneimit\u2010\ntels\u00a0 einerseits\u00a0 (Wirksamkeit\u00a0 unt er\u00a0 Idealbedingungen)\u00a0 und\u00a0 der\u00a0 Um setzung\u00a0 und\u00a0\nAussch\u00f6pfung\u00a0desselben\u00a0unter\u00a0den\u00a0Versorgungsbedingungen\u00a0(Wirksa mkeit\u00a0unter\u00a0\nAlltagsbedingungen)\u00a0in\u00a0der\u00a0allt\u00e4glichen\u00a0\u00e4rztlichen\u00a0Praxis\u00a0und\u00a0i n\u00a0der\u00a0komplexen\u00a0\nLebenswirklichkeit\u00a0von\u00a0Patienten\u00a0eine\u00a0erhebliche\u00a0L\u00fccke\u00a0klaffen. \u00a0Es\u00a0ergeben\u00a0sich\u00a0\ngleichsam\u00a0systemimmanente\u00a0und\u00a0al s\u00a0solche\u00a0anzuerkennende\u00a0Effekti vit\u00e4tsverluste\u00a0\n(siehe\u00a0Abbildung\u00a05.1).\u00a0\u00a0\n\u00a0 \u00a0 \n90\u00a0\n\u00a0Publikationsstrategien\u00a0zur\u00a0Beeinflussung\u00a0des\u00a0Verordnungsverhalt ens\u00a0\nErschwerend\u00a0kommt\u00a0hinzu,\u00a0dass\u00a0es\u00a0bei\u00a0der\u00a0Ver\u00f6ffentlichung\u00a0der\u00a0E rgebnisse\u00a0klini\u2010\nscher\u00a0Studien\u00a0generell\u00a0eine\u00a0Tende nz\u00a0zum\u00a0selektiven\u00a0Publizieren\u00a0 g\u00fcnstiger\u00a0Untersu\u2010\nchungsergebnisse\u00a0( selective\u00a0reporting )\u00a0gibt.\u00a0In\u00a0den\u00a0USA\u00a0wurden\u00a0z.\u00a0B.\u00a0wiederholt\u00a0\nVerfahren\u00a0gegen\u00a0Pharmafirmen\u00a0ein geleitet,\u00a0denen\u00a0das\u00a0Zur\u00fcckhalte n\u00a0von\u00a0Informa\u2010\ntionen\u00a0oder\u00a0andere\u00a0Manipulatione n\u00a0vorgeworfen\u00a0wurden\u00a0(siehe\u00a0z.\u00a0 B.\u00a0Djulbegovic\u00a0\net\u00a0al.,\u00a02000,\u00a0Melander\u00a02003,\u00a0Koch\u00a02004,\u00a0Angell\u00a02005,\u00a0Wild,\u00a0Piso \u00a02010,\u00a0Goldacre\u00a0\n2012,\u00a0G\u00f6tzsche\u00a02016,\u00a0Lieb\u00a0et\u00a0al.,\u00a02018).\u00a0Statistisch\u00a0signifikan te\u00a0Ergebnisse\u00a0werden\u00a0\neher\u00a0ver\u00f6ffentlicht\u00a0als\u00a0nicht\u00a0signifikante,\u00a0obwohl\u00a0eine\u00a0statist ische\u00a0Signifikanz\u00a0nicht\u00a0\ngleichzusetzen\u00a0ist\u00a0mit\u00a0einer\u00a0kli nischen\u00a0Relevanz,\u00a0die\u00a0sich\u00a0zugu nsten\u00a0der\u00a0Patienten\u00a0\nauswirken\u00a0w\u00fcrde.\u00a0Es\u00a0ist\u00a0auch\u00a0von\u00a0Bedeutung,\u00a0dass\u00a0positive\u00a0Studi energebnisse\u00a0\ndeutlich\u00a0schneller\u00a0ver\u00f6ffent licht\u00a0werden\u00a0als\u00a0negative.\u00a0 \u00a0\nWie\u00a0bereits\u00a0mehrfach\u00a0betont,\u00a0int eressiert\u00a0aber\u00a0bei\u00a0der\u00a0Bewertun g\u00a0des\u00a0therapeuti\u2010\nschen\u00a0Nutzens\u00a0eines\u00a0Arzneimittels\u00a0nicht\u00a0nur\u00a0dessen\u00a0Wirksamkeit\u00a0 unter\u00a0klinischen\u00a0\nIdealbedingungen\u00a0( efficacy),\u00a0sondern\u00a0auch\u00a0\u2013\u00a0und\u00a0vielfach\u00a0sogar\u00a0prim\u00e4r\u00a0\u2013\u00a0unter\u00a0den\u00a0\nAlltagsbedingungen\u00a0 ambulanter\u00a0 Versorgung\u00a0 ( effectiveness ).\u00a0 Gleichwohl\u00a0 besteht\u00a0\nbei\u00a0einem\u00a0neu\u00a0zugelassenen\u00a0patent gesch\u00fctzten\u00a0Arzneimittel\u00a0zun\u00e4c hst\u00a0keine\u00a0ande\u2010\nre\u00a0M\u00f6glichkeit,\u00a0als\u00a0dessen\u00a0therapeutische\u00a0Wirksamkeit\u00a0auf\u00a0der\u00a0G rundlage\u00a0der\u00a0zu\u00a0\ndiesem\u00a0 Zeitpunkt\u00a0 vorliegenden\u00a0 k linischen\u00a0 (Zulassungs\u2010)Studien\u00a0 z u\u00a0 bewerten.\u00a0\nDenkbar\u00a0w\u00e4re\u00a0daher\u00a0eine\u00a0Begleitforschung\u00a0nach\u00a0der\u00a0Zulassung\u00a0ein es\u00a0Arzneimittels\u00a0\nim\u00a0Rahmen\u00a0der\u00a0Versorgungsforschung\u00a0zur\u00a0 efficacy\u00a0bzw.\u00a0effectiveness ,\u00a0die\u00a0folgende\u00a0\nmethodische\u00a0Anforderungen\u00a0zu\u00a0ber\u00fccksichtigen\u00a0h\u00e4tte:\u00a0\n\uf0b7 der\u00a0Bezug\u00a0auf\u00a0relevante\u00a0klinische\u00a0Endpunkte\u00a0(d.\u00a0h.\u00a0beispielswei se\u00a0\nnicht\u00a0nur\u00a0Nachweis\u00a0der\u00a0Blutdrucksenkung,\u00a0sondern\u00a0auch\u00a0des\u00a0R\u00fcck\u2010\ngangs\u00a0der\u00a0hypertonieassoziierten \u00a0Morbidit\u00e4t\u00a0und\u00a0Mortalit\u00e4t\u00a0sowi e\u00a0\nder\u00a0Gesamtmortalit\u00e4t),\u00a0\n\uf0b7 die\u00a0Vergleichbarkeit\u00a0von\u00a0St udien\u2010\u00a0und\u00a0Zielpopulation,\u00a0\n\uf0b7 das\u00a0Pr\u00fcfen\u00a0gegen\u00a0die\u00a0vorhandenen\u00a0therapeutischen\u00a0Alternativen\u00a0i n\u00a0\nkorrekter\u00a0Dosierung\u00a0und\u00a0\n\uf0b7 statistische\u00a0Auswertung\u00a0mit\u00a0 intention\u00a0to\u00a0treat \u2010Analyse.\u00a0\nDie\u00a0derzeit\u00a0zur\u00a0Zulassung\u00a0vorgeschriebenen\u00a0 efficacy\u2010Studien\u00a0beschreiben\u00a0die\u00a0Effek\u2010\nte\u00a0an\u00a0der\u00a0Gruppe\u00a0von\u00a0Patienten,\u00a0die\u00a0die\u00a0Pr\u00e4parate\u00a0exakt\u00a0wie\u00a0emp fohlen\u00a0auch\u00a0tat\u2010\ns\u00e4chlich\u00a0eingenommen\u00a0haben.\u00a0Sie\u00a0lassen\u00a0aber\u00a0keine\u00a0Aussagen\u00a0zu,\u00a0 welche\u00a0Auswir\u2010\nkungen\u00a0das\u00a0Medikament\u00a0beim\u00a0Praxiseinsatz\u00a0unter\u00a0den\u00a0verschiedene n\u00a0Einflussfak\u2010\ntoren\u00a0auf\u00a0Verordnungsverhalten\u00a0der\u00a0\u00c4rzte\u00a0und\u00a0Compliance\u00a0der\u00a0Pat ienten\u00a0haben\u00a0\nwird.\u00a0Eine\u00a0Auswertung\u00a0mit\u00a0einer\u00a0 intention\u00a0to\u00a0treat \u2010Analyse\u00a0bewertet\u00a0das\u00a0Arznei\u2010\nmittel\u00a0unabh\u00e4ngig\u00a0davon,\u00a0ob\u00a0die\u00a0S tudienteilnehmer\u00a0das\u00a0ihnen\u00a0auf grund\u00a0der\u00a0Rand\u2010 \n91\u00a0\n\u00a0omisierung\u00a0verordnete\u00a0Medikament\u00a0\u00fcberhaupt\u00a0regelgerecht\u00a0einnehm en,\u00a0und\u00a0l\u00e4sst\u00a0\nso\u00a0eine\u00a0realistischere\u00a0Aussage\u00a0\u00fcber\u00a0die\u00a0Effektivit\u00e4t\u00a0von\u00a0Arznei mitteln\u00a0zu,\u00a0wenn\u00a0z.\u00a0B.\u00a0\nausgepr\u00e4gte\u00a0 unerw\u00fcnschte\u00a0 Wirkungen\u00a0 zu\u00a0 h\u00e4ufigen\u00a0 Therapieabbr\u00fcche n\u00a0 f\u00fchren\u00a0\n(Erektionsst\u00f6rungen\u00a0bei\u00a0Blutdrucksenkern,\u00a0Bl\u00e4hungen\u00a0beim\u00a0Antidi abetikum\u00a0Acar\u2010\nbose).\u00a0Eine\u00a0 intention\u00a0to\u00a0treat \u2010Analyse\u00a0stellt\u00a0demnach\u00a0eine\u00a0notwendige,\u00a0die\u00a0 number\u00a0\nneeded\u00a0to\u00a0treat \u2010Analyse\u00a0(wie\u00a0viele\u00a0Patienten\u00a0m\u00fc ssen\u00a0statistisch\u00a0behandelt\u00a0werd en,\u00a0\ndamit\u00a0einer\u00a0geheilt\u00a0wird)\u00a0eine\u00a0hinreichende\u00a0Bedingung\u00a0von\u00a0 Effectiveness \u2010Studien\u00a0\ndar\u00a0(vgl.\u00a0Hollis,\u00a0Campbell,\u00a01999) .\u00a0Die\u00a0h\u00e4ufig\u00a0zur\u00a0besseren\u00a0Prod uktvermarktung\u00a0\ndurchgef\u00fchrten\u00a0 non\u00a0inferiority \u2010\u00a0bzw.\u00a0\u00c4quivalenzstudien\u00a0erf\u00fcllen\u00a0diese\u00a0Anforderun\u2010\ngen\u00a0in\u00a0der\u00a0Regel\u00a0nicht.\u00a0\nEndpunkte,\u00a0 die\u00a0 den\u00a0 Patientennutzen\u00a0 widerspiegeln,\u00a0 sollten\u00a0 dageg en\u00a0 folgende\u00a0\nErgebnisse\u00a0zeigen\u00a0(siehe\u00a0auch\u00a0\u00a7\u00a035b\u00a0SGB\u00a0V)\u00a0\n\uf0b7 die\u00a0Verringerung\u00a0von\u00a0Mortalit\u00e4t\u00a0und\u00a0Morbidit\u00e4tsbelastung,\u00a0\n\uf0b7 die\u00a0Verbesserung\u00a0der\u00a0Lebensqualit\u00e4t,\u00a0\n\uf0b7 die\u00a0Verl\u00e4ngerung\u00a0des\u00a0Gesamt\u00fcberlebens\u00a0und\u00a0\n\uf0b7 die\u00a0Verringerung\u00a0der\u00a0Nebenwirkung en\u00a0aller\u00a0Art,\u00a0die\u00a0die\u00a0Patiente n\u00a0als\u00a0\nbelastend\u00a0empfinden\u00a0oder\u00a0auch\u00a0f\u00fcr\u00a0das\u00a0Versorgungssystem\u00a0ung\u00fcns\u2010\ntig\u00a0sind.\u00a0\nDie\u00a0 oft\u00a0 angewendeten\u00a0 Surrogatparameter\u00a0 wie\u00a0 zum\u00a0 Beispiel\u00a0 progres sionsfreies\u00a0\n\u00dcberleben\u00a0sind\u00a0unpr\u00e4zise,\u00a0eine\u00a0Korrelation\u00a0mit\u00a0dem\u00a0Gesamt\u00fcberle ben\u00a0kann\u00a0in\u00a0der\u00a0\nRegel\u00a0nicht\u00a0nachgewiesen\u00a0werden.\u00a0Solche\u00a0Parameter\u00a0k\u00f6nnen\u00a0nur\u00a0ak zeptiert\u00a0wer\u2010\nden,\u00a0wenn\u00a0sie\u00a0bezogen\u00a0auf\u00a0eine n\u00a0der\u00a0Endpunkte\u00a0im\u00a0Vorhinein\u00a0vali diert\u00a0wurden.\u00a0\nZulassungsstudien\u00a0sind\u00a0keine\u00a0Nutzenstudien.\u00a0Auf\u00a0der\u00a0Basis\u00a0solch er\u00a0Studien\u00a0sind\u00a0\n\u00c4rzte\u00a0kaum\u00a0in\u00a0der\u00a0Lage,\u00a0f\u00fcr\u00a0ein\u00a0Arzneimittel\u00a0unmittelbar\u00a0nach\u00a0d er\u00a0Zulassung\u00a0eine\u00a0\nentsprechende\u00a0Aufkl\u00e4rung\u00a0f\u00fcr\u00a0die\u00a0Patienten\u00a0\u00fcber\u00a0den\u00a0Nutzen\u00a0des\u00a0 neuen\u00a0Arznei\u2010\nmittels\u00a0anzubieten\u00a0und\u00a0mit\u00a0den\u00a0Patienten\u00a0eine\u00a0gemeinsame\u00a0Entsch eidung\u00a0\u00fcber\u00a0die\u00a0\ntherapeutische\u00a0Intervention\u00a0zu\u00a0treffen.\u00a0Dies\u00a0haben\u00a0auch\u00a0Mariam\u00a0 Ujeyl\u00a0und\u00a0Kolle\u2010\ngen\u00a0 in\u00a0 einer\u00a0 bemerkenswerten\u00a0 wissenschaftlichen\u00a0 Untersuchung\u00a0 f\u00fc r\u00a0 die\u00a0 Jahre\u00a0\n2009\u00a0und\u00a02010\u00a0zeigen\u00a0k\u00f6nnen.\u00a0Sie\u00a0pr\u00fc ften\u00a0darin\u00a0die\u00a0Charakterist ika\u00a0von\u00a081\u00a0Zulas\u2010\nsungsstudien,\u00a0die\u00a0f\u00fcr\u00a039\u00a0Arzneimittel\u00a0bei\u00a0der\u00a0europ\u00e4ischen\u00a0Zula ssungsbeh\u00f6rde\u00a0\nEMA\u00a0vorgelegt\u00a0wurden.\u00a0Das\u00a0Ergebnis\u00a0war\u00a0ern\u00fcchternd\u00a0und\u00a0sollte\u00a0d iejenigen\u00a0nach\u2010\ndenklich\u00a0stimmen,\u00a0die\u00a0noch\u00a0immer\u00a0 eine\u00a0Zulassungsentscheidung\u00a0mi t\u00a0einem\u00a0Nut\u2010\nzennachweis\u00a0gleichsetzen:\u00a0Bei\u00a0nur \u00a046\u00a0%\u00a0der\u00a0Zulassungen\u00a0konnte\u00a0a uch\u00a0ein\u00a0patien\u2010\ntenrelevanter\u00a0Endpunkt\u00a0ber\u00fccksichtigt\u00a0werden\u00a0und\u00a0in\u00a0nur\u00a028\u00a0%\u00a0de r\u00a0Zulassungen\u00a0\nkonnte\u00a0gepr\u00fcft\u00a0werden,\u00a0ob\u00a0das\u00a0neue\u00a0Arzneimittel\u00a0gegen\u00fcber\u00a0einer \u00a0aktiven\u00a0Kon\u2010\ntrolle\u00a0\u00fcberlegen\u00a0war.\u00a0Oft\u00a0kommt\u00a0 es\u00a0in\u00a0diesem\u00a0Zusammenhang\u00a0zu\u00a0ei ner\u00a0\u00dcbersch\u00e4t\u2010\nzung\u00a0der\u00a0Wirksamkeit\u00a0bei\u00a0gleichzeitiger\u00a0Untersch\u00e4tzung\u00a0der\u00a0Risi ken,\u00a0weil\u00a0die\u00a0Gr\u00f6\u00dfe\u00a0 \n92\u00a0\n\u00a0der\u00a0Studienpopulation\u00a0nicht\u00a0ausre icht,\u00a0um\u00a0seltene\u00a0unerw\u00fcnschte\u00a0 Wirkungen\u00a0mit\u00a0\nSicherheit\u00a0erkennen\u00a0zu\u00a0k\u00f6nnen:\u00a0F\u00fcr\u00a0eine\u00a0Identifikation\u00a0eines\u00a0Ri sikos\u00a0von\u00a01\u00a0:\u00a01.000\u00a0\nm\u00fcssen\u00a0mindestens\u00a03.000,\u00a0f\u00fcr\u00a0die\u00a0Identifikation\u00a0eines\u00a0Risikos\u00a0v on\u00a01\u00a0:\u00a010.000\u00a0min\u2010\ndestens\u00a030.000\u00a0Patienten\u00a0in\u00a0eine\u00a0Studie\u00a0eingeschlossen\u00a0werden.\u00a0\nDies\u00a0hat\u00a0auch\u00a0eine\u00a0Studie\u00a0von\u00a0Davis\u00a0et\u00a0al.\u00a0(2017)\u00a0zu\u00a0Onkologika \u00a0gezeigt,\u00a0die\u00a0zwi\u2010\nschen\u00a02009\u00a0und\u00a02013\u00a0von\u00a0der\u00a0 EMA\u00a0zugelassen\u00a0wurden.\u00a0\n\uf0b7 Viele\u00a0Mittel\u00a0waren\u00a0nur\u00a0auf\u00a0Basis\u00a0von\u00a0indirekten\u00a0Ma\u00dfst\u00e4ben\u00a0zugel as\u2010\nsen\u00a0worden,\u00a0wenn\u00a0sich\u00a0z.\u00a0B.\u00a0ein\u00a0etwas\u00a0verlangsamtes\u00a0Tumorwachs\u2010tum\u00a0gezeigt\u00a0hatte.\u00a0Dieser\u00a0Surrogat\u2010Nutzen\u00a0muss\u00a0aber\u00a0noch\u00a0lange\u00a0\nnicht\u00a0zur\u00a0Verbesserung\u00a0der\u00a0Lebensqualit\u00e4t\u00a0oder\u00a0gar\u00a0zur\u00a0Verbesse \u2010\nrung\u00a0der\u00a0\u00dcberlebensc hancen\u00a0beitragen.\u00a0\n\uf0b7 Von\u00a068\u00a0Krebsmedikamenten\u00a0kamen\u00a039\u00a0(57\u00a0%)\u00a0ohne\u00a0einen\u00a0Nachweis\u00a0\nf\u00fcr\u00a0 eine\u00a0 Lebensverl\u00e4ngerung\u00a0 oder \u00a0 f\u00fcr\u00a0 eine\u00a0 Verbesserung\u00a0 der\u00a0 Le\u2010\nbensqualit\u00e4t\u00a0der\u00a0Patienten\u00a0auf\u00a0den\u00a0Markt.\u00a0\n\uf0b7 Nach\u00a0f\u00fcnf\u00a0Jahren\u00a0in\u00a0der\u00a0Praxis\u00a0zeigten\u00a0nur\u00a0noch\u00a0acht\u00a0Medikament e\u00a0\nwirklich\u00a0messbare\u00a0Vorteile.\u00a0Im\u00a0Fazit\u00a0waren\u00a0nur\u00a0wenig\u00a0mehr\u00a0als\u00a0d ie\u00a0\nH\u00e4lfte\u00a0aller\u00a0neuen\u00a0Krebsmittel\u00a0be sser\u00a0wirksam\u00a0als\u00a0\u00e4ltere\u00a0Therap ien\u00a0\noder\u00a0als\u00a0ein\u00a0Placebo.\u00a0\nDie\u00a0Wirksamkeits\u2010,\u00a0aber\u00a0auch\u00a0die \u00a0Risiko\u2010Nutzen\u2010Bewertung\u00a0sind\u00a0P rozesse,\u00a0die\u00a0also\u00a0\nnicht\u00a0mit\u00a0der\u00a0Zulassung\u00a0abgeschlossen\u00a0sind,\u00a0sondern\u00a0die\u00a0den\u00a0ges amten\u00a0Angebots\u2010\nzeitraum\u00a0eines\u00a0Arzneimittels\u00a0umspannen.\u00a0Daher\u00a0sollte\u00a0die\u00a0Phase\u00a0 der\u00a0Unsicherheit\u00a0\nnach\u00a0der\u00a0Zulassung\u00a0konsequent\u00a0\u00fcber\u00a0zwei\u00a0bis\u00a0drei\u00a0Jahre\u00a0durch\u00a0ve rsorgungsrelevan\u2010\nte\u00a0Forschungsaktivit\u00e4ten\u00a0begleitet\u00a0werden,\u00a0mit\u00a0denen\u00a0die\u00a0Fragen \u00a0zum\u00a0patienten\u2010\norientierten\u00a0Nutzen,\u00a0zur\u00a0Angemessenheit\u00a0der\u00a0Behandlung\u00a0und\u00a0der\u00a0 Allokationsge\u2010\nrechtigkeit\u00a0mit\u00a0ad\u00e4quater\u00a0Methodik\u00a0im\u00a0Rahmen\u00a0guter\u00a0Studien\u00a0bean tworten\u00a0kann.\u00a0\nMan\u00a0sollte\u00a0nicht\u00a0dem\u00a0Irrtum\u00a0verfallen,\u00a0dass\u00a0der\u00a0\u00a7\u00a025\u00a0Abs.\u00a02\u00a0Zif .\u00a05\u00a0des\u00a0AMG,\u00a0in\u00a0dem\u00a0\nals\u00a0 Versagensgrund\u00a0 f\u00fcr\u00a0 die\u00a0 Zulassung\u00a0 ein\u00a0 ung\u00fcnstiges\u00a0 Nutzen\u2010Ris iko\u2010Verh\u00e4ltnis\u00a0\ngenannt\u00a0ist,\u00a0den\u00a0Nutzen\u00a0meint,\u00a0de r\u00a0einem\u00a0patientenorientierten\u00a0 Nutzen\u00a0gleichzu\u2010\nsetzen\u00a0ist.\u00a0Die\u00a0Erkenntnisse\u00a0bei\u00a0d er\u00a0Zulassung\u00a0sind\u00a0einfach\u00a0nic ht\u00a0so,\u00a0dass\u00a0aus\u00a0den\u00a0\ndurch\u00a0 Ein\u2010\u00a0 und\u00a0 Ausschlusskriterien\u00a0 charakterisierbaren\u00a0 Zulassun gsstudien\u00a0 ein\u00a0\nNutzen\u00a0f\u00fcr\u00a0nach\u00a0Alter,\u00a0Geschlecht\u00a0und\u00a0Begleitkrankheiten\u00a0unsele ktierten\u00a0Gruppen\u00a0\nvon\u00a0Patienten\u00a0ableitbar\u00a0w\u00e4ren,\u00a0wie\u00a0sie\u00a0im\u00a0klinischen\u00a0Alltag\u00a0in\u00a0 Krankenh\u00e4usern\u00a0oder\u00a0\nPraxen\u00a0behandelt\u00a0werden.\u00a0\n\u00a0\u00a0 \n93\u00a0\n\u00a0Die\u00a0fr\u00fche\u00a0Nutzenbewertung\u00a0im\u00a0Arzneimittelmarkt\u00a0\nWie\u00a0nun\u00a0bereits\u00a0h\u00e4ufiger\u00a0ausgef \u00fchrt,\u00a0sind\u00a0Zulassungsstudien\u00a0nur \u00a0bedingt\u00a0geeignet,\u00a0\num\u00a0einen\u00a0patientenorientierten\u00a0Nutzen\u00a0zu\u00a0belegen,\u00a0da\u00a0sie\u00a0vom\u00a0pU \u00a0vor\u00a0allem\u00a0dazu\u00a0\ngenutzt\u00a0werden,\u00a0um\u00a0die\u00a0im\u00a0Arzneimittelgesetz\u00a0(AMG)\u00a0geforderten\u00a0 Kriterien\u00a0des\u00a0\nNachweises\u00a0der\u00a0Wirksamkeit,\u00a0der\u00a0Unbedenklichkeit\u00a0und\u00a0der\u00a0pharma zeutischen\u00a0\nQualit\u00e4t\u00a0zu\u00a0erf\u00fcllen,\u00a0um\u00a0sein\u00a0n eues\u00a0Produkt\u00a0im\u00a0Markt\u00a0anbieten\u00a0z u\u00a0k\u00f6nnen.\u00a0Ein\u2010\u00a0und\u00a0\nAusschlusskriterien,\u00a0begrenzte\u00a0La ufzeiten,\u00a0gut\u00a0erreichbare\u00a0Pati entengruppen\u00a0und\u00a0\nein\u00a0intensives\u00a0Monitoring\u00a0(\u00dcberwachung\u00a0und\u00a0Dokumentierung)\u00a0in\u00a0d er\u00a0Durchf\u00fch\u2010\nrung\u00a0der\u00a0Studien\u00a0sollen\u00a0vor\u00a0allem\u00a0die\u00a0im\u00a0AMG\u00a0geforderten\u00a0Nachwe ise\u00a0sicherstellen\u00a0\n\u2013\u00a0der\u00a0Nachweis\u00a0von\u00a0Wirksamkeit\u00a0unter\u00a0Alltagsbedingungen\u00a0( effectiveness )\u00a0und\u00a0der\u00a0\nPatientennutzen\u00a0stehen\u00a0daher\u00a0nur\u00a0bedingt\u00a0im\u00a0Fokus\u00a0klinischer\u00a0Zu lassungstudien.\u00a0\nDiese\u00a0Situation\u00a0wird\u00a0sich\u00a0in\u00a0naher\u00a0Zukunft\u00a0noch\u00a0versch\u00e4rfen,\u00a0we nn\u00a0mehr\u00a0und\u00a0mehr\u00a0\nbeschleunigte\u00a0Zulassungsverfahren\u00a0gef\u00f6rdert\u00a0werden\u00a0\u2013\u00a0ein\u00a0Aspekt ,\u00a0der\u00a0insbeson\u2010\ndere\u00a0den\u00a0Bereich\u00a0der\u00a0Onkologie\u00a0und\u00a0der\u00a0 Orphan\u00a0Drugs \u00a0betrifft,\u00a0in\u00a0dem\u00a0die\u00a0meisten\u00a0\nneuen\u00a0Arzneimittel\u00a0angeboten\u00a0werd en.\u00a0Dies\u00a0ist\u00a0deshalb\u00a0besonders \u00a0dramatisch,\u00a0\nweil\u00a0viele\u00a0pU\u00a0die\u00a0Behandlung\u00a0von\u00a0 Krebserkrankungen\u00a0oder\u00a0seltene n\u00a0Krankheiten\u00a0\nals\u00a0lukrative\u00a0Therapiegebiete\u00a0mit\u00a0unver\u00e4ndert\u00a0gro\u00dfem\u00a0Bedarf\u00a0an\u00a0 echten\u00a0therapeu\u2010\ntischen\u00a0Innovationen\u00a0entdeckt\u00a0haben.\u00a0Es\u00a0gibt\u00a0einen\u00a0unverkennbar en\u00a0Trend,\u00a0dass\u00a0\ngerade\u00a0in\u00a0der\u00a0Onkologie\u00a0und\u00a0bei\u00a0 Orphan\u00a0Diseases \u00a0neue\u00a0Wirkstoffe\u00a0nach\u00a0beschleu\u2010\nnigten\u00a0Zulassungsverfahren\u00a0zugel assen\u00a0werden\u00a0(in\u00a0der\u00a0EU\u00a0im\u00a0Rahm en\u00a0der\u00a0soge\u2010\nnannten\u00a0 Conditional\u00a0Marketing\u00a0Authorisation \u00a0und/oder\u00a0des\u00a0 Accelerated\u00a0Assess\u2010\nment).\u00a0Diese\u00a0beschleunigten\u00a0Zulassungsverfahren\u00a0\u2013\u00a0vergleichbar\u00a0mit\u00a0 der\u00a0in\u00a0den\u00a0\nUSA\u00a0 2012\u00a0 neu\u00a0 eingef\u00fchrten,\u00a0 bisher\u00a0 \u00fcberwiegend\u00a0 f\u00fcr\u00a0 onkologische\u00a0 Wirkstoffe\u00a0\nvergebenen,\u00a0 Breakthrough\u2010Therapy\u2010Designation \u00a0\u2013\u00a0werden\u00a0zu\u00a0Recht\u00a0zunehmend\u00a0\nkritisiert\u00a0(a\u2010t,\u00a02015;\u00a0Ludwig\u00a0&\u00a0Schildmann,\u00a02015;\u00a0Hoekman\u00a0et\u00a0al .,\u00a02015;\u00a0Glaeske\u00a0et\u00a0\nal.,\u00a02017).\u00a0Mit\u00a0anderen\u00a0Worten:\u00a0Das\u00a0BfArM\u00a0oder\u00a0die\u00a0EMA\u00a0verlange n\u00a0andere\u00a0Studi\u2010\nendaten\u00a0(Wirksamkeit,\u00a0Unbedenklic hkeit,\u00a0pharmazeutische\u00a0Qualit\u00e4 t)\u00a0als\u00a0der\u00a0G\u2010BA\u00a0\nund\u00a0das\u00a0mit\u00a0der\u00a0Bewertung\u00a0der\u00a0fr\u00fchen\u00a0Nutzendossiers\u00a0beauftragte \u00a0Institut\u00a0f\u00fcr\u00a0\nQualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0im\u00a0Gesundheitswesen\u00a0(IQWiG),\u00a0be i\u00a0Arzneimitteln\u00a0\nmit\u00a0Orphan\u00a0Drug \u00a0Status\u00a0nimmt\u00a0der\u00a0G\u2010BA\u00a0die\u00a0Bewertung\u00a0der\u00a0Dossiers\u00a0des\u00a0pU\u00a0selbst \u00a0\nvor.\u00a0Das\u00a0IQWiG\u00a0hat\u00a0den\u00a0Auftrag,\u00a0auf\u00a0der\u00a0Basis\u00a0von\u00a0Zulassungsstu dien\u00a0und\u00a0der\u00a0dar\u2010\naus\u00a0abgeleiteten\u00a0Fachinformationen\u00a0sowie\u00a0eventuell\u00a0zus\u00e4tzlich\u00a0e ingereichter\u00a0Stu\u2010\ndien\u00a0das\u00a0Ausma\u00df\u00a0eines\u00a0m\u00f6glichen\u00a0Mehrwerts\u00a0zu\u00a0bestimmen.\u00a0Dieses\u00a0 Dossier\u00a0wird\u00a0\ndann\u00a0vom\u00a0G\u2010BA\u00a0als\u00a0Entscheidungsgrundlage\u00a0f\u00fcr\u00a0das\u00a0Ausma\u00df\u00a0des\u00a0Zus atznutzens\u00a0\nherangezogen.\u00a0Der\u00a0G\u2010BA\u00a0folgt\u00a0alle rdings\u00a0nicht\u00a0immer\u00a0den\u00a0Bewertu ngsergebnissen\u00a0\ndes\u00a0IQWiG,\u00a0sondern\u00a0ber\u00fccksichtigt\u00a0auch\u00a0in\u00a0etwa\u00a030\u00a0%\u00a0der\u00a0Entsche idungen\u00a0versor\u2010\ngungsrelevante\u00a0Kriteri en,\u00a0die\u00a0vom\u00a0IQWiG\u00a0bei\u00a0der\u00a0methodisch\u00a0fest gelegten\u00a0Vorge\u2010\nhensweise\u00a0im\u00a0Rahmen\u00a0der\u00a0Auswertung\u00a0der\u00a0Zulassungsstudien\u00a0wenige r\u00a0ber\u00fccksich\u2010\ntigt\u00a0werden\u00a0k\u00f6nnen,\u00a0weil\u00a0diese\u00a0Aspekte\u00a0in\u00a0den\u00a0Zulassungsstudien \u00a0weniger\u00a0bis\u00a0gar\u00a0\nnicht\u00a0von\u00a0Bedeutung\u00a0sind.\u00a0Und\u00a0diese\u00a0Entwicklung\u00a0bekommt\u00a0immer\u00a0d ramatischere\u00a0 \n94\u00a0\n\u00a0Ausma\u00dfe:\u00a0Unter\u00a0den\u00a0im\u00a0Jahre\u00a02018\u00a0neu\u00a0zugelassenen\u00a0neuen\u00a0Arzneim itteln\u00a0befin\u2010\nden\u00a0sich\u00a0auch\u00a0zwei\u00a0CAR\u2010T\u2010Zell\u2010Therapien.\u00a0Diese\u00a0Therapien\u00a0werden \u00a0mit\u00a0ver\u00e4nderten\u00a0\nT\u2010Zellen\u00a0durchgef\u00fchrt.\u00a0Dem\u00a0Patienten\u00a0werden\u00a0zun\u00e4chst\u00a0T\u2010Zellen\u00a0e ntnommen\u00a0und\u00a0\ndann\u00a0nach\u00a0einer\u00a0gentechnischen\u00a0\u201eNachr\u00fcstung\u201c\u00a0im\u00a0Labor\u00a0zur\u00fcckinj iziert.\u00a0Diese\u00a0\nver\u00e4nderten\u00a0T\u2010Zellen\u00a0sollen\u00a0Kre bszellen\u00a0aufsp\u00fcren\u00a0und\u00a0zerst\u00f6ren .\u00a0Eingesetzt\u00a0wird\u00a0\ndiese\u00a0Therapie\u00a0bei\u00a0Patienten\u00a0mit\u00a0bestimmten\u00a0Leuk\u00e4mien\u00a0oder\u00a0Lymp homen.\u00a0Da\u00a0\ngravierende\u00a0unerw\u00fcnschte\u00a0Wirkungen\u00a0vorkommen\u00a0k\u00f6nnen\u00a0und\u00a0auch\u00a0de r\u00a0Patien\u2010\ntennutzen\u00a0noch\u00a0besser\u00a0untersucht\u00a0und\u00a0belegt\u00a0werden\u00a0muss,\u00a0werden \u00a0solche\u00a0Thera\u2010\npien\u00a0nur\u00a0in\u00a0spezialisierten\u00a0Einri chtungen\u00a0angewendet.\u00a0Die\u00a0beide n\u00a0zugelassenen\u00a0\nCAR\u2010T\u2010Zell\u2010Produkte\u00a0Kymriah\u00ae\u00a0und\u00a0 Yescarta\u00ae\u00a0geh\u00f6ren\u00a0zu\u00a0den\u00a0derze it\u00a0besonders\u00a0\nteuren\u00a0Therapien.\u00a0So\u00a0kostet\u00a0eine\u00a0Behandlung\u00a0mit\u00a0Kymriah\u00ae\u00a0nach\u00a0e iner\u00a0Preisreduk\u2010\ntion\u00a0um\u00a017,2\u00a0%\u00a0aktuell\u00a0265.000\u00a0Euro\u00a0(vorher\u00a0320.000\u00a0Euro).\u00a0Beid e\u00a0Mittel\u00a0wurden\u00a0\nals\u00a0Orphan\u00a0Drugs \u00a0zugelassen,\u00a0ausreichende\u00a0Daten\u00a0zur\u00a0Wirksamkeit\u00a0und\u00a0Vertr\u00e4glich \u2010\nkeit\u00a0unter\u00a0Alltagsbedingungen\u00a0sind\u00a0derzeit\u00a0noch\u00a0nicht\u00a0zu\u00a0erwart en.\u00a0Ein\u00a0weiteres\u00a0\nBeispiel\u00a0ist\u00a0das\u00a0Mittel\u00a0Zolgensma\u00ae\u00a0von\u00a0der\u00a0Firma\u00a0Novartis,\u00a0das\u00a0 bei\u00a0Kindern\u00a0unter\u00a0zwei\u00a0\nJahren\u00a0angewendet\u00a0werden\u00a0soll,\u00a0die\u00a0an\u00a0einer\u00a0genetisch\u00a0bedingten \u00a0Muskelatrophie\u00a0\nleiden\u00a0und\u00a0oft\u00a0sterben,\u00a0bevor\u00a0sie \u00a0ein\u00a0Alter\u00a0von\u00a0zwei\u00a0Jahren\u00a0err eicht\u00a0haben.\u00a0Die\u00a0Kos\u2010\nten\u00a0der\u00a0einmaligen\u00a0Behandlung\u00a0betrugen\u00a0zu\u00a0Beginn\u00a0der\u00a0Vermarktun g\u00a0in\u00a0den\u00a0USA\u00a0\n2,1\u00a0Millionen\u00a0 Dollar.\u00a0 Die\u00a0 Zulassungsstudien\u00a0 wurden\u00a0 an\u00a0 15\u00a0 Kinder n\u00a0durchgef\u00fchrt.\u00a0\nDerzeit\u00a0liegen\u00a0nur\u00a0Daten\u00a0f\u00fcr\u00a0den\u00a0Typ\u00a01\u00a0der\u00a0Krankheit\u00a0vor.\u00a0Es\u00a0wi rd\u00a0gesch\u00e4tzt,\u00a0dass\u00a0eins\u00a0\nvon\u00a010.000\u00a0lebend\u00a0geborenen\u00a0Kindern\u00a0unter\u00a0diesem\u00a0Typ\u00a01\u00a0der\u00a0Spin alen\u00a0Muskelatro\u2010\nphie\u00a0(SMA)\u00a0leidet,\u00a0die\u00a0unbehandelt\u00a0entweder\u00a0fr\u00fch\u00a0sterben\u00a0oder\u00a0i hr\u00a0Leben\u00a0lang\u00a0unter\u00a0\nerheblichen\u00a0Einschr\u00e4nkungen\u00a0zu\u00a0leiden\u00a0haben.\u00a0F\u00fcr\u00a0die\u00a0daneben\u00a0ex istierenden\u00a0Typen\u00a0\n2\u00a0und\u00a03\u00a0der\u00a0SMA\u00a0liegen\u00a0noch\u00a0keine\u00a0belastbaren\u00a0Ergebnisse\u00a0in\u00a0Bez ug\u00a0auf\u00a0eine\u00a0Behand\u2010\nlunug\u00a0mit\u00a0Zolgensma\u00ae\u00a0vor.\u00a0F\u00fcr\u00a0Deutschland\u00a0w\u00fcrde\u00a0dies\u00a0bedeuten,\u00a0 dass\u00a0bei\u00a0etwa\u00a0\n890.000\u00a0Geburten\u00a0j\u00e4hrlich\u00a0etwa\u00a090\u00a0Kinder\u00a0mit\u00a0dem\u00a0neuen\u00a0Mittel\u00a0b ehandelt\u00a0werden\u00a0\nk\u00f6nnten,\u00a0was\u00a0zu\u00a0Ausgaben\u00a0von\u00a0gesch\u00e4tzt\u00a0180\u00a0Mio.\u00a0Euro\u00a0pro\u00a0Geburt sjahrgang\u00a0f\u00fchren\u00a0\nw\u00fcrde.\u00a0Ob\u00a0die\u00a0\u00dcbertragung\u00a0der\u00a0Ergebnisse\u00a0aus\u00a0den\u00a0Zulassungsstud ien\u00a0gerechtfertigt\u00a0\nund\u00a0verl\u00e4sslich\u00a0ist,\u00a0sollten\u00a0versorgungsrelevante\u00a0Studien\u00a0zeige n.\u00a0Da\u00a0zu\u00a0erwarten\u00a0ist,\u00a0\ndass\u00a0solche\u00a0Therapien\u00a0nur\u00a0in\u00a0spezialisierten\u00a0Einrichtungen\u00a0vorg enommen\u00a0werden,\u00a0\nm\u00fcssen\u00a0solche\u00a0begleitenden\u00a0Forschungsaktivit\u00e4ten\u00a0zur\u00a0Wirksamkei t\u00a0unter\u00a0Alltagsbe\u2010\ndingungen\u00a0auch\u00a0\u00fcber\u00a0l\u00e4ngere\u00a0Zeit,\u00a0das\u00a0hei\u00dft\u00a0\u00fcber\u00a0viele\u00a0Jahre\u00a0du rchgef\u00fchrt\u00a0werden,\u00a0\num\u00a0einen\u00a0dauerhaften\u00a0Nutzen\u00a0f\u00fcr\u00a0die\u00a0Kinder\u00a0zeigen\u00a0zu\u00a0k\u00f6nnen.\u00a0Au ch\u00a0in\u00a0diesem\u00a0Fall\u00a0\nsind\u00a0Zweifel\u00a0berechtigt,\u00a0ob\u00a0sich\u00a0ein\u00a0patientenbezogener\u00a0Nutzen\u00a0 aus\u00a0der\u00a0vorliegenden\u00a0\nZulassungsstudie\u00a0ableiten\u00a0l\u00e4sst.\u00a0F\u00fcr\u00a0Zolgensma\u00ae\u00a0hat\u00a0der\u00a0G\u2010BA\u00a0er stmals\u00a0einen\u00a0pU\u00a0zu\u00a0\neiner\u00a0anwendungsbegleitenden\u00a0Datenerhebung\u00a0verpflichtet.\u00a0\nDie\u00a0 beiden\u00a0 wichtigsten\u00a0 Instituti onen,\u00a0 die\u00a0 an\u00a0 der\u00a0 Umsetzung\u00a0 der\u00a0 AMNOG\u2010\nAnforderungen\u00a0beteiligt\u00a0sind,\u00a0das\u00a0IQWiG\u00a0und\u00a0der\u00a0G\u2010BA,\u00a0haben\u00a0im\u00a0 \u00dcbrigen\u00a0diese\u00a0\nProblematik\u00a0erkannt\u00a0und\u00a0Vorschl\u00e4ge\u00a0f\u00fcr\u00a0eine\u00a0Optimierung\u00a0in\u00a0der\u00a0 Zukunft\u00a0gemacht.\u00a0\nSo\u00a0weist\u00a0eine\u00a0Publikation\u00a0aus\u00a0dem\u00a0IQWiG\u00a0darauf\u00a0hin,\u00a0dass\u00a0insbes ondere\u00a0die\u00a0an\u2010 \n95\u00a0\n\u00a0steigende\u00a0Anzahl\u00a0von\u00a0beschleunigten\u00a0Zulassungsverfahren\u00a0zu\u00a0Info rmationsdefizi\u2010\nten\u00a0f\u00fchrt,\u00a0weil\u00a0immer\u00a0weniger\u00a0Zeit\u00a0bleibt,\u00a0belastbare\u00a0Daten\u00a0f\u00fcr \u00a0die\u00a0Anwendung\u00a0\nneuer\u00a0Arzneimittel\u00a0zu\u00a0sammeln\u00a0(Wieseler\u00a0et\u00a0al.,\u00a02019).\u00a0Die\u00a0Kons equenz\u00a0aus\u00a0Sicht\u00a0\nder\u00a0Autoren:\u00a0\u201eWissensl\u00fccken\u00a0nach\u00a0der\u00a0Zulassung\u00a0zu\u00a0identifiziere n\u00a0und\u00a0gezielt\u00a0mit\u00a0\naussagekr\u00e4ftigen\u00a0Daten\u00a0zu\u00a0schlie\u00dfe n\u00a0[sic:\u00a0Evidenz\u2010L\u00fccke,\u00a0GG]\u00a0is t\u00a0daher\u00a0eine\u00a0ganz\u00a0\nwesentliche\u00a0 Aufgabe\u00a0 f\u00fcr\u00a0 die\u00a0 Zuk unft.\u00a0 Die\u00a0 Autorinnen\u00a0 und\u00a0 Autoren \u00a0 empfehlen\u00a0\ndar\u00fcber\u00a0hinaus,\u00a0bereits\u00a0zum\u00a0Zeitpunkt\u00a0des\u00a0Marktzugangs\u00a0verbindl ich\u00a0aussagekr\u00e4f\u2010\ntige\u00a0Vergleiche\u00a0zur\u00a0Standardbehandlung\u00a0 zu\u00a0 verlangen.\u00a0 Auch\u00a0neue\u00a0 Ans\u00e4tze\u00a0der\u00a0\nArzneimittelentwicklung,\u00a0die\u00a0st\u00e4rker\u00a0an\u00a0den\u00a0L\u00fccken\u00a0in\u00a0den\u00a0Thera piem\u00f6glichkeiten\u00a0\nbzw.\u00a0an\u00a0den\u00a0Zielen\u00a0von\u00a0Gesundheitssystemen\u00a0orientiert\u00a0sind,\u00a0k\u00f6n nten\u00a0einen\u00a0Bei\u2010\ntrag\u00a0zur\u00a0besseren\u00a0Versorgung\u00a0von \u00a0Patientinnen\u00a0und\u00a0Patienten\u00a0lei sten.\u201c\u00a0(IQWiG,\u00a0\n2019).\u00a0Und\u00a0der\u00a0G\u2010BA\u00a0macht\u00a0in\u00a0einer\u00a0Stellungnahme\u00a0zum\u00a0Entwurf\u00a0ei nes\u00a0Gesetzes\u00a0\nf\u00fcr\u00a0mehr\u00a0Sicherheit\u00a0in\u00a0der\u00a0Arzneimittelversorgung\u00a0(GSAV)\u00a0auch\u00a0g leich\u00a0Vorschl\u00e4ge\u00a0\nf\u00fcr\u00a0eine\u00a0versorgungsbegleitende\u00a0Forschung\u00a0bei\u00a0der\u00a0Vermarktung\u00a0n euer\u00a0Arzneimit\u2010\ntel\u00a0(G\u2010BA,\u00a02019,\u00a011\u00a0ff).\u00a0Dort\u00a0hei\u00dft\u00a0es\u00a0u.\u00a0a.:\u00a0\n\u201eDie\u00a0hauptamtlichen\u00a0unparteiischen\u00a0Mitglieder\u00a0des\u00a0G\u2010BA\u00a0begr\u00fc\u00dfen \u00a0den\u00a0vorliegenden\u00a0\nEntwurf\u00a0und\u00a0die\u00a0M\u00f6glichkeit\u00a0des\u00a0G\u2010BA,\u00a0weitere\u00a0Datenerhebungen\u00a0n ach\u00a0der\u00a0Zulassung\u00a0\nzum\u00a0Zweck\u00a0der\u00a0Nutzenbewertung\u00a0zu\u00a0fordern,\u00a0da\u00a0dies\u00a0eine\u00a0wesentli che\u00a0Grundlage\u00a0f\u00fcr\u00a0die\u00a0\nweitere\u00a0Evidenzgenerierung\u00a0f\u00fcr\u00a0A rzneimittel\u00a0w\u00e4hrend\u00a0der\u00a0Anwendu ng\u00a0in\u00a0der\u00a0klinischen\u00a0\nPraxis\u00a0schafft,\u00a0bei\u00a0denen\u00a0die\u00a0Evidenzlage\u00a0zum\u00a0Zeitpunkt\u00a0der\u00a0Nut zenbewertung\u00a0unzu\u2010\nreichend\u00a0ist.\u00a0[Erg\u00e4nzung:\u00a0Dies\u00a0g ilt\u00a0sowohl\u00a0f\u00fcr\u00a0den\u00a0ambulanten\u00a0w ie\u00a0station\u00e4ren\u00a0Bereich.\u00a0\nGG]\u00a0[\u2026]\u00a0Um\u00a0das\u00a0Instrument\u00a0der\u00a0beg leitenden\u00a0Datenerhebung\u00a0in\u00a0zwe ckverwirklichender\u00a0\nWeise\u00a0zukunftsoffen\u00a0und\u00a0damit\u00a0hi nreichend\u00a0entwicklungsoffen\u00a0ein setzen\u00a0zu\u00a0k\u00f6nnen,\u00a0wird\u00a0\nes\u00a0daher\u00a0als\u00a0sachgerecht\u00a0angesehen,\u00a0den\u00a0Begriff\u00a0\u201eanwendungsbegl eitend\u201c\u00a0durch\u00a0den\u00a0\nBegriff\u00a0\u201eversorgungsbegleitend\u201c\u00a0zu\u00a0ersetzen.\u00a0Gem\u00e4\u00df\u00a0Gesetzesbegr \u00fcndung\u00a0kann\u00a0es\u00a0sich\u00a0\nbei\u00a0den\u00a0Datenerhebungen\u00a0z.\u00a0B.\u00a0um\u00a0Anwendungsbeobachtungen,\u00a0Fall\u2010 Kontroll\u2010Studien\u00a0\noder\u00a0Registerstudien\u00a0handeln,\u00a0solange\u00a0die\u00a0Datenerhebung\u00a0\u201eanwend ungsbegleitend\u201c\u00a0ist.\u00a0\nAus\u00a0methodischer\u00a0Sicht\u00a0k\u00f6nnten\u00a0a uch\u00a0kontrolliert e\u00a0Studien\u00a0(zum\u00a0 Beispiel\u00a0pragmatische\u00a0\nStudiendesigns)\u00a0versorgungsbegleit end\u00a0durchgef\u00fchrt\u00a0werden\u00a0und\u00a0s ollten\u00a0von\u00a0den\u00a0m\u00f6gli\u2010\nchen\u00a0Datenerhebungen\u00a0mit\u00a0umfasst\u00a0sein.\u00a0[\u2026]\u00a0Datenerhebungen\u00a0ohne \u00a0wissenschaftlichen\u00a0\nMehrwert\u00a0und\u00a0ohne\u00a0transparente\u00a0 Ver\u00f6ffentlichung\u00a0der\u00a0Ergebnisse\u00a0 m\u00fcssen\u00a0auch\u00a0im\u00a0Rah\u2010\nmen\u00a0der\u00a0begleitenden\u00a0Datenerhebungsforderung\u00a0vermieden\u00a0werden.\u00a0 [\u2026]\u00a0Zum\u00a0Beispiel\u00a0\nw\u00e4re\u00a0es\u00a0durch\u00a0die\u00a0Einrichtung\u00a0ein er\u00a0unabh\u00e4ngigen\u00a0zentralen\u00a0Date nerfassung,\u00a0z.\u00a0B.\u00a0im\u00a0 \n96\u00a0\n\u00a0Rahmen\u00a0eines\u00a0klinischen\u00a0Registers,\u00a0prinzipiell\u00a0m\u00f6glich,\u00a0therapi erelevante\u00a0Krankheitsver\u2010\nlaufsdaten\u00a0\u00fcberregional\u00a0produktunabh\u00e4ngig\u00a0zu\u00a0erfassen\u00a0und\u00a0die\u00a0i m\u00a0Regierungsentwurf\u00a0\nbezweckte\u00a0Verbesserung\u00a0der\u00a0Evidenzgrundlage\u00a0im\u00a0Rahmen\u00a0der\u00a0Nutze nbewertung\u00a0zu\u00a0\ngew\u00e4hrleisten.\u00a0Die\u00a0\u00dcbermittlung\u00a0p seudonymisierter\u00a0personenbezog ener\u00a0Daten\u00a0aus\u00a0die\u2010\nsen\u00a0Datenerhebungen\u00a0an\u00a0den\u00a0G\u2010BA\u00a0zur\u00a0Bewertung\u00a0der\u00a0Evidenz\u00a0sollt e\u00a0nicht\u00a0ausgeschlos\u2010\nsen\u00a0sein.\u00a0Bei\u00a0sp\u00e4terer\u00a0Zulassung\u00a0von\u00a0Arzneimitteln\u00a0mit\u00a0gleichge lagerter\u00a0Evidenzproblema\u2010\ntik\u00a0in\u00a0selbiger\u00a0oder\u00a0\u00e4hnlicher\u00a0Indikation\u00a0k\u00f6nnten\u00a0die\u00a0versorgun gsbegleitenden\u00a0Daten\u00a0in\u00a0\ndas\u00a0gleiche\u00a0Register,\u00a0ggf.\u00a0mit\u00a0angepassten\u00a0Modulen,\u00a0eingepflegt \u00a0werden,\u00a0ohne\u00a0dass\u00a0neue\u00a0\nStrukturen\u00a0aufgebaut\u00a0werden\u00a0m\u00fcsse n.\u00a0Interoperabilit\u00e4tsproblemat iken,\u00a0die\u00a0mit\u00a0der\u00a0Etab\u2010\nlierung\u00a0verschiedener\u00a0Datenerhebungen\u00a0entstehen,\u00a0w\u00fcrden\u00a0vermied en,\u00a0und\u00a0der\u00a0Aufbau\u00a0\nvon\u00a0Parallelstrukturen\u00a0unterbunden.\u201c\u00a0\nDiese\u00a0Ans\u00e4tze\u00a0aus\u00a0dem\u00a0Entwurf\u00a0ei nes\u00a0Gesetzes\u00a0f\u00fcr\u00a0mehr\u00a0Sicherhei t\u00a0in\u00a0der\u00a0Arznei\u2010\nmittelversorgung\u00a0(GSAV),\u00a0die\u00a0hier \u00a0vom\u00a0G\u2010BA\u00a0kommentiert\u00a0werden,\u00a0 k\u00f6nnen\u00a0auch\u00a0\nals\u00a0Hinwendung\u00a0zur\u00a0Methodik\u00a0einer\u00a0Sp\u00e4tbewertung\u00a0verstanden\u00a0werd en,\u00a0die\u00a0vor\u00a0\nallem\u00a0im\u00a0Zusammenhang\u00a0mit\u00a0den\u00a0beschleunigten\u00a0Zulassungen\u00a0mehr\u00a0u nd\u00a0mehr\u00a0\ngefordert\u00a0wird.\u00a0Das\u00a0AMNOG\u00a0als\u00a0le rnendes\u00a0System\u00a0wird\u00a0eben\u00a0nicht\u00a0 umhin\u00a0kommen,\u00a0\nsich\u00a0den\u00a0neuen\u00a0Herausforderungen \u00a0in\u00a0der\u00a0Arzneimittelbewertung\u00a0z u\u00a0stellen\u00a0\u2013\u00a0die\u00a0\nSchw\u00e4chen\u00a0einer\u00a0ausschlie\u00dflichen\u00a0Fr\u00fchbewertung,\u00a0die\u00a0sicherlich\u00a0 als\u00a0erfolgreicher\u00a0\nBeginn\u00a0einer\u00a0Zugangspr\u00fcfung\u00a0f\u00fcr\u00a0den\u00a0GKV\u2010Markt\u00a0zu\u00a0betrachten\u00a0ist ,\u00a0werden\u00a0immer\u00a0\nsichtbarer,\u00a0die\u00a0Erg\u00e4nzung\u00a0einer\u00a0Sp\u00e4tbewertung\u00a0aufgrund\u00a0versorgu ngsbegleitender\u00a0\nDaten\u00a0in\u00a0der\u00a0Patientenbehandlung\u00a0ist\u00a0daher\u00a0ein\u00a0vielversprechend er\u00a0und\u00a0notwendi\u2010\nger\u00a0Schritt.\u00a0\nMarkteintritt\u00a0und\u00a0Verf\u00fcgbarkeit\u00a0der\u00a0Arzneimittel\u00a0f\u00fcr\u00a0die\u00a0Patien ten\u00a0\nTrotz\u00a0dieser\u00a0eingeschr\u00e4nkten\u00a0Aussagen\u00a0zur\u00a0 effectiveness \u00a0von\u00a0Arzneimitteln,\u00a0also\u00a0\nzum\u00a0nachgewiesenen\u00a0Patientennutzen\u00a0sind\u00a0die\u00a0Zeiten\u00a0f\u00fcr\u00a0die\u00a0Verf \u00fcgbarkeit\u00a0der\u00a0\nneuzugelassenen\u00a0Arzneimittel,\u00a0b erechnet\u00a0nach\u00a0einem\u00a0Marktanteil\u00a0 von\u00a01\u00a0%\u00a0(\u201etime\u00a0\nto\u00a0market\u201c) ,\u00a0international\u00a0sehr\u00a0unterschiedlich\u00a0und\u00a0schwanken\u00a0zwischen\u00a0zwe i\u00a0und\u00a0\n16\u00a0Monaten.\u00a0Am\u00a0schnellsten\u00a0wurde\u00a0 der\u00a0Zugang\u00a0in\u00a0Deutschland\u00a0mit\u00a0 zwei\u00a0Monaten\u00a0\ngemessen,\u00a0es\u00a0folgten\u00a0\u00d6sterreich,\u00a0D\u00e4nemark,\u00a0Finnland\u00a0und\u00a0Schwede n\u00a0mit\u00a0durch\u2010\nschnittliche\u00a0vier\u00a0bis\u00a0f\u00fcnf\u00a0Monaten,\u00a0\u00e4hnlich\u00a0lag\u00a0die\u00a0Zeit\u00a0in\u00a0Gro \u00dfbritannien.\u00a0Die\u00a0l\u00e4ngs\u2010\nte\u00a0durchschnittliche\u00a0Zeit\u00a0des\u00a0Indikators\u00a0 \u201etime\u00a0to\u00a0market\u201c \u00a0findet\u00a0sich\u00a0in\u00a0Belgien\u00a0mit\u00a0\nelf\u00a0Monaten\u00a0sowie\u00a0mit\u00a0\u00fcber\u00a0zw\u00f6lf\u00a0Monaten\u00a0in\u00a0Italien\u00a0und\u00a0Portuga l\u00a0(Panteli\u00a0et\u00a0al.,\u00a0\n2016).\u00a0Dies\u00a0hat\u00a0offenbar\u00a0damit\u00a0zu\u00a0tun,\u00a0dass\u00a0es\u00a0unterschiedlich\u00a0 lange\u00a0dauert,\u00a0bis\u00a0\n\u00fcber\u00a0die\u00a0Aufnahme\u00a0neuer\u00a0Arzneimittel\u00a0in\u00a0nationale\u00a0Empfehlungsli sten\u00a0entschieden\u00a0 \n97\u00a0\n\u00a0wird\u00a0 (z.\u00a0B.\u00a0 im\u00a0 Rahmen\u00a0 von\u00a0 Health\u2010Technology\u2010Assessments ),\u00a0 w\u00e4hrend\u00a0 z.\u00a0B.\u00a0 in\u00a0\nDeutschland\u00a0unmittelbar\u00a0nach\u00a0der\u00a0Zulassung\u00a0jedes\u00a0neue\u00a0Arzneimit tel\u00a0bis\u00a0auf\u00a0weni\u2010\nge\u00a0Ausnahmen\u00a0(z.\u00a0B.\u00a0\u201eBagatellarzneimittel\u201c)\u00a0vom\u00a0ersten\u00a0Tag\u00a0an\u00a0v erordnet\u00a0werden\u00a0\nkann.\u00a0Auch\u00a0dieses\u00a0Privileg\u00a0kann\u00a0wie\u00a0das\u00a0Preissetzungsprivileg\u00a0d er\u00a0pharmazeuti\u2010\nschen\u00a0Unternehmen\u00a0im\u00a0ersten\u00a0Jahr \u00a0nach\u00a0der\u00a0Zulassung\u00a0zu\u00a0einer\u00a0ra schen\u00a0Steige\u2010\nrung\u00a0der\u00a0Arzneimittelausgaben\u00a0f\u00fchren.\u00a0Die\u00a0bisherigen\u00a0Ausgaben\u00a0d er\u00a0Innovations\u2010\nreporte\u00a0haben\u00a0auch\u00a0gezeigt,\u00a0wie\u00a0 schnell\u00a0neue\u00a0Arzneimittel\u00a0in\u00a0Le itlinien\u00a0der\u00a0Fachge\u2010\nsellschaften\u00a0genannt\u00a0werden\u00a0(z.\u00a0B.\u00a0Glaeske,\u00a02019).\u00a0\u00a0\nFazit\u00a0und\u00a0Ausblick\u00a0\nDas\u00a0nun\u00a0seit\u00a02011\u00a0in\u00a0Kraft\u00a0befindl iche\u00a0AMNOG\u2010Verfahren\u00a0kann\u00a0zum indest\u00a0n\u00e4he\u2010\nrungsweise\u00a0die\u00a0Aufgabe\u00a0wahrnehmen,\u00a0die\u00a0fehlende\u00a0relative\u00a0Bewert ung\u00a0mit\u00a0Blick\u00a0\nauf\u00a0die\u00a0bereits\u00a0verf\u00fcgbaren\u00a0Arzneimittel\u00a0durchzuf\u00fchren\u00a0und\u00a0den\u00a0 therapeutischen\u00a0\nNutzen\u00a0von\u00a0neuen\u00a0Arzneimitteln\u00a0abzusch\u00e4tzen\u00a0und\u00a0diese\u00a0Informati on\u00a0als\u00a0Grundla\u2010\nge\u00a0f\u00fcr\u00a0die\u00a0Anwendung\u00a0bei\u00a0GKV\u2010Versi cherten\u00a0heranzuziehen.\u00a0Um\u00a0die s\u00a0zu\u00a0erreichen,\u00a0\nm\u00fcssten\u00a0 die\u00a0 \u00c4rzte\u00a0 allerdings\u00a0 in\u00a0 ihren\u00a0 Entscheidungen\u00a0 den\u00a0 G\u2010BA\u2010B ewertungen\u00a0\nfolgen,\u00a0was\u00a0sie\u00a0aber,\u00a0offenbar\u00a0auch\u00a0unter\u00a0dem\u00a0Marketingdruck\u00a0ph armazeutischer\u00a0\nUnternehmen,\u00a0nur\u00a0bedingt\u00a0tun\u00a0(siehe\u00a0auch\u00a0Greiner\u00a0&\u00a0Witte,\u00a02017) .\u00a0Das\u00a0AMNOG\u00a0\nk\u00f6nnte\u00a0 also\u00a0 in\u00a0 der\u00a0 Tat\u00a0 einen\u00a0 Beitrag\u00a0 zu\u00a0 mehr\u00a0 Versorgungsqualit\u00e4 t\u00a0 und\u00a0 \u2010\ngerechtigkeit\u00a0 leisten,\u00a0 wenn\u00a0 die\u00a0 Nachfrager,\u00a0 also\u00a0 die\u00a0 verordnend en\u00a0 \u00c4rzte,\u00a0 sich\u00a0\ndurch\u00a0 die\u00a0 Bewertungsergebnisse\u00a0 in\u00a0 ihrer\u00a0 jeweiligen\u00a0 abw\u00e4genden\u00a0 E ntscheidung\u00a0\nleiten\u00a0lie\u00dfen.\u00a0Es\u00a0k\u00f6nnte\u00a0damit\u00a0 vor\u00a0allem\u00a0zur\u00a0besseren\u00a0Erf\u00fcllung \u00a0folgender\u00a0konkre\u2010\nter\u00a0Funktionen\u00a0beitragen\u00a0(Schneeweiss,\u00a02001;\u00a0Wille,\u00a02002):\u00a0\n\uf0b7 Im\u00a0Rahmen\u00a0der\u00a0Arzneimitteltherapie\u00a0den\u00a0Fokus\u00a0st\u00e4rker\u00a0auf\u00a0die\u00a0Or i\u2010\nentierung\u00a0zugunsten\u00a0des\u00a0Bedarfs\u00a0des\u00a0jeweiligen\u00a0Patienten\u00a0lenken ,\u00a0\n\uf0b7 im\u00a0Hinblick\u00a0auf\u00a0das\u00a0Nutzen\u2010Kosten\u2010Verh\u00e4ltnis\u00a0von\u00a0vorwiegend\u00a0pa\u2010\ntentgesch\u00fctzten\u00a0Wirkstoffen\u00a0die\u00a0Informationsbasis\u00a0von\u00a0\u00c4rzten\u00a0un d\u00a0\nPatienten\u00a0verbessern,\u00a0\n\uf0b7 durch\u00a0Substitutionen\u00a0oder\u00a0Preissenkungen\u00a0von\u00a0beziehungsweise\u00a0be i\u00a0\nMedikamenten\u00a0 mit\u00a0 vergleichswei se\u00a0 ung\u00fcnstiger\u00a0 Nutzen\u2010Kosten\u2010\nRelation\u00a0Finanzierungsspielr\u00e4ume\u00a0f\u00fcr\u00a0den\u00a0Abbau\u00a0von\u00a0Unterversor\u2010\ngung\u00a0und\u00a0f\u00fcr\u00a0neue\u00a0effektive\u00a0Arzn eimittelinnovationen\u00a0gewinnen\u00a0s o\u2010\nwie\u00a0\n\uf0b7 v e r s t \u00e4 r k t e \u00a0f i n a n z i e l l e \u00a0A n r e i z e \u00a0f \u00fcr\u00a0 solche\u00a0 Arzneimittelinnovatio nen\u00a0\nsetzen,\u00a0die\u00a0nach\u00a0objektivierten\u00a0 Kriterien\u00a0einen\u00a0eindeutig\u00a0h\u00f6her en\u00a0\nNutzen\u00a0stiften\u00a0als\u00a0bisher\u00a0im\u00a0Markt\u00a0befindliche\u00a0Pr\u00e4parate.\u00a0\n\u00c4rzte\u00a0sollten\u00a0derartige\u00a0unabh\u00e4ngige\u00a0Daten\u00a0fordern,\u00a0um\u00a0\u00fcber\u00a0die\u00a0 Verwendung\u00a0der\u00a0\njeweiligen\u00a0Arzneimittel\u00a0optimale\u00a0E ntscheidungen\u00a0treffen\u00a0zu\u00a0k\u00f6nn en.\u00a0Diese\u00a0syste\u2010 \n98\u00a0\n\u00a0matische\u00a0Evaluation\u00a0sollte\u00a0mindestens\u00a0zwei\u00a0bis\u00a0drei\u00a0Jahre\u00a0nach\u00a0 der\u00a0Zulassung\u00a0eines\u00a0\nArzneimittels\u00a0andauern.\u00a0Wegen\u00a0der\u00a0bei\u00a0der\u00a0Zulassung\u00a0oftmals\u00a0feh lenden\u00a0Evidenz\u00a0\nzum\u00a0Nutzen\u00a0beziehungsweise\u00a0zum\u00a0Zusatznutzen\u00a0empfehlen\u00a0Chalkidou \u00a0und\u00a0Kolle\u2010\ngen\u00a0(2008),\u00a0dass\u00a0Entscheidungen\u00a0zur\u00a0Bewertung\u00a0und\u00a0zur\u00a0Finanzier ung\u00a0von\u00a0neuen\u00a0\nTechnologien\u00a0im\u00a0Gesundheitswesen,\u00a0darunter\u00a0fallen\u00a0auch\u00a0neue\u00a0Arz neimittelthera\u2010\npien,\u00a0in\u00a0einen\u00a0breiteren\u00a0Kontext\u00a0der\u00a0Forschungspolitik\u00a0eingegli edert\u00a0werden\u00a0soll\u2010\nten.\u00a0Die\u00a0Versorgungsforschung\u00a0ka nn\u00a0in\u00a0diesem\u00a0Zusammenhang\u00a0einen \u00a0Beitrag\u00a0zu\u00a0\nAllokationsentscheidungen\u00a0leisten,\u00a0die\u00a0letztlich\u00a0der\u00a0patienteno rientierten\u00a0Versor\u2010\ngung\u00a0zugutekommen\u00a0und\u00a0in\u00a0diesem\u00a0 Zusammenhang\u00a0auch\u00a0gesundheits\u00f6k onomi\u2010\nsche\u00a0Aspekte\u00a0ber\u00fccksichtigen\u00a0(Pfaff\u00a0et\u00a0al.\u00a02011;\u00a0Glaeske\u00a0et\u00a0al. ,\u00a02017).\u00a0Daher\u00a0sollten\u00a0\nsich\u00a0alle\u00a0an\u00a0der\u00a0Patientenversorg ung\u00a0beteiligten\u00a0Akteure\u00a0f\u00fcr\u00a0di e\u00a0m\u00f6glichst\u00a0rasche\u00a0\nImplementierung\u00a0einer\u00a0solchen\u00a0 Real\u2010Life\u2010Evaluation\u00a0einsetzen.\u00a0Sie\u00a0schafft\u00a0schlie\u00df\u2010\nlich\u00a0mehr\u00a0Allokationssicherheit\u00a0und\u00a0Verteilungsgerechtigkeit\u00a0f\u00fc r\u00a0das\u00a0Gesundheits\u2010\nsystem,\u00a0und\u00a0damit\u00a0letztlich\u00a0eine\u00a0bessere\u00a0Entscheidungsgrundlage \u00a0der\u00a0\u00c4rzte\u00a0in\u00a0der\u00a0\nVersorgung\u00a0der\u00a0Patienten\u00a0\u2013\u00a0eine\u00a0Erg\u00e4nzung\u00a0der\u00a0Fr\u00fchbewertung\u00a0um\u00a0 eine\u00a0Sp\u00e4tbe\u2010\nwertung\u00a0erscheint\u00a0daher\u00a0als\u00a0ein e\u00a0\u00fcberf\u00e4llig\u00a0Forderung\u00a0(Glaeske\u00a0 et\u00a0al.,\u00a02017).\u00a0\n Das\u00a0Ziel:\u00a0Zentrale\u00a0Pre issetzungsverfahren\u00a0f \u00fcr\u00a0innovative\u00a0Arznei mittel\u00a0 5.3\n\uf0b7 Die\u00a0freie\u00a0Preisfestsetzung\u00a0durch \u00a0die\u00a0pharmazeutischen\u00a0Unternehm er\u00a0\nwird\u00a0aufgehoben\u00a0und\u00a0durch\u00a0ein\u00a0transparentes\u00a0Preisfestsetzungsve r\u2010\nfahren\u00a0ersetzt,\u00a0in\u00a0dem\u00a0die\u00a0pharmazeutische\u00a0Industrie\u00a0mit\u00a0einem\u00a0 ge\u2010\neigneten\u00a0Partner\u00a0(Spitzenverband\u00a0der\u00a0Krankenkassen,\u00a0Gemeinsamer \u00a0\nBundesausschuss,\u00a0Medizinischer\u00a0Dienst)\u00a0einen\u00a0GKV\u2010Erstattungspre is\u00a0\naushandelt.\u00a0\n\uf0b7 Basis\u00a0der\u00a0Preisverhandlung\u00a0soll\u00a0eine\u00a0Kosten\u2010Nutzen\u2010Bewertung\u00a0de s\u00a0\nneuen\u00a0Arzneimittels\u00a0sein.\u00a0Die\u00a0Met hoden\u00a0der\u00a0Kosten\u2010Nutzen\u00a0Bewer\u2010\ntung\u00a0 m\u00fcssen\u00a0 dabei\u00a0 wissenschaftlich\u00a0 abgesichert\u00a0 und\u00a0 transparent\u00a0\nsein.\u00a0\n\uf0b7 Die\u00a0Preisfestsetzung\u00a0wird\u00a0durch\u00a0P reis\u2010Volumen\u2010Abkommen/Rabatte\u00a0\nerg\u00e4nzt,\u00a0um\u00a0zu\u00a0verhindern,\u00a0dass\u00a0bei\u00a0einem\u00a0gegebenen\u00a0Preis\u00a0der\u00a0U m\u2010\nsatz\u00a0\u00fcber\u00a0eine\u00a0Mengenausweitung\u00a0g esteigert\u00a0wird.\u00a0Solche\u00a0Rabattv er\u2010\ntr\u00e4ge\u00a0k\u00f6nnen\u00a0das\u00a0Gesamtvolumen\u00a0ko ntrollieren\u00a0oder\u00a0die\u00a0Tagesdo\u2010\nsen\u00a0pro\u00a0Patienten\u00a0(siehe\u00a0Frankreich).\u00a0\n\uf0b7 Die\u00a0maximal\u00a0zu\u00a0erstattenden\u00a0Jahrestherapiekosten\u00a0werden\u00a0zentral \u00a0\nfestgelegt.\u00a0Nach\u00a0der\u00a0Einf\u00fchrung\u00a0des\u00a0Gesundheitsfonds\u00a0k\u00f6nnen\u00a0die \u00a0\nKrankenkassen\u00a0ihren\u00a0Beitragssatz\u00a0n icht\u00a0mehr\u00a0selber\u00a0festlegen.\u00a0M it\u00a0\nder\u00a0 Festlegung\u00a0 einer\u00a0 H\u00f6chstgrenz e\u00a0 der\u00a0 Ausgaben\u00a0 soll\u00a0 verhindert\u00a0\nwerden,\u00a0 dass\u00a0 die\u00a0 Vertragspartner\u00a0 \u201eMondpreise\u201c\u00a0 fordern\u00a0 und\u00a0\ndadurch\u00a0der\u00a0Beitragssatz\u00a0f\u00fcr\u00a0den\u00a0Fonds\u00a0erh\u00f6ht\u00a0werden\u00a0m\u00fcsste.\u00a0Da ss\u00a0 \n99\u00a0\n\u00a0solche\u00a0Ausgabensteigerungen\u00a0aussc hlie\u00dflich\u00a0\u00fcber\u00a0einen\u00a0Zusatzbei \u2010\ntrag\u00a0alleine\u00a0von\u00a0den\u00a0Versicherten\u00a0aufgebracht\u00a0werden\u00a0m\u00fcssten,\u00a0w i\u2010\nderspricht\u00a0dem\u00a0Grundsatz\u00a0der\u00a0GKV\u00a0einer\u00a0einkommensunabh\u00e4ngigen\u00a0Leistungspflicht.\u00a0\n\uf0b7 Jedes\u00a0zugelassene\u00a0Medikament\u00a0steh t\u00a0wie\u00a0bisher\u00a0ab\u00a0der\u00a0Zulassung\u00a0 so\u2010\nfort\u00a0allen\u00a0Patienten\u00a0zur\u00a0Verf\u00fcgung.\u00a0In\u00a0der\u00a0Onkologie\u00a0findet\u00a0hin sicht\u2010\nlich\u00a0der\u00a0Spezialisten\u00a0nach\u00a0der\u00a0Zulassung\u00a0keine\u00a0Einschr\u00e4nkung\u00a0de s\u00a0\nVerordnerkreises\u00a0 statt.\u00a0 Alternativvorschl\u00e4ge\u00a0 k\u00f6nnten\u00a0 die\u00a0 Verord \u2010\nnung\u00a0 innovativer\u00a0 Medikamente\u00a0 auf\u00a0 eine\u00a0 festgelegte\u00a0 Spezialisten\u2010\ngruppe\u00a0beschr\u00e4nken.\u00a0Durch\u00a0diese\u00a0begrenzte\u00a0Gruppe\u00a0sollen\u00a0dann\u00a0di e\u00a0\nDaten\u00a0der\u00a0fehlenden\u00a0Kosten\u2010Nutze n\u2010Bewertung\u00a0generiert\u00a0werden.\u00a0\nZu\u00a0ber\u00fccksichtigen\u00a0ist\u00a0allerdings,\u00a0dass\u00a0solche\u00a0Regelungen\u00a0evtl. \u00a0zu\u00a0Ra\u2010\ntionierungen\u00a0 f\u00fchren\u00a0 und\u00a0 die\u00a0 Sammlung\u00a0 von\u00a0 Daten\u00a0 zur\u00a0 Kosten\u2010\nNutzen\u2010Bewertung\u00a0unn\u00f6tig\u00a0verz\u00f6gern\u00a0k\u00f6nnen.\u00a0\n\uf0b7 Der\u00a0Erstattungs(h\u00f6chst)betrag\u00a0wird\u00a0zun\u00e4chst\u00a0auf\u00a0nationaler\u00a0Eben e,\u00a0\nwie\u00a0oben\u00a0beschrieben,\u00a0verhandelt.\u00a0Sollten\u00a0zum\u00a0Zeitpunkt\u00a0der\u00a0Zul as\u2010\nsung\u00a0nicht\u00a0gen\u00fcgend\u00a0Daten\u00a0f\u00fcr\u00a0di e\u00a0Kosten\u2010Nutzen\u2010Bewertung\u00a0vorli e\u2010\ngen,\u00a0wird\u00a0ein\u00a0vorl\u00e4ufiger\u00a0Erstattungspreis\u00a0festgelegt\u00a0und\u00a0die\u00a0E rstat\u2010\ntung\u00a0(via\u00a0Richtlinie\u00a0G\u2010BA)\u00a0mit\u00a0der\u00a0Auflage\u00a0verkn\u00fcpft,\u00a0in\u00a0einem\u00a0 festzu\u2010\nlegenden\u00a0Zeitraum\u00a0die\u00a0fehlenden\u00a0Daten\u00a0zu\u00a0generieren\u00a0(z.\u00a0B.\u00a0durc h\u00a0\nRegisterstudien\u00a0 oder\u00a0 durch\u00a0 eine\u00a0 methodisch\u00a0 belastbare\u00a0 Versor\u2010gungsforschung).\u00a0Die\u00a0Erstattungsf\u00e4higkeit\u00a0wird\u00a0zun\u00e4chst\u00a0auf\u00a0die sen\u00a0\nZeitraum\u00a0begrenzt\u00a0(Verfahren\u00a0a nalog\u00a0der\u00a0\u201avierten\u00a0H\u00fcrde\u2018).\u00a0\n\uf0b7 An\u00a0der\u00a0im\u00a0Rahmen\u00a0von\u00a0Postzulassungsstudien\u00a0notwendigen\u00a0Doku\u2010\nmentation\u00a0m\u00fcssen\u00a0alle\u00a0Verordner\u00a0und\u00a0Patienten\u00a0teilnehmen.\u00a0Das\u00a0schlie\u00dft\u00a0die\u00a0Dokumentation\u00a0der\u00a0klinischen\u00a0Daten\u00a0ein.\u00a0Die\u00a0Kosten \u00a0der\u00a0\nTeilnahme\u00a0an\u00a0diesen\u00a0Studien\u00a0werden\u00a0erstattet.\u00a0\n\uf0b7 Befreiung\u00a0von\u00a0Arzneimitteln\u00a0mit\u00a0sinnvollen,\u00a0therapeutischen\u00a0Neu e\u2010\nrungen\u00a0von\u00a0Preisfestsetzung\u00a0\u00fcber\u00a0eine\u00a0Dauer\u00a0von\u00a0zwei\u00a0Jahren\u00a0ab\u00a0 Zu\u2010\nlassung.\u00a0\n\uf0b7 Nach\u00a0Indikationserweiterungen\u00a0wird\u00a0der\u00a0Preis\u00a0mit\u00a0Blick\u00a0auf\u00a0den\u00a0 Nut\u2010\nzen\u00a0f\u00fcr\u00a0die\u00a0Patienten\u00a0(siehe\u00a0\u00a7\u00a035b\u00a0SGB\u00a0V),\u00a0die\u00a0Gr\u00f6\u00dfe\u00a0der\u00a0betrof fenen\u00a0\nBev\u00f6lkerung\u00a0und\u00a0der\u00a0Schwere\u00a0der\u00a0 Erkrankung\u00a0ggf.\u00a0neu\u00a0gesetzt.\u00a0\nDie\u00a0internationalen\u00a0Auswirkungen\u00a0solch\u00a0einer\u00a0gesetzlichen\u00a0Regel ung\u00a0m\u00fcssen\u00a0be\u2010\ndacht\u00a0werden\u00a0\u2013\u00a0Deutschland\u00a0fungiert\u00a0f\u00fcr\u00a0viele\u00a0europ\u00e4ische\u00a0Staat en\u00a0als\u00a0Referenz\u2010\npreisland\u00a0haben.\u00a0Eine\u00a0Preisreduktion\u00a0in\u00a0Deutschland\u00a0kann\u00a0dazu\u00a0f \u00fchren,\u00a0dass\u00a0Un\u2010\nternehmen\u00a0ihre\u00a0Arzneimittel\u00a0in\u00a0D eutschland\u00a0verz\u00f6gert\u00a0vermarkten ,\u00a0damit\u00a0sich\u00a0die\u00a0\nPreise\u00a0nicht\u00a0in\u00a0niedrigere\u00a0Preise\u00a0anderer\u00a0Staaten\u00a0\u00fcbersetzen.\u00a0E ine\u00a0L\u00f6sung\u00a0f\u00fcr\u00a0die\u2010\nses\u00a0Problem\u00a0w\u00e4re\u00a0die\u00a0Trennung\u00a0des \u00a0gelisteten\u00a0und\u00a0des\u00a0effektiven \u00a0Preises,\u00a0d.\u00a0h.\u00a0der\u00a0 \n100\u00a0\n\u00a0Staat\u00a0 akzeptiert\u00a0 hohe\u00a0 Listenpreis e,\u00a0 durch\u00a0 Preis\u2010Volumen\u2010Abkomme n\u00a0 wird\u00a0 der\u00a0\neffektive\u00a0Preise,\u00a0der\u00a0von\u00a0den\u00a0Kra nkenkassen\u00a0bezahlt\u00a0wird,\u00a0aller dings\u00a0gesenkt.\u00a0\u00a0\nDie\u00a0Unternehmen\u00a0m\u00fcssen\u00a0keine\u00a0gesetzlichen\u00a0Eingriffe\u00a0seitens\u00a0der \u00a0Regierung\u00a0w\u00e4h\u2010\nrend\u00a0der\u00a0Vertragsdauer\u00a0bef\u00fcrchten,\u00a0die\u00a0Auswirkungen\u00a0auf\u00a0ihre\u00a0Ei nnahmen\u00a0haben\u00a0\nk\u00f6nnten.\u00a0Zugleich\u00a0erlauben\u00a0die\u00a0Pr eisvereinbarungen\u00a0die\u00a0Planbark eit\u00a0der\u00a0Ausgaben\u00a0\nder\u00a0gesetzlichen\u00a0Krankenkassen,\u00a0indem\u00a0die\u00a0\u00fcber\u00a0den\u00a0erwarteten\u00a0A usgaben\u00a0liegen\u2010\nden\u00a0Kosten\u00a0von\u00a0den\u00a0pharmazeutischen\u00a0Unternehmen\u00a0erstattet\u00a0werde n.\u00a0Rabattver\u2010\ntr\u00e4ge\u00a0nach\u00a0\u00a7\u00a0130a\u00a0SGB\u00a0V\u00a0k\u00f6nnen\u00a0ei n\u00a0j\u00e4hrliches\u00a0Umsatzvolumen\u00a0ode r\u00a0eine\u00a0Abstaffe\u2010\nlung\u00a0von\u00a0Mehrerl\u00f6sen\u00a0vorsehen\u00a0und\u00a0sind\u00a0somit\u00a0eine\u00a0Form\u00a0von\u00a0Prei s\u2010Volumen\u2010\nAbkommen,\u00a0mit\u00a0dem\u00a0Unterschied,\u00a0da ss\u00a0sie\u00a0nicht\u00a0explizit\u00a0in\u00a0ein\u00a0s taatliches\u00a0Preis\u2010\u00a0\nund\u00a0Erstattungssystem\u00a0eingegliedert\u00a0sind.\u00a0\nDen\u00a0pharmazeutischen\u00a0Herstellern\u00a0verbleibt\u00a0auch\u00a0noch\u00a0die\u00a0Altern ative,\u00a0mit\u00a0dem\u00a0\nSpitzenverband\u00a0Bund\u00a0der\u00a0Krankenkassen\u00a0einen\u00a0 Cost\u2010\u00a0oder\u00a0Risk\u2010Sharing \u2010Vertrag\u00a0\nabzuschlie\u00dfen.\u00a0Diese\u00a0Alternative\u00a0bietet\u00a0sich\u00a0f\u00fcr\u00a0den\u00a0Hersteller \u00a0vor\u00a0allem\u00a0dann\u00a0an,\u00a0\nwenn\u00a0der\u00a0Abgabepreis\u00a0seines\u00a0Medikamentes\u00a0in\u00a0Deutschland\u00a0ausl\u00e4nd ischen\u00a0Regu\u2010\nlierungen\u00a0als\u00a0Benchmark\u00a0dient.\u00a0 Cost\u2010Sharing \u2010Vertr\u00e4ge\u00a0setzen\u00a0allerdings\u00a0als\u00a0Pla\u2010\nnungsgrundlage\u00a0f\u00fcr\u00a0die\u00a0Vertragspartner\u00a0ein\u00a0in\u00a0seinem\u00a0Umfang\u00a0wei tgehend\u00a0be\u2010\nkanntes\u00a0 Patientenkollektiv\u00a0 voraus.\u00a0 Sofern\u00a0 der\u00a0 Cost\u2010Sharing\u2010Vertrag \u00a0 auch\u00a0 einen\u00a0\npotenziellen\u00a0 Off\u2010Label\u2010Use \u00a0einschlie\u00dft,\u00a0gew\u00e4hrt\u00a0er\u00a0dem\u00a0Spitzenverband\u00a0Bund\u00a0der\u00a0\nKrankenkassen\u00a0Transparenz\u00a0und\u00a0Sicherheit\u00a0hinsichtlich\u00a0des\u00a0k\u00fcnft igen\u00a0Ausgabenvo\u2010\nlumens.\u00a0Etwaige\u00a0Erweiterungen\u00a0de s\u00a0Patientenkreises\u00a0oder\u00a0(andere )\u00a0angebotsindu\u2010\nzierte\u00a0Nachfrageeffekte\u00a0gehen\u00a0da nn\u00a0zwangsl\u00e4ufig\u00a0zu\u00a0Lasten\u00a0des\u00a0p harmazeutischen\u00a0\nHerstellers,\u00a0dem\u00a0unabh\u00e4ngig\u00a0davon\u00a0nur\u00a0das\u00a0 ex\u00a0ante\u00a0vereinbarte\u00a0Erstattungsvolu\u2010\nmen\u00a0zusteht.\u00a0\nIn\u00a0Risk\u2010Sharing \u2010Vertr\u00e4gen\u00a0 garantiert\u00a0 der\u00a0 phar mazeutische\u00a0 Hersteller\u00a0 dem\u00a0 Ver\u2010\ntragspartner\u00a0das\u00a0sp\u00e4tere\u00a0Eintreten\u00a0eines\u00a0bestimmten\u00a0therapeutis chen\u00a0Zusatznut\u2010\nzens,\u00a0andernfalls\u00a0erstattet\u00a0er\u00a0den\u00a0Preis,\u00a0d.\u00a0h.\u00a0hier\u00a0die\u00a0Preisd ifferenz\u00a0zur\u00a0bisherigen\u00a0\nStandardtherapie,\u00a0ganz\u00a0oder\u00a0teilweise\u00a0zur\u00fcck.\u00a0Der\u00a0Hersteller\u00a0ge ht\u00a0damit\u00a0im\u00a0Ver\u2010\ngleich\u00a0zur\u00a0Festlegung\u00a0eines\u00a0vorl\u00e4 ufigen\u00a0Erstattungsbetrages\u00a0ins ofern\u00a0ein\u00a0erhebli\u2010\nches\u00a0Risiko\u00a0ein,\u00a0als\u00a0er\u00a0dann\u00a0f\u00fcr\u00a0 sein\u00a0Arzneimittel\u00a0im\u00a0ung\u00fcnstig en\u00a0Fall\u00a0auch\u00a0f\u00fcr\u00a0den\u00a0\nErprobungszeitraum\u00a0nur\u00a0eine\u00a0Ersta ttung\u00a0in\u00a0H\u00f6he\u00a0der\u00a0bisherigen\u00a0S tandardtherapie\u00a0\nerh\u00e4lt.\u00a0Er\u00a0d\u00fcrfte\u00a0daher\u00a0nur\u00a0dann\u00a0einen\u00a0 Risk\u2010Sharing \u2010Vertrag\u00a0abschlie\u00dfen,\u00a0wenn\u00a0er\u00a0\naufgrund\u00a0der\u00a0klinischen\u00a0Pr\u00fcfung\u00a0und\u00a0u.U.\u00a0zus\u00e4tzlicher\u00a0Informati onen\u00a0vom\u00a0thera\u2010\npeutischen\u00a0Zusatznutzen\u00a0seines\u00a0Medikamentes\u00a0und\u00a0dessen\u00a0nachtr\u00e4g licher\u00a0Best\u00e4ti\u2010\ngung\u00a0durch\u00a0valide\u00a0Versorgungsstudien\u00a0\u00fcberzeugt\u00a0ist.\u00a0Die\u00a0Problem atik\u00a0besteht\u00a0hier\u00a0\nin\u00a0der\u00a0Formulierung\u00a0eindeutiger\u00a0bzw.\u00a0kontrollierbarer\u00a0und\u00a0justi ziabler\u00a0Kriterien\u00a0f\u00fcr\u00a0\ndie\u00a0Erfassung\u00a0des\u00a0therapeutischen\u00a0Zusatznutzens.\u00a0Die\u00a0Erfahrung\u00a0 mit\u00a0den\u00a0bisheri\u2010\ngen\u00a0\u2013\u00a0noch\u00a0recht\u00a0seltenen\u00a0\u2013\u00a0 Risk\u2010Sharing \u2010Vertr\u00e4gen\u00a0lehrt,\u00a0da ss\u00a0die\u00a0Konzipierung\u00a0 \n101\u00a0\n\u00a0guter\u00a0Vertr\u00e4ge\u00a0auf\u00a0beiden\u00a0Seiten\u00a0mit\u00a0einem\u00a0erheblichen\u00a0Aufwand\u00a0 einhergeht.\u00a0\nGleichwohl\u00a0verdient\u00a0dieses\u00a0 \u201ePayment\u00a0by\u00a0Result\u201c \u00a0schon\u00a0unter\u00a0Zielaspekten\u00a0zumin\u2010\ndest\u00a0als\u00a0Option\u00a0eine\u00a0Chance.\u00a0\n\u00a0 \u00a0 \n102\u00a0\n\u00a0Quellen\u00a0\nAngell\u00a0M\u00a0(2005)\u00a0Der\u00a0Pharma\u00a0Bluf f.\u00a0KomPart,\u00a0Bonn,\u00a0Bad\u00a0Homburg\u00a0\narznei\u2010telegramm:\u00a0EMA\u00a0plant\u00a0\u201eAda ptive\u00a0Zulassungen\u201d.\u00a0Deregulieru ng\u00a0im\u00a0Sinne\u00a0der\u00a0Pharmaindustrie\u00a0mit\u00a0erh\u00f6hten\u00a0Risiken\u00a0f\u00fcr\u00a0\nPatienten,\u00a0a\u2010t\u00a046\u00a0(2015)\u00a0119\u2013121.\u00a0\nBradley\u00a0CP\u00a0(1991):\u00a0Decision\u00a0makin g\u00a0prescribing\u00a0patterns\u00a0\u2013\u00a0a\u00a0lit erature\u00a0review.\u00a0Family\u00a0Practice,\u00a0Vol.\u00a08,\u00a0S.\u00a0276\u2010287.\u00a0\nChalkidou\u00a0K,\u00a0Lord\u00a0J,\u00a0Fischer\u00a0A,\u00a0Littlejohns\u00a0P\u00a0(2008)\u00a0Evidence\u2010b ased\u00a0Decision\u2010making.\u00a0When\u00a0should\u00a0we\u00a0wait\u00a0for\u00a0more\u00a0information, \u00a0in:\u00a0\nHealth\u00a0Affairs\u00a027\u00a0(6)\u00a01642\u2013\u00a01653\u00a0\nDavis\u00a0C,\u00a0Naci\u00a0H,\u00a0Gurpinar\u00a0E,\u00a0Poplavska\u00a0E,\u00a0Pinto\u00a0A,\u00a0Aggarwal\u00a0A\u00a0( 2017)\u00a0Availability\u00a0of\u00a0evidence\u00a0of \u00a0benefits\u00a0on\u00a0overall\u00a0survival\u00a0 and\u00a0\nquality\u00a0of\u00a0life\u00a0of\u00a0cancer\u00a0drugs\u00a0ap proved\u00a0by\u00a0European\u00a0Medicines\u00a0 Agency:\u00a0retrospective\u00a0cohort\u00a0study\u00a0of\u00a0drug\u00a0\napprovals\u00a02009\u201013.\u00a0BMJ\u00a0359:j4530\u00a0\nDjulbegovic\u00a0B,\u00a0Lacevic\u00a0M,\u00a0Cant or\u00a0A,\u00a0Fields\u00a0KK,\u00a0Bennett\u00a0CL,\u00a0Adam s,\u00a0JR,\u00a0Kuderer\u00a0NM,\u00a0Lyman\u00a0GH\u00a0(2000):\u00a0The\u00a0uncertainty\u00a0principle\u00a0a nd\u00a0\nindustry\u2010sponsored\u00a0research.\u00a0Lancet,\u00a0Vol.\u00a0356,\u00a0S.\u00a0635\u2010638.\u00a0\nG\u2010BA\u00a0(2017).\u00a0Nusinersen\u00a0\u2010\u00a0Beschluss\u00a0des\u00a0Gemeinsamen\u00a0Bundesaussc husses\u00a0\u00fcber\u00a0eine\u00a0\u00c4nderung\u00a0der\u00a0Arzneimittel\u2010Richtlinie\u00a0(AM\u2010\nRL):\u00a0Anlage\u00a0XII\u00a0\u2010\u00a0Beschl\u00fcsse\u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung\u00a0von\u00a0Arzne imitteln\u00a0mit\u00a0neuen\u00a0Wirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V.\u00a0\n2017.\u00a0https://www.g\u2010ba.de/downlo ads/39\u2010261\u20103169/2017\u201012\u201021_AM\u2010R L\u2010XII_Nusinersen_D\u2010294_BAnz.pdf,\u00a0letzter\u00a0\nZugriff:\u00a019.07.2021.\u00a0\nG\u2010BA\u00a0(2018):\u00a0Dupilumab.\u00a0Beschluss\u00a0des\u00a0Gemeinsamen\u00a0Bundesausschu sses\u00a0\u00fcber\u00a0eine\u00a0\u00c4nderung\u00a0der\u00a0Arzneimittel\u2010Richtlinie\u00a0(AMRL):\u00a0\nAnlage\u00a0XII\u00a0\u2013\u00a0Beschl\u00fcsse\u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung\u00a0von\u00a0Arzneimitt eln\u00a0mit\u00a0neuen\u00a0Wirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a02018.\u00a0\nhttps://www.g\u2010ba.de/downloads/ 39\u2010261\u20103314/2018\u201005\u201017_AM\u2010RL\u2010XII_ Dupilumab_D\u2010328_BAnz.pdf\u00a0\nG\u2010BA\u00a0(2019).\u00a0Stellungnahme\u00a0der\u00a0hauptamtlichen\u00a0unparteiischen\u00a0Mi tglieder\u00a0des\u00a0Gemeinsamen\u00a0Bu ndesausschusses\u00a0(G\u2010BA)\u00a0vom\u00a0\n04.04.2019\u00a0zur\u00a0\u00f6ffentlichen\u00a0Anh\u00f6rung\u00a0zum\u00a0Gesetzentwurf\u00a0eines\u00a0Ge setzes\u00a0f\u00fcr\u00a0mehr\u00a0Sicherheit\u00a0in\u00a0der\u00a0\nArzneimittelversorgung\u00a0(Drucksache\u00a019/8753).\u00a0https://www.g\u2010ba.d e/downloads/17\u201098\u20104779/2019\u201004\u201004\u2010PA\u2010AfG\u2010\nSN\u2010GSAV\u2010G\u2010BA.pdf,\u00a0letzter\u00a0Zugriff:\u00a014.07.2019.\u00a0\nG\u2010BA\u00a0(2021).\u00a0Nusinersen\u00a0(\u00dcberschreitung\u00a0der\u00a050\u00a0Mio\u00a0\u20ac\u00a0Grenze:\u00a0Sp inale\u00a0Muskelatrophie)\u00a0\u2010\u00a0Beschluss\u00a0des\u00a0Gemeinsamen\u00a0\nBundesausschuss\u00a0\u00fcber\u00a0eine\u00a0\u00c4nderung\u00a0der\u00a0Arzneimittelrichtlinie\u00a0( AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2010\u00a0Nutzenbewertung\u00a0von\u00a0\nArzneimitteln\u00a0mit\u00a0neuen\u00a0Wirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V.\u00a02021.\u00a0htt ps://www.g\u2010ba.de/downloads/39\u2010261\u20104835/2021\u2010\n05\u201020_AM\u2010RL\u2010XII_Nusinersen_D\u2010614 _BAnz.pdf,\u00a0letzter\u00a0Zugriff:\u00a019. 07.2021.\u00a0\nGerber\u2010Grote\u00a0A,\u00a0Windeler\u00a0J\u00a0(2014) \u00a0Welchen\u00a0Beitrag\u00a0leisten\u00a0Koste n\u2010Nutzen\u2010Bewertungen\u00a0bei\u00a0Entscheidungen\u00a0im\u00a0\nGesundheitswesen.\u00a0Erfahrungen\u00a0aus\u00a07\u00a0ausgew\u00e4hlten\u00a0L\u00e4ndern,\u00a0in:\u00a0Z eitschrift\u00a0f\u00fcr\u00a0Evidenz,\u00a0Fortbildung\u00a0und\u00a0Qualit\u00e4t\u00a0im\u00a0\nGesundheitswesen\u00a0108\u00a0(7)\u00a0355\u2013357.\u00a0\nGlaeske\u00a0G,\u00a0Ludwig\u00a0WD,\u00a0Wei\u00dfbach\u00a0L\u00a0(2017)\u00a0AMNOG.\u00a0Pflicht\u00a0zur\u00a0sp\u00e4t en\u00a0Nutzenbewertung,\u00a0in:\u00a0Deutsches\u00a0\u00c4rzteblatt\u00a0114\u00a0(45)\u00a0A\u00a02086\u2013\n2092.\u00a0\nGlaeske\u00a0G,\u00a0Berlit\u00a0P\u00a0(2018)\u00a0Alzheimerdemenz.\u00a0In:\u00a0Glaeske\u00a0G,\u00a0Ludw ig\u00a0WD\u00a0(Hrsg.)\u00a0Innovationsreport\u00a02018.\u00a0291\u2010316.\u00a0\nBremen/Hamburg.\u00a0\nGlaeske\u00a0G\u00a0(2019).\u00a0Gerechtigkeit\u00a0in\u00a0der\u00a0Arzneimittelversorgung\u00a0\u2013 \u00a0aber\u00a0wer\u00a0entscheidet\u00a0dar\u00fcber?\u00a0In:\u00a0Fuchs\u00a0M,\u00a0Greiling\u00a0D,\u00a0\nRosenbergen\u00a0M\u00a0(Hrsg.)\u00a0Gut\u00a0versorgt?\u00a0\u00d6konomie\u00a0und\u00a0Ethik\u00a0im\u00a0Gesun dheits\u2010\u00a0und\u00a0Pflegebereich.\u00a0Nomos.\u00a0S.\u00a057\u201073\u00a0\nG\u00f6tzsche\u00a0PC\u00a0(2014).\u00a0T\u00f6dliche\u00a0Psychopharmaka\u00a0und\u00a0organisiertes\u00a0L eugnen.\u00a0Riva\u00a0\nGoldacre\u00a0B\u00a0(2012).\u00a0Bad\u00a0Pharma.\u00a0How\u00a0drug\u00a0companies\u00a0mislead\u00a0docto rs\u00a0and\u00a0harm\u00a0patients.\u00a0Fourth\u00a0Estate.\u00a0London\u00a0 \n103\u00a0\n\u00a0Greiner\u00a0W,\u00a0Witte\u00a0J(2017).\u00a0\u00a0AMNOG\u2010Report\u00a02017.\u00a0Nutzenbewertung\u00a0v on\u00a0Arzneimitteln\u00a0in\u00a0Deutschland,\u00a0Heidelberg:\u00a0medhochzwei\u00a0\nVerlag\u00a0GmbH.\u00a0\nHoekman\u00a0J,\u00a0Boon\u00a0W,\u00a0Bouvy\u00a0J,\u00a0Ebbers\u00a0HC,\u00a0de\u00a0Jong\u00a0JP,\u00a0De\u00a0Bruin\u00a0ML\u00a0 (2015)\u00a0Use\u00a0of\u00a0the\u00a0conditional\u00a0marketing\u00a0authorization\u00a0pathway\u00a0\nfor\u00a0oncology\u00a0medicines\u00a0in\u00a0Europe ,\u00a0in:\u00a0Clinical\u00a0Pharmacology\u00a0&\u00a0T herapeutics\u00a098\u00a0(5)\u00a0534\u2013541.\u00a0\nHollis\u00a0S,\u00a0Campbell\u00a0F\u00a0(1999).\u00a0What\u00a0is\u00a0meant\u00a0by\u00a0intention\u00a0to\u00a0trea t\u00a0analysis?\u00a0Survey\u00a0of\u00a0published\u00a0 randomised\u00a0controlled\u00a0trials.\u00a0B ritish\u00a0\nMedical\u00a0Journal,\u00a0Vol.\u00a0319,\u00a0S.\u00a0670\u2010674.\u00a0\nIMS\u00a0Health\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0medizinische\u00a0Statistik\u00a0(Hrsg.):\u00a0Der\u00a0p harmazeutische\u00a0Markt\u00a0in\u00a0Deutschland,\u00a0Stand\u00a0der\u00a0Information:\u00a0\nDezember\u00a02019,\u00a0Frankfurt\u00a0a.\u00a0M.:\u00a0Im\u00a0Eigenverlag.\u00a0\nKoch\u00a0K\u00a0(2004)\u00a0Verschweigen\u00a0ist\u00a0Betrug.\u00a0Deutsches\u00a0\u00c4rzteblatt,\u00a0Jg .\u00a0101,\u00a0S.C1365.\u00a0\nLieb\u00a0K,\u00a0Klemperer\u00a0D,\u00a0K\u00f6lbel\u00a0R,\u00a0Ludwig\u00a0WD\u00a0(Hrsg)\u00a0(2018)\u00a0Interess enkonflikte,\u00a0Korruption\u00a0und\u00a0Compliance\u00a0im\u00a0Gesundheitswesen.\u00a0\nMed.Wiss.\u00a0Verlanganstalt,\u00a0Berlin.\u00a0\nLudwig,\u00a0Wolf\u2010Dieter/Schildmann,\u00a0Jan:\u00a0Kostenexplosion\u00a0in\u00a0der\u00a0med ikament\u00f6sen\u00a0Therapie\u00a0onkologischer\u00a0Erkrankungen,\u00a0in:\u00a0Der\u00a0\nOnkologe\u00a021\u00a0(2015)\u00a0708\u2013716.\u00a0\nMelander\u00a0H,\u00a0Ahlqvist\u2010Rastad\u00a0J,\u00a0Meijer\u00a0G,\u00a0Beermann\u00a0B\u00a0(2003):\u00a0Evi dence\u00a0b(i)ased\u00a0medicine\u00a0\u2013\u00a0sele ctive\u00a0reporting\u00a0from\u00a0studies\u00a0\nsponsored\u00a0by\u00a0pharmaceutical\u00a0indu stry:\u00a0review\u00a0of\u00a0studies\u00a0in\u00a0new\u00a0 drug\u00a0applications.\u00a0British\u00a0Medical\u00a0Journal,\u00a0Vol.\u00a0326,\u00a0\nS.\u00a01171\u20101175\u00a0\nPfaff\u00a0H,\u00a0Abholz\u00a0HH,\u00a0Glaeske\u00a0G,\u00a0 Icks\u00a0A,\u00a0Klinkhammer\u2010Schalke\u00a0M,\u00a0N ellessen\u2010Martens\u00a0G,\u00a0Neugebauer\u00a0EAM,\u00a0Ohmann\u00a0C,\u00a0Schrappe\u00a0M,\u00a0\nSelbmann\u00a0HK,\u00a0Stemmer\u00a0R\u00a0(2011)\u00a0Versorgungsforschung:\u00a0unverzichtb ar\u00a0bei\u00a0Allokationsentscheidungen.\u00a0Eine\u00a0\nStellungnahme,\u00a0in:\u00a0Deutsche\u00a0Medizinische\u00a0Wochenschrift\u00a0136:\u00a0249 6\u20132500.\u00a0\nSchneeweiss\u00a0S\u00a0(2001)\u00a0Pillen\u00a0auf\u00a0dem\u00a0Pr\u00fcfstand,\u00a0in:\u00a0Gesundheit\u00a0u nd\u00a0Gesellschaft\u00a04\u00a0(6)\u00a034\u201340.\u00a0\nWieseler\u00a0B,\u00a0McGauran\u00a0N,\u00a0Kaiser\u00a0T \u00a0(2019)\u00a0New\u00a0Drugs:\u00a0where\u00a0did\u00a0we \u00a0gor\u00a0wrong\u00a0and\u00a0what\u00a0can\u00a0we\u00a0do\u00a0better?\u00a0BMJ\u00a0366\u00a0\nWild\u00a0C,\u00a0Piso\u00a0B\u00a0(Hg)\u00a0(2010)\u00a0Zahlenspiele\u00a0in\u00a0der\u00a0Medizin.\u00a0Orac,\u00a0W ien.\u00a0\nWille\u00a0E\u00a0(2002)\u00a0Steuerungsinstrumente\u00a0der\u00a0Arzneimittelausgaben,\u00a0 in:\u00a0Wille\u00a0E,\u00a0Albring\u00a0M\u00a0(Hg.):\u00a0Konfliktfeld\u00a0Arzneimittelversorgu ng,\u00a0\nFrankfurt:\u00a0Lang,\u00a035\u201347.\u00a0\nWindeler\u00a0J,\u00a0Antes\u00a0G\u00a0(2001)\u00a0Efficacy\u00a0und\u00a0Effectiveness.\u00a0Z.\u00a0\u00e4rztl .\u00a0Fortbild.Qual.Sich.\u00a095:153\u2010155\u00a0\nUjeyl\u00a0M,\u00a0Schlegel\u00a0C,\u00a0Walter\u00a0S,\u00a0Gundert\u2010Remy\u00a0U\u00a0(2012)\u00a0New\u00a0drugs: \u00a0\u00a0\u00a0evidence\u00a0relating\u00a0to\u00a0their\u00a0therapeutic\u00a0value\u00a0after\u00a0introduct ion\u00a0\nto\u00a0the\u00a0market.\u00a0Dtsch\u00a0Arztebl\u00a0Int\u00a0109(7):\u00a0117\u201323.\u00a0DOI:\u00a010.3238/a rztebl.2012.0117\u00a02.\u00a0\n\u00a0 \t \n104\u00a0\n\u00a0\u00a0 \u00a0 \n105\u00a0\n\u00a06 Bestehende\u00a0L\u00f6sungsstrategien\u00a0aus\u00a0anderen\u00a0Gesundheitssystemen\u00a0\u00a0\n Frankreich\u00a06.1\nDas\u00a0Preis\u2010\u00a0und\u00a0Erstattungssystem\u00a0Frankreichs\u00a0wird\u00a0im\u00a0Folgenden\u00a0 ausf\u00fchrlicher\u00a0\nbeschrieben,\u00a0da\u00a0Vorschl\u00e4ge\u00a0zur\u00a0Reform\u00a0des\u00a0Preissystems\u00a0in\u00a0Deuts chland\u00a0in\u00a0der\u00a0\nDebatte\u00a0um\u00a0hochpreisige\u00a0onkologis che\u00a0Arzneimittel\u00a0oft\u00a0nach\u00a0Fran kreich\u00a0als\u00a0Bei\u2010\nspiel\u00a0f\u00fcr\u00a0eine\u00a0sinnvolle\u00a0Pre issetzungspraxis\u00a0verweisen.\u00a0\nSeit\u00a01994\u00a0schlie\u00dft\u00a0der\u00a0franz\u00f6sische\u00a0Staat\u00a0vertreten\u00a0durch\u00a0das\u00a0 Comit\u00e9\u00a0Economique\u00a0\ndes\u00a0Produits\u00a0de\u00a0la\u00a0Sant\u00e9 \u00a0(CEPS)\u00a0mit\u00a0der\u00a0pharmazeutischen\u00a0Industrie\u00a0Frankreichs\u00a0\nRahmenvertr\u00e4ge\u00a0 (Accord\u00a0Cadre)\u00a0ab,\u00a0die\u00a0die\u00a0Verfahren\u00a0und\u00a0Bedingungen\u00a0der\u00a0Preis\u2010\nsetzung\u00a0und\u00a0\u2010revision\u00a0bei\u00a0Arzneimitteln\u00a0im\u00a0ambulanten\u00a0und\u00a0stati on\u00e4ren\u00a0Bereich\u00a0\nregeln.\u00a0\u00a0\nIn\u00a0Frankreich\u00a0sind\u00a0das\u00a0Niveau\u00a0des \u00a0therapeutischen\u00a0Zusatznutzens \u00a0eines\u00a0Arzneimit\u2010\ntels,\u00a0das\u00a0durch\u00a0die\u00a0 Commission\u00a0de\u00a0la\u00a0Transparence\u00a0(CT)\u00a0 der\u00a0Haute\u00a0Autorit\u00e9\u00a0de\u00a0\nSant\u00e9\u00a0(HAS) ,\u00a0des\u00a0franz\u00f6sischen\u00a0\u00c4quivalents\u00a0zum\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0W irt\u2010\nschaftlichkeit\u00a0im\u00a0Gesundheitswesen\u00a0(IQWiG)\u00a0festgelegt\u00a0wird,\u00a0und \u00a0der\u00a0Zulassungs\u2010\nweg\u00a0entscheidend\u00a0f\u00fcr\u00a0das\u00a0Verfahren\u00a0der\u00a0Preisfestsetzung\u00a0f\u00fcr\u00a0Arz neimittel\u00a0in\u00a0der\u00a0\nambulanten\u00a0Versorgung.\u00a0Zun\u00e4chst\u00a0wird\u00a0in\u00a0diesem\u00a0Zusammenhang\u00a0die \u00a0grunds\u00e4tzli\u2010\nche\u00a0Entscheidung\u00a0zur\u00a0Kostenerstattung\u00a0getroffen.\u00a0Dann\u00a0erst\u00a0wird \u00a0bei\u00a0einer\u00a0gege\u2010\nbenen\u00a0Wirksamkeit\u00a0der\u00a0niedrigst\u00a0 m\u00f6gliche\u00a0Preis\u00a0ausgehandelt.\u00a0Im \u00a0Falle\u00a0von\u00a0inno\u2010\nvativen\u00a0 Arzneimitteln\u00a0 finden\u00a0 alle rdings\u00a0 keine\u00a0 Preisverhandlunge n\u00a0 statt.\u00a0 Unter\u2010\nnehmen\u00a0k\u00f6nnen\u00a0ihre\u00a0Preise\u00a0frei\u00a0festsetzen,\u00a0m\u00fcssen\u00a0sich\u00a0in\u00a0der\u00a0P reissetzung\u00a0aber\u00a0\nan\u00a0den\u00a0Preisen\u00a0in\u00a0den\u00a0gro\u00dfen\u00a0Arzneimittelm\u00e4rkten\u00a0der\u00a0Europ\u00e4isch en\u00a0Union\u00a0und\u00a0an\u00a0\nden\u00a0Preisen\u00a0therapeutisch\u00a0\u00e4hnlicher\u00a0Produkte\u00a0orientieren.\u00a0Daneb en\u00a0m\u00fcssen\u00a0sie\u00a0\neinen\u00a0\u00dcberblick\u00a0\u00fcber\u00a0den\u00a0Umsatz\u00a0v orlegen,\u00a0der\u00a0f\u00fcr\u00a0die\u00a0Indikatio nen\u00a0erwartet\u00a0wird,\u00a0\nf\u00fcr\u00a0die\u00a0das\u00a0Arzneimittel\u00a0zugelassen\u00a0wurde.\u00a0\u00a0\nBewertungsschritte\u00a0und\u00a0\u2010verfahren\u00a0\nDie\u00a0Bewertung\u00a0der\u00a0CT\u00a0bildet\u00a0die\u00a0Entscheidungsgrundlage\u00a0zur\u00a0Fest setzung\u00a0der\u00a0Kos\u2010\ntenerstattung\u00a0innerhalb\u00a0der\u00a0Krankenversicherung\u00a0und\u00a0der\u00a0Preise\u00a0 f\u00fcr\u00a0das\u00a0jeweilige\u00a0\nArzneimittel.\u00a0Die\u00a0HAS\u00a0nutzt\u00a0ein\u00a0 Bewertungs\u2010\u00a0und\u00a0Klassifikations system,\u00a0das\u00a0den\u00a0\nService\u00a0Medical\u00a0Rendu \u00a0(SMR)\u00a0zugrunde\u00a0legt.\u00a0Die\u00a0Skala\u00a0des\u00a0SMR\u00a0reicht\u00a0von\u00a0wesent\u2010\nlich\u00a0oder\u00a0erheblich,\u00a0zu\u00a0\u00fcberm\u00e4\u00dfig\u00a0und\u00a0gering\u00a0bis\u00a0insuffizient.\u00a0 Der\u00a0SMR\u00a0eines\u00a0Arz\u2010\nneimittels\u00a0wird\u00a0alle\u00a0vier\u00a0Jahre\u00a0 neu\u00a0ermittelt.\u00a0Die\u00a0Re\u2010Evaluieru ng\u00a0kann\u00a0in\u00a0eine\u00a0\u00c4nde\u2010\nrung\u00a0der\u00a0Erstattungsrate\u00a0bzw.\u00a0der\u00a0Patientenzuzahlungsrate\u00a0resul tieren.\u00a0Die\u00a0Einstu\u2010\nfung\u00a0des\u00a0SMR\u00a0legt\u00a0zusammen\u00a0mit\u00a0dem\u00a0Schweregrad\u00a0der\u00a0Erkrankung\u00a0d en\u00a0Anteil\u00a0der\u00a0\n\u00f6ffentlichen\u00a0Kosten\u00fcbernahme\u00a0und\u00a0damit\u00a0die\u00a0erforderliche\u00a0Zuzahl ung\u00a0durch\u00a0Pati\u2010 \n106\u00a0\n\u00a0enten\u00a0fest.\u00a0Ein\u00a0Arzneimittel\u00a0mit\u00a0einem\u00a0SMR\u00a0IV\u00a0(siehe\u00a0Tabelle\u00a06. 1)\u00a0zur\u00a0Behandlung\u00a0\neiner\u00a0Bagatellerkrankung\u00a0wird\u00a0z.\u00a0B.\u00a0nicht\u00a0erstattet.\u00a0\nDie\u00a0Kriterien\u00a0zur\u00a0Festlegung\u00a0des\u00a0SMR\u00a0sind\u00a0\n\uf0b7 Wirksamkeit\u00a0( efficacy)/Toxizit\u00e4t\u00a0\n\uf0b7 Existierende\u00a0Behandlungsalternativen\u00a0\n\uf0b7 Platz\u00a0in\u00a0der\u00a0Behandlungsstrategie\u00a0(Erstlinientherapie,\u00a0Zweitlin ienthe\u2010\nrapie\u00a0etc.)\u00a0\nAus\u00a0der\u00a0Praxis\u00a0der\u00a0Kommission\u00a0hat\u00a0sich\u00a0das\u00a0zus\u00e4tzliche\u00a0Bewertun gskriterium\u00a0\u201eInte\u2010\nresse\u00a0f\u00fcr\u00a0die\u00a0\u00f6ffentliche\u00a0Gesundheit\u201c\u00a0entwickelt,\u00a0das\u00a0\u00a0\n\uf0b7 die\u00a0Schwere\u00a0der\u00a0Erkrankung,\u00a0\n\uf0b7 das\u00a0Ausma\u00df\u00a0des\u00a0Effekts\u00a0bzw.\u00a0die\u00a0G r\u00f6\u00dfe\u00a0des\u00a0positiven\u00a0Unterschied s,\u00a0\n\uf0b7 die\u00a0Wirksamkeit\u00a0( effectiveness )\u00a0und\u00a0das\u00a0Nebenwirkungsprofil,\u00a0\n\uf0b7 die\u00a0Auswirkung\u00a0auf\u00a0das\u00a0Gesundheitssystem\u00a0als\u00a0Ganzes\u00a0\n\uf0b7 die\u00a0Auswirkungen\u00a0auf\u00a0die\u00a0Gesundheit\u00a0der\u00a0Bev\u00f6lkerung\u00a0(Schlie\u00dft\u00a0d ie\u00a0\nArzneimitteltherapie\u00a0eine\u00a0Bedarfsl\u00fccke?\u00a0Gibt\u00a0es\u00a0ein\u00a0verl\u00e4sslich es\u00a0Kri\u2010\nterium\u00a0durch\u00a0das\u00a0eine\u00a0Zielpopulation\u00a0definiert\u00a0werden\u00a0kann?)\u00a0\nber\u00fccksichtigt.\u00a0\u00a0\nDas\u00a0Comit\u00e9\u00a0Economique\u00a0des\u00a0Produits\u00a0de\u00a0Sant\u00e9, \u00a0angesiedelt\u00a0im\u00a0Wirtschaftsministe\u2010\nrium,\u00a0orientiert\u00a0sich\u00a0in\u00a0den\u00a0Pre isverhandlungen\u00a0an\u00a0den\u00a0Verbesse rungen\u00a0des\u00a0medi\u2010\nzinischen\u00a0Nutzens\u00a0 (Am\u00e9lioration\u00a0du\u00a0Service\u00a0M\u00e9dical\u00a0Rendu,\u00a0ASMR), \u00a0die\u00a0durch\u00a0die\u00a0\nCT\u00a0ermittelt\u00a0wurden.\u00a0Ausschlagge bend\u00a0bei\u00a0der\u00a0Bewertung\u00a0ist\u00a0die\u00a0 Bedeutung\u00a0des\u00a0\nneuen\u00a0Arzneimittels\u00a0in\u00a0der\u00a0bisherigen\u00a0therapeutischen\u00a0Strategie .\u00a0Diese\u00a0Verbesse\u2010\nrungen\u00a0werden\u00a0auf\u00a0einer\u00a0Skala\u00a0vo n\u00a0eins\u00a0bis\u00a0f\u00fcnf\u00a0eingeordnet:\u00a0\nTabelle\u00a06.1:\u00a0Niveaus\u00a0der\u00a0Verbesse rung\u00a0des\u00a0therapeutischen\u00a0Nutze ns\u00a0\nNiveau\u00a0\nder\u00a0\nVerbesse\u2010\nrung\u00a0des\u00a0\ntherapeu\u2010\ntischen\u00a0\nNutzens\u00a0\n(ASMR)\u00a0I\u00a0 II\u00a0 III\u00a0 IV\u00a0 V\u00a0\nWesentlicher\u00a0\ntherapeutischer\u00a0\nFortschritt\u00a0Wichtige\u00a0\nVerbesserung\u00a0i.\u00a0\nS.\u00a0von\u00a0Wirksamkeit\u00a0\n(efficacy),\u00a0oder\u00a0\nweniger\u00a0Neben\u2010\nwirkungen\u00a0\n\u00a0Bedeutende\u00a0\nVerbesserung\u00a0Unwesentliche\u00a0\nVerbesserung,\u00a0aber\u00a0\ngeringere\u00a0Behandlungskosten\u00a0\u00a0keine\u00a0\nVerbesserung,\u00a0\naber\u00a0weniger\u00a0\nKosten\u00a0\u00a0\nQuelle:\u00a0PPRI,\u00a02008\u00a0\n\u00a0 \u00a0 \n107\u00a0\n\u00a0Preisfestlegung\u00a0\nDer\u00a0Rahmenvertrag\u00a0zwischen\u00a0CEPS\u00a0und\u00a0der\u00a0pharmazeutischen\u00a0Indust rie\u00a0garantiert\u00a0\nf\u00fcr\u00a0Arzneimittel\u00a0mit\u00a0einem\u00a0ASMR\u00a0I\u2010III\u00a0f\u00fcr\u00a0die\u00a0ersten\u00a0f\u00fcnf\u00a0Jahre \u00a0ab\u00a0dem\u00a0Zeitpunkt\u00a0\nihrer\u00a0Zulassung\u00a0zum\u00a0Erstattungskatalog\u00a0einen\u00a0stabilen\u00a0Preis.\u00a0Da s\u00a0Unternehmen\u00a0\nschl\u00e4gt\u00a0in\u00a0diesem\u00a0Fall\u00a0dem\u00a0CEPS\u00a0einen\u00a0Preis\u00a0vor,\u00a0der\u00a0sich\u00a0an\u00a0de m\u00a0in\u00a0den\u00a0vier\u00a0gr\u00f6\u00df\u2010\nten\u00a0Arzneimittelm\u00e4rkten\u00a0in\u00a0der\u00a0Eu rop\u00e4ischen\u00a0Union\u00a0(Deutschland, \u00a0Spanien,\u00a0Italien\u00a0\nund\u00a0Gro\u00dfbritannien)\u00a0geltenden\u00a0Preisen\u00a0orientieren\u00a0muss.\u00a0Preis\u00e4n derungen\u00a0in\u00a0den\u00a0\nvier\u00a0Referenzl\u00e4ndern\u00a0f\u00fchren\u00a0zu\u00a0Anpassungen\u00a0der\u00a0Arzneimittelprei se\u00a0in\u00a0Frankreich.\u00a0\nDas\u00a0CEPS\u00a0hat\u00a015\u00a0Tage\u00a0Zeit,\u00a0um\u00a0gegen\u00a0den\u00a0vom\u00a0Hersteller\u00a0vorgesch lagenen\u00a0Preis\u00a0\nEinspruch\u00a0zu\u00a0erheben.\u00a0\u00a0\nF\u00fcr\u00a0Arzneimittel,\u00a0die\u00a0an\u00a0Kindern\u00a0nach\u00a0einem\u00a0mit\u00a0der\u00a0Zulassungsb eh\u00f6rde\u00a0abge\u2010\ns t i m m t e n \u00a0P r \u00fc f p l a n \u00a0g e t e s t e t \u00a0w u r d e n , \u00a0v e r l \u00e4 n g e r t \u00a0s i c h \u00a0d i e \u00a0P r e i s s t a bilit\u00e4t\u00a0 um\u00a0 ein\u00a0\nzus\u00e4tzliches\u00a0Jahr.\u00a0Die\u00a0Garantie\u00a0 der\u00a0Preisstabilit\u00e4t\u00a0kann\u00a0f\u00fcr\u00a0Ar zneimittel\u00a0nach\u00a0Indika\u2010\ntionserweiterung\u00a0mit\u00a0einem\u00a0ASMR\u00a0I\u2010III\u00a0verl\u00e4ngert\u00a0werden.\u00a0F\u00fcr\u00a0Ar zneimittel\u00a0mit\u00a0\neiner\u00a0Indikationserweiterung\u00a0mit\u00a0einem\u00a0ASMR\u00a0IV\u00a0und\u00a0V,\u00a0bzw.\u00a0eine r\u00a0tempor\u00e4ren\u00a0\nZulassung\u00a0kann\u00a0sich\u00a0die\u00a0Dauer\u00a0der \u00a0Garantie\u00a0hingegen\u00a0verk\u00fcrzen.\u00a0 Durch\u00a0die\u00a0Indika\u2010\ntionserweiterung\u00a0wird\u00a0ein\u00a0gr\u00f6\u00dfer es\u00a0Volumen\u00a0umgesetzt,\u00a0das\u00a0durch \u00a0eine\u00a0entspre\u2010\nchende\u00a0Preisanpassung\u00a0ausgegliche n\u00a0wird.\u00a0Dabei\u00a0kann\u00a0ein\u00a0therape utischer\u00a0Zuge\u2010\nwinn\u00a0eine\u00a0Verl\u00e4ngerung\u00a0rechtfertigen.\u00a0\nTabelle\u00a06.2:\u00a0Procedere\u00a0der\u00a0Preisfindung\u00a0in\u00a0Frankreich\u00a0\nVerfahren\u00a0 Kategorie\u00a0des\u00a0Arzneimittels\u00a0 Kriterium\u00a0\nPreisregistrierung\u00a0durch\u00a0das\u00a0\npharmazeutische\u00a0Unternehmen\u00a0\nmit\u00a0Einspruchsm\u00f6glichkeit\u00a0durch\u00a0\ndas\u00a0CEPS\u00a0Innovative\u00a0erstattungsf\u00e4hige\u00a0\nArzneimittel\u00a0in\u00a0der\u00a0ambulanten\u00a0\nVersorgung\u00a0\n\u00a0\n(Arzneimittel\u00a0mit\u00a0einem\u00a0ASMR\u00a0I,\u00a0\nII\u00a0oder\u00a0III,\u00a0Arzneimittel\u00a0f\u00fcr\u00a0\nseltene\u00a0Erkrankungen,\u00a0f\u00fcr\u00a0\nKinder)\u00a0Koh\u00e4renz\u00a0mit\u00a0Preisen\u00a0in\u00a0anderen\u00a0\neurop\u00e4ischen\u00a0L\u00e4ndern\u00a0\n(Deutschland,\u00a0Gro\u00dfbritannien,\u00a0\nItalien,\u00a0Spanien)\u00a0\nArzneimittel\u00a0mit\u00a0einer\u00a0\ntempor\u00e4ren\u00a0Zulassung\u00a0\nPreisfestlegung\u00a0durch\u00a0das\u00a0CEPS\u00a0Erstattungsf\u00e4hige\u00a0Arzneimittel\u00a0\nmit\u00a0wenig\u00a0oder\u00a0keinem\u00a0\ntherapeutischen\u00a0Zusatznutzen\u00a0\n(ASMR\u00a0IV,\u00a0V)\u00a0Gesch\u00e4tzte\u00a0Nachfrage\u00a0\nPreise\u00a0von\u00a0Vergl eichsprodukten\u00a0\nKeine\u00a0Preisregulierung\u00a0Nicht\u2010erstattungsf\u00e4hige\u00a0\nArzneimittel\u00a0in\u00a0der\u00a0ambulanten\u00a0\nVersorgung\u00a0\u00a0\nQuelle:\u00a0PHIS,\u00a02011 \u00a0 \n108\u00a0\n\u00a0Preis\u2010Volumen\u2010Abkommen\u00a0\nDas\u00a0CEPS\u00a0und\u00a0die\u00a0Industrie\u00a0beschlie\u00dfen\u00a0nach\u00a0Vereinbarung\u00a0des\u00a0Pr eises\u00a0zus\u00e4tzliche\u00a0\nPreis\u2010Volumen\u2010Abkommen.\u00a0Diese\u00a0Abk ommen\u00a0kontrollieren\u00a0den\u00a0Umsatz \u00a0der\u00a0In\u2010\ndustrie\u00a0anhand\u00a0des\u00a0Verkaufsvolumens,\u00a0der\u00a0Kosten\u00a0der\u00a0t\u00e4glichen\u00a0A rzneimitteldosen\u00a0\noder\u00a0der\u00a0Dosierung.\u00a0In\u00a0diesen\u00a0Vereinbarungen\u00a0definieren\u00a0CEPS\u00a0un d\u00a0das\u00a0jeweilige\u00a0\nUnternehmen\u00a0den\u00a0Umfang\u00a0der\u00a0R\u00fcckz ahlungen,\u00a0die\u00a0das\u00a0Unternehmen\u00a0a n\u00a0die\u00a0Zent\u2010\nrale\u00a0Agentur\u00a0der\u00a0Sozialversicherungsorganisationen\u00a0leisten\u00a0muss ,\u00a0wenn\u00a0die\u00a0erwar\u2010\nteten\u00a0Volumina\u00a0\u00fcberschritten\u00a0wurden.\u00a0Die\u00a0R\u00fcckzahlungen\u00a0werden\u00a0u .\u00a0a.\u00a0auf\u00a0Ebene\u00a0\nder\u00a0Produkte\u00a0und\u00a0auf\u00a0Ebene\u00a0der\u00a0therapeutischen\u00a0Klassen\u00a0errechne t.\u00a0Arzneimittel\u00a0\nmit\u00a0einem\u00a0ASMR\u00a0I\u2010III\u00a0fallen\u00a0in\u00a0den\u00a0ersten\u00a0zwei\u00a0Jahren\u00a0nach\u00a0ihre r\u00a0Marktzulassung\u00a0\nnicht\u00a0unter\u00a0die\u00a0Rabattregelung.\u00a0Der\u00a0Regelung\u00a0liegt\u00a0die\u00a0Annahme\u00a0 zugrunde,\u00a0dass\u00a0\nein\u00a0Produkt\u00a0nur\u00a0in\u00a0den\u00a0ersten\u00a0ein\u00a0bis\u00a0zwei\u00a0Jahren\u00a0nach\u00a0Marktzul assung\u00a0eine\u00a0Inno\u2010\nvation\u00a0darstellt.\u00a0\nR\u00fcckzahlungen\u00a0auf\u00a0Ebene\u00a0der\u00a0Produkte:\u00a0Preisrevisionsklauseln\u00a0\nIn\u00a0Frankreich\u00a0gibt\u00a0es\u00a0zwei\u00a0unterschiedliche\u00a0Ma\u00dfst\u00e4be,\u00a0die\u00a0zur\u00a0P reisrevision\u00a0f\u00fchren\u00a0\nk\u00f6nnen:\u00a0die\u00a0t\u00e4glichen\u00a0Therapiekosten\u00a0und\u00a0das\u00a0Umsatzvolumen.\u00a0Die \u00a0Anbindung\u00a0\neiner\u00a0Preisrevision\u00a0an\u00a0die\u00a0t\u00e4gli chen\u00a0Therapiekosten\u00a0soll\u00a0garant ieren,\u00a0dass\u00a0die\u00a0rea\u2010\nlen\u00a0Kosten\u00a0der\u00a0Arzneimittelanwendung\u00a0pro\u00a0Patient\u00a0auf\u00a0dem\u00a0Niveau \u00a0bleiben,\u00a0das\u00a0\nzwischen\u00a0Unternehmen\u00a0und\u00a0CEPS\u00a0vereinbart\u00a0wurde.\u00a0Durch\u00a0die\u00a0\u00dcberw achung\u00a0der\u00a0\ngesamten\u00a0Ausgaben\u00a0der\u00a0Krankenvers icherung\u00a0f\u00fcr\u00a0ein\u00a0Arzneimittel\u00a0 soll\u00a0gesichert\u00a0\nwerden,\u00a0dass\u00a0die\u00a0Ausgaben\u00a0konform \u00a0mit\u00a0den\u00a0Zielgebungen\u00a0bleiben, \u00a0die\u00a0zwischen\u00a0\nCEPS\u00a0und\u00a0Unternehmen\u00a0gesetzt\u00a0wurden.\u00a0\u00a0\nR\u00fcckzahlungen\u00a0auf\u00a0Ebene\u00a0therapeutischer\u00a0Klassen\u00a0\nBei\u00a0dieser\u00a0Variante\u00a0teilt\u00a0die\u00a0CEPS\u00a0den\u00a0Arzneimittelmarkt\u00a0in\u00a0the rapeutische\u00a0Klassen.\u00a0\nF\u00fcr\u00a0jede\u00a0dieser\u00a0Klassen\u00a0werden\u00a0w\u00fcnschenswerte\u00a0Evolutionsraten\u00a0e rrechnet,\u00a0bei\u00a0\nderen\u00a0\u00dcberschreitung\u00a0die\u00a0Unternehmen\u00a0Rabatte\u00a0an\u00a0die\u00a0Sozialversi cherung\u00a0zahlen\u00a0\nm\u00fcssen.\u00a0Die\u00a0Rabatte\u00a0werden\u00a0verteilt\u00a0auf\u00a0die\u00a0Unternehmen,\u00a0die\u00a0ei n\u00a0Produkt\u00a0in\u00a0\ndieser\u00a0Klasse\u00a0vermarkten:\u00a065\u00a0%\u00a0de r\u00a0Rabatte\u00a0m\u00fcssen\u00a0Unternehmen\u00a0i m\u00a0Verh\u00e4ltnis\u00a0zu\u00a0\nihrem\u00a0Umsatz\u00a0zahlen,\u00a0die\u00a0ein\u00a0Pro dukt\u00a0in\u00a0dieser\u00a0Klasse\u00a0vermarkte n.\u00a035\u00a0%\u00a0der\u00a0Ra\u2010\nbattzahlungen\u00a0m\u00fcssen\u00a0von\u00a0den\u00a0Unternehmen\u00a0geleistet\u00a0werden,\u00a0die\u00a0 die\u00a0vereinbar\u2010\nte\u00a0Evolutionsrate\u00a0\u00fcberschritten\u00a0haben.\u00a0\u00a0\nVorlage\u00a0weiterer\u00a0Studien\u00a0\nDie\u00a0Abkommen\u00a0zwischen\u00a0dem\u00a0CEPS\u00a0und\u00a0der\u00a0Industrie\u00a0k\u00f6nnen\u00a0vertrag liche\u00a0Bindung\u00a0\nder\u00a0Industrie\u00a0vorsehen,\u00a0weitere\u00a0Studien\u00a0durchzuf\u00fchren.\u00a0Dies\u00a0kan n\u00a0eingefordert\u00a0\nwerden,\u00a0wenn\u00a0das\u00a0Arzneimittel\u00a0zur\u00a0Anwendung\u00a0in\u00a0einer\u00a0gro\u00dfen\u00a0Bev \u00f6lkerungs\u2010\ngruppe\u00a0bestimmt\u00a0ist,\u00a0wenn\u00a0es\u00a0au\u00dferhalb\u00a0der\u00a0zugelassenen\u00a0Indikat ion\u00a0verschrieben\u00a0 \n109\u00a0\n\u00a0werden\u00a0kann\u00a0oder\u00a0wenn\u00a0die\u00a0Anwendung\u00a0des\u00a0Arzneimittels\u00a0wesentlic he\u00a0Auswir\u2010\nkung\u00a0auf\u00a0die\u00a0finanzielle\u00a0Lage\u00a0de r\u00a0gesetzlichen\u00a0Krankenversicher ung\u00a0hat.\u00a0Die\u00a0Me\u2010\nthode\u00a0solcher\u00a0Nachmarktstudien\u00a0v.a.\u00a0bez\u00fcglich\u00a0der\u00a0Datengrundlag e\u00a0und\u00a0der\u00a0politi\u2010\nschen\u00a0Konsequenzen\u00a0f\u00fcr\u00a0die\u00a0Preis\u2010\u00a0und\u00a0Erstattungsentscheidungen \u00a0war\u00a0Gegen\u2010\nstand\u00a0intensiver\u00a0Diskussionen.\u00a0\u00a0\nDie\u00a0hohen\u00a0Arzneimittelkosten\u00a0in\u00a0der\u00a0Krebsbehandlung\u00a0sind\u00a0auch\u00a0B estandteil\u00a0der\u00a0\nDebatte\u00a0in\u00a0Frankreich.\u00a0In\u00a0Frankreich\u00a0sind\u00a0innovative\u00a0Therapien\u00a0 f\u00fcr\u00a0alle\u00a0Patienten\u00a0\ngrunds\u00e4tzlich\u00a0zug\u00e4nglich.\u00a0Grundprinzip\u00a0des\u00a0franz\u00f6sischen\u00a0Sozial versicherungssys\u2010\ntems\u00a0ist\u00a0gerade\u00a0die\u00a0Kosten\u00fcbernahme\u00a0f\u00fcr\u00a0teure\u00a0Therapien.\u00a0Schwer e\u00a0chronische\u00a0\nErkrankungen\u00a0wie\u00a0Krebs\u00a0werden\u00a0in\u00a0Frankreich\u00a0zu\u00a0100\u00a0%\u00a0von\u00a0der\u00a0ge setzlichen\u00a0Kran\u2010\nkenversicherung\u00a0getragen.\u00a0Mit\u00a0Blick\u00a0auf\u00a0die\u00a0hohen\u00a0Preise\u00a0und\u00a0Ko sten\u00a0und\u00a0der\u00a0\nwachsenden\u00a0Anzahl\u00a0der\u00a0Patienten\u00a0in\u00a0dieser\u00a0Erstattungsklasse\u00a0ist \u00a0angedacht,\u00a0Arz\u2010\nneimittel,\u00a0die\u00a0momentan\u00a0im\u00a0Rahmen\u00a0der\u00a0Versorgung\u00a0chronischer\u00a0Er krankungen\u00a0zu\u00a0\n100\u00a0%\u00a0erstattet\u00a0werden,\u00a0nur\u00a0noch\u00a0zu\u00a035\u00a0%\u00a0zu\u00a0erstatten\u00a0und\u00a0die\u00a0D ifferenz\u00a0zwischen\u00a0\nder\u00a0Erstattungsgrenze\u00a0und\u00a0dem\u00a0Preis\u00a0durch\u00a0eine\u00a0Zusatzversicheru ng\u00a0abzudecken.\u00a0\nEine\u00a0Antwort\u00a0auf\u00a0die\u00a0steigenden\u00a0Arzneimittelkosten\u00a0durch\u00a0patent ierte\u00a0Arzneimittel\u00a0\nist\u00a0eine\u00a0Verschiebung\u00a0der\u00a0Zuzah lungsgrenze\u00a0auf\u00a0Grundlage\u00a0des\u00a0th erapeutischen\u00a0\nWertes\u00a0eines\u00a0Arzneimittels.\u00a0Die\u00a0HAS\u00a0hat\u00a0ihre\u00a0erweiterte\u00a0Kompete nz\u00a0im\u00a0Bereich\u00a0der\u00a0\nGesundheits\u00f6konomie\u00a0genutzt\u00a0und\u00a0eine\u00a0Kommission\u00a0zur\u00a0gesundheits \u00f6konomischen\u00a0\nBewertung\u00a0eingerichtet.\u00a0Das\u00a0CEPS\u00a0wird\u00a0sich\u00a0zuk\u00fcnftig\u00a0in\u00a0den\u00a0Pre isverhandlungen\u00a0mit\u00a0\nder\u00a0 Industrie\u00a0 auf\u00a0 die\u00a0 gesundheits\u00f6konomischen\u00a0 Bewertungen\u00a0 bezie hen\u00a0 k\u00f6nnen.\u00a0\nDurch\u00a0den\u00a0institutionellen\u00a0Kontext\u00a0in\u00a0Frankreich,\u00a0in\u00a0dem\u00a0die\u00a0Pr eisentscheidung\u00a0durch\u00a0\ndas\u00a0CEPS\u00a0der\u00a0Evaluierung\u00a0durch\u00a0die\u00a0HAS\u00a0nachgeschaltet\u00a0ist,\u00a0sche int\u00a0eine\u00a0gesund\u2010\nheits\u00f6konomische\u00a0 Bewertung\u00a0 als\u00a0 H\u00fcrde\u00a0 zur\u00a0 Erstattungsf\u00e4higkeit\u00a0 a llerdings\u00a0 eher\u00a0\nunwahrscheinlich.\u00a0\u00a0\n Belgien\u00a06.2\nIn\u00a0Belgien\u00a0unterliegen\u00a0alle\u00a0verschreibungspflichtigen\u00a0Arzneimit tel\u00a0Preiskontrollen.\u00a0\nDie\u00a0Antr\u00e4ge\u00a0zur\u00a0Erstattungsf\u00e4higkeit\u00a0werden\u00a0beim\u00a0Wirtschaftsmin isterium\u00a0einge\u2010\nreicht,\u00a0die\u00a0dort\u00a0von\u00a0der\u00a0 Commission\u00a0des\u00a0Prix\u00a0des\u00a0Sp\u00e9cialit\u00e9s\u00a0Pharmaceutiques \u00a0be\u2010\narbeitet\u00a0werden.\u00a0Das\u00a0Wirtschaftsministerium\u00a0setzt\u00a0einen\u00a0H\u00f6chstp reis\u00a0fest,\u00a0auf\u00a0den\u00a0\nsich\u00a0 die\u00a0 sp\u00e4teren\u00a0 Erstattungsverhandlungen\u00a0 zwischen\u00a0 dem\u00a0 pharmaz eutischen\u00a0\nUnternehmer\u00a0und\u00a0der\u00a0zust\u00e4ndigen\u00a0Institution\u00a0beziehen.\u00a0Dieser\u00a0H\u00f6 chstpreis\u00a0wird\u00a0\nauf\u00a0Basis\u00a0eines\u00a0Vergleichs\u00a0mit\u00a0 ex\u2010factory \u00a0Preisen\u00a0in\u00a0anderen\u00a0europ\u00e4ischen\u00a0Staaten,\u00a0\nauf\u00a0Basis\u00a0der\u00a0Preise\u00a0\u00e4hnlicher\u00a0Produkte\u00a0in\u00a0Belgien,\u00a0auf\u00a0Basis\u00a0d er\u00a0Personal\u2010,\u00a0Verwal\u2010\ntungs\u2010\u00a0und\u00a0indirekten\u00a0Kosten\u00a0des\u00a0 Herstellers\u00a0sowie\u00a0auf\u00a0Basis\u00a0se iner\u00a0Forschungs\u2010\u00a0\nund\u00a0Entwicklungskosten\u00a0festgelegt.\u00a0\u00a0 \n110\u00a0\n\u00a0Das\u00a0Entscheidungsverfahren\u00a0zur\u00a0Erstattungsf\u00e4higkeit\u00a0wird\u00a0von\u00a0de r\u00a0Commission\u00a0de\u00a0\nReimboursement\u00a0des\u00a0M\u00e9dicaments \u00a0(CRM)\u00a0des\u00a0In stitut\u00a0National\u00a0d\u2019Assurance\u00a0Mala\u2010\ndie\u00a0 et\u00a0 d\u2019Invalidit\u00e9 \u00a0 gehandhabt.\u00a0 Der\u00a0 Erstattungspreis\u00a0 patentierter\u00a0 Arzneimittel\u00a0\nrichtet\u00a0sich\u00a0nach\u00a0dem\u00a0zus\u00e4tzlichen\u00a0therapeutischen\u00a0Nutzen,\u00a0den\u00a0 die\u00a0CRM\u00a0feststellt,\u00a0\ner\u00a0darf\u00a0den\u00a0vom\u00a0Wirtschaftsministerium\u00a0festgelegten\u00a0H\u00f6chstpreis \u00a0aber\u00a0nicht\u00a0\u00fcber\u2010\nschreiten.\u00a0In\u00a0Belgien\u00a0gibt\u00a0es\u00a0zw ei\u00a0Klassen\u00a0von\u00a0Arzneimitteln.\u00a0I n\u00a0der\u00a0ersten\u00a0Klasse\u00a0\nwerden\u00a0Arzneimittel\u00a0mit\u00a0einem\u00a0th erapeutischen\u00a0Zusatznutzen\u00a0geli stet,\u00a0in\u00a0der\u00a0zwei\u2010\nten\u00a0Klasse\u00a0Arzneimittel\u00a0ohne\u00a0Zus atznutzen.\u00a0Die\u00a0Preise\u00a0der\u00a0Arzne imittel\u00a0in\u00a0der\u00a0ers\u2010\nten\u00a0Klasse\u00a0k\u00f6nnen\u00a0h\u00f6her\u00a0sein\u00a0als \u00a0die\u00a0Preise\u00a0\u00e4hnlicher\u00a0schon\u00a0zug elassener\u00a0Produkte,\u00a0\nwenn\u00a0ein\u00a0nachgewiesener\u00a0therapeutischer\u00a0Zusatznutzen\u00a0besteht.\u00a0\u00a0\nDer\u00a0Hersteller\u00a0schl\u00e4gt\u00a0einen\u00a0Erst attungspreis\u00a0vor,\u00a0der\u00a0von\u00a0der\u00a0 CRM\u00a0nach\u00a0folgenden\u00a0\nKriterien\u00a0beurteilt\u00a0wird:\u00a0\n1. therapeutischer\u00a0Wert\u00a0des\u00a0Arzneimittels,\u00a0\u00a0\n2. der\u00a0durch\u00a0das\u00a0Wirtschaftsminister ium\u00a0festgelegte\u00a0H\u00f6chstpreis,\u00a0\u00a0\n3. der\u00a0durch\u00a0den\u00a0Hersteller\u00a0vorgeschlagene\u00a0Erstattungspreis,\u00a0\n4. die\u00a0Bedeutung\u00a0des\u00a0Arzneimittels\u00a0f\u00fcr\u00a0den\u00a0therapeutischen\u00a0und\u00a0soz ia\u2010\nlen\u00a0Bedarf\u00a0in\u00a0der\u00a0medizinischen\u00a0Praxis,\u00a0\n5. Auswirkungen\u00a0auf\u00a0das\u00a0Budget\u00a0und\u00a0\n6. die\u00a0Kosten\u2010Effektivit\u00e4t.\u00a0\n\u00a0\nHersteller\u00a0sind\u00a0verpflichtet,\u00a0pharmako\u00f6konomische\u00a0Studien\u00a0einzu reichen,\u00a0um\u00a0die\u00a0\nH\u00f6he\u00a0des\u00a0Premiumpreises\u00a0zu\u00a0recht fertigen.\u00a0Laut\u00a0offizieller\u00a0Leit linien\u00a0sollen\u00a0Herstel\u2010\nler\u00a0die\u00a0Gesamtkosten,\u00a0Wirksamkei t,\u00a0Kosten\u2010Effektivit\u00e4tsverh\u00e4ltn isse\u00a0und\u00a0die\u00a0Ziel\u2010\npopulation\u00a0in\u00a0der\u00a0Bewertung\u00a0ihres \u00a0Arzneimittels\u00a0ber\u00fccksichtigte n.\u00a0\nDie\u00a0Entscheidung\u00a0zur\u00a0Erstattungsf \u00e4higkeit\u00a0wird\u00a0vom\u00a0Sozialminist erium\u00a0getroffen,\u00a0\ndas\u00a0auch\u00a0die\u00a0Erstattungskategorien\u00a0f\u00fcr\u00a0jedes\u00a0Arzneimittel\u00a0festl egt,\u00a0um\u00a0die\u00a0H\u00f6he\u00a0\nder\u00a0Zuzahlung\u00a0festzusetzen.\u00a0Das\u00a0Erstattungsniveau\u00a0kann\u00a0von\u00a030\u00a0% \u00a0f\u00fcr\u00a0therapeuti\u2010\nsche\u00a0Gruppen\u00a0wie\u00a0Spasmolytika,\u00a0Ar zneimittel\u00a0gegen\u00a0Migr\u00e4ne\u00a0oder\u00a0 orale\u00a0Verh\u00fc\u2010\ntungsmittel\u00a0bis\u00a0100\u00a0%\u00a0f\u00fcr\u00a0lebens rettende\u00a0Arzneimittel\u00a0liegen.\u00a0\nF\u00fcr\u00a0Arzneimittel,\u00a0bei\u00a0denen\u00a0eine\u00a0 Einordnung\u00a0in\u00a0die\u00a0erste\u00a0Arznei mittelklasse\u00a0erwar\u2010\ntet\u00a0wird,\u00a0wie\u00a0z.\u00a0B.\u00a0 Orphan\u00a0Drugs ,\u00a0kann\u00a0eine\u00a0vorgezogene\u00a0B ewertung\u00a0stattfinden.\u00a0\nDie\u00a0Bewertung\u00a0kann\u00a0beginnen,\u00a0sobald\u00a0das\u00a0 Committee\u00a0for\u00a0Human\u00a0Medicinal\u00a0Pro\u2010\nducts\u00a0(CHMP)\u00a0der\u00a0Europ\u00e4ischen\u00a0Arzneim ittelagentur\u00a0(EMA)\u00a0im\u00a0Rahmen\u00a0de s\u00a0zentra\u2010\nlen\u00a0Arzneimittelzulassungsverfahr ens\u00a0auf\u00a0europ\u00e4ischer\u00a0Ebene\u00a0ein e\u00a0positive\u00a0Bewer\u2010\ntung\u00a0abgegeben\u00a0hat.\u00a0\u00a0 \n111\u00a0\n\u00a0Bei\u00a0einer\u00a0Indikationserweiterung \u00a0findet\u00a0eine\u00a0Neubewertung\u00a0der\u00a0E rstattungsent\u2010\nscheidung\u00a0statt,\u00a0die\u00a0zu\u00a0einer\u00a0Ver \u00e4nderung\u00a0des\u00a0Erstattungspreise s\u00a0innerhalb\u00a0der\u00a0\ngesetzlichen\u00a0Krankenversicherung\u00a0f \u00fchren\u00a0kann.\u00a0Glivec\u00ae\u00a0z.\u00a0B.\u00a0wir d\u00a0als\u00a0ein\u00a0Arzneimit\u2010\ntel\u00a0f\u00fcr\u00a0seltene\u00a0Erkrankungen\u00a0in\u00a0Belgien\u00a0zum\u00a0vom\u00a0Wirtschaftsmini sterium\u00a0festge\u2010\nlegten\u00a0H\u00f6chstpreis\u00a0zu\u00a0100\u00a0%\u00a0erstattet.\u00a0\u00a0\nDie\u00a0Erfahrung\u00a0zeigt,\u00a0dass\u00a0die\u00a0Einteilung\u00a0in\u00a0die\u00a01.\u00a0Klasse,\u00a0die\u00a0 mit\u00a0der\u00a0Setzung\u00a0von\u00a0\nPremiumpreisen\u00a0verbunden\u00a0ist,\u00a0oft\u00a0nur\u00a0auf\u00a0Annahmen\u00a0zum\u00a0therapeu tischen\u00a0Nut\u2010\nzen\u00a0beruht.\u00a0In\u00a0solchen\u00a0F\u00e4llen\u00a0wird\u00a0eine\u00a0vorl\u00e4ufige\u00a0Preis\u2010\u00a0und\u00a0E rstattungsentschei\u2010\ndung\u00a0getroffen,\u00a0die\u00a0f\u00fcr\u00a0einen\u00a0Zeitraum\u00a0zwischen\u00a018\u00a0und\u00a036\u00a0Monat en\u00a0gilt.\u00a0Nach\u00a0der\u00a0\nEinteilung\u00a0in\u00a0die\u00a01.\u00a0Klasse\u00a0nach\u00a0Bewertung\u00a0durch\u00a0das\u00a0CRM\u00a0auf\u00a0Gr undlage\u00a0der\u00a0Krite\u2010\nrien\u00a0Wirksamkeit\u00a0( efficacy),\u00a0Sicherheit,\u00a0Anwendungsfreundlichkeit,\u00a0Anwendbarkeit\u00a0\nund\u00a0Wirksamkeit\u00a0in\u00a0der\u00a0Alltagsanwendung\u00a0listet\u00a0die\u00a0CRM\u00a0die\u00a0unbe kannten\u00a0Fakto\u2010\nren\u00a0der\u00a0Entscheidung\u00a0auf.\u00a0In\u00a0den\u00a0meisten\u00a0F\u00e4llen\u00a0betreffen\u00a0die\u00a0f ehlenden\u00a0Daten\u00a0\nAngaben\u00a0zur\u00a0Wirksamkeit\u00a0in\u00a0der\u00a0klinischen\u00a0Anwendung\u00a0und\u00a0zur\u00a0Wir tschaftlichkeit\u00a0\ndes\u00a0Arzneimittels\u00a0in\u00a0der\u00a0klinischen\u00a0Praxis.\u00a0Das\u00a0pharmazeutische \u00a0Unternehmen,\u00a0\ndessen\u00a0Produkt\u00a0einen\u00a0Premiumpreis\u00a0erh\u00e4lt,\u00a0wird\u00a0aufgefordert,\u00a0in nerhalb\u00a0einer\u00a0\nf e s t g e l e g t e n \u00a0F r i s t \u00a0D o k u m e n t e \u00a0m i t \u00a0 zus\u00e4tzlichen\u00a0 Daten\u00a0 einzureiche n.\u00a0 Wenn\u00a0 die\u00a0\nzus\u00e4tzlich\u00a0eingereichten\u00a0Unterlagen\u00a0die\u00a0Hypothesen,\u00a0auf\u00a0der\u00a0die \u00a0anf\u00e4ngliche\u00a0Be\u2010\nwertung\u00a0 des\u00a0 Arzneimittels\u00a0 beruht,\u00a0 best\u00e4tigen,\u00a0 werden\u00a0 die\u00a0 Entsch eidungen\u00a0 zur\u00a0\nErstattungsklasse\u00a0und\u00a0zum\u00a0Preis\u00a0aufrechterhalten.\u00a0Andernfalls\u00a0k ann\u00a0die\u00a0Patienten\u2010\ngruppe,\u00a0f\u00fcr\u00a0die\u00a0die\u00a0Anwendung\u00a0des\u00a0Arzneimittels\u00a0bestimmt\u00a0ist,\u00a0e ingegrenzt,\u00a0die\u00a0\nVerordnung\u00a0des\u00a0Arzneimittels\u00a0nur\u00a0einer\u00a0bestimmten\u00a0\u00c4rztegruppe\u00a0g estattet\u00a0\u00a0oder\u00a0\ndas\u00a0Arzneimittel\u00a0von\u00a0der\u00a0Ersta ttungsliste\u00a0genommen\u00a0werden.\u00a0\u00a0\n Niederlande\u00a06.3\nPharmaceutical\u00a0Pricing \u00a0and\u00a0Reimbursement \u00a0(PPRI)\u00a0\nDie\u00a0Gesundheit\u00a0\u00d6sterreich\u00a0GmbH\u00a0hat\u00a0als\u00a0 WHO\u00a0Collaborating\u00a0Centre \u00a0f\u00fcr\u00a0pharma\u2010\nzeutische\u00a0Preisbildung\u00a0und\u00a0Erstattungspolitik\u00a0in\u00a0Kooperation\u00a0mi t\u00a0dem\u00a0Gesund\u2010\nheitsministerium\u00a0der\u00a0Niederlande\u00a0Informationen\u00a0zur\u00a0Lage\u00a0der\u00a0Jah re\u00a02007\u00a0bis\u00a02019\u00a0\nver\u00f6ffentlicht,\u00a0die\u00a0nachfolgend\u00a0kurz\u00a0zusammengefasst\u00a0werden.\u00a0Zu \u00a0beachten\u00a0ist\u00a0\nhierbei,\u00a0dass\u00a0die\u00a0Preisbildung\u00a0von \u00a0Arzneimitteln\u00a0bei\u00a0Abgabe\u00a0\u00fcbe r\u00a0Krankenhausapo\u2010\ntheken\u00a0(in\u2010patient )\u00a0von\u00a0der\u00a0Abgabe\u00a0\u00fcber\u00a0\u00f6ffentlic he\u00a0bzw.\u00a0Offizin\u2010Apotheken\u00a0( out\u2010\npatient)\u00a0zu\u00a0unterscheiden\u00a0ist.\u00a0\nIm\u00a0Jahr\u00a02007\u00a0k\u00f6nnen\u00a0die\u00a0Preise\u00a0v on\u00a0OTC\u2010Produkten,\u00a0d.\u00a0h.\u00a0freiver k\u00e4uflichen,\u00a0apo\u2010\nthekenpflichtigen\u00a0Arzneimitte ln,\u00a0frei\u00a0gestaltet\u00a0werden.\u00a0 Out\u2010patient \u00a0gelten\u00a0gesetzli\u2010\nche\u00a0H\u00f6chstpreise\u00a0f\u00fcr\u00a0nicht\u2010\u00a0und\u00a0erstattungsf\u00e4hige\u00a0Produkte\u00a0sowi e\u00a0seit\u00a01996\u00a0eine\u00a0\nexterne\u00a0Referenzierung\u00a0der\u00a0Preis e\u00a0mit\u00a0den\u00a0Vergleichsl\u00e4ndern\u00a0Bel gien,\u00a0Deutsch\u2010\nland,\u00a0 Frankreich\u00a0 sowie\u00a0 Gro\u00dfbritannien.\u00a0 Die\u00a0 Gro\u00dfhandelsspanne\u00a0 is t\u00a0 unbekannt.\u00a0 \n112\u00a0\n\u00a0Apotheken\u00a0erheben\u00a0eine\u00a0maximale\u00a0 Dispensiergeb\u00fchr\u00a0von\u00a06,10\u00a0\u20ac\u00a0je\u00a0 Verordnung,\u00a0\neine\u00a0R\u00fcckerstattung\u00a0an\u00a0den\u00a0Kostentr\u00e4ger\u00a0(\u201e Claw\u00a0back\u201c )\u00a0liegt\u00a0bei\u00a06,82\u00a0%\u00a0des\u00a0\u00f6ffent\u2010\nlichen\u00a0Listenpreises\u00a0mit\u00a0einem\u00a0Maximum\u00a0in\u00a0H\u00f6he\u00a0von\u00a06,80\u00a0\u20ac\u00a0je\u00a0Ve rordnung.\u00a0Die\u00a0\nUmsatzsteuer\u00a0betr\u00e4gt\u00a019\u00a0%\u00a0in\u00a0den\u00a0Niederlanden,\u00a0f\u00fcr\u00a0Arzneimittel \u00a0gilt\u00a0aber\u00a0der\u00a0\nverminderte\u00a0Satz\u00a0in\u00a0H\u00f6he\u00a0von\u00a06\u00a0% .\u00a0Seit\u00a02004\u00a0wird\u00a0der\u00a0Wettbewerb \u00a0bei\u00a0patent\u2010\nfreien\u00a0Arzneimitteln\u00a0gef\u00f6rdert,\u00a0d.\u00a0h.\u00a0Generika\u00a0m\u00fcssen\u00a040\u00a0%\u00a0unte rhalb\u00a0des\u00a0Preises\u00a0\nvon\u00a0Altoriginalen\u00a0liegen.\u00a0Rund\u00a071\u00a0 %\u00a0der\u00a0Arzneimittel\u00a0k\u00f6nnen\u00a0vol l\u00a0erstattet\u00a0werden,\u00a0\nhiervon\u00a0liegen\u00a031\u00a0%\u00a0generisch\u00a0vor.\u00a0Seit\u00a01992\u00a0existiert\u00a0in\u00a0den\u00a0N iederlanden\u00a0ein\u00a0\ninterner\u00a0Referenzpreis,\u00a0kostene ffektive\u00a0Arzneimittel\u00a0mit\u00a0zus\u00e4tz lichem,\u00a0therapeuti\u2010\nschem\u00a0Stellenwert\u00a0erhalten\u00a0eine\u00a0besondere\u00a0Erstattung.\u00a0Eigenante ile\u00a0sind\u00a0zu\u00a0ver\u2010\nnachl\u00e4ssigen\u00a0und\u00a0liegen\u00a0unter\u00a00,5\u00a0%.\u00a0Einige\u00a0nichterstattungsf\u00e4h ige\u00a0Arzneimittel\u00a0\nwerden\u00a0dennoch\u00a0f\u00fcr\u00a0chronisch\u00a0Erkrankte\u00a0erstattet\u00a0(PPRI,\u00a02007).\u00a0 \u00a0\nIm\u00a0Jahr\u00a02009\u00a0wurden\u00a0nachfolgende\u00a0Neuerungen\u00a0seit\u00a02007\u00a0berichtet ,\u00a0d.\u00a0h.\u00a0der\u00a0\nWegfall\u00a0einer\u00a0Kosten\u00fcbernahme\u00a0f\u00fcr \u00a0Benzodiazepine\u00a0seit\u00a0Januar\u00a020 09,\u00a0teuere\u00a0Sta\u2010\ntine\u00a0werden\u00a0nur\u00a0bei\u00a0leitlinienk onformer\u00a0Verordnung\u00a0finanziell\u00a0g etragen,\u00a0die\u00a0maxi\u2010\nmale\u00a0Dispensiergeb\u00fchr\u00a0der\u00a0Apotheken\u00a0wurde\u00a0ab\u00a0Januar\u00a02009\u00a0auf\u00a07, 28\u00a0\u20ac\u00a0erh\u00f6ht,\u00a0\ndie\u00a0R\u00fcckerstattung\u00a0an\u00a0die\u00a0Krankenversicherung\u00a0(\u201e claw\u00a0back \u201c)\u00a0bleibt\u00a0bei\u00a0maximal\u00a0\n6,80\u00a0\u20ac\u00a0je\u00a0Verordnung.\u00a0Rund\u00a046\u00a0%\u00a0der\u00a0Arzneimittel\u00a0sind\u00a0erstattun gsf\u00e4hig,\u00a026\u00a0%\u00a0nicht\u00a0\nund\u00a028\u00a0%\u00a0teilweise\u00a0(PPRI,\u00a02009).\u00a0\nDie\u00a0Arzneimittel\u00a0f\u00fcr\u00a0Krankenh\u00e4user\u00a0( in\u2010patient )\u00a0werden\u00a0\u00fcber\u00a0Krankenhausapothe\u2010\nken\u00a0beschafft.\u00a0Die\u00a0Preise\u00a0hierf\u00fcr\u00a0sind\u00a0nicht\u00a0\u00f6ffentlich,\u00a0Rabatt e\u00a0k\u00f6nnen\u00a0gew\u00e4hrt\u00a0\nwerden,\u00a0die\u00a0Kostenerstattung\u00a0erfolgt\u00a0im\u00a0Kontext\u00a0der\u00a0Behandlung\u00a0 (DRG).\u00a0Zus\u00e4tzlich\u00a0\nzu\u00a0 den\u00a0 Fallpauschalen\u00a0 k\u00f6nnen\u00a0 hochpreisige\u00a0 Pharmakotherapien\u00a0 bzw .\u00a0Orphan\u2010\nDrugs\u00a0in\u00a0Rechnung\u00a0gestellt\u00a0werden.\u00a0Alle\u00a0 out\u2010patient \u00a0zugelassenen\u00a0Arzneimittel\u00a0\nwerden\u00a0auch\u00a0bei\u00a0 in\u2010patient \u00a0Gebrauch\u00a0erstattet\u00a0(PHIS,\u00a02010).\u00a0Der\u00a0Anteil,\u00a0d.\u00a0h.\u00a0Pro\u2010\nzent\u00a0der\u00a0defined\u00a0daily\u00a0doses \u00a0[%\u00a0DDD]\u00a0der\u00a0generischen\u00a0Verordnungen\u00a0nahm\u00a0zu\u00a0von\u00a0\n51,25\u00a0%\u00a0der\u00a0DDD\u00a0im\u00a0Jahr\u00a02008,\u00a0\u00fcber\u00a053,9\u00a0%\u00a0in\u00a02009\u00a0bzw.\u00a059,1\u00a0%\u00a0i n\u00a02010\u00a0sowie\u00a0\n62,5\u00a0%\u00a0in\u00a02011\u00a0auf\u00a065,7\u00a0%\u00a0im\u00a0Jahr\u00a02012\u00a0(PPRI,\u00a02012b).\u00a0Beachtlic h\u00a0erscheint\u00a0hierbei,\u00a0\ndass\u00a0im\u00a0Jahr\u00a02011\u00a0bei\u00a0einem\u00a0Anteil\u00a0von\u00a062\u00a0%\u00a0der\u00a0DDD\u00a0im\u00a0ambulant en\u00a0Bereich\u00a0nur\u00a0\n27\u00a0%\u00a0der\u00a0Arzneimittelkosten\u00a0hierf\u00fcr\u00a0anfielen,\u00a0d.\u00a0h.\u00a0Einsparunge n\u00a0bei\u00a0generischer\u00a0\nVerordnung\u00a0realisiert\u00a0werden\u00a0k\u00f6nnen.\u00a0\nIm\u00a0Jahr\u00a02012\u00a0dokumentiert\u00a0der\u00a0Bericht\u00a0die\u00a0folgenden\u00a0Punkte:\u00a0d.\u00a0 h.\u00a0Protonenpum\u2010\npeninhibitoren\u00a0(PPI)\u00a0werden\u00a0mit\u00a0Ausnahme\u00a0chronischer\u00a0F\u00e4lle\u00a0ab\u00a02 012\u00a0nicht\u00a0mehr\u00a0\nerstattet.\u00a0Die\u00a0Verg\u00fctung\u00a0von\u00a0Apotheken\u00a0hat\u00a0fortan\u00a0keine\u00a0fixen\u00a0H \u00f6chsts\u00e4tze\u00a0mehr,\u00a0\nApotheken\u00a0und\u00a0Krankenversicherungen\u00a0sollen\u00a0diese\u00a0verhandeln.\u00a0Tu mornekrose\u2010\nfaktor\u2010alpha\u2010\u00a0(TNF)\u2010Inhibitore n\u00a0werden\u00a0vollumf\u00e4nglich\u00a0\u00fcber\u00a0Kran kenhausapothe\u2010\nken\u00a0abgerechnet,\u00a0da\u00a0diese\u00a0niedri gere\u00a0Preise\u00a0aushandeln\u00a0k\u00f6nnen,\u00a0 ab\u00a0Januar\u00a02013\u00a0\nwird\u00a0diese\u00a0Abrechnungspraxis\u00a0auch\u00a0f\u00fcr\u00a0Wachstumshormone\u00a0und\u00a0kost enintensive\u00a0 \n113\u00a0\n\u00a0Onkologika\u00a0angewendet\u00a0(PPRI,\u00a02012a).\u00a0Zudem\u00a0werden\u00a0in\u00a0kleinem\u00a0Um fang\u00a0Preise\u00a0\nf\u00fcr\u00a0neue\u00a0Arzneimittel\u00a0im\u00a0Rahmen\u00a0eines\u00a0regulierten\u00a0Marktzugangs\u00a0 (managed\u00a0entry\u00a0\nscheme\u00a0bzw.\u00a0im\u00a0weiteren\u00a0Sinne \u00a0managed\u00a0entry\u00a0agreements\u00a0MEA )\u00a0verhandelt.\u00a0Im\u00a0\nJahr\u00a02012\u00a0wurden\u00a0f\u00fcr\u00a0die\u00a0direkten\u00a0oralen\u00a0Antikoagulanzien\u00a0(DOAK \u00a0bzw.\u00a0NOAK)\u00a0\nDabigatran\u00a0und\u00a0Rivaroxaban\u00a0mit\u00a0den\u00a0pharmazeutischen\u00a0Unternehmer n\u00a0mengen\u2010\ngebundene\u00a0Preise\u00a0sowie\u00a0mit\u00a0den\u00a0\u00c4rzten\u00a0eine\u00a0Vereinbarung\u00a0zum\u00a0rat ionalen\u00a0und\u00a0\nsicheren\u00a0Gebrauch\u00a0dieser\u00a0beiden\u00a0 Arzneimittel\u00a0geschlossen\u00a0(PPRI, \u00a02013).\u00a0\nF\u00fcr\u00a02014\u00a0liegen\u00a0zwei\u00a0Berichte\u00a0vor.\u00a0Im\u00a0Bereich\u00a0der\u00a0hochpreisigen \u00a0Arzneimittel\u00a0nut\u2010\nzen\u00a0die\u00a0Niederlande\u00a0 in\u2010\u00a0und\u00a0out\u2010patient \u00a0zentrale\u00a0MEA,\u00a0um\u00a0einerseits\u00a0einen\u00a0fr\u00fchen\u00a0\nZugang\u00a0zu\u00a0neuen\u00a0Arzneimitteln\u00a0zu\u00a0erhalten,\u00a0andererseits\u00a0als\u00a0Wer kzeug\u00a0zur\u00a0Reduk\u2010\ntion\u00a0von\u00a0Unsicherheiten\u00a0und\u00a0Risiken\u00a0einer\u00a0Erstattung\u00a0der\u00a0innova tiven\u00a0Arzneimittel,\u00a0\nwie\u00a0sie\u00a0bei\u00a0einer\u00a0Arznei mittelzulassung\u00a0unter\u00a0 exceptional\u00a0circumstances ,\u00a0hohen\u00a0\nArzneimittelkosten\u00a0oder\u00a0einem\u00a0Ma ngel\u00a0an\u00a0Wettbewerb\u00a0(Monopoliste n\u00a0mit\u00a0Patent\u2010\nschutz)\u00a0vorliegen.\u00a0Im\u00a0Einzelnen\u00a0wurden\u00a0in\u00a0diesem\u00a0Zeitraum\u00a0acht\u00a0 MEA\u00a0pilotiert,\u00a0\nd.\u00a0h.\u00a0f\u00fcr\u00a0Omalizumab,\u00a0Dabigatran ,\u00a0Rivaroxaban,\u00a0Apixaban,\u00a0Algluc osidase\u00a0alfa,\u00a0Agal\u2010\nsidase\u00a0alfa\u00a0bzw.\u00a0beta,\u00a0Ruxolitinib\u00a0sowie\u00a0Pirfenidon\u00a0wurden\u00a0Prei s\u2010\u00a0bzw.\u00a0Mengenver\u2010\neinbarungen\u00a0sowie\u00a0vertrauliche\u00a0Ra batte\u00a0mit\u00a0den\u00a0pharmazeutischen \u00a0Unternehmern\u00a0\nvereinbart\u00a0(PPRI,\u00a02014).\u00a0Im\u00a0Jahr\u00a02015\u00a0kamen\u00a0zwei\u00a0weitere\u00a0MEAs\u00a0h inzu,\u00a0im\u00a0Einzel\u2010\nnen\u00a0f\u00fcr\u00a0Sofosbuvir\u00a0und\u00a0Daclatasvir\u00a0(PPRI,\u00a02015).\u00a0Im\u00a0Juli\u00a02015\u00a0k am\u00a0f\u00fcr\u00a0Kranken\u2010\nhausapotheken\u00a0ein\u00a0neues\u00a0Instrument\u00a0der\u00a0Marktregulation\u00a0auf,\u00a0mit tels\u00a0\u201elock\u201c,\u00a0d.\u00a0h.\u00a0\nAusschluss\u00a0 neuer\u00a0 Arzneimittel\u00a0 von\u00a0 der\u00a0 Basis\u2010Kostenerstattung.\u00a0 D ieser\u00a0 soll\u00a0 die\u00a0\nM\u00f6glichkeit\u00a0f\u00fcr\u00a0Preisverhandlunge n\u00a0gew\u00e4hrleisten\u00a0bzw.\u00a0die\u00a0Einri chtung\u00a0von\u00a0Pati\u2010\nentenregistern\u00a0erm\u00f6glichen.\u00a0Im\u00a0Rahmen\u00a0des\u00a0 Medicines\u00a0Policy\u00a0Plan \u00a0sollen\u00a0die\u00a0Kos\u2010\ntenerstattungssysteme\u00a0optimiert\u00a0werden.\u00a0Zunehmend\u00a0preisintensiv e,\u00a0vorwiegend\u00a0\nin\u00a0Krankenh\u00e4usern\u00a0eingesetzte\u00a0Arzneimittel\u00a0k\u00f6nnen\u00a0von\u00a0Preisverh andlungen\u00a0flan\u2010\nkiert\u00a0werden.\u00a0Zudem\u00a0wird\u00a0mehr\u00a0Transparenz\u00a0mittels\u00a0freiwilliger\u00a0 internationaler\u00a0\nKooperation\u00a0angestrebt,\u00a0im\u00a0Einzelnen\u00a0tragen\u00a0hierzu\u00a0die\u00a0Beobacht ung\u00a0der\u00a0Entwick\u2010\nlung\u00a0neuer\u00a0Arzneimittel\u00a0bzw. \u00a0deren\u00a0Zulassungsverfahren\u00a0( horizon\u00a0scanning ),\u00a0ge\u2010\nmeinsame\u00a0Bewertungen\u00a0( joint\u00a0Health\u00a0Technology\u00a0Assessment ),\u00a0Teilen\u00a0von\u00a0Infor\u2010\nmationen\u00a0( Information\u00a0sharing )\u00a0sowie\u00a0Verhandlung\u00a0der\u00a0 Preise\u00a0bei\u00a0Markteintritt\u00a0\n(price\u00a0negotiation )\u00a0bei.\u00a0Ein\u00a0weiterer\u00a0Schwerpunkt\u00a0liegt\u00a0auf\u00a0der\u00a0Substitution\u00a0durc h\u00a0\nBiosimilars.\u00a0Deren\u00a0Preisbildung\u00a0beruht\u00a0auf\u00a0einem\u00a0Vergleich\u00a0mit\u00a0 den\u00a0Nachbarl\u00e4n\u2010\ndern\u00a0(Belgien,\u00a0Frankreich,\u00a0Gro\u00dfbritannien\u00a0und\u00a0Deutschland).\u00a0Pat ienten\u00a0sollten\u00a0als\u00a0\nErstverordnung\u00a0stets\u00a0Biosimilars\u00a0erhalten,\u00a0bei\u00a0Umstellung\u00a0von\u00a0O riginal\u00a0auf\u00a0Biosimi\u2010\nlar\u00a0ist\u00a0eine\u00a0engmaschige\u00a0Betreuung\u00a0der\u00a0Patienten\u00a0zu\u00a0gew\u00e4hrleist en.\u00a0Eine\u00a0Marktbe\u2010\nobachtung\u00a0 ( horizon\u00a0 scanning) \u00a0 soll\u00a0 f\u00fcr\u00a0 Biosimilars\u00a0 zeitnahe\u00a0 Ma\u00dfnahmen\u00a0 zum\u00a0\nMarkteintritt\u00a0erm\u00f6glichen\u00a0(PPRI,\u00a02016).\u00a0\nSeitens\u00a0des\u00a0PPRI\u00a0wurden\u00a0in\u00a02017\u00a0zwei\u00a0Berichte\u00a0publiziert,\u00a0ein\u00a0S chwerpunkt\u00a0stellt\u00a0 e\u2010\nhealth\u00a0dar,\u00a0ein\u00a0zweiter\u00a0die\u00a0Arzneimitte lversorgung\u00a0im\u00a0Krankenhaus.\u00a0Se itens\u00a0des\u00a0 \n114\u00a0\n\u00a0Ministeriums\u00a0f\u00fcr\u00a0Gesundheit\u00a0der\u00a0Niederlande\u00a0sind\u00a0Preis\u00fcbersicht en\u00a0der\u00a0Kranken\u2010\nhausapotheken\u00a0angedacht,\u00a0externe\u00a0Referenzpreise\u00a0werden\u00a0zweimal\u00a0 j\u00e4hrlich,\u00a0in\u2010\nterne\u00a0 Preisvergleiche\u00a0 monatlich\u00a0 erhoben.\u00a0 Krankenhaustr\u00e4ger\u00a0 und\u00a0 Kostentr\u00e4ger\u00a0\nvereinbaren\u00a0vertraglich\u00a0DRGs,\u00a0we lche\u00a0die\u00a0Arzneimittelkosten\u00a0ink ludieren,\u00a0jedoch\u00a0\nk\u00f6nnen\u00a0f\u00fcr\u00a0Arzneimittel\u00a0mit\u00a0Kosten\u00a0h\u00f6her\u00a0als\u00a01.000\u00a0Euro\u00a0zus\u00e4tzl iche\u00a0Kosten\u00fcber\u2010\nnahmen\u00a0beantragt\u00a0werden.\u00a0Die\u00a0Arz neimittelausgaben\u00a0im\u00a0Krankenhau s\u00a0werden\u00a0im\u00a0\nJahr\u00a02014\u00a0auf\u00a01.740\u00a0Millionen\u00a0Euro\u00a0und\u00a0im\u00a0Jahr\u00a02015\u00a0auf\u00a01.857\u00a0M io.\u00a0Euro\u00a0ge\u2010\nsch\u00e4tzt,\u00a0d.\u00a0h.\u00a0ein\u00a0Zuwachs\u00a0um\u00a06,7\u00a0%.\u00a0In\u00a0Folge\u00a0von\u00a0wettbewerblic hen\u00a0Vertragsab\u2010\nschl\u00fcssen\u00a0werden\u00a0viele\u00a0Preise\u00a0f\u00fc r\u00a0Arzneimittel\u00a0vertraulich\u00a0beha ndelt.\u00a0Als\u00a0zuk\u00fcnfti\u2010\nge\u00a0Optionen\u00a0gelten\u00a0eine\u00a0B\u00fcndelung\u00a0der\u00a0Nachfrage\u00a0in\u00a0Gruppen,\u00a0auf \u00a0Landesebene\u00a0\noder\u00a0gar\u00a0unter\u00a0Beteiligung\u00a0der\u00a0Nachbarl\u00e4nder,\u00a0d.\u00a0h.\u00a0Belgien\u00a0und \u00a0Luxemburg.\u00a0Des\u2010\ngleichen\u00a0w\u00e4ren\u00a0trilaterale\u00a0Verhandlungen,\u00a0d.\u00a0h.\u00a0die\u00a0pharmazeuti schen\u00a0Unterneh\u2010\nmer\u00a0einerseits\u00a0und\u00a0Krankenh\u00e4user\u00a0s owie\u00a0Kostentr\u00e4gen\u00a0gemeinsam\u00a0a uf\u00a0der\u00a0ande\u2010\nren\u00a0Seite\u00a0eine\u00a0M\u00f6glichkeit.\u00a0Im\u00a0Kontext\u00a0der\u00a0HTA\u2010( Health\u00a0Technology\u00a0Appraisal )\u00a0\nBewertung\u00a0erfolgt\u00a0diese\u00a0erst\u00a0ab\u00a0einem\u00a0j\u00e4hrlichen\u00a0Volumen\u00a0\u00fcber\u00a02 ,5\u00a0Millionen\u00a0\nEuro,\u00a0wobei\u00a0das\u00a0Ergebnis\u00a0richtungsweisend\u00a0f\u00fcr\u00a0eine\u00a0weitere\u00a0Kost en\u00fcbernahmen\u00a0\nseitens\u00a0der\u00a0Krankenversicherung\u00a0steht.\u00a0Weiterhin\u00a0ist\u00a0die\u00a0bereit s\u00a0erl\u00e4uterte\u00a0 lock\u2010\nProzedur\u00a0m\u00f6glich\u00a0(PPRI,\u00a02017b).\u00a0In\u00a0Kontext\u00a0von\u00a0 e\u2010health\u00a0wurden\u00a0mehrere\u00a0Pro\u2010\ngramme\u00a0entwickelt.\u00a0Eine\u00a0App\u00a0\u201e Receptprijs \u201c\u00a0informiert\u00a0\u00fcber\u00a0den\u00a0aktuellen\u00a0Preis,\u00a0\nVertriebsstatus,\u00a0H\u00f6he\u00a0und\u00a0Umfang\u00a0der\u00a0Kostenerstattung\u00a0sowie\u00a0m\u00f6g liche\u00a0g\u00fcnstige\u2010\nre\u00a0Alternativen.\u00a0Eine\u00a0weitere\u00a0A pp\u00a0soll\u00a0die\u00a0am\u00a0Medikationsprozes s\u00a0Beteiligten\u00a0un\u2010\nterst\u00fctzen,\u00a0d.\u00a0h.\u00a0die\u00a0App\u00a0\u201e Farmacotherapeutisch\u00a0Kompas \u201c\u00a0informiert\u00a0\u00fcber\u00a0zugelas\u2010\nsene\u00a0 Arzneimittel,\u00a0 deren\u00a0 Indikati onen,\u00a0 Darreichungsformen,\u00a0 Dosi erungen\u00a0 und\u00a0\nNebenwirkungen.\u00a0Eine\u00a0weitere\u00a0App,\u00a0\u201e GnmVerkeer \u201c,\u00a0informiert\u00a0\u00fcber\u00a0die\u00a0Einschr\u00e4n\u2010\nkung\u00a0 zur\u00a0 Teilnahme\u00a0 am\u00a0 Stra\u00dfenverkehr,\u00a0 eine\u00a0 andere\u00a0 \u201e Paediatric\u00a0 Formulary \u201c\u00a0\n(www.kinderformularium.nl)\u00a0unterst \u00fctzt\u00a0bei\u00a0der\u00a0Pharmakotherapie \u00a0in\u00a0der\u00a0P\u00e4diat\u2010\nrie\u00a0(PPRI,\u00a02017a).\u00a0\nIm\u00a0Jahr\u00a02018\u00a0erschienen\u00a0zwei\u00a0PPRI\u2010Berichte.\u00a0Im\u00a0Krankenhaussekto r\u00a0wurde\u00a0die\u00a0\nlock\u2010Prozedur\u00a0bis\u00a0Ende\u00a02018\u00a0bereits\u00a0ac htmal\u00a0genutzt,\u00a0wobei\u00a0diese\u00a0be i\u00a0Therapiekos\u2010\nten\u00a0von\u00a0\u00fcber\u00a040\u00a0Millionen\u00a0Euro\u00a0 pro\u00a0Behandlungsjahr\u00a0f\u00fcr\u00a0alle\u00a0Ind ikationen\u00a0und\u00a0die\u00a0\nGesamtpopulation\u00a0bzw.\u00a0\u00fcber\u00a050.000\u00a0Euro\u00a0pro\u00a0Kopf\u00a0und\u00a0Jahr\u00a0bzw.\u00a0\u00fc ber\u00a010\u00a0Millio\u2010\nnen\u00a0Euro\u00a0Budget\u2010Impact\u00a0eingesetzt\u00a0wird.\u00a0Die\u00a0Umsatzsteuer\u00a0f\u00fcr\u00a0Ar zneimittel\u00a0wird\u00a0\nzum\u00a01.1.2019\u00a0von\u00a06\u00a0%\u00a0auf\u00a09\u00a0%\u00a0erh\u00f6ht.\u00a0Desgleichen\u00a0steigt\u00a0die\u00a0Zuz ahlung\u00a0auf\u00a0maxi\u2010\nmal\u00a0250\u00a0Euor\u00a0pro\u00a0Jahr.\u00a0Im\u00a0L\u00e4nderkorb\u00a0der\u00a0externen\u00a0Referenzpreis e\u00a0wird\u00a0Deutsch\u2010\nland\u00a0durch\u00a0Norwegen\u00a0ab\u00a02020\u00a0ersetzt\u00a0werden.\u00a0Die\u00a0internen\u00a0(GENMI D)\u00a0und\u00a0exter\u2010\nnen\u00a0(GENEUR)\u00a0Preisreferenzierung ssysteme\u00a0werden\u00a0neu\u00a0aufgesetzt. \u00a0Eine\u00a0Herstel\u2010\nlung\u00a0von\u00a0Arzneimitteln\u00a0mit\u00a0Patentschutz\u00a0in\u00a0Krankenhausapotheken \u00a0[als\u00a0Defektur\u00a0\nbzw.\u00a0Rezeptur]\u00a0wird\u00a0am\u00a0Beispiel\u00a0von\u00a0Chenodeoxychols\u00e4ure\u00a0diskuti ert,\u00a0d.\u00a0h.\u00a0wie\u00a0bei\u00a0\nNeuzulassungen\u00a0von\u00a0generisch\u00a0verf\u00fcgbaren\u00a0Arzneimitteln\u00a0als\u00a0 Orphan\u00a0drugs \u00a0mit\u00a0 \n115\u00a0\n\u00a0hierdurch\u00a0bedingter,\u00a0enormer\u00a0Prei ssteigerung\u00a0verfahren\u00a0werden\u00a0s oll\u00a0(PPRI,\u00a02018a;\u00a0\n2018b).\u00a0\nIm\u00a0Jahr\u00a02019\u00a0wurden\u00a0wiederum\u00a0zwei\u00a0Poster\u00a0publiziert.\u00a0Einzelimpo rte\u00a0von\u00a0Arznei\u2010\nmitteln\u00a0in\u00a0die\u00a0Niederlande\u00a0sind\u00a0m\u00f6glich,\u00a0eine\u00a0Kosten\u00fcbernahme\u00a0j edoch\u00a0nur,\u00a0wenn\u00a0\nes\u00a0sich\u00a0um\u00a0eine\u00a0seltene\u00a0Erkrankung\u00a0handelt\u00a0(ein\u00a0Fall\u00a0pro\u00a0150.00 0\u00a0Einwohner)\u00a0und\u00a0\neine\u00a0rationale\u00a0Pharmakotherapie\u00a0hierf\u00fcr\u00a0belegt\u00a0werden\u00a0kann.\u00a0Die \u00a0Niederlande\u00a0\nwiesen\u00a0im\u00a0Jahr\u00a02018\u00a0eine\u00a0Bev\u00f6lkerung\u00a0von\u00a018,3\u00a0Millionen\u00a0auf,\u00a0in sgesamt\u00a0wurden\u00a0\n76,9\u00a0Milliarden\u00a0Euro\u00a0f\u00fcr\u00a0Gesundhe it\u00a0ausgegeben\u00a0(PPRI,\u00a02019a;\u00a020 19b).\u00a0\n Gro\u00dfbritannien\u00a06.4\nIn\u00a0Gro\u00dfbritannien,\u00a0d.\u00a0h.\u00a0England,\u00a0Nordirland,\u00a0Schottland\u00a0und\u00a0Wa les,\u00a0wird\u00a0mittels\u00a0\nSteuergeldern\u00a0das\u00a0staatliche\u00a0Gesundheitssystem,\u00a0 National\u00a0Health\u00a0Service \u00a0(NHS),\u00a0\nund\u00a0 somit\u00a0 auch\u00a0 die\u00a0 Arzneimittelver sorgung\u00a0 finanziert.\u00a0 Bei\u00a0 Markt eintritt\u00a0 neuer\u00a0\nArzneimittel\u00a0k\u00f6nnen\u00a0pharmazeutische\u00a0Unternehmer\u00a0einen\u00a0Preis\u00a0fre i\u00a0w\u00e4hlen.\u00a0F\u00fcr\u00a0\nEngland\u00a0und\u00a0Wales\u00a0nimmt\u00a0das\u00a0 National\u00a0Institute\u00a0for\u00a0Health\u00a0and\u00a0Care\u00a0Excellence\u00a0\n(NICE),\u00a0vormals\u00a0als\u00a0 National\u00a0Institute\u00a0for\u00a0Clinical\u00a0Excellence \u00a0im\u00a0Jahr\u00a01999\u00a0gegr\u00fcn\u2010\ndet,\u00a0eine\u00a0gesundheits\u00f6konomische\u00a0Bewertung\u00a0im\u00a0Sinne\u00a0eines\u00a0 Value\u2010Based\u2010Pricings \u00a0\nmit\u00a0 Hilfe\u00a0 von\u00a0 Quality\u2010adjusted\u00a0 life\u00a0 years \u00a0( Q A L Y ) \u00a0b z w . \u00a0d e r \u00a0 Incremental\u00a0 Cost\u2010\nEffectiveness\u00a0Ratio \u00a0(ICER)\u00a0vor.\u00a0Die\u00a0Bewertung\u00a0des\u00a0NICE\u00a0beinhaltet\u00a0verbindliche\u00a0\nEmpfehlungen\u00a0 zum\u00a0therapeutischen\u00a0Gebrauch\u00a0im\u00a0NHS\u00a0und\u00a0der\u00a0Defini tion\u00a0von\u00a0\noberen\u00a0Richtwerten\u00a0(\u00a3\u00a0pro\u00a0QALY).\u00a0Wenn\u00a0das\u00a0NICE\u00a0im\u00a0Rahmen\u00a0der\u00a0Ev aluation\u00a0des\u00a0\nneuen\u00a0 Arzneimittels\u00a0 von\u00a0 einem\u00a0 kosten\u2010effektiven\u00a0 Einsatz\u00a0 im\u00a0 ther apeutischen\u00a0\nAlltag\u00a0des\u00a0NHS\u00a0ausgeht,\u00a0findet\u00a0das\u00a0Mittel\u00a0Eingang\u00a0in\u00a0die\u00a0Behand lungsempfehlun\u2010\ngen.\u00a0Diese\u00a0werden\u00a0binnen\u00a090\u00a0Tagen\u00a0 in\u00a0den\u00a0Regionen\u00a0umgesetzt.\u00a0Ei ne\u00a0generische\u00a0\nPreisbildung\u00a0folgt\u00a0im\u00a0UK\u00a0frei,\u00a0jedoch\u00a0stets\u00a0unterhalb\u00a0der\u00a0H\u00f6chs tpreise\u00a0der\u00a0Altorigi\u2010\nnale\u00a0zum\u00a0Zeitpunkt\u00a0des\u00a0Patentab laufes\u00a0(TLV,\u00a02021;\u00a0NICE,\u00a02021a). \u00a0\nIm\u00a0NHS\u00a0England\u00a0werden\u00a0vier\u00a0Kategorien\u00a0der\u00a0Nutzen\u2010Kosten\u2010Effekti vit\u00e4t\u00a0mittels\u00a0\nICER\u00a0differenziert:\u00a0\n\uf0b7 Standardfall\u00a0 mit\u00a0 bis\u00a0 zu\u00a0 \u00a3\u00a020.000\u00a0 bzw.\u00a0 \u00a3\u00a030.000\u00a0 [23.314\u00a0\u20ac\u00a0 bis\u00a0\n34.971\u00a0\u20ac]1\u00a0je\u00a0QALY\u00a0(NICE,\u00a02018),\u00a0\n\uf0b7 Therapie\u00a0am\u00a0Lebensende\u00a0( End\u00a0of\u00a0Life ,\u00a0EoL),\u00a0d.\u00a0h.\u00a0bei\u00a0Patienten\u00a0mit\u00a0\n<24\u00a0Monaten\u00a0Lebenserwartung\u00a0und\u00a0Verl\u00e4ngerung\u00a0von\u00a0>3\u00a0Monaten\u00a0\ndes\u00a0 Gesamt\u00fcberlebens\u00a0 ( overall\u00a0 survival [s] , \u00a0O S ) \u00a0m i t \u00a0\u00a3 \u00a0 2 0 . 0 0 0 \u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n1\u00a0Kurs:\u00a01\u00a0\u20ac\u00a0\u2010\u00a0\u00a3\u00a00,85785;\u00a0Sta nd:\u00a019.06.2021\u00a0(EZB,\u00a02021)\u00a0 \u00a0 \n116\u00a0\n\u00a0[23.314\u00a0\u20ac]\u00a0bei\u00a0einer\u00a0m\u00f6glichen\u00a0Gewichtung\u00a0um\u00a0den\u00a0Faktor\u00a02,5,\u00a0d. \u00a0h.\u00a0\neffektiv\u00a0bis\u00a0zu\u00a0\u00a3\u00a050.000\u00a0[58.285\u00a0\u20ac]\u00a0je\u00a0QALY\u00a0(NICE,\u00a02018),\u00a0\n\uf0b7 Therapie\u00a0in\u00a0Spezialf\u00e4llen\u00a0[bspw.\u00a0Enzymersatztherapie\u00a0bei\u00a0selten en\u00a0\nLeiden]\u00a0( Highly\u00a0Specialised\u00a0Technology ,\u00a0HST)\u00a0mit\u00a0bis\u00a0zu\u00a0\u00a3\u00a0100.000\u00a0\n[116.571\u00a0\u20ac]\u00a0je\u00a0QALY\u00a0(NICE,\u00a02017)\u00a0sowie\u00a0\n\uf0b7 Onkologie\u00a0 ( Cancer\u00a0 Drug\u00a0 Fund ,\u00a0 CDF)\u00a0 mit\u00a0 \u00a3\u00a020.000\u00a0 bis\u00a0 \u00a3\u00a030.000\u00a0\n[23.314\u00a0\u20ac\u00a0bis\u00a034.971\u00a0\u20ac]\u00a0je\u00a0QALY\u00a0b ei\u00a0mitunter\u00a0unsicherer\u00a0Evidenz .\u00a0\nBereits\u00a0im\u00a0Jahr\u00a02007\u00a0analysierte\u00a0Sikora\u00a0im\u00a0Beitrag\u00a0\u201e Paying\u00a0for\u00a0cancer\u00a0care\u00a0\u2013\u00a0a\u00a0new\u00a0\ndilemma\u201c\u00a0die\u00a0Versorgung\u00a0von\u00a0Patienten\u00a0in\u00a0Gro\u00dfbritannien\u00a0in\u00a0der\u00a0Onkolog ie.\u00a0Im\u00a0\nEinzelnen\u00a0widmete\u00a0er\u00a0sich\u00a0dem\u00a0Zu gang\u00a0zur\u00a0Strahlentherapie\u00a0und\u00a0z u\u00a0neuen,\u00a0hoch\u2010\npreisigen\u00a0 Pharmakotherapien\u00a0 (Kosten\u00a0 von\u00a0 \u00a3\u00a030.000\u00a0 bis\u00a0 \u00a3\u00a070.000\u00a0 [ 34.971\u00a0\u20ac\u00a0 bis\u00a0\n81.599\u00a0\u20ac]\u00a0pro\u00a0Jahr)\u00a0am\u00a0Beispiel\u00a0monoklonaler\u00a0Antik\u00f6rper\u00a0und\u00a0der \u00a0Gruppe\u00a0der\u00a0\nTyrosinkinase\u2010Inhibitoren\u00a0(TKI),\u00a0aber\u00a0auch\u00a0der\u00a0Diagnostik,\u00a0d.\u00a0h .\u00a0Bildgebung\u00a0(PET\u2010\nCT)\u00a0und\u00a0molekularbiologische\u00a0Analytik,\u00a0die\u00a0im\u00a0NHS\u00a0durch\u00a0die\u00a0Bew ertungen\u00a0mitun\u2010\nter\u00a0erst\u00a0ein\u00a0Jahr\u00a0sp\u00e4ter\u00a0als\u00a0in\u00a0anderen\u00a0EU\u2010L\u00e4ndern\u00a0erfolgt.\u00a0Sik ora\u00a0schl\u00e4gt\u00a0zur\u00a0Finan\u2010\nzierung\u00a0des\u00a0in\u00a0England\u00a0limitierten\u00a0Budgets\u00a0im\u00a0Kontext\u00a0steigende r\u00a0Ausgaben\u00a0einen\u00a0\nerh\u00f6hten\u00a0 staatlichen\u00a0 Zuschuss\u00a0 und/oder\u00a0 die\u00a0 Einf\u00fchrung\u00a0 von\u00a0 Zuzah lungen\u00a0 vor.\u00a0\nZudem\u00a0stellt\u00a0er\u00a0fest,\u00a0dass\u00a0dies\u00a0weiter\u00a0zu\u00a0einer\u00a0Diskrepanz\u00a0bzw. \u00a0sozialer\u00a0Ungleich\u2010\nheit\u00a0im\u00a0Zugang\u00a0f\u00fchren\u00a0k\u00f6nnte,\u00a0da\u00a0zahlungskr\u00e4ftige\u00a0Patienten\u00a0die \u00a0Leistungen\u00a0\u00fcber\u00a0\ninternationale\u00a0Versandapotheken\u00a0oder\u00a0den\u00a0privat\u00e4rztlichen\u00a0Sekto r\u00a0au\u00dferhalb\u00a0des\u00a0\nNHS\u00a0in\u00a0Anspruch\u00a0nehmen\u00a0k\u00f6nnten.\u00a0Hierbei\u00a0kritisiert\u00a0Sikora\u00a0das\u00a0A gieren\u00a0pharma\u2010\nzeutischer\u00a0Unternehmer\u00a0in\u00a0Kooperation\u00a0mit\u00a0Werbeagenturen\u00a0in\u00a0For m\u00a0subtiler\u00a0PR,\u00a0\nd.\u00a0h.\u00a0der\u00a0\u201e direct\u00a0to\u00a0consumer \u201c\u2010Kampagnen.\u00a0Er\u00a0fordert\u00a0daher,\u00a0global\u00a0neue\u00a0ethische\u00a0\nStandards\u00a0im\u00a0Pharma\u2010Marketing\u00a0 zu\u00a0etablieren\u00a0(Sikora,\u00a02007).\u00a0\nF\u00fcr\u00a0hochpreisige\u00a0Arzneimittel\u00a0in\u00a0der\u00a0Onkologie\u00a0wurde\u00a0in\u00a0Gro\u00dfbri tannien\u00a0ein\u00a0spezi\u2010\nelles\u00a0Verfahren\u00a0im\u00a0Jahr\u00a02010\u00a0etabliert,\u00a0der\u00a0 Cancer\u00a0Drug\u00a0Fund \u00a0(CDF).\u00a0Dieser\u00a0CDF\u00a0\n\u00fcberbr\u00fcckt\u00a0mittels\u00a0Kosten\u00fcbernahme\u00a0f\u00fcr\u00a0neue,\u00a0hochpreisige\u00a0Arzne imittel\u00a0 \u00fcber\u00a0\nzwei\u00a0Jahre\u00a0die\u00a0Zeit\u00a0bis\u00a0zum\u00a0Vor liegen\u00a0ausreichender\u00a0Evidenz\u00a0der \u00a0Therapie\u00a0( Real\u00a0\nWorld\u00a0Data ,\u00a0RWD),\u00a0die\u00a0ansonsten\u00a0aufgrund\u00a0fehlender\u00a0Kosteneffizienz\u00a0(zu\u00a0ho he\u00a0\nKosten\u00a0je\u00a0QALY,\u00a0d.\u00a0h.\u00a0ung\u00fcnstige\u00a0I CER\u00a0bei\u00a0fehlendem\u00a0Nutzenbeleg )\u00a0nicht\u00a0im\u00a0NHS\u00a0\nverf\u00fcgbar\u00a0w\u00e4ren.\u00a0Der\u00a0CDF\u00a0war\u00a0als\u00a0Interimsl\u00f6sung\u00a0konzipiert,\u00a0bis \u00a0ein\u00a0System\u00a0des\u00a0\nValue\u2010Based\u2010Pricings \u00a0d e n \u00a0C D F \u00a0a b l \u00f6 s e n \u00a0s o l l . \u00a0L a g e n \u00a0d i e \u00a0A u s g a b e n \u00a0d e s \u00a0C D F \u00a0i n \u00a0\n2011/12\u00a0noch\u00a0bei\u00a0\u00a3\u00a0200\u00a0Millionen,\u00a0waren\u00a0es\u00a0in\u00a02014/15\u00a0bereits\u00a0\u00a3 \u00a0400\u00a0Millionen\u00a0\nund\u00a0bis\u00a0Juli\u00a02016\u00a0\u00a3\u00a01\u00a0Milliarde,\u00a0sodass\u00a0im\u00a0Jahr\u00a02016\u00a0eine\u00a0Refor m\u00a0des\u00a0CDF\u00a0n\u00f6tig\u00a0\nwurde.\u00a0Morrell\u00a0et\u00a0al.\u00a0analysierten\u00a0die\u00a0Bewertungen\u00a0des\u00a0NICE\u00a0(HT A)\u00a0von\u00a0n=31\u00a0neu\u2010\nen\u00a0Arzneimitteln\u00a0in\u00a0der\u00a0Onkologie\u00a0im\u00a0Zeitraum\u00a0von\u00a0Januar\u00a02014\u00a0b is\u00a0M\u00e4rz\u00a02016\u00a0und\u00a0\nkonnten\u00a0aus\u00a0den\u00a0HTA\u2010Bewertungen\u00a0des\u00a0NICE\u00a0nachfolgende\u00a0Punkte\u00a0al s\u00a0seitens\u00a0der\u00a0\npharmazeutischen\u00a0 Unternehmen\u00a0 verbesserungsw\u00fcrdig\u00a0 im\u00a0 Hinblick\u00a0 au f\u00a0 die\u00a0 Evi\u2010\ndenzgewinnung\u00a0definieren:\u00a0\u00a0 \n117\u00a0\n\u00a0\uf0b7 Unvollst\u00e4ndige\u00a0Daten\u00a0zum\u00a0Gesamt\u00fcberleben\u00a0( Overall\u00a0survival \u00a0(OS)),\u00a0\n\uf0b7 Fehlen\u00a0von\u00a0relevanten\u00a0Vergleichstherapien,\u00a0d.\u00a0h.\u00a0in\u00a0der\u00a0Zulassu ngs\u2010\nstudie\u00a0wurden\u00a0andere\u00a0als\u00a0im\u00a0NHS\u00a0\u00fcbliche\u00a0Standardtherapie\u00a0ange\u2010wendet,\u00a0\n\uf0b7 Typ\u00a0der\u00a0Studie\u00a0( trial\u00a0design ),\u00a0\n\uf0b7 Zusammensetzung\u00a0der\u00a0Studienteilnehmer\u00a0( relevant\u00a0patient\u00a0popula\u2010\ntion),\u00a0\n\uf0b7 Daten\u00a0zur\u00a0Lebensqualit\u00e4t\u00a0( Quality\u00a0of\u00a0Life\u00a0Data ),\u00a0\n\uf0b7 Berechnung\u00a0bzw.\u00a0Absch\u00e4tzung\u00a0der\u00a0Therapiekosten,\u00a0\n\uf0b7 Behandlungspfade\u00a0in\u00a0Studien\u00a0und\u00a0im\u00a0klinischen\u00a0Alltag\u00a0( downstream\u00a0\npathway),\u00a0\n\uf0b7 Daten\u00a0aus\u00a0Anwendungsbeobachtungen,\u00a0\n\uf0b7 Optimale\u00a0Behandlungsdauer,\u00a0\n\uf0b7 Struktur\u00a0des\u00a0 Cost\u2010Effectiveness \u00a0Modells\u00a0sowie\u00a0\n\uf0b7 Inzidenz\u00a0unerw\u00fcnschter\u00a0 Arzneimitteleffekte\u00a0( Adverse\u00a0effects \u00a0(AE)).\u00a0\nMorrell\u00a0et\u00a0al.\u00a0bewerten\u00a0die\u00a0Reform\u00a0des\u00a0CDF\u00a0als\u00a0Verbesserung,\u00a0un terstreichen\u00a0aber,\u00a0\ndass\u00a0zweij\u00e4hrige\u00a0RWD\u00a0allein\u00a0nic ht\u00a0zur\u00a0Gewinnung\u00a0der\u00a0notwendigen \u00a0Datenbasis,\u00a0\nbspw.\u00a0Langzeitdaten\u00a0oder\u00a0Fortset zung\u00a0randomisierter,\u00a0klinischer \u00a0Studien,\u00a0ausrei\u2010\nchen\u00a0werden\u00a0(Morrell\u00a0et\u00a0al.,\u00a02018).\u00a0\u00a0\nLakdawalla\u00a0et\u00a0al.\u00a0gehen\u00a0in\u00a0ihrer\u00a0Publikation\u00a0zur\u00a0Reform\u00a0des\u00a0CDF \u00a0des\u00a0NHS\u00a0auf\u00a0das\u00a0\nethische\u00a0und\u00a0gesundheits\u00f6konomische\u00a0Dilemma\u00a0der\u00a0Allokation\u00a0von\u00a0 Ressourcen,\u00a0\nd.\u00a0h.\u00a0des\u00a0fixen\u00a0Budgets,\u00a0im\u00a0NHS\u00a0basierend\u00a0auf\u00a0unsicherer\u00a0Datenl age\u00a0ein\u00a0und\u00a0for\u2010\ndern\u00a0hierbei\u00a0andere\u00a0Ma\u00dfst\u00e4be\u00a0als \u00a0in\u00a0den\u00a0regul\u00e4ren\u00a0HTA\u2010Verfahren \u00a0(Lakdawalla\u00a0et\u00a0\nal.,\u00a02014).\u00a0\nDixon\u00a0et\u00a0al.\u00a0hingegen\u00a0hinterfragen\u00a0kritisch\u00a0die\u00a0Entscheidungspr ozesse\u00a0des\u00a0CDF\u00a0\n(Prioritization\u00a0Tool )\u00a0en\u00a0d\u00e9tail ,\u00a0welche\u00a0die\u00a0Parameter\u00a0Gesamt\u00fcberleben\u00a0( overall\u00a0\nsurvival,\u00a0OS),\u00a0progressionsfreies\u00a0\u00dcberleben\u00a0( progression\u00a0free\u00a0survival ,\u00a0PFS),\u00a0Toxizi\u2010\nt\u00e4t,\u00a0Lebensqualit\u00e4t\u00a0( Quality\u00a0of\u00a0life ,\u00a0QoL)\u00a0sowie\u00a0ggf.\u00a0bisher\u00a0unerf\u00fcllten\u00a0medizini\u2010\nschen\u00a0Behandlungsbedarf\u00a0( unmet\u00a0medical\u00a0need )\u00a0ber\u00fccksichtigen.\u00a0Sie\u00a0kritisieren,\u00a0\ndass\u00a0der\u00a0CDF\u00a0unabh\u00e4ngig\u00a0vom\u00a0NICE\u00a0agiere.\u00a0Am\u00a0Beispiel\u00a0der\u00a0Kombin ation\u00a0von\u00a0Nin\u2010\ntedanib\u00a0plus\u00a0Docetaxel\u00a0zeigen\u00a0sie\u00a0auf,\u00a0dass\u00a0mitunter\u00a0parallel\u00a0B ewertungen\u00a0seitens\u00a0\nCDF\u00a0bzw.\u00a0NICE\u00a0mit\u00a0diametralem\u00a0Ergebnis\u00a0erfolgten.\u00a0Im\u00a0zitierten\u00a0 Fall\u00a0verweigerte\u00a0\nder\u00a0CDF\u00a0die\u00a0Kosten\u00fcbernahme,\u00a0das\u00a0NICE\u00a0akzeptierte\u00a0zwei\u00a0Monate\u00a0s p\u00e4ter\u00a0im\u00a0Rah\u2010\nmen\u00a0einer\u00a0 end\u2010of\u2010life \u2010Therapie\u00a0Ausgaben\u00a0von\u00a0knapp\u00a0\u00a3\u00a050.000\u00a0je\u00a0QALY.\u00a0Als\u00a0weite\u2010\nren\u00a0kritikw\u00fcrdigen\u00a0Punkt\u00a0f\u00fchren\u00a0d ie\u00a0Autoren\u00a0die\u00a0Dauer\u00a0der\u00a0Bewer tung\u00a0an,\u00a0d.\u00a0h.\u00a0\nbeim\u00a0CDF\u00a0liegen\u00a0Ergebnisse\u00a0nach\u00a0nur\u00a0acht\u00a0Wochen,\u00a0beim\u00a0NICE\u00a0mitu nter\u00a0erst\u00a0nach\u00a0 \n118\u00a0\n\u00a048\u00a0bis\u00a074\u00a0Wochen\u00a0vor.\u00a0Als\u00a0Lehren\u00a0aus\u00a0der\u00a0ersten\u00a0Phase\u00a0des\u00a0CDF\u00a0f olgern\u00a0Dixon\u00a0et\u00a0\nal.,\u00a0dass\u00a0Preisverhandlungen\u00a0mit\u00a0 einem\u00a0Ergebnis\u00a0im\u00a0kosteneffizi enten\u00a0Bereich\u00a0eine\u00a0\nbessere\u00a0Alternative\u00a0darstellen,\u00a0als\u00a0eine\u00a0Kosten\u00fcbernahme\u00a0zum\u00a0vo m\u00a0pharmazeuti\u2010\nschen\u00a0Unternehmer\u00a0gew\u00e4hlten\u00a0Prei s\u00a0bei\u00a0unklarer\u00a0Evidenz\u00a0und\u00a0somi t\u00a0nicht\u00a0vorlie\u2010\ngender\u00a0Nutzen\u2010Kosten\u2010Effizienz\u00a0(Dixon\u00a0et\u00a0al.,\u00a02016).\u00a0\nBovenberg\u00a0et\u00a0al.\u00a0analysierten\u00a0in\u00a0einer\u00a0\u00dcbersichtsarbeit\u00a0die\u00a0zwi schen\u00a02009\u00a0und\u00a0\n2019\u00a0durchgef\u00fchrten\u00a0Bewertungen\u00a0des\u00a0NICE\u00a0( Technology\u00a0Appraisals ,\u00a0TA;\u00a0n=350),\u00a0\ndie\u00a0das\u00a0EoL\u2010Kriterium\u00a0beinhalten\u00a0(n=121;\u00a035\u00a0%)\u00a0und\u00a0stellten\u00a0Ver besserungsbedarf\u00a0\nder\u00a0Begutachtungsleitlinie\u00a0des\u00a0NICE\u00a0fest.\u00a0Sie\u00a0mahnen\u00a0eine\u00a0exakt e\u00a0Definition\u00a0des\u00a0OS\u00a0\nan,\u00a0da\u00a0mitunter\u00a0der\u00a0Mittel\u2010\u00a0( mean)\u00a0oder\u00a0der\u00a0mittlere\u00a0Wert\u00a0( median)\u00a0entweder\u00a0aus\u00a0\nden\u00a0klinischen\u00a0Studien\u00a0(Kaplan\u2010Meier\u2010Kurven)\u00a0oder\u00a0aus\u00a0gesundhei ts\u00f6konomischen\u00a0\nModellen,\u00a0der\u00a0Literatur\u00a0oder\u00a0Expertenmeinung\u00a0ber\u00fccksichtigt\u00a0wur den,\u00a0was\u00a0ihrer\u00a0\nMeinung\u00a0nach\u00a0einen\u00a0zu\u00a0gro\u00dfen\u00a0Interpretationsspielraum\u00a0darstelle .\u00a0Seit\u00a0Nutzung\u00a0\nder\u00a0erg\u00e4nzenden\u00a0Begutachtungsleitlinie\u00a0EoL\u00a0des\u00a0NICE\u00a0habe\u00a0sich\u00a0d er\u00a0Schwellenwert\u00a0\nder\u00a0 Kosteneffizienz\u00a0 ( cost\u2010effectivity\u00a0 threshold )\u00a0 von\u00a0 \u00a3\u00a020.000\u00a0 bis\u00a0 \u00a3\u00a030.000\u00a0 zu\u00a0\n\u00a3\u00a030.000\u00a0bis\u00a0\u00a3\u00a050.000\u00a0verschoben.\u00a0Die\u00a0Autoren\u00a0stellten\u00a0weiterhi n\u00a0fest,\u00a0dass\u00a0die\u00a0\npharmazeutischen\u00a0Unternehmer\u00a0im\u00a0Kontext\u00a0der\u00a0Preisbildungsstrate gie\u00a0diese\u00a0h\u00f6\u2010\nheren\u00a0Schwellenwerte\u00a0zunehmend\u00a0be r\u00fccksichtigen\u00a0(Bovenberg\u00a0et\u00a0al .,\u00a02021).\u00a0\nEs\u00a0f\u00e4llt\u00a0in\u00a0der\u00a0Diskussion\u00a0um\u00a0die\u00a0Reformation\u00a0des\u00a0CDF\u00a0aber\u00a0auch \u00a0der\u00a0EoL\u2010Kriterien\u00a0\ndes\u00a0NICE\u00a0auf,\u00a0dass\u00a0die\u00a0Markteintrittspreise\u00a0der\u00a0pharmazeutische n\u00a0Industrie,\u00a0d.\u00a0h.\u00a0\ndie\u00a0zentrale\u00a0Stellschraube\u00a0und\u00a0der\u00a0Ausgangspunkt\u00a0der\u00a0Preisbildu ng,\u00a0als\u00a0sakrosankt\u00a0\nangesehen\u00a0und\u00a0nicht\u00a0kritisch\u00a0gew\u00fcrdigt\u00a0werden.\u00a0Als\u00a0weiterer\u00a0L\u00f6s ungsansatz\u00a0w\u00e4re\u00a0\nes\u00a0nur\u00a0folgerichtig,\u00a0auch\u00a0die\u00a0fr eie\u00a0Preisbildung\u00a0der\u00a0pharmazeut ischen\u00a0Unternehmer\u00a0\nkritisch\u00a0zu\u00a0hinterfragen,\u00a0sich\u00a0europa\u2010\u00a0bzw.\u00a0weltweit\u00a0seitens\u00a0de r\u00a0Kostentr\u00e4ger\u00a0zu\u00a0\nkoordinieren\u00a0 und\u00a0 f\u00fcr\u00a0 mehr\u00a0 Transparenz\u00a0 und\u00a0 gerechtere\u00a0 Arzneimitt elpreise\u00a0 zu\u00a0\nstreben,\u00a0bevor\u00a0zu\u00a0Lasten\u00a0der\u00a0Patienten\u00a0eine\u00a0Rationierung\u00a0oder\u00a0P riorisierung\u00a0der\u00a0\nRessourcen\u00a0der\u00a0Gesundheitssysteme\u00a0zu\u00a0eingeschr\u00e4nktem\u00a0Zugang\u00a0nac h\u00a0individuel\u2010\nler\u00a0Zahlungsf\u00e4higkeit\u00a0f\u00fchren.\u00a0\nDas\u00a0NICE\u00a0verfolgt\u00a0gem\u00e4\u00df\u00a0des\u00a0aktuellen\u00a0F\u00fcnfjahresplans\u00a02021\u00a0bis\u00a0 2026\u00a0die\u00a0Strate\u2010\ngie,\u00a0weiterhin\u00a0als\u00a0global\u00a0f\u00fchrende\u00a0Institution\u00a0zur\u00a0Bewertung\u00a0vo n\u00a0Arzneimitteln\u00a0\n(Health\u00a0Technology\u00a0Assessment ,\u00a0HTA)\u00a0zu\u00a0agieren.\u00a0Basierend\u00a0auf\u00a0weltweiten\u00a0Exper\u2010\nteninterviews\u00a0wurden\u00a0als\u00a0zuk\u00fcnftige\u00a0Herausforderungen\u00a0aber\u00a0auch \u00a0Chancen\u00a0nach\u2010\nfolgende\u00a0Punkte\u00a0herauskristallisiert:\u00a0\n\uf0b7 Hohes\u00a0Tempo\u00a0bei\u00a0Innovationen\u00a0von\u00a0Behandlungsm\u00f6glichkeiten\u00a0im\u00a0Ge \u2010\nsundheitswesen\u00a0 ( Advanced\u00a0 Therapies\u00a0 Medicinal\u00a0 Products ,\u00a0 ATMP\u2019s,\u00a0\u00a0\nDigital\u00a0Health ,\u00a0Diagnostik,\u00a0Medizintechnologie,\u00a0Genomik)\u00a0mit\u00a0zuneh\u2010\nmend\u00a0hybriden\u00a0Produkten\u00a0 \n119\u00a0\n\u00a0\uf0b7 Digitalisierung,\u00a0Daten\u00a0und\u00a0Eviden zgenerierung\u00a0im\u00a0klinischen\u00a0All tag\u00a0\n\uf0b7 Integrierte\u00a0Versorgungssysteme\u00a0 und\u00a0Abbau\u00a0traditioneller\u00a0Barrier en\u00a0\n\uf0b7 Zunehmende\u00a0Vernetzung\u00a0nach\u00a0COVID\u201019\u00a0und\u00a0EU\u2010Austritt\u00a0\n\uf0b7 Zunehmende\u00a0Fokussierung\u00a0auf\u00a0den\u00a0Abbau\u00a0von\u00a0Ungleichheiten\u00a0bei\u00a0\nder\u00a0Gesundheit\u00a0\n\uf0b7 \u00d6konomische\u00a0 Herausforderungen\u00a0 zwingen\u00a0 zum\u00a0 optimalen\u00a0 Einsatz\u00a0\nvon\u00a0Ressourcen,\u00a0d.\u00a0h.\u00a0dass\u00a0in\u00a0Zeiten\u00a0einer\u00a0\u00f6konomischen\u00a0Rezessi on\u00a0\nals\u00a0Folge\u00a0der\u00a0COVID\u201019\u00a0Pandemie\u00a0 bei\u00a0neuen,\u00a0hochpreisigen\u00a0thera\u2010\npeutischen\u00a0Interventionen\u00a0eine\u00a0Optimierung\u00a0der\u00a0Opportunit\u00e4tskos \u2010\nten\u00a0unerl\u00e4sslich\u00a0wird\u00a0und\u00a0hierzu\u00a0die\u00a0Interventionen\u00a0mit\u00a0dem\u00a0gr\u00f6 \u00dften\u00a0\nNutzen\u00a0f\u00fcr\u00a0Patienten\u00a0zu\u00a0detektieren\u00a0sind.\u00a0\nHierzu\u00a0sollen\u00a0eine\u00a0verbesserte\u00a0Zu sammenarbeit\u00a0mit\u00a0der\u00a0britische n\u00a0Zulassungsbe\u2010\nh\u00f6rde\u00a0Medicine\u00a0and\u00a0Healthcare\u00a0products\u00a0Regulatory\u00a0Agency \u00a0(MHRA)\u00a0und\u00a0ein\u00a0fr\u00fch\u2010\nzeitig\u00a0einsetzender\u00a0Dialog\u00a0mit\u00a0den\u00a0pharmazeutischen\u00a0Unternehmer n\u00a0erfolgen.\u00a0Als\u00a0\neine\u00a0von\u00a0vier\u00a0S\u00e4ulen\u00a0dieser\u00a0zuk \u00fcnftigen\u00a0Strategie\u00a0wird\u00a0eine\u00a0\u201ez\u00fc gige,\u00a0verl\u00e4ssliche\u00a0\nund\u00a0angepasste\u00a0Bewertung\u201c\u00a0(\u201e Rapid,\u00a0robust\u00a0and\u00a0responsive\u00a0technology\u00a0evaluati\u2010\non\u201c,\u00a0NICE,\u00a02021b,\u00a0S.\u00a019)\u00a0genannt,\u00a0als\u00a0zweite\u00a0S\u00e4ule\u00a0werden\u00a0\u201edynami sche,\u00a0gelebte\u00a0\nLeitlinien\u2010Empfehlungen\u201c\u00a0(\u201e Dynamic,\u00a0living\u00a0guideline\u00a0recommendations \u201c,\u00a0ebd.\u00a0S.\u00a0\n22),\u00a0d.\u00a0h.\u00a0auch\u00a0eine\u00a0Vernetzung\u00a0mit\u00a0Patienten\u00a0und\u00a0im\u00a0Gesundheit swesen\u00a0Agieren\u2010\nden,\u00a0definiert,\u00a0als\u00a0dritte\u00a0S\u00e4ule\u00a0dient\u00a0\u201eEine\u00a0wirksame\u00a0Umsetzung \u00a0der\u00a0Empfehlungen,\u00a0\num\u00a0deren\u00a0Wirkungsgrad\u00a0zu\u00a0erh\u00f6hen\u201c\u00a0(\u201e Effective\u00a0guidance\u00a0uptake\u00a0to\u00a0maximise\u00a0our\u00a0\nimpact\u201c,\u00a0ebd.\u00a0S.\u00a024)\u00a0sowie\u00a0als\u00a0vierte\u00a0S\u00e4ule\u00a0die\u00a0\u201eF\u00fchrungsposition\u00a0bei \u00a0Daten,\u00a0For\u2010\nschung\u00a0und\u00a0Wissenschaft\u201c\u00a0(\u201e Leadership\u00a0in\u00a0data,\u00a0research\u00a0and\u00a0science \u201c,\u00a0ebd.\u00a0S.\u00a026).\u00a0\nZudem\u00a0werden\u00a0als\u00a0 NICE\u00a0International \u00a0im\u00a0Nachgang\u00a0des\u00a0Brexit\u00a0verst\u00e4rkt\u00a0weltweite\u00a0\nKooperationen\u00a0angestrebt\u00a0(NICE,\u00a02021b).\u00a0\nF\u00fcr\u00a0die\u00a0rund\u00a05,4\u00a0Mio.\u00a0Menschen\u00a0in\u00a0Schottland,\u00a0d.\u00a0h.\u00a0rund\u00a08\u00a0%\u00a0de r\u00a0Einwohner\u00a0in\u00a0UK,\u00a0\nb\u00fcndelt\u00a0das\u00a0 Scottish\u00a0Medicines\u00a0Consortium \u00a0(SMC)\u00a0seit\u00a02002\u00a0die\u00a0Bewertung\u00a0aller\u00a0\nneuen\u00a0Arzneimittel\u00a0(HTA),\u00a0zuvor\u00a0l ag\u00a0diese\u00a0Aufgabe\u00a0bei\u00a014\u00a0region alen\u00a0Arzneimittel\u2010\u00a0\nund\u00a0 Therapiekomitees\u00a0 ( local\u00a0 Area\u00a0 Drug\u00a0 and\u00a0 Therapeutic\u00a0 Committees ,\u00a0 ADTCs)\u00a0\n(OECD,\u00a02018;\u00a0SMC,\u00a02018).\u00a0Pharmazeutische\u00a0Unternehmer\u00a0nutzen\u00a0die \u00a0im\u00a0Vergleich\u00a0\nzum\u00a0NICE\u00a0binnen\u00a018\u00a0Wochen\u00a0schneller\u00a0vorliegenden\u00a0Bewertungen\u00a0de s\u00a0SMC\u00a0zur\u00a0\nAbsch\u00e4tzung\u00a0der\u00a0tendenziellen\u00a0Bewertung\u00a0des\u00a0NICE.\u00a0Das\u00a0SMC\u00a0unter scheidet\u00a0im\u00a0\nErgebnis\u00a0der\u00a0HTA\u00a0drei\u00a0Kategorien,\u00a0d.\u00a0h.\u00a0Kosten\u00fcbernahme\u00a0genehmi gt\u00a0(accepted),\u00a0\nmit\u00a0Einschr\u00e4nkung\u00a0auf\u00a0bestimmte\u00a0Patientengruppen\u00a0genehmigt\u00a0( accepted\u00a0with\u00a0\nsome\u00a0restrictions )\u00a0sowie\u00a0nicht\u00a0empfohlen\u00a0( not\u00a0recommended ).\u00a0Als\u00a0h\u00e4ufige\u00a0Gr\u00fcnde\u00a0\nf\u00fcr\u00a0eine\u00a0ablehnende\u00a0Entscheidung\u00a0nennt\u00a0das\u00a0SMC\u00a0ungeeignete\u00a0Wahl \u00a0der\u00a0Ver\u2010\ngleichstherapie\u00a0des\u00a0pU,\u00a0keine\u00a0th erapeutische\u00a0\u00dcberlegenheit\u00a0der\u00a0 Vergleichsthera\u2010\npie,\u00a0kein\u00a0\u00fcberzeugender\u00a0Nachweis \u00a0der\u00a0gesundheits\u00f6konomischen\u00a0Nu tzen\u2010Kosten\u2010\nEffektivit\u00e4t\u00a0oder\u00a0fehlende\u00a0Vorlage\u00a0von\u00a0Daten\u00a0( non\u2010submission ).\u00a0Um\u00a0bei\u00a0ansonsten\u00a0 \n120\u00a0\n\u00a0ung\u00fcnstiger\u00a0Nutzen\u2010Kosten\u2010Effektivit\u00e4t\u00a0dennoch\u00a0Marktzugang\u00a0zu\u00a0e rlangen,\u00a0k\u00f6nnen\u00a0\npU\u00a0im\u00a0Rahmen\u00a0von\u00a0Patientenzugangsprogrammen\u00a0( Patient\u00a0Access\u00a0Scheme [s],\u00a0PAS)\u00a0\neine\u00a0Bewertung\u00a0der\u00a0vom\u00a0SMC\u00a0getrennt\u00a0agierenden\u00a0 Patient\u00a0Access\u00a0Scheme\u00a0Asses\u2010\nsment\u00a0Group \u00a0(PASAG)\u00a0vornehmen\u00a0lassen\u00a0(SMC,\u00a02018).\u00a0Seit\u00a0April\u00a02014\u00a0bietet\u00a0d as\u00a0\nSMC\u00a0f\u00fcr\u00a0EoL\u00a0oder\u00a0Arzneimittel\u00a0zur\u00a0Therapie\u00a0seltener\u00a0bzw.\u00a0sehr\u00a0s eltener\u00a0Leiden\u00a0\n(orphan\u00a0bzw.\u00a0ultra\u2010orphan\u00a0diseases ),\u00a0welche\u00a0im\u00a0Rahmen\u00a0der\u00a0regul\u00e4ren\u00a0Bewertung\u00a0\ndes\u00a0New\u00a0Drug\u00a0Committees\u00a0 (NDC)\u00a0keine\u00a0Empfehlung\u00a0erhalten\u00a0k\u00f6nnen,\u00a0zus\u00e4tzlich\u00a0\nauf\u00a0Antrag\u00a0des\u00a0pharmazeutischen\u00a0Unternehmers\u00a0eine\u00a0Beteiligung\u00a0v on\u00a0Patienten\u00a0\nund\u00a0klinischen\u00a0Experten\u00a0( Patient\u00a0and\u00a0Clinician\u00a0Engagement ,\u00a0PACE)\u00a0im\u00a0Rahmen\u00a0\neiner\u00a0vertraulichen\u00a0Anh\u00f6rung\u00a0a n\u00a0(Barham,\u00a02019;\u00a0SMC,\u00a02021).\u00a0\u00a0\nGro\u00dfbritannien\u00a0nutzt\u00a0keine\u00a0externe \u00a0Preisreferenzierung\u00a0von\u00a0Arzn eimitteln,\u00a0dient\u00a0\njedoch\u00a0Frankreich\u00a0und\u00a016\u00a0weiteren \u00a0EU\u2010L\u00e4ndern\u00a0als\u00a0Referenzland.\u00a0 Busse\u00a0et\u00a0al.\u00a0er\u2010\nmittelten\u00a0in\u00a0einem\u00a0Vergleich\u00a0der\u00a0Preise\u00a0f\u00fcr\u00a0Arzneimittel\u00a0mit\u00a0Pa tentschutz\u00a0von\u00a0f\u00fcnf\u00a0\nEU\u00a0L\u00e4ndern,\u00a0dass\u00a0bei\u00a0230\u00a0Arzneimi tteln\u00a0bei\u00a0Nutzung\u00a0BIP\u2010adjustie rter\u00a0Preise\u00a0das\u00a0\nNiveau\u00a0im\u00a0Mittel\u00a0um\u00a016\u00a0%\u00a0unter\u00a0dem\u00a0Preisniveau\u00a0in\u00a0Deutschland\u00a0l ag.\u00a0Werden\u00a0\nKaufkraftstandards\u00a0in\u00a0diesen\u00a0Ver gleich\u00a0mit\u00a0einbezogen,\u00a0so\u00a0liegt \u00a0der\u00a0Wert\u00a0bei\u00a013\u00a0%\u00a0\nunterhalb\u00a0der\u00a0deutschen\u00a0Arzneimittelpreise.\u00a0Busse\u00a0et\u00a0al.\u00a0leiten \u00a0hieraus\u00a0ein\u00a0Ein\u2010\nsparpotenzial\u00a0von\u00a01,3\u00a0Mrd.\u00a0Euro\u00a0ab\u00a0(Busse\u00a0et\u00a0al.,\u00a02016).\u00a0\n S\u00fcdkorea\u00a06.5\nS\u00fcdkorea\u00a0hat\u00a0in\u00a0den\u00a0letzten\u00a0einhundert\u00a0Jahren\u00a0einen\u00a0beachtliche n\u00a0Wandel\u00a0vollzo\u2010\ngen.\u00a0Einen\u00a0Meilenstein\u00a0in\u00a0der\u00a0Gesundheitsversorgung\u00a0stellt\u00a0die\u00a0 Einf\u00fchrung\u00a0der\u00a0\nstaatlichen\u00a0Krankenversicherung,\u00a0der\u00a0 National\u00a0Health\u00a0Insurance \u00a0(NHI)\u00a0bzw.\u00a0opera\u2010\ntiv\u00a0des\u00a0National\u00a0Health\u00a0Insurance\u00a0Service \u00a0(NHIS),\u00a0im\u00a0Jahr\u00a01977\u00a0dar,\u00a0welche\u00a0zu\u2010\nn\u00e4chst\u00a0nur\u00a0Arbeitern\u00a0in\u00a0gro\u00dfen\u00a0Unternehmen\u00a0(>500\u00a0Mitarbeiter)\u00a0o ffenstand\u00a0und\u00a0\nzw\u00f6lf\u00a0Jahre\u00a0sp\u00e4ter,\u00a0d.\u00a0h.\u00a0im\u00a0Jahr\u00a01989,\u00a0als\u00a0allgemeine\u00a0Krankenv ersicherung\u00a0wirk\u2010\nsam\u00a0wurde.\u00a0Finanziert\u00a0wird\u00a0diese\u00a0anteilig\u00a0von\u00a0Arbeitnehmern\u00a0und \u00a0\u2010gebern.\u00a0Der\u00a0\nUmfang\u00a0der\u00a0NHI\u00a0deckt\u00a0nicht\u00a0alle\u00a0Kosten\u00a0im\u00a0Krankheitsfall\u00a0ab,\u00a0so dass\u00a0private\u00a0Zu\u2010\nsatzversicherungen,\u00a0 Voluntary\u00a0Health\u00a0Insurances \u00a0(VHI)\u00a0ben\u00f6tigt\u00a0werden.\u00a0\u00a0\nIn\u00a0S\u00fcdkorea\u00a0agiert\u00a0ein\u00a0sehr\u00a0hoher\u00a0Anteil\u00a0an\u00a0privaten\u00a0Leistungse rbringern.\u00a0Im\u00a0Jahr\u00a0\n2000\u00a0kam\u00a0es\u00a0zu\u00a0zwei\u00a0gro\u00dfen\u00a0Reformen,\u00a0einerseits\u00a0der\u00a0\u201e integration\u00a0reform \u201c,\u00a0welche\u00a0\n366\u00a0 Versicherungsgesellschaften\u00a0 zu\u00a0 einem\u00a0 einheitlichen\u00a0 Kostentr \u00e4ger\u00a0 vereinte,\u00a0\nandererseits\u00a0die\u00a0\u201e separation\u00a0reform \u201c,\u00a0die\u00a0eine\u00a0strikte\u00a0Trennung\u00a0von\u00a0Apotheken\u00a0\nund\u00a0Arztpraxen\u00a0umsetzte\u00a0und\u00a0als\u00a0Kostend\u00e4mpfungsinstrument\u00a0gegen \u00a0einen\u00a0zu\u00a0\nhohen\u00a0Medikamentenkonsum\u00a0diene n\u00a0sollte.\u00a0Die\u00a0Gesundheitsausgaben \u00a0f\u00fcr\u00a0Medi\u2010\nkamente\u00a0lagen\u00a0zu\u00a0diesem\u00a0Zeitpunk t\u00a0mit\u00a031\u00a0%\u00a0\u00fcber\u00a0dem\u00a0OECD\u2010Durchs chnitt\u00a0von\u00a0\n20\u00a0%.\u00a0In\u00a0Apotheken\u00a0wurde\u00a0allgemei nmedizinisch\u00a0therapiert.\u00a0Die\u00a0B ehandlung\u00a0fu\u00dfte\u00a0\ntraditionell\u00a0auf\u00a0zwei\u00a0S\u00e4ulen,\u00a0der\u00a0\u201ewestlichen\u00a0Medizin\u201c\u00a0sowie\u00a0de r\u00a0\u201etraditionellen\u00a0 \n121\u00a0\n\u00a0koreanischen\u00a0Medizin\u00a0(TKM)\u201c.\u00a0Der\u00a0Zuwachs\u00a0des\u00a0Anteils\u00a0der\u00a0korean ischen\u00a0Bev\u00f6lke\u2010\nrung\u00a0\u00fcber\u00a065\u00a0Jahre\u00a0auf\u00a0voraussichtlich\u00a0\u00fcber\u00a034\u00a0%\u00a0im\u00a0Jahr\u00a02050\u00a0s tellt\u00a0f\u00fcr\u00a0die\u00a0NHI\u00a0\neine\u00a0Herausforderung\u00a0dar,\u00a0d.\u00a0h.\u00a0in\u00a0S\u00fcdkorea\u00a0lebt\u00a0dann\u00a0die\u00a0zweit \u00e4lteste\u00a0Bev\u00f6lke\u2010\nrung\u00a0nach\u00a0Japan.\u00a0Als\u00a0Folge\u00a0der\u00a0hierdurch\u00a0bedingten,\u00a0rapide\u00a0stei genden\u00a0Leistungs\u2010\nausgaben\u00a0gestaltet\u00a0sich\u00a0eine\u00a0Fin anzierung\u00a0der\u00a0NHI\u00a0anspruchsvoll \u00a0(Huang\u00a0et\u00a0al.,\u00a0\n2018;\u00a0Kern\u00a0&\u00a0Nam,\u00a02020;\u00a0WHO\u00a02015).\u00a0\nDie\u00a0NHI\u00a0versichert\u00a097\u00a0%\u00a0der\u00a0Kore aner,\u00a03\u00a0%\u00a0mit\u00a0niedrigem\u00a0Einkomm en\u00a0erhalten\u00a0eine\u00a0\nKosten\u00fcbernahme\u00a0 \u00fcber\u00a0 das\u00a0 steuerfinanzierte\u00a0 Medical\u00a0 Aid\u00a0 Program .\u00a0 Nicht\u00a0 alle\u00a0\nLeistungen\u00a0werden\u00a0von\u00a0der\u00a0NHI\u00a0\u00fcbernommen,\u00a0sodass\u00a0im\u00a0Vergleich\u00a0z u\u00a0den\u00a0Mit\u2010\ngliedsstaaten\u00a0der\u00a0OECD\u00a0h\u00f6here\u00a0Eigenanteile\u00a0(20\u00a0%\u00a0 inpatient\u00a0 (im\u00a0Krankenhaus),\u00a030\u00a0\nbis\u00a0 60\u00a0%\u00a0 outpatient\u00a0 (ambulant))\u00a0 geleistet\u00a0 werden\u00a0 m\u00fcssen.\u00a0 Unter\u00a0 Aufsicht\u00a0 des\u00a0\nGesundheitsministeriums,\u00a0 Ministry\u00a0of\u00a0Health\u00a0and\u00a0Welfare ,\u00a0handeln\u00a0sowohl\u00a0opera\u2010\ntiv\u00a0 die\u00a0 einheitliche\u00a0 Krankenversicherung,\u00a0 NHIS,\u00a0 als\u00a0 auch\u00a0 die\u00a0 Be wertungsstelle\u00a0\nHealth\u00a0Review\u00a0and\u00a0Assessment\u00a0Service \u00a0(HIRA).\u00a0Der\u00a0HIRA\u00a0liegen\u00a0die\u00a0Daten\u00a0von\u00a0na\u2010\nhezu\u00a0der\u00a0gesamten\u00a0koreanischen\u00a0B ev\u00f6lkerung\u00a0vor,\u00a0die\u00a0im\u00a0Kontext\u00a0 des\u00a0Bewer\u2010\ntungsauftrages\u00a0als\u00a0auch\u00a0der\u00a0Versorgungsforschung\u00a0genutzt\u00a0werden \u00a0k\u00f6nnen.\u00a0Zwi\u2010\nschen\u00a0den\u00a0Jahren\u00a02000\u00a0und\u00a02013\u00a0stie gen\u00a0die\u00a0Arzneimittelausgaben \u00a0in\u00a0Korea\u00a0um\u00a0\n275,3\u00a0%,\u00a0sodass\u00a0umfangreiche\u00a0Pre isregulierungsmechanismen\u00a0notwe ndig\u00a0wurden\u00a0\n(Kim\u00a0et\u00a0al.,\u00a02017;\u00a0Kwon\u00a0&\u00a0Godman,\u00a02017).\u00a0\nPreisregulierungsmechanismen\u00a0in\u00a0der\u00a0s\u00fcdkoreanischen\u00a0Krankenvers icherung\u00a0\nBei\u00a0Markteintritt\u00a0neuer\u00a0Arzneimi ttel\u00a0in\u00a0S\u00fcdkorea\u00a0m\u00fcssen\u00a0neben\u00a0d er\u00a0arzneimittel\u2010\nrechtlichen\u00a0 Zulassung\u00a0 durch\u00a0 das\u00a0 Ministerium\u00a0 f\u00fcr\u00a0 Lebens\u2010\u00a0 und\u00a0 Arz neimittel\u2010\nSicherheit,\u00a0 Ministry\u00a0of\u00a0Food\u00a0and\u00a0Drug\u00a0Safety ,\u00a0im\u00a0Rahmen\u00a0des\u00a0 Drug\u00a0Expenditure\u00a0\nRationalization\u00a0Plan \u00a0(DERP)\u00a0seit\u00a02007\u00a0einerseits\u00a0der\u00a0therapeutische\u00a0Stellenwert,\u00a0\nd.\u00a0h.\u00a0 die\u00a0 c linical\u00a0 usefulness\u00a0 and\u00a0 effectiveness, \u00a0i m \u00a0R a h m e n \u00a0e i n e s \u00a0H T A \u2010\nBewertungsverfahrens\u00a0bei\u00a0der\u00a0HIRA\u00a0bzw.\u00a0deren\u00a0 Drug\u00a0Reimbursement\u00a0Evaluation\u00a0\nCommittee \u00a0(DREC)\u00a0sowie\u00a0andererseits\u00a0der\u00a0Preis\u00a0im\u00a0NHIS,\u00a0d.\u00a0h.\u00a0der\u00a0sogenan nte\u00a0\nH\u00f6chstpreis,\u00a0 Maximum\u00a0Reimbursement\u00a0Price \u00a0(MRP)\u00a0mit\u00a0dem\u00a0pU\u00a0verhandelt\u00a0wer\u2010\nden\u00a0(Tabelle:\u00a06.3).\u00a0\u00a0\n\u00a0 \u00a0 \n122\u00a0\n\u00a0Tabelle\u00a06.3:\u00a0Institutioneller\u00a0Ablauf\u00a0der\u00a0zweistufigen\u00a0Bewertung \u00a0neuer\u00a0Arzneimit\u2010\ntel\u00a0in\u00a0Korea\u00a0\nOrganisation\u00a0 HIRA\u00a0 NHIS\u00a0\nAusschuss\u00a0 DREC\u00a0 \u2010\u00a0\nEntscheidung\u00a0\u00fcber\u00a0 Erstattung\u00a0des\u00a0Arzneimittels\u00a0und\u00a0Rahmen\u00a0 Erstattungsbetrag\u00a0im\u00a0NH IS\u00a0\nZeitrahmen\u00a0 \u00a0150\u00a0Tage\u00a0 60\u00a0Tage\u00a0\nKriterien\u00a0 Klinischer\u00a0und\u00a0\u00f6konomischer\u00a0Stellenwert\u00a0 Verhandlungsmacht\u00a0\nZu\u00a0ber\u00fccksichtigende\u00a0\nKriterien\u00a0\u2010\u00a0Klinischer\u00a0Stellenwert\u00a0\n\u2010\u00a0Kosteneffizienz\u00a0\n\u2010\u00a0Auswirkung\u00a0auf\u00a0die\u00a0Ausgaben\u00a0des\u00a0NHIS\u00a0\n\u2010\u00a0Pr\u00fcfung\u00a0der\u00a0Erstattungsf\u00e4higkeit\u00a0\n(Positivliste)\u00a0und\u00a0exte rner\u00a0Preisvergleich\u00a0\nmittels\u00a0L\u00e4nderkorb\u00a0(USA,\u00a0Frankreich,\u00a0\nItalien,\u00a0Gro\u00dfbritannien,\u00a0Schweiz,\u00a0Japan,\u00a0\nDeutschland,\u00a0Taiwan,\u00a0Australien)\u00a0\u2010\u00a0DREC\u00a0review\u00a0report\u00a0\n\u2010\u00a0Wirkung\u00a0auf\u00a0die\u00a0Ausgaben\u00a0des\u00a0NHIS\u00a0\n\u2010\u00a0Ber\u00fccksichtigung\u00a0der\u00a0zVT,\u00a0\nArzneimittelpreise,\u00a0Erstattungsbetr\u00e4ge\u00a0\nsowie\u00a0Lieferf\u00e4higkeit\u00a0und\u00a0\nZulassungsstatus\u00a0der\u00a0Arzneimittel\u00a0in\u00a0\nanderen\u00a0L\u00e4ndern\u00a0\n\u2010\u00a0Koreanische\u00a0und\u00a0internationale\u00a0Daten,\u00a0\nwie\u00a0Patentstatus,\u00a0eigene\u00a0Forschung,\u00a0\nForschungs\u2010\u00a0und\u00a0Entwicklungskosten\u00a0\n\u2010\u00a0Weitere\u00a0Kriterien\u00a0k\u00f6nnen\u00a0die\u00a0Bildung\u00a0\ndes\u00a0Erstattungsbetrages\u00a0beeinflussen.\u00a0\nQuelle:\u00a0nach\u00a0Kwon\u00a0&\u00a0Godman,\u00a02017,\u00a0S.\u00a0449\u00a0\nF\u00fcr\u00a0 den\u00a0 MRP\u00a0 erfolgt\u00a0 eine\u00a0 externe\u00a0 Referenzierung\u00a0 mittels\u00a0 L\u00e4nderv ergleich\u00a0 (USA,\u00a0\nJapan,\u00a0UK,\u00a0Deutschland,\u00a0Frankreich,\u00a0Schweiz,\u00a0Italien,\u00a0Taiwan\u00a0un d\u00a0Australien)\u00a0der\u00a0\nArzneimittelpreise,\u00a0zudem\u00a0werden\u00a0die\u00a0Kosten\u00a0der\u00a0in\u00a0Korea\u00a0\u00fcblich en\u00a0Standardthera\u2010\npie\u00a0und\u00a0der\u00a0Einfluss\u00a0des\u00a0neuen\u00a0Arzneimittels\u00a0auf\u00a0die\u00a0Gesundheit sausgaben,\u00a0d.h.\u00a0der\u00a0\nbudget\u00a0impact \u00a0im\u00a0NHIS\u00a0ber\u00fccksichtigt\u00a0(s.\u00a0Abb.\u00a06.2).\u00a0F\u00fcr\u00a0Arzneimittel\u00a0in\u00a0der\u00a0 Onkologie,\u00a0\nOrphan\u00a0 Drugs \u00a0 oder\u00a0 Antibiotika\u00a0 kann\u00a0 eine\u00a0 Ausnahme\u00a0 von\u00a0 der\u00a0 pharmako\u2010\n\u00f6konomischen,\u00a0 pharmaco\u2010economic (PE)\u2010pathway,\u00a0Bewertung\u00a0erfolgen,\u00a0indem\u00a0soge\u2010\nnannte\u00a0risk\u00a0sharing\u00a0agreements \u00a0(RSA)\u00a0mit\u00a0den\u00a0pU\u00a0verhandelt\u00a0werden\u00a0(Choi\u00a0&\u00a0Lee,\u00a0\n2021).\u00a0Auch\u00a0nach\u00a0erstmaliger\u00a0Bewertung\u00a0von\u00a0Arzneimitteln\u00a0bei\u00a0Au fnahme\u00a0in\u00a0die\u00a0seit\u00a0\ndem\u00a0 Jahr\u00a0 2007\u00a0 etablierte\u00a0 Positivliste\u00a0 erfolgt\u00a0 eine\u00a0 kontinuierli che\u00a0 Bewertung\u00a0 der\u00a0\nErstattungspreise\u00a0von\u00a0Arzneimitt eln\u00a0im\u00a0NHIS\u00a0(Kim\u00a0&\u00a0Lee,\u00a02020;\u00a0W HO\u00a02015).\u00a0 \n123\u00a0\n\u00a0\u00a0\nAbb.\u00a06.1:\u00a0Evaluation\u00a0des\u00a0Nutzens\u00a0und\u00a0der\u00a0Kosten\u00a0neuer\u00a0Arzneimit tel\u00a0im\u00a0NHIS\u00a0\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0Quelle:\u00a0Yoo\u00a0et\u00a0al.,\u00a02019,\u00a0S.\u00a04\u00a0 \n124\u00a0\n\u00a0Im\u00a0Ergebnis\u00a0f\u00fchrten\u00a0die\u00a0Verhandlungen\u00a0\u00fcber\u00a0die\u00a0Arzneimittelprei se\u00a0zwischen\u00a0NHIS\u00a0\nund\u00a0pU\u00a0in\u00a0den\u00a0Jahren\u00a02007\u00a0bis\u00a02013\u00a0zu\u00a0einer\u00a0Preisreduktion\u00a0von\u00a0 durchschnittlich\u00a0\n13\u00a0%\u00a0(Standardabweichung\u00a011,7\u00a0%)\u00a0im\u00a0Vergleich\u00a0zum\u00a0vom\u00a0pU\u00a0gew\u00fcns chten\u00a0Erstat\u2010\ntungsbetrag\u00a0(Kwon\u00a0&\u00a0Godman,\u00a02017).\u00a0\nIn\u00a0S\u00fcdkorea\u00a0wird\u00a0f\u00fcr\u00a0Generika\u00a0ein\u00a0Preis\u00a0in\u00a0H\u00f6he\u00a0von\u00a053,55\u00a0%\u00a0des \u00a0Alt\u2010Originals\u00a0bei\u00a0\nMarkteintritt\u00a0staatlich\u00a0festgele gt,\u00a0was\u00a0bei\u00a0fehlendem\u00a0Wettbewer b\u00a0zu\u00a0einem\u00a0wei\u2010\nterhin\u00a0hohen\u00a0Anteil\u00a0des\u00a0Alt\u2010Originals\u00a0f\u00fchrt.\u00a0In\u00a0Europa\u00a0belaufen \u00a0sich\u00a0die\u00a0Kosten\u00a0f\u00fcr\u00a0\nGenerika\u00a0 in\u00a0 Folge\u00a0 der\u00a0 Marktmechanismen\u00a0 auf\u00a0 zwei\u00a0 bis\u00a0 10\u00a0%\u00a0 des\u00a0 Al t\u2010Originals\u00a0\n(Kwon\u00a0&\u00a0Godman,\u00a02017).\u00a0\nBewertung\u00a0von\u00a0Arzneimitteln\u00a0der\u00a0Positivliste\u00a0\nNach\u00a0Aufnahme\u00a0von\u00a0Arzneimitteln\u00a0in\u00a0eine\u00a0Positivliste\u00a0erfolgt\u00a0di e\u00a0Anpassung\u00a0der\u00a0\nErstattungsbetr\u00e4ge\u00a0 \u00fcber\u00a0 verschiedene\u00a0 Mechanismen.\u00a0 Eine\u00a0 Streichu ng\u00a0 von\u00a0 der\u00a0\nPositivliste\u00a0erfolgt,\u00a0wenn\u00a0das\u00a0Ar zneimittel\u00a0\u00fcber\u00a0zwei\u00a0Jahre\u00a0nic ht\u00a0produziert\u00a0bzw.\u00a0\nVerordnungen\u00a0 zur\u00a0 Kostenerstattung\u00a0 hierf\u00fcr\u00a0 eingereicht\u00a0 werden.\u00a0 E ine\u00a0 zun\u00e4chst\u00a0\nangedachte\u00a0Bewertung\u00a0der\u00a0vor\u00a020 07\u00a0gelisteten\u00a0Arzneimittel\u00a0erfuh r\u00a0ein\u00a0\u00e4hnliches\u00a0\nSchicksal\u00a0wie\u00a0die\u00a0Bestrebungen\u00a0zur\u00a0Bewertung\u00a0des\u00a0Bestandmarktes \u00a0in\u00a0Deutsch\u2010\nland.\u00a0Aufgrund\u00a0der\u00a0Gr\u00f6\u00dfe\u00a0des\u00a0Projekts\u00a0sowie\u00a0des\u00a0Protestes\u00a0der\u00a0p harmazeutischen\u00a0\nIndustrie\u00a0in\u00a0S\u00fcdkorea\u00a0fand\u00a0lediglich\u00a0eine\u00a0moderate\u00a0Preisredukti on\u00a0ohne\u00a0Kosten\u2010\nNutzen\u2010Bewertung\u00a0statt\u00a0(Lee\u00a0&\u00a0Kim,\u00a02012).\u00a0\nKonsequent\u00a0erscheint\u00a0das\u00a0Vorgehen\u00a0gegen\u00a0finanzielle\u00a0R\u00fcckfl\u00fcsse\u00a0 von\u00a0pU\u00a0an\u00a0Leis\u2010\ntungserbringer,\u00a0sogenannte\u00a0 Kickback\u2010Zahlungen.\u00a0PU\u00a0m\u00fcssen\u00a0den\u00a0Betrag\u00a0des\u00a0 Kick\u2010\nbacks\u00a0bei\u00a0Bekanntwerden\u00a0als\u00a0Rabatt\u00a0an\u00a0den\u00a0NHIS\u00a0gew\u00e4hren\u00a0und\u00a0\u00c4rzten\u00a0d roht\u00a0eine\u00a0\nHaftstrafe\u00a0von\u00a0bis\u00a0zu\u00a0zwei\u00a0Jahren,\u00a0eine\u00a0Geldstrafe\u00a0in\u00a0H\u00f6he\u00a0von\u00a0 30\u00a0Mio.\u00a0Koreanische\u00a0\nWon\u00a0sowie\u00a0ein\u00a0potenzieller\u00a0Verlus t\u00a0der\u00a0Lizenz\u00a0zur\u00a0Behandlung\u00a0im \u00a0NHIS\u00a0von\u00a0bis\u00a0zu\u00a0\neinem\u00a0Jahr.\u00a0\u00a0\nMonatlich\u00a0werden\u00a0verhandelte\u00a0Erstattungsbetr\u00e4ge\u00a0des\u00a0NHIS\u00a0mit\u00a0de n\u00a0tats\u00e4chlichen\u00a0\nMarktpreisen\u00a0abgeglichen\u00a0und\u00a0angepasst\u00a0( actual\u00a0transaction\u00a0pricing ,\u00a0ATP).\u00a0Preis\u2010\nVolumen\u2010Vereinbarungen\u00a0( Price\u2010Volume\u00a0Agreement ,\u00a0PVA)\u00a0finden\u00a0bei\u00a0Markteintritt\u00a0\nneuer\u00a0Arzneimittel\u00a0Anwendung,\u00a0inde m\u00a0bei\u00a0Anstieg\u00a0der\u00a0Erstattung\u00a0 f\u00fcr\u00a0dieses\u00a0Arz\u2010\nneimittel\u00a0um\u00a030\u00a0%\u00a0der\u00a0Rabat\u00a0des\u00a0 NHIS\u00a0mit\u00a0dem\u00a0Ziel\u00a0der\u00a0Ausgabend \u00e4mpfung\u00a0neu\u00a0\nverhandelt\u00a0werden\u00a0muss\u00a0(Kwon\u00a0&\u00a0Godman,\u00a02017).\u00a0\nIn\u00a0einer\u00a0Studie\u00a0widmen\u00a0sich\u00a0Kim\u00a0und\u00a0Lee\u00a0der\u00a0seit\u00a02007\u00a0in\u00a0S\u00fcdkor ea\u00a0eingef\u00fchrten\u00a0\nBewertung\u00a0neuer\u00a0Arzneimittel\u00a0der\u00a0Positivliste\u00a0mit\u00a0Fokus\u00a0auf\u00a0den \u00a0Preis\u00e4nderungen\u00a0\nnach\u00a0Listung\u00a0\u00fcber\u00a0einen\u00a0Zeitraum\u00a0von\u00a0elf\u00a0Jahren,\u00a0d.h.\u00a0bis\u00a02017. \u00a0Hierbei\u00a0unterschei\u2010\nden\u00a0sie\u00a0die\u00a0Preisbildung\u00a0bei\u00a0Mark teintritt\u00a0nach\u00a0den\u00a0drei\u00a0Katego rien:\u00a0 \n125\u00a0\n\u00a01. Cost\u2010effectiveness\u00a0 (CE)\u2010Pathway :\u00a0 Bei\u00a0 \u00fcberlegener,\u00a0 klinischer\u00a0 Wirk\u2010\nsamkeit\u00a0erfolgte\u00a0eine\u00a0Preisanpass ung,\u00a0bei\u00a0der\u00a0ein\u00a0h\u00f6herer\u00a0Preis \u00a0im\u00a0\nVergleich\u00a0zur\u00a0Standardtherapie\u00a0akzeptiert\u00a0wird.\u00a0\n2. Weighted\u00a0average\u00a0price\u00a0(WAP)\u2010Pathway :\u00a0Der\u00a0Weg\u00a0des\u00a0gewichteten\u00a0\nDurchschnittspreises\u00a0kommt\u00a0bei\u00a0\u00dcb er\u2010\u00a0oder\u00a0Nicht\u2010Unterlegenheit\u00a0 im\u00a0\nHinblick\u00a0auf\u00a0die\u00a0klinische\u00a0Wertigkeit\u00a0des\u00a0Arzneimittels\u00a0im\u00a0Verg leich\u00a0\nzur\u00a0zVT\u00a0zum\u00a0Einsatz,\u00a0der\u00a0Preis\u00a0wird\u00a0unterhalb\u00a0des\u00a0WAP\u00a0angesetzt .\u00a0\n3. Without\u00a0 CE\u2010Pathway :\u00a0 Bei\u00a0 lebensbedrohlichen\u00a0 Erkrankungen,\u00a0 d.\u00a0h.\u00a0\nKrebs\u00a0oder\u00a0seltenen\u00a0Leiden;\u00a0mit\u00a0f ehlenden\u00a0Therapiealternativen\u00a0 o\u2010\nder\u00a0kleiner\u00a0Anzahl\u00a0an\u00a0Patienten\u00a0und\u00a0nicht\u00a0m\u00f6glichem\u00a0Nachweis\u00a0ei ner\u00a0\nKosteneffizienz\u00a0 erfolgt\u00a0 die\u00a0 Bil dung\u00a0 eines\u00a0 Erstattungsbetrages\u00a0 i m\u00a0\nNHIS\u00a0auf\u00a0Basis\u00a0externer\u00a0Referenz preise\u00a0des\u00a0Arzneimittels\u00a0in\u00a0sie ben\u00a0\nL\u00e4ndern\u00a0(\u201eA7\u201c:\u00a0USA,\u00a0Japan,\u00a0Deuts chland,\u00a0Frankreich,\u00a0Schweiz,\u00a0Gr o\u00df\u2010\nbritannien\u00a0und\u00a0Italien).\u00a0Zudem\u00a0k\u00f6nnen\u00a0im\u00a0Sinne\u00a0eines\u00a0begleitete n\u00a0\nMarktzugangs,\u00a0 managed\u00a0entry\u00a0agreement ,\u00a0RSA\u00a0f\u00fcr\u00a0das\u00a0NHIS\u00a0getrof\u2010\nfen\u00a0werden.\u00a0\nDas\u00a0System\u00a0der\u00a0Preissenkung\u00a0nach\u00a0 Aufnahme\u00a0in\u00a0die\u00a0Positivliste,\u00a0 post\u2010listing\u00a0price\u2010\ncutting\u00a0system ,\u00a0in\u00a0Korea\u00a0weist\u00a0vier\u00a0Typen\u00a0auf:\u00a0\n1. Price\u2010volume\u2010agreements \u00a0(PVA):\u00a0Bei\u00a0neuer\u00a0Aufnahme\u00a0in\u00a0die\u00a0Positiv\u2010\nliste\u00a0im\u00a0NHIS\u00a0werden\u00a0j\u00e4hrliche\u00a0Absatzmengen\u00a0und\u00a0somit\u00a0auch\u00a0Um\u2010s\u00e4tze,\u00a0d.\u00a0h.\u00a0der\u00a0 Budget\u00a0Impact \u00a0definiert,\u00a0bei\u00a0\u00dcberschreiten\u00a0um\u00a030\u00a0%\u00a0\nwird\u00a0der\u00a0Preis\u00a0des\u00a0Arzneimittels\u00a0im\u00a0Wege\u00a0der\u00a0Verhandlung\u00a0mit\u00a0de m\u00a0\npU\u00a0um\u00a0bis\u00a0zu\u00a010\u00a0%\u00a0reduziert.\u00a0Bei\u00a0Steigerung\u00a0der\u00a0Ausgaben\u00a0um\u00a060\u00a0 %\u00a0\nim\u00a0Vergleich\u00a0zum\u00a0Vorjahr\u00a0oder\u00a0bei\u00a0einem\u00a0Zuwachs\u00a0von\u00a0gr\u00f6\u00dfer\u00a010\u00a0% \u00a0\nbei\u00a0 Ausgaben\u00a0 \u00fcber\u00a0 f\u00fcnf\u00a0 Milliarden\u00a0 koreanischer\u00a0 Won\u00a0 (KRW)\n1\u00a0( = \u00a0\n3.752.542,35\u00a0\u20ac)\u00a0erfolgt\u00a0eine\u00a0erneute\u00a0Verhandlung\u00a0mit\u00a0wiederum\u00a0b is\u00a0\nzu\u00a010\u00a0%iger\u00a0Preisreduktion.\u00a0\u00a0\n2. Die\u00a0Transaction\u00a0price\u00a0policy \u00a0beinhaltet\u00a0die\u00a0Analyse\u00a0eines\u00a0zweij\u00e4hri\u2010\ngen\u00a0Zeitraumes.\u00a0Liegt\u00a0der\u00a0aktuelle\u00a0Handelspreis\u00a0( transaction\u00a0price )\u00a0\nunter\u00a0dem\u00a0vereinbarten\u00a0Erstattungspreis\u00a0( reimbursement\u00a0price )\u00a0des\u00a0\nNHIS,\u00a0kann\u00a0ein\u00a0zehnprozenti ger\u00a0Abschlag\u00a0erfolgen.\u00a0\u00a0\n3. Erhalten\u00a0Arzneimittel\u00a0neue\u00a0Anwendungsgebiete\u00a0( expanded\u00a0indicati\u2010\non)\u00a0im\u00a0Rahmen\u00a0einer\u00a0Zulassungserweiterung,\u00a0erfolgt\u00a0eine\u00a0Preisan\u2010\npassung.\u00a0Steigen\u00a0die\u00a0Ausgaben\u00a0des\u00a0NHIS\u00a0zwischen\u00a01,5\u00a0und\u00a010\u00a0Mill i\u2010\narden\u00a0KRW,\u00a0wird\u00a0eine\u00a0Obergrenze\u00a0( Cap)\u00a0definiert\u00a0mit\u00a0einer\u00a0ein\u00a0bis\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n1\u00a0Wechselkurs\u00a01\u00a0\u20ac=1.332,4300\u00a0KRW\u00a0\nhttps://www.finanzen.net/waehrung srechner/euro_suedkoreanischer \u2010won\u00a0 \n126\u00a0\n\u00a0f\u00fcnf\u00a0prozentigen\u00a0Preisreduktion.\u00a0Liegt\u00a0der\u00a0Einfluss\u00a0auf\u00a0die\u00a0Aus gaben\u00a0\ndes\u00a0NHIS\u00a0h\u00f6her\u00a0als\u00a0KRW\u00a010\u00a0Mrd.\u00a0(>7,5\u00a0Mio.\u00a0Euro)\u00a0erfolgen\u00a0Verhan d\u2010\nlungen\u00a0zur\u00a0Definition\u00a0der\u00a0Obergrenze\u00a0( Price\u00a0Cutting\u00a0with\u00a0Expanded\u00a0\nIndication ).\u00a0\n4. Nach\u00a0Ablauf\u00a0des\u00a0Patents\u00a0wird\u00a0der\u00a0Preis\u00a0von\u00a0Alt\u2010Originalen\u00a0um\u00a070 \u00a0%\u00a0\nreduziert,\u00a0f\u00fcr\u00a0generische\u00a0Arzneimittel\u00a0um\u00a059,5\u00a0%.\u00a0Ein\u00a0Jahr\u00a0nach \u00a0ge\u2010\nnerischem\u00a0Markteintritt\u00a0wird\u00a0der\u00a0Preis\u00a0auf\u00a053,55\u00a0%\u00a0des\u00a0Alt\u2010Orig inals\u00a0\ngesetzt,\u00a0gleicherma\u00dfen\u00a0f\u00fcr\u00a0Generika\u00a0oder\u00a0Alt\u2010Original\u00a0( Price\u2010cutting\u00a0\nof\u00a0patent\u2010expired\u00a0originals\u00a0and\u00a0generics ).\u00a0\nKim\u00a0und\u00a0Lee\u00a0haben\u00a0die\u00a0Auswirkungen\u00a0der\u00a0Mechanismen\u00a0der\u00a0Preisbil dung\u00a0in\u00a0S\u00fcdko\u2010\nrea\u00a0von\u00a0198\u00a0Arzneimitteln\u00a0\u00fcber\u00a0einen\u00a0Zeitraum\u00a0von\u00a0elf\u00a0Jahren\u00a0an alysiert.\u00a0Der\u00a0 WAP\u2010\nPathway\u00a0fand\u00a0bei\u00a0123\u00a0neuen\u00a0Arzneimitteln\u00a0bzw.\u00a062,1\u00a0%\u00a0der\u00a0Verfahren\u00a0Anw endung.\u00a0\nBei\u00a0135\u00a0neuen\u00a0Arzneimitteln,\u00a0d.\u00a0h.\u00a068\u00a0%,\u00a0erfolgte\u00a0eine\u00a0Preisred uktion,\u00a0im\u00a0Median\u00a0um\u00a0\n5,6\u00a0%\u00a0[<0,1\u00a0bis\u00a058,1\u00a0%]\u00a0nach\u00a0f\u00fcnf\u00a0Jahren\u00a0und\u00a0um\u00a010,1\u00a0%\u00a0[<0,1\u00a0bi s\u00a050,3\u00a0%]\u00a0nach\u00a0zehn\u00a0\nJahren\u00a0positiver\u00a0Listung.\u00a0Im\u00a0Ergebnis\u00a0unterstreichen\u00a0Kim\u00a0und\u00a0Le e\u00a0den\u00a0Stellenwert\u00a0der\u00a0\nkontinuierlichen\u00a0Bewertung\u00a0der\u00a0Arzneimittelpreise\u00a0nach\u00a0Aufnahme \u00a0in\u00a0die\u00a0Positivliste\u00a0\nsowie\u00a0die\u00a0Effekte\u00a0der\u00a0externen\u00a0R eferenzpreise\u00a0(Kim\u00a0&\u00a0Lee,\u00a02020) .\u00a0\n\u00dcbertragen\u00a0auf\u00a0die\u00a0Preisbildung\u00a0in\u00a0Deutschland\u00a0zeigt\u00a0sich\u00a0eine\u00a0 Regelungsl\u00fccke:\u00a0Nach\u00a0\ne r f o l g t e r \u00a0V e r h a n d l u n g \u00a0e i n e s \u00a0E r s t a t t u n g s b e t r a g e s \u00a0b i s \u00a0z u m \u00a0P a t e n t a blauf\u00a0 wird\u00a0 der\u00a0\nErstattungsbetrag\u00a0n\u00e4mlich\u00a0nicht\u00a0an\u00a0die\u00a0klinische\u00a0Wertigkeit\u00a0des \u00a0Arzneimittels\u00a0ange\u2010\npasst,\u00a0wie\u00a0es\u00a0bei\u00a0Markteintritt\u00a0neuer\u00a0Therapieoptionen\u00a0im\u00a0Indik ationsgebiet\u00a0n\u00f6tig\u00a0\nw\u00e4re,\u00a0au\u00dfer\u00a0bei\u00a0einer\u00a0Nutzenbewe rtung\u00a0im\u00a0Rahmen\u00a0einer\u00a0Indikatio nserweiterung.\u00a0\nL\u00e4nder\u00a0 wie\u00a0 Gro\u00dfbritannien\u00a0 und\u00a0 Australien\u00a0 verf\u00fcgen\u00a0 \u00fcber\u00a0 separate \u00a0 Fonds\u00a0 f\u00fcr\u00a0\nKrebsmedikamente,\u00a0die\u00a0ein\u00a0klinisch\u00a0plausibles\u00a0Potenzial\u00a0mit\u00a0zus \u00e4tzlichen\u00a0Daten\u00a0\nhaben,\u00a0aber\u00a0noch\u00a0nicht\u00a0bewertet\u00a0wurden.\u00a0Die\u00a0Fonds\u00a0verbessern\u00a0de n\u00a0Zugang\u00a0der\u00a0\nPatienten\u00a0zu\u00a0neuen\u00a0innovativen\u00a0Arzneimitteln\u00a0zur\u00a0Behandlung\u00a0sel tener\u00a0Krankhei\u2010\nten\u00a0oder\u00a0Krebsarten,\u00a0die\u00a0bestimmte\u00a0Kriterien\u00a0erf\u00fcllen,\u00a0wobei\u00a0di e\u00a0Regeln\u00a0des\u00a0Kran\u2010\nkenversicherungssystems\u00a0eingehal ten\u00a0werden.\u00a0Da\u00a0S\u00fcdkorea\u00a0keine\u00a0v ergleichbare\u00a0\nPolitik\u00a0verfolgt\u00a0und\u00a0sich\u00a0nur\u00a0auf\u00a0die\u00a0Krankenversicherungsbeitr \u00e4ge\u00a0st\u00fctzt,\u00a0ist\u00a0es\u00a0\n\u00e4u\u00dferst\u00a0schwierig,\u00a0die\u00a0Kosten\u00a0f\u00fcr\u00a0teure\u00a0Krebsmedikamente\u00a0oder\u00a0M edikamente\u00a0f\u00fcr\u00a0\nseltene\u00a0Krankheiten\u00a0zu\u00a0erstatten, \u00a0f\u00fcr\u00a0die\u00a0ein\u00a0hoher\u00a0gesellschaf tlicher\u00a0Bedarf\u00a0be\u2010\nsteht,\u00a0deren\u00a0klinische\u00a0Ergebnisse\u00a0aber\u00a0ungewiss\u00a0sind.\u00a0Die\u00a0Koste n\u00fcbernahme\u00a0f\u00fcr\u00a0\ndiese\u00a0 Medikamente\u00a0 im\u00a0 Rahmen\u00a0 des\u00a0 Krankenversicherungssystems\u00a0 w\u00fcr de\u00a0 den\u00a0\nGrunds\u00e4tzen\u00a0der\u00a0Universalversicherung\u00a0widersprechen\u00a0und\u00a0k\u00f6nnte\u00a0 die\u00a0Chancen\u2010\ngleichheit\u00a0verringern,\u00a0weil\u00a0im\u00a0\u201e without\u2010CE\u2010Pathway \u201c\u00a0andere\u00a0Regeln\u00a0zur\u00a0Nutzenbe\u2010\nwertung\u00a0 gelten.\u00a0 Daher\u00a0 sollten\u00a0 zus\u00e4tzliche\u00a0 Finanzierungsquellen\u00a0 au\u00dferhalb\u00a0 der\u00a0\nKrankenversicherung\u00a0erschlossen\u00a0werden.\u00a0 \n127\u00a0\n\u00a0Das\u00a0nationale\u00a0Krankenversicherung ssystem\u00a0in\u00a0S\u00fcdkorea\u00a0hat\u00a0die\u00a0Qu alit\u00e4t\u00a0der\u00a0medi\u2010\nzinischen\u00a0Leistungen\u00a0und\u00a0den\u00a0Zuga ng\u00a0zu\u00a0Medikamenten\u00a0zu\u00a0angemess enen\u00a0Preisen\u00a0\nschrittweise\u00a0verbessert.\u00a0Allerdin gs\u00a0liegt\u00a0der\u00a0Deckungsgrad\u00a0der\u00a0 Krankenversiche\u2010\nrung\u00a0derzeit\u00a0bei\u00a0nur\u00a063\u00a0%\u00a0und\u00a0damit\u00a0weit\u00a0unter\u00a0dem\u00a0OECD\u2010Durchsc hnitt\u00a0von\u00a080\u00a0%.\u00a0\nUm\u00a0die\u00a0Deckungsrate\u00a0zu\u00a0verbessern,\u00a0hat\u00a0die\u00a0Regierung\u00a0k\u00fcrzlich\u00a0e inen\u00a0Fahrplan\u00a0\nangek\u00fcndigt,\u00a0der\u00a0die\u00a0Erstattung\u00a0aller\u00a0derzeit\u00a0nicht\u00a0erstattungs f\u00e4higen\u00a0Behandlun\u2010\ngen\u00a0und\u00a0Medikamente\u00a0vorsieht.\u00a0Es\u00a0wird\u00a0erwartet,\u00a0dass\u00a0sie\u00a0erhebl iche\u00a0\u00c4nderungen\u00a0\nin\u00a0Bezug\u00a0auf\u00a0den\u00a0Anwendungsbereich,\u00a0die\u00a0Art\u00a0der\u00a0Erstattung\u00a0und\u00a0 die\u00a0Preisfestset\u2010\nzung\u00a0vornehmen\u00a0wird.\u00a0Nach\u00a0der\u00a0Einf\u00fchrung\u00a0des\u00a0Systems\u00a0der\u00a0Positi vliste\u00a0im\u00a0Jahr\u00a0\n2007\u00a0wurden\u00a0verschiedene\u00a0Ma\u00dfnahmen\u00a0ergriffen,\u00a0und\u00a0sowohl\u00a0die\u00a0Ko stenwirk\u2010\nsamkeitsbewertung\u00a0durch\u00a0das\u00a0HIRA\u00a0als\u00a0auch\u00a0die\u00a0finanziellen\u00a0Vere inbarungen\u00a0mit\u00a0\ndem\u00a0NHIS\u00a0spielten\u00a0und\u00a0spielen\u00a0auch\u00a0in\u00a0Zukunft\u00a0eine\u00a0wichtige\u00a0Rol le\u00a0bei\u00a0der\u00a0Auf\u2010\nnahme\u00a0von\u00a0Arzneimitteln\u00a0in\u00a0die\u00a0nationale\u00a0Arzneimittelliste.\u00a0Die \u00a0kontinuierliche\u00a0\nVerbesserung\u00a0der\u00a0derzeitigen\u00a0Politik\u00a0und\u00a0die\u00a0Einf\u00fchrung\u00a0neuer\u00a0M a\u00dfnahmen\u00a0wer\u2010\nden\u00a0den\u00a0Zugang\u00a0der\u00a0Patienten\u00a0zu\u00a0 neuen\u00a0und\u00a0fortschrittlichen\u00a0Arz neimitteln\u00a0in\u00a0\nS\u00fcdkorea\u00a0wahrscheinlich\u00a0verbessern,\u00a0und\u00a0Empfehlungen\u00a0zur\u00a0Umsetz ung\u00a0von\u00a0Fi\u2010\nnanzmanagementma\u00dfnahmen,\u00a0die\u00a0die \u00a0Nachhaltigkeit\u00a0der\u00a0finanzielle n\u00a0Ressourcen\u00a0\nf\u00fcr\u00a0die\u00a0Versicherung\u00a0sicherstellen,\u00a0werden\u00a0diese\u00a0beiden\u00a0Aspekte \u00a0weiter\u00a0ausglei\u2010\nchen\u00a0(Yoo\u00a0et\u00a0al.,\u00a02019).\u00a0\nIn\u00a0S\u00fcdkorea\u00a0werden\u00a0ganz\u00a0\u00e4hnliche\u00a0\u00dcberlegungen\u00a0wie\u00a0in\u00a0europ\u00e4isch en\u00a0Staaten\u00a0zur\u00a0\nPr\u00fcfung\u00a0der\u00a0therapeutischen\u00a0Wirksamkeit\u00a0nach\u00a0der\u00a0Zulassung\u00a0und\u00a0 zu\u00a0einer\u00a0ange\u2010\nmessenen\u00a0Preisfindung\u00a0angestellt\u00a0(Yoo\u00a0et\u00a0al.,\u00a02019).\u00a0Das\u00a0Ziel\u00a0i st\u00a0die\u00a0Verbesserung\u00a0des\u00a0\nPatientenzugangs\u00a0zu\u00a0neuen\u00a0Medikamenten,\u00a0deren\u00a0Nutzen\u00a0positiv\u00a0be wertet\u00a0wurde.\u00a0\nDazu\u00a0nutzt\u00a0die\u00a0nationale\u00a0Krankenversicherung\u00a0drei\u00a0Strategien:\u00a0V ereinbarungen\u00a0zur\u00a0\nRisikobeteiligung,\u00a0die\u00a0bei\u00a0besonders\u00a0teuren\u00a0Arzneimitteln,\u00a0die\u00a0 Auflistung\u00a0von\u00a0essen\u2010\ntiellen\u00a0Medikamenten\u00a0und\u00a0den\u00a0Verzicht\u00a0auf\u00a0Kosten\u2010Effektivit\u00e4ts\u2010 Analysen.\u00a0Die\u00a0s\u00fcd\u2010\nkoreanische\u00a0 Krankenversicherung\u00a0 geht\u00a0 davon\u00a0 aus,\u00a0 dass\u00a0 Patienten\u00a0 eine\u00a0 schnelle\u00a0\nAbwicklung\u00a0der\u00a0Kostenerstattung\u00a0f\u00fcr\u00a0neue\u00a0Medikamente\u00a0w\u00fcnschen,\u00a0 um\u00a0ihren\u00a0Zu\u2010\ngang\u00a0zu\u00a0diesen\u00a0Medikamenten\u00a0zu\u00a0verbessern.\u00a0Die\u00a0Kostentr\u00e4ger\u00a0seh en\u00a0sich\u00a0dabei\u00a0\nallerdings\u00a0mit\u00a0dem\u00a0Problem\u00a0konfrontiert,\u00a0dass\u00a0die\u00a0finanziellen\u00a0 Belastungen\u00a0ange\u2010\nsichts\u00a0der\u00a0Ungewissheit\u00a0der\u00a0Kosteneffektivit\u00e4t\u00a0auch\u00a0zu\u00a0kaum\u00a0ste uerbaren\u00a0Ausgaben\u2010\nsteigerungen\u00a0f\u00fchren\u00a0k\u00f6nnen.\u00a0Die\u00a0 pU\u00a0vertreten\u00a0dagegen\u00a0den\u00a0Standp unkt,\u00a0dass\u00a0die\u00a0\nMedikamentenpreise\u00a0oberhalb\u00a0bestimmter\u00a0Schwellenwerte\u00a0liegen\u00a0so llten,\u00a0um\u00a0die\u00a0\nglobalen\u00a0Preisstrategien\u00a0aufrechterhalten,\u00a0die\u00a0Kosten\u00a0der\u00a0Medik amentenentwick\u2010\nlung\u00a0decken\u00a0und\u00a0zuk\u00fcnftige\u00a0Investitionen\u00a0in\u00a0Forschung\u00a0und\u00a0Entwi cklung\u00a0finanzieren\u00a0\nzu\u00a0k\u00f6nnen.\u00a0Von\u00a0der\u00a0s\u00fcdkoreanischen\u00a0Regierung\u00a0wird\u00a0erwartet,\u00a0das s\u00a0sie\u00a0den\u00a0Zugang\u00a0\nvon\u00a0Patienten\u00a0zu\u00a0Medikamenten\u00a0mi t\u00a0ungedecktem\u00a0Bedarf\u00a0verbessern \u00a0und\u00a0den\u00a0Kran\u2010\nkenversicherungsschutz\u00a0mit\u00a0di esem\u00a0Ziel\u00a0zu\u00a0erweitern.\u00a0\u00a0 \n128\u00a0\n\u00a0Derzeit\u00a0machen\u00a0die\u00a0\u00f6ffentlichen\u00a0Gesundheitsausgaben\u00a0in\u00a0S\u00fcdkorea \u00a08,2\u00a0%\u00a0des\u00a0Bruttoin\u2010\nlandsprodukts\u00a0aus.\u00a0Bezogen\u00a0auf\u00a0die\u00a0Kaufkraftparit\u00e4t\u00a0liegen\u00a0dies e\u00a0Ausgaben\u00a0pro\u00a0Person\u00a0\nbei\u00a0$\u00a03.406,3\u00a0und\u00a0damit\u00a0unter\u00a0dem\u00a0OECD\u2010Durchschnitt\u00a0(OECD,\u00a02019 );\u00a0tats\u00e4chlich\u00a0liegt\u00a0\nS\u00fcdkorea\u00a0auf\u00a0Platz\u00a023\u00a0der\u00a038\u00a0OECD\u2010Nationen,\u00a0sodass\u00a0die\u00a0s\u00fcdkorea nischen\u00a0Gesund\u2010\nheitsausgaben\u00a0nicht\u00a0sehr\u00a0hoch\u00a0sind.\u00a0Im\u00a0Gegensatz\u00a0dazu\u00a0machen\u00a0di e\u00a0Ausgaben\u00a0f\u00fcr\u00a0\nMedikamente\u00a0in\u00a0S\u00fcdkorea\u00a021,4\u00a0%\u00a0der\u00a0gesamten\u00a0Gesundheitsausgaben \u00a0aus,\u00a0was\u00a0h\u00f6her\u00a0\nist\u00a0als\u00a0der\u00a0OECD\u2010Durchschnitt\u00a0von\u00a016,2\u00a0%.\u00a0Mit\u00a0diesem\u00a0Anteil\u00a0lie gt\u00a0S\u00fcdkorea\u00a0auf\u00a0Platz\u00a06\u00a0\nunter\u00a0den\u00a0OECD\u2010L\u00e4ndern.\u00a0Bei\u00a0der\u00a0Entscheidungsfindung\u00a0in\u00a0S\u00fcdkore a\u00a0bez\u00fcglich\u00a0der\u00a0\nBudgetallokation\u00a0 wird\u00a0 der\u00a0 Anteil\u00a0 der\u00a0 Arzneimittelausgaben\u00a0 am\u00a0 ge samten\u00a0 Gesund\u2010\nheitsbudget\u00a0im\u00a0Vergleich\u00a0zum\u00a0Anteil\u00a0der\u00a0Arzneimittelausgaben\u00a0an \u00a0den\u00a0Gesundheits\u2010\nausgaben\u00a0in\u00a0anderen\u00a0OECD\u2010L\u00e4ndern \u00a0als\u00a0wichtiger,\u00a0allerdings\u00a0umst rittener\u00a0Index\u00a0f\u00fcr\u00a0die\u00a0\nRichtungsbestimmung\u00a0der\u00a0staatlich en\u00a0Gesundheitspolitik\u00a0verwende t.\u00a0\u00a0\nQuellen\u00a0\nBarham\u00a0L\u00a0(2019).\u00a0Keeping\u00a0up\u00a0the\u00a0PACE\u00a0at\u00a0the\u00a0Scottish\u00a0Medicines\u00a0 Consortium\u00a0(SMC).\u00a02019.\u00a0https://pharmaphorum.com/views\u2010\nanalysis\u2010market\u2010access/keeping\u2010up\u2010the\u2010pace\u2010at\u2010the\u2010scottish\u2010medi cines\u2010consortium\u2010smc/,\u00a0letzter\u00a0Zugriff:\u00a021.06.2021.\u00a0\nBovenberg\u00a0J,\u00a0Penton\u00a0H,\u00a0Buyukkaramikli\u00a0N\u00a0(2021).\u00a010\u00a0Years\u00a0of\u00a0End \u2010of\u2010Life\u00a0Criteria\u00a0in\u00a0the\u00a0United\u00a0Kingdom.\u00a0Value\u00a0in\u00a0health\u00a0:\u00a0the\u00a0\njournal\u00a0of\u00a0the\u00a0International\u00a0Society\u00a0for\u00a0Pharmacoeconomics\u00a0and\u00a0 Outcomes\u00a0Research\u00a024(5).\u00a0\nBusse\u00a0R,\u00a0Panteli\u00a0D,\u00a0Schaufler\u00a0J,\u00a0 Schr\u00f6der\u00a0H,\u00a0Telschow\u00a0C,\u00a0Weiss\u00a0 J\u00a0(2016).\u00a0Preise\u00a0patentgesch\u00fctzter\u00a0Arzneimittel\u00a0im\u00a0europ\u00e4ischen \u00a0Vergleich\u00a0\nzu\u00a0den\u00a0Listenpreisen\u00a0in\u00a0f\u00fcnf\u00a0ausgew\u00e4hlten\u00a0europ\u00e4ischen\u00a0L\u00e4ndern. \u00a02016.\u00a0https://www.wido.de/fileadmin/Dateien/\u00a0\nDokumente/Forschung_Projekte/Arzneimittel/wido_arz_preise_eu_ve rgleich_2016.pdf,\u00a0letzter\u00a0Zugriff:\u00a015.05.2021.\u00a0\nChoi\u00a0KK,\u00a0Lee\u00a0Y\u00a0(2021).\u00a0 Pricing\u00a0&\u00a0Reimbursement\u00a0Laws\u00a0and\u00a0Regulat ions\u00a02021/Korea.\u00a02021.\u00a0https://www.globallega\u00a0\nlinsights.com/practice\u2010areas/pric ing\u2010and\u2010reimbursement\u2010laws\u2010and \u2010regulations/korea,\u00a0letzter\u00a0Zugriff:\u00a001.12.2021.\u00a0\nDixon\u00a0P,\u00a0Chamberlain\u00a0C,\u00a0Hollingworth\u00a0W\u00a0(2016).\u00a0Did\u00a0It\u00a0Matter\u00a0Th at\u00a0the\u00a0Cancer\u00a0Drugs\u00a0Fund\u00a0Was\u00a0Not\u00a0NICE?\u00a0A\u00a0Retrospective\u00a0Review.\u00a0\nValue\u00a0in\u00a0health\u00a0:\u00a0the\u00a0journal\u00a0of \u00a0the\u00a0International\u00a0Society\u00a0for\u00a0 Pharmacoeconomics\u00a0and\u00a0Outcomes\u00a0Research\u00a019(6).\u00a0\nHuang\u00a0C\u2010W,\u00a0Hwang\u00a0I\u2010H,\u00a0Lee\u00a0Y\u2010S,\u00a0Hwang\u00a0S\u2010J,\u00a0Ko\u00a0S\u2010G,\u00a0Chen\u00a0F\u2010P\u00a0et\u00a0a l.\u00a0(2018).\u00a0Utilization\u00a0patterns\u00a0of\u00a0traditional\u00a0medicine\u00a0in\u00a0Taiw an\u00a0and\u00a0\nSouth\u00a0Korea\u00a0by\u00a0using\u00a0national\u00a0health\u00a0insurance\u00a0data\u00a0in\u00a02011.\u00a0Pl oS\u00a0one\u00a013(12).\u00a0\nKern\u00a0T,\u00a0Nam\u00a0S\u00a0H\u00a0(2005).\u00a0Das\u00a0s\u00fcdkoreanische\u00a0Gesundheitswesen:\u00a0Hi storische\u00a0Entwicklung,\u00a0Leistungsf\u00e4higkeit,\u00a0Herausforderungen.\u00a0I n:\u00a0K\u00f6llner\u00a0P\u00a0\n(Hg.)\u00a0Korea:\u00a0Politik,\u00a0Wirtschaft,\u00a0Gesellschaft.\u00a0https://fis.uni \u2010bamberg.de/handle/uniba/48147,\u00a0letzter\u00a0Zugriff:\u00a006.12.2021.\u00a0\nKim\u00a0JA,\u00a0Yoon\u00a0S,\u00a0Kim\u00a0LY,\u00a0Kim\u00a0DS\u00a0(2017).\u00a0Towards\u00a0Actualizing\u00a0the\u00a0 Value\u00a0Potential\u00a0of\u00a0Korea\u00a0Health\u00a0Insurance\u00a0Review\u00a0and\u00a0Assessment \u00a0\n(HIRA)\u00a0Data\u00a0as\u00a0a\u00a0Resource\u00a0for\u00a0Health\u00a0Research.\u00a0J\u00a0Korean\u00a0med\u00a0sci \u00a032(5):\u00a0718\u2010728.\u00a0\nKim\u00a0S,\u00a0Lee\u00a0JH\u00a0(2020).\u00a0Price\u2010Cuttin g\u00a0Trends\u00a0in\u00a0New\u00a0Drugs\u00a0after\u00a0L isting\u00a0in\u00a0South\u00a0Korea.\u00a0Healthcare\u00a08(3):\u00a0233.\u00a0\nKwon\u00a0H\u00a0Y,\u00a0Godman\u00a0B\u00a0(2017).\u00a0Drug\u00a0pricing\u00a0in\u00a0South\u00a0Korea.\u00a0 Appl\u00a0Health\u00a0Econ\u00a0Health\u00a0Policy \u00a015:\u00a0447\u2010453.\u00a0\nLakdawalla\u00a0DN,\u00a0Jena\u00a0AB,\u00a0Doctor\u00a0JN\u00a0(2014).\u00a0Careful\u00a0use\u00a0of\u00a0scienc e\u00a0to\u00a0advance\u00a0the\u00a0debate\u00a0on\u00a0the\u00a0UK\u00a0Cancer\u00a0Drugs\u00a0Fund.\u00a0JAMA\u00a0311(1 ).\u00a0\nLee\u00a0H,\u00a0Kim\u00a0J\u00a0(2012).\u00a0Delisting\u00a0po licy\u00a0reform\u00a0in\u00a0South\u00a0Korea.\u00a0Va lue\u00a0in\u00a0health:\u00a0the\u00a0journal\u00a0of\u00a0the\u00a0International\u00a0Society\u00a0for\u00a0\nPharmacoeconomics\u00a0and\u00a0Outcomes\u00a0Research\u00a015(1):\u00a0204\u2010212.\u00a0 \n129\u00a0\n\u00a0Morrell\u00a0L,\u00a0Wordsworth\u00a0S,\u00a0Schuh\u00a0A,\u00a0Middleton\u00a0MR,\u00a0Rees\u00a0S,\u00a0Barker\u00a0 RW\u00a0(2018).\u00a0Will\u00a0the\u00a0reformed\u00a0Cancer\u00a0Drugs\u00a0Fund\u00a0address\u00a0the\u00a0\nmost\u00a0common\u00a0types\u00a0of\u00a0uncertainty?\u00a0An\u00a0analysis\u00a0of\u00a0NICE\u00a0cancer\u00a0dr ug\u00a0appraisals.\u00a0BMC\u00a0health\u00a0services\u00a0research\u00a018(1).\u00a0\nNICE\u00a0(2017).\u00a0Interim\u00a0Process\u00a0and\u00a0Methods\u00a0of\u00a0the\u00a0Highly\u00a0Speciali sed\u00a0Technologies\u00a0Programme\u00a0Updated\u00a0to\u00a0reflect\u00a02017\u00a0changes.\u00a0\n2017.\u00a0https://www.nice.org.uk/Media/Default/About/what\u2010we\u2010do/NI CE\u2010guidance/NICE\u2010highly\u2010specialised\u2010\ntechnologies\u2010guidance/HST\u2010interim\u2010methods\u2010process\u2010guide\u2010may\u201017. pdf,\u00a0letzter\u00a0Zugriff:\u00a018.06.2021.\u00a0\nNICE\u00a0(2018).\u00a0Guide\u00a0to\u00a0the\u00a0methods\u00a0of\u00a0technology\u00a0appraisal\u00a02013\u00a0 (PMG9).\u00a02018.\u00a0\nhttps://www.nice.org.uk/process/pmg9/resources/guide\u2010to\u2010the\u2010met hods\u2010of\u2010technology\u2010appraisal\u20102013\u2010pdf\u2010\n2007975843781,\u00a0letzter\u00a0Zugriff:\u00a018.06.2021.\u00a0\nNICE\u00a0(2021a).\u00a0History\u00a0of\u00a0NICE.\u00a02021.\u00a0https://www.nice.org.uk/ab out/who\u2010we\u2010are/history\u2010of\u2010nice,\u00a0letzter\u00a0Zugriff:\u00a006.06.2021.\u00a0\nNICE\u00a0(2021b).\u00a0NICE\u00a0strategy\u00a02021\u00a0to\u00a02026.\u00a02021.\u00a0https://static. nice.org.uk/NICE%20strategy%202021%20to%202026%20\u2010\n%20Dynamic,%20Collaborative,%20Excellent.pdf,\u00a0letzter\u00a0Zugriff:\u00a0 07.06.2021.\u00a0\nOECD\u00a0(2018).\u00a0OECD\u00a0Data\u00a0Population.\u00a02018.\u00a0https://data.oecd.org/ pop/population.htm,\u00a0letzter\u00a0Zugriff:\u00a021.06.2021.\u00a0\nOECD\u00a0(2019).\u00a0OECD.Stat.\u00a0https://stats.oecd.org/Index.aspx?Theme TreeId=9,\u00a0letzer\u00a0Zugriff:\u00a019.01.2022.\u00a0\nPHIS\u00a0(2010).\u00a0The\u00a0Netherlands.\u00a0PHIS\u00a0Hospital\u00a0Pharma\u00a0Report.\u00a0Fina l\u00a0Version,\u00a0January\u00a02010.\u00a0\nhttps://ppri.goeg.at/sites/ppri. goeg.at/files/inline\u2010files/PHIS %20NL%20Hospital%20Pharma%20Report\u00a0\n%202009_5.pdf,\u00a0letzter\u00a0Zugriff:\u00a023.05.2021.\u00a0\nPHIS\u00a0Pharma\u00a0Profile\u00a0(2011).\u00a0Franc e.\u00a0PHIS\u00a0Pharma\u00a0Profile.\u00a0Final\u00a0 Version,\u00a0April\u00a02011.\u00a0\nhttps://ppri.goeg.at/sites/ppri. goeg.at/files/inline\u2010files/PHIS _Pharma%20Profile%20FR_2011_final_1.pdf,\u00a0letzter\u00a0\nZugriff:\u00a009.03.2022\u00a0\nPPRI\u2013\u00a0Pharmaceutical\u00a0Pricing\u00a0and\u00a0Reimbursement\u00a0Information\u00a0proj ect\u00a0(2007).\u00a0PPRI\u00a0Poster\u00a02007\u00a0NL\u00a0\u2010\u00a0Out\u2010patient\u00a0system.\u00a0\nhttps://ppri.goeg.at/sites/ppri.goeg.at/files/inline\u2010files/Neth erlands_Poster_15.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\n23.05.2021.PPRI\u2013\u00a0Pharmaceutical\u00a0Pricing\u00a0and\u00a0Reimbursement\u00a0Infor mation\u00a0(2008).\u00a0France.\u00a0Pharma\u00a0Profile.\u00a0Final\u00a0\nversion,\u00a0July\u00a02008.\u00a0https://ppri.goeg.at/sites/ppri.goeg.at/fil es/inline\u2010files/France_PPRI_2008_3.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\n09.03.2022\u00a0\nPPRI\u00a0\u2013Pharmaceutical\u00a0Pricing\u00a0and\u00a0Reimbursement\u00a0Information\u00a0proj ect\u00a0(2009).\u00a0PPRI\u00a0Poster\u00a0\u2010\u00a0NL\u00a0\u2010\u00a02009\u00a0\u2010\u00a0Out\u2010patient\u00a0System.\u00a0\nhttps://ppri.goeg.at/sites/ppri. goeg.at/files/inline\u2010files/Post er_Berlin09_NL_14.pdf,\u00a0letzter\u00a0Zugriff:\u00a023.05.2021.\u00a0\nPPRI\u00a0\u2013\u00a0Pharmaceutical\u00a0Pricing\u00a0and\u00a0Reimbursement\u00a0Information\u00a0pro ject\u00a0(2012a).\u00a0PPRI\u00a0Poster\u00a0\u2010\u00a0NL\u00a0\u2010\u00a02012\u00a0changes\u00a02011/2012\u00a0high\u2010\ncost\u00a0medicints\u00a0generic\u00a0policies. \u00a0https://ppri.goeg.at/\u00a0sites/pp ri.goeg.at/files/inline\u2010\nfiles/10p_NL%20Poster_Schreurs_2012_10.pdf,\u00a0letzter\u00a0Zugriff:\u00a023 .05.2021.\u00a0\nPPRI\u00a0\u2013\u00a0Pharmaceutical\u00a0Pricing\u00a0and\u00a0Reimbursement\u00a0Information\u00a0pro ject\u00a0(2012b).\u00a0PPRI\u00a0Poster\u00a0\u2010\u00a0NL\u00a0\u2010\u00a0Rational\u00a0use\u00a0of\u00a0medicines.\u00a0\nhttps://ppri.goeg.at/sites/ppri. goeg.at/files/inline\u2010files/NL_R ational%20Use_Poster_11.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\n23.05.2021.\u00a0\nPPRI\u00a0\u2013\u00a0Pharmaceutical\u00a0Pricing\u00a0and\u00a0Reimbursement\u00a0Information\u00a0pro ject\u00a0(2013).\u00a0PPRI\u00a0Poster\u00a0\u2010\u00a0NL\u00a0\u2010\u00a02013\u00a0Recent\u00a0changes\u00a0and\u00a0\ndevelopments\u00a0in\u00a0pharmaceutical\u00a0expenditure.\u00a0https://ppri.goeg.a t/\u00a0sites/ppri.goeg.at/files/inline\u2010\nfiles/Netherlands_PPRI%202013_9.pdf,\u00a0letzter\u00a0Zugriff:\u00a023.05.202 1.\u00a0\nPPRI\u00a0\u2013\u00a0Pharmaceutical\u00a0Pricing\u00a0and\u00a0Reimbursement\u00a0Information\u00a0pro ject\u00a0(2014).\u00a0PPRI\u00a0Poster\u00a0\u2010\u00a0NL\u00a0\u2010\u00a02014\u00a0policies\u00a0related\u00a0to\u00a0high\u00a0c ost\u00a0\nmedicines.\u00a0https://ppri.goeg.at/sites/ppri.goeg.at/files/inline \u2010files/NL_PPRI_Meeting_Poster_TheHague_Nov\u00a0\n2014_7.pdf,\u00a0letzter\u00a0Zugriff:\u00a023.05.2021.\u00a0\nPPRI\u00a0\u2013\u00a0Pharmaceutical\u00a0Pricing\u00a0and\u00a0Reimbursement\u00a0Information\u00a0pro ject\u00a0(2015).\u00a0PPRI\u00a0Poster\u00a0\u2010\u00a0NL\u00a0\u2010\u00a02015\u00a0Recent\u00a0and\u00a0planned\u00a0\ndevelopments\u00a0in\u00a0pharmaceutical\u00a0policies\u00a02015.\u00a0https://ppri.goeg .at/sites/ppri.goeg.at/files/inline\u2010\nfiles/NL_Poster_2015_5.pdf,\u00a0letzter\u00a0Zugriff:\u00a023.05.2021.\u00a0 \n130\u00a0\n\u00a0PPRI\u00a0\u2013\u00a0Pharmaceutical\u00a0Pricing\u00a0and\u00a0Reimbursement\u00a0Information\u00a0pro ject\u00a0(2016).\u00a0PPRI\u00a0Poster\u00a0\u2010\u00a0NL\u00a0\u2010\u00a02016\u00a0Changes\u00a0in\u00a0pharmaceutical\u00a0\npolicies\u00a02016\u00a0&\u00a0special\u00a0topic:\u00a0 biosimilars.\u00a0https://ppri.goeg.a t/sites/ppri.goeg.at/files/inline\u2010\nfiles/NL_Poster_PPRI_Meeting_Lisbon_Apr2016_4.pdf,\u00a0letzter\u00a0Zugr iff:\u00a023.05.2021.\u00a0\nPPRI\u00a0\u2013\u00a0Pharmaceutical\u00a0Pricing\u00a0and\u00a0Reimbursement\u00a0Information\u00a0pro ject\u00a0(2017a).\u00a0PPRI\u00a0Poster\u00a0\u2010\u00a0NL\u00a0\u2010\u00a02017\u00a0Changes\u00a0in\u00a0pharmaceutical \u00a0\npolicies\u00a02017\u00a0&\u00a0Special\u00a0topic:\u00a0e\u2010 health\u00a0for\u00a0medicines.\u00a0https:// ppri.goeg.at/sites/\u00a0ppri.goeg.at/files/inline\u2010\nfiles/NL_Poster_PPRI_Meeting_Stockholm_Apr2017_2.pdf,\u00a0letzter\u00a0Z ugriff:\u00a023.05.2021.\u00a0\nPPRI\u00a0\u2013\u00a0Pharmaceutical\u00a0Pricing\u00a0and\u00a0Reimbursement\u00a0Information\u00a0pro ject\u00a0(2017b):\u00a0PPRI\u00a0Poster\u00a0\u2010\u00a0NL\u00a0\u2010\u00a02017\u00a0Recent\u00a0and\u00a0planned\u00a0\ndevelopments\u00a0in\u00a0pharmaceutical\u00a0 policies\u00a02017\u00a0Special\u00a0topic:\u00a0hos pital\u00a0medicines.\u00a0https://ppri.goeg.at\u00a0\n/sites/ppri.goeg.at/files/inline\u2010 files/PPRI_Country_Poster\u2010Neth erlands_Athens_2017_3.pdf,\u00a0letzter\u00a0Zugriff:\u00a023.05.2021.\u00a0\nPPRI\u00a0\u2013\u00a0Pharmaceutical\u00a0Pricing\u00a0and\u00a0Reimbursement\u00a0Information\u00a0pro ject\u00a0(2018a).\u00a0PPRI\u00a0Poster\u00a0\u2010\u00a0NL\u00a0\u2010\u00a02018\u00a0Recent\u00a0and\u00a0planned\u00a0\ndevelopments\u00a0in\u00a0pharmaceutical\u00a0policies\u00a02017/2018\u00a0\u2010\u00a0Special\u00a0top ic:\u00a0patient\u00a0involvement\u00a0in\u00a0pricing\u00a0and\u00a0\nreimbursement\u00a0of\u00a0medicines.\u00a0http s://ppri.goeg.at/sites/ppri.goe g.at/files/inline\u2010\nfiles/PPRI_Country_Poster_Netherlands_Dublin2018_1.pdf,\u00a0letzter \u00a0Zugriff:\u00a023.05.2021.\u00a0\nPPRI\u00a0\u2013\u00a0Pharmaceutical\u00a0Pricing\u00a0and\u00a0Reimbursement\u00a0Information\u00a0pro ject\u00a0(2018b).\u00a0PPRI\u00a0Poster\u00a0\u2010\u00a0NL\u00a0\u2010\u00a02018\u00a0the\u00a0recent\u00a0and\u00a0planned\u00a0\ndevelopment\u00a0in\u00a0pharmaceutical\u00a0policies\u00a02018.\u00a0Special\u00a0topic:\u00a0nat ional\u00a0incentives\u00a0and\u00a0derogatory\u00a0procedures\u00a0fo\u00a0\norphan\u00a0medicines.\u00a0https://ppri.goeg.at/sites/ppri.goeg.at/files /inline\u2010\nfiles/PPRI_Country_Poster_Netherlands_Ljubljana2018_1.pdf,\u00a0letz ter\u00a0Zugriff:\u00a023.05.2021.\u00a0\nPPRI\u00a0\u2013\u00a0Pharmaceutical\u00a0Pricing\u00a0and\u00a0Reimbursement\u00a0Information\u00a0pro ject\u00a0(2019a).\u00a0PPRI\u00a0Poster\u00a0\u2010\u00a0NL\u00a0\u2010\u00a02019\u00a0Pharmaceutical\u00a0Pricing\u00a0an d\u00a0\nreimbursement\u00a0policies\u00a0in\u00a0the\u00a0in\u2010\u00a0and\u00a0out\u2010patient\u00a0sector.\u00a0https ://ppri.goeg.at/sites/ppri.goeg.at/files/inline\u2010\nfiles/The%20Netherlands.pdf,\u00a0letzter\u00a0Zugriff:\u00a023.05.2021.\u00a0\nPPRI\u00a0\u2013\u00a0Pharmaceutical\u00a0Pricing\u00a0and\u00a0Reimbursement\u00a0Information\u00a0pro ject\u00a0(2019b).\u00a0PPRI\u00a0Poster\u00a0\u2010\u00a0NL\u00a0\u2010\u00a02019\u00a0recent\u00a0and\u00a0planned\u00a0\ndevelopments\u00a0in\u00a0pharmaceutical\u00a0pricing\u00a0and\u00a0reimbursement\u00a0polici es\u00a02019\u00a0and\u00a0special\u00a0topic:\u00a0patient\u2010based\u00a0\nreimbursement.\u00a0https://ppri.goeg.at/sites/ppri.goeg.at/files/in line\u2010\nfiles/PPRI_Country_Poster_Talli nn_2019_Netherlands_0.pdf,\u00a0letzt er\u00a0Zugriff:\u00a023.05.2021.\u00a0\nSikora\u00a0K\u00a0(2007).\u00a0Paying\u00a0for\u00a0cancer\u00a0care\u2014a\u00a0new\u00a0dilemma.\u00a0Journal\u00a0 of\u00a0the\u00a0Royal\u00a0Society\u00a0of\u00a0Medicine\u00a0100(4).\u00a0\nSMC\u00a0(2018).\u00a0A\u00a0Guide\u00a0to\u00a0the\u00a0Scottish\u00a0Medicines\u00a0Consortium.\u00a02018. \u00a0https://www.scottishmedicines.org.uk/media/3574/20180712\u2010\na\u2010guide\u2010to\u2010the\u2010scottish\u2010medicines\u2010consortium.pdf,\u00a0letzter\u00a0Zugri ff:\u00a021.06.2021.\u00a0\nSMC\u00a0(2021).\u00a0Patient\u00a0a nd\u00a0Clinician\u00a0Engagement \u00a0(PACE)\u00a0Meetings\u00a0Ov erview.\u00a02021.\u00a0\nhttps://www.scottishmedicines.org.uk/media/5423/pace\u2010overview\u2010d ocument\u2010v32.pdf,\u00a0letzter\u00a0Zugriff:\u00a021.06.2021.\u00a0\nTVL\u00a0(2021).\u00a0International\u00a0price\u00a0comparison\u00a02020.\u00a0An\u00a0analysis\u00a0of \u00a0Swedish\u00a0pharmaceutical\u00a0prices\u00a0in\u00a0relation\u00a0to\u00a019\u00a0other\u00a0European \u00a0\ncountries.\u00a0English\u00a0Version.\u00a0Unter\u00a0Mitarbeit\u00a0von\u00a0David\u00a0Sj\u00f6berg,\u00a0 Oskar\u00a0Johansson,\u00a0Daniel\u00a0H\u00f6gberg\u00a0und\u00a0Per\u00a0Hortlund.\u00a0\nHg.\u00a0v.\u00a0Dental\u00a0and\u00a0Pharmaceutical\u00a0Benefits\u00a0Agency.\u00a0Tandvards\u00a0\u2010\u00a0o ch\u00a0L\u00e4kemedelsf\u00f6rmansverket.\u00a0Stockholm.\u00a0\nhttps://www.tlv.se/download/18. b0963dd176e8cb6883cd3cc/16116942 97210/international_price_comparison_20\n20.pdf,\u00a0letzter\u00a0Zugriff:\u00a023.05.2021.\u00a0\nWHO\u00a0\u2013\u00a0World\u00a0Health\u00a0Organization\u00a0 (2015).\u00a0Republic\u00a0of\u00a0Korea\u00a0healt h\u00a0system\u00a0review.\u00a02015.\u00a0\nhttps://apps.who.int/iris/handle/10665/208215,\u00a0letzter\u00a0Zugriff: \u00a001.12.2021.\u00a0\nYoo\u00a0S\u2010L,\u00a0Kim\u00a0D\u2010J,\u00a0Lee\u00a0S\u2010M,\u00a0Kang\u00a0W\u2010G,\u00a0Kim\u00a0S\u2010Y,\u00a0Lee\u00a0JH\u00a0et\u00a0al.\u00a0(20 19).\u00a0Improving\u00a0Patient\u00a0Access\u00a0to\u00a0New\u00a0Drugs\u00a0in\u00a0South\u00a0Korea:\u00a0\nEvaluation\u00a0of\u00a0the\u00a0National\u00a0Drug\u00a0Formulary\u00a0System.\u00a0Int\u00a0J\u00a0Environ \u00a0Res\u00a0Public\u00a0Health\u00a016(2):\u00a0288.\u00a0\n\u00a0 \u00a0 \n131\u00a0\n\u00a07 L\u00f6sungsvorschl\u00e4ge\u00a0f\u00fcr\u00a0das\u00a0deutsche\u00a0Gesundheitssystem\u00a0\n Dynamischer\u00a0Evidenzpreis\u00a0(dynEP)\u00a07.1\nDas\u00a0Modell\u00a0des\u00a0dynamischen\u00a0Evidenzpreis\u00a0(s.\u00a0Abb.\u00a07.1)\u00a0ist\u00a0erg\u00e4n zend\u00a0zum\u00a0derzeiti\u2010\ngen\u00a0AMNOG\u2010Prozess\u00a0zu\u00a0sehen.\u00a0Sechs\u00a0Monate\u00a0vor\u00a0der\u00a0Zulassung\u00a0ents cheidet\u00a0der\u00a0G\u2010\nBA\u00a0dar\u00fcber,\u00a0ob\u00a0der\u00a0Preis\u00a0f\u00fcr\u00a0ein\u00a0Arzneimittel\u00a0nach\u00a0dem\u00a0AMNOG\u2010Ve rfahren\u00a0oder\u00a0\nnach\u00a0dem\u00a0Modell\u00a0des\u00a0dynamischen\u00a0 Evidenzpreises\u00a0ermittelt\u00a0wird.\u00a0\nAbb.\u00a07.1:\u00a0Der\u00a0dynamische\u00a0Evidenzpreis\u00a0\n\u00a0\nGrundlage\u00a0des\u00a0dynamischen\u00a0Evidenzpreises\u00a0ist\u00a0die\u00a0systematische\u00a0 Generierung\u00a0von\u00a0\nPhase\u2010IV\u2010\"Real\u2010World\"\u2010Daten,\u00a0um\u00a0 Evidenzl\u00fccken\u00a0zu\u00a0schlie\u00dfen.\u00a0Daf \u00fcr\u00a0werden\u00a0Pati\u2010\nenten,\u00a0die\u00a0mit\u00a0dem\u00a0entsprechende n\u00a0Arzneimittel\u00a0behandelt\u00a0werden ,\u00a0verpflichtend\u00a0\nin\u00a0Register\u00a0aufgenommen.\u00a0Es\u00a0ist\u00a0zwingend\u00a0erforderlich,\u00a0dass\u00a0die se\u00a0Register\u00a0von\u00a0\neiner\u00a0unabh\u00e4ngigen\u00a0Stelle\u00a0verwaltet\u00a0werden,\u00a0um\u00a0Neutralit\u00e4t\u00a0zu\u00a0g ew\u00e4hrleisten.\u00a0So\u00a0\nk\u00f6nnen\u00a0die\u00a0bei\u00a0Markteintritt\u00a0bestehenden\u00a0Evidenzl\u00fccken\u00a0sukzessi ve\u00a0geschlossen\u00a0\nwerden,\u00a0was\u00a0zu\u00a0einer\u00a0gr\u00f6\u00dftm\u00f6glic hen\u00a0Patientensicherheit\u00a0beitr\u00e4g t.\u00a0\u00a0\nDie\u00a0erste\u00a0Phase\u00a0der\u00a0Datenerhe bung\u00a0dauert\u00a024\u00a0Monate.\u00a0Dann\u00a0erfolg t\u00a0die\u00a0erste\u00a0\nErstattungsbetragsverhandlung\u00a0auf \u00a0Grundlage\u00a0der\u00a0zuvor\u00a0generiert en\u00a0Daten.\u00a0Dieser\u00a0\nProzess\u00a0wird\u00a0alle\u00a0zw\u00f6lf\u00a0Monate\u00a0wiederholt.\u00a0Somit\u00a0wird\u00a0der\u00a0Ersta ttungsbetrag\u00a0alle\u00a0\n12\u00a0Monate\u00a0aufgrund\u00a0der\u00a0aktuellsten\u00a0Datenbasis\u00a0neu\u00a0verhandelt,\u00a0a lso\u00a0dynamisch\u00a0\nangepasst.\u00a0Diese\u00a0Anpassung\u00a0kann\u00a0be i\u00a0positiven\u00a0Daten\u00a0zur\u00a0Langzei twirksamkeit\u00a0und\u00a0\n\u2010sicherheit\u00a0nach\u00a0oben,\u00a0aber\u00a0bei\u00a0negativen\u00a0auch\u00a0nach\u00a0unten\u00a0erfol gen.\u00a0So\u00a0entspricht\u00a0\nder\u00a0Preis\u00a0des\u00a0Arzneimittels\u00a0jeder zeit\u00a0seinem\u00a0therapeutischen\u00a0We rt\u00a0und\u00a0das\u00a0Risiko\u00a0\nder\u00a0Kostentr\u00e4ger\u00a0wird\u00a0minimiert.\u00a0Nicht\u00a0nur\u00a0die\u00a0Versichertengeme inschaft\u00a0profitiert\u00a0\nan\u00a0dieser\u00a0Stelle\u00a0von\u00a0fairen\u00a0Preisen,\u00a0sondern\u00a0auch\u00a0die\u00a0pharmazeu tische\u00a0Industrie.\u00a0\nDenn\u00a0hochwirksame\u00a0Pr\u00e4parate\u00a0werden\u00a0st\u00e4rker\u00a0honoriert\u00a0als\u00a0wenige r\u00a0wirksame\u00a0\nPr\u00e4parate.\u00a0\u00a0\n \n132\u00a0\n\u00a0Der\u00a0Preis\u00a0des\u00a0Arzneimittels\u00a0in\u00a0den\u00a0ersten\u00a024\u00a0Monaten\u00a0kann\u00a0durch \u00a0den\u00a0pharmazeu\u2010\ntischen\u00a0Unternehmer\u00a0bis\u00a0zu\u00a0einer\u00a0durch\u00a0EU\u2010Preise\u00a0definierten\u00a0Ob ergrenze\u00a0frei\u00a0\ngew\u00e4hlt\u00a0werden.\u00a0M\u00f6chte\u00a0der\u00a0Herst eller\u00a0die\u00a0in\u00a0den\u00a0Registern\u00a0erho benen\u00a0Daten\u00a0\nnutzen,\u00a0muss\u00a0er\u00a0einen\u00a0Abschlag\u00a0auf\u00a0seinen\u00a0Preis\u00a0hinnehmen.\u00a0Date n\u00a0erhalten\u00a0damit\u00a0\neinen\u00a0\u00f6konomischen\u00a0Gegenwert.\u00a0Um\u00a0die\u00a0Forschung\u00a0und\u00a0Entwicklung\u00a0 von\u00a0Arznei\u2010\nmitteln\u00a0in\u00a0Deutschland\u00a0und\u00a0Europa\u00a0zu\u00a0f\u00f6rdern,\u00a0soll\u00a0es\u00a0m\u00f6glich\u00a0s ein,\u00a0dass\u00a0Unter\u2010\nnehmer,\u00a0die\u00a0in\u00a0Deutschland\u00a0und\u00a0Europa\u00a0forschen\u00a0und\u00a0entwickeln\u00a0e inen\u00a0Aufschlag\u00a0\nauf\u00a0ihren\u00a0Preis\u00a0nehmen\u00a0d\u00fcrften\u00a0\u2010 \u00a0den\u00a0sogenannten\u00a0Engagement\u2010Bon us.\u00a0\u00a0\nDer\u00a0dynamische\u00a0Evidenzpreis\u00a0ste llt\u00a0ebenso\u00a0wie\u00a0der\u00a0Erstattungsbe trag\u00a0(gem.\u00a0\u00a7\u00a0130b\u00a0\nSGB\u00a0V)\u00a0die\u00a0Preisobergrenze\u00a0im\u00a0st ation\u00e4ren\u00a0Bereich\u00a0dar.\u00a0Dies\u00a0erm \u00f6glicht\u00a0den\u00a0be\u2010\ntroffenen\u00a0Patienten\u00a0\u00fcber\u00a0alle\u00a0Sek torgrenzen\u00a0hinaus\u00a0einen\u00a0schnel len\u00a0und\u00a0struktu\u2010\nrierten\u00a0Zugang\u00a0zu\u00a0innovativen\u00a0Arzneimitteln.\u00a0\n Modell\u00a0GKV\u2010SV\u00a07.2\nDer\u00a0GKV\u2010Spitzenvervand\u00a0schl\u00e4gt\u00a0zur\u00a0L\u00f6sung\u00a0der\u00a0st\u00e4ndig\u00a0wachsende n\u00a0Preisspirale\u00a0\ndie\u00a0Festsetzung\u00a0sog.\u00a0Interimsprei se\u00a0ab\u00a0den\u00a0Beginn\u00a0der\u00a0Vermarktu ng\u00a0vor.\u00a0Es\u00a0fehlt\u00a0\nallerding\u00a0ein\u00a0klares\u00a0Konzept,\u00a0auf\u00a0welcher\u00a0methodischen\u00a0Basis\u00a0ei ne\u00a0solcher\u00a0Inte\u2010\nrimspreis\u00a0erstellt\u00a0werden\u00a0soll.\u00a0Es\u00a0wird\u00a0in\u00a0diesem\u00a0Zusammenhang\u00a0 vorgeschlagen,\u00a0\ndass\u00a0das\u00a0AMNOG\u2010Verfahren\u00a0um\u00a0sog.\u00a0Indikationsregister\u00a0erg\u00e4nzt\u00a0we rden\u00a0soll,\u00a0mit\u00a0\ndenen\u00a0 aufgrund\u00a0 einer\u00a0 belastbaren \u00a0 Begleit\u2010\u00a0 und\u00a0 Versorgungsforsch ung\u00a0 bei\u00a0 der\u00a0\nEinf\u00fchrung\u00a0eines\u00a0neuen\u00a0Arzneimittels\u00a0Daten\u00a0zum\u00a0Patientennutzen\u00a0 erhoben\u00a0wer\u2010\nden\u00a0k\u00f6nnen.\u00a0Wie\u00a0allerdings\u00a0der\u00a0Bas is\u2010Interimspreis,\u00a0der\u00a0dann\u00a0na ch\u00a0Vorliegen\u00a0der\u00a0\nDaten\u00a0zum\u00a0Patientennutzen\u00a0(siehe\u00a0Kapitel\u00a05.2\u00a0zu\u00a0 Efficacy\u00a0und\u00a0Effectiveness )\u00a0modi\u2010\nfiziert\u00a0werden\u00a0soll\u00a0\u2010\u00a0entweder\u00a0zugunsten\u00a0oder\u00a0zu\u00a0Ungunsten\u00a0der\u00a0 pU\u00a0\u2013\u00a0ermittelt\u00a0\nwird,\u00a0bleibt\u00a0unklar.\u00a0\u00a0\n AIM\u00a0Fair\u00a0Pricing\u00a0Calculator \u00a0f\u00fcr\u00a0patentgesch\u00fctzte\u00a0Arzneimittel\u00a0 7.3\nWie\u00a0 bereits\u00a0 beschrieben\u00a0 sind\u00a0 patentgesch\u00fctzte\u00a0 Arzneimittel\u00a0 eine r\u00a0 der\u00a0 gr\u00f6\u00dften\u00a0\nKostentreiber\u00a0f\u00fcr\u00a0die\u00a0gesetzliche\u00a0Krankenversicherung\u00a0(GKV).\u00a0Tr otz\u00a0einer\u00a0relativ\u00a0\ngeringen\u00a0Verordnungsh\u00e4ufigkeit\u00a0verursachen\u00a0sie\u00a0aufgrund\u00a0sehr\u00a0ho her\u00a0Preise\u00a0fast\u00a0\ndie\u00a0H\u00e4lfte\u00a0aller\u00a0Arzneimittelkosten.\u00a0Die\u00a0 International\u00a0Association\u00a0of\u00a0Mutual\u00a0Benefit\u00a0\nSocieties\u00a0(AIM)\u00a0hat\u00a0deswegen\u00a0ein\u00a0Modell\u00a0 zur\u00a0Berechnung\u00a0fairer\u00a0und\u00a0transp arenter\u00a0\nArzneimittelpreise\u00a0anhand\u00a0objektiver\u00a0Kriterien\u00a0entwickelt.\u00a0Dies e\u00a0basieren\u00a0auf\u00a0den\u00a0\nKosten\u00a0der\u00a0Hersteller\u00a0sowie\u00a0markt\u00fcblichen\u00a0Renditeaufschl\u00e4gen.\u00a0I m\u00a0Folgenden\u00a0wird\u00a0\ngezeigt,\u00a0wie\u00a0die\u00a0mit\u00a0dem\u00a0 Fair\u00a0Pricing\u00a0Calculator \u00a0der\u00a0AIM\u00a0ermittelten\u00a0Preise\u00a0f\u00fcr\u00a0eine\u00a0\nAuswahl\u00a0kostenintensiver\u00a0Arzneimittel\u00a0im\u00a0Vergleich\u00a0zu\u00a0den\u00a0tats\u00e4 chlichen\u00a0Jahrest\u2010\nherapiekosten\u00a0ausfallen.\u00a0Die\u00a0tats\u00e4chlichen\u00a0Preise\u00a0sind\u00a0etwa\u00a0zwe i\u2010\u00a0bis\u00a013\u2010mal\u00a0so\u00a0\nhoch,\u00a0wie\u00a0sie\u00a0fairerweise\u00a0sein\u00a0s ollten.\u00a0Umsatzgewichtet\u00a0ergibt\u00a0 dies\u00a0\u00fcbersch\u00fcssige\u00a0 \n133\u00a0\n\u00a0Kosten\u00a0 in\u00a0 H\u00f6he\u00a0 von\u00a0 etwa\u00a0 173\u00a0%\u00a0 f\u00fcr\u00a0 patentgesch\u00fctzte\u00a0 Arzneimittel .\u00a0 Das\u00a0 AIM\u2010\nModell\u00a0zeigt\u00a0\u00fcbertragen\u00a0auf\u00a0die\u00a0 GKV\u2010Gesamtausgaben\u00a0demnach\u00a0ein\u00a0 Einsparpoten\u2010\nzial\u00a0von\u00a0etwa\u00a013\u00a0Mrd.\u00a0Euro\u00a0pro\u00a0J ahr\u00a0auf,\u00a0mit\u00a0steigender\u00a0Tendenz .\u00a0Der\u00a0Fair\u00a0Pricing\u00a0\nCalculator \u00a0ist\u00a0eine\u00a0Bereicherung\u00a0in\u00a0der\u00a0Diskussion\u00a0um\u00a0faire\u00a0Arzneimittelp reise\u00a0und\u00a0\nsollte\u00a0als\u00a0erg\u00e4nzende\u00a0Information\u00a0f\u00fcr\u00a0Preisverhandlungen\u00a0gesehe n\u00a0werden\u00a0sowie\u00a0\nals\u00a0Anreiz\u00a0f\u00fcr\u00a0die\u00a0Hersteller,\u00a0Transparenz\u00a0\u00fcber\u00a0Forschungs\u2010\u00a0und \u00a0Produktionskosten\u00a0\nherzustellen.\u00a0\nDie\u00a0Problematik\u00a0hoher\u00a0Arzneimittelpreise  \nVergleichende\u00a0Studien\u00a0der\u00a0Listenpreise\u00a0patentgesch\u00fctzter\u00a0Arznei mittel\u00a0verdeutli\u2010\nchen,\u00a0dass\u00a0die\u00a0in\u00a0der\u00a0deutschen\u00a0Lauer\u2010Taxe\u00a0gelisteten\u00a0Herstelle rabgabepreise\u00a0im\u00a0\nVergleich\u00a0 zu\u00a0 anderen\u00a0 europ\u00e4ischen\u00a0 Gesundheitssystemen\u00a0 am\u00a0 h\u00f6chst en\u00a0 liegen\u00a0\n(Vogler\u00a0et\u00a0al.,\u00a02018).\u00a0Busse\u00a0et\u00a0al.\u00a0kamen\u00a0in\u00a0ihrer\u00a0Analyse\u00a0auf\u00a0 eine\u00a0Differenz\u00a0eines\u00a0\nBIP\u2010adjustierten\u00a0Warenkorbs\u00a0vo n\u00a016\u00a0bis\u00a027\u00a0%\u00a0(Busse\u00a0et\u00a0al.,\u00a02016 ).\u00a0\u00a0\nEine\u00a0Erkl\u00e4rung\u00a0hierf\u00fcr\u00a0ist,\u00a0dass\u00a017\u00a0andere\u00a0europ\u00e4ische\u00a0L\u00e4nder\u00a0b ei\u00a0der\u00a0eigenen\u00a0\nPreisbildung\u00a0auf\u00a0die\u00a0deutschen\u00a0Listenpreise\u00a0referenzieren\u00a0(Haas ,\u00a02016;\u00a0R\u00e9muzat\u00a0et\u00a0\nal.,\u00a02015)\u00a0und\u00a0die\u00a0pU\u00a0daher\u00a0f\u00fcr\u00a0Deutschland\u00a0h\u00f6here\u00a0Listenpreise \u00a0definieren\u00a0sowie\u00a0\nfr\u00fcher\u00a0in\u00a0den\u00a0deutschen\u00a0Markt\u00a0dr\u00e4ngen\u00a0(Vogler\u00a0Vitry\u00a0Babar,\u00a02016 ).\u00a0Von\u00a0152\u00a0neu\u00a0in\u00a0\nder\u00a0EU\u00a0zugelassenen\u00a0Arzneimitteln\u00a0der\u00a0Jahre\u00a02016\u20102019\u00a0waren\u00a0in\u00a0 Deutschland\u00a0133\u00a0\n(87,5\u00a0%)\u00a0verf\u00fcgbar,\u00a0was\u00a0dem\u00a0h\u00f6chsten\u00a0Wert\u00a0in\u00a0der\u00a0EU\u00a0entspricht\u00a0 (Newton\u00a0et\u00a0al.,\u00a0\n2021).\u00a0\u00a0\n\u00c4rzte\u00a0ohne\u00a0Grenzen,\u00a0Brot\u00a0f\u00fcr\u00a0die\u00a0Welt\u00a0aber\u00a0auch\u00a0die\u00a0Bundestagsf raktionen\u00a0\"DIE\u00a0\nLINKE.\"\u00a0und\u00a0\"B\u00fcndnis\u00a090/Die\u00a0Gr\u00fcnen\"\u00a0forderten\u00a0im\u00a0Rahmen\u00a0einer\u00a0R esolution\u00a0der\u00a0\nWeltgesundheitsorganisation\u00a0(WHO)\u00a0mehr\u00a0Transparenz\u00a0bei\u00a0den\u00a0Hers tellerabgabe\u2010\npreisen\u00a0von\u00a0Arzneimitteln,\u00a0insbesondere\u00a0eine\u00a0Offenlegung\u00a0der\u00a0Ko sten\u00a0f\u00fcr\u00a0For\u2010\nschung\u00a0und\u00a0Entwicklung\u00a0( Research\u00a0and\u00a0Development,\u00a0 R&D)\u00a0zum\u00a0Zeitpunkt\u00a0der\u00a0\nArzneimittelzulassung.\u00a0Vom\u00a0Bundesministerium\u00a0f\u00fcr\u00a0Gesundheit\u00a0(BM G)\u00a0werde\u00a0dies\u00a0\naus\u00a0ihrer\u00a0Sicht\u00a0nicht\u00a0ausreichend\u00a0gef\u00f6rdert.\u00a0Das\u00a0BMG\u00a0geht\u00a0von\u00a0a usreichender\u00a0\nTransparenz\u00a0der\u00a0Arzneimittelpreise\u00a0in\u00a0Deutschland\u00a0aus\u00a0und\u00a0verwi es\u00a0auf\u00a0die\u00a0Beson\u2010\nderheit\u00a0der\u00a0Rabatte\u00a0nach\u00a0\u00a7\u00a0130a\u00a0(8)\u00a0SGB\u00a0V,\u00a0welche\u00a0als\u00a0Gesch\u00e4fts geheimnisse\u00a0anzu\u2010\nsehen\u00a0 seien.\u00a0 Die\u00a0 Nichtregierungsorganisationen\u00a0 ( Non\u2010Governmental\u00a0 Organiza\u2010\ntions,\u00a0NGO)\u00a0jedoch\u00a0mahnen,\u00a0dass\u00a0Verhandlungen\u00a0fairer\u00a0Arzneimittelpre ise\u00a0[oder\u00a0\nauch\u00a0die\u00a0H\u00f6he\u00a0der\u00a0Rabatte\u00a0auf\u00a0diese\u00a0Arzneimittel]\u00a0nur\u00a0auf\u00a0Basis \u00a0von\u00a0Transparenz\u00a0\nerfolgen\u00a0k\u00f6nnten\u00a0(hil,\u00a02019).\u00a0\nDer\u00a0internationale\u00a0Verband\u00a0der\u00a0Krankenkassenverb\u00e4nde\u00a0und\u00a0Kranke nversicherun\u2010\ngen\u00a0auf\u00a0Gegenseitigkeit\u00a0( The\u00a0International\u00a0Association\u00a0of\u00a0Mutual\u00a0Benefit\u00a0Societies\u00a0\n(AIM))\u00a0z\u00e4hlt\u00a057\u00a0Mitglieder\u00a0aus\u00a030\u00a0L\u00e4ndern\u00a0in\u00a0Afrika,\u00a0Europa,\u00a0Lateina merika\u00a0sowie\u00a0\ndem\u00a0Mittleren\u00a0Osten\u00a0und\u00a0repr\u00e4sentiert\u00a0die\u00a0Interessen\u00a0von\u00a0240\u00a0Mi llionen\u00a0Men\u2010 \n134\u00a0\n\u00a0schen.\u00a0Aus\u00a0Deutschland\u00a0sind\u00a0die\u00a0Gemeinsame\u00a0Vertretung\u00a0der\u00a0Innun gskrankenkas\u2010\nsen\u00a0(IKK\u00a0e.V.),\u00a0die\u00a0Knappschaft,\u00a0die\u00a0Sozialversicherung\u00a0f\u00fcr\u00a0Lan dwirtschaft,\u00a0Forsten\u00a0\nund\u00a0Gartenbau\u00a0(SVLFG)\u00a0sowie\u00a0der\u00a0Verband\u00a0der\u00a0Ersatzkassen\u00a0(vdek) \u00a0vertreten\u00a0(AIM,\u00a0\n2021c).\u00a0Historisch\u00a0reichen\u00a0die\u00a0W urzeln\u00a0von\u00a0AIM\u00a0bzw.\u00a0deren\u00a0Vorl\u00e4 uferorganisationen\u00a0\nbis\u00a0ins\u00a0Jahr\u00a01906\u00a0zur\u00fcck.\u00a0Die\u00a0Gr\u00fcndung\u00a0von\u00a0AIM\u00a0erfolgte\u00a0am\u00a028.1 .1950\u00a0(AIM,\u00a02021d).\u00a0\nAm\u00a04.\u00a0Dezember\u00a02019\u00a0hat\u00a0die\u00a0NGO\u00a0\u201eAIM\u201c\u00a0ihr\u00a0Konzept\u00a0zur\u00a0Bildung\u00a0f airer\u00a0Arzneimit\u2010\ntelpreise\u00a0im\u00a0EU\u2010Parlament\u00a0vorgestellt\u00a0(AIM,\u00a02019b).\u00a0Es\u00a0handelt\u00a0 sich\u00a0um\u00a0ein\u00a0EDV\u2010\ngest\u00fctztes\u00a0 Online\u2010Werkzeug\u00a0 (http s://fairpricingc alculator.eu)\u00a0 z u r \u00a0b r e i t e n \u00a0A n w e n \u2010\ndung\u00a0und\u00a0wurde\u00a0am\u00a011.\u00a0Juni\u00a02021\u00a0der\u00a0\u00d6ffentlichkeit\u00a0pr\u00e4sentiert\u00a0 (AIM,\u00a02021a).\u00a0\u00a0\nNachfolgend\u00a0werden\u00a0die\u00a0Gr\u00fcnde\u00a0der\u00a0AIM\u00a0f\u00fcr\u00a0die\u00a0Entwicklung\u00a0eines \u00a0fairen\u00a0Arznei\u2010\nmittelpreisrechners\u00a0f\u00fcr\u00a0die\u00a0Preis bildung\u00a0von\u00a0Arzneimitteln\u00a0in\u00a0d er\u00a0EU\u00a0erl\u00e4utert,\u00a0\ndessen\u00a0 Parameter\u00a0 dargestellt\u00a0 und\u00a0 der\u00a0 Rechner\u00a0 mittels\u00a0 ausgew\u00e4hlt er\u00a0 Beispiele\u00a0\ninnovativer\u00a0Arzneimittel\u00a0eine m\u00a0Praxistest\u00a0unterzogen.\u00a0\nIn\u00a0ihrer\u00a0Pr\u00e4sentation\u00a0zur\u00a0Vorstellung\u00a0des\u00a0fairen\u00a0Arzneimittelpr eisrechners\u00a0f\u00fcr\u00a0die\u00a0\nEU\u00a0 erl\u00e4utert\u00a0 Anne\u00a0 Hendrickx\u00a0 vom\u00a0 Socialist\u00a0 mutual\u00a0 Fund \u00a0Belgien\u00a0 zun\u00e4chst\u00a0 die\u00a0\nGr\u00fcnde\u00a0f\u00fcr\u00a0den\u00a0Bedarf\u00a0eines\u00a0solchen\u00a0Rechenmodells:\u00a0gro\u00dfe\u00a0Preiss teigerungen\u00a0bei\u00a0\nneuen\u00a0Produkten\u00a0im\u00a0derzeitigen\u00a0Pharmamarkt\u00a0(Bach,\u00a02021),\u00a0Zugang \u00a0zu\u00a0neuen,\u00a0\ninnovativen\u00a0Therapien\u00a0in\u00a0der\u00a0EU\u00a0nicht\u00a0in\u00a0allen\u00a0Mitgliedsstaaten \u00a0zeitgleich\u00a0m\u00f6glich\u00a0\n(Newton\u00a0et\u00a0al.,\u00a02021),\u00a0nicht\u00a0gen\u00fcgend\u00a0Investitionen\u00a0der\u00a0pU\u00a0in\u00a0R &D\u00a0(van\u00a0der\u00a0Gron\u2010\nde\u00a0et\u00a0al.,\u00a02017)\u00a0sowie\u00a0Rendite\u2010o rientierte\u00a0Gesch\u00e4ftsmodelle\u00a0der \u00a0pU\u00a0(Hendrickx,\u00a0\n2021;\u00a0Alonso\u2010Zaldivar,\u00a02015).\u00a0Eine\u00a0Analyse\u00a0der\u00a0globalen\u00a0Top\u00a010\u00a0 pU\u00a0ergibt\u00a0R&D\u2010\nKosten\u00a0von\u00a0durchschnittlich\u00a019\u00a0%\u00a0bei\u00a0Ausgaben\u00a0f\u00fcr\u00a0Vertrieb\u00a0und\u00a0 Marketing\u00a0in\u00a0\nH\u00f6he\u00a0von\u00a029\u00a0%\u00a0und\u00a0einer\u00a0durchschni ttlichen\u00a0Umsatzrendite\u00a0von\u00a020 ,9\u00a0%,\u00a0mit\u00a0dem\u00a0\nSpitzenreiter\u00a0Pfizer\u00a0bei\u00a0einer\u00a0Umsatzrendite\u00a0von\u00a043\u00a0%\u00a0sowie\u00a0der \u00a0nicht\u00a0zu\u00a0den\u00a0\nTop\u00a010\u00a0z\u00e4hlende\u00a0pU\u00a0Gilead\u00a0mit\u00a055\u00a0%\u00a0Gewinnmarge\u00a0im\u00a0Jahr\u00a02015\u00a0(va n\u00a0der\u00a0Gronde\u00a0\net\u00a0al.,\u00a02017;\u00a0at,\u00a02016).\u00a0Als\u00a0verbesserungsw\u00fcrdige\u00a0Punkte\u00a0f\u00fchrt\u00a0 Hendrickx\u00a0weiterhin\u00a0\ndie\u00a0schwierigen\u00a0Preisverhandlung en\u00a0und\u00a0ambivalenten\u00a0bzw.\u00a0riskan ten\u00a0Konzepte\u00a0\nan,\u00a0mit\u00a0denen\u00a0die\u00a0Verhandlungsparteien\u00a0gegens\u00e4tzliche\u00a0Ziele\u00a0ver folgen,\u00a0[in\u00a0Folge\u00a0\nvon\u00a0 Informationsdefiziten]\u00a0 nicht\u00a0 auf\u00a0 Augenh\u00f6he\u00a0 verhandeln,\u00a0 das\u00a0 Konzept\u00a0 der\u00a0\nWert\u2010basierten\u2010Preisbildung\u00a0( value\u2010based\u00a0pricing )\u00a0fehlerbehaftet\u00a0und\u00a0die\u00a0Systema\u2010\ntik\u00a0von\u00a0Preisnachl\u00e4ssen\u00a0knifflig\u00a0und\u00a0intransparent\u00a0seien.\u00a0In\u00a0de r\u00a0Praxis\u00a0werden\u00a0ob\u2010\njektive\u00a0wertbasierte\u00a0Preisbildungsmechanismen\u00a0mittels\u00a0emotional \u00a0aufgeladener\u00a0\nKampagnen\u00a0[Therapie\u00a0f\u00fcr\u00a0erkrankte\u00a0Kinder]\u00a0durch\u00a0die\u00a0pU\u00a0ausgeheb elt\u00a0und\u00a0\u00fcber\u2010\nh\u00f6hte\u00a0Preise\u00a0selbst\u00a0f\u00fcr\u00a0 me\u2010too\u2010Pr\u00e4parate,\u00a0zumeist\u00a0Schein innovationen ,\u00a0eingefor\u2010\ndert.\u00a0Einem\u00a0gr\u00f6\u00dftm\u00f6glichen\u00a0Zugewinn\u00a0an\u00a0Gesundheit\u00a0bei\u00a0limitiert en\u00a0Budgets\u00a0ste\u2010\nhen\u00a0in\u00a0der\u00a0Praxis\u00a0unsichere\u00a0Zugewinne\u00a0an\u00a0Gesundheit\u00a0gegen\u00fcber.\u00a0 Steigende\u00a0Preise\u00a0\nk\u00f6nnen\u00a0aber\u00a0bei\u00a0begrenzten\u00a0Gesundheitsbudgets\u00a0zur\u00a0Beschr\u00e4nkung\u00a0 der\u00a0Leistungs\u2010\ninanspruchnahme\u00a0f\u00fchren.\u00a0Aus\u00a0einer\u00a0Bereitschaft\u00a0und\u00a0F\u00e4higkeit\u00a0( willingness\u00a0and\u00a0\nability\u00a0to\u00a0pay )\u00a0der\u00a0EU\u2010Mitgliedsstaaten,\u00a0f\u00fcr\u00a0i nnovative\u00a0Produkte\u00a0zu\u00a0zahlen,\u00a0w erde\u00a0 \n135\u00a0\n\u00a0eine\u00a0Preisbildung\u00a0gem\u00e4\u00df\u00a0dem\u00a0Grundsatz\u00a0\u201e was\u00a0der\u00a0Markt\u00a0hergibt \u201c\u00a0verfolgt,\u00a0die\u00a0\nzudem\u00a0nicht\u00a0am\u00a0jeweiligen\u00a0Bruttoinlandsprodukt\u00a0(BIP)\u00a0adjustiert \u00a0ist\u00a0(Hendrickx,\u00a0\n2021).\u00a0\nAls\u00a0 L\u00f6sungsansatz\u00a0 k\u00f6nnen\u00a0 laut\u00a0 AIM\u00a0 bzw.\u00a0 Hendrickx\u00a0 neue\u00a0 transpare nte\u00a0 Regeln\u00a0\ndienen,\u00a0gem\u00e4\u00df\u00a0der\u00a0Definition\u00a0der\u00a0WHO\u00a0f\u00fcr\u00a0einen\u00a0fairen\u00a0Preis,\u00a0d. \u00a0h.\u00a0\u201eeiner\u00a0der\u00a0be\u2010\nzahlbar\u00a0f\u00fcr\u00a0Gesundheitssysteme\u00a0und\u00a0Patienten\u00a0ist\u00a0und\u00a0zugleich\u00a0f \u00fcr\u00a0die\u00a0pharmazeu\u2010\ntische\u00a0Industrie\u00a0einen\u00a0suffizienten\u00a0Anreiz\u00a0am\u00a0Markt\u00a0bietet,\u00a0in\u00a0 Innovation\u00a0und\u00a0Her\u2010\nstellung\u00a0der\u00a0Arzneimittel\u00a0zu\u00a0inv estieren.\u201c\u00a0Nach\u00a0Moon\u00a0et\u00a0al.\u00a0bei nhaltet\u00a0dieser\u00a0faire\u00a0\nPreis\u00a0im\u00a0Einzelnen\u00a0die\u00a0f\u00fcr\u00a0den\u00a0pU\u00a0tats\u00e4chlichen\u00a0Kosten\u00a0f\u00fcr\u00a0R&D, \u00a0Produktion,\u00a0Ver\u2010\ntrieb,\u00a0Zulassung,\u00a0Pharmakovigilanz\u00a0sowie\u00a0einen\u00a0fairen\u00a0Profit\u00a0( Return\u00a0on\u00a0Investment \u00a0\n(RoI)).\u00a0Auf\u00a0Seiten\u00a0der\u00a0Krankenkassen\u00a0(oft\u00a0auf\u00a0die\u00a0Rolle\u00a0als\u00a0\u201eKostent r\u00e4ger\u201c\u00a0reduziert)\u00a0\nund\u00a0somit\u00a0auch\u00a0der\u00a0Patienten\u00a0bedeutet\u00a0dies\u00a0eine\u00a0Finanzierbarkei t\u00a0des\u00a0Arzneimit\u2010\ntels\u00a0in\u00a0ausreichender\u00a0Menge\u00a0unter\u00a0Ber\u00fccksichtigung\u00a0der\u00a0Versorgu ngssicherheit\u00a0\nund\u00a0letztendlich\u00a0dem\u00a0Wert\u00a0f\u00fcr\u00a0das\u00a0Individuum\u00a0und\u00a0die\u00a0Gesellscha ft\u00a0(Moon\u00a0et\u00a0al.,\u00a0\n2020).\u00a0Auf\u00a0die\u00a0EU\u00a0bezogen\u00a0geht\u00a0Hendrickx\u00a0von\u00a0einem\u00a0gesamten\u00a0und \u00a0einheitlichen\u00a0\nMarkt\u00a0aus,\u00a0d.\u00a0h.\u00a0alle\u00a027\u00a0Mitgliedsstaaten\u00a0sollten\u00a0gemeinsam\u00a0mit \u00a0dem\u00a0pU\u00a0verhan\u2010\ndeln,\u00a0ein\u00a0Bezug\u00a0zu\u00a0realen\u00a0Kosten \u00a0der\u00a0pU\u00a0sollte\u00a0dabei\u00a0als\u00a0Basis\u00a0 etabliert\u00a0werden,\u00a0\nworaus\u00a0sich\u00a0eine\u00a0Vorhersehbarkei t\u00a0der\u00a0Arzneimittelausgaben\u00a0der\u00a0 Mitgliedsstaaten\u00a0\nergebe\u00a0(Hendrickx,\u00a02021).\u00a0\nFunktionsweise\u00a0des\u00a0AIM\u00a0Fair\u00a0Pricing\u00a0Calculators\u00a0\nDer\u00a0Algorithmus\u00a0der\u00a0NGO\u00a0AIM\u00a0beruht\u00a0auf\u00a0Kosten\u2010\u00a0sowie\u00a0Ertragsele menten\u00a0und\u00a0\nbezieht\u00a0die\u00a0Anzahl\u00a0der\u00a0zu\u00a0erwartenden\u00a0Patienten\u00a0mit\u00a0ein\u00a0(siehe\u00a0 Abb.\u00a07.2).\u00a0Sofern\u00a0\nder\u00a0 pU\u00a0 die\u00a0 exakten\u00a0 Kosten\u00a0 nicht\u00a0 plausibel\u00a0 offenbart,\u00a0 werden\u00a0 Pau schalbetr\u00e4ge\u00a0\nber\u00fccksichtigt\u00a0(AIM,\u00a02021b).\u00a0So\u00a0kann\u00a0das\u00a0Ziel\u00a0eines\u00a0EU\u2010weiten\u00a0P reises\u00a0f\u00fcr\u00a0jedes\u00a0\nneue,\u00a0von\u00a0der\u00a0europ\u00e4ischen\u00a0Arzneimittelbeh\u00f6rde\u00a0(EMA)\u00a0zugelassen e\u00a0Arzneimittel\u00a0\nrealisiert\u00a0werden.\u00a0Gegebenenfalls\u00a0kann\u00a0unter\u00a0Beachtung\u00a0der\u00a0jewe iligen\u00a0Bruttoin\u2010\nlandsprodukte\u00a0der\u00a0Mitgliedsstaaten\u00a0eine\u00a0faire\u00a0Anpassung\u00a0an\u00a0die\u00a0 jeweilige\u00a0Kauf\u2010\nkraft\u00a0erfolgen,\u00a0bspw.\u00a0f\u00fcr\u00a0Deutschland\u00a0plus\u00a020\u00a0%.\u00a0\u00a0\nDem\u00a0Rechner\u00a0f\u00fcr\u00a0faire\u00a0Arzneimitte lpreise\u00a0liegen\u00a0vier\u00a0Archetypen \u00a0zu\u00a0Grunde,\u00a0d.\u00a0h.\u00a0\u00a0\n\uf0b7 chronische\u00a0Erkrankungen,\u00a0\u00a0\n\uf0b7 onkologische\u00a0Erkrankungen,\u00a0\u00a0\n\uf0b7 seltene\u00a0Leiden\u00a0( rare\u00a0diseases )\u00a0mit\u00a0einer\u00a0Inzidenz\u00a0von\u00a0<5/10.000\u00a0in\u00a0\nder\u00a0EU\u00a0sowie\u00a0\u00a0\n\uf0b7 sehr\u00a0 seltene\u00a0 Leiden\u00a0 ( ultra\u2010rare\u00a0 diseases )\u00a0 mit\u00a0 einer\u00a0 Inzidenz\u00a0 von\u00a0\n<2/100.000.\u00a0 \n136\u00a0\n\u00a0Im\u00a0Einzelnen\u00a0werden\u00a0f\u00fcnf\u00a0Elemente\u00a0zur\u00a0Berechnung\u00a0des\u00a0Preises\u00a0he rangezogen:\u00a0der\u00a0\nQuotient\u00a0aus\u00a0Entwicklungskosten\u00a0und\u00a0der\u00a0Anzahl\u00a0der\u00a0therapierbar en\u00a0Patienten,\u00a0die\u00a0\nProduktionskosten,\u00a0die\u00a0Kosten\u00a0f\u00fcr\u00a0Vertrieb\u00a0und\u00a0medizinische\u2010wis senschaftliche\u00a0Infor\u2010\nmation,\u00a0ein\u00a0Basisertrag\u00a0sowie\u00a0ge gebenenfalls\u00a0ein\u00a0Innovationsbon us\u00a0(AIM,\u00a02019a).\u00a0\nDie\u00a0globalen\u00a0R&D\u2010Kosten\u00a0werden\u00a0bis\u00a0zu\u00a0einer\u00a0H\u00f6he\u00a0von\u00a0maximal\u00a02, 5\u00a0Milliarden\u00a0\nEuro\u00a0ber\u00fccksichtigt,\u00a0wobei\u00a0auch\u00a0Fehlschl\u00e4ge\u00a0der\u00a0Forschung\u00a0gew\u00fcr digt\u00a0werden\u00a0und\u00a0\nmit\u00a0klaren\u00a0Vorgaben\u00a0\u00f6ffentliche\u00a0F \u00f6rdergelder,\u00a0Steuererstattunge n,\u00a0Opportunit\u00e4ts\u2010\nkosten\u00a0oder\u00a0Unternehmens\u00fcbernahmen\u00a0( Buy\u2010out)\u00a0hierbei\u00a0einflie\u00dfen.\u00a0Legt\u00a0ein\u00a0pU\u00a0\ndiese\u00a0Kosten\u00a0nicht\u00a0offen,\u00a0wird\u00a0eine\u00a0Pauschale\u00a0f\u00fcr\u00a0R&D\u2010Kosten\u00a0in \u00a0H\u00f6he\u00a0von\u00a0250\u00a0\nMillionen\u00a0Euro\u00a0akzeptiert.\u00a0Die\u00a0globalen\u00a0Entwicklungskosten\u00a0werd en\u00a0mit\u00a0einem\u00a0\nMarktanteil\u00a0der\u00a027\u00a0EU\u2010Mitgliedsst aaten\u00a0in\u00a0H\u00f6he\u00a0von\u00a035,9\u00a0%\u00a0gewic htet\u00a0und\u00a0auf\u00a0die\u00a0\nZielpopulation\u00a0im\u00a0Anwendungsgebie t\u00a0(Pr\u00e4valenz\u00a0oder\u00a0Inzidenz)\u00a0so wie\u00a0einer\u00a0Be\u2010\nhandlungsrate\u00a0von\u00a050\u00a0%\u00a0adjustiert.\u00a0Final\u00a0ergeben\u00a0sich\u00a0hieraus\u00a0R &D\u2010Kosten\u00a0je\u00a0Pati\u2010\nent\u00a0bzw.\u00a0Behandlung\u00a0sowie\u00a0Jahrestherapiekosten\u00a0(Hendrickx,\u00a02021 ).\u00a0\nLegt\u00a0der\u00a0pU\u00a0seine\u00a0Produktionskosten\u00a0offen,\u00a0werden\u00a0diese\u00a0ber\u00fccks ichtigt.\u00a0Als\u00a0Pau\u2010\nschalen\u00a0werden\u00a0andernfalls\u00a0f\u00fcr\u00a0\n\uf0b7 Gen\u2010\u00a0bzw.\u00a0Zelltherapien\u00a060.000\u00a0Euro\u00a0je\u00a0Anwendung,\u00a0\n\uf0b7 biotechnologisch\u00a0 hergestellte\u00a0 Ar zneimittel\u00a0 f\u00fcr\u00a0 seltene\u00a0 Leiden\u00a0\n750\u00a0Euro\u00a0je\u00a0Monat,\u00a0\n\uf0b7 f\u00fcr\u00a0biotechnologisch\u00a0produzierte\u00a0Arzneimittel\u00a0(Biologika)\u00a0150\u00a0E uro\u00a0je\u00a0\nMonat,\u00a0\n\uf0b7 f\u00fcr\u00a0chemisch\u2010synthetische\u00a0Arznei mittel\u00a0zur\u00a0Therapie\u00a0seltener\u00a0Le iden\u00a0\n(Orphan\u00a0Drugs )\u00a0250\u00a0Euro\u00a0je\u00a0Monat,\u00a0\n\uf0b7 f\u00fcr\u00a0chemisch\u00a0synthetisierte\u00a0Wirkstoffe\u00a050\u00a0Euro\u00a0je\u00a0Monat\u00a0\nangesetzt,\u00a0die\u00a0wiederum\u00a0mit\u00a0de r\u00a0durchschnittlichen\u00a0Therapiedaue r\u00a0multipliziert\u00a0\nwerden.\u00a0F\u00fcr\u00a0Vertrieb\u00a0und\u00a0medizini sche\u00a0Fachinformation\u00a0werden\u00a020 \u00a0%\u00a0der\u00a0R&D\u2010\nKosten\u00a0in\u00a0die\u00a0\u00dcberlegung\u00a0einbezogen\u00a0(Hendrickx,\u00a02021;\u00a0AIM,\u00a02021 b).\u00a0\nAls\u00a0Basisprofit\u00a0erh\u00e4lt\u00a0der\u00a0pU\u00a08\u00a0%\u00a0der\u00a0Gesamtkosten,\u00a0der\u00a0Bonus\u00a0f \u00fcr\u00a0Innovation\u00a0kann\u00a0\nggf.\u00a0gew\u00e4hrt\u00a0werden\u00a0und\u00a0zwischen\u00a05\u00a0und\u00a040\u00a0%\u00a0der\u00a0Gesamtkosten\u00a0va riieren\u00a0(siehe\u00a0\nAbb.\u00a07.3).\u00a0Hierzu\u00a0werden\u00a0eine\u00a0Verbesserung\u00a0der\u00a0Lebensqualit\u00e4t,\u00a0 die\u00a0Verl\u00e4ngerung\u00a0\ndes\u00a0Gesamt\u00fcberlebens\u00a0( Overall\u00a0Survival ,\u00a0OS)\u00a0bzw.\u00a0eine\u00a0Phase\u00a0ohne\u00a0Fortschreiten\u00a0\nder\u00a0Symptome\u00a0einer\u00a0Erkrankung\u00a0( Progression\u00a0free\u00a0Survival ,\u00a0PFS),\u00a0die\u00a0kurative\u00a0The\u2010\nrapie,\u00a0der\u00a0Status\u00a0als\u00a0Solit\u00e4rar zneimittel\u00a0oder\u00a0eine\u00a0Anwendung\u00a0d es\u00a0Arzneimittels\u00a0bei\u00a0\neiner\u00a0lebensbedrohlichen\u00a0bzw.\u00a0chronisch\u00a0beeintr\u00e4chtigenden\u00a0Erkr ankung\u00a0gew\u00fcr\u2010\ndigt.\u00a0Im\u00a0Ergebnis\u00a0soll\u00a0hierbei\u00a0der\u00a0therapeutische\u00a0Wert\u00a0der\u00a0real en\u00a0Innovation\u00a0be\u2010\nlohnt\u00a0werden\u00a0(Hendrickx,\u00a02021;\u00a0AIM,\u00a02021b).\u00a0 \n137\u00a0\n\u00a0Vergleicht\u00a0 man\u00a0 die\u00a0 mit\u00a0 diesem\u00a0 Mo dell\u00a0 ermittelten\u00a0 Arzneimittelpr eise\u00a0 mit\u00a0 den\u00a0\nderzeit\u00a0\u201emarkt\u00fcblichen\u00a0der\u00a0pU\u201c,\u00a0so\u00a0ergeben\u00a0sich\u00a0um\u00a0den\u00a0Faktor\u00a0f \u00fcnf\u00a0bis\u00a0zehn\u00a0nied\u2010\nrigere,\u00a0aus\u00a0Sicht\u00a0der\u00a0AIM,\u00a0faire \u00a0Arzneimittelpreise\u00a0(Hendrickx, \u00a02021;\u00a0AIM,\u00a02021b).\u00a0\nDie\u00a0NGO\u00a0AIM\u00a0m\u00f6chte\u00a0das\u00a0Modell\u00a0der\u00a0fairen\u00a0Preisberechnung\u00a0stufen weise\u00a0umsetzen.\u00a0\nDie\u00a0Intransparenz\u00a0der\u00a0Kosten\u00a0bzw.\u00a0unterschiedlichen\u00a0Nettopreise \u00a0in\u00a0den\u00a0einzelnen\u00a0\nEU\u2010Staaten\u00a0sollen\u00a0einer\u00a0neuen\u00a0Transparenz\u00a0weichen.\u00a0Kostentr\u00e4ger \u00a0und\u00a0Verantwortli\u2010\nche\u00a0sollten\u00a0den\u00a0Rechner\u00a0bei\u00a0Preisverhandlungen\u00a0nutzen\u00a0und\u00a0die\u00a0v om\u00a0pU\u00a0vorgeschla\u2010\ngenen\u00a0Preise\u00a0kritisch\u00a0w\u00fcrdigen,\u00a0auch\u00a0au\u00dferhalb\u00a0der\u00a0EU\u2010Mitglieds staaten.\u00a0Langfristig\u00a0\nw\u00fcnscht\u00a0sich\u00a0die\u00a0AIM\u00a0eine\u00a0Etablierung\u00a0einer\u00a0paneurop\u00e4ischen,\u00a0dr eistufigen\u00a0Preisbil\u2010\ndung\u00a0als\u00a0Zugangsvoraussetzung\u00a0f\u00fcr\u00a0den\u00a0europ\u00e4ischen\u00a0Pharmamarkt. \u00a0Der\u00a0pU\u00a0soll\u00a0\nhierzu\u00a0der\u00a0EMA\u00a0alle\u00a0erforderlichen\u00a0Daten\u00a0im\u00a0Kontext\u00a0des\u00a0Zulassu ngsantrages\u00a0\u00fcber\u2010\nmitteln,\u00a0ggf.\u00a0k\u00f6nnte\u00a0ein\u00a0Innovationsbonus\u00a0durch\u00a0eine\u00a0Technologi ebewertung\u00a0( health\u00a0\ntechnology\u00a0assessment ,\u00a0HTA)\u00a0bef\u00fcrwortet\u00a0und\u00a0schlie\u00dflich\u00a0seitens\u00a0der\u00a0Europ\u00e4ischen\u00a0\nKommission\u00a0beschlossen\u00a0werden\u00a0(Hendrickx,\u00a02021).\u00a0\nAbb.\u00a07.2:\u00a0Eingabemaske\u00a0des\u00a0AIM\u00a0 Fair\u00a0Pricing\u00a0Calculators \u00a0\u00a0\n\u00a0\nAIM,\u00a02021;\u00a0https://fairpricingcalculator.eu/\u00a0\u00a0\n\u00a0\u00a0\n \n138\u00a0\n\u00a0\nAbb.\u00a07.3:\u00a0Eingabemaske\u00a02\u00a0des\u00a0AIM\u00a0Fair\u00a0Pricing\u00a0Calculators\u00a0\u2013\u00a0Lev el\u00a0of\u00a0Innovation\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0AIM,\u00a02021;\u00a0https://fairpricingcalculator.eu/\u00a0\u00a0\nNachfolgend\u00a0werden\u00a0die\u00a0Arche\u2010Typen\u00a0des\u00a0AIM\u2010Rechners\u00a0anhand\u00a0der\u00a0 in\u00a0den\u00a0voran\u2010\ngegangenen\u00a0Innovationsreporten\u00a0b ewerteten\u00a0Arzneimittel\u00a0dargeste llt.\u00a0\nOrphan\u00a0Drugs\u00a0bzw.\u00a0Ultra\u2010Rare\u2010Diseases \u00a0\nOnasemnogen\u2010Abeparvovec\u00a0(Zolgensma\u00ae)\u00a0\nZur\u00a0Therapie\u00a0der\u00a05q\u2010assoziierten\u2010spinalen\u00a0Muskelatrophie\u00a0(SMA), \u00a0einer\u00a0progre\u2010\ndienten,\u00a0neurodegenerativen\u00a0Erkrankung,\u00a0welche\u00a0je\u00a0nach\u00a0Beginn\u00a0( in\u00a0utero\u00a0bzw.\u00a0im\u00a0\nErwachsenenalter)\u00a0in\u00a0f\u00fcnf\u00a0Subtypen\u00a0mit\u00a0je\u00a0unterschiedlichen\u00a0Sch weregraden\u00a0un\u2010\nterschieden\u00a0wird\u00a0(0\u00a0bis\u00a04),\u00a0steh en\u00a0nunmehr\u00a0verschiedene\u00a0Therapi ealternativen\u00a0zur\u00a0\nVerf\u00fcgung.\u00a0 Diese\u00a0 umfassen\u00a0 Arznei mittel\u00a0 zur\u00a0 t\u00e4glichen\u00a0 oralen\u00a0 Gab e\u00a0 (Risdiplam\u00a0\n(Evrysdi\u00ae)),\u00a0zur\u00a0wiederholten\u00a0intrathekalen\u00a0Injektion\u00a0(Nusiners en\u00a0(Spinraza\u00ae))\u00a0oder\u00a0\neinmaligen\u00a0Gentherapie\u00a0(Onasemno gen\u2010Abeparvovec\u00a0(Zolgensma\u00ae))\u00a0( G\u2010BA,\u00a02021g;\u00a0\nG\u2010BA,\u00a02021f;\u00a0G\u2010BA,\u00a02017a;\u00a0EMA\u00a0CHMP,\u00a02017;\u00a0EMA\u00a0CHMP\u00a0EMA\u00a0CAT,\u00a0202 0;\u00a0EMA\u00a0\nCHMP,\u00a02021).\u00a0Letztere\u00a0war\u00a0bei\u00a0Markteinf\u00fchrung\u00a0weltweit\u00a0die\u00a0Arzn eitherapie\u00a0mit\u00a0\nden\u00a0 h\u00f6chsten\u00a0 Kosten.\u00a0 Onasemnogen\u2010Abeparvovec\u00a0 bietet\u00a0 Hoffnung\u00a0 f\u00fc r\u00a0 Eltern,\u00a0\nderen\u00a0Neugeborene\u00a0mit\u00a0SMA\u00a0Typ\u00a01\u00a0 ohne\u00a0 Therapie\u00a0eine\u00a0 schwere\u00a0Behi nderung\u00a0\nerleiden\u00a0oder\u00a0gar\u00a0in\u00a0den\u00a0ersten\u00a0Lebensjahren\u00a0versterben\u00a0k\u00f6nnten .\u00a0Eine\u00a0rationale\u00a0\nBewertung\u00a0dieser\u00a0Therapieoption\u00a0gestaltet\u00a0sich\u00a0jedoch\u00a0anspruchs voll.\u00a0Das\u00a0emotio\u2010\nnale\u00a0Marketing\u00a0des\u00a0pU\u00a0mit\u00a0einer\u00a0 \u201eLotterie\u201c\u00a0von\u00a0weltweit\u00a0100\u00a0Anw endungen\u00a0f\u00fcr\u00a0\nPatienten\u00a0 ohne\u00a0 medizinische\u00a0 Priorisierung\u00a0 nach\u00a0 Schweregrad\u00a0 der\u00a0 Symptome,\u00a0\nmanipulierte,\u00a0pr\u00e4klinische\u00a0Tierversuchsdaten\u00a0im\u00a0Kontext\u00a0der\u00a0FDA \u2010Zulassung\u00a0(FDA,\u00a0 \n139\u00a0\n\u00a02019)\u00a0und\u00a0der\u00a0Zukauf\u00a0des\u00a0mit\u00a0\u00f6ffentlichen\u00a0Geldern\u00a0gef\u00f6rderten\u00a0E ntwicklungsun\u2010\nternehmens\u00a0der\u00a0Therapie\u00a0(Beckmann\u00a0Schillinger,\u00a02020)\u00a0AveXis\u00a0f\u00fcr \u00a08,7\u00a0Mrd.\u00a0US\u00a0\nDollar\u00a0 werfen\u00a0 substanzielle\u00a0 sowie\u00a0 ethische\u00a0 Fragen\u00a0 auf\u00a0 (Kirschne r\u00a0 et\u00a0 al.,\u00a0 2020;\u00a0\nNaumann\u2010Winter\u00a0et\u00a0al.,\u00a02020).\u00a0On asemnogen\u2010Abeparvovec\u00a0wird\u00a0derz eit\u00a0nur\u00a0stati\u2010\non\u00e4r\u00a0 in\u00a0 spezialisierten\u00a0 Zentren\u00a0 angewendet,\u00a0 wobei\u00a0 eine\u00a0 einmalig e\u00a0 Applikation\u00a0\nerfolgt.\u00a0Mit\u00a0Eintrag\u00a0in\u00a0die\u00a0Laue r\u2010Taxe,\u00a0dem\u00a0Preisverzeichnis\u00a0de utscher\u00a0Apotheken,\u00a0\nzum\u00a01.\u00a0Juli\u00a02020\u00a0wurde\u00a0daher\u00a0nur\u00a0der\u00a0Klinik\u2010Einkaufspreis\u00a0von\u00a01 .945.000\u00a0Euro\u00a0\npubliziert.\u00a0Berechnet\u00a0man\u00a0die\u00a0Therapiekosten\u00a0mit\u00a0dem\u00a0 Fair\u00a0Pricing\u00a0Calculator \u00a0von\u00a0\nAIM\u00a0unter\u00a0Nutzung\u00a0entsprechender\u00a0Parameter,\u00a0so\u00a0ergibt\u00a0sich\u00a0ein\u00a0 fairer\u00a0Preis\u00a0von\u00a0\n894.457,25\u00a0Euro,\u00a0d.\u00a0h.\u00a046\u00a0%\u00a0des\u00a0aktuellen\u00a0Krankenhausapotheken\u2010 Einkaufspreises.\u00a0\nBer\u00fccksichtigt\u00a0man\u00a0die\u00a0Kaufkraft\u00a0Deutschlands\u00a0mit\u00a0einem\u00a020\u00a0%ige n\u00a0Aufschlag,\u00a0so\u00a0\nergibt\u00a0sich\u00a0ein\u00a0Preis\u00a0von\u00a01.073.348,709\u00a0Euro,\u00a0mithin\u00a055\u00a0%\u00a0des\u00a0d erzeitigen\u00a0Klinik\u2010EK\u2010\nPreises.\u00a0 Der\u00a0 G\u2010BA\u00a0 bewertete\u00a0 Onas emnogen\u2010Abeparvovec\u00a0 zweimal,\u00a0 ei nmal\u00a0 als\u00a0\nOrphan\u00a0Drug \u00a0und\u00a0ein\u00a0zweites\u00a0Mal\u00a0nach\u00a0\u00dcberschreiten\u00a0der\u00a050\u00a0Mio.\u00a0Euro\u2010Grenze \u00a0im\u00a0\nRahmen\u00a0eines\u00a0regul\u00e4ren\u00a0Verfahrens.\u00a0Im\u00a0aktuellen\u00a0Beschluss\u00a0vom\u00a00 4.11.2021\u00a0konn\u2010\nte\u00a0in\u00a0allen\u00a0Subgruppen\u00a0mangels\u00a0ad \u00e4quater\u00a0Daten\u00a0des\u00a0pU\u00a0kein\u00a0Zusa tznutzen\u00a0gegen\u2010\n\u00fcber\u00a0zVT\u00a0Nusinersen\u00a0belegt\u00a0werden.\u00a0Die\u00a0Verhandlung\u00a0eines\u00a0Erstat tungsbetages\u00a0\nzwischen\u00a0pU\u00a0und\u00a0GKV\u2010SV\u00a0dauert\u00a0noch\u00a0an.\u00a0\u00a0\n[Parameter:\u00a0ultra\u2010rare\u2010disease;\u00a0Pr\u00e4valenz\u00a0SMA\u00a0Typ\u00a0I\u00a00,17\u00a0pro\u00a010 0.000\u00a0(G\u2010BA,\u00a02021c);\u00a0761\u00a0Patien\u2010\nten\u00a0in\u00a010\u00a0Jahren;\u00a050\u00a0%\u00a0Behandlungsquote;\u00a0R&D\u2010Kosten\u00a0250\u00a0Mio.\u00a0Eu ro;\u00a01\u00a0competitor\u00a0(1/2\u00a0of\u00a0the\u00a0\nmarket)\u00a0Risdiplam\u00a0war\u00a0zum\u00a0Zeitpunkt\u00a0der\u00a0Markteinf\u00fchrung\u00a0noch\u00a0ni cht\u00a0zugelassen;\u00a0Gentherapie\u00a0\n60.000\u00a0\u20ac\u00a0je\u00a0Anwendung;\u00a0Sales\u00a0und\u00a0Med\u2010Wiss\u2010Kosten\u00a020\u00a0%\u00a0der\u00a0R&D\u2010K osten;\u00a0Basis\u2010Profit\u00a08\u00a0%\u00a0der\u00a0\nVollkosten;\u00a0Innovationsbonus\u00a035\u00a0%\u00a0(life\u2010threatening\u00a0disease:\u00a05\u00a0 %;\u00a0plus\u00a0major\u00a0impact\u00a0on\u00a0the\u00a0course\u00a0\nof\u00a0the\u00a0disease:\u00a030\u00a0%)]\u00a0\nNusinersen\u00a0(Spinraza\u00ae)\u00a0\nMit\u00a0Nusinersen\u00a0(Spinraza\u00ae)\u00a0kam\u00a0zur\u00a0Therapie\u00a0der\u00a0SMA\u00a0bereits\u00a0im\u00a0 Jahr\u00a02017\u00a0ein\u00a0\nAntisense\u2010Oligonukleotid\u00a0zu\u00a0in trathekalen\u00a0Anwendung\u00a0(Lumbalpunk tion)\u00a0auf\u00a0den\u00a0\nMarkt.\u00a0Anfangs\u00a0werden\u00a0vier\u00a0Gaben\u00a0an\u00a0den\u00a0Tagen\u00a00,\u00a014,\u00a028\u00a0und\u00a063\u00a0 verabreicht,\u00a0\nsodann\u00a0sind\u00a0alle\u00a0vier\u00a0Monate\u00a0(120\u00a0Tage)\u00a0Erhaltungsdosen\u00a0erforde rlich,\u00a0mithin\u00a034\u00a0\nGaben\u00a0binnen\u00a0zehn\u00a0Jahren\u00a0(EMA\u00a0CHMP,\u00a02017).\u00a0Der\u00a0G\u2010BA\u00a0bewertete\u00a0N usinersen\u00a0im\u00a0\nzweiten\u00a0 Beschluss\u00a0 vom\u00a0 20.05.2021\u00a0 nach\u00a0 \u00dcberschreiten\u00a0 der\u00a0 50\u00a0 Mill ionen\u00a0 Euro\u00a0\nUmsatzgrenze\u00a0 in\u00a0 diversen\u00a0 Subgruppe n,\u00a0 d.\u00a0h.\u00a0 je\u00a0 nach\u00a0 5q\u2010SMA\u2010Typ\u00a0 b zw.\u00a0 Anzahl\u00a0\nvorhandener\u00a0Kopien\u00a0des\u00a0SMN2\u2010Gens.\u00a0F\u00fcr\u00a05q\u2010SMA\u00a0Typ\u00a01\u00a0attestierte\u00a0 er\u00a0einen\u00a0Hin\u2010\nweis\u00a0auf\u00a0einen\u00a0erheblichen\u00a0Zusatznutzen\u00a0(ZN).\u00a0Bei\u00a0SMA\u00a0Typ\u00a02\u00a0ste llte\u00a0der\u00a0G\u2010BA\u00a0\neinen\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0betr\u00e4chtlichen\u00a0ZN\u00a0fest,\u00a0bei\u00a0Typ\u00a03\u00a0 bzw.\u00a04\u00a0konnte\u00a0ein\u00a0\nZN\u00a0jedoch\u00a0nicht\u00a0belegt\u00a0werden.\u00a0Bei\u00a0pr\u00e4symptomatischen\u00a0Patienten \u00a0mit\u00a0noch\u00a0zwei\u00a0\nSMN2\u2010Genkopien\u00a0gab\u00a0es\u00a0einen\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0erheblichen\u00a0 ZN,\u00a0bei\u00a0drei\u00a0\nSMN2\u2010Genkopien\u00a0einen\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0nicht\u00a0quantifizierb aren\u00a0ZN,\u00a0jedoch\u00a0\nbei\u00a0mehr\u00a0als\u00a0drei\u00a0SMN2\u2010Genkopien\u00a0konnte\u00a0ein\u00a0ZN\u00a0nicht\u00a0belegt\u00a0wer den\u00a0(G\u2010BA,\u00a0\n2021d).\u00a0 \n140\u00a0\n\u00a0Im\u00a0Innovationsreport\u00a02020\u00a0wurde\u00a0Nusinersen\u00a0mit\u00a0zwei\u00a0gr\u00fcnen\u00a0Ampe ln\u00a0bewertet,\u00a0\neine\u00a0f\u00fcr\u00a0verf\u00fcgbare\u00a0[neue]\u00a0Therapien\u00a0und\u00a0eine\u00a0f\u00fcr\u00a0(Zusatz\u2010)\u00a0Nut zen.\u00a0Ein\u00a0Kostenver\u2010\ngleich\u00a0wurde\u00a0aufgrund\u00a0des\u00a0 Orphan\u2010Drug \u2010Status\u00a0nicht\u00a0durchgef\u00fchrt\u00a0(Glaeske\u00a0et\u00a0al.,\u00a0\n2020).\u00a0\nDer\u00a0G\u2010BA\u00a0weist\u00a0f\u00fcr\u00a0das\u00a0erste\u00a0Jahr\u00a0der\u00a0Therapie\u00a0GKV\u2010Nettokosten\u00a0 in\u00a0H\u00f6he\u00a0von\u00a0\n566.745,01\u00a0Euro\u00a0aus,\u00a0hiernach\u00a0261.574,62\u00a0Euro\u00a0j\u00e4hrlich,\u00a0woraus\u00a0 sich\u00a0im\u00a0Rahmen\u00a0\neiner\u00a0Zehnjahresperiode\u00a0durchschnittliche\u00a0Kosten\u00a0in\u00a0H\u00f6he\u00a0von\u00a029 2.091,66\u00a0Euro\u00a0\npro\u00a0Jahr\u00a0ergeben.\u00a0Aus\u00a0dem\u00a0zweiten\u00a0Beschluss\u00a0des\u00a0G\u2010BA\u00a0zu\u00a0Nusiner sen\u00a0errechnet\u00a0\nsich\u00a0 eine\u00a0 minimale\u00a0 Pr\u00e4valenz\u00a0 von\u00a0 1,22/100.000\u00a0 sowie\u00a0 eine\u00a0 maxima le\u00a0 von\u00a0\n1,44/100.000.\u00a0Mit\u00a0dem\u00a0 Fair\u00a0Pricing\u00a0Calculator \u00a0ergibt\u00a0sich\u00a0bei\u00a0einer\u00a0Pr\u00e4valenz\u00a0von\u00a0\n1,44/100.000\u00a0 ein\u00a0 fairer\u00a0 Preis\u00a0 f\u00fcr\u00a0 die\u00a0 Therapie\u00a0 mit\u00a0 Nusinersen\u00a0 i n\u00a0 H\u00f6he\u00a0 von\u00a0\n21.876,08\u00a0Euro\u00a0 bzw.\u00a0 von\u00a0 25.020,29\u00a0Euro\u00a0 pro\u00a0 Jahr\u00a0 bei\u00a0 einer\u00a0 Pr\u00e4va lenz\u00a0 von\u00a0\n1,22/100.000.\u00a0Ber\u00fccksichtigt\u00a0man\u00a0die\u00a0Kaufkraft\u00a0in\u00a0Deutschland\u00a0m it\u00a0einem\u00a020\u00a0%\u2010\nigen\u00a0 Aufschlag,\u00a0 so\u00a0 erh\u00f6ht\u00a0 sich\u00a0 der\u00a0 faire\u00a0 Preis\u00a0 auf\u00a0 26.151,30\u00a0Eu ro\u00a0 bzw.\u00a0\n30.024,35\u00a0Euro\u00a0pro\u00a0Jahr,\u00a0d.\u00a0h.\u00a010\u00a0%\u00a0bzw.\u00a012\u00a0%\u00a0der\u00a0derzeitigen\u00a0d urchschnittlichen\u00a0\nJahrestherapiekosten\u00a0(APU),\u00a0die\u00a0in\u00a0Folge\u00a0freier\u00a0Preiswahl\u00a0des\u00a0p U\u00a0definiert\u00a0werden.\u00a0\nIm\u00a0Rahmen\u00a0der\u00a0Erstattungsbetragsverhandlungen\u00a0wurde\u00a0der\u00a0Preis\u00a0d es\u00a0pU\u00a0um\u00a0rund\u00a0\n16\u00a0%\u00a0gesenkt.\u00a0Legt\u00a0man\u00a0Forschungs\u2010\u00a0und\u00a0Entwicklungskosten\u00a0(R&D) \u00a0in\u00a0H\u00f6he\u00a0von\u00a0\n30,5\u00a0 Mio.\u00a0 US\u00a0 Dollar\u00a0 bzw.\u00a0 25.656.124\u00a0Euro\u00a0 (Kurs\u00a0 02.08.2021\u00a0 1\u00a0 US\u00a0 Dollar\u00a0 =\u00a0\n0,84\u00a0Euro)\u00a0zu\u00a0Grunde,\u00a0so\u00a0ergeben\u00a0sich\u00a0mittels\u00a0 AIM\u00a0Fair\u00a0Pricing\u00a0Calculator \u00a0kauf\u2010\nkraftadjustierte\u00a0Jahrestherapiekosten\u00a0von\u00a07.475,24\u00a0Euro\u00a0bzw.\u00a07. 862,45\u00a0Euro,\u00a0d.\u00a0h.\u00a0\nca.\u00a03\u00a0%\u00a0des\u00a0derzeit\u00a0vom\u00a0pU\u00a0beanspruchten\u00a0Preises\u00a0(APU)\u00a0f\u00fcr\u00a0eine \u00a0einj\u00e4hrige\u00a0Thera\u2010\npie.\u00a0\nDieses\u00a0Beispiel\u00a0verdeutlicht\u00a0den\u00a0immensen\u00a0Bedarf\u00a0an\u00a0Transparenz \u00a0im\u00a0Rahmen\u00a0der\u00a0\nMarkteintrittspreise\u00a0neuer\u00a0Arzne imittel\u00a0im\u00a0paneurop\u00e4ischen\u00a0Kont ext.\u00a0\u00a0\n[Parameter:\u00a0ultra\u00a0rare\u00a0disease;\u00a01,22\u00a0bzw.\u00a01,44\u00a0Patienten\u00a0je\u00a0100 .000\u00a0Personen;\u00a05.460\u00a0bzw.\u00a06.444\u00a0\nbehandelte\u00a0Personen\u00a0binnen\u00a010\u00a0Jahren,\u00a0Anteil\u00a050\u00a0%;\u00a0250\u00a0Mio.\u00a0Eur o\u00a0R&D\u2010Kosten;\u00a00\u00a0competitors\u00a0(total\u00a0\nmarket);\u00a0orphan\u00a0chemical\u00a0250\u00a0Euro/\u00a0Monat;\u00a034\u00a0Anwendungen\u00a0in\u00a010\u00a0 Jahren;\u00a020\u00a0%\u00a0der\u00a0R&D\u2010Kosten\u00a0f\u00fcr\u00a0\nSales\u00a0&\u00a0Med\u2010Wiss;\u00a0Basis\u2010Profit\u00a08\u00a0%\u00a0der\u00a0Vollkosten;\u00a0Innovationsb onus\u00a040\u00a0%:\u00a0medicine\u00a0has\u00a0no\u00a0alternati\u2010\nve\u00a0[Markteintritt]:\u00a05\u00a0%\u00a0plus\u00a0life\u2010threatening\u00a0disease:\u00a05\u00a0%\u00a0plus \u00a0major\u00a0impact\u00a0on\u00a0disease:\u00a030\u00a0%] \u00a0\n\u00a0 \u00a0 \n141\u00a0\n\u00a0Tabelle\u00a07.1:\u00a0Nusinersen\u00a0(Spinraza\u00ae)\u00a0im\u00a0AIM\u00a0Fair\u00a0Pricing\u00a0Calcula tor\u00a0\n\u00a0 \u00a0AIM\u00a0Fair\u00a0Pricing\u00a0Calculator\u00a0\nArt\u00a0der\u00a0Krankheit\u00a0 sehr\u00a0selten\u00a0\nPr\u00e4valenz\u00a0 1,44\u00a0pro\u00a0100.000\u00a0\nZielpopulation\u00a0(automat isch)\u00a0 6.444\u00a0pro\u00a010\u00a0Jahre\u00a0\nBehandelte\u00a0Population\u00a0(automatisch)\u00a0 50\u00a0%\u00a0\nGlobale\u00a0R&D\u00a0Kosten\u00a0f \u00fcr\u00a0das\u00a0pU\u00a0 250\u00a0Mio\u00a0.\u20ac\u00a030,5\u00a0Mio.\u00a0US\u00a0$\u00a0=\u00a0\n25.656.124 \u00a0\u20ac\u00a0\nAnzahl\u00a0erwarteter\u00a0Konkurrenten\u00a0(Marktanteil)\u00a0 0\u00a0Konkurrentenr\u00a0(Gesamtmarkt)\u00a0\nZusammenstellung\u00a0des\u00a0Arzneimittels/Produktionskosten\u00a0 Orphan\u00a0Chemikalie\u00a0250\u00a0\u20ac/Monat\u00a0\nDurchschnittliche\u00a0Behandlungsdauer\u00a0[Monate]\u00a0 34\u00a0\nVertrieb\u00a0und\u00a0Med\u2010Wiss\u2010Info\u00a0(automatisch)\u00a0 20\u00a0%\u00a0der\u00a0R&D\u00a0Kosten\u00a0\nBasis\u2010Profit\u00a0 8\u00a0%\u00a0der\u00a0Vollkosten\u00a0\nInnovationslevel\u00a0basierend\u00a0auf\u00a0therapeutischen\u00a0Nutzen\u00a0 40\u00a0%\u00a0\nAIM\u00a0\u2010>\u00a0Bestandteile\u00a0des\u00a0fairen\u00a0Preises\u00a0(pro\u00a0Behandlung,\u00a0pro\u00a0Pat ient)\u00a0\nR&D\u00a0Kosten\u00a0 27.816,57\u00a0\u20ac\u00a0 2.854,66\u00a0\u20ac\u00a0\nProduktionskosten\u00a0 8.500,00\u00a0\u20ac\u00a0 8.500,00\u00a0\u20ac\u00a0\nVerkauf\u00a0und\u00a0mediznische\u00a0Informationen\u00a0 5.563,31\u00a0\u20ac\u00a0 570,93\u00a0\u20ac\u00a0\nBasisprofit\u00a0 3.350,39\u00a0\u20ac\u00a0 954,05\u00a0\u20ac\u00a0\nInnovationsbonus\u00a0 16.751,96\u00a0\u20ac\u00a0 4.770,24\u00a0\u20ac\u00a0\nFaire\u00a0Preiskalkulation\u00a0\u00a0\u00a0\u00a0\u00a0\nFairer\u00a0Preis\u00a0pro\u00a0Behandlung,\u00a0pro\u00a0Patient\u00a0 61.982,23\u00a0\u20ac\u00a0 17.649,88\u00a0\u20ac\u00a0\nFairer\u00a0Preis\u00a0pro\u00a0Behandlungsmon at,\u00a0pro\u00a0Patient\u00a0 1.823,01\u00a0\u20ac\u00a0 519,1 1\u00a0\u20ac\u00a0\nFaire\u00a0Preise\u00a0pro\u00a0Behandlungsjahr\u00a0\u00a0 21.876,08\u00a0\u20ac\u00a0 6.229,37\u00a0\u20ac\u00a0\nFaire\u00a0Jahrestherapiekosten\u00a0a n\u00a0Kaufkraft\u00a0D\u00a0adjustiert\u00a0 26.251,30\u00a0\u20ac\u00a0 7.475,24\u00a0\u20ac\u00a0 \n142\u00a0\n\u00a0Chronische\u00a0Erkrankungen\u00a0\nSacubitril\u2010Valsartan\u00a0(Entresto\u00ae)\u00a0\nDie\u00a0Kombination\u00a0der\u00a0Wirkstoffe\u00a0S acubitril\u00a0und\u00a0des\u00a0bereits\u00a0gener isch\u00a0verf\u00fcgbaren\u00a0\nValsartan\u00a0(Handelsname:\u00a0Entresto\u00ae)\u00a0wurde\u00a0zur\u00a0Therapie\u00a0der\u00a0sympt omatischen,\u00a0\nchronischen\u00a0Herzinsuffizienz\u00a0mit\u00a0 reduzierter\u00a0Ejektionsfraktion\u00a0 zugelassen\u00a0und\u00a0zum\u00a0\nJanuar\u00a02016\u00a0erstmals\u00a0in\u00a0der\u00a0Laue r\u2010Taxe\u00a0gelistet\u00a0(EMA,\u00a02021b).\u00a0D er\u00a0G\u2010BA\u00a0attestierte\u00a0\nim\u00a0Beschluss\u00a0zur\u00a0fr\u00fchen\u00a0Nutzenbewertung\u00a0vom\u00a016.06.2016\u00a0bei\u00a0Pati enten\u00a0ohne\u00a0\nDiabetes\u00a0mellitus\u00a0(ca.\u00a068\u00a0%)\u00a0einen\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0betr\u00e4 chtlichen\u00a0ZN,\u00a0bei\u00a0\nPatienten\u00a0mit\u00a0Diabetes\u00a0mellitus\u00a0(ca.\u00a032\u00a0%)\u00a0jedoch\u00a0nur\u00a0einen\u00a0Anh altspunkt\u00a0f\u00fcr\u00a0einen\u00a0\ngeringen\u00a0ZN.\u00a0Die\u00a0Preise\u00a0des\u00a0Kombinationspr\u00e4parates\u00a0werden\u00a0nach\u00a0 Packungsgr\u00f6\u2010\n\u00dfen\u00a0 (20/56/196\u00a0 St\u00fcck)\u00a0 unabh\u00e4ngig\u00a0 von\u00a0 der\u00a0 jeweiligen\u00a0 Wirkst\u00e4rke\u00a0 (24/26\u00a0mg;\u00a0\n49/51\u00a0mg\u00a0oder\u00a097/103\u00a0mg)\u00a0gestaffelt,\u00a0d.\u00a0h.\u00a0es\u00a0besteht\u00a0hierbei\u00a0s eitens\u00a0des\u00a0pU\u00a0kein\u00a0\noffensichtlicher\u00a0Bezug\u00a0zwischen\u00a0d em\u00a0Preis\u00a0des\u00a0Fertigarzneimitte ls\u00a0und\u00a0den\u00a0Kosten\u00a0\nder\u00a0Wirkstoffmenge\u00a0bzw.\u00a0Wirkst\u00e4rke.\u00a0Der\u00a0G\u2010BA\u00a0gibt\u00a0als\u00a0Jahresthe rapiekosten\u00a0bei\u00a0\nzweimal\u00a0 t\u00e4glich\u00a0 einer\u00a0 Tablette \u00a0 Sacubitril/Valsartan\u00a0 2.431,91\u00a0Eu ro\u00a0 GKV\u2010Netto\u00a0\n(16.06.2016)\u00a0an.\u00a0Durch\u00a0den\u00a0Erstattungsbetrag\u00a0wurden\u00a0die\u00a0Jahrest herapiekosten\u00a0\num\u00a023\u00a0%\u00a0reduziert.\u00a0Legt\u00a0man\u00a0die\u00a0 aktuell\u00a0verf\u00fcgbare\u00a0N3\u2010Packung\u00a0m it\u00a0196\u00a0Tabletten\u00a0\nmit\u00a0einem\u00a0St\u00fcckpreis\u00a0von\u00a02,66\u00a0Euro\u00a0und\u00a0einen\u00a0Verbrauch\u00a0von\u00a0730\u00a0 Tabletten\u00a0pro\u00a0\nJahr\u00a0zu\u00a0Grunde,\u00a0so\u00a0ergeben\u00a0sich\u00a0Jahrestherapiekosten\u00a0in\u00a0H\u00f6he\u00a0vo n\u00a01.945,15\u00a0Euro\u00a0\nGKV\u2010netto\u00a0[Stand:\u00a015.07.2021].\u00a0\nNach\u00a0dem\u00a0AIM\u00a0 Fair\u00a0Pricing\u00a0Calculator \u00a0errechnen\u00a0sich\u00a0Jahrestherapiekosten\u00a0in\u00a0H\u00f6he\u00a0\nvon\u00a0898,74\u00a0Euro\u00a0bis\u00a0917,84\u00a0\u20ac\u00a0unter\u00a0Ber\u00fccksichtigung\u00a0der\u00a0Kaufkra ft\u00a0des\u00a0deutschen\u00a0\nMarktes\u00a0(entsprechend\u00a020\u00a0%\u00a0Aufschlag),\u00a0mithin\u00a056\u00a0bis\u00a057\u00a0%\u00a0der\u00a0d erzeitigen\u00a0Jahres\u2010\ntherapiekosten\u00a0[APU].\u00a0\n[Parameter: \u00a0chronic\u00a0disease;\u00a00,66\u00a0%\u00a0bzw.\u00a01,62\u00a0%\u00a0Anteil\u00a0der\u00a0Patienten\u00a0an\u00a0der \u00a0Bev\u00f6lkerung\u00a0[Daten\u00a0\ndes\u00a0G\u2010BA\u00a0Beschlusses];\u00a0mithin\u00a02.953.500\u00a0bis\u00a07.249.500\u00a0Patienten \u00a0binnen\u00a010\u00a0Jahren;\u00a050\u00a0%\u00a0Behand\u2010\nlungsquote;\u00a0250\u00a0Mio.\u00a0Euro\u00a0R&D\u2010cost;\u00a02\u00a0competitors\u00a0(1/3\u00a0of\u00a0the\u00a0m arket);\u00a0Chemical\u00a0(50\u00a0Euro/month)\u00a0\nproduction\u00a0cost;\u00a0120\u00a0Behandlungsmonate;\u00a0Sales\u00a0&\u00a0Med.\u2010Wiss.\u00a020\u00a0% \u00a0of\u00a0R&D\u00a0cost;\u00a08\u00a0%\u00a0of\u00a0total\u00a0cost\u00a0\nas\u00a0Basis\u00a0Profit;\u00a0Innovations\u2010Bonus\u00a015\u00a0%:\u00a0life\u2010threatening\u00a0disea se\u00a05\u00a0%\u00a0plus\u00a0improvement\u00a0of\u00a0the\u00a0\nquality\u00a0of\u00a0life:\u00a010\u00a0%] .\u00a0\nEmpagliflozin\u00a0(Jardiance\u00ae)\u00a0\nDer\u00a0Hemmstoff\u00a0des\u00a0renalen\u00a0Natrium\u2010Glukose\u2010Kotransporters\u00a02\u00a0( Sodium\u2010glucose\u00a0\ncotransporter\u00a0 2,\u00a0 SGLT\u00a02)\u00a0 Empagliflozin\u00a0 (Handels name:\u00a0 Jardiance\u00ae)\u00a0 erhielt\u00a0 nach \u00a0\nDapagliflozin\u00a0und\u00a0Canagliflozin\u00a0 als\u00a0drittes\u00a0Gliflozin\u00a0am\u00a022.05. 2014\u00a0die\u00a0Zulassung.\u00a0In\u00a0\nder\u00a0EU\u00a0kann\u00a0Empagliflozin\u00a0f\u00fcr\u00a0Er wachsene\u00a0mit\u00a0Typ\u20102\u2010Diabetes\u00a0mel litus\u00a0zur\u00a0Verbes\u2010\nserung\u00a0der\u00a0Blutzuckerkontrolle\u00a0als\u00a0Monotherapie\u00a0verordnet\u00a0werde n,\u00a0sofern\u00a0Di\u00e4t\u00a0\nund\u00a0Sport\u00a0nicht\u00a0ausreichen\u00a0bzw.\u00a0Metformin\u00a0aufgrund\u00a0von\u00a0Kontrain dikationen\u00a0nicht\u00a0 \n143\u00a0\n\u00a0angewendet\u00a0werden\u00a0kann\u00a0sowie\u00a0in\u00a0Kombination\u00a0mit\u00a0 oralen\u00a0Antidiab etika\u00a0und\u00a0\nInsulin.\u00a0Empagliflozin\u00a0wurde\u00a0erstmals\u00a0zum\u00a015.08.2014\u00a0in\u00a0der\u00a0Lau er\u2010Taxe\u00a0gelistet.\u00a0\nIm\u00a0Juli\u00a02021\u00a0wurde\u00a0das\u00a0Anwendungsgebiet\u00a0auf\u00a0die\u00a0Behandlung\u00a0der\u00a0 symptomati\u2010\nschen,\u00a0chronischen\u00a0Herzinsuffizienz\u00a0ausgeweitet.\u00a0\nDer\u00a0G\u2010BA\u00a0konnte\u00a0im\u00a0ersten\u00a0Beschluss\u00a0vom\u00a015.02.2015\u00a0bei\u00a0Empaglif lozin\u00a0basierend\u00a0\nauf\u00a0den\u00a0vom\u00a0pU\u00a0eingereichten\u00a0Dat en\u00a0keinen\u00a0Zusatznutzen\u00a0erkennen .\u00a0In\u00a0einem\u00a0\nzweiten\u00a0 Verfahren\u00a0 basierend\u00a0 auf\u00a0 neuen\u00a0 Studien\u00a0 wurden\u00a0 im\u00a0 Beschlu ss\u00a0 vom\u00a0\n01.09.2016\u00a0f\u00fcnf\u00a0Subgruppen\u00a0unterschieden.\u00a0In\u00a0Monotherapie\u00a0sowie \u00a0in\u00a0Kombinati\u2010\nonstherapie\u00a0bei\u00a0Patienten\u00a0ohne\u00a0bzw.\u00a0mit\u00a0manifester\u00a0kardiovaskul \u00e4rer\u00a0Erkrankung\u00a0\ngilt\u00a0ein\u00a0Zusatznutzen\u00a0als\u00a0nicht\u00a0belegt\u00a0(Subgruppe\u00a0a),\u00a0entsprech end\u00a015,2\u00a0%\u00a0der\u00a0\nPatienten.\u00a0In\u00a0Kombination\u00a0mit\u00a0Metformin\u00a0konnte\u00a0der\u00a0G\u2010BA\u00a0bei\u00a0Pat ienten\u00a0ohne\u00a0\nkardiovaskul\u00e4re\u00a0Erkrankung\u00a0einen\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0geringe n\u00a0ZN\u00a0attestieren,\u00a0\nmit\u00a0kardiovaskul\u00e4rer\u00a0Erkrankung\u00a0stellte\u00a0der\u00a0G\u2010BA\u00a0einen\u00a0Anhaltsp unkt\u00a0f\u00fcr\u00a0einen\u00a0\nbetr\u00e4chtlichen\u00a0ZN\u00a0fest.\u00a0In\u00a0einer\u00a0Zweifachkombination\u00a0mit\u00a0weiter en\u00a0Antidiabetika\u00a0\nau\u00dfer\u00a0Metformin\u00a0und\u00a0Insulin\u00a0konnte\u00a0bei\u00a0Patienten\u00a0ohne\u00a0kardiovas kul\u00e4re\u00a0Erkran\u2010\nkung\u00a0kein\u00a0ZN\u00a0belegt\u00a0werden,\u00a0mit\u00a0 kardiovaskul\u00e4rer\u00a0Erkrankung\u00a0hin gegen\u00a0ergab\u00a0sich\u00a0\nein\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0betr\u00e4chtlichen\u00a0ZN.\u00a0Im\u00a0Rahmen\u00a0einer\u00a0D reifachkombina\u2010\ntion\u00a0konnte\u00a0bei\u00a0Patienten\u00a0ohne\u00a0manifeste\u00a0kardiovaskul\u00e4re\u00a0Erkran kung\u00a0kein\u00a0ZN\u00a0\nbelegt\u00a0werden,\u00a0mit\u00a0kardiovaskul\u00e4rer\u00a0Erkrankung\u00a0ergab\u00a0sich\u00a0wiede r\u00a0ein\u00a0Anhalts\u2010\npunkt\u00a0f\u00fcr\u00a0einen\u00a0betr\u00e4chtlichen\u00a0ZN. \u00a0F\u00fcr\u00a0die\u00a0Kombination\u00a0mit\u00a0Insu lin\u00a0ergibt\u00a0sich\u00a0das\u00a0\ngleiche\u00a0Ergebnis,\u00a0d.\u00a0h.\u00a0ohne\u00a0kardi ovaskul\u00e4re\u00a0Erkrankung\u00a0kein\u00a0Be leg\u00a0f\u00fcr\u00a0einen\u00a0ZN,\u00a0\nmit\u00a0hingegen\u00a0ein\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0betr\u00e4chtlichen\u00a0ZN\u00a0(G\u2010BA ,\u00a02016).\u00a0\nDas\u00a0Beispiel\u00a0Empagliflozin\u00a0zeigt \u00a0eindr\u00fccklich,\u00a0dass\u00a0die\u00a0Preisbi ldung\u00a0basierend\u00a0auf\u00a0\ndem\u00a0Nutzen\u00a0f\u00fcr\u00a0Patienten\u00a0in\u00a0Subgruppen\u00a0spezifisch\u00a0erfolgen\u00a0soll te,\u00a0um\u00a0einen\u00a0fai\u2010\nren\u00a0Preis\u00a0erzielen\u00a0zu\u00a0k\u00f6nnen.\u00a0Die\u00a0beiden\u00a0Wirkst\u00e4rken\u00a010\u00a0mg\u00a0und\u00a0 25\u00a0mg\u00a0weisen\u00a0je\u00a0\nPackungsgr\u00f6\u00dfe\u00a0(30\u00a0bzw.\u00a0100\u00a0St\u00fcck)\u00a0den\u00a0gleichen\u00a0Preis\u00a0auf,\u00a0d.\u00a0h. \u00a0vom\u00a0pU\u00a0erfolgt\u00a0\neine\u00a0Preisbildung\u00a0ohne\u00a0\u00f6ffentlich\u00a0 nachvollziehbaren\u00a0Zusammenhan g\u00a0zu\u00a0den\u00a0tat\u2010\ns\u00e4chlichen\u00a0Wirkstoffmengen\u00a0bzw.\u00a0\u2013 kosten.\u00a0Gem\u00e4\u00df\u00a0Lauer\u2010Taxe\u00a0sind\u00a0 die\u00a0Tabletten\u00a0\nmit\u00a025\u00a0mg\u00a0nicht\u00a0dosisgleich\u00a0teilbar,\u00a0sodass\u00a0eine\u00a0theoretisch\u00a0sp arsame\u00a0\u00e4rztliche\u00a0\nVerordnung\u00a0mit\u00a0Dosierungsvorgabe\u00a0 des\u00a0Halbierens\u00a0der\u00a0Tabletten\u00a0s eitens\u00a0des\u00a0pU\u00a0\nausgeschlossen\u00a0wird.\u00a0Geht\u00a0man\u00a0von\u00a0Kosten\u00a0in\u00a0H\u00f6he\u00a0von\u00a01,81\u00a0Euro\u00a0 je\u00a0Tablette\u00a0GKV\u2010\nNetto\u00a0aus,\u00a0ergeben\u00a0sich\u00a0f\u00fcr\u00a0Empagliflozin\u00a0bei\u00a0einem\u00a0Verbrauch\u00a0v on\u00a0365\u00a0Tabletten\u00a0\nJahrestherapiekosten\u00a0in\u00a0H\u00f6he\u00a0von\u00a0659,15\u00a0Euro\u00a0[Lauer\u2010Taxe:\u00a015.07 .2021].\u00a0Durch\u00a0\nden\u00a0Erstattungsbetrag\u00a0sank\u00a0der\u00a0urspr\u00fcnglich\u00a0vom\u00a0pU\u00a0geforderte\u00a0P reis\u00a0bereits\u00a0um\u00a0\n14\u00a0%.\u00a0Mittels\u00a0AIM\u00a0 Fair\u00a0Pricing\u00a0Calculator \u00a0ergibt\u00a0sich\u00a0adjustiert\u00a0an\u00a0die\u00a0Kaufkraft\u00a0in\u00a0\nDeutschland\u00a0 ein\u00a0 fairer\u00a0 Preis\u00a0 f\u00fcr\u00a0 eine\u00a0 zw\u00f6lfmonatige\u00a0 Therapie\u00a0 in \u00a0H \u00f6 h e \u00a0v o n \u00a0\n861,26\u00a0Euro\u00a0bis\u00a0863,12\u00a0Euro\u00a0unter\u00a0Ber\u00fccksichtigung\u00a0entsprechend er\u00a0Parameter.\u00a0Es\u00a0\nerstaunt,\u00a0dass\u00a0der\u00a0faire\u00a0Preis\u00a0rund\u00a065\u00a0%\u00a0\u00fcber\u00a0dem\u00a0aktuellen\u00a0Mar ktpreis\u00a0(APU)\u00a0liegt.\u00a0\nZu\u00a0beachten\u00a0ist,\u00a0dass\u00a0Empagliflo zin\u00a0als\u00a0dritter\u00a0SGLT2\u2010Hemmer\u00a0au f\u00a0den\u00a0Markt\u00a0kam\u00a0 \n144\u00a0\n\u00a0und\u00a0man\u00a0an\u00a0den\u00a0Innovationsgrad\u00a0andere\u00a0Ma\u00dfst\u00e4be\u00a0anlegen\u00a0sollte\u00a0( siehe\u00a0auch\u00a0\nsogenannte\u00a0\u201eMe\u2010Too\u2010Pr\u00e4p arate\u201c).\u00a0Zudem\u00a0gab\u00a0es\u00a0neue\u00a0Signale\u00a0zum\u00a0N utzen\u2010Risiko\u2010\nVerh\u00e4ltnis\u00a0 in\u00a0 Form\u00a0 von\u00a0 Warnhinweisen\u00a0 (\u201eRote\u2010Hand\u2010Briefe\u201c\u00a0 und\u00a0 In formations\u2010\nschreiben)\u00a0zum\u00a0Risiko\u00a0des\u00a0Auftretens\u00a0von\u00a0atypischen\u00a0diabetische n\u00a0Ketoazidosen\u00a0\noder\u00a0Fourniergangr\u00e4n\u00a0(AKdAE,\u00a02016;\u00a0AKdAE,\u00a02019).\u00a0Somit\u00a0stellt\u00a0s ich\u00a0die\u00a0Frage,\u00a0\ninwiefern\u00a0 der\u00a0 F a i r \u00a0P r i c i n g \u00a0C a l c u l a t o r \u00a0 von\u00a0 AIM\u00a0 Me\u2010too\u2010Pr\u00e4parate\u00a0 und\u00a0 negative\u00a0\nEffekte\u00a0von\u00a0neuen\u00a0Arzneimitteln\u00a0(Rote\u2010Hand\u2010Briefe)\u00a0mit\u00a0noch\u00a0l\u00fcc kenhafter\u00a0Daten\u2010\nlage\u00a0zuk\u00fcnftig\u00a0ber\u00fccksichtigen\u00a0k\u00f6nnte.\u00a0\n[Parameter:\u00a0chronic\u00a0disease;\u00a01,51\u00a0%\u00a0bzw.\u00a01,75\u00a0%\u00a0Anteil\u00a0Erkrankt er\u00a0an\u00a0der\u00a0Bev\u00f6lkerung;\u00a0d.\u00a0h.\u00a0Target\u00a0\npopulation\u00a06.757.250\u00a0bzw.\u00a07.831.250\u00a0Personen;\u00a050\u00a0%\u00a0treated\u00a0Popu lation;\u00a0250\u00a0Mio.\u00a0Euro\u00a0global\u00a0\nR&D\u00a0cost;\u00a02\u00a0competitors\u00a0(1/3\u00a0of\u00a0the\u00a0market);\u00a0Production\u00a0cost\u00a050 \u00a0Euro/\u00a0month\u00a0chemical;\u00a0120\u00a0\nMonate\u00a0Behandlungsdauer;\u00a0Sales\u00a0&\u00a0Med\u2010Wiss.\u00a020\u00a0%\u00a0der\u00a0R&D\u2010Kosten; \u00a0Basis\u2010Profit\u00a08\u00a0%\u00a0der\u00a0Ge\u2010\nsamtkosten;\u00a0 10\u00a0%\u00a0 Innovationsbonus:\u00a0 nur\u00a0 bei\u00a0 Subgruppen\u00a0 entsprech ende\u00a0 Effekte,\u00a0 daher\u00a0 life\u2010\nthreatening\u00a0disease\u00a05\u00a0%\u00a0plus\u00a0minor\u00a0impact\u00a0on\u00a0disease\u00a05\u00a0%] .\u00a0\nSecukinumab\u00a0(Cosentyx\u00ae)\u00a0\nDer\u00a0 vollst\u00e4ndig\u00a0 humane\u00a0 monoklonal e\u00a0 Antik\u00f6rper\u00a0 Secukinumab\u00a0 (Hand elsname:\u00a0\nCosentyx\u00ae)\u00a0bindet\u00a0selektiv\u00a0an\u00a0Interleukin\u00a017A,\u00a0ein\u00a0Entz\u00fcndungen \u00a0f\u00f6rderndes\u00a0Zyto\u2010\nkin,\u00a0und\u00a0neutralisiert\u00a0dies.\u00a0Secukinumab\u00a0erhielt\u00a0am\u00a014.01.2015\u00a0 die\u00a0Zulassung\u00a0f\u00fcr\u00a0\ndas\u00a0erste\u00a0Anwendungsgebiet\u00a0Plaque\u2010Psoriasis\u00a0in\u00a0der\u00a0EU,\u00a0Erweiter ungen\u00a0der\u00a0An\u2010\nwendungsgebiete\u00a0auf\u00a0Psoriasis\u2010Arthritis,\u00a0Morbus\u00a0Bechterew\u00a0sowie \u00a0axiale\u00a0Spondy\u2010\nloarthritis\u00a0folgten\u00a0(EMA,\u00a02021a) .\u00a0Erstmals\u00a0wurde\u00a0das\u00a0biotechnol ogisch\u00a0hergestellte\u00a0\nSecukinumab\u00a0am\u00a001.06.2015\u00a0in\u00a0der\u00a0Lauer\u2010Taxe\u00a0gelistet.\u00a0Der\u00a0G\u2010BA\u00a0 attestierte\u00a0Secu\u2010\nkinumab\u00a0 in\u00a0 mehreren\u00a0 Bewertungsverfahren\u00a0 zur\u00a0 Indikation\u00a0 Plaque\u2010P soriasis\u00a0 bei\u00a0\nrund\u00a0zwei\u00a0Dritteln\u00a0der\u00a0Patienten\u00a0einen\u00a0Hinweis\u00a0auf\u00a0einen\u00a0betr\u00e4c htlichen\u00a0Zusatz\u2010\nnutzen,\u00a0auch\u00a0im\u00a0Innovationsreport\u00a02018\u00a0erhielt\u00a0Secukinumab\u00a0folg lich\u00a0eine\u00a0gr\u00fcne\u00a0\nAmpel\u00a0f\u00fcr\u00a0den\u00a0(Zusatz\u2010)\u00a0Nutzen\u00a0(G\u2010BA,\u00a02017c;\u00a0Glaeske\u00a0et\u00a0al.,\u00a020 18).\u00a0Andererseits\u00a0\nwarnte\u00a0die\u00a0Arzneimittelkommission\u00a0der\u00a0deutschen\u00a0\u00c4rzteschaft\u00a0vor \u00a0einem\u00a0Grup\u2010\npeneffekt\u00a0 bei\u00a0 der\u00a0 Anwendung\u00a0 von\u00a0 Anti\u2010IL\u201017A\u2010Therapeutika\u00a0 im\u00a0 Kon text\u00a0 einer\u00a0\nm\u00f6glichen\u00a0Induktion\u00a0und/oder\u00a0Demaskierung\u00a0von\u00a0chronisch\u00a0entz\u00fcnd lichen\u00a0Dar\u2010\nmerkrankungen\u00a0(AKdAE,\u00a02018).\u00a0Secukinumab\u00a0wird\u00a0subkutan\u00a0angewend et,\u00a0im\u00a0ers\u2010\nten\u00a0Monat\u00a0w\u00f6chentlich\u00a0(vier\u00a0Gaben),\u00a0sodann\u00a0reicht\u00a0eine\u00a0Erhaltun gsdosis\u00a0einmal\u00a0im\u00a0\nMonat\u00a0aus,\u00a0was\u00a0zum\u00a0Verbrauch\u00a0von\u00a015\u00a0Dosen\u00a0im\u00a0ersten\u00a0Jahr\u00a0und\u00a0fo rtfolgend\u00a012\u00a0\nDosen\u00a0p.\u00a0a.\u00a0f\u00fchrt,\u00a0mithin\u00a0123\u00a0An wendungen\u00a0binnen\u00a0zehn\u00a0Jahren\u00a0bz w.\u00a0durchschnitt\u2010\nlich\u00a012,3\u00a0pro\u00a0Jahr.\u00a0Secukinumab\u00a0wird\u00a0in\u00a0Fertigspritzen\u00a0bzw.\u00a0Fer tigpens\u00a0mit\u00a0150\u00a0mg\u00a0\nbzw.\u00a0300\u00a0mg\u00a0Wirkstoff\u00a0angeboten.\u00a0In\u00a0Folge\u00a0des\u00a0von\u00a0pU\u00a0und\u00a0GKV\u2010SV \u00a0verhandelten\u00a0\nErstattungsbetrages\u00a0sank\u00a0der\u00a0Preis\u00a0um\u00a013\u00a0%.\u00a0Aktuell\u00a0belaufen\u00a0si ch\u00a0die\u00a0Kosten\u00a0einer\u00a0\nTherapie\u00a0mit\u00a0Secukinumab\u00a0auf\u00a023.259,95\u00a0Euro\u00a0im\u00a0ersten\u00a0Jahr\u00a0(15\u00a0 Anwendungen),\u00a0\nfortan\u00a018.607,96\u00a0Euro\u00a0j\u00e4hrlich,\u00a0d.\u00a0h.\u00a0im\u00a0Durchschnitt\u00a0liegen\u00a0di e\u00a0Jahrestherapiekos\u2010\nten\u00a0bei\u00a019.073,16\u00a0Euro\u00a0[Stand:\u00a0Lauer\u2010Taxe:\u00a015.07.2021].\u00a0Der\u00a0Ant eil\u00a0der\u00a0therapier\u2010\nten\u00a0Bev\u00f6lkerung\u00a0liegt\u00a0bei\u00a00,07\u00a0%\u00a0bis\u00a00,33\u00a0%\u00a0bzw.\u00a0einer\u00a0Pr\u00e4valen z\u00a0von\u00a0je\u00a072,6\u00a0bis\u00a0 \n145\u00a0\n\u00a0326,0/\u00a0100.000\u00a0in\u00a0der\u00a0erstzugelassenen\u00a0Indikation.\u00a0Bezieht\u00a0man\u00a0 alle\u00a0bis\u00a0heute\u00a0\nzugelassenen\u00a0Patientengruppen\u00a0mit\u00a0ein,\u00a0ergeben\u00a0sich\u00a0Werte\u00a0von\u00a00 ,13\u00a0%\u00a0bis\u00a00,48\u00a0%\u00a0\nbzw.\u00a0eine\u00a0Pr\u00e4valenz\u00a0von\u00a0155,9\u00a0bis\u00a0550,1/\u00a0100.000.\u00a0Dieser\u00a0Unters chied\u00a0gewinnt\u00a0an\u00a0\nBedeutung,\u00a0da\u00a0die\u00a0Anzahl\u00a0der\u00a0pote nziell\u00a0therapierten\u00a0Patienten\u00a0 f\u00fcr\u00a0die\u00a0Berechnung\u00a0\neines\u00a0fairen\u00a0Preises\u00a0im\u00a0 Fair\u00a0Pricing\u00a0Calculator \u00a0von\u00a0AIM\u00a0ber\u00fccksichtigt\u00a0werden.\u00a0Je\u00a0\ngr\u00f6\u00dfer\u00a0das\u00a0m\u00f6gliche\u00a0Patientenkollektiv\u00a0ist,\u00a0desto\u00a0geringer\u00a0f\u00e4ll t\u00a0der\u00a0faire\u00a0Preis\u00a0aus.\u00a0\nZu\u00a0Markteintritt\u00a0ohne\u00a0weitere\u00a0Ant i\u2010IL17A\u2010Therapeutika,\u00a0wie\u00a0die\u00a0 zwischenzeitlich\u00a0\nverf\u00fcgbaren\u00a0Ixekizumab\u00a0oder\u00a0Brodalumab,\u00a0ergeben\u00a0sich\u00a0j\u00e4hrliche\u00a0 Therapiekosten\u00a0\nvon\u00a03.113,80\u00a0Euro\u00a0bis\u00a0 3.206,63\u00a0Euro\u00a0pro\u00a0 Jahr\u00a0bzw.\u00a0unter\u00a0 Ber\u00fccks ichtigung\u00a0der\u00a0\nMitbewerber\u00a0und\u00a0gr\u00f6\u00dferer\u00a0Patientenkollektive\u00a03.140,35\u00a0Euro\u00a0bis\u00a0 3.279,14\u00a0Euro\u00a0pa.\u00a0\nIm\u00a0Ergebnis\u00a0liegt\u00a0der\u00a0faire\u00a0Preis\u00a0einer\u00a0Therapie\u00a0mit\u00a0Secukinuma b\u00a0bei\u00a021\u00a0%\u00a0bis\u00a022\u00a0%\u00a0\ndes\u00a0aktuell\u00a0vom\u00a0pU\u00a0geforderten\u00a0Preises\u00a0(APU)\u00a0pro\u00a0Jahr.\u00a0\nDas\u00a0Beispiel\u00a0Secukinumab\u00a0verdeutlicht,\u00a0dass\u00a0im\u00a0Rahmen\u00a0der\u00a0Berec hnung\u00a0eines\u00a0\nfairen\u00a0Arzneimittelpreises\u00a0auch\u00a0die\u00a0stufenweise\u00a0Erweiterung\u00a0der \u00a0Anwendungsge\u2010\nbiete\u00a0mit\u00a0ber\u00fccksichtigt\u00a0werden\u00a0muss,\u00a0bestenfalls\u00a0anhand\u00a0einer\u00a0 kontinuierlichen\u00a0\nPr\u00fcfung\u00a0 von\u00a0 vorliegender\u00a0 Evidenz,\u00a0 neuen\u00a0 Therapieoptionen\u00a0 und\u00a0 ne uen\u00a0 uner\u2010\nw\u00fcnschten\u00a0Effekten.\u00a0\n[Parameter:\u00a0chronic\u00a0disease;\u00a00,13\u00a0%\u00a0bzw.\u00a00,48\u00a0%\u00a0Anteil\u00a0Erkrankt er\u00a0an\u00a0der\u00a0Bev\u00f6lkerung;\u00a0d.\u00a0h.\u00a0Target\u00a0\npopulation\u00a0581.750\u00a0bzw.\u00a02.148.000\u00a0Personen;\u00a050\u00a0%\u00a0treated\u00a0Popula tion;\u00a0250\u00a0Mio.\u00a0Euro\u00a0global\u00a0R&D\u00a0\ncost;\u00a02\u00a0competitors\u00a0(1/3\u00a0of\u00a0the\u00a0market);\u00a0Production\u00a0cost\u00a0150\u00a0Eu ro/\u00a0month\u00a0biological;\u00a0120\u00a0Monate\u00a0\nBehandlungsdauer;\u00a0Sales\u00a0&\u00a0Med\u2010Wiss.\u00a020\u00a0%\u00a0der\u00a0R&D\u2010Kosten;\u00a0Basis\u2010 Profit\u00a08\u00a0%\u00a0der\u00a0Gesamtkosten;\u00a0\n35\u00a0%\u00a0Innovationsbonus:\u00a0life\u2010threatening\u2010disease:\u00a05\u00a0%\u00a0plus\u00a0medic ine\u00a0is\u00a0curative:\u00a030\u00a0%)] .\u00a0\nOnkologie\u00a0\nPeter\u00a0Bach\u00a0vom\u00a0 Memorial\u00a0Sloan\u00a0Kettering\u00a0Cancer\u00a0Center \u00a0hat\u00a0die\u00a0Entwicklung\u00a0der\u00a0\nmonatlichen\u00a0Therapiekosten\u00a0von\u00a0neuen\u00a0Arzneimitteln\u00a0in\u00a0der\u00a0Onkol ogie\u00a0zum\u00a0Zeit\u2010\npunkt\u00a0der\u00a0FDA\u2010Zulassung,\u00a0d.\u00a0h.\u00a0zu meist\u00a0weltweit\u00a0erstem\u00a0Marktzug ang,\u00a0von\u00a01965\u00a0\nbis\u00a02019\u00a0analysiert.\u00a0Nachfolgende\u00a0Darstellung\u00a0verdeutlicht\u00a0den\u00a0 Trend\u00a0zu\u00a0stark\u00a0\nwachsenden\u00a0Preisen.\u00a0Lagen\u00a0die\u00a0monatlichen\u00a0Therapiekosten\u00a0bzw.\u00a0m edianen\u00a0mo\u2010\nnatlichen\u00a0Kosten\u00a0im\u00a0Jahr\u00a01965\u00a0noch\u00a0bei\u00a0100\u00a0bis\u00a01.000\u00a0US\u00a0Dollar, \u00a0so\u00a0sind\u00a0im\u00a0Jahr\u00a0\n2019\u00a0Kosten\u00a0von\u00a0rund\u00a010.000\u00a0bis\u00a0\u00fcber\u00a0100.000\u00a0US\u00a0Dollar\u00a0monatlic h\u00a0f\u00fcr\u00a0eine\u00a0Krebs\u2010\ntherapie\u00a0zu\u00a0verzeichnen,\u00a0die\u00a0logarithmische\u00a0Skala\u00a0ist\u00a0hierbei\u00a0z u\u00a0beachten\u00a0(Bach,\u00a0\n2021).\u00a0\n\u00a0\u00a0 \n146\u00a0\n\u00a0\nAbb.\u00a07.4:\u00a0\u201eMonatliche\u00a0und\u00a0mediane\u00a0Kosten\u00a0von\u00a0Arzneimitteln\u00a0in\u00a0d er\u00a0Onkolo\u2010\ngie\u00a0zum\u00a0Zeitpunkt\u00a0der\u00a0FDA\u2010Zulassung\u00a01965\u00a0bis\u00a02019\u201c\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\nmodifiziert\u00a0nach\u00a0Peter\u00a0Bach\u00a0MSKCC\u00a0\nIm\u00a0Folgenden\u00a0werden\u00a0exemplarisch \u00a0die\u00a0Arzneimittelpreise\u00a0eines\u00a0b iotechnologisch\u00a0\nhergestellten\u00a0Antik\u00f6rpers\u00a0und\u00a0einer\u00a0klassischen,\u00a0chemisch\u00a0synth etisch\u00a0produzier\u2010\nten\u00a0Wirkstoffkombination\u00a0dargestellt.\u00a0\nNivolumab\u00a0(Handelsname:\u00a0Opdivo\u00ae)\u00a0\nIn\u00a0der\u00a0Gruppe\u00a0der\u00a0sogenannten\u00a0Im mun\u2010Checkpoint\u2010Inhibitoren\u00a0(ICI )\u00a0stehen\u00a0derzeit\u00a0\ndie\u00a0Wirkstoffe\u00a0Ipilimumab\u00a0(Markteintritt:\u00a001.08.2011),\u00a0Nivoluma b\u00a0(15.07.2015),\u00a0\nPembrolizumab\u00a0 (15.08.2015),\u00a0 Atezolizumab\u00a0 (15.10.2017),\u00a0 Durvalum ab\u00a0\n(15.10.2018)\u00a0sowie\u00a0Cemiplimab\u00a0(01.08.2019)\u00a0in\u00a0diversen,\u00a0stetig\u00a0 wachsenden\u00a0An\u2010\nwendungsgebieten\u00a0 zur\u00a0 Verf\u00fcgung.\u00a0 IC I\u00a0 aktivieren\u00a0 indirekt\u00a0 die\u00a0 k\u00f6r pereigene\u00a0 T\u2010\nzellul\u00e4re\u00a0 Abwehr,\u00a0 indem\u00a0 physiologische\u00a0 Mechanismen\u00a0 zum\u00a0 Schutz\u00a0 e iner\u00a0 \u00fcber\u2010 \n147\u00a0\n\u00a0schie\u00dfenden\u00a0 Autoimmunantwort\u00a0 aus gehebelt\u00a0 werden.\u00a0 Nivolumab\u00a0 bloc kiert\u00a0 als\u00a0\nhumaner,\u00a0 monoklonaler\u00a0 Antik\u00f6rper\u00a0 den\u00a0 auf\u00a0 T\u2010Lymphozyten\u00a0 gebildet en\u00a0Pro\u2010\ngrammed\u00a0(cell)\u00a0death \u20101\u2010\u00a0Rezeptor,\u00a0PD\u20101\u2010Rezeptor,\u00a0wodurch\u00a0eine\u00a0Schw\u00e4chung\u00a0der\u00a0\nAbwehr\u00a0durch\u00a0PD\u2010L1\u00a0bzw.\u00a0PD\u2010L2\u00a0auf\u00a0Tumorzellen\u00a0unterbleibt\u00a0(at,\u00a0 2021).\u00a0\nDer\u00a0G\u2010BA\u00a0f\u00fchrt\u00a0in\u00a0den\u00a0Tragenden\u00a0Gr\u00fcnden\u00a0zu\u00a0den\u00a0Beschl\u00fcssen\u00a0zum\u00a0 Wirkstoff\u00a0Nivo\u2010\nlumab\u00a0aus,\u00a0dass\u00a0die\u00a0Berechnung\u00a0der\u00a0Jahrestherapiekosten\u00a0basiere nd\u00a0auf\u00a0der\u00a0Arz\u2010\nneimittelpreisverordnung\u00a0und\u00a0der\u00a0Anlage\u00a03\u00a0der\u00a0zwischen\u00a0Deutsche m\u00a0Apotheker\u2010\nverband\u00a0(DAV)\u00a0und\u00a0GKV\u2010Spitzenverband\u00a0(GKV\u2010SV)\u00a0verhandelten\u00a0Prei se\u00a0der\u00a0Hilfsta\u2010\nxe\u00a0n\u00e4herungsweise\u00a0basierend\u00a0auf\u00a0den\u00a0Preisen\u00a0der\u00a0ben\u00f6tigten\u00a0Fert igarzneimittel\u2010\npackungen\u00a0plus\u00a0Arbeitspreis\u00a0(71\u00a0Euro\u00a0je\u00a0applikationsfertiger\u00a0L\u00f6 sung\u00a0monoklonaler\u00a0\nAntik\u00f6rper)\u00a0erfolgt.\u00a0Zu\u00a0beachten \u00a0sei\u00a0laut\u00a0G\u2010BA\u00a0hierbei\u00a0wiederum ,\u00a0dass\u00a0die\u00a0Hilfstaxe\u00a0\nstetig,\u00a0dynamisch\u00a0verhandelt\u00a0wer de\u00a0und\u00a0sich\u00a0zudem\u00a0eine\u00a0Intransp arenz\u00a0dadurch\u00a0\nergebe,\u00a0 dass\u00a0 gesetzliche\u00a0 Kranken versicherungen\u00a0 mit\u00a0 herstellende n\u00a0 Apotheken\u00a0\nauch\u00a0vertrauliche\u00a0Preise\u00a0unterha lb\u00a0der\u00a0Hilfstaxenpreise\u00a0verhand eln\u00a0k\u00f6nnten,\u00a0die\u00a0\ndem\u00a0G\u2010BA\u00a0nicht\u00a0vorli egen\u00a0(G\u2010BA,\u00a02017b).\u00a0\u00a0\nDer\u00a0G\u2010BA\u00a0hat\u00a0bisher\u00a017\u00a0Bewertungsv erfahren\u00a0zum\u00a0Wirkstoff\u00a0Nivolu mab\u00a0durchge\u2010\nf\u00fchrt\u00a0(G\u2010BA,\u00a02021e).\u00a0Im\u00a0Zuge\u00a0ans chlie\u00dfender\u00a0Verhandlungen\u00a0von\u00a0p U\u00a0und\u00a0GKV\u2010SV\u00a0\nergaben\u00a0die\u00a0Erstattungsbetr\u00e4ge\u00a0einen\u00a0um\u00a026\u00a0%\u00a0gegen\u00fcber\u00a0dem\u00a0Mark teintrittspreis\u00a0\ngesenkten\u00a0Preis.\u00a0\nVereinfachend\u00a0werden\u00a0die\u00a0Jahrest herapiekosten\u00a0f\u00fcr\u00a0eine\u00a0Monother apie\u00a0mit\u00a0Nivo\u2010\nlumab\u00a0in\u00a0der\u00a0Dosierung\u00a0von\u00a0240\u00a0mg\u00a0fix\u00a0alle\u00a0zwei\u00a0Wochen,\u00a0d.\u00a0h.\u00a02 6\u00a0Zyklen\u00a0pro\u00a0Jahr\u00a0\nberechnet.\u00a0Diese\u00a0belaufen\u00a0sich\u00a0auf\u00a079.308,84\u00a0Euro\u00a0GKV\u2010netto\u00a0bzw .\u00a065.799,50\u00a0Euro\u00a0\nauf\u00a0Basis\u00a0des\u00a0APU\u00a0pa.\u00a0F\u00fcr\u00a0die\u00a0Preisanalysen\u00a0fallen\u00a0die\u00a0Kosten\u00a0d er\u00a0Herstellung\u00a0der\u00a0\nInfusionsl\u00f6sung\u00a0unter\u00a0aseptischen\u00a0Bedingungen\u00a0in\u00a0Apotheken\u00a0nich t\u00a0ins\u00a0Gewicht,\u00a0\nsie\u00a0belaufen\u00a0sich\u00a0aber\u00a0auf\u00a01.846\u00a0Euro\u00a0(26\u00a0x\u00a071\u00a0Euro)\u00a0[Lauer\u2010Tax e\u00a0Stand:\u00a015.\u00a0Juli\u00a0\n2021]\u00a0(G\u2010BA,\u00a02021b;\u00a0G\u2010BA,\u00a02021a).\u00a0\nMittels\u00a0AIM\u00a0 Fair\u00a0Pricing\u00a0Calculator \u00a0ergibt\u00a0sich\u00a0f\u00fcr\u00a0die\u00a0erstzugelassene\u00a0Indikation\u00a0\nMelanom\u00a0(ICD\u201010\u00a0C43;\u00a0Inzidenz\u00a0na ch\u00a0GEKID\u00a0(GEKID\u2010Atlas,\u00a02021):\u00a03 9,3/100.000)\u00a0\nunter\u00a0 Ber\u00fccksichtigung\u00a0 entspreche nder\u00a0 Parameter\u00a0 ein\u00a0 fairer\u00a0 Prei s\u00a0 von\u00a0\n13.825,58\u00a0Euro\u00a0 pro\u00a0 Jahr.\u00a0 Im\u00a0 Anwendungsgebiet\u00a0 malignes\u00a0 Pleurames otheliom\u00a0\n(ICD10:\u00a0C45.0)\u00a0mit\u00a0der\u00a0niedrigsten\u00a0Inzidenz\u00a0aller\u00a0zugelassenen\u00a0 Indikationen\u00a0von\u00a0\n2,2/100.000\u00a0ermittelt\u00a0AIM\u00a0faire\u00a0Jahrestherapiekosten\u00a0in\u00a0H\u00f6he\u00a0vo n\u00a022.958,58\u00a0Euro.\u00a0\nSetzt\u00a0man\u00a0bei\u00a0ansonsten\u00a0gleichen \u00a0Parametern\u00a0eine\u00a0kumulative\u00a0Inz idenz\u00a0\u00fcber\u00a0alle\u00a0\nAnwendungsgebiete\u00a0von\u00a0254,9/100.000\u00a0in\u00a0den\u00a0 Fair\u00a0Pricing\u00a0Calculator \u00a0ein,\u00a0so\u00a0erge\u2010\nben\u00a0sich\u00a0faire\u00a0Kosten\u00a0in\u00a0H\u00f6he\u00a0 von\u00a013.367,50\u00a0Euro\u00a0pro\u00a0Jahr.\u00a0 \n148\u00a0\n\u00a0Im\u00a0Ergebnis\u00a0liegen\u00a0die\u00a0mittels\u00a0AIM\u00a0 Fair\u00a0Pricing\u00a0Calculator \u00a0berechneten\u00a0Jahresthe\u2010\nrapiekosten\u00a0f\u00fcr\u00a0Nivolumab\u00a0um\u00a0den\u00a0Faktor\u00a03\u00a0bis\u00a05\u00a0unterhalb\u00a0den\u00a0v om\u00a0pU\u00a0derzeit\u00a0\nam\u00a0Markt\u00a0realisierten\u00a0Preisen\u00a0[APU].\u00a0\nTabelle\u00a07.2:\u00a0G\u2010BA\u00a0Bewertungsverfah renen\u00a0zu\u00a0Nivolumab\u00a0(n=17)\u00a0(G\u2010 BA,\u00a02021e).\u00a0\nG\u2010BA\u2010Verfahren\u00a0 Beginn\u00a0\nHodgkin\u2010Lymphom\u00a0 01.01.2017\u00a0\nMalignes\u00a0Pleuramesotheliom;\u00a0Erstlinie\u00a0+\u00a0Ipilimumab\u00a0 01.07.2021\u00a0\nMelanom\u00a0 15.07.2015\u00a0\nMelanom,\u00a0adjuvante\u00a0Therapie\u00a0 01.09.2018\u00a0\nMelanom;\u00a0Kombination\u00a0+\u00a0Ipilimumab\u00a0 15.06.2016\u00a0\nMelanom;\u00a0Neubewertung\u00a0adj uvante\u00a0Therapie\u00a0 01.04.2021\u00a0\nMelanom;\u00a0Neubewertung\u00a0BRAF\u2010V 600\u2010WT\u00a0Erstlinie\u00a0+\u00a0Ipilimumab\u00a0 15.06.2018\u00a0\nMelanom;\u00a0Neubewertung\u00a0BRAF\u2010V600\u2010 WT\u00a0Erstlinie\u00a0+\u00a0Ipilimumab\u00a0 15.06 .2017\u00a0\nNierenzellkarzinom\u00a0 01.05.2016\u00a0\nNierenzellkarzinom;\u00a0Erstlinie\u00a0+\u00a0Cabozantinib\u00a0 01.05.2021\u00a0\nNierenzellkarzinom;\u00a0Erstlinie\u00a0+\u00a0Ipilimumab\u00a0 15.02.2019\u00a0\nNSCLC;\u00a0Kombination\u00a0+\u00a0Ipilimumab\u00a0+\u00a0Pt\u2010CT\u00a0Erstlinie\u00a0 15.12.2020\u00a0\nNSCLC;\u00a0Nichtplattenepithelhistologie;\u00a0nach\u00a0CT\u00a0 01.05.2016\u00a0\nNSCLC;\u00a0Plattenepithelhistologie;\u00a0nach\u00a0CT\u00a0 15.08.2015\u00a0\nPlattenepithelkarzinom\u00a0des\u00a0\u00d6sophagus;\u00a0nach\u00a0Vortherapie\u00a0 01.01.2021\u00a0\nPlattenepithelkarzinom\u00a0K opf\u2010Hals\u2010Bereich\u00a0 01.06.2017\u00a0\nUrothelkarzinom\u00a0 01.06.2017\u00a0\nDas\u00a0Beispiel\u00a0Nivolumab\u00a0unterstreicht\u00a0die\u00a0Komplexit\u00e4t\u00a0der\u00a0Nutzen bewertung\u00a0von\u00a0\nArzneimitteln\u00a0mit\u00a0neuen\u00a0Wirkstoffen\u00a0bzw.\u00a0von\u00a0bekannten\u00a0Wirkstof fen\u00a0bei\u00a0Auswei\u2010\ntung\u00a0der\u00a0Zulassung\u00a0auf\u00a0neue\u00a0Anwendungsgebiete\u00a0sowie\u00a0deren\u00a0Preis bildung.\u00a0Mit\u00a0\nzunehmender\u00a0Anwendung\u00a0steigen\u00a0eine rseits\u00a0die\u00a0Einnahmen\u00a0des\u00a0pU\u00a0u nd\u00a0anderer\u2010\nseits\u00a0relativieren\u00a0sich\u00a0auch\u00a0die\u00a0fixen\u00a0Kosten\u00a0in\u00a0Folge\u00a0von\u00a0Skal eneffekten.\u00a0Eine\u00a0kon\u2010\ntinuierliche\u00a0Anpassung\u00a0der\u00a0Bewertung\u00a0aber\u00a0auch\u00a0der\u00a0Preisbildung \u00a0an\u00a0Kosten\u00a0und\u00a0\nNutzen\u00a0im\u00a0gesamten\u00a0Patientenkolle ktiv\u00a0erscheint\u00a0dringend\u00a0notwen dig.\u00a0In\u00a0Erg\u00e4n\u2010\nzung\u00a0zur\u00a0fr\u00fchen\u00a0Nutzenbewertung\u00a0nach\u00a0AMNOG\u00a0w\u00e4re\u00a0eine\u00a0L\u00f6sung\u00a0in\u00a0 Form\u00a0einer\u00a0\nkontinuierlichen\u00a0 Bewertung\u00a0 anhand\u00a0 bestm\u00f6glicher\u00a0 Evidenz\u00a0 und\u00a0 ein es\u00a0 hiervon\u00a0\nabgeleiteten\u00a0dynamischen\u00a0Preises\u00a0zu\u00a0suchen.\u00a0\u00a0\n[Parameter:\u00a0cancer;\u00a039,3/100.000;\u00a01.758.675\u00a0Patienten\u00a0in\u00a010\u00a0Jah ren;\u00a050\u00a0%\u00a0Behandlungsquote;\u00a0\n250\u00a0Mio.\u00a0Euro\u00a0R&D\u2010cost;\u00a02\u00a0competitors\u00a0(2/3\u00a0of\u00a0the\u00a0market);\u00a0Biol ogical\u00a0150\u00a0Euro\u00a0Production\u00a0cost;\u00a0\n60\u00a0Monate\u00a0Therapiedauer;\u00a0Sales\u00a0&\u00a0Med.\u2010Wiss.\u2010Kosten\u00a020\u00a0%\u00a0der\u00a0R&D \u2010Kosten;\u00a0Basis\u2010Profit\u00a08\u00a0%\u00a0of\u00a0\ntotal\u00a0cost;\u00a015\u00a0%\u00a0Innovation\u00a0Bonus:\u00a0life\u2010threatening\u00a0disease\u00a05\u00a0% \u00a0plus\u00a0OS\u00a0gain\u00a0>6\u00a0months\u00a010\u00a0%].\u00a0 \n149\u00a0\n\u00a0Trifluridin/Tipiracil\u00a0(Handelsname:\u00a0Lonsurf\u00ae)\u00a0\nDie\u00a0 Kombination\u00a0 des\u00a0 Nukleosid\u2010An alogons\u00a0 Trifluridin\u00a0 mit\u00a0 dem\u00a0 Thy midin\u2010\nPhosphorylase\u2010Inhibitor\u00a0Tipiracil\u00a0 (Handelsname:\u00a0Lonsurf\u00ae)\u00a0erhie lt\u00a0am\u00a025.04.2016\u00a0\ndie\u00a0Zulassung\u00a0zur\u00a0Therapie\u00a0des\u00a0metastasierten\u00a0kolorektalen\u00a0Karz inoms\u00a0(mKRK)\u00a0in\u00a0\nder\u00a0EU\u00a0als\u00a0Monotherapie\u00a0bei\u00a0Patienten,\u00a0die\u00a0bereits\u00a0verf\u00fcgbare\u00a0A rzneimittel\u00a0erhiel\u2010\nten\u00a0oder\u00a0diese\u00a0in\u00a0Folge\u00a0von\u00a0Kontraindikationen\u00a0nicht\u00a0erhalten\u00a0k \u00f6nnen.\u00a0Im\u00a0Jahr\u00a0\n2019\u00a0kam\u00a0die\u00a0Anwendung\u00a0bei\u00a0metastasiertem\u00a0Magenkarzinom\u00a0hinzu,\u00a0 die\u00a0auch\u00a0\nAdenokarzinome\u00a0des\u00a0gastro\u2010oesophagealen\u00a0\u00dcbergangs\u00a0umfasst\u00a0(EMA, \u00a02016).\u00a0Beim\u00a0\nmKRK\u00a0attestierte\u00a0der\u00a0G\u2010BA\u00a0in\u00a0zwei \u00a0Bewertungsverfahren\u00a0einen\u00a0Anh altspunkt\u00a0f\u00fcr\u00a0\neinen\u00a0geringen\u00a0ZN,\u00a0in\u00a0der\u00a0zweite n\u00a0Indikation\u00a0lediglich\u00a0einen\u00a0Hi nweis\u00a0auf\u00a0einen\u00a0\ngeringen\u00a0 ZN\u00a0 basierend\u00a0 auf\u00a0 einer\u00a0 Verl\u00e4ngerung\u00a0 des\u00a0 Gesamt\u00fcberlebe ns\u00a0 (Overall\u00a0\nsurvival,\u00a0OS)\u00a0um\u00a02\u00a0bzw.\u00a02,1\u00a0Monate.\u00a0Das\u00a0progressionsfreie\u00a0\u00dcberleben\u00a0( Progression\u00a0\nfree\u00a0survival ,\u00a0PFS)\u00a0wurde\u00a0je\u00a0nach\u00a0Studie\u00a0um\u00a00,2\u00a0bis\u00a00,4\u00a0Monate\u00a0verl\u00e4ngert,\u00a0D aten\u00a0\nzur\u00a0gesundheitsbezogenen\u00a0Lebensqualit\u00e4t\u00a0wurden\u00a0vom\u00a0pU\u00a0nicht\u00a0ein gereicht\u00a0und\u00a0\nbei\u00a0unerw\u00fcnschten\u00a0Arzneimittelwirkungen\u00a0(UAW)\u00a0fielen\u00a0mehr\u00a0schwe rwiegende\u00a0\nUAW\u00a0des\u00a0CT\u2010CAE\u2010Grades\u00a0\u22653\u00a0auf\u00a0(G\u2010BA,\u00a02020).\u00a0Im\u00a0Innovationsreport \u00a02019\u00a0erhielt\u00a0\ndas\u00a0Kombinationspr\u00e4parat\u00a0gelbe\u00a0A mpeln\u00a0(Glaeske\u00a0et\u00a0al.,\u00a02019).\u00a0\u00a0\nDie\u00a0 Jahrestherapiekosten\u00a0 belaufen\u00a0 sich\u00a0 auf\u00a0 43.985,80\u00a0Euro\u00a0 GKV\u2010n etto\u00a0 bzw.\u00a0\n35.099,96\u00a0Euro\u00a0(APU)\u00a0[Lauer\u2010Taxe \u00a0mit\u00a0Preisen\u00a0zum\u00a015.07.2021].\u00a0I m\u00a0Zuge\u00a0der\u00a0Ver\u2010\nhandlungen\u00a0 des\u00a0 Erstattungsbetrages\u00a0 kam\u00a0 es\u00a0 zu\u00a0 einer\u00a0 Preisredukti on\u00a0 um\u00a0 35\u00a0%\u00a0\n(APU).\u00a0Mit\u00a0dem\u00a0 Fair\u00a0Pricing\u00a0Calculator\u00a0 von\u00a0AIM\u00a0ergeben\u00a0sich\u00a0basierend\u00a0auf\u00a0Inzi\u2010\ndenzen\u00a0 des\u00a0 Zentrums\u00a0 f\u00fcr\u00a0 Krebsregisterdaten\u00a0 des\u00a0 Robert\u00a0 Koch\u2010Inst itutes\u00a0 (RKI,\u00a0\n2021)\u00a0Jahrestherapiekosten\u00a0von\u00a01. 196,50\u00a0Euro\u00a0bis\u00a02.689,20\u00a0Euro, \u00a0mithin\u00a03,5\u00a0%\u00a0bis\u00a0\n7,7\u00a0%\u00a0des\u00a0vom\u00a0pU\u00a0aktuell\u00a0berechne ten\u00a0Preises\u00a0(APU)\u00a0unter\u00a0Ber\u00fcck sichtigung\u00a0ent\u2010\nsprechender\u00a0Parameter.\u00a0Im\u00a0Ergebni s\u00a0ruft\u00a0der\u00a0pU\u00a0somit\u00a0einen\u00a013\u00a0b is\u00a029\u2010fach\u00a0h\u00f6he\u2010\nren\u00a0Preis\u00a0im\u00a0Verglei ch\u00a0APU\u00a0vs.\u00a0AIM\u00a0auf.\u00a0\n[Parameter:\u00a0Cancer,\u00a0Inzidenz\u00a0pro\u00a0Jahr\u00a022,2\u00a0mMagenCA/83,2\u00a0mKRK/\u00a0 alle\u00a0Indikationen\u00a0105,4;\u00a0target\u00a0\npopulation\u00a0 bezogen\u00a0 auf\u00a0 zehn\u00a0 Jahre\u00a0 993.450/3.723.200/4.716.650;\u00a0 50\u00a0%\u00a0 treated\u00a0 population;\u00a0\n250\u00a0Mio.\u00a0Euro\u00a0globale\u00a0R&D\u00a0Kosten;\u00a00\u00a0competitors;\u00a0Produktionskos ten\u00a050\u00a0Euro\u00a0pro\u00a0Monat;\u00a0durch\u2010\nschnittliche\u00a0Behandlungsdauer\u00a0zwei\u00a0Monate;\u00a0Sales\u00a0und\u00a0Med.\u2010Wiss. \u00a020\u00a0%\u00a0der\u00a0R&D\u2010Kosten;\u00a0Basis\u2010\nProfit\u00a08\u00a0%\u00a0der\u00a0Gesamtkosten;\u00a0Innovationsbonus\u00a010\u00a0%:\u00a0life\u2010threat ening\u00a0disease:\u00a05\u00a0%\u00a0plus\u00a0OS\u2010gain\u00a0up\u00a0\nto\u00a06\u00a0months:\u00a05\u00a0%] .\u00a0\nDas\u00a0Beispiel\u00a0des\u00a0Kombinationspr\u00e4parates\u00a0Trifluridin/Tipiracil\u00a0z eigt\u00a0einerseits,\u00a0dass\u00a0\ndie\u00a0Preisbildung\u00a0bei\u00a0Arzneimitteln\u00a0in\u00a0der\u00a0Onkologie\u00a0losgel\u00f6st\u00a0v on\u00a0den\u00a0tats\u00e4chlichen\u00a0\nProduktionskosten\u00a0erfolgt\u00a0und\u00a0eine\u00a0Bewertung\u00a0des\u00a0Nutzens\u00a0und\u00a0de r\u00a0Preisbildung\u00a0\nkontinuierlich\u00a0erfolgen\u00a0sollte,\u00a0mithin\u00a0die\u00a0Erstattungsbetr\u00e4ge\u00a0d ynamisch\u00a0am\u00a0Stand\u00a0\nder\u00a0Evidenz\u00a0adjustiert\u00a0werden\u00a0sollten.\u00a0\n\u00a0 \n150\u00a0\n\u00a0Fazit\u00a0\nDas\u00a0Konzept\u00a0zur\u00a0Berechnung\u00a0fairer\u00a0Arzneimittelpreise\u00a0und\u00a0dessen \u00a0Umsetzung\u00a0in\u00a0\nForm\u00a0des\u00a0 Fair\u00a0Pricing\u00a0Calculators \u00a0der\u00a0NGO\u00a0AIM\u00a0stellt\u00a0in\u00a0diesem\u00a0Kontext\u00a0eine\u00a0Berei\u2010\ncherung\u00a0dar.\u00a0Es\u00a0adressiert\u00a0explizit\u00a0die\u00a0Frage\u00a0nach\u00a0ad\u00e4quaten,\u00a0d .\u00a0h.\u00a0auf\u00a0Basis\u00a0trans\u2010\nparenter\u00a0Vollkostenrechnungen\u00a0ermittelten,\u00a0Markteintrittspreise n\u00a0neuer\u00a0Arznei\u2010\nmittel\u00a0mit\u00a0patentgesch\u00fctzten\u00a0Wir kstoffen.\u00a0Im\u00a0allt\u00e4glichen\u00a0Gebra uch\u00a0im\u00a0Rahmen\u00a0\nvon\u00a0Verhandlungen\u00a0mit\u00a0pU\u00a0zu\u00a0Arzneimittelpreisen\u00a0liefert\u00a0es\u00a0Argu mente\u00a0f\u00fcr\u00a0die\u00a0\nKostentr\u00e4ger\u00a0und\u00a0animiert\u00a0die \u00a0pU\u00a0zu\u00a0mehr\u00a0Transparenz.\u00a0\nDie\u00a0exemplarisch\u00a0berechneten\u00a0Jahr estherapiekosten\u00a0und\u00a0der\u00a0Vergl eich\u00a0mit\u00a0den\u00a0\naktuellen\u00a0zeigen\u00a0akuten\u00a0Ha ndlungsbedarf\u00a0der\u00a0Politik.\u00a0\u00a0\nTabelle\u00a0 7.3:\u00a0 Vergleich\u00a0 der\u00a0 Jahrestherapiekosten\u00a0 innovativer\u00a0 Arz neimittel\u00a0 auf\u00a0\nBasis\u00a0des\u00a0APU\u00a0zu\u00a0Markteintritt/aktuellen\u00a0APU\u00a0vs.\u00a0AIM\u00a0Fair\u00a0Prici ng\u00a0Tool\u00a0\u00a0\n\u00a0\u00a0Jahrestherapiekosten\u00a0auf\u00a0Basis\u00a0des\u00a0ApU\u00a0 Relation\u00a0\nWirkstoff\u00a0\n(Handelsname)\u00a0zu\u00a0Markteintritt\u00a0\n(MA)\u00a0am\u00a0\n15.07.2021\u00a0Fairer\u00a0Preis\u00a0\nAIM*\u00a0AIM\u00a0vs.\u00a0\nMA\u00a0AIM\u00a0vs.\u00a0\n15.07.2021\u00a0\nOnasemnogen\u2010Abeparvovec\u00a0\n(Zolgensma \u00ae)\u00a0 1.945.000,00\u00a0\u20ac\u00a0 1.945.000,00\u00a0\u20ac\u00a0 1.073.348,70\u00a0\u20ac\u00a0 1,8\u00a0 1,8\u00a0\nNusinersen\u00a0\u00a0\n(Spinraza\u00ae)\u00a0 304.640,00\u00a0\u20ac\u00a0 256.609,90\u00a0\u20ac\u00a0 30.024,35\u00a0\u20ac\u00a0 10,1\u00a0 8,5\u00a0\nSacubitril\u2010Valsartan\u00a0\u00a0\n(Entresto\u00ae)\u00a0 2.007,50\u00a0\u20ac\u00a0 1.599,78\u00a0\u20ac\u00a0 917,84\u00a0\u20ac\u00a0 2,2\u00a0 1,7\u00a0\nEmpagliflozin\u00a0\u00a0\n(Jardiance\u00ae)\u00a0 616,85\u00a0\u20ac\u00a0 523,56\u00a0\u20ac\u00a0 863,12\u00a0\u20ac\u00a0 0,7\u00a0 0,6\u00a0\nSecukinumab\u00a0\u00a0\n(Cosentyx\u00ae)\u00a0 18.588,16\u00a0\u20ac\u00a0 15.187,50\u00a0\u20ac\u00a0 3.279,14\u00a0\u20ac\u00a0 5,7\u00a0 4,6\u00a0\nNivolumab\u00a0\u00a0\n(Opdivo\u00ae)\u00a0 88.920,00\u00a0\u20ac\u00a0 65.799,50\u00a0\u20ac\u00a0 13.367,50\u00a0\u20ac\u00a0 6,7\u00a0 4,9\u00a0\nTrifluridin/Tipiracil\u00a0\u00a0\n(Lonsurf\u00ae)\u00a0 54.220,83\u00a0\u20ac\u00a0 35.099,96\u00a0\u20ac\u00a0 2.689,20\u00a0\u20ac\u00a0 20,2\u00a0 13,1\u00a0\n*\u00a0adaptiert\u00a0an\u00a0die\u00a0Kaufkraft\u00a0in\u00a0Deutschland\u00a0nach\u00a0OECD\u00a0(AIM\u00a0plus \u00a020%)\u00a0\nMit\u00a0Ausnahme\u00a0von\u00a0Empagliflozin\u00a0s ind\u00a0die\u00a0derzeitigen\u00a0Jahresthera piekosten\u00a0zwei\u2010\u00a0\nbis\u00a013\u2010mal\u00a0so\u00a0hoch,\u00a0bezogen\u00a0auf\u00a0den\u00a0Markteintritt\u00a0zwei\u00a0bis\u00a020\u2010m al\u00a0so\u00a0hoch,\u00a0wie\u00a0sie\u00a0\ngemessen\u00a0an\u00a0fairen\u00a0Kriterien\u00a0sein\u00a0sollten.\u00a0Die\u00a0pU\u00a0sollten\u00a0erl\u00e4u tern,\u00a0wie\u00a0es\u00a0zu\u00a0dieser\u00a0\nDiskrepanz\u00a0kommt.\u00a0\nAnalysiert\u00a0man\u00a0die\u00a0durch\u00a0Erstattungsbetragsverhandlungen\u00a0erziel ten\u00a0Reduktionen\u00a0\nder\u00a0Arzneimittelpreise\u00a0gegen\u00fcber\u00a0dem\u00a0Stand\u00a0zum\u00a0Markteintritt,\u00a0s o\u00a0f\u00e4llt\u00a0auf,\u00a0dass\u00a0\ndiese\u00a0bei\u00a013\u00a0bis\u00a031\u00a0%\u00a0liegen.\u00a0Bereits\u00a0im\u00a0Jahr\u00a02016\u00a0hatten\u00a0Busse \u00a0und\u00a0Kollegen\u00a0f\u00fcr\u00a0\neinen\u00a0Warenkorb\u00a0um\u00a016\u00a0bis\u00a027\u00a0%\u00a0erh\u00f6hte\u00a0Preise\u00a0patentgesch\u00fctzter \u00a0Arzneimittel\u00a0in\u00a0\nDeutschland\u00a0im\u00a0Kaufkraft\u00a0adjustierten\u00a0europ\u00e4ischen\u00a0Vergleich\u00a0er mittelt\u00a0(Busse\u00a0et\u00a0\nal.,\u00a02016).\u00a0Dies\u00a0f\u00fchrt\u00a0zur\u00a0Frage,\u00a0inwiefern\u00a0die\u00a0Zugest\u00e4ndnisse\u00a0 der\u00a0pU\u00a0im\u00a0Rahmen\u00a0 \n151\u00a0\n\u00a0der\u00a0Verhandlungen\u00a0des\u00a0Erstattung sbetrages\u00a0relevant\u00a0\u00fcber\u00a0die\u00a0Dif ferenz\u00a0der\u00a0h\u00f6he\u2010\nren\u00a0Marktpreise\u00a0in\u00a0Deutschland\u00a0hinausgehen.\u00a0\nNutzt\u00a0man\u00a0den\u00a0 Fair\u00a0Pricing\u00a0Calculator \u00a0der\u00a0NGO\u00a0AIM,\u00a0so\u00a0fallen\u00a0um\u00a045\u00a0bis\u00a095\u00a0%\u00a0ge\u2010\nminderte\u00a0Jahrestherapiekosten\u00a0geg en\u00fcber\u00a0der\u00a0bei\u00a0Markteintritt\u00a0b eanspruchten\u00a0\nauf\u00a0(ApU).\u00a0Zu\u00a0beachten\u00a0ist\u00a0hierbei,\u00a0dass\u00a0die\u00a0NGO\u00a0AIM\u00a0auch\u00a0die\u00a0P roduktionskosten\u00a0\nbei\u00a0der\u00a0Berechnung\u00a0eines\u00a0fairen\u00a0Arzneimittelpreises\u00a0ber\u00fccksicht igt\u00a0und\u00a0die\u00a0Ge\u2010\nwinnmarge\u00a0staffelt,\u00a0d.\u00a0h.\u00a0von\u00a08\u00a0%\u00a0Basisprofit\u00a0plus\u00a0optionalen\u00a0I nnovationsbonus\u00a0von\u00a0\nbis\u00a0zu\u00a040\u00a0%,\u00a0je\u00a0nach\u00a0evidentem\u00a0Nutzenbeleg.\u00a0Ausgenommen\u00a0sind\u00a0di e\u00a0Aufschl\u00e4ge\u00a0\nvon\u00a0pharmazeutischem\u00a0Gro\u00dfhandel\u00a0und\u00a0Apotheken.\u00a0\nTabelle\u00a07.4:\u00a0Prozentuale\u00a0Preisreduktion\u00a0vs.\u00a0Effekt\u00a0des\u00a0AIM\u00a0 Fair\u00a0Pricing\u00a0Calcula\u2010\ntors\u00a0\n\u00a0\u00a0 Preisreduktion\u00a0\nWirkstoff\u00a0 Handelsname\u00a0 MA\u00a0vs\u00a0EB\u00a0[GKV\u00a0netto] AIM\u00a0vs.\u00a0MA\u00a0[ApU\u00a0Markteintritt]\nOnasemnogen\u2010Abeparvovec Zolgensma\u00a0 kein 45\u00a0%\nNusinersen\u00a0 Spinraza\u00a0 16\u00a0% 90\u00a0%\nSacubitril\u2010Valsartan\u00a0 Entresto\u00a0 23\u00a0% 54\u00a0%\nEmpagliflozin\u00a0 Jardiance\u00a0 14\u00a0% \u201040\u00a0%\nSecukinumab\u00a0 Cosentyx\u00a0 13\u00a0% 82\u00a0%\nNivolumab\u00a0 Opdivo\u00a0 26\u00a0% 85\u00a0%\nTrifluridin/Tipiracil\u00a0 Lonsurf\u00a0 31\u00a0% 95\u00a0%\nDer\u00a0Umsatz\u00a0der\u00a0ausgew\u00e4hlten\u00a0Arzn eimittel\u00a0ohne\u00a0Zolgensma\u00ae\u00a0lag\u00a0be i\u00a01,212\u00a0Mrd.\u00a0\nE u r o \u00a0b z w . \u00a05 , 9 \u00a0 % \u00a0d e r \u00a0A u s g a b e n \u00a0d e r \u00a0G K V \u00a0f \u00fc r \u00a0A r z n e i m i t t e l \u00a0m i t \u00a0P a t e n tschutz\u00a0\n(20,637\u00a0Mrd.\u00a0Euro\u00a0GKV\u2010netto)\u00a0im\u00a0Jahr\u00a02019\u00a0(Schwabe\u00a0&\u00a0Ludwig,\u00a020 20).\u00a0Mit\u00a0Hilfe\u00a0der\u00a0\nDDD\u2010Ums\u00e4tze\u00a0je\u00a0PZN\u00a0in\u00a02019\u00a0kann\u00a0man\u00a0zum\u00a0Vergleich\u00a0die\u00a0Kosten\u00a0er rechnen,\u00a0die\u00a0bei\u00a0\nVerwendung\u00a0der\u00a0fairen\u00a0AIM\u2010Preise\u00a0entstanden\u00a0w\u00e4ren.\u00a0Diese\u00a0betrag en\u00a0in\u00a0der\u00a0Stich\u2010\nprobe\u00a0insgesamt\u00a0etwa\u00a0444\u00a0Mio.\u00a0Euro,\u00a0woraus\u00a0sich\u00a0potentielle\u00a0Ein sparungen\u00a0in\u00a0H\u00f6he\u00a0\nvon\u00a063,3\u00a0%\u00a0der\u00a0Ausgaben\u00a0des\u00a0Jahres\u00a02019\u00a0ergeben.\u00a0Auf\u00a0das\u00a0Segmen t\u00a0der\u00a0Patent\u2010\nArzneimittel\u00a0der\u00a0GKV\u00a0bezogen\u00a0w\u00e4ren\u00a0dies\u00a0Einsparungen\u00a0von\u00a0rund\u00a01 3\u00a0Mrd.\u00a0Euro.\u00a0\n\u00a0 \u00a0 \n152\u00a0\n\u00a0Tabelle\u00a07.5:\u00a0Potenzielle\u00a0Einsparungen\u00a0der\u00a0GKV\u00a0bei\u00a0innovativen\u00a0W irkstoffen\u00a0unter\u00a0\nNutzung\u00a0des\u00a0AIM\u00a0 Fair\u00a0Pricing\u00a0Calculators \u00a0an\u00a0ausgew\u00e4hlten\u00a0Beispiel\u2010Arzneimitteln\u00a0\nbei\u00a0aktuellem\u00a0APU\u00a0\u00a0\nAusgaben\u00a0der\u00a0GKV\u00a0im\u00a0Jahr\u00a02019\u00a0\n\u00a0Hypothetisches\u00a0\nEinsparpotenzial\u00a0der\u00a0GKV\u00a0\nINN\u00a0 FAM\u00a0 Netto\u00a0hypothetisch\u00a0\nnach\u00a0AIM\u00a0Preise\u00a0\n[15.07.2021]\u00a0 Prozentual\u00a0\nOnasemnogen\u2010\nAbeparvovec\u00a0 Zolgensma\u00a0 NN\u00a0 NN\u00a0 NN\u00a0 \u00a0\u00a0\nNusinersen\u00a0 Spinraza\u00a0 13.729.200\u00a0\u20ac\u00a0 1.571.137\u00a0\u20ac\u00a0 12.158.063\u00a0\u20ac\u00a0 88,56\u00a0%\u00a0\nSacubitril\u2010Valsartan\u00a0 Entresto\u00a0 186.611.500\u00a0\u20ac\u00a0 86.421.551\u00a0\u20ac\u00a0 100.189.949\u00a0\u20ac\u00a0 53,69\u00a0%\u00a0\nEmpagliflozin\u00a0 Jardiance\u00a0 198.084.200\u00a0\u20ac\u00a0 221.467.133\u00a0\u20ac\u00a0 \u201023.382.933\u00a0\u20ac\u00a0 \u201011,80\u00a0%\u00a0\nSecukinumab\u00a0 Cosentyx\u00a0 336.341.700\u00a0\u20ac\u00a0 51.255.204\u00a0\u20ac\u00a0 285.086.496\u00a0\u20ac\u00a0 84,76\u00a0%\u00a0\nNivolumab\u00a0 Opdivo\u00a0 453.619.400\u00a0\u20ac\u00a0 82.197.307\u00a0\u20ac\u00a0 371.422.093\u00a0\u20ac\u00a0 81,88\u00a0%\u00a0\nTrifluridin/Tipiracil\u00a0 Lons urf\u00a0 23.807.800\u00a0\u20ac\u00a0 1.497.111\u00a0\u20ac\u00a0 22.310.6 89\u00a0\u20ac\u00a0 93,71\u00a0%\u00a0\nAuswahl\u00a0neuer\u00a0\u00a0\nArzneimittel\u00a0 1.212.193.800\u00a0\u20ac\u00a0 444.409.443\u00a0\u20ac\u00a0 767.784.357\u00a0\u20ac\u00a0 63,34\u00a0%\u00a0\nGKV\u2010Patent\u2010Arzneimittel\u00a0\u00a0 20.637.000.000\u00a0\u20ac\u00a0 13.071.148.992\u00a0\u20ac\u00a0 63,34\u00a0%\u00a0\nGKV\u2010Arzneimittel\u2010\u00a0\nausgaben\u00a0gesamt\u00a0 43.859.000.000\u00a0\u20ac\u00a0\nStand\u00a0Lauer\u2010Taxe\u00a015.7.2021\u00a0\nIn\u00a0der\u00a0Gesamtschau\u00a0ist\u00a0der\u00a0 Fair\u00a0Pricing\u00a0Calculator \u00a0von\u00a0AIM\u00a0als\u00a0sinnvolle\u00a0Erg\u00e4nzung\u00a0\nzu\u00a0bewerten.\u00a0Die\u00a0Details\u00a0der\u00a0Beschl\u00fcsse\u00a0und\u00a0tragenden\u00a0Gr\u00fcnde\u00a0ei ner\u00a0Nutzenbe\u2010\nwertung\u00a0von\u00a0Arzneimitteln\u00a0seitens\u00a0des\u00a0G\u2010BA\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0k\u00f6n nen\u00a0in\u00a0ihrer\u00a0\nKomplexit\u00e4t\u00a0jedoch\u00a0nur\u00a0bedingt\u00a0dargestellt\u00a0werden.\u00a0Bei\u00a0vielfach en\u00a0Erweiterungen\u00a0\nder\u00a0Anwendungsgebiete\u00a0(Bsp.\u00a0Nivolu mab)\u00a0oder\u00a0Me\u2010too\u2010Pr\u00e4paraten\u00a0s ind\u00a0die\u00a0Er\u2010\ngebnisse\u00a0des\u00a0 Fair\u00a0Pricing\u00a0Calculators \u00a0entsprechend\u00a0zu\u00a0w\u00fcrdigen.\u00a0Er\u00a0ist\u00a0aber\u00a0als\u00a0\nlernendes\u00a0System\u00a0zu\u00a0bewerten,\u00a0viele\u00a0Aspekte\u00a0des\u00a0Preiskalkulator s\u00a0m\u00fcssen\u00a0sicher\u00a0\n\u00fcberdacht\u00a0und\u00a0nachjustiert\u00a0werden.\u00a0Trotzdem\u00a0kann\u00a0dieser\u00a0Preisfi ndungsansatz\u00a0als\u00a0\neine\u00a0Aufforderung\u00a0an\u00a0die\u00a0pharmazeutischen\u00a0Unternehmer\u00a0verstande n\u00a0werden,\u00a0\nmehr\u00a0Transparenz\u00a0f\u00fcr\u00a0die\u00a0Preisge staltung\u00a0anzubieten,\u00a0weil\u00a0nur\u00a0d ann\u00a0auf\u00a0einer\u00a0\nrealistischeren\u00a0Basis\u00a0als\u00a0derzei t\u00a0Preisverhandlungen\u00a0durchgef\u00fch rt\u00a0werden\u00a0k\u00f6nnen\u00a0\n\u2013\u00a0zum\u00a0Nutzen\u00a0der\u00a0europ\u00e4ischen\u00a0Gesundheitssysteme\u00a0und\u00a0damit\u00a0der\u00a0 Krankenkas\u2010\nsen\u00a0und\u00a0deren\u00a0Versicherten,\u00a0aber\u00a0auch\u00a0zur\u00a0Weiterentwicklung\u00a0des \u00a0Vertrauens\u00a0in\u00a0\nden\u00a0Willen\u00a0der\u00a0pharmazeutischen\u00a0 Unternehmen,\u00a0die\u00a0Gesundheitssys teme\u00a0finanzi\u2010\nell\u00a0nicht\u00a0zu\u00a0\u00fcberfordern.\u00a0Daher\u00a0 sollte\u00a0der\u00a0AIM\u2010Vorschlag\u00a0als\u00a0An lass\u00a0zu\u00a0einer\u00a0drin\u2010\ngend\u00a0notwendigen\u00a0Diskussion\u00a0Beachtung\u00a0finden.\u00a0\n\u00a0 \n153\u00a0\n\u00a0Abb.\u00a07.5:\u00a0Vergleich\u00a0der\u00a0GKV\u2010Ne ttoausgaben\u00a0in\u00a02019\u00a0mit\u00a0den\u00a0hypot hetischen\u00a0\nAusgaben\u00a0unter\u00a0fairen\u00a0AIM\u2010Preisen\u00a0\n\u00a0\nQuellen\u00a0\nAIM\u00a0(2019a).\u00a0AIM\u00a0proposes\u00a0to\u00a0establish\u00a0a\u00a0European\u00a0drug\u00a0pricing\u00a0 model\u00a0for\u00a0fair\u00a0and\u00a0transparent\u00a0prices\u00a0for\u00a0accessible\u00a0\npharmaceutical\u00a0innovations.\u00a02019.\u00a0https://www.aim\u2010mutual.org/wp \u2010\ncontent/uploads/2019/12/AIMfairpricingModel.pdf,\u00a0letzter\u00a0Zugrif f:\u00a013.07.2021.\u00a0\nAIM\u00a0(2019b).\u00a0European\u00a0patients\u00a0need\u00a0fair\u00a0medicines\u00a0prices.\u00a02019 .\u00a0https://www.aim\u2010mutual.org/mediaroom/aim\u2010presents\u2010its\u2010\nmodel\u2010for\u2010fair\u2010and\u2010transparent\u2010prices\u2010for\u2010pharmaceuticals/?lang =de,\u00a0letzter\u00a0Zugriff:\u00a023.07.2021.\u00a0\nAIM\u00a0(2021a).\u00a0AIM\u00a0launches\u00a0its\u00a0calculator\u00a0for\u00a0fair\u00a0medicines\u00a0pri ces\u00a0in\u00a0Europe.\u00a02021.\u00a0https://www.aim\u2010mutual.org/wp\u2010\ncontent/uploads/2021/06/PRAIMFairPricingJune2021.pdf,\u00a0letzter\u00a0Z ugriff:\u00a013.07.2021.\u00a0\nAIM\u00a0(2021b).\u00a0AIM\u00a0offers\u00a0a\u00a0tool\u00a0to \u00a0calculate\u00a0fair\u00a0and\u00a0transparen t\u00a0European\u00a0prices\u00a0for\u00a0accessible\u00a0pharmaceutical\u00a0innovations.\u00a020 21.\u00a0\nhttps://www.aim\u2010mutual.org/wp\u2010content/uploads/2021/06/AIMs\u2010fair \u2010pricing\u2010model\u2010Accompanying\u2010paper\u2010to\u2010the\u2010\nfair\u2010pricing\u2010calculator_June2021.pdf,\u00a0letzter\u00a0Zugriff:\u00a002.08.20 21.\u00a0\nAIM\u00a0(2021c).\u00a0Mitglieder\u00a0der\u00a0AIM. \u00a02021.\u00a0https://www.aim\u2010mutual.o rg/mitglieder\u2010der\u2010aim/?lang=de,\u00a0letzter\u00a0Zugriff:\u00a013.07.2021.\u00a0\nAIM\u00a0(2021d).\u00a0Wer\u00a0wir\u00a0sind.\u00a02021.\u00a0https://www.aim\u2010mutual.org/wer \u2010sind\u2010wir/?lang=de,\u00a0letzter\u00a0Zugriff:\u00a013.07.2021.\u00a0\nAKdAE\u00a0(2016).\u00a0Aktualisierte\u00a0Hinweise\u00a0zum\u00a0Risiko\u00a0einer\u00a0diabetisc hen\u00a0Ketoazidose\u00a0w\u00e4hrend\u00a0der\u00a0Behandlung\u00a0mit\u00a0SGLT2\u2010Inhibitoren.\u00a0\n2016.\u00a0https://www.akdae.de/Arzneim ittelsicherheit/Weitere/Archi v/2016/20160314.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\n28.07.2021.\u00a0\n \n154\u00a0\n\u00a0AKdAE\u00a0(2018).\u00a0Induktion\u00a0und/oder\u00a0Demaskierung\u00a0von\u00a0chronisch\u2010ent z\u00fcndlichen\u00a0Darmerkrankungen\u00a0unter\u00a0Secukinumab\u00a0(\u201eAus\u00a0der\u00a0\nUAW\u2010Datenbank\u201c).\u00a02018.\u00a0https://www.akdae.de/Arzneimittelsicherheit/Bekanntgaben/Archiv /2018/20180406.html,\u00a0letzter\u00a0Zugriff:\u00a0\n29.07.2021.\u00a0\nAKdAE\u00a0(2019).\u00a0Risiko\u00a0einer\u00a0Fournier\u00a0Gangr\u00e4n\u00a0(Nekrotisierende\u00a0Fa sziitis\u00a0des\u00a0Perineums)\u00a0bei\u00a0der\u00a0Anwendung\u00a0von\u00a0SGLT2\u2010Inhibitoren\u00a0\n(\u201eSodium\u2010Glucose\u2010Co\u2010Transporter\u00a02\u00a0Inhibitors\u201c).\u00a02019.\u00a0https://www.akdae.de/Arzneimittelsicherheit/RHB/Archiv/2019/201 90122.pdf,\u00a0letzter\u00a0Zugriff:\u00a028.07.2021.\u00a0\nAlonso\u2010Zaldivar\u00a0R\u00a0(2015).\u00a0Maker\u00a0 of\u00a0$1,000\u00a0hepatitis\u00a0C\u00a0pill\u00a0was\u00a0 focused\u00a0on\u00a0profits,\u00a0not\u00a0patients,\u00a0report\u00a0finds.\u00a02015.\u00a0\nhttps://www.pbs.org/newshour/health/maker\u2010of\u20101000\u2010hepatitis\u2010c\u2010p ill\u2010was\u2010focused\u2010on\u2010profits\u2010not\u2010patients\u2010report\u2010\nfinds,\u00a0letzter\u00a0Zugriff:\u00a023.07.2021.\u00a0\nat\u00a0(2016).\u00a0Finanzielle\u00a0Spekulationen\u00a0behindern\u00a0Versorgung\u00a0mit\u00a0A rzneimitteln\u00a0\u2026\u00a0Strategien\u00a0der\u00a0Industrie\u00a0am\u00a0Beispiel\u00a0Gilead\u00a0und\u00a0\nSofosbuvir\u00a0(Sovaldi).\u00a0arzneitelegramm;\u00a047(09/2016).\u00a0\nat\u00a0(2021).\u00a0Wirkstoffgruppe:\u00a0Checkpoint\u2010Hemmer.\u00a02021.\u00a0https://ww w.arznei\u2010\ntelegramm.de/db/01anzgruppe.php3?&knr=&art=Gruppe&nummer=Checkp oint\u2010Hemmer&ord=uaw,\u00a0letzter\u00a0Zugriff:\u00a0\n31.07.2021.\u00a0\nBach\u00a0PB\u00a0(2021).\u00a0Price\u00a0&\u00a0Value\u00a0of\u00a0Cancer\u00a0Drug.\u00a02021.\u00a0https://www .mskcc.org/research\u2010programs/health\u2010policy\u2010outcomes/cost\u2010\ndrugs,\u00a0letzter\u00a0Zugriff:\u00a023.07.2021.\u00a0\nBeckmann\u00a0S,\u00a0Schillinger\u00a0G\u00a0(2020).\u00a0Gentherapie\u00a0\u2010\u00a0Gesch\u00e4ft\u00a0mit\u00a0de r\u00a0Hoffnung\u00a0auf\u00a0Heilung.\u00a0Gesundheit\u00a0und\u00a0Gesellschaft(02).\u00a0\nBMG\u00a0(2021).\u00a0Sozialgesetzbuch\u00a0(SGB)\u00a0F\u00fcnftes\u00a0Buch\u00a0(V)\u00a0\u2010\u00a0Gesetzlic he\u00a0Krankenversicherung.\u00a02021.\u00a0http://www.gesetze\u2010im\u2010\ninternet.de/sgb_5/SGB_5.pdf,\u00a0letzter\u00a0Zugriff:\u00a009.07.2021.\u00a0\nBusse\u00a0R,\u00a0Panteli\u00a0D,\u00a0Schaufler\u00a0J,\u00a0 Schr\u00f6der\u00a0H,\u00a0Telschow\u00a0C,\u00a0Weiss\u00a0 J\u00a0(2016).\u00a0Preise\u00a0patentgesch\u00fctzter\u00a0Arzneimittel\u00a0im\u00a0europ\u00e4ischen \u00a0\nVergleich\u00a0zu\u00a0den\u00a0Listenpreisen\u00a0in\u00a0f\u00fcnf\u00a0ausgew\u00e4hlten\u00a0europ\u00e4ische n\u00a0L\u00e4ndern.\u00a02016.\u00a0\nhttps://www.wido.de/fileadmin/Dateien/Dokumente/Forschung_Proje kte/Arzneimittel/wido_arz_preise_eu_vergle\nich_2016.pdf,\u00a0letzter\u00a0Zugriff:\u00a015.05.2021.\u00a0\nEckert\u00a0N,\u00a0Osterloh\u00a0F\u00a0(2020).\u00a0Kritik\u00a0an\u00a0steigenden\u00a0Preisen.\u00a0Deut sches\u00a0\u00c4rzteblatt\u00a0117(40).\u00a0\nEMA\u00a0(2016).\u00a0Lonsurf\u00a0\u2010\u00a0trifluridine\u00a0/\u00a0tipiracil.\u00a02016.\u00a0https://w ww.ema.europa.eu/en/medicines/human/EPAR/lonsurf,\u00a0letzter\u00a0Zugri ff:\u00a0\n29.07.2021.\u00a0\nEMA\u00a0(2021a).\u00a0Cosentyx\u00a0\u2010\u00a0secukinum ab.\u00a02021.\u00a0https://www.ema.euro pa.eu/en/medicines/human/EPAR/cosentyx,\u00a0letzter\u00a0Zugriff:\u00a0\n28.07.2021.\u00a0\nEMA\u00a0(2021b).\u00a0Entresto\u00a0\u2010\u00a0sacubitril\u00a0/\u00a0valsartan.\u00a02021.\u00a0https://w ww.ema.europa.eu/en/medicines/human/EPAR/entresto,\u00a0letzter\u00a0\nZugriff:\u00a028.07.2021.\u00a0\nEMA\u00a0CHMP\u00a0(2017).\u00a0Spinraza\u00a0(INN:\u00a0Nusinersen)\u00a0\u2010\u00a0EPAR.\u00a02017.\u00a0https ://www.ema.europa.eu/en/documents/assessment\u2010\nreport/spinraza\u2010epar\u2010public\u2010assessment\u2010report_en.pdf,\u00a0letzter\u00a0Z ugriff:\u00a024.07.2021.\u00a0\nEMA\u00a0CHMP\u00a0(2021).\u00a0Evrysdi\u00a0(INN:\u00a0risdiplam)\u00a0\u2010\u00a0EPAR.\u00a02021.\u00a0https:/ /www.ema.europa.eu/en/documents/assessment\u2010report/evrysdi\u2010\nepar\u2010public\u2010assessment\u2010report_en.pdf,\u00a0letzter\u00a0Zugriff:\u00a024.07.20 21.\u00a0\nEMA\u00a0CHMP,\u00a0EMA\u00a0CAT\u00a0(2020).\u00a0Zolgensma\u00a0(INN:\u00a0onasemnogene\u00a0abeparvo vec)\u00a0\u2010\u00a0EPAR.\u00a02020.\u00a0\nhttps://www.ema.europa.eu/en/documents/assessment\u2010report/zolgen sma\u2010epar\u2010public\u2010assessment\u2010report_en.pdf,\u00a0\nletzter\u00a0Zugriff:\u00a024.07.2021.\u00a0 \n155\u00a0\n\u00a0FDA\u00a0(2019).\u00a0Statement\u00a0on\u00a0data\u00a0accuracy\u00a0issues\u00a0with\u00a0recently\u00a0app roved\u00a0gene\u00a0therapy.\u00a02019.\u00a0https://www.fda.gov/news\u2010\nevents/press\u2010announcements/statement\u2010data\u2010accuracy\u2010issues\u2010recen tly\u2010approved\u2010gene\u2010therapy,\u00a0letzter\u00a0Zugriff:\u00a0\n02.08.2021.\u00a0\nG\u2010BA\u00a0(2008).\u00a0Verfahrensordnung\u00a0des\u00a0Gemeinsamen\u00a0Bundesausschusse s.\u00a02008.\u00a0https://www.g\u2010ba.de/downloads/62\u2010492\u2010\n2504/VerfO_2017\u201011\u201017_iK\u20102021\u201006\u201003.pdf,\u00a0letzter\u00a0Zugriff:\u00a009.07 .2021.\u00a0\nG\u2010BA\u00a0(2016).\u00a0Empagliflozin\u00a0\u2010\u00a0Beschluss\u00a0des\u00a0Gemeinsamen\u00a0Bundesau sschusses\u00a0\u00fcber\u00a0eine\u00a0\u00c4nderung\u00a0der\u00a0Arzneimittel\u2010Richtlinie\u00a0(AM\u2010\nRL):\u00a0Anlage\u00a0XII\u00a0\u2010\u00a0Beschl\u00fcsse\u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung\u00a0von\u00a0Arzne imitteln\u00a0mit\u00a0neuen\u00a0Wirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V.\u00a0\n2016.\u00a0https://www.g\u2010ba.de/downlo ads/39\u2010261\u20102694/2016\u201009\u201001_AM\u2010R L\u2010XII_Empagliflozin_D\u2010214_BAnz.pdf,\u00a0letzter\u00a0\nZugriff:\u00a028.07.2021.\u00a0\nG\u2010BA\u00a0(2017a).\u00a0Nusinersen\u00a0\u2010\u00a0Beschluss\u00a0des\u00a0Gemeinsamen\u00a0Bundesauss chusses\u00a0\u00fcber\u00a0eine\u00a0\u00c4nderung\u00a0der\u00a0Arzneimittel\u2010Richtlinie\u00a0(AM\u2010\nRL):\u00a0Anlage\u00a0XII\u00a0\u2010\u00a0Beschl\u00fcsse\u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung\u00a0von\u00a0Arzne imitteln\u00a0mit\u00a0neuen\u00a0Wirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V.\u00a0\n2017.\u00a0https://www.g\u2010ba.de/downlo ads/39\u2010261\u20103169/2017\u201012\u201021_AM\u2010R L\u2010XII_Nusinersen_D\u2010294_BAnz.pdf,\u00a0letzter\u00a0\nZugriff:\u00a019.07.2021.\u00a0\nG\u2010BA\u00a0(2017b).\u00a0Nutzenbewertungsverfahren\u00a0zum\u00a0Wirkstoff\u00a0Nivolumab \u00a0(neues\u00a0Anwendungsgebiet:\u00a0Hodgkin\u2010Lymphom).\u00a0\nNutzenbewertung\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V.2017.\u00a0https://www.g\u2010ba.de/bewe rtungsverfahren/nutzenbewertung/272/,\u00a0\nletzter\u00a0Zugriff\u00a006.12.2021\u00a0\nG\u2010BA\u00a0(2017c).\u00a0Secukinumab\u00a0\u2010\u00a0Geltende\u00a0Fassung\u00a0Arzneimittel\u2010Richt linie\u00a0/\u00a0Anlage\u00a0XII.\u00a02017.\u00a0https://www.g\u2010ba.de/downloads/91\u2010\n1385\u2010280/2017\u201008\u201017_Geltende\u2010Fassung_Secukinumab_D\u2010167_D\u2010276.pd f,\u00a0letzter\u00a0Zugriff:\u00a029.07.2021.G\u2010BA\u00a0(2020).\u00a0\nTrifluridin/Tipiracil\u00a0\u2010\u00a0Geltende\u00a0Fassung\u00a0der\u00a0Arzneimittel\u2010Richt linie/Anlage\u00a0XII.\u00a02020.\u00a0https://www.g\u2010\nba.de/downloads/91\u20101385\u2010541/2020\u201010\u201001_Geltende\u2010Fassung_Triflur idin\u2010Tipiracil_D\u2010535.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\n29.07.2020.\u00a0\nG\u2010BA\u00a0(2021a).\u00a0Nivolumab\u00a0\u2010\u00a0Nutzenbewertungsverfahren\u00a0nach\u00a0\u00a7\u00a035a\u00a0 SGB\u00a0V\u00a0zum\u00a0Wirkstoff.\u00a02021.\u00a0https://www.g\u2010\nba.de/bewertungsverfahren/nutzenbewertung/631/#beschluesse,\u00a0let zter\u00a0Zugriff:\u00a003.08.2021.\u00a0\nG\u2010BA\u00a0(2021b).\u00a0Nivolumab\u00a0\u2010\u00a0Nutzenbewertungsverfahren\u00a0zum\u00a0Wirksto ff\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2010\u00a0Neues\u00a0\nAnwendungsgebiet:\u00a0Plattenepithelkarzinom\u00a0des\u00a0\u00d6sophagus,\u00a0vorbeha ndelte\u00a0Patienten.\u00a02021.\u00a0https://www.g\u2010\nba.de/bewertungsverfahren/nutzenbewertung/635/#beschluesse,\u00a0let zter\u00a0Zugriff:\u00a002.08.2021.\u00a0\nG\u2010BA\u00a0(2021c).\u00a0Nusinersen\u00a0(\u00dcberschreitung\u00a0der\u00a050\u00a0Mio\u00a0\u20ac\u00a0Grenze:\u00a0S pinale\u00a0Muskelatrophie)\u00a0\u2010\u00a0Beschluss\u00a0des\u00a0Gemeinsamen\u00a0\nBundesausschuss\u00a0\u00fcber\u00a0eine\u00a0\u00c4nderung\u00a0der\u00a0Arzneimittelrichtlinie\u00a0( AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2010\u00a0Nutzenbewertung\u00a0von\u00a0\nArzneimitteln\u00a0mit\u00a0neuen\u00a0Wirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V.\u00a02021.\u00a0htt ps://www.g\u2010ba.de/downloads/39\u2010261\u20104835/2021\u2010\n05\u201020_AM\u2010RL\u2010XII_Nusinersen_D\u2010614 _BAnz.pdf,\u00a0letzter\u00a0Zugriff:\u00a019. 07.2021.\u00a0\nG\u2010BA\u00a0(2021d).\u00a0Nusinersen\u00a0(\u00dcberschreitung\u00a0der\u00a050\u00a0Mio\u00a0\u20ac\u00a0Grenze:\u00a0S pinale\u00a0Muskelatrophie)\u00a0\u2010\u00a0Tragende\u00a0Gr\u00fcnde\u00a0zum\u00a0Beschluss\u00a0des\u00a0\nGemeinsamen\u00a0Bundesausschusses\u00a0\u00fcber\u00a0eine\u00a0\u00c4nderung\u00a0der\u00a0Arzneimitt el\u2010Richtlinie\u00a0(AM\u2010R L):\u00a0Anlage\u00a0XII\u00a0\u2010\u00a0\nNutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0mit\u00a0neuen\u00a0Wirkstoffen\u00a0nach\u00a0\u00a7\u00a0 35a\u00a0SGB\u00a0V.\u00a02021.\u00a0https://www.g\u2010\nba.de/downloads/40\u2010268\u20107541/2021\u201005\u201020_AM\u2010RL\u2010XII_Nusinersen_D\u20106 14_TrG.pdf,\u00a0letzter\u00a0Zugriff:\u00a019.07.2021.\u00a0\nG\u2010BA\u00a0(2021e).\u00a0Nutzenbewertungen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2010\u00a0Nivolumab.\u00a02 021.\u00a0https://www.g\u2010\nba.de/bewertungsverfahren/nutzenbewertung/filter/b\u2010N\u2010st\u2010\u2010od\u2010\u2010tg \u2010\u2010e\u20100/ab/30/,\u00a0letzter\u00a0Zugriff:\u00a030.07.2021.\u00a0\nG\u2010BA\u00a0(2021f).\u00a0Onasemnogen\u2010Abeparvovec\u00a0(5q\u2010assoziierte\u00a0spinale\u00a0M uskelatrophie)\u00a0\u2010\u00a0Nutzenbewertungsverfahren\u00a0zum\u00a0Wirkstoff\u00a0\nnach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V.\u00a02021.\u00a0https://www.g\u2010ba.de/bewertungsverfahren /nutzenbewertung/561/,\u00a0letzter\u00a0Zugriff:\u00a0\n24.07.2021.\u00a0\nG\u2010BA\u00a0(2021g).\u00a0Risdiplam\u00a0(5q\u2010assoziierte\u00a0spinale\u00a0Muskelatrophie\u00a0 (SMA)\u00a0\u2010\u00a0Nutzenbewertungsverfahren\u00a0nach\u00a0\u00a735a\u00a0SGB\u00a0V\u00a0zum\u00a0\nWirkstoff.\u00a02021.\u00a0https://www.g\u2010b a.de/bewertungsverfahren/nutzen bewertung/680/,\u00a0letzter\u00a0Zugriff:\u00a024.07.2021.\u00a0\nGEKID\u2010Atlas\u00a0(2021).\u00a0Krebsneuerkrankungen\u00a0(Inzidenz),\u00a0altersstan dardisierte\u00a0Rate\u00a0[Europastanda rd](je\u00a0100.000\u00a0Einwohner).\u00a0C00\u2010\nC97\u00a0Krebs\u00a0gesamt\u00a0ohne\u00a0sonstige\u00a0Tumoren\u00a0der\u00a0Haut\u00a0(C44),\u00a0incl.\u00a0D0 9.0\u00a0und\u00a0D41.4.\u00a0\nhttps://atlas.gekid.de/Tabellen/Tabellen_D.php.,\u00a0letzter\u00a0Zugrif f\u00a006.12.21\u00a0 \n156\u00a0\n\u00a0GKV\u2010SV\u00a0(2021a).\u00a0Ausgaben\u00a0f\u00fcr\u00a0Arzneimittel\u00a0(Apotheken,\u00a0Versandha ndel\u00a0und\u00a0Sonstige).\u00a02021.\u00a0https://www.gkv\u2010\nspitzenverband.de/media/grafiken/gkv_kennzahlen/kennzahlen_gkv_ 2021_q1/300dpi_11/GKV\u2010\nKennzahlen_Arzneimittel_B_2020_300.jpg,\u00a0letzter\u00a0Zugriff:\u00a009.07. 2021.\u00a0\nGKV\u2010SV\u00a0(2021b).\u00a0Ausgaben\u00a0f\u00fcr\u00a0einzelne\u00a0Leistungsbereiche\u00a0der\u00a0GKV \u00a02020\u00a0in\u00a0Mrd.\u00a0Euro.\u00a02021.\u00a0https://www.gkv\u2010\nspitzenverband.de/media/grafiken/gkv_kennzahlen/kennzahlen_gkv_ 2021_q1/300dpi_11/GKV\u2010\nKennzahlen_Leistungsbereiche_Euro_2020_300.jpg,\u00a0letzter\u00a0Zugriff :\u00a009.07.2021.\u00a0\nGKV\u2010SV\u00a0(2021c).\u00a0Ausgaben\u00a0f\u00fcr\u00a0einzelne\u00a0Leistungsbereiche\u00a0der\u00a0GKV \u00a02020\u00a0in\u00a0Prozent.\u00a02021.\u00a0https://www.gkv\u2010\nspitzenverband.de/media/grafiken/gkv_kennzahlen/kennzahlen_gkv_ 2021_q1/300dpi_11/GKV\u2010\nKennzahlen_Leistungsbereiche_Prozent_2020\u20101_300.jpg,\u00a0letzter\u00a0Zu griff:\u00a009.07.2021.\u00a0\nGKV\u2010SV\u00a0(2021d).\u00a0Echte\u00a0Arzneimittelinnovationen\u00a0f\u00f6rdern\u00a0und\u00a0die\u00a0 Versorgung\u00a0st\u00e4rken.\u00a02021.\u00a0https://www.gkv\u2010\nspitzenverband.de/media/dokumente/service_1/publikationen/20210 716_Positionspapier_Arzneimittelinnovatione\nn_barrierefrei.pdf,\u00a0letzter\u00a0Zugriff:\u00a031.07.2021.\u00a0\nGKV\u2010SV\u00a0(2021e).\u00a0Leistungsausgaben\u00a0insgesamt:\u00a0Entwicklung\u00a02016\u00a0\u2010 \u00a02020.\u00a02021.\u00a0https://www.gkv\u2010\nspitzenverband.de/media/grafiken/gkv_kennzahlen/kennzahlen_gkv_ 2021_q1/300dpi_11/GKV\u2010\nKennzahlen_Leistungsausg_insg_B_2020_300.jpg,\u00a0letzter\u00a0Zugriff:\u00a0 09.07.2021.\u00a0\nGlaeske\u00a0G,\u00a0Broich\u00a0K,\u00a0Dicheva\u2010Rad ev\u00a0S,\u00a0Fuchs\u00a0D,\u00a0Haberkamp\u00a0M,\u00a0Hin neburg\u00a0I\u00a0et\u00a0al.\u00a0(2020).\u00a0Innovationsreport\u00a02020.\u00a02020.\u00a0\nhttps://www.socium.uni\u2010bremen.de/uploads/News/2020/Innovationsr eport_2020_Kurzfassung.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\n28.07.2021.\u00a0\nGlaeske\u00a0G,\u00a0Dicheva\u2010Radev\u00a0S,\u00a0Fuchs\u00a0D,\u00a0G\u00fcnther\u00a0J,\u00a0Hinneburg\u00a0I,\u00a0Mu th\u00a0L\u00a0et\u00a0al.\u00a0(2018).\u00a0Innovationsreport\u00a02018.\u00a02018.\u00a0\nhttps://www.socium.uni\u2010bremen. de/uploads/News/2018/121124_Innov ationsreport_2018_Kurzfassung.pdf,\u00a0letzter\u00a0\nZugriff:\u00a028.07.2021.\u00a0\nGlaeske\u00a0G,\u00a0Dicheva\u2010Radev\u00a0S,\u00a0Fuch s\u00a0D,\u00a0Hinneburg\u00a0I,\u00a0L\u00fcbs\u00a0A,\u00a0Moraw etz\u00a0AS\u00a0et\u00a0al.\u00a0(2019).\u00a0Innovationsreport\u00a02019.\u00a02019.\u00a0\nhttps://www.socium.uni\u2010bremen. de/uploads/News/2019/190930_Langf assung_Innovationsreport_2019.pdf,\u00a0\nletzter\u00a0Zugriff:\u00a029.07.2021.\u00a0\nGlaeske\u00a0G,\u00a0Ludwig\u00a0W\u2010D,\u00a0Wei\u00dfbach\u00a0L\u00a0(2017).\u00a0Pflicht\u00a0zur\u00a0sp\u00e4ten\u00a0Nu tzenbewertung.\u00a0Deutsches\u00a0\u00c4rzteblatt\u00a0114(45).\u00a0\nHaas\u00a0A\u00a0(08.07.2016).\u00a0Nutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0und\u00a0Erst attung.\u00a0Vortrag.\u00a0Berlin.\u00a0\nHendrickx\u00a0A\u00a0(11.06.2021).\u00a0AIM\u2019s\u00a0European\u00a0fair\u00a0price\u00a0calculator\u00a0 for\u00a0medicines.\u00a0Vor trag.\u00a0Br\u00fcssel.\u00a0\nhil\u00a0(2019).\u00a0Streit\u00a0um\u00a0 WHO\u2010Resolution\u00a0f\u00fcr\u00a0mehr\u00a0Transparenz\u00a0bei\u00a0A rzneimittelkosten.\u00a02019.\u00a0\nhttps://www.aerzteblatt.de/nachrichten/103372/Streit\u2010um\u2010WHO\u2010Res olution\u2010fuer\u2010mehr\u2010Transparenz\u2010bei\u2010\nArzneimittelkosten,\u00a0letzter\u00a0Zugriff:\u00a013.07.2021.\u00a0\nIyengar\u00a0S,\u00a0Tay\u2010Teo\u00a0K,\u00a0Vogler\u00a0S,\u00a0Be yer\u00a0P,\u00a0Wiktor\u00a0S,\u00a0Joncheere\u00a0K\u00a0 de\u00a0et\u00a0al.\u00a0(2016).\u00a0Prices,\u00a0Costs,\u00a0and\u00a0Affordability\u00a0of\u00a0New\u00a0Medic ines\u00a0for\u00a0\nHepatitis\u00a0C\u00a0in\u00a030\u00a0Countries.\u00a0PLoS\u00a0medicine\u00a013(5).\u00a0\nKirschner\u00a0J,\u00a0Fuchs\u00a0D,\u00a0Richter\u00a0L,\u00a0Glaeske\u00a0G\u00a0(2020).\u00a0Spinale\u00a0Musk elatrophie.\u00a0In:\u00a0Glaeske,\u00a0G\u00a0(Hrsg. )\u00a0Innovationsreport.\u00a0Bremen:\u00a0\nEigenverlag:\u00a0325\u2013350.\u00a0\nLaschet\u00a0H\u00a0(2014).\u00a0Hepatitis\u00a0C\u00a0\u2010\u00a0Eine\u00a0Arznei\u00a0wertvoller\u00a0als\u00a0Gold .\u00a02014.\u00a0https://www.aerztezeitung .de/Politik/Eine\u2010Arznei\u2010wertvo ller\u2010\nals\u2010Gold\u2010242458.html,\u00a0letzter\u00a0Zugriff:\u00a004.08.2021.\u00a0\nMoon\u00a0S,\u00a0Mariat\u00a0S,\u00a0Kamae\u00a0I,\u00a0Pedersen\u00a0HB\u00a0(2020).\u00a0Defining\u00a0the\u00a0con cept\u00a0of\u00a0fair\u00a0pricing\u00a0for\u00a0medicin es.\u00a0BMJ\u00a0(Clinical\u00a0research\u00a0ed.) \u00a0368.\u00a0\nNaumann\u2010Winter\u00a0F,\u00a0Haberkamp\u00a0M,\u00a0L\u00f6bker\u00a0W,\u00a0Broich\u00a0K\u00a0(2020).\u00a0Zulas sung\u00a0von\u00a0Nusinersen\u00a0durch\u00a0FDA\u00a0und\u00a0EMA.\u00a0In:\u00a0Glaeske,\u00a0G\u00a0\n(Hrsg.)\u00a0Innovationsreport.\u00a0Bre men:\u00a0Eigenverlag:\u00a0351\u2010362.\u00a0 \n157\u00a0\n\u00a0Newton\u00a0M,\u00a0Scott\u00a0K,\u00a0Troein\u00a0P\u00a0(2021).\u00a0EFPIA\u00a0Patients\u00a0W.A.I.T.\u00a0Ind icator\u00a02020\u00a0Survey.\u00a02021.\u00a0\nhttps://www.efpia.eu/media/602652/efpia\u2010patient\u2010wait\u2010indicator\u2010 final\u2010250521.pdf,\u00a0letzter\u00a0Zugriff:\u00a013.07.2021.\u00a0\nOsterloh\u00a0F\u00a0(2021).\u00a0Die\u00a0erzielbare n\u00a0Einsparungen\u00a0sind\u00a0durch\u00a0eine n\u00a0wesentlichen\u00a0Konstruktionsfehler\u00a0begrenzt.\u00a02021.\u00a0\nhttps://www.aerzteblatt.de/nachr ichten/120633/Die\u2010erzielbaren\u2010E insparungen\u2010sind\u2010durch\u2010einen\u2010wesentlichen\u2010\nKonstruktionsfehler\u2010begrenzt,\u00a0letzter\u00a0Zugriff:\u00a012.07.2021.\u00a0\nR\u00e9muzat\u00a0C,\u00a0Urbinati\u00a0D,\u00a0Mzoughi\u00a0O ,\u00a0El\u00a0Hammi\u00a0E,\u00a0Belgaied\u00a0W,\u00a0Toumi \u00a0M\u00a0(2015).\u00a0Overview\u00a0of\u00a0external\u00a0reference\u00a0pricing\u00a0systems\u00a0in\u00a0\nEurope.\u00a0Journal\u00a0of\u00a0market\u00a0access\u00a0&\u00a0health\u00a0policy\u00a03.\u00a0\nRKI\u00a0(2021).\u00a0Krebsarten.\u00a02021.\u00a0htt ps://www.krebsdaten.de/Krebs/D E/Content/Krebsarten/krebsarten_node.html,\u00a0letzter\u00a0Zugriff:\u00a0\n29.07.2021.\u00a0\nSchwabe\u00a0U,\u00a0Ludwig\u00a0W\u2010D\u00a0(2020).\u00a0Arzneiverordnungs\u2010Report\u00a02020.\u00a0Be rlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\nSucker\u2010Sket\u00a0K\u00a0(2018).\u00a0Sieben\u00a0Jahre[n]\u00a0Haft\u00a0f\u00fcr\u00a0\u201ePharma\u00a0Bro\u201c\u00a0Shk reli.\u00a02018.\u00a0https ://www.deutsche\u2010apotheker\u2010\nzeitung.de/news/artikel/2018/03/12/sieben\u2010jahren\u2010haft\u2010fuer\u2010shkr eli,\u00a0letzter\u00a0Zugriff:\u00a003.08.2021.\u00a0\nSucker\u2010Sket\u00a0K\u00a0(2021).\u00a0Aspen\u00a0senkt\u00a0Preise\u00a0f\u00fcr\u00a0sechs\u00a0Krebsarzneim ittel.\u00a02021.\u00a0https://www.deutsche\u2010apotheker\u2010\nzeitung.de/news/artikel/2021/02/10/aspen\u2010senkt\u2010preise\u2010fuer\u2010sech s\u2010krebsarzneimittel,\u00a0letzter\u00a0Zugriff:\u00a003.08.2021.\u00a0\nvan\u00a0der\u00a0Gronde\u00a0T,\u00a0Uyl\u2010de\u00a0Groot\u00a0CA,\u00a0Pieters\u00a0T\u00a0(2017).\u00a0Addressing \u00a0the\u00a0challenge\u00a0of\u00a0high\u2010priced\u00a0prescription\u00a0drugs\u00a0in\u00a0the\u00a0era\u00a0of\u00a0\nprecision\u00a0medicine.\u00a0PloS\u00a0one\u00a012(8).\u00a0\nVogler\u00a0S,\u00a0Schneider\u00a0P,\u00a0Zimmerman n\u00a0N,\u00a0Zuba\u00a0M\u00a0(2018).\u00a0Preisvergle ich\u00a0ausgabenstarker\u00a0Arzneispezia lit\u00e4ten\u00a02017\u00a0\u2010\u00a0Kurzbericht.\u00a0201 8.\u00a0\nhttps://jasmin.goeg.at/428/2/GOeG_Preisstudie2017_Kurzbericht_d t_0F.pdf,\u00a0letzter\u00a0Zugriff:\u00a012.07.2021.\u00a0\nVogler\u00a0S,\u00a0Vitry\u00a0A,\u00a0Babar\u00a0Z\u2010U\u2010D\u00a0(2016).\u00a0Cancer\u00a0drugs\u00a0in\u00a016\u00a0Europ ean\u00a0countries,\u00a0Australia,\u00a0and\u00a0New\u00a0Zealand.\u00a0The\u00a0Lancet\u00a0Oncology\u00a0\n17(1).\u00a0\nZiegler\u00a0J\u00a0(2014a).\u00a0Mondpreise\u00a0f\u00fcr\u00a0Sovaldi\u00a0\u2010\u00a0Entwicklung\u00a0macht\u00a0R egierung\u00a0nachdenklich.\u00a02014.\u00a0https://www.deutsche\u2010apotheker\u2010\nzeitung.de/news/artikel/2014/09/29/entwicklung\u2010macht\u2010regierung\u2010 nachdenklich,\u00a0letzter\u00a0Zugriff:\u00a003.08.2021.\u00a0\nZiegler\u00a0J\u00a0(2014b).\u00a0Sovaldi\u00a0macht\u00a0nachdenklich\u00a0\u2010\u00a0Verfahren\u00a0der\u00a0f r\u00fchen\u00a0Nutzenbewertung\u00a0unter\u00a0Beobachtung.\u00a0Deutsche\u00a0\nApothekerzeitung\u00a0154(40).\u00a0 \u00a0 \n158\u00a0\n\u00a0\u00a0 \u00a0 \n159\u00a0\n\u00a08 Blick\u00a0in\u00a0die\u00a0Zukunft:\u00a0Evidenz\u00a0\n Generierung\u00a08.1\nEinrichtung\u00a0einer\u00a0Kommission\u00a0der \u00a0Versorgungsforschung\u00a0im\u00a0Sinne\u00a0 eines\u00a0\u201eClea\u2010\nringhouses\u201c\u00a0\nAngesicht\u00a0fehlender\u00a0Evidenz\u00a0empfehlen\u00a0Chalkidou\u00a0et\u00a0al.\u00a0(2008),\u00a0 dass\u00a0Entscheidun\u2010\ngen\u00a0 zur\u00a0 Finanzierung\u00a0 von\u00a0 neuen\u00a0 Technologien\u00a0 im\u00a0 Gesundheitswesen \u00a0 in\u00a0 einen\u00a0\nbreiteren\u00a0Kontext\u00a0der\u00a0Forschungsp olitik\u00a0eingegliedert\u00a0werden\u00a0so llten.\u00a0In\u00a0diesem\u00a0\nZusammenhang\u00a0gewinnt\u00a0die\u00a0Versorgungsforschung,\u00a0ein\u00a0relativ\u00a0neue s\u00a0Forschungs\u2010\ngebiet\u00a0in\u00a0Deutschland,\u00a0zusammen\u00a0mit\u00a0der\u00a0klinischen\u00a0Forschung\u00a0un d\u00a0dem\u00a0Health\u00a0\nTechnology\u00a0Assessment \u00a0an\u00a0Bedeutung.\u00a0Im\u00a0Fokus\u00a0der\u00a0Versorgungsforschung\u00a0steht\u00a0\nder\u00a0Bedarf,\u00a0die\u00a0Qualit\u00e4t\u00a0(Prozess,\u00a0Ergebnis)\u00a0und\u00a0die\u00a0Verbesseru ng\u00a0der\u00a0im\u00a0Alltag\u00a0des\u00a0\nSystems\u00a0erbrachten\u00a0Versorgung.\u00a0Sie\u00a0evaluiert\u00a0und\u00a0f\u00f6rdert\u00a0somit\u00a0 den\u00a0Innovations\u2010\ntransfer\u00a0aus\u00a0klinischen\u00a0Studien\u00a0 (efficacy)\u00a0in\u00a0die\u00a0klinische\u00a0Praxis\u00a0 (effectiveness) .\u00a0\nUm\u00a0die\u00a0Evidenzl\u00fccken \u00a0im\u00a0Allgemeinen,\u00a0bei\u00a0 Orphan\u00a0Drugs \u00a0sowie\u00a0im\u00a0Speziellen\u00a0in\u00a0der\u00a0\nOnkologie\u00a0mit\u00a0hohem\u00a0Bedarf,\u00a0d.\u00a0h.\u00a0 unmet\u00a0medical\u00a0need ,\u00a0zu\u00a0f\u00fcllen,\u00a0bedarf\u00a0es\u00a0einer\u00a0\neigenen\u00a0Kommission,\u00a0di e\u00a0als\u00a0Koordinierungsgremium\u00a0im\u00a0Sinne\u00a0eine s\u00a0Clearinghou\u2010\nses\u00a0die\u00a0Aufgabe\u00a0der\u00a0Forschungskoordinierung\u00a0und\u00a0\u2013genehmigung\u00a0zwisc hen\u00a0der\u00a0\nNeuzulassung\u00a0innovativer\u00a0Arzneimittel\u00a0bis\u00a0zur\u00a0Bewertung\u00a0durch\u00a0d as\u00a0Institut\u00a0f\u00fcr\u00a0\nQualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0im\u00a0Gesundheitswesen\u00a0zur\u00a0Evidenz generierung\u00a0auf\u00a0\nGrundlage\u00a0 vorab\u00a0 abgestimmter\u00a0 Regeln\u00a0 und\u00a0 Kriterien\u00a0 \u00fcbernimmt.\u00a0 Di e\u00a0 Zeit\u00a0 der\u00a0\nUnsicherheit\u00a0\u00fcber\u00a0die\u00a0 effectiveness \u00a0neuer\u00a0Arzneimittel\u00a0wird\u00a0mit\u00a0mindestens\u00a0zwei\u00a0\nbis\u00a0drei\u00a0Jahren\u00a0kalkuliert,\u00a0wenn\u00a0Qualit\u00e4tskriterien\u00a0von\u00a0klinisc hen\u00a0Studien\u00a0eingehal\u2010\nten\u00a0und\u00a0eine\u00a0gro\u00dfe\u00a0Anzahl\u00a0an\u00a0Patienten\u00a0in\u00a0Studien\u00a0eingeschlosse n\u00a0werden\u00a0sollen.\u00a0\nAlle\u00a0Wege\u00a0der\u00a0Evidenzgenerierung \u00a0(Register,\u00a0Nicht\u2010interventione lle\u00a0Studien,\u00a0 Hori\u2010\nzon\u00a0Scanning \u00a0Systeme,\u00a0 Mini\u2010Health\u00a0Technology\u00a0Assessments ,\u00a0kontrollierte\u00a0klini\u2010\nsche\u00a0Studien)\u00a0und\u00a0alle\u00a0m\u00f6glichen\u00a0Datenlieferer\u00a0(Kliniken,\u00a0Ambul anzen\u00a0in\u00a0Kliniken,\u00a0\nambulante\u00a0 Schwerpunktpraxen)\u00a0 sowie\u00a0 Sponsoren\u00a0 (Industrie\u00a0 und\u00a0 ind ustrie\u2010\nunabh\u00e4ngige\u00a0Sponsoren)\u00a0sollten\u00a0grunds\u00e4tzlich\u00a0in\u00a0Betracht\u00a0gezoge n\u00a0werden,\u00a0um\u00a0\nEvidenz\u00a0\u00fcber\u00a0den\u00a0Nutzen\u00a0und\u00a0das\u00a0Ri siko\u00a0von\u00a0neuen\u00a0onkologischen\u00a0 Arzneimitteln\u00a0so\u00a0\nrasch\u00a0wie\u00a0m\u00f6glich\u00a0zu\u00a0sammeln.\u00a0Ausschlaggebend\u00a0ist,\u00a0dass\u00a0ein\u00a0Kri terienkatalog\u00a0\ndefiniert\u00a0wird,\u00a0der\u00a0die\u00a0Anforderungen\u00a0an\u00a0qualitative\u00a0Aspekte\u00a0un d\u00a0die\u00a0Defizite\u00a0der\u00a0\nEvidenzgenerierung\u00a0benennt,\u00a0und\u00a0Fr agestellung,\u00a0Studiendesign,\u00a0p rim\u00e4re\u00a0und\u00a0se\u2010\nkund\u00e4re\u00a0Endpunkte\u00a0festlegt.\u00a0\u00a0\nDurch\u00a0klinische\u00a0Krebsregister\u00a0kann\u00a0Transparenz\u00a0insbesondere\u00a0bez \u00fcglich\u00a0der\u00a0Ergeb\u2010\nnisqualit\u00e4t\u00a0der\u00a0erbrachten\u00a0Leistungen\u00a0geschaffen\u00a0werden.\u00a0In\u00a0Kre bsregistern\u00a0wer\u2010\nden\u00a0 sektor\u00fcbergreifend\u00a0 therapeutische\u00a0 Module\u00a0 umfassende\u00a0 prognos erelevante\u00a0\nBefund\u2010\u00a0und\u00a0Behandlungsdaten\u00a0zum\u00a0Zeitpunkt\u00a0der\u00a0Diagnose,\u00a0sowie\u00a0 im\u00a0weiteren\u00a0 \n160\u00a0\n\u00a0Krankheitsverlauf\u00a0(Nachsorge\u00a0mi t\u00a0evtl.\u00a0auftretender\u00a0Progression )\u00a0unter\u00a0Angabe\u00a0des\u00a0\njeweiligen\u00a0Versorgungstr\u00e4gers\u00a0gesammelt.\u00a0Zeitliche\u00a0Vergleiche\u00a0d er\u00a0Ergebnisquali\u2010\nt\u00e4t,\u00a0vor\u00a0und\u00a0nach\u00a0Einf\u00fchrung\u00a0einer\u00a0Innovation,\u00a0mittels\u00a0Krebsreg ister\u00a0erlauben\u00a0das\u00a0\nHerauslesen\u00a0neuer\u00a0 innovativer\u00a0Arzneimitteltherapien.\u00a0\nDiese\u00a0Anforderungen\u00a0an\u00a0die\u00a0Eviden zgenerierung\u00a0sollten\u00a0von\u00a0einer \u00a0Kommission\u00a0\nausgearbeitet\u00a0und\u00a0bestimmt\u00a0werden,\u00a0die\u00a0direkt\u00a0als\u00a0eine\u00a0Untergru ppe\u00a0im\u00a0G\u2010BA\u00a0\neingerichtet\u00a0wird\u00a0oder\u00a0in\u00a0einer\u00a0 G\u2010BA\u00a0nahen\u00a0Institution.\u00a0Diese\u00a0K ommission\u00a0setzt\u00a0\nsich\u00a0aus\u00a0Fachleuten\u00a0zusammen,\u00a0wie\u00a0z.\u00a0B.\u00a0Vertretern\u00a0aus\u00a0Studieng ruppen\u00a0(Kompe\u2010\ntenznetzwerken),\u00a0Klinikern,\u00a0dem\u00a0medizinischen\u00a0Dienst\u00a0und\u00a0Vertre tern\u00a0der\u00a0Arznei\u2010\nmittelkommission\u00a0der\u00a0deutschen\u00a0\u00c4rzteschaft.\u00a0Das\u00a0Gremium\u00a0kann\u00a0\u2013\u00a0 jeweils\u00a0indika\u2010\ntionsorientiert\u00a0\u2013\u00a0Experten\u00a0aus\u00a0der\u00a0ambulanten\u00a0und\u00a0station\u00e4ren\u00a0V ersorgung\u00a0zur\u00a0\nBeratung\u00a0hinzuziehen.\u00a0Nur\u00a0so\u00a0ist\u00a0gew\u00e4hrleistet,\u00a0dass\u00a0praxisnahe r\u00a0medizinischer\u00a0\nSachverstand\u00a0in\u00a0die\u00a0Entscheidungen\u00a0\u00fcber\u00a0die\u00a0Fragestellungen\u00a0und \u00a0das\u00a0Design\u00a0von\u00a0\nStudien\u00a0einflie\u00dft.\u00a0\u00a0\nInitiierung\u00a0klinischer\u00a0Studien\u00a0durch\u00a0die\u00a0Krankenkassen\u00a0\nKassen\u00a0m\u00fcssen\u00a0vor\u00a0allem\u00a0solche\u00a0St udien\u00a0initiieren,\u00a0die\u00a0au\u00dferhal b\u00a0des\u00a0Interesses\u00a0\nvon\u00a0 pharmazeutischen\u00a0 Herstellern\u00a0 l iegen,\u00a0 die\u00a0 aber\u00a0 gleichwohl\u00a0 vo n\u00a0 erheblicher\u00a0\nRelevanz\u00a0im\u00a0Versorgungsalltag\u00a0sind.\u00a0Dabei\u00a0 geht\u00a0es\u00a0um\u00a0den\u00a0direkt en\u00a0Vergleich\u00a0\nunterschiedlicher\u00a0therapeutischer\u00a0 Interventionen\u00a0oder\u00a0gleichart ig\u00a0wirkender\u00a0ver\u2010\nschiedener\u00a0Arzneimittel\u00a0bzw.\u00a0Kom binationen\u00a0von\u00a0verschiedenen\u00a0Th erapieregimen.\u00a0\nIm\u00a0Rahmen\u00a0der\u00a0deutschen\u00a0Gesetzgebung\u00a0ist\u00a0es\u00a0bereits\u00a0nach\u00a0\u00a7\u00a035c\u00a0 SGB\u00a0V\u00a0gesetzlich\u00a0\nm\u00f6glich,\u00a0dass\u00a0der\u00a0\u201ezulassungs\u00fcbe rschreitende\u00a0Einsatz\u00a0von\u00a0Arznei mitteln\u00a0in\u00a0klini\u2010\nschen\u00a0 Pr\u00fcfungen\u201c\u00a0 auf\u00a0 Antrag\u00a0 nicht\u2010industrieller\u00a0 Sponsoren\u00a0 und\u00a0 n ach\u00a0 Pr\u00fcfung\u00a0\ndurch\u00a0den\u00a0Gemeinsamen\u00a0Bundesausschuss\u00a0erstattet\u00a0wird.\u00a0Die\u00a0Ersta ttung\u00a0ist\u00a0an\u00a0\nmehrere\u00a0Bedingungen\u00a0gekn\u00fcpft:\u00a0\n1. Es\u00a0ist\u00a0ein\u00a0\u201etherapierelevante\u00a0 Verbesserung\u00a0 der\u00a0Behandlung\u00a0einer \u00a0\nschwerwiegenden\u00a0 Erkrankung\u201c\u00a0 im \u00a0 Vergleich\u00a0 zu\u00a0 bestehenden\u00a0 Be\u2010\nhandlungsm\u00f6glichkeiten\u00a0zu\u00a0erwarten,\u00a0\n2. die\u00a0damit\u00a0verbundenen\u00a0Mehrkosten\u00a0stehen\u00a0in\u00a0einem\u00a0angemessenen\u00a0\nVerh\u00e4ltnis\u00a0zum\u00a0erwarteten\u00a0me dizinischen\u00a0Zusatznutzen,\u00a0\n3. die\u00a0Behandlung\u00a0erfolgt\u00a0durch\u00a0einen\u00a0Arzt,\u00a0der\u00a0an\u00a0der\u00a0vertrags\u00e4rz tli\u2010\nchen\u00a0 Versorgung\u00a0 oder\u00a0 an\u00a0 der\u00a0 ambulanten\u00a0 Versorgung\u00a0 nach\u00a0 den\u00a0\n\u00a7\u00a7\u00a0116b\u00a0und\u00a0117\u00a0SGB\u00a0V\u00a0teilnimmt.\u00a0\u00a0\nDa\u00a0letztlich\u00a0das\u00a0Ziel\u00a0die\u00a0Zulassungserweiterung\u00a0sein\u00a0soll,\u00a0die\u00a0 aber\u00a0dem\u00a0pharmazeu\u2010\ntischen\u00a0Unternehmen\u00a0zu\u00a0Gute\u00a0kommen\u00a0w\u00fcrde,\u00a0ist\u00a0f\u00fcr\u00a0diesen\u00a0Fall\u00a0a uch\u00a0durch\u00a0den\u00a0\n\u00a7\u00a035c\u00a0SGB\u00a0V\u00a0die\u00a0Regelung\u00a0eingef\u00fchrt\u00a0worden,\u00a0dass\u00a0die\u00a0pharmazeut ische\u00a0Industrie\u00a0\ndie\u00a0Kosten\u00a0an\u00a0die\u00a0Krankenkasse\u00a0zu r\u00fcckerstattet.\u00a0In\u00a0der\u00a0Onkologi e\u00a0gibt\u00a0es\u00a0nicht\u00a0nur\u00a0 \n161\u00a0\n\u00a0Bedarf\u00a0an\u00a0Studien,\u00a0die\u00a0ein\u00a0Arzneimittel\u00a0au\u00dferhalb\u00a0seiner\u00a0zugela ssenen\u00a0Indikation\u00a0\ntesten,\u00a0sondern\u00a0auch\u00a0in\u00a0vergleichenden\u00a0Studien\u00a0mit\u00a0Arzneimittel n\u00a0und\u00a0deren\u00a0Kom\u2010\nbinationen\u00a0 innerhalb\u00a0 der\u00a0 Zulass ungsgrenzen.\u00a0 Durch\u00a0 die\u00a0 Neufassun g\u00a0 des\u00a0 \u00a7\u00a035c\u00a0\nSGB\u00a0V\u00a0soll\u00a0die\u00a0Initiierung\u00a0von\u00a0Arzneimittelstudien\u00a0durch\u00a0nicht\u2010 industrielle\u00a0Sponso\u2010\nren\u00a0und\u00a0die\u00a0Erstattung\u00a0durch\u00a0Krankenkassen\u00a0grunds\u00e4tzlich\u00a0f\u00fcr\u00a0zu gelassene\u00a0Arz\u2010\nneimittel\u00a0m\u00f6glich\u00a0sein,\u00a0unabh\u00e4ngig \u00a0von\u00a0der\u00a0zugelassenen\u00a0Indikat ion,\u00a0wobei\u00a0die\u00a0im\u00a0\n\u00a7\u00a035c\u00a0SGB\u00a0V\u00a0genannten\u00a0Voraussetzungen\u00a0bestehen\u00a0bleiben.\u00a0Die\u00a0pha rmazeutische\u00a0\nIndustrie\u00a0soll\u00a0sich\u00a0sowohl\u00a0an\u00a0den\u00a0Kosten\u00a0der\u00a0Studienmedikation\u00a0 beteiligen,\u00a0als\u00a0\nauch\u00a0an\u00a0den\u00a0Overhead\u2010Kosten\u00a0der\u00a0Studien.\u00a0Damit\u00a0sollen\u00a0sowohl\u00a0Kr ankenkassen\u00a0als\u00a0\nauch\u00a0die\u00a0pharmazeutische\u00a0Industrie\u00a0in\u00a0die\u00a0Verantwortung\u00a0klinisc h\u00a0relevanter\u00a0Stu\u2010\ndien\u00a0 gezogen\u00a0 und\u00a0 Auseinandersetzungen\u00a0 \u00fcber\u00a0 Verantwortungszuweis ungen\u00a0\n\u00fcberwunden\u00a0werden.\u00a0Die\u00a0Krankenkassen\u00a0erhalten\u00a0f\u00fcr\u00a0die\u00a0Studienme dikation\u00a0einen\u00a0\nAbschlag\u00a0von\u00a050\u00a0%\u00a0von\u00a0den\u00a0Herstellern.\u00a0Die\u00a0Finanzierung\u00a0des\u00a0Stu dien\u2010Overheads\u00a0\nerfolgt\u00a0durch\u00a0einen\u00a0Studienfonds, \u00a0in\u00a0den\u00a0die\u00a0Krankenkassen\u00a0als\u00a0 auch\u00a0die\u00a0pharma\u2010\nzeutische\u00a0Industrie\u00a0einzahlen.\u00a0 Krankenkassen\u00a0oder\u00a0stellvertrete nd\u00a0der\u00a0G\u2010BA\u00a0k\u00f6n\u2010\nnen\u00a0entscheiden,\u00a0die\u00a0Erstattung\u00a0neuer\u00a0innovativer\u00a0Arzneimittel\u00a0 (v.\u00a0a.\u00a0\u201eSolisten\u201c)\u00a0\nvon\u00a0der\u00a0Durchf\u00fchrung\u00a0von\u00a0Studien\u00a0zur\u00a0Evidenzgewinnung\u00a0abh\u00e4ngig\u00a0 zu\u00a0machen.\u00a0Es\u00a0\nsollte\u00a0ein\u00a0gesetzlicher\u00a0Auftrag\u00a0an\u00a0Krankenkassen\u00a0ergehen,\u00a0verso rgungsrelevante\u00a0\nStudie\u00a0zu\u00a0initiieren,\u00a0die\u00a0Versorgungsforschung\u00a0und\u00a0die\u00a0Krankenk assen\u00a0sollten\u00a0be\u2010\nz\u00fcglich\u00a0dieses\u00a0Auftrags\u00a0ggf.\u00a0finanziell\u00a0unterst\u00fctzt\u00a0werden.\u00a0Von \u00a0dem\u00a0Evidenzgewinn,\u00a0\nder\u00a0durch\u00a0die\u00a0GKV\u00a0finanziert\u00a0wird,\u00a0profitieren\u00a0letztlich\u00a0auch\u00a0p rivat\u00a0versicherte\u00a0\nPatienten\u00a0und\u00a0ihre\u00a0Kassen.\u00a0Damit\u00a0d ie\u00a0private\u00a0Krankenversicherun g\u00a0(PKV)\u00a0und\u00a0das\u00a0\nLand\u00a0bzw.\u00a0der\u00a0Bund\u00a0f\u00fcr\u00a0die\u00a0Beihilfeempf\u00e4nger\u00a0nicht\u00a0als\u00a0 \u201efree\u2010rider\u201c \u00a0von\u00a0diesen\u00a0\nDaten\u00a0profitieren,\u00a0k\u00f6nnte\u00a0ein\u00a0gemeinsamer\u00a0Studienfond\u00a0eingerich tet\u00a0werden,\u00a0an\u00a0\ndem\u00a0sich\u00a0die\u00a0PKV,\u00a0sowie\u00a0die\u00a0L\u00e4nder\u00a0und\u00a0der\u00a0Bund\u00a0anteilig\u00a0gemess en\u00a0an\u00a0der\u00a0be\u2010\ntroffenen\u00a0Population\u00a0der\u00a0Privatve rsicherten\u00a0und\u00a0Beihilfeempf\u00e4ng er\u00a0mitbeteiligen.\u00a0\nFinanzierung\u00a0durch\u00a0Marketingsteuer\u00a0\nDas\u00a0Beispiel\u00a0der\u00a0italienischen\u00a0Zulassungsbeh\u00f6rde\u00a0(AIFA)\u00a0illustr iert\u00a0eine\u00a0weitere\u00a0\nL\u00f6sung\u00a0industrie\u2010unabh\u00e4ngiger\u00a0Forschung.\u00a0Die\u00a0pharmazeutischen\u00a0U nternehmen\u00a0\nzahlen\u00a0eine\u00a0prozentuale\u00a0Abgabe\u00a0von\u00a05\u00a0%\u00a0f\u00fcr\u00a0jeden\u00a0Euro,\u00a0den\u00a0sie\u00a0 in\u00a0die\u00a0Vermark\u2010\ntung\u00a0ihrer\u00a0Produkte\u00a0investieren,\u00a0in\u00a0einen\u00a0Pool\u00a0ein,\u00a0aus\u00a0dem\u00a0die \u00a0AIFA\u00a0Studien\u00a0finan\u2010\nzieren\u00a0kann.\u00a0In\u00a0den\u00a0ersten\u00a0drei\u00a0Jahren\u00a0dieses\u00a0Programms\u00a0standen \u00a045\u00a0Millionen\u00a0\nEuro\u00a0pro\u00a0Jahr\u00a0zu\u00a0jeweils\u00a050\u00a0%\u00a0zur\u00a0industrie\u2010unabh\u00e4ngigen\u00a0Forsch ung\u00a0und\u00a0zur\u00a0Er\u2010\nstattung\u00a0 von\u00a0 orphan\u00a0 und\u00a0 lebensrettenden\u00a0 Arzneimitteln\u00a0 zur\u00a0 Verf\u00fcgung\u00a0 (AIFA,\u00a0\n2010).\u00a0Im\u00a0Fokus\u00a0des\u00a0Interesses\u00a0der\u00a0AIFA\u00a0stehen:\u00a0\u00a0\n1. Studien\u00a0an\u00a0 Orphan\u00a0Drugs ,\u00a0Studien\u00a0zur\u00a0 off\u2010label\u00a0Anwendungen\u00a0von\u00a0\nArzneimitteln\u00a0zur\u00a0Behandlung\u00a0von\u00a0seltenen\u00a0Erkrankungen,\u00a0Nutzen\u2010\nRisiko\u2010Bewertungen\u00a0von\u00a0Therapien\u00a0f\u00fcr\u00a0Patienten,\u00a0die\u00a0nicht\u00a0auf\u00a0d ie\u00a0 \n162\u00a0\n\u00a0Standardtherapie\u00a0ansprechen.\u00a0Die\u00a0AIFA\u00a0legte\u00a0fest,\u00a0dass\u00a0all\u00a0dies e\u00a0Stu\u2010\ndien\u00a0ein\u00a0vergleichendes\u00a0 Design\u00a0haben\u00a0sollten.\u00a0\n2. Vergleichende\u00a0 Studien\u00a0 der\u00a0 Phase\u00a0 III\u2010IV,\u00a0 die\u00a0 Arzneimittel\u00a0 head\u2010to\u2010\nhead\u00a0 hinsichtlich\u00a0 ihres\u00a0 Nutzen\u2010Risiko\u2010Profils\u00a0 miteinander\u00a0 verglei\u2010\nchen.\u00a0Als\u00a0Bedingung\u00a0wurde\u00a0festge legt,\u00a0dass\u00a0mindestens\u00a0eines\u00a0der \u00a0\nArzneimittel\u00a0durch\u00a0die\u00a0gesetzliche\u00a0Krankenkasse\u00a0( Italien\u00a0NHS )\u00a0erstat\u2010\ntet\u00a0wurde.\u00a0\n3. Therapieoptimierung,\u00a0Pharmakovi gilanz\u00a0und\u00a0Versorgungsforschung\u00a0\nsollen\u00a0zur\u00a0Verbesserung\u00a0der\u00a0Erkenntnisse\u00a0zu\u00a0bereits\u00a0zugelassene n\u00a0\nArzneimitteln\u00a0mit\u00a0noch\u00a0l\u00fcckenhafter\u00a0Datenlage\u00a0mit\u00a0Fokus\u00a0auf\u00a0das \u00a0Ri\u2010\nsiko\u2010Nutzen\u2010Profil\u00a0beitragen.\u00a0In\u00a0diesem\u00a0Bereich\u00a0werden\u00a0auch\u00a0For \u2010\nschungsantr\u00e4ge\u00a0 f\u00fcr\u00a0 systemati sche\u00a0 \u00dcbersichtsarbeiten\u00a0 ( Systematic\u00a0\nReviews)\u00a0zur\u00a0Entdeckung\u00a0von\u00a0Erkenntnisl\u00fccken\u00a0akzeptiert.\u00a0\nEin\u00a0weiteres\u00a0Konzept:\u00a0 Horizon\u00a0Scanning \u00a0System\u00a0zur\u00a0Fr\u00fcherkennung\u00a0und\u00a0Bewer\u2010\ntung\u00a0von\u00a0neuen\u00a0medikament\u00f6sen\u00a0Therapiekonzepten\u00a0vor\u00a0der\u00a0Zulassu ng\u00a0\u00a0\nDurch\u00a0die\u00a0Einf\u00fchrung\u00a0von\u00a0 Horizon\u00a0Scanning \u00a0Systemen\u00a0f\u00fcr\u00a0die\u00a0fr\u00fche\u00a0Identifizierung\u00a0\nund\u00a0Evaluierung\u00a0neuer\u00a0Arzneimitte ltherapien\u00a0in\u00a0der\u00a0Onkologie\u00a0vo r\u00a0der\u00a0routinem\u00e4\u2010\n\u00dfigen\u00a0Anwendung\u00a0sollen\u00a0die\u00a0Entscheider\u00a0im\u00a0Gesundheitswesen\u00a0bei\u00a0 Allokationsent\u2010\nscheidungen,\u00a0z.\u00a0B.\u00a0in\u00a0der\u00a0Budgetplanung,\u00a0unterst\u00fctzt\u00a0werden.\u00a0\nHorizon\u00a0Scanning \u00a0Systeme\u00a0zur\u00a0Fr\u00fcherkennung\u00a0und\u00a0 Bewertung\u00a0von\u00a0neuen\u00a0Arznei\u2010\nmitteln\u00a0bzw.\u00a0medikament\u00f6sen\u00a0Therapiekonzepten\u00a0sind\u00a0in\u00a0Gro\u00dfbrita nnien,\u00a0Norwe\u2010\ngen,\u00a0Schweden,\u00a0Belgien,\u00a0Kanada \u00a0und\u00a0Australien\u00a0bereits\u00a0eingef\u00fchr t\u00a0worden\u00a0und\u00a0bei\u00a0\nden\u00a0dortigen\u00a0HTA\u2010Organisationen\u00a0 angesiedelt.\u00a0In\u00a0\u00d6sterreich\u00a0wurd e\u00a0im\u00a0Jahre\u00a02007\u00a0\nvom\u00a0Ludwig\u00a0Boltzmann\u00a0Institut\u00a0(LBI),\u00a0der\u00a0\u00f6sterreichischen\u00a0 Health\u00a0Technology\u00a0As\u2010\nsessment \u00a0 \u2010Organisation,\u00a0 ein\u00a0 Pilotprojekt\u00a0 zu\u00a0 Horizon\u00a0 Scanning \u00a0S y s t e m e n \u00a0i n \u00a0d e r \u00a0\nOnkologie\u00a0durchgef\u00fchrt\u00a0(LBI,\u00a02008).\u00a0Im\u00a0Fokus\u00a0solcher\u00a0Fr\u00fchwarnsy steme\u00a0stehen\u00a0\nneue\u00a0Arzneimittel\u00a0bzw.\u00a0neue\u00a0Anwendungsgebiete\u00a0bestehender\u00a0Arzne imittel,\u00a0die\u00a0\neiner\u00a0raschen\u00a0Neubewertung\u00a0bez\u00fcg lich\u00a0ihrer\u00a0sozialen\u00a0und\u00a0\u00f6konomi schen\u00a0Auswir\u2010\nkungen\u00a0unterzogen\u00a0werden\u00a0sollen\u00a0oder\u00a0die\u00a0\u00c4nderungen\u00a0in\u00a0den\u00a0klin ischen\u00a0Empfeh\u2010\nlungen\u00a0und\u00a0Leitlinien\u00a0nach\u00a0sich\u00a0ziehen.\u00a0\u00a0\nErfahrungen\u00a0aus\u00a0Gro\u00dfbritannien\u00a0zeigen,\u00a0dass\u00a0sich\u00a0insbesondere\u00a0d er\u00a0Kontakt\u00a0mit\u00a0\nForschern\u00a0und\u00a0der\u00a0Industrie,\u00a0mit\u00a0 medizinischen\u00a0Fachzeitschrifte n\u00a0und\u00a0Konferen\u2010\nzen,\u00a0Kooperationen\u00a0mit\u00a0Registern\u00a0und\u00a0Arzneimittelinstituten,\u00a0Um fragen\u00a0bei\u00a0Fach\u2010\ngesellschaften,\u00a0Kliniken\u00a0und\u00a0pers\u00f6 nliche\u00a0Kontakte\u00a0zu\u00a0Spezialist en\u00a0als\u00a0n\u00fctzlich\u00a0er\u2010\nwiesen\u00a0hat,\u00a0neue,\u00a0sich\u00a0noch\u00a0in\u00a0der\u00a0Entwicklung\u00a0befindende\u00a0Wirks toffe\u00a0zu\u00a0identifi\u2010\nzieren,\u00a0die\u00a0f\u00fcr\u00a0die\u00a0Versorgung \u00a0relevant\u00a0werden\u00a0k\u00f6nnten.\u00a0\u00a0 \n163\u00a0\n\u00a0In\u00a0dem\u00a0\u00f6sterreichischen\u00a0Pilotprojekt\u00a0wurde\u00a0ein\u00a0Expertenpanel\u00a0vo n\u00a0drei\u00a0Onkologen\u00a0\neingesetzt,\u00a0die\u00a0anhand\u00a0eines\u00a0Priorisierungsinstruments\u00a0ein\u00a0Arzn eimittel\u2010Ranking\u00a0\ndurchf\u00fchren\u00a0sollten.\u00a0Es\u00a0zeigt\u00a0sich\u00a0dabei,\u00a0dass\u00a0es\u00a0sinnvoll\u00a0ist, \u00a0die\u00a0ausgew\u00e4hlten\u00a0\nWirkstoffe\u00a0in\u00a0Indikationsgruppen\u00a0zusammenzufassen\u00a0und\u00a0von\u00a0Fachg ebietsspezia\u2010\nlisten,\u00a0sowie\u00a0Vertretern\u00a0von\u00a0Arzneimittelkommissionen\u00a0aus\u00a0Krank enh\u00e4usern\u00a0be\u2010\ngutachten\u00a0zu\u00a0lassen,\u00a0da\u00a0diese\u00a0am\u00a0besten\u00a0den\u00a0m\u00f6glichen\u00a0Platz\u00a0die ser\u00a0neuen\u00a0Wirk\u2010\nstoffe\u00a0 in\u00a0 der\u00a0 Therapie\u00a0 bestimmen\u00a0 k\u00f6nnen.\u00a0 Die\u00a0 individuellen\u00a0 Bewe rtungen\u00a0 der\u00a0\neinzelnen\u00a0 Arzneimittel\u00a0 k\u00f6nnen\u00a0 aber\u00a0 durchaus\u00a0 unterschiedlich\u00a0 aus fallen,\u00a0 daher\u00a0\nwerden\u00a0 Konsensuskonferenzen\u00a0 und\u00a0 Delphi\u2010Verfahren\u00a0 zur\u00a0 Abstimmung \u00a0v o r g e \u2010\nschlagen.\u00a0\nEine\u00a0fr\u00fchere\u00a0Bewertung\u00a0wird\u00a0immer\u00a0erschwert\u00a0sein\u00a0durch\u00a0die\u00a0fehl ende\u00a0Evidenz\u00a0\nund\u00a0den\u00a0begrenzten\u00a0Zugang\u00a0zu\u00a0Informationen.\u00a0Daten,\u00a0mit\u00a0denen\u00a0di e\u00a0\u00f6konomi\u2010\nschen\u00a0Auswirkungen\u00a0auf\u00a0Krankenhausbudgets\u00a0und\u00a0das\u00a0Budget\u00a0der\u00a0Kr ankenkassen\u00a0\nberechnet\u00a0werden\u00a0k\u00f6nnten,\u00a0fehlen.\u00a0In\u00a0diesem\u00a0fr\u00fchen\u00a0Stadium\u00a0st\u00fcn den\u00a0nur\u00a0Daten\u00a0\nder\u00a0pharmazeutischen\u00a0Industrie\u00a0zur\u00a0Verf\u00fcgung,\u00a0die\u00a0von\u00a0der\u00a0Indus trie\u00a0f\u00fcr\u00a0die\u00a0Be\u2010\nwertungsprozesse\u00a0zur\u00a0Verf\u00fcgung\u00a0gestellt\u00a0werden\u00a0sollten.\u00a0\nHorizon\u00a0Scannning \u00a0Systeme\u00a0sind\u00a0in\u00a0der\u00a0Zwischenzeit\u00a0international\u00a0weit\u00a0verbreitet .\u00a0\nSie\u00a0werden\u00a0z.\u00a0B.\u00a0in\u00a0Australien,\u00a0B elgien,\u00a0Zypern,\u00a0in\u00a0der\u00a0Tschech ischen\u00a0Republik,\u00a0in\u00a0\nFrankreich,\u00a0in\u00a0den\u00a0Niederlanden\u00a0und\u00a0in\u00a0Schweden\u00a0genutzt.\u00a0Eine\u00a0i m\u00a0Jahre\u00a02018\u00a0ins\u00a0\nLeben\u00a0gerufene\u00a0Initiative\u00a0mit\u00a0Na men\u00a0BeNeLuxA\u00a0(Belgien,\u00a0Niederla nde,\u00a0Luxemburg\u00a0\u00a0\nund\u00a0\u00d6sterreich)\u00a0l\u00e4dt\u00a0alle\u00a0anderen\u00a0 L\u00e4nder\u00a0ein,\u00a0sich\u00a0an\u00a0diesem\u00a0Zu sammenschluss\u00a0zu\u00a0\nbeteiligen.\u00a0Dies\u00a0ist\u00a0auch\u00a0unter\u00a0dem\u00a0Aspekt\u00a0nachvollziehbar,\u00a0das s\u00a0sich\u00a0der\u00a0Pharma\u2010\nmarkt\u00a0in\u00a0der\u00a0Zwischenzeit\u00a0als\u00a0gl obaler\u00a0Markt\u00a0international\u00a0agie render\u00a0pharmazeu\u2010\ntischer\u00a0Unternehmen\u00a0entwickelt\u00a0hat\u00a0und\u00a0die\u00a0Bewertung\u00a0der\u00a0gleich en\u00a0Mittel\u00a0in\u00a0\nunterschiedlichen\u00a0L\u00e4ndern\u00a0nicht\u00a0unterschiedlich\u00a0ausfallen\u00a0sollt e.\u00a0Die\u00a0evidenzba\u2010\nsierte\u00a0Beurteilung\u00a0neuer\u00a0Arzneimittel\u00a0ist\u00a0unter\u00a0Ber\u00fccksichtigun g\u00a0der\u00a0Methodik\u00a0der\u00a0\nEvidenz\u00a0unteilbar\u00a0\u2013\u00a0insofern\u00a0ist\u00a0eine\u00a0international\u00a0abgestimmte \u00a0Strategie\u00a0der\u00a0Be\u2010\nwertung\u00a0neuer\u00a0Arzneimittel\u00a0ein\u00a0wi chtiger\u00a0Schritt\u00a0auf\u00a0dem\u00a0Weg\u00a0zu \u00a0einer\u00a0gemeinsa\u2010\nmen\u00a0Reaktion\u00a0staatlicher\u00a0Gesundheitssystems\u00a0gegen\u00fcber\u00a0den\u00a0Anbie tern\u00a0aus\u00a0den\u00a0\nReihen\u00a0der\u00a0pharmzeutischen\u00a0Hersteller\u00a0(OECD,\u00a02019).\u00a0\nEine\u00a0europ\u00e4ische\u00a0Vision\u00a0\nDie\u00a0bestehende\u00a0Kollaboration\u00a0nat ionaler\u00a0HTA\u2010Organisationen\u00a0(EUn etHTA)\u00a0kann\u00a0als\u00a0\nintergouvernementales\u00a0Koordinierungsorgan\u00a0von\u00a0Seiten\u00a0der\u00a0europ\u00e4 ischen\u00a0Kom\u2010\nmission,\u00a0EC,\u00a0bei\u00a0der\u00a0EMA\u00a0in\u00a0Amsterdam\u00a0eingesetzt\u00a0werden.\u00a0Es\u00a0beg leitet\u00a0die\u00a0weite\u2010\nre\u00a0Bewertung\u00a0durch\u00a0die\u00a0europ\u00e4ische\u00a0Ebene\u00a0zentral\u00a0zugelassener\u00a0A rzneimittel.\u00a0Es\u00a0\nbezieht\u00a0seine\u00a0wissenschaftliche\u00a0Expertise\u00a0aus\u00a0seinen\u00a0nationalen \u00a0Mitgliedsorganisa\u2010\ntionen\u00a0(NICE,\u00a0IQWiG,\u00a0LBI).\u00a0W\u00e4hrend\u00a0des\u00a0Zulassungsprozesses\u00a0und\u00a0 nach\u00a0der\u00a0Zulas\u2010\nsung\u00a0koordiniert\u00a0es\u00a0in\u00a0Zusammenarbeit\u00a0mit\u00a0der\u00a0EMA\u00a0die\u00a0weitere\u00a0B ewertung\u00a0von\u00a0 \n164\u00a0\n\u00a0Arzneimittel\u00a0unter\u00a0Ber\u00fccksichtigung\u00a0von\u00a0arzneimittelrechtlichen \u00a0und\u00a0im\u00a0deutschen\u00a0\nFalle\u00a0 sozialrechtlichen\u00a0 Anforderungen\u00a0 an\u00a0 den\u00a0 Wirksamkeitsnachwe is.\u00a0 Mit\u00a0 der\u00a0\nZulassung\u00a0der\u00a0Arzneimittel\u00a0kann\u00a0so\u00a0bereits\u00a0ein\u00a0Plan\u00a0\u00fcber\u00a0weiter e\u00a0Schritte\u00a0zur\u00a0Evi\u2010\ndenzgenerierung\u00a0erstellt\u00a0werden. \u00a0Durch\u00a0die\u00a0Zusammenarbeit\u00a0mit\u00a0d er\u00a0EMA\u00a0k\u00f6nnen\u00a0\ndie\u00a0HTA\u2010Organisationen\u00a0von\u00a0der\u00a0bestehenden\u00a0Expertise\u00a0in\u00a0den\u00a0Ind ikationsgebieten\u00a0\nbzgl.\u00a0Studienplanung\u00a0profitieren.\u00a0 Diese\u00a0Koordinierungsstelle\u00a0al s\u00a0Clearinghouse \u00a0auf\u00a0\neurop\u00e4ischer\u00a0Ebene\u00a0setzt\u00a0sich\u00a0indikationsorientiert\u00a0aus\u00a0Vertret ern\u00a0nationaler\u00a0HTA\u2010\nOrganisationen\u00a0 zusammen.\u00a0 Die\u00a0 pha rmazeutische\u00a0 Industrie\u00a0 soll\u00a0 ein \u00a0 Anh\u00f6rrecht\u00a0\nerhalten,\u00a0aber\u00a0nicht\u00a0mitentscheiden\u00a0d\u00fcrfen.\u00a0Denkbar\u00a0w\u00e4re\u00a0es\u00a0auc h,\u00a0die\u00a0EMA\u00a0um\u00a0\neine\u00a0 Abteilung\u00a0 zu\u00a0 erweitern,\u00a0 in\u00a0 die\u00a0 Experten\u00a0 von\u00a0 den\u00a0 nationalen \u00a0 HTA\u2010\nOrganisationen\u00a0abgesandt\u00a0werden, \u00a0um\u00a0miteinander\u00a0die\u00a0notwendigen \u00a0Entschei\u2010\ndungen\u00a0und\u00a0Bewertungen\u00a0 zu\u00a0treffen.\u00a0Das\u00a0 Beispiel\u00a0des\u00a0internation al\u00a0besetzten\u00a0\nP\u00e4diatrieausschusses\u00a0bei\u00a0der\u00a0EMA,\u00a0der\u00a0dar\u00fcber\u00a0entscheidet,\u00a0f\u00fcr\u00a0 welche\u00a0neu\u00a0zuge\u2010\nlassenen\u00a0Wirkstoffe\u00a0eine\u00a0Relevanz \u00a0f\u00fcr\u00a0die\u00a0Versorgung\u00a0von\u00a0Kinder n\u00a0besteht,\u00a0was\u00a0\ndann\u00a0zu\u00a0der\u00a0Verpflichtung\u00a0der\u00a0pharmazeutischen\u00a0Unternehmer\u00a0f\u00fchr t,\u00a0entspre\u2010\nchende\u00a0klinische\u00a0Studien\u00a0mit\u00a0Kindern\u00a0durchzuf\u00fchren,\u00a0k\u00f6nnte\u00a0f\u00fcr\u00a0 eine\u00a0solche\u00a0HTA\u2010\nKommission\u00a0bei\u00a0der\u00a0EMA \u00a0beispielgebend\u00a0sein.\u00a0\n Evidenzindikator\u00a08.2\nKriterien\u00a0zur\u00a0Bewertung\u00a0und\u00a0Preisfindung\u00a0von\u00a0Arzneimitteln\u00a0\nZiel\u00a0jeder\u00a0Bewertung\u00a0muss\u00a0es\u00a0sei n,\u00a0Arzneimittel\u00a0anhand\u00a0gesicher ten\u00a0Wissens\u00a0aus\u00a0\nder\u00a0klinisch\u2010pharmakologischen\u00a0Forschung\u00a0zu\u00a0klassifizieren\u00a0und\u00a0 zu\u00a0bewerten.\u00a0Wird\u00a0\nein\u00a0Wirkstoff\u00a0n\u00e4her\u00a0untersucht,\u00a0sind\u00a0ganz\u00a0verschiedene\u00a0Untersuc hungsmethoden\u00a0\nm\u00f6glich.\u00a0Geht\u00a0es\u00a0um\u00a0die\u00a0therapeu tische\u00a0Wirksamkeit,\u00a0sind\u00a0Doppel blindstudien\u00a0\nerforderlich,\u00a0um\u00a0auch\u00a0den\u00a0bekannten\u00a0Placeboeffekt\u00a0zu\u00a0erkennen.\u00a0 Diese\u00a0bieten\u00a0\neine\u00a0besonders\u00a0sichere\u00a0Basis\u00a0zur\u00a0Bewertung\u00a0der\u00a0Wirksamkeit\u00a0von\u00a0 Arzneimitteln.\u00a0In\u00a0\nDoppelblindstudien\u00a0wissen\u00a0weder\u00a0Arzt\u00a0noch\u00a0Patient,\u00a0ob\u00a0jeweils\u00a0d as\u00a0zu\u00a0pr\u00fcfenden\u00a0\nArzneimittel\u00a0oder\u00a0ein\u00a0Scheinmedikament\u00a0(Placebo)\u00a0ohne\u00a0Wirkstoff \u00a0bzw.\u00a0eigenen\u00a0\nwirksamen\u00a0Bestandteil\u00a0verabreicht\u00a0werden.\u00a0Die\u00a0Zuteilung\u00a0der\u00a0Stu dienteilnehmer\u00a0\nauf\u00a0die\u00a0Untersuchungsgruppen\u00a0erfolgt\u00a0nach\u00a0dem\u00a0Zufallsprinzip\u00a0(R andomisierung).\u00a0\u00a0\nAlles\u00a0andere\u00a0jedoch,\u00a0 was\u00a0zur\u00a0Behandlung\u00a0 dazugeh\u00f6rt,\u00a0ist\u00a0bei\u00a0bei den\u00a0Gruppen\u00a0\ngleich:\u00a0zum\u00a0Beispiel\u00a0die\u00a0Art\u00a0der\u00a0Betreuung\u00a0durch\u00a0die\u00a0\u00c4rzte\u00a0und\u00a0 die\u00a0Zeit,\u00a0die\u00a0sie\u00a0f\u00fcr\u00a0\ndie\u00a0Behandlung\u00a0aufwenden.\u00a0Erst\u00a0wenn\u00a0die\u00a0Effekte\u00a0der\u00a0Therapie\u00a0er mittelt\u00a0und\u00a0\ndokumentiert\u00a0sind,\u00a0wird\u00a0aufgedeckt,\u00a0wer\u00a0das\u00a0Arzneimittel\u00a0und\u00a0we r\u00a0das\u00a0Scheinmit\u2010\ntel\u00a0beziehungsweise\u00a0den\u00a0Standard wirkstoff\u00a0bekam.\u00a0Mit\u00a0dieser\u00a0Vor gehensweise\u00a0soll\u00a0\ngekl\u00e4rt\u00a0werden,\u00a0welcher\u00a0Anteil\u00a0de r\u00a0beschriebenen\u00a0Effekte\u00a0wirkli ch\u00a0dem\u00a0Arzneimit\u2010\ntel\u00a0zuzuschreiben\u00a0ist\u00a0und\u00a0welcher\u00a0auf\u00a0dem\u00a0gesamten\u00a0Prozess\u00a0des\u00a0 Behandelns\u00a0be\u2010\nruht.\u00a0 Schlie\u00dflich\u00a0 kann\u00a0 bereits\u00a0 da s\u00a0 Gef\u00fchl,\u00a0 behandelt\u00a0 zu\u00a0 werden, \u00a0 Beschwerden\u00a0\nlindern,\u00a0und\u00a0die\u00a0Hoffnung,\u00a0dass\u00a0nun\u00a0alles\u00a0besser\u00a0wird,\u00a0kann\u00a0die \u00a0Heilung\u00a0vorantrei\u2010 \n165\u00a0\n\u00a0ben.\u00a0 All\u00a0 dies\u00a0 geh\u00f6rt\u00a0 zum\u00a0 Placeboeffekt \u00a0dazu.\u00a0 Das\u00a0 Ausma\u00df\u00a0 des\u00a0 Placeboeffekts\u00a0\nschwankt\u00a0je\u00a0nach\u00a0Art\u00a0der\u00a0Krankheit\u00a0und\u00a0Anordnung\u00a0der\u00a0Studie\u00a0zwi schen\u00a020\u00a0und\u00a070\u00a0\nProzent.\u00a0Das\u00a0bedeutet,\u00a0dass\u00a0die\u00a0Behandlung\u00a0die\u00a0Krankheit\u00a0bei\u00a020 \u00a0bis\u00a070\u00a0von\u00a0100\u00a0\nPatienten\u00a0bessert,\u00a0ohne\u00a0dass\u00a0dies\u00a0auf\u00a0die\u00a0spezifische\u00a0Wirkung\u00a0d es\u00a0Medikaments\u00a0\nzur\u00fcckzuf\u00fchren\u00a0ist.\u00a0In\u00a0dieser\u00a0klinischen\u00a0Pr\u00fcfphase\u00a0vor\u00a0der\u00a0Zula ssung\u00a0eines\u00a0Arznei\u2010\nmittels\u00a0werden\u00a0Wirksamkeit\u00a0( Efficacy\u00a0(siehe\u00a0Kapitel\u00a05.2)\u00a0und\u00a0die\u00a0Unbedenklichkeit\u00a0\n(Vertr\u00e4glichkeit\u00a0(siehe\u00a0dazu\u00a0ebenfalls\u00a0das\u00a0Kapitel\u00a05.2,\u00a0in\u00a0dem\u00a0 die\u00a0Grenzen\u00a0dieser\u00a0\nPr\u00fcfungen\u00a0 wegen\u00a0 der\u00a0 selektiven\u00a0 Studienpopulationen\u00a0 problematisi ert\u00a0 werden)\u00a0\nevaluiert.\u00a0Diese\u00a0Daten,\u00a0die\u00a0der\u00a0 Zulassungsbeh\u00f6rde\u00a0vorgelegt\u00a0wer den\u00a0m\u00fcssen,\u00a0sind\u00a0\nletztlich\u00a0die\u00a0Basis\u00a0f\u00fcr\u00a0oder\u00a0gegen\u00a0eine\u00a0Zulassung\u00a0zum\u00a0Arzneimit telmarkt.\u00a0Die\u00a0Einge\u2010\nschr\u00e4nktheit\u00a0der\u00a0\u00dcbertragbarkeit\u00a0von\u00a0Ergebnissen\u00a0der\u00a0Zulassungs studien\u00a0zeigt\u00a0sich\u00a0\ndann\u00a0aber\u00a0oft\u00a0in\u00a0der\u00a0realen\u00a0Versorgung,\u00a0in\u00a0der\u00a0dann\u00a0nicht\u00a0mehr\u00a0 selektierte\u00a0Patien\u2010\ntenpopulationen\u00a0 behandelt\u00a0 werden\u00a0 (siehe\u00a0 auch\u00a0 hier\u00a0 die\u00a0 \u00dcberlegun gen\u00a0 zu\u00a0 der\u00a0\nDichotomie\u00a0von\u00a0 Efficacy\u00a0und\u00a0Effectiveness \u00a0a.a.O).\u00a0In\u00a0den\u00a0Nachweis\u00a0der\u00a0therapeuti\u2010\nschen\u00a0Wirksamkeit,\u00a0d.\u00a0h.\u00a0in\u00a0den\u00a0Evidenzindikator,\u00a0geht\u00a0also\u00a0das \u00a0Ergebnis\u00a0der\u00a0Pr\u00fc\u2010\nfung\u00a0ein.\u00a0Das\u00a0hei\u00dft,\u00a0ob\u00a0das\u00a0Mittel\u00a0f\u00fcr\u00a0Patienten\u00a0tats\u00e4chlich\u00a0vo n\u00a0Nutzen\u00a0ist.\u00a0Dabei\u00a0\nwird\u00a0das\u00a0Anwendungsgebiet\u00a0ber\u00fccksichtigt,\u00a0das\u00a0der\u00a0Hersteller\u00a0fe stgelegt\u00a0hat.\u00a0Pr\u00fc\u2010\nfungen\u00a0neuer\u00a0Arzneimittel\u00a0im\u00a0Rahmen\u00a0der\u00a0Zulassung\u00a0k\u00f6nnen\u00a0sowohl \u00a0gegen\u00fcber\u00a0\nScheinmedikament\u00a0(Placebo)\u00a0als\u00a0a uch\u00a0gegen\u00fcber\u00a0bereits\u00a0zugelasse nen\u00a0Arzneimit\u2010\nteln\u00a0im\u00a0zu\u00a0pr\u00fcfenden\u00a0Anwendungsgebiet\u00a0erfolgen.\u00a0\nDie\u00a0pharmakologische\u00a0Wirkung\u00a0ei nes\u00a0Medikaments\u00a0und\u00a0dessen\u00a0thera peutische\u00a0\nWirksamkeit\u00a0sind\u00a0n\u00e4mlich\u00a0nicht\u00a0das\u00a0Gleiche.\u00a0Die\u00a0pharmakologisch e\u00a0Wirkung\u00a0be\u2010\nschreibt,\u00a0wie\u00a0das\u00a0Mittel\u00a0K\u00f6rperfunktionen\u00a0beeinflusst:\u00a0Es\u00a0hemmt \u00a0zum\u00a0Beispiel\u00a0ein\u00a0\nEnzym,\u00a0 blockiert\u00a0 bestimmte\u00a0 Bindungsstellen\u00a0 oder\u00a0 behindert\u00a0 die\u00a0 B lugerinnung.\u00a0\nDieses\u00a0l\u00e4sst\u00a0sich\u00a0biochemisch\u00a0 messen\u00a0und\u00a0nachweisen.\u00a0Die\u00a0klinis che\u00a0oder\u00a0thera\u2010\npeutische\u00a0Wirkamkeit\u00a0gibt\u00a0an,\u00a0was\u00a0sich\u00a0bei\u00a0den\u00a0Anwendern\u00a0konkre t\u00a0verbessert,\u00a0\nwie\u00a0gro\u00df\u00a0also\u00a0der\u00a0Nutzen\u00a0f\u00fcr\u00a0die\u00a0Patienten\u00a0ist.\u00a0Medikamente\u00a0k\u00f6n nen\u00a0beispielswei\u2010\nse\u00a0die\u00a0Anzahl\u00a0der\u00a0Todesf\u00e4lle\u00a0verringern,\u00a0die\u00a0Krankheitsdauer\u00a0ve rk\u00fcrzen,\u00a0die\u00a0Krank\u2010\nheitsbelastung\u00a0verringern,\u00a0die\u00a0Lebensqualit\u00e4t\u00a0verbessern\u00a0oder\u00a0a uch\u00a0das\u00a0Auftreten\u00a0\neiner\u00a0Krankheit\u00a0verhindern.\u00a0\u00a0\nDie\u00a0therapeutische\u00a0Wirksamkeit\u00a0gilt\u00a0aber\u00a0letztlich\u00a0nur\u00a0dann\u00a0als \u00a0erbracht,\u00a0wenn\u00a0\nmehrere\u00a0Institutionen\u00a0unabh\u00e4ngig\u00a0voneinander\u00a0unter\u00a0wissenschaft lich\u00a0anerkann\u2010\nten\u00a0und\u00a0reproduzierbaren\u00a0Bedingungen\u00a0in\u00a0kontrollierten\u00a0Studien\u00a0 zu\u00a0vergleichbar\u00a0\npositiven\u00a0Ergebnissen\u00a0gelangt\u00a0sind.\u00a0Bei\u00a0der\u00a0Bewertung\u00a0der\u00a0Mitte l\u00a0werden\u00a0auch\u00a0die\u00a0\nGutachten\u00a0des\u00a0Instituts\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0im\u00a0 Gesundheitswesen\u00a0\n(IQWiG)\u00a0und\u00a0\u00e4hnlicher\u00a0Institutione n\u00a0ber\u00fccksichtigt.\u00a0Klinische\u00a0S tudien,\u00a0die\u00a0f\u00fcr\u00a0die\u00a0\nBewertung\u00a0des\u00a0Evidenzindikators \u00a0herangezogen\u00a0werden,\u00a0m\u00fcssen\u00a0\n\uf0b7 prospektiv\u00a0 \n166\u00a0\n\u00a0\uf0b7 randomisiert\u00a0\n\uf0b7 kontrolliert\u00a0\n\uf0b7 mit\u00a0 vorab\u00a0 definierten\u00a0 und\u00a0 der\u00a0 Fragestellung\u00a0 angemessenen\u00a0 End\u2010\npunkten\u00a0sowie\u00a0\n\uf0b7 mit\u00a0einer\u00a0angemessenen\u00a0statistisc hen\u00a0Auswertung\u00a0versehen\u00a0sein.\u00a0\nDabei\u00a0bedeutet\u00a0prospektiv,\u00a0dass\u00a0die\u00a0Studien\u00a0als\u00a0Verlaufsstudien \u00a0in\u00a0die\u00a0Zukunft\u00a0\nausgerichtet\u00a0und\u00a0geplant\u00a0sind.\u00a0In\u00a0diesen\u00a0Studien\u00a0werden\u00a0die\u00a0Aus wirkungen\u00a0eines\u00a0\nArzneimittels\u00a0auf\u00a0die\u00a0Behandelten\u00a0direkt\u00a0beobachtet\u00a0und\u00a0begleit end\u00a0dokumen\u2010\ntiert.\u00a0Randomisiert\u00a0bedeutet,\u00a0dass\u00a0die\u00a0Studienteilnehmenden\u00a0den \u00a0Behandlungs\u2010\ngruppen\u00a0nach\u00a0dem\u00a0Zufallsprinzip\u00a0zugeteilt\u00a0wurden.\u00a0Weder\u00a0Arzt\u00a0no ch\u00a0Teilnehmer\u00a0\nbestimmen\u00a0also\u00a0dar\u00fcber,\u00a0wer\u00a0w\u00e4hrend\u00a0der\u00a0Studie\u00a0welche\u00a0Behandlun g\u00a0bekommt.\u00a0\nAls\u00a0kontrolliert\u00a0gelten\u00a0Studien,\u00a0in\u00a0denen\u00a0eine\u00a0Patientengruppe\u00a0 das\u00a0neu\u00a0zu\u00a0pr\u00fcfende\u00a0\nArzneimittel\u00a0(Verum)\u00a0erh\u00e4lt\u00a0und\u00a0 weitere\u00a0Patientengruppen\u00a0ein\u00a0be reits\u00a0lange\u00a0in\u00a0\nseinem\u00a0Nutzen\u00a0best\u00e4tigtes,\u00a0gleic hartig\u00a0wirksames\u00a0(Standard\u00a0oder \u00a0zweckm\u00e4\u00dfige\u00a0\nVergleichstherapie)\u00a0oder\u00a0ein\u00a0wirkstofffreies\u00a0Mittel\u00a0(Placebo).\u00a0 Aus\u00a0den\u00a0Unterschie\u2010\nden\u00a0in\u00a0den\u00a0therapeutischen\u00a0Effekten\u00a0\u2013\u00a0sowohl\u00a0bez\u00fcglich\u00a0der\u00a0erw\u00fc nschten\u00a0als\u00a0auch\u00a0\nder\u00a0unerw\u00fcnschten\u00a0Wirkungen\u00a0\u2013\u00a0k\u00f6nnen\u00a0dann\u00a0die\u00a0therapeutische\u00a0Wi rksamkeit\u00a0\nund\u00a0gegebenenfalls\u00a0auch\u00a0der\u00a0Stelle nwert\u00a0des\u00a0gepr\u00fcften\u00a0Mittels\u00a0b ei\u00a0der\u00a0Therapie\u00a0\nder\u00a0jeweiligen\u00a0Krankheit \u00a0insgesamt\u00a0bestimmt\u00a0werden.\u00a0Pr\u00fcfungen\u00a0o hne\u00a0Kontroll\u2010\ngruppe\u00a0k\u00f6nnen\u00a0zum\u00a0Nachweis\u00a0einer\u00a0t herapeutischen\u00a0Wirksamkeit\u00a0ni cht\u00a0anerkannt\u00a0\nwerden.\u00a0Ausgenommen\u00a0sind\u00a0davon\u00a0lediglich\u00a0Krebstherapien,\u00a0bei\u00a0de nen\u00a0eine\u00a0Be\u2010\nhandlung\u00a0im\u00a0Vergleich\u00a0 zu\u00a0einer\u00a0Scheinbehandlung\u00a0aus\u00a0ethischen\u00a0G r\u00fcnden\u00a0nur\u00a0\nselten\u00a0infrage\u00a0kommt.\u00a0Sinnvoller weise\u00a0sollten\u00a0Vergleiche\u00a0mit\u00a0de r\u00a0bisherigen\u00a0Stan\u2010\ndardtherapie\u00a0oder,\u00a0wenn\u00a0dies\u00a0nicht\u00a0m\u00f6glich\u00a0ist,\u00a0mit\u00a0der\u00a0g\u00e4ngige n\u00a0unterst\u00fctzenden\u00a0\nTherapie\u00a0durchgef\u00fchrt\u00a0werden.\u00a0\nDie\u00a0untersuchte\u00a0Fragestellung\u00a0muss\u00a0klinisch\u00a0und\u00a0therapeutisch\u00a0r elevant\u00a0und\u00a0vorab\u00a0\ndefiniert\u00a0sein.\u00a0Effekte,\u00a0die\u00a0sich\u00a0nachtr\u00e4glich\u00a0zeigen,\u00a0k\u00f6nnen\u00a0n icht\u00a0als\u00a0nachgewiesen\u00a0\ngelten,\u00a0wenn\u00a0nicht\u00a0von\u00a0Beginn\u00a0an\u00a0geplant\u00a0war,\u00a0dieser\u00a0Frage\u00a0in\u00a0d ieser\u00a0Studie\u00a0nach\u2010\nzugehen.\u00a0Au\u00dferdem\u00a0m\u00fcssen\u00a0die\u00a0untersuchten\u00a0Endpunkte\u00a0der\u00a0Fragest ellung\u00a0ange\u2010\nmessen\u00a0und\u00a0f\u00fcr\u00a0die\u00a0Behandelten\u00a0wir klich\u00a0wichtig\u00a0sein.\u00a0Bei\u00a0einer \u00a0Studie\u00a0zu\u00a0einem\u00a0\nblutdrucksenkenden\u00a0Mittel\u00a0sind\u00a0sinnvolle\u00a0Endpunkte\u00a0beispielswei se\u00a0die\u00a0Fragen,\u00a0ob\u00a0\ndas\u00a0Mittel\u00a0Folgeerkrankungen\u00a0des\u00a0hohen\u00a0Blutdrucks\u00a0wie\u00a0Herzinfar kt\u00a0und\u00a0Schlagan\u2010\nfall\u00a0verhindern\u00a0kann\u00a0und\u00a0ob\u00a0die\u00a0B ehandlung\u00a0das\u00a0Sterberisiko\u00a0ver ringert.\u00a0\nF\u00fcr\u00a0die\u00a0statistische\u00a0Auswertung\u00a0gibt\u00a0es\u00a0internationale\u00a0\u00dcbereink \u00fcnfte.\u00a0Danach\u00a0kann\u00a0\nein\u00a0Wirksamkeitsnachweis\u00a0nur\u00a0als\u00a0erbracht\u00a0gelten,\u00a0wenn\u00a0aufgrund \u00a0der\u00a0Statistik\u00a0die\u00a0\nIrrtumswahrscheinlichkeit\u00a0f\u00fcr\u00a0das\u00a0Ergebnis\u00a0unter\u00a0f\u00fcnf\u00a0Prozent\u00a0l iegt.\u00a0Dabei\u00a0ist\u00a0die\u00a0\nklinische\u00a0 Relevanz\u00a0 h\u00f6her\u00a0 zu\u00a0 bewerten\u00a0 als\u00a0 die\u00a0 alleinige\u00a0 statisti sche\u00a0 Signifikanz.\u00a0 \n167\u00a0\n\u00a0Deshalb\u00a0reichen\u00a0auch\u00a0statistisch\u00a0gesicherte\u00a0Ergebnisse\u00a0von\u00a0geme ssenen\u00a0Effekten\u00a0\nzum\u00a0Nachweis\u00a0einer\u00a0therapeutischen\u00a0Wirksamkeit\u00a0nicht\u00a0aus.\u00a0So\u00a0is t\u00a0zum\u00a0Beispiel\u00a0\ndie\u00a0 statistisch\u00a0 signifikante\u00a0 Senkung\u00a0 des\u00a0 Bluthochdrucks\u00a0 nicht\u00a0 g runds\u00e4tzlich\u00a0 ein\u00a0\nNachweis\u00a0f\u00fcr\u00a0den\u00a0Nutzen\u00a0eines\u00a0Blutdrucksenkers,\u00a0diese\u00a0statistis che\u00a0Senkung\u00a0kann\u00a0\nauch\u00a0als\u00a0Surrogatparameter\u00a0gewer tet\u00a0werden,\u00a0also\u00a0ein\u00a0Parameter, \u00a0der\u00a0in\u00a0keiner\u00a0\ndirekten\u00a0Korrelation\u00a0zum\u00a0Nutzen\u00a0 des\u00a0Arzneimittels\u00a0zu\u00a0sehen\u00a0ist. \u00a0Im\u00a0Bereich\u00a0der\u00a0\nOnkologie\u00a0 werden\u00a0 solche\u00a0 Surrogatparameter\u00a0 auff\u00e4llig\u00a0 h\u00e4ufig\u00a0 genu t z t , \u00a0z . \u00a0 B . \u00a0d e r \u00a0\nprogressionsfreie\u00a0Zeitraum\u00a0bis\u00a0zum\u00a0n\u00e4chsten\u00a0auftretenden\u00a0Rezidi v,\u00a0der\u00a0aber\u00a0nur\u00a0\nselten\u00a0mit\u00a0dem\u00a0gesamten\u00a0\u00dcberlebenszeitraum\u00a0zu\u00a0tun\u00a0hat,\u00a0der\u00a0als\u00a0 wichtiger\u00a0Para\u2010\nmeter\u00a0eines\u00a0Patientennutzens\u00a0zu\u00a0bewerten\u00a0ist\u00a0(siehe\u00a0auch\u00a7\u00a035b\u00a0S GB\u00a0V;\u00a0zur\u00a0Surro\u2010\ngatdiskussion\u00a0siehe\u00a0Glaeske,\u00a02012).\u00a0\nFazit\u00a0zu\u00a0Surrogatparametern\u00a0in\u00a0klinischen\u00a0Studien:\u00a0\u00a0\n\u201eUse\u00a0of\u00a0invalid\u00a0surrogate\u00a0end\u00a0points\u00a0causes\u00a0illness\u00a0and\u00a0death.\u00a0C linical\u00a0use\u00a0of\u00a0un\u2010\nproven\u00a0surrogate\u00a0end\u00a0points\u00a0is\u00a0unscientific\u00a0and\u00a0potentially\u00a0dan gerous.\u00a0Adoption\u00a0\nand\u00a0use\u00a0of\u00a0surrogate\u00a0end\u00a0points\u00a0lacking\u00a0validation,\u00a0especially\u00a0 in\u00a0cardiovascular\u00a0\nmedicine,\u00a0have\u00a0caused\u00a0thousands\u00a0of\u00a0patients\u2018\u00a0death,\u00a0a\u00a0serious\u00a0v iolation\u00a0of\u00a0the\u00a0\nethical\u00a0principle\u00a0of\u00a0beneficience. \u201c\u00a0(Grimes\u00a0et\u00a0al.,\u00a02010)\u00a0\u201eErgebnisse\u00a0aus\u00a0Surrogat\u2010\nmarkerstudien\u00a0sollten\u00a0nur\u00a0dann\u00a0Eingang\u00a0in\u00a0ein\u00a0Behandlungskonzep t\u00a0finden,\u00a0wenn\u00a0\ndie\u00a0Krankheit\u00a0lebensbedrohlich\u00a0ist,\u00a0ein\u00a0sehr\u00a0hoher\u00a0Leidensdruck \u00a0des\u00a0Patienten\u00a0\nbesteht,\u00a0die\u00a0Effektgr\u00f6\u00dfe\u00a0der\u00a0Intervention\u00a0auf\u00a0den\u00a0Surrogatendpu nkt\u00a0gro\u00df,\u00a0pr\u00e4zise\u00a0\nund\u00a0klinisch\u00a0relevant\u00a0ist\u00a0und\u00a0keine\u00a0gute\u00a0andere\u00a0Behandlungsalte rnative\u00a0vorliegt.\u201c\u00a0\n(Bucher,\u00a02008).\u00a0Daher\u00a0gilt\u00a0auch\u00a0 das\u00a0Fazit\u00a0mit\u00a0Blick\u00a0auf\u00a0den\u00a0Pat ientennutzen:\u00a0Surro\u2010\ngatparameter\u00a0 sind\u00a0 nur\u00a0 sehr\u00a0 selten\u00a0 unverzichtbar,\u00a0 meist\u00a0 aber\u00a0 ind iskutabel\u00a0 und\u00a0\nsogar\u00a0sch\u00e4dlich.\u00a0Daher\u00a0taugen\u00a0klinische\u00a0Studien,\u00a0deren\u00a0Aussagen \u00a0auf\u00a0Surrogatpa\u2010\nrametern\u00a0basieren,\u00a0in\u00a0den\u00a0meiste n\u00a0F\u00e4llen\u00a0nicht\u00a0als\u00a0Nutzennachwe is\u00a0f\u00fcr\u00a0ein\u00a0Arznei\u2010\nmittel\u00a0und\u00a0sollten\u00a0daher\u00a0nicht\u00a0al s\u00a0relevant\u00a0in\u00a0einem\u00a0Evidenzind ikator\u00a0akzeptiert\u00a0\nwerden\u00a0(Glaeske,\u00a02012).\u00a0\nGrunds\u00e4tzlich\u00a0gilt:\u00a0Eine\u00a0positive\u00a0Bewertung\u00a0ist\u00a0immer\u00a0am\u00a0Indika tionsanspruch\u00a0zu\u00a0\nmessen\u00a0\u2013\u00a0und\u00a0im\u00a0Mittelpunkt\u00a0steht\u00a0 der\u00a0Vergleich\u00a0zu\u00a0bew\u00e4hrten\u00a0an deren\u00a0Arzneimit\u2010\nteln.\u00a0\u00a0\nDazu\u00a0ein\u00a0aktuelles\u00a0Beispiel,\u00a0um\u00a0die\u00a0Inhalte\u00a0eines\u00a0Evidenzindika tors\u00a0besser\u00a0verste\u2010\nhen\u00a0zu\u00a0k\u00f6nnen:\u00a0\nEs\u00a0kommt\u00a0h\u00e4ufiger\u00a0vor,\u00a0dass\u00a0bestimmte,\u00a0auf\u00a0Grund\u00a0ihres\u00a0Wirkmech anismus\u00a0breiter\u00a0\neinsetzbare\u00a0Arzneimittel\u00a0nach\u00a0ihrer\u00a0Erstzulassung\u00a0f\u00fcr\u00a0ein\u00a0besti mmtes\u00a0Indikations\u2010\ngebiet\u00a0weitere\u00a0Zulassungen\u00a0beantragen\u00a0und\u00a0auch\u00a0den\u00a0Marktzutritt \u00a0erreichen.\u00a0Eine\u00a0\ngerade\u00a0 zugelassene\u00a0 Indikationserweiterung\u00a0 gab\u00a0 es\u00a0 f\u00fcr\u00a0 den\u00a0 Janusk inase\u00a0 (JAK)\u2010\nHemmer\u00a0Baricitinib\u00a0(in\u00a0Olumiant\u00ae),\u00a0der\u00a0urspr\u00fcnglich\u00a02017\u00a0f\u00fcr\u00a0di e\u00a0Behandlung\u00a0der\u00a0 \n168\u00a0\n\u00a0rheumatoiden\u00a0Arthritis\u00a0auf\u00a0den\u00a0Markt\u00a0kam,\u00a0nun\u00a0aber\u00a0auch\u00a0eine\u00a0Zu lassung\u00a0f\u00fcr\u00a0die\u00a0\nBehandlung\u00a0der\u00a0atopischen\u00a0Dermatitis\u00a0erhielt.\u00a0Basis\u00a0f\u00fcr\u00a0die\u00a0Zul assung\u00a0waren\u00a0drei\u00a0\nplacebokontrollierte\u00a0Phase\u2010III\u2010Studien\u00a0als\u00a0Monotherapie\u00a0oder\u00a0al s\u00a0Zusatz\u00a0zu\u00a0einer\u00a0\nGlukokortikoid\u2010Behandlung.\u00a0Es\u00a0fehlten\u00a0aber\u00a0direkte\u00a0Vergleichsst udien\u00a0mit\u00a0den\u00a0seit\u00a0\nlanger\u00a0Zeit\u00a0eingesetzten\u00a0Wirkstoffen\u00a0Ciclosporin\u00a0(dieses\u00a0Mittel \u00a0ist\u00a0seit\u00a0langem\u00a0ne\u2010\nben\u00a0dem\u00a0Original\u00a0Sandimmun\u00ae\u00a0auch\u00a0als\u00a0preisg\u00fcnstiges\u00a0Generikum\u00a0v erf\u00fcgbar)\u00a0bzw.\u00a0\ndem\u00a0Wirkstoff\u00a0Dupilumab\u00a0(in\u00a0Duxipent\u00ae),\u00a0wobei\u00a0Dupilumab\u00a0offenba r\u00a0nach\u00a0einem\u00a0\nindirekten\u00a0Vergleich\u00a0besser\u00a0abschneidet.\u00a0Die\u00a0Kostenunterschiede \u00a0f\u00fcr\u00a0die\u00a0jeweiligen\u00a0\nBehandlungen\u00a0sind\u00a0aber\u00a0bemerkenswert:\u00a0Gegen\u00fcber\u00a0der\u00a0Behandlung\u00a0 mit\u00a0Ciclospo\u2010\nrin,\u00a0d.h.\u00a02.263\u00a0bis\u00a04.526\u00a0Euro\u00a0p\u00a0a\u00a0bei\u00a0einer\u00a0Dosierung\u00a0von\u00a02,5\u00a0 bis\u00a05\u00a0mg/kg\u00a0KG\u00a0und\u00a0\n77kg\u00a0KG\u00a0sowie\u00a03,10\u00a0Euro\u00a0je\u00a0Kapsel\u00a0mit\u00a0100\u00a0mg\u00a0Ciclosporin\u00a0als\u00a0Ge nerikum,\u00a0verteuert\u00a0\nsich\u00a0die\u00a0monatliche\u00a0Behandlung\u00a0mit\u00a04\u00a0mg\u00a0Baricitinib\u00a0[14.328,26\u00a0 Euro\u00a0p\u00a0a1]\u00a0um\u00a0das\u00a0\ndrei\u2010\u00a0bis\u00a0sechsfache,\u00a0statt\u00a0ca.\u00a0 183\u00a0Euro\u00a0f\u00fcr\u00a0Cic losporin\u00a0fallen \u00a01.165\u00a0Euro\u00a0an,\u00a0lediglich\u00a0\ndas\u00a0besser\u00a0bewertete\u00a0Mittel\u00a0Dupilumab\u00a0(17.795,11\u00a0Euro\u00a0p\u00a0a),\u00a0f\u00fcr \u00a0das\u00a0im\u00a0gleichen\u00a0\nBehandlungszeitraum\u00a0Ausgaben\u00a0von\u00a01.446\u00a0Euro\u00a0entstehen,\u00a0verteuer t\u00a0die\u00a0Behand\u2010\nlung\u00a0um\u00a0etwa\u00a024\u00a0%.\u00a0Wegen\u00a0der\u00a0unklaren\u00a0Evidenz,\u00a0der\u00a0fehlenden\u00a0no twendigen\u00a0\nVergleichsstudien\u00a0und\u00a0der\u00a0unerw\u00fcnschten\u00a0Wirkungen\u00a0von\u00a0Baricitin ib\u00a0(Infektionen,\u00a0\nOberbauchschmerzen,\u00a0Thrombosen\u00a0u.\u00a0a.)\u00a0wird\u00a0dieses\u00a0Mittel\u00a0in\u00a0der \u00a0neuzugelassenen\u00a0\nIndikation\u00a0nur\u00a0als\u00a0letzte\u00a0Behandlungsoption\u00a0eingestuft.\u00a0Bei\u00a0der \u00a0Preisfindung\u00a0m\u00fcs\u2010\nsen\u00a0diese\u00a0Aspekte\u00a0als\u00a0wesentliche\u00a0und\u00a0ausschlaggebende\u00a0Kriterie n\u00a0Ber\u00fccksichti\u2010\ngung\u00a0finden2.\u00a0\u00a0\nDie\u00a0Bewertungsstufen\u00a0in\u00a0einem\u00a0Evidenzindikator\u00a0\u2013\u00a0Unterschiede\u00a0b ei\u00a0Mono\u2010\u00a0und\u00a0\nKombinationspr\u00e4paraten\u00a0\nEin\u00a0Monopr\u00e4parat\u00a0wird\u00a0dann\u00a0als\u00a0positiv\u00a0bewertet,\u00a0wenn\u00a0seine\u00a0the rapeutische\u00a0\nWirksamkeit\u00a0in\u00a0entsprechenden\u00a0indikationsbezogenen\u00a0Studien\u00a0(s.o .)\u00a0nachgewie\u2010\nsen\u00a0ist\u00a0und\u00a0keine\u00a0weiteren\u00a0Einsch r\u00e4nkungen\u00a0vorlie gen.\u00a0Die\u00a0posit ive\u00a0Bewertung\u00a0\nmuss\u00a0sich\u00a0aus\u00a0ad\u00e4quat\u00a0geplanten\u00a0und\u00a0ausgewerteten\u00a0Studien\u00a0zweif elsfrei\u00a0erge\u2010\nben,\u00a0die\u00a0auch\u00a0geschlechtsspezifisch\u00a0angelegt\u00a0sind\u00a0und\u00a0die\u00a0patie ntenorientierten\u00a0\nNutzenkriterien\u00a0ausdr\u00fccklich\u00a0ber\u00fccksichtigen\u00a0(Verringerung\u00a0der\u00a0 Gesamtmortali\u2010\nt\u00e4t,\u00a0der\u00a0Krankheitslast\u00a0und\u00a0der\u00a0unerw\u00fcnschten\u00a0Begleiterscheinun gen\u00a0und\u00a0Ver\u2010\nbesserung\u00a0der\u00a0Lebensqualit\u00e4t).\u00a0\nEin\u00a0Monopr\u00e4parat\u00a0gilt\u00a0dann\u00a0als\u00a0positiv\u00a0mit\u00a0Einschr\u00e4nkungen,\u00a0wen n\u00a0zwar\u00a0die\u00a0thera\u2010\npeutische\u00a0Wirksamkeit\u00a0belegt\u00a0ist,\u00a0aber\u00a0die\u00a0weiteren\u00a0Anforderung en\u00a0an\u00a0den\u00a0Patien\u2010\ntennutzen\u00a0(s.o.)\u00a0eher\u00a0unber\u00fccksichtigt\u00a0bleiben\u00a0oder\u00a0gar\u00a0nicht\u00a0b er\u00fccksichtigt\u00a0wurden.\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n1\u00a0https://www.g\u2010ba.de/bewertungsver fahren/nutzenbewertung/608/#b eschluesse\u00a02\u00a0https://www.arznei\u2010tel egramm.de/html/2021_0 4/2104027_ 01.html\u00a0 \n169\u00a0\n\u00a0F\u00fcr\u00a0ein\u00a0Monopr\u00e4parat\u00a0ist\u00a0eine\u00a0positive\u00a0Bewertung\u00a0nicht\u00a0m\u00f6glich, \u00a0wenn\u00a0weitere\u00a0kon\u2010\ntrollierte\u00a0klinische\u00a0Studien\u00a0f\u00fcr\u00a0eine\u00a0abschlie\u00dfende\u00a0Bewertung\u00a0v orliegen\u00a0m\u00fcssen.\u00a0Die\u00a0\nStudien\u00a0m\u00fcssen\u00a0vom\u00a0pharmazeutischen\u00a0Unternehmer\u00a0nachgefordert\u00a0w erden.\u00a0\nEin\u00a0Monopr\u00e4parat\u00a0gilt\u00a0dann\u00a0als\u00a0nicht\u00a0beurteilbar,\u00a0wenn\u00a0seine\u00a0Be wertbarkeit\u00a0durch\u00a0\ndie\u00a0vorliegenden\u00a0Informationsque llen\u00a0nicht\u00a0m\u00f6glich\u00a0ist.\u00a0Aus\u00a0die ser\u00a0Kategorie\u00a0k\u00f6n\u2010\nnen\u00a0weder\u00a0positive\u00a0noch\u00a0negative \u00a0Schlussfolgerungen\u00a0gezogen\u00a0wer den.\u00a0Auch\u00a0dann\u00a0\nsollten\u00a0die\u00a0pharmazeutischen\u00a0Unternehmen\u00a0aufgefordert\u00a0werden,\u00a0w eitere\u00a0und\u00a0\ndeutlich\u00a0aussagekr\u00e4ftigere\u00a0Studi en\u00a0als\u00a0die\u00a0bisher\u00a0publizierten\u00a0 vorzulegen.\u00a0\nNegativ\u00a0werden\u00a0Monopr\u00e4parate\u00a0bewertet,\u00a0die\u00a0nicht\u00a0als\u00a0therapeuti sch\u00a0wirksam\u00a0nach\u00a0\nden\u00a0oben\u00a0genannten\u00a0Kriterien\u00a0beu rteilt\u00a0werden\u00a0k\u00f6nnen.\u00a0Dies\u00a0kann \u00a0auch\u00a0z.\u00a0B.\u00a0durch\u00a0\ngravierende\u00a0unerw\u00fcnschte\u00a0Wirkungen\u00a0(schwere\u00a0Herzrhythmusst\u00f6rung en,\u00a0sich\u00a0rasch\u00a0\nentwickelndes\u00a0Abh\u00e4ngigkeitspotenzial,\u00a0St\u00f6rungen\u00a0der\u00a0Blutbildung \u00a0u.\u00a0a.)\u00a0bedingt\u00a0sein.\u00a0\nEs\u00a0ist\u00a0denkbar,\u00a0dass\u00a0mit\u00a0anderen\u00a0Methoden\u00a0oder\u00a0anderen\u00a0Pr\u00fcfkrit erien\u00a0andere\u00a0\nBeurteilungen\u00a0zustande\u00a0kommen\u00a0als\u00a0hier\u00a0f\u00fcr\u00a0den\u00a0Evidenzindikator \u00a0gefordert\u00a0wer\u2010\nden.\u00a0Dies\u00a0kann\u00a0sich\u00a0auch\u00a0auf\u00a0die\u00a0Arbeit\u00a0des\u00a0Bundesinstituts\u00a0f\u00fcr \u00a0Arzneimittel\u00a0und\u00a0\nMedizinprodukte\u00a0(BfArM)\u00a0beziehen,\u00a0das\u00a0unter\u00a0Betrachtung\u00a0der\u00a0Dat en\u00a0zu\u00a0Einzelarz\u2010\nneimitteln\u00a0 Zulassungsentscheidungen\u00a0 trifft\u00a0 und\u00a0 den\u00a0 Marktzugang\u00a0 regelt.\u00a0 Das\u00a0\nBfArM\u00a0hat\u00a0einen\u00a0beschr\u00e4nkten\u00a0Pr\u00fcfauftrag.\u00a0Es\u00a0ber\u00fccksichtigt\u00a0bei \u00a0der\u00a0Zulassung\u00a0\neines\u00a0Arzneimittels\u00a0vor\u00a0allem\u00a0den\u00a0Nachweis\u00a0von\u00a0Wirksamkeit,\u00a0Unb edenklichkeit\u00a0\nund\u00a0pharmazeutischer\u00a0Qualit\u00e4t\u00a0sowie\u00a0gegebenenfalls\u00a0die\u00a0Zweckm\u00e4\u00df igkeit\u00a0einer\u00a0\nKombination.\u00a0Die\u00a0Zulassungsbeh\u00f6rde\u00a0darf\u00a0weder\u00a0pr\u00fcfen,\u00a0ob\u00a0neue\u00a0M ittel\u00a0in\u00a0Relati\u2010\non\u00a0zum\u00a0bereits\u00a0vorhandenen\u00a0Markt\u00a0aus\u00a0therapeutischen\u00a0Gr\u00fcnden\u00a0er forderlich\u00a0sind\u00a0\n(Verbot\u00a0der\u00a0Bed\u00fcrfnispr\u00fcfung),\u00a0noch\u00a0welchen\u00a0Rang\u00a0sie\u00a0unter\u00a0den\u00a0 Alternativen\u00a0\neinnehmen.\u00a0Ihre\u00a0Arbeit\u00a0beschr\u00e4nkt \u00a0sich\u00a0vor\u00a0allem\u00a0darauf,\u00a0ob\u00a0ein e\u00a0Zulassung\u00a0zum\u00a0\nMarkt\u00a0wegen\u00a0unzureichender\u00a0Daten\u00a0oder\u00a0wegen\u00a0bestimmter\u00a0Risiken, \u00a0die\u00a0in\u00a0sich\u00a0\naus\u00a0den\u00a0vorgelegten\u00a0Unterlagen\u00a0e rgeben,\u00a0versagt\u00a0werden\u00a0muss.\u00a0We nn\u00a0sich\u00a0derar\u2010\ntige\u00a0Gr\u00fcnde\u00a0aus\u00a0den\u00a0Zulassungsstudien\u00a0nicht\u00a0ableiten\u00a0lassen,\u00a0we il\u00a0z.\u00a0B.\u00a0die\u00a0Risiken\u00a0\nnach\u00a0 einer\u00a0 Anwendung\u00a0 die\u00a0 zu\u00a0 erwartende\u00a0 wahrscheinliche\u00a0 Wirksamk eit\u00a0 nicht\u00a0\n\u00fcbersteigen,\u00a0wird\u00a0eine\u00a0Zulassung \u00a0zum\u00a0Markt\u00a0ausgesprochen.\u00a0\u00a0\nEin\u00a0nach\u00a0wie\u00a0vor\u00a0besonderes\u00a0Problem\u00a0im\u00a0Arzneimittelmarkt:\u00a0Fixe\u00a0 Wirkstoff\u2010\nKombinationen\u00a0\nKombinationspr\u00e4parate\u00a0enthalten\u00a0 mehrere\u00a0Wirkstoffe\u00a0in\u00a0einem\u00a0bes timmten\u00a0fest\u2010\ngelegten\u00a0 Mischungsverh\u00e4ltnis.\u00a0 Das \u00a0 ist\u00a0 gegen\u00fcber\u00a0 Arzneimitteln\u00a0 m it\u00a0 nur\u00a0 einem\u00a0\nWirkstoff\u00a0nur\u00a0selten\u00a0von\u00a0Vorteil,\u00a0denn\u00a0in\u00a0der\u00a0Regel\u00a0m\u00fcssen\u00a0die\u00a0 Wirkstoffe\u00a0individu\u2010\nell\u00a0dosiert\u00a0werden.\u00a0Bevor\u00a0eine\u00a0fixe\u00a0Kombination\u00a0bezogen\u00a0auf\u00a0ihr en\u00a0positiven\u00a0Bei\u2010\ntrag\u00a0zu\u00a0einer\u00a0Therapie\u00a0bewertet\u00a0werden\u00a0kann,\u00a0muss\u00a0zun\u00e4chst\u00a0die\u00a0 Zweckm\u00e4\u00dfigkeit\u00a0\nder\u00a0Mischung\u00a0der\u00a0einzelnen\u00a0Komponenten\u00a0beurteilt\u00a0werden.\u00a0F\u00e4llt\u00a0 diese\u00a0nicht\u00a0posi\u2010 \n170\u00a0\n\u00a0tiv\u00a0aus,\u00a0er\u00fcbrigt\u00a0sich\u00a0letztlich\u00a0ein\u00a0Wirksamkeitsnachweis,\u00a0da\u00a0d ie\u00a0jeweilige\u00a0Kombina\u2010\ntion\u00a0grunds\u00e4tzlich\u00a0nicht\u00a0als\u00a0sinnvolles\u00a0Arzneimittel\u00a0anerkannt\u00a0 werden\u00a0kann,\u00a0gleich\u00a0\nin\u00a0 welchem\u00a0 Anwendungsbereich.\u00a0 F\u00fcr\u00a0 die\u00a0 Bewertung\u00a0 von\u00a0 festen\u00a0 Wirk stoff\u2010\nKombinationen\u00a0 haben\u00a0 sich\u00a0 die\u00a0 sogenannten\u00a0 Crout\u2010Kriterien\u00a0 als\u00a0 in ternationaler\u00a0\nStandard\u00a0 bew\u00e4hrt.\u00a0 J.\u00a0R.\u00a0 Crout\u00a0 war\u00a0 in\u00a0 den\u00a0 1970er\u2010Jahren\u00a0 Direktor \u00a0d e r \u00a0U S \u2010\namerikanischen\u00a0 Zulassungsbeh\u00f6rde\u00a0 Food\u00a0 and\u00a0 Drug\u00a0 Administration .\u00a0 Die\u00a0 Crout\u2010\nKriterien\u00a0tragen\u00a0den\u00a0Erfordernissen\u00a0der\u00a0praktischen\u00a0Anwendung\u00a0v on\u00a0Arzneimitteln\u00a0\nRechnung.\u00a0Sie\u00a0werden\u00a0der\u00a0Forderung\u00a0nach\u00a0Unbedenklichkeit\u00a0und\u00a0Si cherheit\u00a0von\u00a0\nArzneimitteln\u00a0ebenso\u00a0gerecht\u00a0wie \u00a0dem\u00a0Problem\u00a0des\u00a0Missbrauchs\u00a0un d\u00a0m\u00f6glichen\u00a0\nVorteilen\u00a0 im\u00a0 Hinblick\u00a0 auf\u00a0 die\u00a0 richtige\u00a0 Anwendung\u00a0 (fr\u00fcher:\u00a0 Compliance ,\u00a0 heute:\u00a0\nAdherence ).\u00a0\nWenn\u00a0zum\u00a0Beispiel\u00a0mehrere\u00a0Wirks toffe\u00a0nebeneinander\u00a0eingesetzt\u00a0w erden\u00a0m\u00fcs\u2010\nsen,\u00a0kann\u00a0es\u00a0einfacher\u00a0sein,\u00a0sie\u00a0in\u00a0Form\u00a0eines\u00a0Kombinationspr\u00e4p arats\u00a0einzuneh\u2010\nmen.\u00a0Voraussetzung\u00a0ist\u00a0dann\u00a0allerdings,\u00a0dass\u00a0die\u00a0Dosierung\u00a0der\u00a0 Einzelbestandteile\u00a0\nf\u00fcr\u00a0den\u00a0jeweiligen\u00a0Einzelfall\u00a0pa ssend\u00a0ist.\u00a0Die\u00a0Crout\u2010Kriterien\u00a0 sollen\u00a0daher\u00a0auch\u00a0\nkeineswegs\u00a0jegliche\u00a0Anwendung\u00a0von \u00a0Kombinationspr\u00e4paraten\u00a0verhin dern.\u00a0Viel\u2010\nmehr\u00a0gibt\u00a0es\u00a0Indikationsbereiche,\u00a0in\u00a0denen\u00a0sie\u00a0wichtig\u00a0und\u00a0sinn voll\u00a0sind,\u00a0etwa\u00a0bei\u00a0\nhohem\u00a0Blutdruck,\u00a0zur\u00a0Empf\u00e4ngnisverh\u00fctung\u00a0oder\u00a0bei\u00a0der\u00a0Behandlun g\u00a0von\u00a0bakteri\u2010\nellen\u00a0Infektionen\u00a0mit\u00a0Antibiotika.\u00a0\nCrout\u2010Kriterien\u00a0im\u00a0Einzelnen\u00a0\nNach\u00a0den\u00a0Crout\u2010Kriterien\u00a0gelten\u00a0 Kombinationspr\u00e4parate\u00a0als\u00a0sinnv oll,\u00a0wenn\u00a0nach\u2010\ngewiesen\u00a0ist,\u00a0dass\u00a0\n\uf0b7 jeder\u00a0einzelne\u00a0Inhaltsstoff\u00a0in\u00a0Bezug\u00a0auf\u00a0das\u00a0beanspruchte\u00a0Anwen \u2010\ndungsgebiet\u00a0therapeutisch\u00a0wirksam\u00a0ist\u00a0und\u00a0\n\uf0b7 die\u00a0Dosierung\u00a0jedes\u00a0einzelnen\u00a0Inhaltstoffs\u00a0im\u00a0Hinblick\u00a0auf\u00a0H\u00f6ch stdo\u2010\nsierung,\u00a0Anwendungsh\u00e4ufigkeit\u00a0und\u00a0 \u2010dauer\u00a0so\u00a0bemessen\u00a0ist,\u00a0dass\u00a0 ei\u2010\nne\u00a0nennenswerte\u00a0Patientenanzahl\u00a0 einer\u00a0solchen\u00a0festgelegten\u00a0Kom\u2010\nbination\u00a0bedarf\u00a0und\u00a0sie\u00a0wirksam\u00a0und\u00a0unbedenklich\u00a0(im\u00a0Sinne\u00a0des\u00a0\nVerh\u00e4ltnisses\u00a0von\u00a0Nutzen\u00a0zu\u00a0Risiko)\u00a0ist\u00a0und\u00a0\n\uf0b7 die\u00a0zugef\u00fcgten\u00a0Inhaltsstoffe\u00a0die\u00a0Wirksamkeit\u00a0und/oder\u00a0Unbedenk\u2010\nlichkeit\u00a0 des\u00a0 Hauptinhaltsstoffs\u00a0 erh\u00f6hen\u00a0 oder\u00a0 die\u00a0 M\u00f6glichkeit\u00a0 de s\u00a0\nMissbrauchs\u00a0des\u00a0Hauptinhaltsstoffs\u00a0verringern\u00a0oder\u00a0\n\uf0b7 die\u00a0festgelegte\u00a0Kombination\u00a0von\u00a0Inhaltsstoffen\u00a0einen\u00a0gr\u00f6\u00dferen\u00a0t he\u2010\nrapeutischen\u00a0Nutzen\u00a0bringt\u00a0ode r\u00a0gr\u00f6\u00dfere\u00a0Unbedenklichkeit\u00a0bietet \u00a0als\u00a0\njeder\u00a0einzelne\u00a0Inhaltsstoff\u00a0f\u00fcr\u00a0sich.\u00a0 \n171\u00a0\n\u00a0Diese\u00a0Aspekte\u00a0sind\u00a0im\u00a0deutschen\u00a0A rzneimittelgesetz\u00a0zwar\u00a0ber\u00fccks ichtigt,\u00a0ob\u00a0sie\u00a0\nallerdings\u00a0immer\u00a0ausreichend\u00a0ange wendet\u00a0werden,\u00a0wird\u00a0immer\u00a0wied er\u00a0diskutiert,\u00a0\nobwohl\u00a0 der\u00a0 Anteil\u00a0 der\u00a0 fixen\u00a0 Kombinationen\u00a0 im\u00a0 rezeptpflichtigen\u00a0 verordneten\u00a0\nMarkt,\u00a0im\u00a0Unterschied\u00a0zum\u00a0Markt\u00a0 der\u00a0rezeptfreien\u00a0Mittel,\u00a0in\u00a0den \u00a0letzten\u00a0Jahren\u00a0\ndeutlich\u00a0zur\u00fcckgegangen\u00a0ist.\u00a0Es\u00a0f ordert\u00a0f\u00fcr\u00a0Arzneimittel,\u00a0die\u00a0m ehr\u00a0als\u00a0einen\u00a0arznei\u2010\nlich\u00a0wirksamen\u00a0Bestandteil\u00a0enthalten,\u00a0eine\u00a0ausreichende\u00a0Begr\u00fcnd ung\u00a0daf\u00fcr,\u00a0dass\u00a0\njeder\u00a0dieser\u00a0Bestandteile\u00a0einen\u00a0Beitrag\u00a0zur\u00a0positiven\u00a0Beurteilu ng\u00a0leistet\u00a0\u2013\u00a0hier\u00a0hilft\u00a0\ndie\u00a0Anwendung\u00a0der\u00a0Crout\u2010Kriterien,\u00a0um\u00a0Kombinationspr\u00e4parate\u00a0auf \u00a0ihre\u00a0zweck\u2010\nm\u00e4\u00dfige\u00a0Zusammensetzung\u00a0hin\u00a0zu\u00a0pr\u00fcfen.\u00a0Erst\u00a0bei\u00a0einem\u00a0positiven\u00a0 Ergebnis\u00a0dieser\u00a0\nPr\u00fcfung\u00a0kommt\u00a0die\u00a0m\u00f6glicherweise\u00a0n achgewiesene\u00a0therapeutische\u00a0W irksamkeit\u00a0\ndes\u00a0Mittels\u00a0f\u00fcr\u00a0die\u00a0Behandlung\u00a0zum\u00a0Tragen.\u00a0\nWenn\u00a0es\u00a0sich\u00a0um\u00a0eine\u00a0Kombination\u00a0aus\u00a0unbedenklichen\u00a0Einzelkompo nenten\u00a0han\u2010\ndelt,\u00a0m\u00fcssen\u00a0mehrere\u00a0Institutionen\u00a0unabh\u00e4ngig\u00a0voneinander\u00a0unter \u00a0wissenschaft\u2010\nlich\u00a0anerkannten\u00a0und\u00a0reproduzierbaren\u00a0Bedingungen\u00a0in\u00a0kontrollie rten\u00a0Studien\u00a0\u2013\u00a0\nwie\u00a0im\u00a0Abschnitt\u00a0Wirksamkeitsnachweise\u00a0beschrieben\u00a0\u2013\u00a0zu\u00a0gleicha rtigen\u00a0Ergebnis\u2010\nsen\u00a0bez\u00fcglich\u00a0der\u00a0therapeutische n\u00a0Wirksamkeit\u00a0gelangt\u00a0sein.\u00a0Wen n\u00a0die\u00a0Kombinati\u2010\non\u00a0aber\u00a0einen\u00a0oder\u00a0mehrere\u00a0Bestandteile\u00a0enth\u00e4lt,\u00a0f\u00fcr\u00a0den\u00a0oder\u00a0d ie\u00a0Probleme\u00a0bei\u00a0\nWirksamkeit\u00a0oder\u00a0Vertr\u00e4glichkeit\u00a0 bekannt\u00a0sind,\u00a0muss\u00a0hierf\u00fcr\u00a0gem \u00e4\u00df\u00a0den\u00a0Crout\u2010\nKriterien\u00a0ein\u00a0eigener\u00a0Nutzen\u00a0der\u00a0 Kombination\u00a0nachgewiesen\u00a0werde n.\u00a0Ebenfalls\u00a0\nmuss\u00a0gem\u00e4\u00df\u00a0den\u00a0Crout\u2010Erfordernissen\u00a0ein\u00a0eigener\u00a0Nutzen\u00a0solcher\u00a0 Bestandteile\u00a0f\u00fcr\u00a0\ndie\u00a0Kombination\u00a0nachgewiesen\u00a0werden,\u00a0f\u00fcr\u00a0die\u00a0in\u00a0den\u00a0Produktinfo rmationen\u00a0der\u00a0\npharmazeutischen\u00a0Hersteller\u00a0ein\u00a0 Zusatznutzen\u00a0propagiert\u00a0wird.\u00a0\nEin\u00a0Beispiel\u00a0soll\u00a0die\u00a0Folgen\u00a0f\u00fcr \u00a0eine\u00a0solch\u00a0unsachgem\u00e4\u00dfe\u00a0Zulass ung\u00a0verdeutlichen:\u00a0\u00a0\nSeit\u00a0Oktober\u00a02007\u00a0ist\u00a0das\u00a0Mittel\u00a0Targin\u00ae\u00a0der\u00a0Firma\u00a0Mundipharma\u00a0 im\u00a0Handel,\u00a0eine\u00a0\nFixkombination\u00a0des\u00a0Opioids\u00a0Oxycodon\u00a0mit\u00a0dem\u00a0Opioidantagonisten\u00a0 Naloxon.\u00a0Targin\u00ae\u00a0\nwurde\u00a0im\u00a0Fast\u2010track\u2010Verfahren\u00a0nach\u00a0\u00a7\u00a028\u00a0(3)\u00a0Arzneimittelgesetz\u00a0 zugelassen.\u00a0Dieses\u00a0\nVerfahren\u00a0 kann\u00a0 angewendet\u00a0 werden,\u00a0 wenn\u00a0 \"hinreichende\u00a0 Anhaltspun kte\u00a0 daf\u00fcr\u00a0\nvorliegen,\u00a0dass\u00a0das\u00a0Arzneimittel\u00a0einen\u00a0gro\u00dfen\u00a0therapeutischen\u00a0W ert\u00a0haben\u00a0kann\u00a0\nund\u00a0deshalb\u00a0ein\u00a0\u00f6ffentliches\u00a0Interesse\u00a0an\u00a0seinem\u00a0unverz\u00fcglichen \u00a0Inverkehrbringen\u00a0\nbesteht\".\u00a0Im\u00a0Fall\u00a0von\u00a0Targin\u00ae\u00a0bedeutet\u00a0dies:\u00a0Es\u00a0wurde\u00a0allein\u00a0au f\u00a0der\u00a0Basis\u00a0von\u00a0Pha\u2010\nse\u2010I\u2010\u00a0und\u00a0\u2010II\u2010Daten\u00a0zu gelassen.\u00a0Im\u00a0Phase\u2010 III\u2010Programm\u00a0wird\u00a0das\u00a0 Mittel\u00a0in\u00a0Abstim\u2010\nmung\u00a0mit\u00a0der\u00a0Zulassungsbeh\u00f6rde\u00a0erst\u00a0noch\u00a0gepr\u00fcft.\u00a0Ver\u00f6ffentlich te\u00a0Studien\u00a0zu\u00a0\nTargin\u00ae\u00a0sind\u00a0bei\u00a0der\u00a0Zulassung\u00a0nicht\u00a0publiziert.\u00a0Die\u00a0Beimischun g\u00a0von\u00a0Naloxon\u00a0soll\u00a0\nder\u00a0Vorbeugung\u00a0oder\u00a0Therapie\u00a0einer\u00a0Opioid\u2010bedingten\u00a0Obstipation \u00a0dienen.\u00a0Das\u00a0\nKonzept\u00a0wurde\u00a0bislang\u00a0allerdings\u00a0nur\u00a0in\u00a0wenigen\u00a0kleinen\u00a0kurzen\u00a0 und\u00a0zum\u00a0Teil\u00a0un\u2010\nkontrollierten\u00a0klinischen\u00a0Studien\u00a0mit\u00a0drei\u00a0bis\u00a046\u00a0Patienten\u00a0gep r\u00fcft.\u00a0Danach\u00a0scheint\u00a0\nNaloxon\u00a0in\u00a0freier\u00a0Kombination\u00a0mit\u00a0der\u00a0bisherigen\u00a0Opioidmedikati on\u00a0zumindest\u00a0bei\u00a0\neinem\u00a0Teil\u00a0der\u00a0Patienten\u00a0abf\u00fchrend\u00a0zu\u00a0wirken.\u00a0Es\u00a0kann\u00a0aber\u00a0auch \u00a0lokale\u00a0und\u00a0syste\u2010\nmische\u00a0Entzugssymptome\u00a0einschlie\u00dflich\u00a0Wiederauftreten\u00a0der\u00a0Schme rzen\u00a0und\u00a0aus\u2010 \n172\u00a0\n\u00a0gepr\u00e4gter\u00a0gastrointestinaler\u00a0Beschwerden\u00a0wie\u00a0Durchfall\u00a0oder\u00a0Kol iken\u00a0provozieren.\u00a0\nDas\u00a0therapeutische\u00a0Fenster\u00a0scheint\u00a0klein\u00a0zu\u00a0sein.\u00a0Effektive,\u00a0ab er\u00a0zugleich\u00a0sichere\u00a0\nDosierungen\u00a0scheinen\u00a0zudem\u00a0interindividuell\u00a0erheblich\u00a0zu\u00a0variie ren.\u00a0Soweit\u00a0sich\u00a0aus\u00a0\nden\u00a0sp\u00e4rlichen\u00a0Daten\u00a0\u00fcberhaupt\u00a0Schl\u00fcsse\u00a0ziehen\u00a0lassen,\u00a0scheint\u00a0 es\u00a0erforderlich,\u00a0mit\u00a0\neiner\u00a0niedrigen\u00a0Dosis\u00a0anzufangen\u00a0und\u00a0unter\u00a0sorgf\u00e4ltiger\u00a0\u00dcberwac hung\u00a0vorsichtig\u00a0\naufzutitrieren.\u00a0\u00dcberpr\u00fcfbare\u00a0Daten\u00a0mit\u00a0gr\u00f6\u00dferen\u00a0Kollektiven\u00a0und \u00a0zum\u00a0l\u00e4ngerfristi\u2010\ngen\u00a0Verlauf\u00a0fehlen\u00a0auch\u00a0f\u00fcr\u00a0die\u00a0freie\u00a0Kombination\u00a0von\u00a0Naloxon\u00a0m it\u00a0Opioiden.\u00a0\nEin\u00a0Monopr\u00e4parat\u00a0mit\u00a0Naloxon\u00a0zur\u00a0Anwendung\u00a0per\u00a0os\u00a0steht\u00a0nicht\u00a0z ur\u00a0Verf\u00fcgung.\u00a0\nAuf\u00a0die\u00a0Fixkombination\u00a0sind\u00a0die\u00a0bisherigen\u00a0sp\u00e4rlichen\u00a0Erkenntni sse\u00a0jedoch\u00a0in\u00a0keiner\u00a0\nWeise\u00a0\u00fcbertragbar.\u00a0Angesichts\u00a0der\u00a0Variabilit\u00e4t\u00a0des\u00a0Ansprechens\u00a0 auf\u00a0Naloxon\u00a0ist\u00a0der\u00a0\nmedizinische\u00a0Sinn\u00a0einer\u00a0fixen\u00a0Kombination\u00a0mit\u00a0Oxycodon\u00a0ohnehin\u00a0 nicht\u00a0nachvoll\u2010\nziehbar.\u00a0Laut\u00a0Fachinformation\u00a0wurde\u00a0in\u00a0bisherigen\u00a0klinischen\u00a0St udien\u00a0die\u00a0Umstel\u2010\nlung\u00a0auf\u00a0Targin\u00ae\u00a0nur\u00a0bei\u00a0solchen\u00a0Patienten\u00a0gepr\u00fcft,\u00a0die\u00a0zuvor\u00a0a uf\u00a0Oxycodon\u00a0einge\u2010\nstellt\u00a0waren.\u00a0Oxycodon\u00a0ist\u00a0jedoch\u00a0nicht\u00a0Mittel\u00a0der\u00a0Wahl\u00a0zur\u00a0Beh andlung\u00a0starker\u00a0\nSchmerzen.\u00a0Zur\u00a0Umstellung\u00a0von\u00a0and eren\u00a0Opioiden\u00a0wie\u00a0dem\u00a0Erstwahl mittel\u00a0Morphin\u00a0\nauf\u00a0Targin\u00ae\u00a0liegen\u00a0keine\u00a0Erfahrungen\u00a0vor.\u00a0F\u00fcr\u00a0die\u00a0Therapie\u00a0von\u00a0 Dauerschmerzen,\u00a0\nbei\u00a0der\u00a0eine\u00a0gleichm\u00e4\u00dfige\u00a0Analgesie\u00a0angestrebt\u00a0wird,\u00a0ist\u00a0eine\u00a0s olche\u00a0Kinetik\u00a0nicht\u00a0\nangemessen.\u00a0Welches\u00a0\u00f6ffentliche\u00a0Interesse\u00a0sollte\u00a0am\u00a0unverz\u00fcglic hen\u00a0Inverkehrbrin\u2010\ngen\u00a0eines\u00a0Behandlungsprinzips\u00a0wie\u00a0Targin\u00ae\u00a0bestehen,\u00a0\u00fcber\u00a0das\u00a0fa st\u00a0nichts\u00a0bekannt\u00a0\nist,\u00a0dessen\u00a0wenige\u00a0bekannte\u00a0Eckdaten\u00a0aber\u00a0mit\u00a0medizinischer\u00a0Rat io\u00a0nicht\u00a0in\u00a0Einklang\u00a0\nzu\u00a0bringen\u00a0sind? \u00a0\nAbb.\u00a08.1:\u00a0 Prescire\u00a0international \u00a0zum\u00a0Thema\u00a0Targin\u00a0\n\u00a0\nEs\u00a0bestand\u00a0bei\u00a0der\u00a0Einf\u00fchrung\u00a0von\u00a0Targin\u00ae\u00a0der\u00a0Verdacht,\u00a0dass\u00a0de r\u00a0Markterfolg\u00a0von\u00a0\nOxygesic\u00ae\u00a0durch\u00a0die\u00a0Einf\u00fchrung\u00a0dieses\u00a0neuen,\u00a0durch\u00a0ein\u00a0Patent\u00a0g esch\u00fctztes\u00a0Produkt\u00a0\n \n173\u00a0\n\u00a0aufrecht\u00a0erhalten\u00a0werden\u00a0sollte,\u00a0weil\u00a0das\u00a0Patent\u00a0f\u00fcr\u00a0Oxygesic\u00ae\u00a0 in\u00a0der\u00a0Zeit\u00a0des\u00a0\nMarktzugangs\u00a0von\u00a0Targin\u00ae\u00a0auslief,\u00a0also\u00a0eine\u00a0\u00f6konomisch\u00a0veranlas ste\u00a0\u201eInnovation\u201c\u00a0\ndes\u00a0pharmazeutischen\u00a0Unternehmer s,\u00a0die\u00a0nach\u00a0der\u00a0therapeutischen \u00a0(wirklicher\u00a0und\u00a0\nevidenzbasierter\u00a0 therapeutischer\u00a0 Fortschritt)\u00a0 und\u00a0 technologisch en\u00a0 Innovationen\u00a0\n(verbesserte\u00a0patientenorienterte\u00a0Anwendung,\u00a0z.\u00a0B.\u00a0Schmerzpflast er\u00a0bei\u00a0Kranken,\u00a0\ndie\u00a0Schwierigkeiten\u00a0beim\u00a0Schlucken\u00a0von\u00a0Tabletten\u00a0haben)\u00a0rangier t.\u00a0\u00a0\u00a0\nTargin\u00ae\u00a0wurde\u00a0seinerzeit\u00a0exakt\u00a0zum\u00a0gleichen\u00a0Preis\u00a0wie\u00a0Oxygesic\u00ae \u00a0in\u00a0entsprechender\u00a0\nWirkst\u00e4rke\u00a0 angeboten.\u00a0 100\u00a0 Tabletten\u00a0 10/5\u00a0mg\u00a0 Targin\u00ae\u00a0 beziehungsw eise\u00a0 10\u00a0mg\u00a0\nOxygesic\u00ae\u00a0 kosteten\u00a0 121,53\u00a0Euro,\u00a0 100\u00a0 Tabletten\u00a0 der\u00a0 doppelten\u00a0 Wir kst\u00e4rke\u00a0\n209,28\u00a0Euro.\u00a0\nDie\u00a0Auswirkungen\u00a0dieser\u00a0Zulassung\u00a0f\u00fcr\u00a0die\u00a0GKV\u00a0sind\u00a0aber\u00a0heute\u00a0n och\u00a0sp\u00fcrbar:\u00a0Trotz\u00a0\nder\u00a0langj\u00e4hrigen\u00a0Kritik\u00a0an\u00a0der\u00a0Zusammensetzung\u00a0dieses\u00a0Kombinati onspr\u00e4parates\u00a0\nrangiert\u00a0Targin\u00ae\u00a0mit\u00a0der\u00a0Wirkstoffkombination\u00a0Oxycodon\u00a0plus\u00a0Nal oxon\u00a0des\u00a0pU\u00a0\nMundipharma,\u00a0 d.\u00a0h.\u00a0 der\u00a0 europ\u00e4ischen\u00a0 Tochterfirma\u00a0 von\u00a0 purdue\u2010pha rma,\u00a0 2019\u00a0\nnach\u00a0den\u00a0Daten\u00a0des\u00a0AVR\u00a02020\u00a0(Schwabe\u00a0&\u00a0Ludwig,\u00a02020)\u00a0bei\u00a0der\u00a0Me nge\u00a0der\u00a0ver\u2010\nordneten\u00a0DDD\u00a0(trotz\u00a0 des\u00a0R\u00fcckgangs\u00a0 um\u00a032\u00a0%\u00a0gegen\u00fcber\u00a0dem\u00a0Jahr\u00a020 18)\u00a0auf\u00a0\nPlatz\u00a01,\u00a0obgleich\u00a0diese\u00a0Wirkstoffkombination\u00a0inzwischen\u00a0auch\u00a0ge nerisch\u00a0vorhanden\u00a0\nist.\u00a0Die\u00a0Ausgaben\u00a0f\u00fcr\u00a0die\u00a0GKV\u00a0betrugen\u00a041,5\u00a0Mio.\u00a0Euro,\u00a0f\u00fcr\u00a0das\u00a0 gesamte\u00a0Sortiment\u00a0\ndieser\u00a0zweifelhaften\u00a0Kombination,\u00a0die\u00a0wegen\u00a0des\u00a0Markterfolges\u00a0a uch\u00a0von\u00a0vielen\u00a0\nGenerika\u2010Herstellern\u00a0nachgeahmt\u00a0wurde.\u00a02019\u00a0kamen\u00a0Ausgaben\u00a0von\u00a0 insgesamt\u00a0\n116\u00a0Mio.\u00a0Euro\u00a0zusammen.\u00a0Ein\u00a0unerw\u00fcnschter\u00a0Umsatz\u00a0f\u00fcr\u00a0ein\u00a0Produk t,\u00a0das\u00a0in\u00a0dieser\u00a0\nZusammensetzung\u00a0aufgrund\u00a0der\u00a0unzureichenden\u00a0Plausibilit\u00e4t\u00a0der\u00a0K ombination\u00a0von\u00a0\nzwei\u00a0Wirkstoffen\u00a0nicht\u00a0h\u00e4tte\u00a0zugelassen\u00a0werden\u00a0d\u00fcrfen.\u00a0\u00a0\nTabelle\u00a08.1:\u00a0Verordnungsmenge\u00a0der\u00a0Wirkstoffkombination\u00a0Oxycodon /Naloxon\u00a0in\u00a0\nder\u00a0GKV\u00a0im\u00a0Jahr\u00a02019\u00a0\nOxycodon\u00a0plus\u00a0Naloxon\u00a0\u00a0\nPr\u00e4parat\u00a0DDD\u00a0in\u00a0\nMio.\u00a0\u00c4nderung\u00a0zum\u00a0\nVorjahr\u00a0in%\u00a0DDD\u2010Nettokosten\u00a0in\u00a0\nEuro\u00a0\nTargin\u00ae\u00a0 4,3\u00a0 (\u201032,0)\u00a0 9,65\u00a0\nOxycodon/Naloxon\u00a0Krugmann\u00a0 3,9\u00a0 (\u201039,0)\u00a0 7,64\u00a0\nOxycodon\u00a0comp\u00a0AbZ\u00a0 1,4\u00a0 (+183,5)\u00a0 4,12\u00a0\nOxycodon\u00a0com\u20101\u00a0A\u00a0Pharma\u00a0 1,0\u00a0 (+302,7)\u00a0 6,30\u00a0\nOxycodon\u2010ratiopharm\u00a0 0,96\u00a0 (+7,8)\u00a0 7,17\u00a0\nOxycodon\u2010HCL/\u00a0\nNaloxon\u2010HCL\u00a0AL\u00a00,84\u00a0 (>1.000)\u00a0 4,28\u00a0\nOcycodon\u2010HCL/\u00a0\nNaloxon\u2010HCL\u00a0beta\u00a00,74\u00a0 (+69,7)\u00a0 4,24\u00a0\nOxycodon/Naloxon\u00a0Aristo\u00a0 0,71\u00a0 (>1.000)\u00a0 5,94\u00a0 \n174\u00a0\n\u00a0Quelle:\u00a0nach\u00a0Schwabe\u00a0&\u00a0Ludwig,\u00a02020\u00a0\nDie\u00a0Arzneimittelkommission\u00a0der\u00a0deu tschen\u00a0\u00c4rzteschaft\u00a0fasste\u00a0Ihr \u00a0Urteil\u00a0daher\u00a0wie\u00a0\nfolgt\u00a0zusammen:\u00a0\nAbb.\u00a08.2:\u00a0Empfehlung\u00a0der\u00a0AKd\u00c4\u00a0zu\u00a0Targin \u00a0\n\u00a0\nUnd\u00a0die\u00a0Konsequenzen\u00a0f\u00fcr\u00a0einen\u00a0flexibel\u00a0von\u00a0der\u00a0Evidenz\u00a0abh\u00e4ngi gen\u00a0Preis?\u00a0\nDer\u00a0Grad\u00a0der\u00a0Evidenz\u00a0f\u00fcr\u00a0ein\u00a0neu \u00a0zugelassenes\u00a0Arzneimittel\u00a0ist\u00a0 nur\u00a0im\u00a0Vergleich\u00a0mit\u00a0\nden\u00a0bisherigen\u00a0Therapien\u00a0absch\u00e4tzbar.\u00a0Die\u00a0Zulassung\u00a0durch\u00a0das\u00a0B fArM\u00a0hat\u00a0daher\u00a0\nf\u00fcr\u00a0die\u00a0GKV\u00a0eine\u00a0besondere\u00a0Bedeutung,\u00a0da\u00a0sie\u00a0sich\u00a0in\u00a0ihrem\u00a0Arzn eimittelleistungs\u2010\nkatalog\u00a0bis\u00a0auf\u00a0einige\u00a0Ausnahmen \u00a0(v.\u00a0a.\u00a0Mittel\u00a0der\u00a0Selbstmedika tion)\u00a0\u00fcberwiegend\u00a0\nan\u00a0die\u00a0Zulassungsentscheidungen\u00a0bindet.\u00a0Die\u00a0Zulassungsunterlage n\u00a0liefern\u00a0jedoch\u00a0\nnur\u00a0ein\u00a0eingeschr\u00e4nktes\u00a0Bild.\u00a0Besonders\u00a0f\u00e4llt\u00a0dies\u00a0in\u00a0Bezug\u00a0auf \u00a0die\u00a0in\u00a0die\u00a0klinischen\u00a0\nStudien\u00a0einbezogenen\u00a0selektierten\u00a0Patientengruppen\u00a0auf,\u00a0die\u00a0zwa r\u00a0zur\u00a0Beantwor\u2010\ntung\u00a0 von\u00a0 Fragestellungen\u00a0 aus\u00a0 dem \u00a0 Arzneimittelgesetz\u00a0 optimal\u00a0 die nen,\u00a0 jedoch\u00a0\nOxycodon\u00a0plus\u00a0Naloxon\u00a0\u00a0\nPr\u00e4parat\u00a0DDD\u00a0in\u00a0\nMio.\u00a0\u00c4nderung\u00a0zum\u00a0\nVorjahr\u00a0in %\u00a0DDD\u2010Nettokosten\u00a0in\u00a0\nEuro\u00a0\nOxycodon\u00a0comp\u00a0Amneal\u00a0 0,63\u00a0 (+231,3)\u00a0 4,53\u00a0\nOxycodon\u00a0comp\u00a0HEXAL\u00a0 0,55\u00a0 (+36,6)\u00a0 7,66\u00a0\nOxycodon/Naloxon\u00a0Hormosan\u00a0 0,53\u00a0 (+49,7)\u00a0 4,46\u00a0\nOxycodon\u2010HCI/\u00a0\nNaloxon\u2010HCI\u00a0Mylan\u00a00,48\u00a0 (+54,9)\u00a0 3,96\u00a0\nOxycaloxon\u00a0TAD\u00a0 0,40\u00a0 (\u201027,9)\u00a0 6,13\u00a0\nOxycodon\u2010HCI/\u00a0\nNaloxon\u2010HCI\u00a0Ethypharm\u00a00,27\u00a0 (+234,8)\u00a0 3,94\u00a0\n\u00a0 16,7\u00a0 (\u20100,2)\u00a0 6,95\u00a0 \n175\u00a0\n\u00a0kaum\u00a0patientenorientierte\u00a0Erfahrungen\u00a0und\u00a0Ergebnisse\u00a0aus\u00a0der\u00a0re alen\u00a0Versorgung\u00a0\ndokumentieren.\u00a0Daher\u00a0sind\u00a0auch\u00a0die\u00a0Kalkulationen\u00a0und\u00a0Festlegung en\u00a0eines\u00a0ersten\u00a0\nErstattungsbetrages\u00a0nur\u00a0approximativ\u00a0zu\u00a0bestimmen.\u00a0\nEs\u00a0muss\u00a0daher\u00a0der\u00a0Vergleich\u00a0mit\u00a0den\u00a0bisherigen\u00a0bew\u00e4hrten\u00a0und\u00a0ev idenzbasierten\u00a0\nArzneimitteltherapien\u00a0zu\u00a0den\u00a0wahrscheinlichen\u00a0therapeutischen\u00a0V erbesserungen\u00a0\ndurch\u00a0ein\u00a0neues\u00a0Arzneimittel\u00a0auf\u00a0der\u00a0Basis\u00a0belastbarer\u00a0 Effectiveness \u2010Daten\u00a0gefun\u2010\nden\u00a0werden,\u00a0da\u00a0die\u00a0 Efficacy\u2010Daten\u00a0aus\u00a0Zulassungsstudien\u00a0eine\u00a0allenfalls\u00a0vorl\u00e4ufige\u00a0\nBegr\u00fcndungsbasis\u00a0f\u00fcr\u00a0einen\u00a0Preis\u00a0zulassen\u00a0(siehe\u00a0das\u00a0Kapitel\u00a05. 2\u00a0zur\u00a0Dichtomie\u00a0von\u00a0\nEfficacy\u00a0und\u00a0Effectiveness ).\u00a0\nDaher\u00a0muss\u00a0das\u00a0Wirtschaftlichkeitsgebot\u00a0und\u00a0die\u00a0Anforderung\u00a0der \u00a0Effizienzanfor\u2010\nderung\u00a0in\u00a0der\u00a0GKV\u00a0Ber\u00fccksichtig ung\u00a0finden.\u00a0Dabei\u00a0geht\u00a0es\u00a0darum, \u00a0das\u00a0angestrebte\u00a0\nTherapieziel\u00a0mit\u00a0einem\u00a0m\u00f6glichst \u00a0geringen\u00a0Ressourceneinsatz\u00a0zu\u00a0 erreichen,\u00a0um\u00a0\ndurch\u00a0die\u00a0m\u00f6glichen\u00a0Einsparpotenziale\u00a0einen\u00a0\u201efinanziellen\u00a0 Headroom \u00a0f\u00fcr\u00a0thera\u2010\npeutisch\u00a0wichtige\u00a0Innovationen\u201c\u00a0zu\u00a0schaffen.\u00a0Dieser\u00a0Abgleich\u00a0ka nn\u00a0in\u00a0einen\u00a0\u201eKom\u2010\nbinierten\u00a0Evidenzindikator\u201c\u00a0einflie\u00dfen\u00a0und\u00a0Leitplanken\u00a0f\u00fcr\u00a0eine \u00a0Preisfindung\u00a0er\u2010\nleichtern.\u00a0\nDabei\u00a0muss\u00a0abgesch\u00e4tzt\u00a0werden\u00a0\u2013\u00a0m\u00f6glichst\u00a0durch\u00a0ein\u00a0unabh\u00e4ngig\u00a0 beratendes\u00a0\nGremium\u00a0von\u00a0\u00c4rzten,\u00a0\u00d6konomen,\u00a0Sachverst\u00e4ndigen\u00a0f\u00fcr\u00a0die\u00a0jeweilig e\u00a0Indikation\u00a0\nund\u00a0f\u00fcr\u00a0die\u00a0Belange\u00a0der\u00a0GKV\u00a0(z.\u00a0B.\u00a0Mitglieder\u00a0des\u00a0Sachverst\u00e4ndi genrates\u00a0zur\u00a0Beur\u2010\nteilung\u00a0der\u00a0Entwicklung\u00a0im\u00a0Gesundheitswesen\u00a0(SVR)\u00a0oder\u00a0eines\u00a0zu \u00a0etablierenden\u00a0\nClearinghouses ,\u00a0beide\u00a0\u201eangeh\u00e4ngt\u201c\u00a0beim\u00a0G\u2010BA\u00a0oder\u00a0IQWiG),\u00a0um\u00a0welchen\u00a0Prozent\u2010\nsatz\u00a0die\u00a0positiv,\u00a0positiv\u00a0mit\u00a0Einschr\u00e4nkungen,\u00a0eine\u00a0positive\u00a0Be wertung\u00a0(noch)\u00a0nicht\u00a0\nm\u00f6glich,\u00a0nicht\u00a0beurteilbar\u00a0oder\u00a0negativ\u00a0bewerteten\u00a0neuen\u00a0Arznei mittel\u00a0\u00fcber\u00a0dem\u00a0\nPreis\u00a0der\u00a0Mittel\u00a0liegen\u00a0d\u00fcrfen,\u00a0die\u00a0bisher\u00a0mit\u00a0einem\u00a0hohen\u00a0Bew\u00e4 hrungsgrad\u00a0und\u00a0\n\u00fcberzeugender\u00a0Evidenz\u00a0eingesetzt\u00a0wurden.\u00a0Da\u00a0kaum\u00a0zu\u00a0erwarten\u00a0se in\u00a0d\u00fcrfte,\u00a0dass\u00a0\ndie\u00a0pharmazeutischen\u00a0Hersteller\u00a0ihre\u00a0Ausgaben\u00a0f\u00fcr\u00a0die\u00a0Forschung \u00a0und\u00a0Entwicklung\u00a0\neines\u00a0neuen\u00a0Arzneimittels\u00a0transparent\u00a0darstellen\u00a0werden,\u00a0sind\u00a0s olche\u00a0Sch\u00e4tzwerte\u00a0\nein\u00a0erster\u00a0Schritt,\u00a0um\u00a0\u00fcber\u00a0Preisverhandlungen\u00a0zu\u00a0einem\u00a0vertret baren\u00a0Ergebnis\u00a0zu\u00a0\nkommen,\u00a0das\u00a0Evidenz\u00a0und\u00a0Effizienz\u00a0gleicherma\u00dfen\u00a0ber\u00fccksichtigt. \u00a0Dabei\u00a0spielen\u00a0\nauch\u00a0die\u00a0Indikationen,\u00a0die\u00a0Charakteristika\u00a0von\u00a0Subgruppen\u00a0und\u00a0d ie\u00a0Erfolgswahr\u2010\nscheinlichkeiten\u00a0f\u00fcr\u00a0die\u00a0Therapie\u00a0eine\u00a0wesentliche\u00a0Rolle.\u00a0Langz eittherapien\u00a0sind\u00a0in\u00a0\ndiesem\u00a0Zusammenhang\u00a0sicherlich\u00a0anders\u00a0zu\u00a0bewerten\u00a0als\u00a0Therapien ,\u00a0die\u00a0bisher\u00a0\n\u00fcber\u00a0l\u00e4ngere\u00a0Zeitr\u00e4ume\u00a0durchgef\u00fchrt\u00a0werden\u00a0mussten,\u00a0nun\u00a0aber\u00a0du rch\u00a0wirkliche\u00a0\nInnovationen\u00a0deutlich\u00a0verk\u00fcrzt\u00a0w erden\u00a0k\u00f6nnen\u00a0(siehe\u00a0die\u00a0Therapi e\u00a0bei\u00a0Hepatitis\u00a0C).\u00a0\nWie\u00a0k\u00f6nnte\u00a0eine\u00a0derartige\u00a0Absch\u00e4t zung\u00a0aussehen\u00a0\u2013\u00a0sowohl\u00a0anwendb ar\u00a0f\u00fcr\u00a0Mono\u2010\nals\u00a0auch\u00a0f\u00fcr\u00a0Kombinationspr\u00e4parate?\u00a0\u00a0\n\u00a0 \u00a0 \n176\u00a0\n\u00a0Tabelle\u00a08.2:\u00a0Absch\u00e4tzung\u00a0Grad\u00a0des\u00a0Preiszuschlages\u00a0\nBei\u00a0allen\u00a0mit\u00a0einem\u00a0*\u00a0markierten\u00a0Bewertungen\u00a0sind\u00a0weitere\u00a0Studi en\u00a0zur\u00a0patientenorientierten\u00a0Evidenzgenerierung\u00a0nach\u00a0den\u00a0\nVorgaben\u00a0des\u00a0\u00a7\u00a035b\u00a0SGB\u00a0V\u00a0auf\u00a0Kosten\u00a0der\u00a0pharmazeutischen\u00a0Herste ller\u00a0nach\u00a0Beratungen\u00a0und\u00a0Vorschl\u00e4gen\u00a0unverzichtbar,\u00a0um\u00a0die\u00a0\nKriterien\u00a0Reduktion\u00a0der\u00a0Mortalit\u00e4t,\u00a0Verringerung\u00a0der\u00a0Morbidit\u00e4t slast\u00a0und\u00a0der\u00a0unerw\u00fcnschten\u00a0Wirkungen\u00a0sowie\u00a0die\u00a0Verbesserung\u00a0\nder\u00a0Lebensqualit\u00e4t\u00a0der\u00a0Patienten\u00a0zu\u00a0bestimmen.\u00a0Bedenkenswert\u00a0si nd\u00a0in\u00a0diesem\u00a0Zusammenhang\u00a0auch\u00a0die\u00a0Kriterien\u00a0\u201e\u00dcberlebens\u2010\nzeit\u201c\u00a0oder\u00a0das\u00a0\u201eErreichen\u00a0eines\u00a0notwendigen\u00a0oder\u00a0eines\u00a0m\u00f6gliche n\u00a0Therapieziels\u201c\u00a0im\u00a0Vergleich\u00a0der\u00a0aufzuwendenden\u00a0Ressourcen.\u00a0\nVorl\u00e4ufiges\u00a0Fazit:\u00a0\nEin\u00a0kombinierter\u00a0Evidenzindikator\u00a0ist\u00a0aus\u00a0mehreren\u00a0Anforderunge n\u00a0zusammenge\u2010\nsetzt:\u00a0\n\uf0b7 Es\u00a0muss\u00a0eine\u00a0m\u00f6glichst\u00a0uneingesc hr\u00e4nkt\u00a0positive\u00a0Bewertung\u00a0des\u00a0\nMono\u2010\u00a0oder\u00a0Kombinationspr\u00e4parates\u00a0vorliegen.\u00a0\n\uf0b7 Es\u00a0handelt\u00a0sich\u00a0bei\u00a0den\u00a0neuen\u00a0Arzneimittel\u00a0um\u00a0eine\u00a0m\u00f6glichst\u00a0th era\u2010\npeutische,\u00a0minimal\u00a0aber\u00a0um\u00a0ein e\u00a0technologische\u00a0Innovation.\u00a0\n\uf0b7 \u00d6konomisch\u00a0getriebene\u00a0Neuerungen ,\u00a0die\u00a0nicht\u00a0als\u00a0wirkliche\u00a0Innov a\u2010\ntionen\u00a0bezeichnet\u00a0werden\u00a0k\u00f6nnen, \u00a0m\u00fcssen\u00a0fr\u00fchzeitig\u00a0in\u00a0einem\u00a0kom \u2010\nbinierten\u00a0Evidenzindikator\u00a0diskreditiert\u00a0werden.\u00a0\n\uf0b7 Es\u00a0werden,\u00a0gemessen\u00a0an\u00a0den\u00a0erste n\u00a0m\u00f6glichen\u00a0Bewertungen,\u00a0Erstat \u2010\ntungspreise\u00a0auf\u00a0der\u00a0Basis\u00a0unterschiedlicher\u00a0prozentualer\u00a0Aufsch l\u00e4ge\u00a0\ngegen\u00fcber\u00a0den\u00a0bisherigen\u00a0Preisen\u00a0d er\u00a0zweckm\u00e4\u00dfigen\u00a0Vergleichsthe \u2010\nrapie\u00a0vorgeschlagen\u00a0und\u00a0zur\u00a0Verhandlung\u00a0angeboten.\u00a0\n\uf0b7 Insbesondere\u00a0bei\u00a0Defiziten\u00a0bez\u00fcg lich\u00a0der\u00a0belastbaren\u00a0Absch\u00e4tzun g\u00a0\nf\u00fcr\u00a0Evidenz\u00a0und\u00a0Effizienz\u00a0sind\u00a0ob ligatorisch\u00a0weitere\u00a0begleitend e\u00a0Stu\u2010\ndien\u00a0(Registerstudien\u00a0oder\u00a0andere\u00a0ad\u00e4quate,\u00a0dem\u00a0Forschungsgegen \u2010\nstand\u00a0 angemessene\u00a0 methodische\u00a0 Ans\u00e4tze\u00a0 der\u00a0 Versorgungsfor\u2010\nschung)\u00a0durch\u00a0den\u00a0pharmazeutischen\u00a0Unternehmer\u00a0(u.\u00a0U.\u00a0unter\u00a0Nut \u2010\nzung\u00a0von\u00a0Krankenkassendaten)\u00a0in\u00a0Kooperation\u00a0mit\u00a0daf\u00fcr\u00a0kompeten\u2010ten\u00a0unabh\u00e4ngigen\u00a0Experten\u00a0obligatorisch\u00a0durchzuf\u00fchren.\u00a0Bewertungsgrad\u00a0 Vorschlag\u00a0erster\u00a0festgelegter\u00a0Erstattungspreis\u00a0\nPositiv\u00a030\u00a0\u2013\u00a050\u00a0%\u00a0\u00fcber\u00a0den\u00a0bisherigen\u00a0Monatstherapiekosten\u00a0\nbew\u00e4hrter\u00a0Mittel\u00a0(zweckm\u00e4\u00dfige\u00a0Vergleichstherapie)\nPositiv\u00a0mit\u00a0Einschr\u00e4nkungen,\u00a0z.\u00a0B.\u00a0wegen\u00a0\nunerw\u00fcnschter\u00a0Wirkungen*\u00a0\u00a020\u00a0\u2013\u00a030\u00a0%\u00a0(Erl\u00e4uterung\u00a0wie\u00a0bei\u00a0positiv)\u00a0\nEine\u00a0positive\u00a0Bewertung\u00a0ist\u00a0(noch)\u00a0nicht\u00a0m\u00f6glich*\u00a0Ein\u00a0geringer\u00a0finanzieller\u00a0Zuschlag\u00a0(z.\u00a0B.\u00a010\u00a0%)\u00a0\ngegen\u00fcber\u00a0einer\u00a0bew\u00e4hrten\u00a0zweckm\u00e4\u00dfigen\u00a0\nVergleichstherapie\u00a0\nNicht\u00a0beurteilbar*\u00a0Kein\u00a0Zuschlag\u00a0gegen\u00fcber\u00a0einer\u00a0zweckm\u00e4\u00dfigen\u00a0\nVergleichstherapie\nNegativ*\u00a0 Keine\u00a0Ber\u00fccksichtigung\u00a0bei\u00a0Preisverhandlungen\u00a0 \n177\u00a0\n\u00a0\uf0b7 Fallen\u00a0im\u00a0Verlauf\u00a0der\u00a0Studienzeit\u00a0wesentliche\u00a0preisbestimmende\u00a0 Er\u2010\ngebnisse\u00a0an,\u00a0k\u00f6nnen\u00a0nach\u00a0dem\u00a0Konzept\u00a0des\u00a0dynamischen\u00a0Evidenz\u2010\npreises\u00a0Nachverhandlungen\u00a0mit\u00a0dem\u00a0pharmazeutischen\u00a0Unterneh\u2010mer\u00a0stattfinden. \u00a0\nQuellen\u00a0\nAIFA\u00a0\u2013\u00a0Italian\u00a0Medicines\u00a0Agency\u00a0(2010).\u00a0Research\u00a0&\u00a0Development\u00a0 Working\u00a0Group.\u00a0Feasibility\u00a0and\u00a0challenges\u00a0of\u00a0independent\u00a0\nresearch\u00a0on\u00a0drugs:\u00a0the\u00a0Italian\u00a0medicines\u00a0agency\u00a0(AIFA)\u00a0experien ce.\u00a0Eur\u00a0J\u00a0Clin\u00a0Invest\u00a040(1):69\u201086.\u00a0\nBucher\u00a0H\u00a0(2008).\u00a0Studien\u00a0mit\u00a0Surrogatendpunkten.\u00a0Internist\u00a0(49) :\u00a0681\u2010687.\u00a0\nChalkidou\u00a0K,\u00a0Lord\u00a0J,\u00a0Fischer\u00a0A,\u00a0Littlejohns\u00a0P\u00a0(2008)\u00a0Evidence\u2010b ased\u00a0Decision\u2010making.\u00a0When\u00a0should\u00a0we\u00a0wait\u00a0for\u00a0more\u00a0information, \u00a0in:\u00a0\nHealth\u00a0Affairs\u00a027\u00a0(6)\u00a01642\u2013\u00a01653\u00a0\nGlaeske\u00a0G\u00a0(2012).\u00a0Surrogatendpunkte\u00a0\u2013\u00a0irgendwo\u00a0zwischen\u00a0unverzi chtbar\u00a0und\u00a0indiskutabel.\u00a0Z\u00a0Evid\u00a0Fortbild\u00a0Qual\u00a0Gesundhwes\u00a0\n106(3):\u00a0161\u2010167.\u00a0\nGrimes\u00a0DA,\u00a0Schulz\u00a0KF,\u00a0Raymond\u00a0EG \u00a0(2010).\u00a0Surrogate\u00a0end\u00a0points\u00a0i n\u00a0women's\u00a0health\u00a0research:\u00a0science,\u00a0protoscience,\u00a0and\u00a0\npseudoscience.\u00a0Fertil\u00a0Steril\u00a093(6):\u00a01731\u20101734.\u00a0\nLBI\u00a0\u2013\u00a0Ludwig\u00a0Boltzmann\u00a0Institut\u00a0(2008).\u00a0Horizon\u00a0Scanning\u00a0in\u00a0Onc ology.\u00a0Concept\u00a0Development\u00a0for\u00a0the\u00a0Preparation\u00a0of\u00a0a\u00a0Horizon\u00a0\nScanning\u00a0System\u00a0in\u00a0Austria.\u00a0Final \u00a0Report.\u00a0https://eprints.aihta .at/798/1/HTA_Projektbericht_Nr14.pdf,\u00a0letzter\u00a0\nZugriff\u00a002.12.2021\u00a0\nOECD\u00a0(2019).\u00a0Improving\u00a0Forecasting\u00a0of\u00a0Pharmaceutical\u00a0Spending.\u00a0 Insights\u00a0From\u00a023\u00a0OECD\u00a0and\u00a0EU\u00a0Countries.\u00a0\nhttps://www.oecd.org/health/health\u2010systems/Improving\u2010Forecastin g\u2010of\u2010Pharmaceutical\u2010Spending\u2010Report.pdf,\u00a0\nletzter\u00a0Zugriff:\u00a008.12.2021.\u00a0(S.\u00a017\u00a0ff).\u00a0\nSchwabe\u00a0U,\u00a0Ludwig\u00a0W\u2010D\u00a0(2020).\u00a0Arzneiverordnungs\u2010Report\u00a02020.\u00a0Be rlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\n\u00a0 \u00a0 \n178\u00a0\n\u00a0\u00a0 \u00a0 \n179\u00a0\n\u00a09 Ma\u00dfnahmen\u00a0zur\u00a0Stabilisierung\u00a0und\u00a0Senkung\u00a0von\u00a0Arzneimittelkosten \u00a0\nDie\u00a0vorhergehenden\u00a0Ausf\u00fchrungen\u00a0haben\u00a0die\u00a0Schw\u00e4chen\u00a0des\u00a0aktuell en\u00a0AMNOG\u2010\nVerfahrens\u00a0 zur\u00a0 Bildung\u00a0 von\u00a0 Arzneim ittelpreisen\u00a0 in\u00a0 Deutschland\u00a0 g ezeigt.\u00a0 Das\u00a0\nAMNOG\u00a0ist\u00a0in\u00a0seiner\u00a0derzeitigen\u00a0Form\u00a0nicht\u00a0in\u00a0der\u00a0Lage\u00a0die\u00a0sich \u00a0nach\u00a0oben\u00a0dre\u2010\nhende\u00a0Preisspirale\u00a0bei\u00a0neuen\u00a0Arzneimitteln\u00a0zu\u00a0unterbrechen.\u00a0Um\u00a0 die\u00a0Ausgaben\u00a0\u2013\u00a0\ngerade\u00a0f\u00fcr\u00a0patentgesch\u00fctzte\u00a0Arzn eimittel\u00a0\u2013\u00a0in\u00a0einem\u00a0f\u00fcr\u00a0die\u00a0GKV \u00a0tragbaren\u00a0Rah\u2010\nmen\u00a0zu\u00a0halten,\u00a0bedarf\u00a0es\u00a0verschiedener\u00a0Ma\u00dfnahmen.\u00a0Neben\u00a0einer\u00a0l angfristigen\u00a0\nAnpassung\u00a0des\u00a0AMNOG\u00a0sind\u00a0kurzfristige\u00a0Schritte\u00a0zu\u00a0unternehmen,\u00a0 um\u00a0die\u00a0GKV\u00a0zu\u00a0\nentlasten.\u00a0\u00a0\n Kurzfristige\u00a0Ma\u00dfnahmen\u00a09.1\nDie\u00a0kurzfristigen\u00a0Ma\u00dfnahmen\u00a0lassen\u00a0sich\u00a0weiter\u00a0unterteilen.\u00a0Die \u00a0Politik\u00a0sollte\u00a0zum\u00a0\neinen\u00a0selbst\u00a0die\u00a0Initiative\u00a0er greifen\u00a0und\u00a0mittels\u00a0dirigistische r\u00a0Ma\u00dfnahmen\u00a0die\u00a0Aus\u2010\ngaben\u00a0senken.\u00a0Zum\u00a0anderen\u00a0sollte\u00a0 sie\u00a0den\u00a0Krankenkassen\u00a0die\u00a0M\u00f6gl ichkeit\u00a0geben,\u00a0\n\u00fcber\u00a0neue\u00a0Steuerungsma\u00dfnahmen\u00a0wei tere\u00a0Einsparungen\u00a0zu\u00a0erzielen. \u00a0\u00a0\nDirigistische\u00a0Ma\u00dfnahmen\u00a0\nUmsatzsteuer\u00a0absenken\u00a0\nDie\u00a0Ausgaben\u00a0der\u00a0gesetzlichen\u00a0Krankenkassen\u00a0h\u00e4ngen\u00a0stark\u00a0von\u00a0de r\u00a0zu\u00a0zahlenden\u00a0\nUmsatzsteuer\u00a0ab.\u00a0Eine\u00a0Absenkung\u00a0d er\u00a0Umsatzsteuer\u00a0w\u00fcrde\u00a0also\u00a0dir ekt\u00a0entlastend\u00a0\nauf\u00a0die\u00a0Finanzlage\u00a0der\u00a0GKV\u00a0wirken,\u00a0zumindest\u00a0kurzfristig.\u00a0Da\u00a0au ch\u00a0f\u00fcr\u00a0andere\u00a0le\u2010\nbensnotwendige\u00a0Produkte\u00a0in\u00a0Deutschland\u00a0eine\u00a0reduzierte\u00a0Umsatzst euer\u00a0gilt,\u00a0w\u00e4re\u00a0\neine\u00a0derartige\u00a0Anpassung\u00a0in\u00a0der\u00a0Folge\u00a0nur\u00a0konsequent.\u00a0In\u00a0der\u00a0\u00fcb erwiegenden\u00a0Zahl\u00a0\nder\u00a0EU\u2010Mitgliedesstaaten\u00a0werden\u00a0 f\u00fcr\u00a0Arzneimittel\u00a0ebenfalls\u00a0nur\u00a0 verminderte\u00a0Um\u2010\nsatzsteuers\u00e4tze\u00a0f\u00e4llig.\u00a0Nicht\u00a0zuletzt\u00a0die\u00a0Minderung\u00a0der\u00a0Umsatzs teuer\u00a0w\u00e4hrend\u00a0der\u00a0\nCorona\u2010Pandemie\u00a0hat\u00a0gezeigt,\u00a0dass\u00a0die\u00a0Umsetzung\u00a0einer\u00a0solchen\u00a0M a\u00dfnahme\u00a0ziel\u2010\nf\u00fchrend\u00a0ist.\u00a0Nach\u00a0Einsch\u00e4tzung\u00a0des\u00a0GKV\u2010SV\u00a0wurden\u00a0die\u00a0GKV\u2010weiten \u00a0Ausgaben\u00a0f\u00fcr\u00a0\nArzneimittel\u00a0im\u00a0zweiten\u00a0Halbjahr\u00a02020\u00a0durch\u00a0die\u00a0Umsatzsteuer\u00a0um \u00a0etwa\u00a0620\u00a0Mio.\u00a0\nEuro\u00a0gesenkt.\u00a0\u00dcbertr\u00e4gt\u00a0man\u00a0diesen\u00a0Effekt\u00a0auf\u00a0die\u00a0erwarteten\u00a0Ar zneimittelausga\u2010\nben\u00a0in\u00a02022,\u00a0ergeben\u00a0sich\u00a0bei\u00a0einer\u00a0Absenkung\u00a0von\u00a019\u00a0auf\u00a07\u00a0%\u00a0Ei nsparungen\u00a0in\u00a0\nH\u00f6he\u00a0von\u00a05,6\u00a0Mrd.\u00a0Euro\u00a0f\u00fcr\u00a0die\u00a0GKV\u00a0(NOZ,\u00a02021).\u00a0Dieses\u00a0Vorgehen \u00a0sollte\u00a0allerdings\u00a0\nmit\u00a0Vorsicht\u00a0bedacht\u00a0werden,\u00a0da\u00a0es\u00a0potenziell\u00a0Raum\u00a0f\u00fcr\u00a0die\u00a0phar mazeutische\u00a0\nIndustrie\u00a0\u00f6ffnet,\u00a0die\u00a0Umsatzsteuerentlastung\u00a0einzustreichen\u00a0und \u00a0sie\u00a0nur\u00a0teilweise\u00a0\noder\u00a0 gar\u00a0 nicht\u00a0 an\u00a0 die\u00a0 Krankenkassen\u00a0 weiterzureichen.\u00a0 Diese\u00a0 Gefa hr\u00a0 best\u00fcnde\u00a0\ninsbesondere\u00a0 bei\u00a0einer\u00a0dauerhaften\u00a0Anpassung\u00a0der\u00a0Umsatzsteuer.\u00a0 Diese\u00a0Ma\u00df\u2010\nnahme\u00a0sollte\u00a0daher\u00a0mit\u00a0bindenden\u00a0Regeln\u00a0f\u00fcr\u00a0die\u00a0Steuerinzidenz\u00a0 f\u00fcr\u00a0die\u00a0pharma\u2010\nzeutische\u00a0Industrie\u00a0einhergehen.\u00a0 \n180\u00a0\n\u00a0Herstellerabschlag\u00a0f\u00fcr\u00a0patentgesch\u00fctzte\u00a0Arzneimittel\u00a0anheben\u00a0\nDie\u00a0Menge\u00a0der\u00a0definierten\u00a0Tagesdosen\u00a0patentgesch\u00fctzter\u00a0Original pr\u00e4parate\u00a0ent\u2010\nsprach\u00a0im\u00a0Jahr\u00a02020\u00a010,4\u00a0%\u00a0des\u00a0Gesamtverbrauchs,\u00a0jedoch\u00a0machte\u00a0 ihr\u00a0Umsatz\u00a0mit\u00a0\n21,9\u00a0Mrd.\u00a0Euro\u00a0etwas\u00a0mehr\u00a0als\u00a0die\u00a0H\u00e4lfte\u00a0der\u00a0GKV\u2010Arzneimittelau sgaben\u00a0aus\u00a0(GKV\u2010\nSV,\u00a02021a).\u00a0Diese\u00a0Zahlen\u00a0verdeutlichen\u00a0die\u00a0enorme\u00a0Bedeutung\u00a0wen iger\u00a0patentge\u2010\nsch\u00fctzter\u00a0Arzneimittel\u00a0f\u00fcr\u00a0die\u00a0GK V\u2010Arzneimittelausgaben.\u00a0Berech nungen\u00a0mit\u00a0dem\u00a0\nFair\u00a0Pricing\u00a0Calculator \u00a0der\u00a0AIM\u00a0kommen\u00a0zu\u00a0dem\u00a0Ergebnis,\u00a0dass\u00a0GKV\u2010weit\u00a0bis\u00a0zu\u00a0\n13\u00a0Mrd.\u00a0Euro\u00a0eingespart\u00a0werden\u00a0k\u00f6nnten,\u00a0wenn\u00a0man\u00a0die\u00a0Preise\u00a0fai rer\u00a0kalkulieren\u00a0\nw\u00fcrde\u00a0(Muth\u00a0et\u00a0al.,\u00a02021).\u00a0Trotz\u00a0 einiger\u00a0Ungenauigkeiten\u00a0im\u00a0Mod ell\u00a0gibt\u00a0diese\u00a0Zahl\u00a0\neinen\u00a0guten\u00a0Hinweis\u00a0auf\u00a0die\u00a0immensen\u00a0Gewinnspannen\u00a0der\u00a0pU.\u00a0Um\u00a0z umindest\u00a0\neinen\u00a0Teil\u00a0dieser\u00a0\u00fcberh\u00f6hten\u00a0Preise\u00a0auszugleichen,\u00a0k\u00f6nnte\u00a0man\u00a0d ie\u00a0Herstellerab\u2010\nschl\u00e4ge\u00a0 f\u00fcr\u00a0 patentgesch\u00fctzte\u00a0 Arzneimittel\u00a0 von\u00a0 derzeit\u00a0 7\u00a0 auf\u00a0 17\u00a0 %\u00a0 erh\u00f6hen.\u00a0\nDadurch\u00a0lie\u00dfen\u00a0sich\u00a0die\u00a0Arzneimittelausgaben\u00a0der\u00a0GKV\u00a0um\u00a02,4\u00a0Mrd .\u00a0Euro\u00a0senken.\u00a0\nEs\u00a0ist\u00a0jedoch\u00a0zu\u00a0bef\u00fcrchten,\u00a0dass\u00a0eine\u00a0Reihe\u00a0von\u00a0Firmen\u00a0den\u00a0Zug ang\u00a0zu\u00a0patentge\u2010\nsch\u00fctzten\u00a0Arzneimitteln\u00a0k\u00fcnstlich\u00a0verknappen\u00a0w\u00fcrde.\u00a0Insgesamt\u00a0w irkt\u00a0diese\u00a0Ma\u00df\u2010\nnahme\u00a0aber\u00a0wesentlich\u00a0passgenauer \u00a0auf\u00a0das\u00a0relevante\u00a0Marktsegmen t,\u00a0welches\u00a0in\u00a0\nden\u00a0letzten\u00a0Jahren\u00a0haupts\u00e4chlich \u00a0f\u00fcr\u00a0die\u00a0Kostensteigerungen\u00a0ver antwortlich\u00a0war.\u00a0\nHerstellerabschlag\u00a0f\u00fc r\u00a0Generika\u00a0anheben\u00a0\nGenerika\u00a0waren\u00a0in\u00a0den\u00a0vergangenen\u00a0Jahren\u00a0zwar\u00a0nicht\u00a0Kostentreib er\u00a0im\u00a0Arzneimit\u2010\ntelbereich,\u00a0dennoch\u00a0waren\u00a0sie\u00a0in\u00a02020\u00a0mit\u00a019,4\u00a0Mrd.\u00a0Euro\u00a0f\u00fcr\u00a0et was\u00a0weniger\u00a0als\u00a0\ndie\u00a0H\u00e4lfte\u00a0des\u00a0Umsatzes\u00a0im\u00a0Fertigarzneimittelmarkt\u00a0verantwortli ch\u00a0und\u00a0damit\u00a0ein\u00a0\nrelevanter\u00a0 Kostenfaktor.\u00a0 Eine\u00a0 St eigerung\u00a0 des\u00a0 Herstellerabschlag s\u00a0 f\u00fcr\u00a0 Generika\u00a0\nw\u00fcrde\u00a0der\u00a0GKV\u00a0Einsparungen\u00a0von\u00a0etwas\u00a0mehr\u00a0als\u00a0900\u00a0Mio.\u00a0Euro\u00a0ein bringen.\u00a0Zu\u00a0\nbedenken\u00a0ist\u00a0hierbei\u00a0jedoch,\u00a0dass\u00a0eine\u00a0derartige\u00a0Erh\u00f6hung\u00a0dem\u00a0Z iel,\u00a0vor\u00a0allem\u00a0die\u00a0\nProduktion\u00a0von\u00a0Generika\u00a0wieder\u00a0nach\u00a0Deutschland\u00a0zu\u00a0holen,\u00a0zuwid erlaufen\u00a0w\u00fcrde.\u00a0\nAn\u00a0dieser\u00a0Stelle\u00a0m\u00fcssen\u00a0wir\u00a0uns\u00a0als\u00a0Gesellschaft\u00a0die\u00a0Frage\u00a0stel len,\u00a0was\u00a0uns\u00a0vor\u00a0Ort\u00a0\nhergestellte\u00a0 Arzneimittel\u00a0 wert\u00a0 si n d . \u00a0S o l l t e n \u00a0w i r \u00a0b e r e i t \u00a0s e i n , \u00a0m ehr\u00a0 Geld\u00a0 f\u00fcr\u00a0 in\u00a0\nDeutschland\u00a0produzierte\u00a0Arzenimittel\u00a0zu\u00a0bezahlen,\u00a0m\u00fcssen\u00a0diese\u00a0 Mehrausgaben\u00a0\ndurch\u00a0Einsparungen\u00a0an\u00a0anderer\u00a0Stelle\u00a0kompensiert\u00a0werden.\u00a0Sonst\u00a0 ist\u00a0eine\u00a0Erh\u00f6\u2010\nhung\u00a0der\u00a0Beitr\u00e4ge\u00a0zur\u00a0gesetzlichen\u00a0Krankenversicherung\u00a0unauswei chlich,\u00a0um\u00a0die\u00a0\nFinanzierungsl\u00fccke\u00a0zu\u00a0schlie\u00dfen.\u00a0\u00a0\nAlle\u00a0beschriebenen\u00a0Ma\u00dfnahmen\u00a0sollten\u00a0nur\u00a0f\u00fcr\u00a0eine\u00a0begrenzte\u00a0Zei t\u00a0eingef\u00fchrt\u00a0\nwerden.\u00a0In\u00a0der\u00a0Zwischenzeit\u00a0m\u00fcssen\u00a0eine\u00a0Reihe\u00a0von\u00a0Reparaturma\u00dfn ahmen\u00a0am\u00a0\nAMNOG\u00a0vorgenommen\u00a0werden,\u00a0um\u00a0identifizierte\u00a0Schw\u00e4chen\u00a0des\u00a0AMNOG \u00a0(vgl.\u00a0\nKapitel\u00a05)\u00a0auszubessern.\u00a0Ein\u00a0erster\u00a0Schritt\u00a0in\u00a0diese\u00a0Richtung\u00a0w \u00e4re\u00a0die\u00a0Umsetzung\u00a0\ndes\u00a0Koalitionsvertrags,\u00a0um\u00a0\u201edie\u00a0 M\u00f6glichkeiten\u00a0der\u00a0Krankenkassen \u00a0zur\u00a0Begrenzung\u00a0\nder\u00a0Arzneimittelpreise\u00a0[zu\u00a0st\u00e4rken]\u201c\u00a0(SPD,\u00a0B\u00fcndnis\u00a090/Die\u00a0Gr\u00fcne n,\u00a0FDP,\u00a02021).\u00a0Im\u00a0 \n181\u00a0\n\u00a0Folgenden\u00a0werden\u00a0einige\u00a0m\u00f6gliche \u00a0Steuerungsma\u00dfnahmen\u00a0und\u00a0deren\u00a0 finanzielle\u00a0\nAuswirkungen\u00a0beschrieben.\u00a0\nSteuerungsma\u00dfnahmen\u00a0der\u00a0Krankenkassen\u00a0\nR\u00fcckwirkung\u00a0des\u00a0Erstattungsbetrags\u00a0\nDie\u00a0erste\u00a0schnell\u00a0umzusetzende\u00a0Ma\u00dfnahme,\u00a0dass\u00a0der\u00a0Erstattungsbe trag\u00a0ab\u00a0dem\u00a0\nsiebten\u00a0Monat\u00a0nach\u00a0Markteintritt\u00a0r\u00fcckwirkend\u00a0gelten\u00a0soll,\u00a0wurde \u00a0bereits\u00a0im\u00a0Koali\u2010\ntionsvertrag\u00a0festgeschrieben\u00a0(SPD,\u00a0B\u00fcndnis\u00a090/Die\u00a0Gr\u00fcnen,\u00a0FDP,\u00a0 2021).\u00a0Nach\u00a0Be\u2010\nrechnungen\u00a0des\u00a0GKV\u2010SV\u00a0sollen\u00a0dadurch\u00a0etwa\u00a0110\u00a0Mio.\u00a0Euro\u00a0pro\u00a0Jah r\u00a0eingespart\u00a0\nwerden\u00a0k\u00f6nnen.\u00a0Der\u00a0GKV\u2010SV\u00a0w\u00fcrde\u00a0zwar\u00a0eine\u00a0R\u00fcckwirkung\u00a0ab\u00a0dem\u00a0er sten\u00a0Tag\u00a0\nbevorzugen.\u00a0Doch\u00a0auch\u00a0die\u00a0Sieben\u2010Monats\u2010L\u00f6sung\u00a0sei\u00a0ein\u00a0Schritt\u00a0 in\u00a0die\u00a0richtige\u00a0\nRichtung,\u00a0meint\u00a0Stefanie\u00a0Stoff\u2010Ahnis,\u00a0Vorsitzende\u00a0des\u00a0GKV\u2010SV\u00a0(W oratschka,\u00a02022).\u00a0\nDie\u00a0Umsetzung\u00a0dieser\u00a0Ma\u00dfnahme\u00a0h\u00e4tte\u00a0zur\u00a0Folge,\u00a0dass\u00a0sich\u00a0die\u00a0Pr eise\u00a0bereits\u00a0vom\u00a0\nMarkteintritt\u00a0an\u00a0am\u00a0nachgewiesen en\u00a0Nutzen\u00a0orientieren\u00a0und\u00a0nicht \u00a0mehr\u00a0der\u00a0Will\u2010\nk\u00fcr\u00a0der\u00a0pharmazeutischen\u00a0Industrie\u00a0unterliegen.\u00a0Der\u00a0vfa\u2010Pr\u00e4side nt\u00a0Han\u00a0Steutel\u00a0\nsprach\u00a0in\u00a0einem\u00a0Interview\u00a0von\u00a0Einsparungen\u00a0zwischen\u00a050\u00a0und\u00a075\u00a0M io.\u00a0Euro\u00a0f\u00fcr\u00a0die\u00a0\nKrankenkassen\u00a0(Haarhoff,\u00a02022a).\u00a0\u00a0\nPrivilegien\u00a0f\u00fcr\u00a0Orphan\u00a0Drugs\u00a0aufheben\u00a0\nF\u00fcr\u00a0Orphan\u00a0Drugs \u00a0gilt\u00a0mit\u00a0der\u00a0Zulassung\u00a0der\u00a0Zusatznutzen\u00a0im\u00a0Rahmen\u00a0der\u00a0fr\u00fchen\u00a0\nNutzenbewertung\u00a0als\u00a0belegt.\u00a0Dies es\u00a0Privileg\u00a0wurde\u00a0eingef\u00fchrt,\u00a0u m\u00a0die\u00a0Entwicklung\u00a0\nvon\u00a0Arzneimitteln\u00a0f\u00fcr\u00a0seltene\u00a0Er krankungen\u00a0zu\u00a0f\u00f6rdern\u00a0und\u00a0so\u00a0ei nen\u00a0medizinischen\u00a0\nBedarf\u00a0zu\u00a0decken.\u00a0Erst\u00a0wenn\u00a0ein\u00a0 Orphan\u00a0Drug \u00a0einen\u00a0Jahresumsatz\u00a0von\u00a050\u00a0Mio.\u00a0\nEuro\u00a0\u00fcberschreitet,\u00a0erfolgt\u00a0eine\u00a0regul\u00e4re\u00a0Nutzenbewertung.\u00a0Eine \u00a0Auswertung\u00a0des\u00a0\nIQWiGs\u00a0f\u00fcr\u00a0alle\u00a0 Orphan\u00a0Drugs ,\u00a0die\u00a0sich\u00a0seit\u00a0Inkrafttret en\u00a0des\u00a0AMNOGs\u00a0aufgrund\u00a0\nder\u00a0\u00dcberschreitung\u00a0dieser\u00a0Umsatzgrenze\u00a0einer\u00a0regul\u00e4ren\u00a0Nutzenbe wertung\u00a0unter\u2010\nziehen\u00a0mussten,\u00a0zeigt,\u00a0dass\u00a0bei\u00a0mehr\u00a0als\u00a0der\u00a0H\u00e4lfte\u00a0der\u00a0F\u00e4lle\u00a0( 22/40)\u00a0der\u00a0fiktive\u00a0\nZusatznutzen\u00a0nicht\u00a0best\u00e4tigt\u00a0werden\u00a0konnte\u00a0(IQWiG,\u00a02021).\u00a0Vor\u00a0d em\u00a0Hintergrund\u00a0\ndieser\u00a0Ergebnisse\u00a0ist\u00a0zu\u00a0fordern,\u00a0dass\u00a0sich\u00a0auch\u00a0 Orphan\u00a0Drugs \u00a0bei\u00a0Markteintritt\u00a0\neiner\u00a0regul\u00e4ren\u00a0Nutzenbewertung\u00a0unterziehen\u00a0m\u00fcssen.\u00a0Gem\u00e4\u00df\u00a0GKV\u2010S V\u00a0k\u00f6nnten\u00a0\nso\u00a0350\u00a0Mio.\u00a0Euro\u00a0j\u00e4hrlich\u00a0eingespart\u00a0werden\u00a0(Woratschka,\u00a02022). \u00a0Betrachtet\u00a0man\u00a0\ndie\u00a0 Ver\u00e4nderung\u00a0 des\u00a0 Erstattungsbetrags\u00a0 von\u00a0 Orphan\u00a0 Drugs ,\u00a0 die\u00a0 eine\u00a0 regul\u00e4re\u00a0\nNutzenbewertung\u00a0 durchlaufen\u00a0 haben,\u00a0 kommt\u00a0 man\u00a0 auf\u00a0 eine\u00a0 durchschn ittliche\u00a0\nReduktion\u00a0des\u00a0Erstattungsbetrags\u00a0von\u00a09,5\u00a0%.\u00a0Bei\u00a0Ausgaben\u00a0in\u00a0H\u00f6h e\u00a0von\u00a02,7\u00a0Mrd.\u00a0\nEuro\u00a0f\u00fcr\u00a0Orphan\u00a0Drugs \u00a0in\u00a02020,\u00a0entspr\u00e4che\u00a0diese\u00a0Reduktion\u00a0Einsparungen\u00a0in\u00a0H\u00f6he\u00a0\nvon\u00a0gut\u00a0260\u00a0Mio.\u00a0Euro.\u00a0\u00a0\nDer\u00a0Vorsitzende\u00a0des\u00a0G\u2010BA\u00a0Josef\u00a0Hecken\u00a0forderte\u00a0unl\u00e4ngst,\u00a0dass\u00a0e ine\u00a0regul\u00e4re\u00a0Nut\u2010\nzenbewertung\u00a0bereits\u00a0bei\u00a0\u00dcberschr eiten\u00a0einer\u00a0Grenze\u00a0von\u00a025\u00a0Mio. \u00a0Euro\u00a0vorge\u2010 \n182\u00a0\n\u00a0nommen\u00a0werden\u00a0sollte.\u00a0So\u00a0m\u00fcssten\u00a0extrem\u00a0hochpreisige\u00a0Produkte\u00a0f r\u00fcher\u00a0ihren\u00a0\nBeitrag\u00a0f\u00fcr\u00a0die\u00a0Patientenversorg ung\u00a0belegen.\u00a0Hecken\u00a0ist\u00a0au\u00dferde m\u00a0der\u00a0Meinung,\u00a0\ndass\u00a0nur\u00a0noch\u00a0das\u00a0erste\u00a0neue\u00a0Medikament\u00a0zur\u00a0Behandlung\u00a0einer\u00a0se ltenen\u00a0Erkran\u2010\nkung\u00a0den\u00a0 Orphan\u00a0Drug \u00a0Status\u00a0und\u00a0die\u00a0damit\u00a0verbundenen\u00a0Privilegien\u00a0erhalten\u00a0\nsollte.\u00a0So\u00a0w\u00fcrde\u00a0einerseits\u00a0der\u00a0Anreiz\u00a0zur\u00a0Forschung\u00a0in\u00a0diesen\u00a0 Bereichen\u00a0f\u00fcr\u00a0die\u00a0\nIndustrie\u00a0 erhalten\u00a0 bleiben,\u00a0 andere rseits\u00a0 k\u00f6nnten\u00a0 Einsparungen\u00a0 e rzielt\u00a0 werden,\u00a0\nwenn\u00a0sich\u00a0die\u00a0folgenden\u00a0Produkte\u00a0f \u00fcr\u00a0diese\u00a0Erkrankung\u00a0einer\u00a0reg ul\u00e4ren\u00a0Nutzen\u2010\nbewertung\u00a0unterziehen\u00a0m\u00fcssen\u00a0(Haarhoff,\u00a02022b).\u00a0\nFokusliste\u00a0der\u00a0K rankenkassen\u00a0\nIn\u00a0den\u00a0letzten\u00a0Jahren\u00a0sind\u00a0in\u00a0vielen\u00a0Therapiegebieten\u00a0in\u00a0kurzer \u00a0Zeit\u00a0mehrere\u00a0ver\u2010\ngleichbare\u00a0Arzneimittel\u00a0auf\u00a0den\u00a0 Markt\u00a0gekommen.\u00a0J\u00fcngstes\u00a0Beispi el\u00a0sind\u00a0die\u00a0CGRP\u2010\nAntik\u00f6rper\u00a0zur\u00a0Prophylaxe\u00a0der\u00a0Migr\u00e4ne.\u00a0Ob\u00a0f\u00fcr\u00a0die\u00a0Versorgung\u00a0de r\u00a0Patienten\u00a0in\u00a0\ndiesem\u00a0konkreten\u00a0Fall\u00a0drei\u00a0verschiedene\u00a0Antik\u00f6rper\u00a0notwendig\u00a0si nd,\u00a0die\u00a0sich\u00a0in\u00a0\nihrer\u00a0Wirksamkeit\u00a0kaum\u00a0von\u00a0einander\u00a0unterscheiden,\u00a0ist\u00a0fraglich .\u00a0Der\u00a0G\u2010BA\u00a0sollte\u00a0\nhier\u00a0einen\u00a0Katalog\u00a0medizinisch\u2010therapeutisch\u00a0vergleichbarer\u00a0Arz neimittel\u00a0erstellen.\u00a0\nDie\u00a0Krankenkassen\u00a0haben\u00a0anschlie\u00dfend\u00a0die\u00a0M\u00f6glichkeit\u00a0einzelne\u00a0A rzneimittel\u00a0f\u00fcr\u00a0\ndie\u00a0bevorzugte\u00a0Versorgung\u00a0ihrer\u00a0Versicherten\u00a0auszuw\u00e4hlen.\u00a0Es\u00a0is t\u00a0davon\u00a0auszuge\u2010\nhen,\u00a0dass\u00a0die\u00a0pU\u00a0bereit\u00a0sind,\u00a0f\u00fcr\u00a0diesen\u00a0\u201eFokusstatus\u201c\u00a0h\u00f6here\u00a0R abatte\u00a0zu\u00a0gew\u00e4h\u2010\nren.\u00a0Nimmt\u00a0man\u00a0eine\u00a0durchschnittliche\u00a0Erh\u00f6hung\u00a0der\u00a0Rabatts\u00e4tze\u00a0 f\u00fcr\u00a0patentge\u2010\nsch\u00fctzte\u00a0Arzneimittel\u00a0von\u00a05\u00a0%\u00a0durch\u00a0die\u00a0Einf\u00fchrung\u00a0einer\u00a0Fokusl iste\u00a0an,\u00a0k\u00f6nnten\u00a0\ndamit\u00a0Einsparungen\u00a0in\u00a0H\u00f6he\u00a0von\u00a01,4\u00a0Mrd.\u00a0Euro\u00a0GKV\u2010weit\u00a0erzielt\u00a0w erden,\u00a0bei\u00a0einer\u00a0\ngleichbleibend\u00a0hohen\u00a0Versorgungsqualit\u00e4t.\u00a0\u00a0\nKombinationsabschlag\u00a0einf\u00fchren\u00a0\nVor\u00a0allem\u00a0in\u00a0der\u00a0Onkologie\u00a0sind\u00a0 die\u00a0Ausgaben\u00a0in\u00a0den\u00a0letzten\u00a0Jah ren\u00a0rasant\u00a0ange\u2010\nstiegen.\u00a0 Seit\u00a0 2014\u00a0 bilden\u00a0 Onkologika\u00a0 die\u00a0 ausgabenst\u00e4rkste\u00a0 Arzne imittelgruppe.\u00a0\n2010\u00a0waren\u00a0unter\u00a0den\u00a050\u00a0umsatzst\u00e4rksten\u00a0Arzneimitteln\u00a0nur\u00a0f\u00fcnf\u00a0 Onkologika\u00a0zu\u00a0\nfinden,\u00a02018\u00a0waren\u00a0es\u00a0schon\u00a0elf\u00a0in\u00a0den\u00a0Top\u00a030\u00a0(Schwabe\u00a0und\u00a0Ludw ig,\u00a02020).\u00a0Der\u00a0\nAusgabenanstieg\u00a0ist\u00a0jedoch\u00a0nicht\u00a0nur\u00a0auf\u00a0die\u00a0hohen\u00a0Preise\u00a0der\u00a0e inzelnen\u00a0Wirkstof\u2010\nfe\u00a0zur\u00fcckzuf\u00fchren,\u00a0sondern\u00a0vor\u00a0allem\u00a0auf\u00a0die\u00a0verst\u00e4rkte\u00a0Anwendu ng\u00a0dieser\u00a0Mittel\u00a0\nin\u00a0Kombination.\u00a0So\u00a0wird\u00a0zum\u00a0Beispiel\u00a0h\u00e4ufig\u00a0die\u00a0bereits\u00a0hochpre isige\u00a0Zweitlinien\u2010\ntherapie\u00a0in\u00a0der\u00a0n\u00e4chsten\u00a0Therapiestufe\u00a0um\u00a0einen\u00a0neuen\u00a0ebenfalls \u00a0hochpreisigen\u00a0\nWirkstoff\u00a0erg\u00e4nzt.\u00a0Dies\u00a0f\u00fchrt\u00a0zu\u00a0einer\u00a0Addition\u00a0der\u00a0Kosten,\u00a0geh t\u00a0aber\u00a0nur\u00a0in\u00a0selte\u2010\nnen\u00a0F\u00e4llen\u00a0auch\u00a0mit\u00a0einer\u00a0Addition\u00a0des\u00a0Nutzens\u00a0f\u00fcr\u00a0den\u00a0Patiente n\u00a0einher.\u00a0Im\u00a0un\u2010\ng\u00fcnstigsten\u00a0Fall\u00a0kann\u00a0es\u00a0sogar\u00a0zu\u00a0einer\u00a0Verst\u00e4rkung\u00a0der\u00a0Nebenwi rkungen\u00a0f\u00fchren.\u00a0\nDaher\u00a0bed\u00fcrfte\u00a0es\u00a0neben\u00a0dem\u00a0jeweiligen\u00a0Erstattungsbetrag\u00a0eines\u00a0 Arzneimittels\u00a0\nauch\u00a0noch\u00a0eines\u00a0Therapiepreises\u00a0f\u00fcr\u00a0die\u00a0Kombinationsanwendung.\u00a0 Derartige\u00a0Rege\u2010\nlungen\u00a0sind\u00a0im\u00a0aktuellen\u00a0AMNOG\u00a0jedoch\u00a0nicht\u00a0vorgesehen\u00a0und\u00a0w\u00e4re n\u00a0vermutlich\u00a0\nauch\u00a0nicht\u00a0praktikabel,\u00a0da\u00a0es\u00a0vor\u00a0allem\u00a0in\u00a0der\u00a0Onkologie\u00a0auch\u00a0v iele\u00a0Kombinations\u2010 \n183\u00a0\n\u00a0therapien\u00a0gibt,\u00a0die\u00a0nicht\u00a0expliz it\u00a0zugelassen\u00a0sind.\u00a0Zudem\u00a0gibt\u00a0 es\u00a0auch\u00a0Kombinatio\u2010\nnen\u00a0mit\u00a0pr\u00e4\u2010AMNOG\u2010Wirkstoffen.\u00a0Hier\u00a0ist\u00a0die\u00a0Evidenzl\u00fccke\u00a0als\u00a0no ch\u00a0gr\u00f6\u00dfer\u00a0anzu\u2010\nsehen\u00a0\u2010\u00a0mit\u00a0enormer\u00a0Ausgabenrele vanz.\u00a0Nichtsdestotroz\u00a0bedarf\u00a0es \u00a0einer\u00a0ad\u00e4qua\u2010\nten\u00a0Regelung,\u00a0um\u00a0den\u00a0bezogen\u00a0auf\u00a0den\u00a0Patiennutzen\u00a0unverh\u00e4ltnism \u00e4\u00dfig\u00a0hohen\u00a0\nKosten\u00a0dieser\u00a0Kombinationsanwendungen\u00a0zu\u00a0begegnen.\u00a0Um\u00a0den\u00a0Aufwa nd\u00a0m\u00f6g\u2010\nlichst\u00a0gering\u00a0zu\u00a0halten,\u00a0w\u00e4re\u00a0die\u00a0Einf\u00fchrung\u00a0eines\u00a0pauschalen\u00a0K ombinationsab\u2010\nschlags\u00a0 sinnvoll,\u00a0 von\u00a0 diesem\u00a0 w\u00e4r en\u00a0 beide\u00a0 Kombinationspartner\u00a0 gl eicherma\u00dfen\u00a0\nbetroffen.\u00a0Zur\u00a0Ermittlumg\u00a0der\u00a0H\u00f6he\u00a0wurden\u00a0exemplarisch\u00a0f\u00fcr\u00a0vier \u00a0verschiedene\u00a0\nWirkstoffkombinationen\u00a0mittels\u00a0des\u00a0 Fair\u00a0Pricing\u00a0Calculators \u00a0die\u00a0Preise\u00a0f\u00fcr\u00a0die\u00a0je\u2010\nweiligen\u00a0Einzelwirkstoffe\u00a0und\u00a0die\u00a0Kombination\u00a0f\u00fcr\u00a0ein\u00a0Jahr\u00a0Kauf kraft\u00a0adjustiert\u00a0\nermittelt\u00a0(Tab.\u00a09.1).\u00a0Bei\u00a0der\u00a0Berechnung\u00a0des\u00a0fairen\u00a0Kombination spreises\u00a0mittels\u00a0\ndes\u00a0Fair\u00a0Pricing\u00a0Calculators \u00a0wurde\u00a0diese\u00a0als\u00a0ein\u00a0Wirkstoff\u00a0betrachtet.\u00a0Lediglich\u00a0bei\u00a0\nden\u00a0Kosten\u00a0f\u00fcr\u00a0Forschung\u00a0und\u00a0Entwicklung\u00a0wurde\u00a0das\u00a01,5\u00a0fache\u00a0de r\u00a0Einzelwirkstof\u2010\nfe\u00a0(375\u00a0Mio.\u00a0Euro)\u00a0angenommen.\u00a0Die\u00a0Produktionskosten\u00a0wurden\u00a0f\u00fcr \u00a0beide\u00a0Wirk\u2010\nstoffe\u00a0additiv\u00a0ber\u00fccksichtigt.\u00a0\nTabelle\u00a09.1:\u00a0Faire\u00a0Preise\u00a0f\u00fcr\u00a0Kombinationen\u00a0anhand\u00a0des\u00a0 Fair\u00a0Pricing\u00a0Calculators \u00a0\nKombination\u00a0 Summe\u00a0der\u00a0Einzelkomponenten Preis\u00a0der\u00a0Kombination Differenz\nNivolumab\u00a0+\u00a0Ipilimumab\u00a0 6.427,82\u00a0\u20ac 5.836,99\u00a0\u20ac 10,1\u00a0%\nDaratumumab\u00a0+\u00a0Pomaldomid\u00a0 5.402,90\u00a0\u20ac 4.645,99\u00a0\u20ac 16,3\u00a0%\nCabozantinib\u00a0+\u00a0Nivolumab\u00a0 5.387,26\u00a0\u20ac 4.283,54\u00a0\u20ac 25,8\u00a0%\nIbrutinib\u00a0+\u00a0Obinutuzumab\u00a0 5.604,79\u00a0\u20ac 4.856,89\u00a0\u20ac 15,4\u00a0%\n\u00a0\nAuf\u00a0Basis\u00a0dieser\u00a0Beispiele\u00a0ersch eint\u00a0ein\u00a0Kombinationsabschlag\u00a0i n\u00a0H\u00f6he\u00a0von\u00a015\u00a0%\u00a0als\u00a0\nangemessen.\u00a0Geht\u00a0man\u00a0nun\u00a0davon\u00a0aus,\u00a0dass\u00a010\u00a0%\u00a0des\u00a0Umsatzes\u00a0pate ntgesch\u00fctzter\u00a0\nArzneimittel\u00a0 auf\u00a0 Kombinationen\u00a0 e ntfallen,\u00a0 k\u00f6nnte\u00a0 man\u00a0 durch\u00a0 dies en\u00a0 Abschlag\u00a0\nEinsparungen\u00a0von\u00a0etwas\u00a0mehr\u00a0als\u00a0400\u00a0Mio.\u00a0Euro\u00a0realisieren.\u00a0In\u00a0d er\u00a0praktischen\u00a0\nUmsetzung\u00a0stellt\u00a0sich\u00a0jedoch\u00a0noch\u00a0 die\u00a0Frage,\u00a0wie\u00a0man\u00a0Kombinatio nstherapien\u00a0\nerkennt.\u00a0So\u00a0gibt\u00a0es\u00a0bislang\u00a0keine\u00a0Kennzeichnung\u00a0von\u00a0Kombination stherapien\u00a0in\u00a0der\u00a0\nRezeptabrechnung.\u00a0Au\u00dferdem\u00a0k\u00f6nnen\u00a0Kombinationstherapien\u00a0sowohl\u00a0 simultan\u00a0als\u00a0\nauch\u00a0sequentiell\u00a0erfolgen,\u00a0weshal b\u00a0die\u00a0zeitgleiche\u00a0Verordnung\u00a0e benfalls\u00a0kein\u00a0aus\u2010\nreichendes\u00a0 Kriterium\u00a0 darstellt.\u00a0 Hi er\u00a0 bedarf\u00a0 es\u00a0 bevorzugt\u00a0 einer\u00a0 regulatorischen\u00a0\nL\u00f6sung\u00a0im\u00a0Rahmen\u00a0des\u00a0E\u2010Rezepts.\u00a0\u00a0\n\u00a0 \u00a0 \n184\u00a0\n\u00a0Herstellerabschlag\u00a0nach\u00a0opt\u2010out\u00a0erh\u00f6hen\u00a0\nDerzeit\u00a0haben\u00a0Hersteller\u00a0die\u00a0M\u00f6glichkeit\u00a0ihr\u00a0Pr\u00e4parat\u00a0vor\u00a0Ende\u00a0 der\u00a0Erstattungsbe\u2010\ntragsverhandlungen\u00a0vom\u00a0Markt\u00a0zu\u00a0nehmen.\u00a0Es\u00a0wird\u00a0dann\u00a0kein\u00a0Ersta ttungsbetrag\u00a0\ngelistet.\u00a0Diese\u00a0M\u00f6glichkeit\u00a0soll \u00a0grunds\u00e4tzlich\u00a0erhalten\u00a0bleiben .\u00a0Die\u00a0Hersteller\u00a0nut\u2010\nzen\u00a0dies\u00a0in\u00a0den\u00a0Preisverhandlungen\u00a0jedoch\u00a0gern\u00a0als\u00a0Druckmittel\u00a0 dem\u00a0die\u00a0GKV\u00a0bis\u2010\nlang\u00a0 nichts\u00a0 entgegenzusetzen\u00a0 hat .\u00a0 Daher\u00a0 sollte\u00a0 der\u00a0 Herstellerab schlag\u00a0 f\u00fcr\u00a0 alle\u00a0\nweiteren\u00a0und\u00a0zuk\u00fcnftigen\u00a0Produkte \u00a0des\u00a0Herstellers\u00a0um\u00a00,5\u00a0Prozen tpunkte\u00a0erh\u00f6ht\u00a0\nwerden,\u00a0um\u00a0den\u00a0Anreiz\u00a0f\u00fcr\u00a0die\u00a0Wahl\u00a0der\u00a0Opt\u2010out\u2010Option\u00a0zu\u00a0verrin gern\u00a0und\u00a0die\u00a0\nTherapievielfalt\u00a0zu\u00a0erhalten.\u00a0Au f\u00a0Basis\u00a0der\u00a0bisherigen\u00a0opt\u2010out\u2010 Arzneimittel\u00a0kom\u2010\nmen\u00a0so\u00a0Einsparungen\u00a0in\u00a0H\u00f6he\u00a0von\u00a0gut\u00a045\u00a0Mio.\u00a0Euro\u00a0zustande.\u00a0\u00a0\nMan\u00a0sollte\u00a0ebenfalls\u00a0erw\u00e4gen,\u00a0diesen\u00a0zus\u00e4tzlichen\u00a0Abschlag\u00a0auch \u00a0f\u00fcr\u00a0Hersteller\u00a0zu\u00a0\nerheben,\u00a0die\u00a0den\u00a0gesamten\u00a0Prozess\u00a0der\u00a0Preisverhandlung\u00a0durchlau fen\u00a0und\u00a0ihr\u00a0\nProdukt\u00a0danach\u00a0vom\u00a0Markt\u00a0nehmen.\u00a0Denn\u00a0dieses\u00a0Verhalten\u00a0f\u00fchrt\u00a0da zu,\u00a0dass\u00a0Pati\u2010\nenten\u00a0zun\u00e4chst\u00a0auf\u00a0ein\u00a0Pr\u00e4parat\u00a0eingestellt\u00a0werden.\u00a0Wenn\u00a0dieses \u00a0nach\u00a0einem\u00a0Jahr\u00a0\nnicht\u00a0mehr\u00a0verf\u00fcgbar\u00a0ist,\u00a0m\u00fcssen\u00a0die\u00a0Patienten\u00a0entweder\u00a0aufw\u00e4nd ig\u00a0umgestellt\u00a0\noder\u00a0die\u00a0Pr\u00e4parate\u00a0aus\u00a0dem\u00a0Ausla nd\u00a0importiert\u00a0werden.\u00a0Beides\u00a0f\u00fc hrt\u00a0zu\u00a0einem\u00a0\nerheblichen\u00a0Mehraufwand\u00a0f\u00fcr\u00a0\u00c4rzte\u00a0und/oder\u00a0Apotheker\u00a0und\u00a0zu\u00a0ste igenden\u00a0Kos\u2010\nten.\u00a0\u00a0\nE\u2010ATMP\u2010Rezept\u00a0\nDer\u00a0Prozess\u00a0der\u00a0Verg\u00fctung\u00a0und\u00a0K osten\u00fcbernahme\u00a0von\u00a0Arzneimitteln \u00a0f\u00fcr\u00a0neuartige\u00a0\nTherapien,\u00a0Advanced\u00a0Therapy\u00a0Medicinal\u00a0Products\u00a0(ATMPs),\u00a0im\u00a0stat ion\u00e4ren\u00a0Sektor\u00a0\nist\u00a0 bislang\u00a0 intransparent\u00a0 und\u00a0 uneinheitlich\u00a0 geregelt.\u00a0 Zum\u00a0 Teil\u00a0 \"versickern\"\u00a0 die\u00a0\nKosten\u00a0f\u00fcr\u00a0ATMPs\u00a0im\u00a0DRG\u2010System,\u00a0 sodass\u00a0nicht\u00a0explizit\u00a0nachvollz ogen\u00a0werden\u00a0\nkann,\u00a0welche\u00a0Arzneimittelkosten\u00a0durch\u00a0ein\u00a0ATMP\u00a0entstanden\u00a0sind. \u00a0Dies\u00a0erschwert\u00a0\nz.\u00a0B.\u00a0 dem\u00a0 G\u2010BA\u00a0 die\u00a0 Ermittlung\u00a0 des\u00a0 Zeitpunktes,\u00a0 an\u00a0 dem\u00a0 die\u00a0 50\u00a0 Mi o.\u00a0 Euro\u2010\nUmsatzgrenze\u00a0f\u00fcr\u00a0 Orphan\u00a0Drugs \u00a0\u00fcberschritten\u00a0wurde,\u00a0obwohl\u00a0seit\u00a0dem\u00a0GSAV\u00a0auch\u00a0\nUms\u00e4tze\u00a0aus\u00a0dem\u00a0station\u00e4ren\u00a0Bere ich\u00a0dabei\u00a0miteinbezogen\u00a0werden\u00a0 sollen.\u00a0\u00a0\nDie\u00a0Einf\u00fchrung\u00a0eines\u00a0E\u2010ATMP\u2010Rezeptes\u00a0w\u00fcrde\u00a0diesen\u00a0Prozess\u00a0struk turieren\u00a0und\u00a0f\u00fcr\u00a0\nmehr\u00a0 Transparenz\u00a0 und\u00a0 Klarheit\u00a0 sorgen.\u00a0 \u00dcber\u00a0 das\u00a0 E\u2010ATMP\u2010Rezept\u00a0 er folgen\u00a0 die\u00a0\nGenehmigung\u00a0und\u00a0die\u00a0Kosten\u00fcbernahme\u00a0durch\u00a0die\u00a0Krankenkassen.\u00a0Da durch\u00a0w\u00fcr\u2010\nde\u00a0die\u00a0NUB\u2010\u00a0und\u00a0Off\u2010lable\u2010use\u2010Be willigung\u00a0ersetzt\u00a0und\u00a0weiter\u00a0st andardisiert.\u00a0Zu\u2010\ndem\u00a0h\u00e4tte\u00a0die\u00a0GKV\u00a0so\u00a0die\u00a0M\u00f6glichk eit\u00a0nachzuvollziehen,\u00a0ob\u00a0die\u00a0E rstattungsbetr\u00e4ge\u00a0\nwirklich\u00a0auch\u00a0die\u00a0Preisobergrenze\u00a0im\u00a0station\u00e4ren\u00a0Bereich\u00a0bilden \u00a0und\u00a0das\u00a0Monito\u2010\nring\u00a0der\u00a0station\u00e4ren\u00a0Arzneimittelausgaben\u00a0w\u00fcrde\u00a0erleichtert.\u00a0\u00a0\nInsgesamt\u00a0k\u00f6nnte\u00a0man\u00a0durch\u00a0diese\u00a0kurzfristigen\u00a0Ma\u00dfnahmen\u00a0gut\u00a011 \u00a0Mrd.\u00a0Euro\u00a0\neinsparen\u00a0 (Abb.\u00a0 9.1).\u00a0 Langfristiges\u00a0 Ziel\u00a0 muss\u00a0 die\u00a0 Einf\u00fchrung\u00a0 kr iterienbasierter\u00a0 \n185\u00a0\n\u00a0Arzneimitelpreise\u00a0sein,\u00a0mit\u00a0denen\u00a0sich\u00a0Einsparungen\u00a0von\u00a0rund\u00a013 \u00a0Mrd.\u00a0Euro\u00a0reali\u2010\nsieren\u00a0lassen\u00a0(Muth\u00a0et\u00a0al.,\u00a02021).\u00a0\nAbb.\u00a09.1:\u00a0Einsparungen\u00a0aus\u00a0dir igistischen\u00a0und\u00a0Steuerungsma\u00dfnahm en\u00a0der\u00a0\nKrankenkassen\u00a0\n\u00a0\nL\u00f6sungsans\u00e4tze\u00a0des\u00a0GKV\u2010SV\u00a0\nErste\u00a0Vorschl\u00e4ge\u00a0wie\u00a0eine\u00a0Anpassung\u00a0des\u00a0AMNOG\u00a0aussehen\u00a0kann,\u00a0un terbreitete\u00a0\nder\u00a0GKV\u2010SV\u00a0Ende\u00a0Juli\u00a02021\u00a0in\u00a0einem\u00a0Positionspapier\u00a0zu\u00a0patentges ch\u00fctzten\u00a0Arznei\u2010\nmitteln.\u00a0Darin\u00a0hei\u00dft\u00a0es:\u00a0\"Eine\u00a0nachhaltige\u00a0und\u00a0qualitativ\u00a0hochw ertige\u00a0Versorgung\u00a0\nmit\u00a0Arzneimitteln\u00a0ist\u00a0jedoch\u00a0nur\u00a0m\u00f6glich,\u00a0wenn\u00a0sich\u00a0die\u00a0Kosten\u00a0 f\u00fcr\u00a0neue\u00a0Arzneimit\u2010\ntel\u00a0an\u00a0nachgewiesenen\u00a0Behandlungserfolgen\u00a0orientieren.\"\u00a0(GKV\u2010SV ,\u00a02021b).\u00a0Das\u00a0\nkann\u00a0das\u00a0AMNOG\u00a0in\u00a0seiner\u00a0derzeitigen\u00a0Form\u00a0vor\u00a0allem\u00a0bei\u00a0Arzneim itteln\u00a0mit\u00a0be\u2010\nschleunigter\u00a0Zulassung,\u00a0bei\u00a0dene n\u00a0zum\u00a0Zeitpunkt\u00a0der\u00a0Nutzenbewer tung\u00a0nur\u00a0sehr\u00a0\nwenige\u00a0Daten\u00a0vorliegen,\u00a0nicht\u00a0leisten.\u00a0Daher\u00a0schl\u00e4gt\u00a0der\u00a0GKV\u2010SV \u00a0in\u00a0seinem\u00a0Papier\u00a0\nals\u00a0 Weiterentwicklung\u00a0 des\u00a0 AMNOG\u00a0 das\u00a0 sogenannte\u00a0 \"Interimspreis\u2010M odell\u00a0 f\u00fcr\u00a0\nArzneimittel\u00a0mit\u00a0beschleunigter\u00a0Zulassung\"\u00a0vor\u00a0(s.\u00a0Abb.\u00a09.2)\u00a0(G KV\u2010SV,\u00a02021b).\u00a0Ziel\u00a0\ndes\u00a0Modells\u00a0ist\u00a0es,\u00a0Preis\u00a0und\u00a0Evid enz\u00a0in\u00a0ein\u00a0angemessenes\u00a0Verh\u00e4 ltnis\u00a0zu\u00a0setzen.\u00a0\nEin\u00a0wesentlicher\u00a0Unterschied\u00a0zum\u00a0aktuellen\u00a0Vorgehen\u00a0ist,\u00a0dass\u00a0d ie\u00a0Hersteller\u00a0den\u00a0\nMarkteinf\u00fchrungspreis\u00a0nicht\u00a0mehr\u00a0frei\u00a0w\u00e4hlen\u00a0d\u00fcrfen.\u00a0Stattdesse n\u00a0wird\u00a0auf\u00a0Basis\u00a0\nder\u00a0zweckm\u00e4\u00dfigen\u00a0Vergleichsthera pie\u00a0ein\u00a0Interimspreis\u00a0gebildet. \u00a0Dieser\u00a0gilt,\u00a0bis\u00a0\nausreichend\u00a0 Daten\u00a0 vorliegen,\u00a0 anha nd\u00a0 derer\u00a0 man\u00a0 eine\u00a0 Zusatznutzen bewertung\u00a0\nvornehmen\u00a0kann.\u00a0Zus\u00e4tzlich\u00a0werden\u00a0ab\u00a0dem\u00a0ersten\u00a0Tag\u00a0der\u00a0Anwendu ng\u00a0anwen\u2010\ndungsbegleitende\u00a0Datenerhebungen\u00a0in\u00a0einheitlichen\u00a0Indikationsre gistern\u00a0vorge\u2010\nnommen.\u00a0\n \n186\u00a0\n\u00a0Diese\u00a0Register\u00a0sollen\u00a0unabh\u00e4ngig\u00a0b etrieben\u00a0werden.\u00a0Die\u00a0Kosten\u00a0t ragen\u00a0die\u00a0phar\u2010\nmazeutischen\u00a0Unternehmer.\u00a0\nF\u00fcr\u00a0alle\u00a0Arzneimittel\u00a0soll\u00a0dar \u00fcber\u00a0hinaus\u00a0die\u00a0Nutzenbewertung\u00a0r egelm\u00e4\u00dfig\u00a0und\u00a0\nsystematisch\u00a0aktualisiert\u00a0werden.\u00a0In\u00a0Folge\u00a0dessen\u00a0erfolgt\u00a0auch\u00a0 eine\u00a0Dynamisierung\u00a0\ndes\u00a0Erstattungsbetrags.\u00a0Dieser\u00a0soll\u00a0zuk\u00fcnftig\u00a0neben\u00a0der\u00a0Zusatzn utzenbewertung\u00a0\nauf\u00a0den\u00a0rationalen\u00a0Preisbildungskriterien\u00a0tats\u00e4chliche\u00a0Forschun gs\u2010\u00a0und\u00a0Entwick\u2010\nlungskosten\u00a0sowie\u00a0tats\u00e4chliche\u00a0Preise\u00a0des\u00a0Arzneimittels\u00a0in\u00a0ande ren\u00a0europ\u00e4ischen\u00a0\nL\u00e4ndern\u00a0beruhen.\u00a0Machen\u00a0die\u00a0Herst eller\u00a0dazu\u00a0zweifelhafte\u00a0Angabe n,\u00a0drohen\u00a0ihnen\u00a0\nSanktionen.\u00a0\u00a0\nF\u00fcr\u00a0Arzneimittel\u00a0mit\u00a0e iner\u00a0regul\u00e4ren\u00a0Zulassung\u00a0soll\u00a0der\u00a0erste\u00a0E rstattungsbetrag\u00a0\nzuk\u00fcnftig\u00a0r\u00fcckwirkend\u00a0ab\u00a0dem\u00a0ers ten\u00a0Tag\u00a0des\u00a0Inverkehrbringens\u00a0g elten.\u00a0\nAll\u00a0diese\u00a0Ma\u00dfnahmen\u00a0l\u00f6sen\u00a0jedoch\u00a0noch\u00a0nicht\u00a0das\u00a0Problem\u00a0von\u00a0Mis chpreisen,\u00a0\nwenn\u00a0f\u00fcr\u00a0ein\u00a0Arzneimittel\u00a0nur\u00a0Date n\u00a0f\u00fcr\u00a0eine\u00a0eng\u00a0umschriebene\u00a0P opulation\u00a0vorlie\u2010\ngen,\u00a0die\u00a0Zulassung\u00a0jedoch\u00a0wesentlich\u00a0breiter\u00a0ausgesprochen\u00a0wurd e.\u00a0In\u00a0solchen\u00a0\nF\u00e4llen\u00a0soll\u00a0der\u00a0G\u2010BA\u00a0in\u00a0einer\u00a0Fokus\u2010Liste\u00a0die\u00a0Verordnung\u00a0eines\u00a0 Arzneimittels\u00a0f\u00fcr\u00a0ein\u00a0\nbegrenztes\u00a0Anwendungsgebiet\u00a0vorgeben\u00a0k\u00f6nnen,\u00a0bis\u00a0auch\u00a0f\u00fcr\u00a0die\u00a0w eiteren\u00a0zuge\u2010\nlassenen\u00a0Anwendungsgebiete\u00a0aussage kr\u00e4ftige\u00a0Daten\u00a0zur\u00a0Verf\u00fcgung\u00a0 stehen.\u00a0\u00a0\u00a0\nUnabh\u00e4ngig\u00a0von\u00a0den\u00a0Neuregelungen\u00a0zu\u00a0den\u00a0Erstattungsbetr\u00e4gen\u00a0sch l\u00e4gt\u00a0der\u00a0GKV\u2010\nSV\u00a0weiterhin\u00a0vor,\u00a0das\u00a0Gesamtvolu men\u00a0der\u00a0Arzneimittelausgaben\u00a0zu \u00a0begrenzen\u00a0und\u00a0\nden\u00a0Krankenkassen\u00a0die\u00a0M\u00f6glichkeit\u00a0einzur\u00e4umen,\u00a0aus\u00a0einen\u00a0Vertra gskatalog\u00a0medi\u2010\nzinisch\u2010therapeutisch\u00a0 vergleichba rer\u00a0 Arzneimittel\u00a0 einzelne\u00a0 Arzn eimittel\u00a0 f\u00fcr\u00a0 die\u00a0\nbevorzugte\u00a0Versorgung\u00a0ihrer\u00a0 Versicherten\u00a0auszuw\u00e4hlen.\u00a0\n\u00a0 \u00a0 \n187\u00a0\n\u00a0\nEBV\u00a0=\u00a0Erstattungsbetragsverhandl ung,\u00a0AbD\u00a0=\u00a0Anwendungsbegleitend e\u00a0Datenerhebung\u00a0\nQuelle:\u00a0nach\u00a0GKV\u2010SV ,\u00a02021b,\u00a0S.8\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nAbb.\u00a09.2:\u00a0Interimspreis\u2010Modell\u00a0f\u00fcr\u00a0Arzneimittel\u00a0mit\u00a0beschleunig ter\u00a0Zulassung\u00a0 \n188\u00a0\n\u00a0 Langfristiges\u00a0Ziel\u00a09.2\nFasst\u00a0man\u00a0die\u00a0vorangegangenen\u00a0Ausf\u00fchrungen\u00a0zusammen,\u00a0wird\u00a0deutl ich,\u00a0dass\u00a0es\u00a0\neiner\u00a0nachhaltigen,\u00a0fairen\u00a0und\u00a0i nnovationsf\u00f6rder nden\u00a0Preislogik \u00a0bedarf,\u00a0um\u00a0einer\u2010\nseits\u00a0die\u00a0Finanzierbarkeit\u00a0des\u00a0G KV\u2010Systems\u00a0zu\u00a0gew\u00e4hrleisten\u00a0und \u00a0andererseits\u00a0der\u00a0\nVersichertengemeinschaft\u00a0den\u00a0Zug ang\u00a0zu\u00a0innovativen\u00a0Therapieform en\u00a0auch\u00a0zu\u2010\nk\u00fcnftig\u00a0zu\u00a0erm\u00f6glichen.\u00a0Grundlage\u00a0dieser\u00a0Preislogik\u00a0m\u00fcssen\u00a0obje ktivierbare\u00a0und\u00a0\ntransparente\u00a0Kriterien\u00a0sein,\u00a0um\u00a0allen\u00a0Interessengruppen\u00a0gerecht \u00a0zu\u00a0werden\u00a0und\u00a0\nder\u00a0Strategieanf\u00e4lligkeit\u00a0vorzubeugen.\u00a0\nDaher\u00a0schlagen\u00a0wir\u00a0als\u00a0zuk\u00fcnftige s\u00a0Modell\u00a0f\u00fcr\u00a0eine\u00a0kontinuierli che\u00a0Berichtigung\u00a0der\u00a0\nArzneimittelpreise\u00a0das\u00a0nachfolgende\u00a0Modell\u00a0vor:\u00a0\nAbb.\u00a09.3:\u00a0Kriterienbasierte\u00a0Pre isfindung\u00a0f\u00fcr\u00a0neue\u00a0Arzneimittel\u00a0 \u2013\u00a0Weiterent\u2010\nwicklung\u00a0des\u00a0AMNOG\u00a0\n\u00a0\nQuelle:\u00a0eigene\u00a0Darstellung\u00a0\nNeue\u00a0Arzneimittel\u00a0werden\u00a0zun\u00e4chs t\u00a0nach\u00a0ihrer\u00a0Nutzenevidenz\u00a0bei\u00a0 Markteinf\u00fch\u2010\nrung\u00a0eingestuft.\u00a0Bei\u00a0positiver\u00a0N utzenevidenz\u00a0gilt\u00a0ein\u00a0fairer\u00a0Ei nf\u00fchrungspreis\u00a0f\u00fcr\u00a0\nInnovationen,\u00a0welcher\u00a0bis\u00a0hin\u00a0zu \u00a0einer\u00a0kriterienbasierten\u00a0Preis obergrenze\u00a0reichen\u00a0\nkann.\u00a0M\u00f6gliche\u00a0Kriterien\u00a0sind\u00a0medical\u00a0need,\u00a0Evidenz,\u00a0Versorgung ssicherheit,\u00a0For\u2010\nschung\u00a0in\u00a0der\u00a0EU\u00a0und\u00a0Bereitstellung\u00a0von\u00a0Daten\u00a0zu\u00a0Forschungszwec ken.\u00a0Wie\u00a0der\u00a0\nfaire\u00a0Einf\u00fchrungspreis\u00a0bzw.\u00a0die\u00a0P reisobergrenze\u00a0definiert\u00a0werde n\u00a0kann,\u00a0hat\u00a0die\u00a0\nAIM\u00a0mit\u00a0dem\u00a0Fair\u00a0Pricing\u00a0Calcula tor\u00a0gezeigt.\u00a0Ausgehend\u00a0von\u00a0dies em\u00a0Einf\u00fchrungs\u2010\npreis\u00a0als\u00a0Startpunkt\u00a0wird\u00a0das\u00a0Preisniveau\u00a0verfl\u00fcssigt.\u00a0Das\u00a0bede utet,\u00a0dass\u00a0\u00fcber\u00a0die\u00a0\n \n189\u00a0\n\u00a0Zeit\u00a0ein\u00a0Preisverfall\u00a0\u00fcber\u00a0gestaffelte\u00a0Abschl\u00e4ge\u00a0definiert\u00a0wird ,\u00a0der\u00a0mit\u00a0Ablauf\u00a0des\u00a0\nPatents\u00a0ins\u00a0generische\u00a0Preisnive au\u00a0m\u00fcndet.\u00a0Die\u00a0Abschl\u00e4ge\u00a0richte n\u00a0sich\u00a0nach\u00a0der\u00a0\nvorliegenden\u00a0Evidenz.\u00a0Diese\u00a0wir d\u00a0mittels\u00a0anwendungsbegleitender \u00a0Datenerhebun\u2010\ngen\u00a0\u00fcber\u00a0unabh\u00e4ngige\u00a0Indikationsr egister\u00a0erhoben\u00a0und\u00a0regelm\u00e4\u00dfig \u00a0bewertet.\u00a0Je\u00a0\ngr\u00f6\u00dfer\u00a0der\u00a0Nutzen\u00a0eines\u00a0Arzneimittels,\u00a0desto\u00a0h\u00f6her\u00a0der\u00a0Preis.\u00a0S o\u00a0werden\u00a0Innovati\u2010\nonen\u00a0gef\u00f6rdert\u00a0und\u00a0Kosten\u00a0f\u00fcr\u00a0weniger\u00a0n\u00fctzliche\u00a0Pr\u00e4parate\u00a0gesen kt.\u00a0\u00a0\nBei\u00a0unsicherer\u00a0oder\u00a0fehlender\u00a0Nutzenevidenz\u00a0gilt\u00a0zun\u00e4chst\u00a0ein\u00a0I nterimspreis,\u00a0der\u00a0\nsich\u00a0an\u00a0Vergleichstherapien\u00a0mit\u00a0Preisen\u00a0auch\u00a0aus\u00a0dem\u00a0generische n\u00a0Markt\u00a0orien\u2010\ntiert.\u00a0Je\u00a0nach\u00a0vorhandener\u00a0Evidenz\u00a0kann\u00a0der\u00a0Interimspreis\u00a0mit\u00a0e inem\u00a0Aufschlag\u00a0\nversehen\u00a0werden,\u00a0sodass\u00a0er\u00a0\u00fcber\u00a0 dem\u00a0generischen\u00a0Preisniveau\u00a0lie gt.\u00a0Liegt\u00a0zu\u00a0ei\u2010\nnem\u00a0sp\u00e4teren\u00a0Zeitpunkt\u00a0eine\u00a0positive\u00a0Nutzenevidenz\u00a0vor,\u00a0kann\u00a0de r\u00a0Preis\u00a0anhand\u00a0\nfairer\u00a0Kriterien\u00a0bis\u00a0hin\u00a0zur\u00a0Pre isobergrenze\u00a0bewegt\u00a0werden.\u00a0In\u00a0 beiden\u00a0F\u00e4llen\u00a0bewe\u2010\ngen\u00a0 Abschl\u00e4ge\u00a0 das\u00a0 Preisniveau\u00a0 mit\u00a0 der\u00a0 Zeit\u00a0 automatisch\u00a0 hin\u00a0 zum\u00a0 generischen\u00a0\nPreisniveau,\u00a0in\u00a0welches\u00a0das\u00a0Arzn eimittel\u00a0mit\u00a0Patentauslauf\u00a0m\u00fcnd et.\u00a0\u00a0\nL\u00e4sst\u00a0sich\u00a0f\u00fcr\u00a0das\u00a0Arzneimittel\u00a0keine\u00a0Evidenz\u00a0nachweisen,\u00a0wird\u00a0 es\u00a0in\u00a0eine\u00a0Festbe\u2010\ntragsgruppe\u00a0eingegliedert.\u00a0\u00a0\nMit\u00a0diesem\u00a0Modell\u00a0k\u00f6nnen\u00a0bei\u00a0Markteintritt,\u00a0in\u00a0der\u00a0Zeit\u00a0des\u00a0Pat entschutzes\u00a0und\u00a0\nb e i m \u00a0E i n t r i t t \u00a0i n \u00a0d i e \u00a0p a t e n t f r e i e \u00a0V e r m a r k t u n g s p h a s e \u00a0n a c h h a l t i g \u00a0m arktgerechte\u00a0\nPreise\u00a0realisiert\u00a0werden.\u00a0Innovationen\u00a0werden\u00a0gef\u00f6rdert\u00a0und\u00a0die \u00a0Kosten\u00a0f\u00fcr\u00a0Arz\u2010\nneimittel\u00a0ohne\u00a0therapeutischen\u00a0Benefit\u00a0fr\u00fchzeitig\u00a0und\u00a0nachhalti g\u00a0gesenkt.\u00a0\nQuellen\u00a0\nGKV\u2010SV\u00a0(2021a).\u00a0GKV\u2010Arzneimittel\u2010Schnellinformation\u00a0f\u00fcr\u00a0Deutsch land.\u00a0Januar\u00a0bis\u00a0Dezember\u00a02020.\u00a0https://www.gkv\u2010\ngamsi.de/media/dokumente/quartalsberichte/2020/q4_23/Bundesberi cht_GAmSi_202012_konsolidiert.pdf\u00a0\nGKV\u2010SV\u00a0(2021b).\u00a0Echte\u00a0Arzneimittelinnovationen\u00a0f\u00f6rdern\u00a0und\u00a0die\u00a0 Versorgung\u00a0st\u00e4rken.\u00a0https://gkv\u2010\nspitzenverband.de/media/dokumente/service_1/publikationen/20210 716_Positionspapier_Arzneimittelinnovatione\nn_barrierefrei.pdf,\u00a0letzter\u00a0Zugriff:\u00a008.12.2021.\u00a0\nHaarhoff\u00a0(2022a).\u00a0\u201eSpiel\u00a0mit\u00a0dem\u00a0Feuer\u201c,\u00a0Tagesspiegel\u00a0Backgroun d,\u00a021.02.2022.\u00a0\nhttps://background.tagesspiegel.de/gesundheit/spiel\u2010mit\u2010dem\u2010feu er,\u00a0letzter\u00a0Zugriff:\u00a009.03.2022\u00a0\nHaarhoff\u00a0(2022b).\u00a0\u201ePay\u2010for\u2010Performance\u00a0ist\u00a0die\u00a0Zukunft\u201c,\u00a0Tagess piegel\u00a0Background,\u00a010.02.2022.\u00a0\nhttps://background.tagesspiegel.de/gesundheit/pay\u2010for\u2010performan ce\u2010ist\u2010die\u2010zukunft,\u00a0letzter\u00a0Zugriff:\u00a009.03.2022\u00a0\nIQWiG\u00a0(2021).\u00a0Evidenz\u00a0zu\u00a0Orphan\u00a0Drugs.\u00a023.12.2021\u00a0Muth\u00a0L,\u00a0Neitemeier\u00a0S,\u00a0Dammann\u00a0D,\u00a0 Steimle\u00a0T,\u00a0Glaeske\u00a0G\u00a0(2021).\u00a0A IM\u00a0Fair\u00a0Pricing\u00a0Calculator\u00a0f\u00fcr\u00a0p atentgesch\u00fctzte\u00a0Arzneimittel.\u00a0. \u00a0\nwww.socium.uni\u2010bremen.de/uploads/AIM_Fair_Pricing_Calculator_fu r_patentgeschutzte_Arzneimittel.pdf,\u00a0letzter\u00a0\nZugriff:\u00a008.12.2021.\u00a0\nNOZ\u00a0\u2010\u00a0Neue\u00a0Osnabr\u00fccker\u00a0Zeitung\u00a0(2021).\u00a0Gesetzliche\u00a0Krankenkasse n\u00a0fordern\u00a0von\u00a0Ampel\u2010Verhandlern\u00a0drei\u00a0Ma\u00dfnahmen\u00a0zur\u00a0\nBeitragsstabilisierung .\u00a0file:///C:/Users/julia/AppData/Local/Te mp/presseportal_gesetzliche\u2010krankenkassen\u2010fordern\u2010\nvon\u2010ampel\u2010verhan_5060542.pdf,\u00a0letzter\u00a0Zugriff:\u00a009.03.2022\u00a0 \n190\u00a0\n\u00a0Schwabe\u00a0U,\u00a0Ludwig\u00a0W\u2010D\u00a0(2020).\u00a0Arzneiverordnungs\u2010Report\u00a02020.\u00a0Be rlin,\u00a0Heidelberg:\u00a0Springer\u00a0\nSPD,\u00a0B\u00fcndnis\u00a090/Die\u00a0Gr\u00fcnen,\u00a0FDP\u00a0(2021).\u00a0Mehr\u00a0Fortschritt\u00a0wagen\u00a0 \u2013\u00a0B\u00fcndnis\u00a0f\u00fcr\u00a0Freiheit,\u00a0Gerechtig keit\u00a0und\u00a0Nachhaltigkeit,\u00a0S.\u00a087 \u00a0\nWoratschka\u00a0(2022).\u00a0\u201eFallpauschalen\u00a0als\u00a0Grundger\u00fcst\u00a0erhalten\u201c,\u00a0T agesspiegel\u00a0Background,\u00a006.01.2022.\u00a0\nhttps://background.tagesspiegel.de/gesundheit/fallpauschalen\u2010al s\u2010grundgeruest\u2010erhalten,\u00a0letzter\u00a0Zugriff:\u00a0\n09.03.2022\u00a0\n\u00a0\u00a0 \n191\u00a0\n\u00a010 Methodik\u00a0\nF\u00fcr\u00a0die\u00a0Innovationsreporte\u00a02013\u00a0bis\u00a02020\u00a0wurden\u00a0Arzneimittel\u00a0mi t\u00a0neuen\u00a0Wirk\u2010\nstoffen\u00a0bewertet,\u00a0die\u00a0jeweils\u00a0dre i\u00a0Jahre\u00a0zuvor\u00a0erstmals\u00a0in\u00a0den\u00a0 deutschen\u00a0Arznei\u2010\nmittelmarkt\u00a0eingef\u00fchrt\u00a0wurden.\u00a0Au\u00dfer\u00a0in\u00a0den\u00a0Jahren\u00a02019\u00a0sowie\u00a0i m\u00a0Jahr\u00a02020\u00a0\nwurden\u00a0in\u00a0den\u00a0vorangegangenen\u00a0Innovationsreporten\u00a0keine\u00a0Impfsto ffe\u00a0bewertet,\u00a0\nda\u00a0ihre\u00a0Zulassung\u00a0anderen\u00a0Bedingungen\u00a0unterliegt.\u00a0Im\u00a0Jahr\u00a02019\u00a0 wurde\u00a0der\u00a0Me\u2010\nningokokken\u2010B\u2010Impfstoff\u00a0 Trumenba \u00ae\u00a0 aufgenommen\u00a0 und\u00a0 in\u00a0 2020\u00a0 die\u00a0 H PV\u2010\nImpfstoffe.\u00a0Generell\u00a0wurden\u00a0neue\u00a0Arzneimittel\u00a0mit\u00a0bereits\u00a0in\u00a0an deren\u00a0zugelasse\u2010\nnen\u00a0Pr\u00e4paraten\u00a0verf\u00fcgbaren\u00a0Wirkstoffen\u00a0(z.\u00a0B.\u00a0Generika)\u00a0oder\u00a0ne ue\u00a0Kombinatio\u2010\nnen\u00a0aus\u00a0bereits\u00a0bekannten\u00a0Wirkstoffen\u00a0nicht\u00a0ber\u00fccksichtigt.\u00a0Die \u00a0Ausnahme\u00a0im\u00a0\nInnovationsreport\u00a0 2020\u00a0 bilden\u00a0 die\u00a0 beiden\u00a0 Wirkstoffe\u00a0 Dimethylfum arat\u00a0 (Ski\u2010\nlarence\u00ae)\u00a0 und\u00a0 Cladribin\u00a0 (Mavencla d\u00ae)\u00a0 aufgrund\u00a0 deren\u00a0 pharmako\u00f6ko nomischer\u00a0\nRelevanz\u00a0im\u00a0Sinne\u00a0des\u00a0 Life\u2010Cycle \u2010Managements,\u00a0die\u00a0bereits\u00a0zuvor\u00a0als\u00a0Tecfidera\u00ae\u00a0\n(Indikation\u00a0MS)\u00a0bzw.\u00a0Leustatin\u00ae\u00a0( Indikation:\u00a0Haarzell\u2010Leuk\u00e4mie) \u00a0als\u00a0Fertigarznei\u2010\nmittel\u00a0verf\u00fcgbar\u00a0waren.\u00a0Von\u00a0den\u00a0neuen\u00a0Wirkstoffen\u00a0bzw.\u00a0Wirkstof fkombinationen\u00a0\nder\u00a0jeweiligen\u00a0Jahrg\u00e4nge\u00a0wurden\u00a0P r\u00e4parate\u00a0nicht\u00a0in\u00a0unsere\u00a0Bewer tung\u00a0miteinbe\u2010\nzogen,\u00a0die\u00a0in\u00a0der\u00a0ambulanten\u00a0Versorgung\u00a0keine\u00a0Rolle\u00a0spielen,\u00a0d. \u00a0h.\u00a0wenn\u00a0zu\u00a0diesen\u00a0\nkeine\u00a0auswertbaren\u00a0Abrechnungsdat en\u00a0vorliegen.\u00a0Dies\u00a0trifft\u00a0mitu nter\u00a0auch\u00a0auf\u00a0\nArzneimittel\u00a0mit\u00a0speziellen\u00a0und/oder\u00a0seltenen\u00a0Indikationen\u00a0zu,\u00a0 die\u00a0ggf.\u00a0ebenso\u00a0\nnicht\u00a0in\u00a0unsere\u00a0Bewertung\u00a0mit\u00a0einbezogen\u00a0wurden.\u00a0\nDie\u00a0Bewertung\u00a0der\u00a0Studienlage\u00a0basierte\u00a0zum\u00a0einen\u00a0auf\u00a0den\u00a0Ergebn issen\u00a0der\u00a0Zulas\u2010\nsungsstudien\u00a0sowie\u00a0dem\u00a0Beurteilungsbericht\u00a0der\u00a0verantwortlichen \u00a0Zulassungsbe\u2010\nh\u00f6rde\u00a0und\u00a0zum\u00a0anderen\u00a0auf\u00a0Litera turrecherchen,\u00a0welche\u00a0die\u00a0jewei ligen\u00a0Autoren\u00a0\nunabh\u00e4ngig\u00a0voneinander\u00a0durchf\u00fchrten.\u00a0Haupts\u00e4chlich\u00a0wurde\u00a0in\u00a0der \u00a0Literaturda\u2010\ntenbank\u00a0MEDLINE\u00a0\u00fcber\u00a0PubMed\u00a0recherchiert.\u00a0Zus\u00e4tzlich\u00a0zur\u00a0Suche\u00a0 \u00fcber\u00a0Literatur\u2010\ndatenbanken\u00a0wurden\u00a0Standardwerke\u00a0 der\u00a0wissenschaftlichen\u00a0Literat ur\u00a0genutzt.\u00a0\nGem\u00e4\u00df\u00a0den\u00a0Grunds\u00e4tzen\u00a0der\u00a0Evidenzbasierten\u00a0Medizin\u00a0(EbM),\u00a0dem\u00a0M ethodenpa\u2010\npier\u00a0des\u00a0IQWiG,\u00a0analog\u00a0zum\u00a0Vorgehen\u00a0nach\u00a0\u00a7\u00a035\u00a0Absatz\u00a01b\u00a0Satz\u00a01\u00a0 bis\u00a05\u00a0SGB\u00a0V\u00a0und\u00a0\nnach\u00a0\u00a7\u00a013\u00a0Absatz\u00a02\u00a0der\u00a0Verfahrensordnung\u00a0des\u00a0G\u2010BA\u00a0wurden\u00a0im\u00a0Wes entlichen\u00a0\nkontrollierte\u00a0und\u00a0bzw.\u00a0oder\u00a0versorgungsrelevante\u00a0klinische\u00a0Stud ien\u00a0mit\u00a0patienten\u2010\nrelevanten\u00a0Endpunkten\u00a0eingeschlo ssen,\u00a0insbesondere\u00a0zur\u00a0Mortalit \u00e4t,\u00a0Morbidit\u00e4t\u00a0\nund\u00a0Lebensqualit\u00e4t.\u00a0Bei\u00a0der\u00a0Extraktion\u00a0der\u00a0Ergebnisse\u00a0zu\u00a0prim\u00e4r en\u00a0und\u00a0sekund\u00e4ren\u00a0\nEndpunkten\u00a0der\u00a0Studien\u00a0wurde\u00a0auf\u00a0die\u00a0Verf\u00fcgbarkeit\u00a0von\u00a0Ergebnis sen\u00a0zur\u00a0Health\u00a0\nRelated\u00a0Quality\u00a0of\u00a0Life \u00a0(HRQoL)\u00a0geachtet;\u00a0sofern\u00a0vorhanden,\u00a0wurden\u00a0sie\u00a0in\u00a0den\u00a0\nBericht\u00a0aufgenommen.\u00a0\nDie\u00a0Bewertung\u00a0neuer\u00a0Arzneimittel\u00a0wird\u00a0durch\u00a0Sekund\u00e4rliteratur\u00a0u nter\u00a0dem\u00a0Aspekt\u00a0\n\"Wie\u00a0bewerten\u00a0andere\"\u00a0erg\u00e4nzt.\u00a0D azu\u00a0geh\u00f6ren\u00a0die\u00a0Bewertungen\u00a0des \u00a0Innovations\u2010\ngrades\u00a0A\u00a0bis\u00a0D\u00a0nach\u00a0der\u00a0Methode\u00a0von\u00a0Fricke\u00a0und\u00a0Klaus,\u00a0die\u00a0Bewer tungen\u00a0des\u00a0arz\u2010 \n192\u00a0\n\u00a0neitelegramms\u00a0(a\u2010t)\u00a0und\u00a0seiner\u00a0Datenbank\u00a0(atd),\u00a0des\u00a0Arzneimitte lbriefes\u00a0(AMB)\u00a0\nsowie\u00a0die\u00a0sieben\u00a0Bewertungsstufen\u00a0von\u00a0 Prescrire\u00a0International \u00a0zwischen\u00a0\u201e BRAVO\u201c\u00a0\nund\u00a0\u201enot\u00a0acceptable \u201c.\u00a0Die\u00a0Methode\u00a0von\u00a0Fricke\u00a0und\u00a0Kollegen\u00a0basiert\u00a0auf\u00a0pharmako\u2010\nlogischen\u00a0Kriterien\u00a0und\u00a0beurteilt \u00a0prim\u00e4r\u00a0die\u00a0Neuartigkeit\u00a0des\u00a0W irkungsmechanis\u2010\nmus\u00a0der\u00a0Arzneistoffe.\u00a0Das\u00a0Hauptgewicht\u00a0der\u00a0Bewertung\u00a0liegt\u00a0dabe i\u00a0auf\u00a0dem\u00a0ange\u2010\nstrebten\u00a0therapeutischen\u00a0Effekt:\u00a0\u201eF\u00fchrt\u00a0ein\u00a0neuartiger\u00a0Wirkungs mechanismus\u00a0(A)\u00a0\nnicht\u00a0zu\u00a0der\u00a0entsprechenden\u00a0Verbesserung\u00a0des\u00a0therapeutischen\u00a0Nu tzens,\u00a0wird\u00a0die\u00a0\nunterschiedliche\u00a0Bewertung\u00a0der\u00a0klinischen\u00a0Eigenschaften\u00a0durch\u00a0e ine\u00a0zus\u00e4tzliche\u00a0\nKennzeichnung\u00a0 hervorgehoben.\u00a0 Solc he\u00a0 Doppelbewertungen\u00a0 ergeben\u00a0 s ich\u00a0 aus\u00a0\neiner\u00a0unterschiedlichen\u00a0Beurteilung\u00a0der\u00a0pharmakologischen\u00a0Aspek te\u00a0(z.\u00a0B.\u00a0neuarti\u2010\nges\u00a0 Wirkprinzip)\u00a0 und\u00a0 der\u00a0 klinischen\u00a0 Studiendaten,\u00a0 wenn\u00a0 ein\u00a0 phar makologisch\u00a0\ninnovatives\u00a0Arzneimittel\u00a0keine\u00a0th erapeutische\u00a0\u00dcberlegenheit\u00a0geg en\u00a0\u00fcber\u00a0bereits\u00a0\nverf\u00fcgbaren\u00a0Arzneimitteln\u00a0mit\u00a0gle icher\u00a0Indikation\u00a0gezeigt\u00a0hat\u00a0( A/C)\u201c\u00a0(Fricke,\u00a02016).\u00a0\u00a0\nDie\u00a0anschlie\u00dfende\u00a0Beurteilung\u00a0der\u00a0Evidenz\u00a0nahmen\u00a0die\u00a0Autoren\u00a0im \u00a0Konsensver\u2010\nfahren\u00a0vor.\u00a0\u00a0\nF\u00fcr\u00a0die\u00a0Leitlinienempfehlungen\u00a0zu\u00a0den\u00a0einzelnen\u00a0Arzneimitteln\u00a0u nd\u00a0ihren\u00a0jeweili\u2010\ngen\u00a0Indikationsgebieten\u00a0wurden\u00a0Leitlinien\u00a0genutzt,\u00a0die\u00a0im\u00a0Regis ter\u00a0der\u00a0Arbeitsge\u2010\nmeinschaft\u00a0der\u00a0Wissenschaftliche n\u00a0Medizinischen\u00a0Fachgesellschaf ten\u00a0e.V.\u00a0(AWMF)\u00a0\neingetragen\u00a0 sind.\u00a0 Wurde\u00a0 zu\u00a0 den\u00a0 en tsprechenden\u00a0 Indikationsgebiet en\u00a0 keine\u00a0\nAWMF\u2010Leitlinie\u00a0gefunden,\u00a0erfolgte\u00a0eine\u00a0Recherche\u00a0nach\u00a0anderen\u00a0n ationalen\u00a0oder\u00a0\ninternationalen\u00a0Handlungsempfehlungen.\u00a0\u00a0\nBei\u00a0den\u00a0einzelnen\u00a0Wirkstoffen\u00a0wurden\u00a0verschiedene\u00a0Punkte\u00a0separa t\u00a0bewertet:\u00a0\nerstens\u00a0die\u00a0Verf\u00fcgbarkeit\u00a0bestehender\u00a0medikament\u00f6ser\u00a0Therapien, \u00a0zweitens\u00a0der\u00a0\npatientenorientierte\u00a0(Zusatz\u2010)\u00a0N utzen\u00a0und\u00a0drittens\u00a0die\u00a0Kosten\u00a0d es\u00a0neuen\u00a0Arznei\u2010\nmittels\u00a0im\u00a0Vergleich\u00a0zu\u00a0bisher\u00a0verf\u00fcgbaren\u00a0Arzneimitteln.\u00a0Waren \u00a0bis\u00a0dato\u00a0keine\u00a0\nmedikament\u00f6sen\u00a0Therapien\u00a0f\u00fcr\u00a0die\u00a0jeweilige\u00a0Erkrankung\u00a0verf\u00fcgbar ,\u00a0so\u00a0wurde\u00a0die\u00a0\ntherapeutische\u00a0Wirksamkeit\u00a0des\u00a0neuen\u00a0Arzneimittels\u00a0bewertet.\u00a0F\u00fc r\u00a0jeden\u00a0der\u00a0drei\u00a0\ngenannten\u00a0Punkte\u00a0wurde\u00a0ein\u00a0Ampelschema\u00a0genutzt,\u00a0wobei\u00a0die\u00a0Farbe n\u00a0das\u00a0Folgen\u2010\nde\u00a0bedeuten:\u00a0\n1.\u00a0Verf\u00fcgbare\u00a0Therapien\u00a0\u00a0\n\uf0b7 Rot:\u00a0Das\u00a0neue\u00a0Arzneimittel\u00a0stellt \u00a0lediglich\u00a0eine\u00a0weitere\u00a0Therap ieopti\u2010\non\u00a0f\u00fcr\u00a0das\u00a0zugelassene\u00a0Anwendungsgebiet\u00a0dar,\u00a0es\u00a0gibt\u00a0f\u00fcr\u00a0die\u00a0Be \u2010\nhandlung\u00a0der\u00a0jeweiligen\u00a0Erkrankung(en)\u00a0bereits\u00a0zugelassene\u00a0Arzn ei\u2010\nmittel\u00a0mit\u00a0vergleichbaren\u00a0pharmakodynamischen\u00a0und\u00a0pharmakoki\u2010\nnetischen\u00a0Eigenschaften\u00a0auf\u00a0dem\u00a0deutschen\u00a0Markt.\u00a0\u00a0\n\uf0b7 Gelb:\u00a0Das\u00a0neue\u00a0Arzneimittel\u00a0stellt\u00a0aufgrund\u00a0eines\u00a0neuartigen\u00a0Wi r\u2010\nkungsmechanismus\u00a0 oder\u00a0 verbesserter\u00a0 pharmakokinetischer\u00a0 Eigen\u2010 \n193\u00a0\n\u00a0schaften\u00a0(z.\u00a0B.\u00a0einer\u00a0neuen\u00a0Applikationsform)\u00a0eine\u00a0Novit\u00e4t\u00a0dar, \u00a0die\u00a0\nzumindest\u00a0f\u00fcr\u00a0eine\u00a0bestimmte\u00a0Untergruppe\u00a0der\u00a0Erkrankten\u00a0eine\u00a0zu \u2010\ns\u00e4tzliche\u00a0Therapiem\u00f6glichkeit\u00a0bietet,\u00a0z.\u00a0B.\u00a0weil\u00a0gegen\u00a0bisher\u00a0z ugelas\u2010\nsene\u00a0Arzneimittel\u00a0Resistenzen\u00a0vorliegen.\u00a0\u00a0\n\uf0b7 Gr\u00fcn:\u00a0Das\u00a0neue\u00a0Arzneimittel\u00a0bietet \u00a0erstmals\u00a0die\u00a0M\u00f6glichkeit,\u00a0di e\u00a0Er\u2010\nkrankung,\u00a0f\u00fcr\u00a0die\u00a0es\u00a0zugelassen\u00a0 ist,\u00a0medikament\u00f6s\u00a0zu\u00a0behandeln\u00a0\n(therapeutische\u00a0Innovation).\u00a0\u00a0\n2.\u00a0(Zusatz\u2010)Nutzen\u00a0\u00a0\n\uf0b7 Rot:\u00a0Das\u00a0neue\u00a0Arzneimittel\u00a0bie tet\u00a0f\u00fcr\u00a0die\u00a0Behandlung\u00a0gegen\u00fcber\u00a0 den\u00a0\nbisher\u00a0verf\u00fcgbaren\u00a0Arzneimitteln \u00a0keine\u00a0patientenrelevante\u00a0Verbe s\u2010\nserung\u00a0oder\u00a0weist\u00a0sogar\u00a0eine\u00a0sch lechtere\u00a0Nutzen\u2010Schaden\u2010Relatio n\u00a0\nauf\u00a0als\u00a0bisher\u00a0verf\u00fcgbare\u00a0Arznei mittel\u00a0(z.\u00a0B.\u00a0mehr\u00a0Nebenwirkung en).\u00a0\u00a0\n\uf0b7 Gelb:\u00a0Das\u00a0neue\u00a0Arzneimittel\u00a0bietet\u00a0Verbesserungen\u00a0in\u00a0Bezug\u00a0auf\u00a0 die\u00a0\ntherapeutische\u00a0Wirksamkeit\u00a0oder\u00a0die\u00a0Vertr\u00e4glichkeit\u00a0bzw.\u00a0Therap ie\u2010\nsicherheit,\u00a0wobei\u00a0die\u00a0Evidenz\u00a0nicht\u00a0eindeutig\u00a0ist\u00a0(z.\u00a0B.\u00a0hetero gene\u00a0\nStudienergebnisse)\u00a0oder\u00a0die\u00a0beoba chteten\u00a0Verbesserungen\u00a0eher\u00a0ge \u2010\nring\u00a0ausfallen.\u00a0\u00a0\n\uf0b7 Gr\u00fcn:\u00a0Das\u00a0neue\u00a0Arzneimittel\u00a0bietet\u00a0f\u00fcr\u00a0die\u00a0zugelassene\u00a0Behandlu ng\u00a0\nder\u00a0jeweiligen\u00a0Erkrankung\u00a0bez\u00fcglich\u00a0klinisch\u00a0relevanter\u00a0Endpunk te\u00a0\neine\u00a0Verbesserung\u00a0gegen\u00fcber\u00a0den\u00a0bisher\u00a0verf\u00fcgbaren\u00a0Arzneimittel n.\u00a0\nDer\u00a0erforderliche\u00a0Zusatzeffekt\u00a0w ird\u00a0hier\u00a0in\u00a0Abh\u00e4ngigkeit\u00a0von\u00a0de r\u00a0je\u2010\nweiligen\u00a0Indikation\u00a0festgelegt,\u00a0so\u00a0dass\u00a0z.\u00a0B.\u00a0auch\u00a0kleinere,\u00a0ab er\u00a0pati\u2010\nentenrelevante\u00a0Verbesserungen\u00a0bei \u00a0seltenen\u00a0Erkrankungen,\u00a0f\u00fcr\u00a0di e\u00a0\nes\u00a0noch\u00a0keine\u00a0Therapie\u00a0gibt,\u00a0an\u00a0Gewicht\u00a0gewinnen.\u00a0Ebenfalls\u00a0wur de\u00a0\nmit\u00a0\u201egr\u00fcn\u201c\u00a0bewertet,\u00a0wenn\u00a0es\u00a0eindeutige\u00a0Belege\u00a0daf\u00fcr\u00a0gibt,\u00a0dass \u00a0die\u00a0\nNutzen\u2010Schaden\u2010Bilanz\u00a0 gegen\u00fcber\u00a0 bi sherigen\u00a0 Therapien,\u00a0 z.\u00a0B.\u00a0 auf \u2010\ngrund\u00a0einer\u00a0Verminderung\u00a0schwere r\u00a0unerw\u00fcnschter\u00a0Wirkungen,\u00a0re\u2010\nduziert\u00a0ist.\u00a0\u00a0\n3.\u00a0Kosten\u00a0\u00a0\n\uf0b7 Rot:\u00a0Das\u00a0neue\u00a0Arzneimittel\u00a0ist\u00a0in\u00a0Bezug\u00a0auf\u00a0einen\u00a0vergleichbare n\u00a0\nAnwendungszeitraum\u00a0teurer\u00a0als\u00a0a ndere\u00a0bisher\u00a0f\u00fcr\u00a0das\u00a0jeweilige\u00a0A n\u2010\nwendungsgebiet\u00a0 zugelassene\u00a0 Arzneim ittel\u00a0 bzw.\u00a0 die\u00a0 zweckm\u00e4\u00dfige\u00a0\nVergleichstherapie.\u00a0Bei\u00a0mehreren \u00a0Indikationen\u00a0ist\u00a0prim\u00e4r\u00a0die\u00a0In dika\u2010\ntion\u00a0f\u00fcr\u00a0die\u00a0Bewertung\u00a0relevant,\u00a0bei\u00a0welcher\u00a0aufgrund\u00a0epidemiol ogi\u2010\nscher\u00a0Daten\u00a0die\u00a0meisten\u00a0An wender\u00a0zu\u00a0erwarten\u00a0sind.\u00a0\u00a0\n\uf0b7 Gelb:\u00a0Das\u00a0neue\u00a0Arzneimittel\u00a0kost et\u00a0in\u00a0Bezug\u00a0auf\u00a0einen\u00a0vergleich ba\u2010\nren\u00a0Anwendungszeitraum\u00a0ungef\u00e4hr\u00a0gleich\u00a0viel\u00a0wie\u00a0bisher\u00a0f\u00fcr\u00a0das\u00a0 je\u2010 \n194\u00a0\n\u00a0weilige\u00a0 Anwendungsgebiet\u00a0 zugelassene\u00a0 Arzneimittel\u00a0 bzw.\u00a0 die\u00a0\nzweckm\u00e4\u00dfige\u00a0Vergleichstherapie.\u00a0 Oder\u00a0einige\u00a0wichtige\u00a0Arzneimitt el\u2010\ngruppen\u00a0sind\u00a0g\u00fcnstiger,\u00a0w\u00e4hrend\u00a0a ndere\u00a0relevante\u00a0Alternativen\u00a0t eu\u2010\nrer\u00a0sind\u00a0als\u00a0das\u00a0neue\u00a0Arzneimitte l.\u00a0Nur\u00a0bei\u00a0einem\u00a0quantifizierb aren\u00a0\nZusatznutzen\u00a0wird\u00a0auch\u00a0ein\u00a0h\u00f6herer\u00a0Preis\u00a0akzeptiert.\u00a0Bei\u00a0mehrer en\u00a0\nIndikationen\u00a0ist\u00a0prim\u00e4r\u00a0die\u00a0Indikation\u00a0f\u00fcr\u00a0die\u00a0Bewertung\u00a0releva nt,\u00a0bei\u00a0\nwelcher\u00a0aufgrund\u00a0epidemiologisc her\u00a0Daten\u00a0die\u00a0meisten\u00a0Anwender\u00a0\nzu\u00a0erwarten\u00a0sind.\u00a0\u00a0\n\uf0b7 Gr\u00fcn:\u00a0Das\u00a0neue\u00a0Arzneimittel\u00a0ist\u00a0in\u00a0Bezug\u00a0auf\u00a0einen\u00a0vergleichbar en\u00a0\nAnwendungszeitraum\u00a0g\u00fcnstiger\u00a0als\u00a0bisher\u00a0f\u00fcr\u00a0das\u00a0jeweilige\u00a0Anwen \u2010\ndungsgebiet\u00a0 zugelassene\u00a0 Arzneimi ttel\u00a0 bzw.\u00a0 als\u00a0 die\u00a0 zweckm\u00e4\u00dfige\u00a0\nVergleichstherapie.\u00a0Bei\u00a0mehreren \u00a0Indikationen\u00a0ist\u00a0prim\u00e4r\u00a0die\u00a0In dika\u2010\ntion\u00a0f\u00fcr\u00a0die\u00a0Bewertung\u00a0relevant,\u00a0bei\u00a0welcher\u00a0aufgrund\u00a0epidemiol ogi\u2010\nscher\u00a0Daten\u00a0die\u00a0meisten\u00a0An wender\u00a0zu\u00a0erwarten\u00a0sind.\u00a0\n\uf0b7 Wei\u00df:\u00a0Ein\u00a0aktueller\u00a0Kostenvergleich\u00a0mit\u00a0Arzneimitteln,\u00a0die\u00a0sich \u00a0be\u2010\nreits\u00a0l\u00e4nger\u00a0auf\u00a0dem\u00a0Markt\u00a0befinden,\u00a0ist\u00a0entweder\u00a0aufgrund\u00a0eine r\u00a0\nfehlenden\u00a0Markteinf\u00fchrung\u00a0bzw.\u00a0einer\u00a0Marktr\u00fccknahme\u00a0des\u00a0neuen\u00a0Arzneimittels\u00a0oder\u00a0aufgrund\u00a0des\u00a0 Fehlens\u00a0einer\u00a0zweckm\u00e4\u00dfigen\u00a0medi \u2010\nkament\u00f6sen\u00a0Vergleichsthe rapie\u00a0nicht\u00a0m\u00f6glich.\u00a0\nWenn\u00a0die\u00a0Ampel\u00a0bei\u00a0den\u00a0\u201everf\u00fcgbaren\u00a0Therapien\u201c\u00a0rot\u00a0gekennzeichn et\u00a0ist,\u00a0ist\u00a0dies\u00a0\nnicht\u00a0automatisch\u00a0negativ\u00a0zu\u00a0seh en.\u00a0Sofern\u00a0diese\u00a0neue\u00a0Substanz\u00a0 einen\u00a0therapeuti\u2010\nschen\u00a0Fortschritt\u00a0mit\u00a0sich\u00a0bringt,\u00a0also\u00a0eine\u00a0gr\u00fcne\u00a0Ampel\u00a0beim\u00a0\u201e (Zusatz\u2010)\u00a0Nutzen\u201c\u00a0\naufweist,\u00a0kann\u00a0immer\u00a0noch\u00a0eine\u00a0relevante\u00a0therapeutische\u00a0Innovat ion\u00a0vorliegen.\u00a0In\u00a0\nder\u00a0Regel\u00a0ist\u00a0jedoch\u00a0bei\u00a0einem\u00a0nachgewiesenen\u00a0(Zusatz\u2010)\u00a0Nutzen\u00a0 die\u00a0Verf\u00fcgbar\u2010\nkeitsampel\u00a0mindestens\u00a0auf\u00a0\u201egelb\u201c\u00a0gestellt,\u00a0weil\u00a0mit\u00a0der\u00a0Anwendu ng\u00a0des\u00a0Mittels\u00a0\nVorteile\u00a0verbunden\u00a0sein\u00a0k\u00f6nnen,\u00a0z .\u00a0B.\u00a0f\u00fcr\u00a0definierte\u00a0kleine\u00a0Pat ientengruppen.\u00a0Die\u00a0\nVerf\u00fcgbarkeit\u00a0bestehender\u00a0Therapien\u00a0orientiert\u00a0sich\u00a0hier\u00a0an\u00a0der \u00a0Situation\u00a0zum\u00a0\nZeitpunkt\u00a0 des\u00a0 Redaktionsschlusses\u00a0 des\u00a0 jeweiligen\u00a0 Innovationsrep ortes,\u00a0 ebenso\u00a0\nwird\u00a0der\u00a0(Zusatz\u2010)\u00a0Nutzen\u00a0auf\u00a0Basis\u00a0der\u00a0aktuellen\u00a0Literatur\u00a0zum \u00a0jeweiligen\u00a0Redakti\u2010\nonsschluss\u00a0bestimmt.\u00a0Die\u00a0Kosten\u00a0in\u00a0den\u00a0Innovationsreporten\u00a02013 \u00a0bis\u00a02020\u00a0wur\u2010\nden\u00a0auf\u00a0Basis\u00a0der\u00a0entsprechend\u00a0publizierten\u00a0Preisst\u00e4nde\u00a0gem\u00e4\u00df\u00a0L auer\u2010Taxe\u00a0beur\u2010\nteilt.\u00a0Sollte\u00a0das\u00a0neue\u00a0Arzneimittel\u00a0f\u00fcr\u00a0mehrere\u00a0Anwendungsgebie te\u00a0zugelassen\u00a0\nsein,\u00a0wurde\u00a0unsere\u00a0Bewertung\u00a0durch\u00a0die\u00a0Haupt\u2010\u00a0bzw.\u00a0Erstindikati on\u00a0geleitet,\u00a0so\u2010\nfern\u00a0diese\u00a0identifizierbar\u00a0war.\u00a0\u00a0\nIm\u00a0 Rahmen\u00a0 der\u00a0 klinischen\u00a0 Studien\u00a0 m\u00f6glicherweise\u00a0 auftretende\u00a0 une rw\u00fcnschte\u00a0\nEreignisse\u00a0bzw.\u00a0Nebenwirkungen\u00a0wurden\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a03\u00a0Abs.\u00a06,\u00a07\u00a0und\u00a08 \u00a0der\u00a0\u201eVerord\u2010\nnung\u00a0\u00fcber\u00a0die\u00a0Anwendung\u00a0der\u00a0Guten\u00a0Klinischen\u00a0Praxis\u00a0bei\u00a0der\u00a0Dur chf\u00fchrung\u00a0von\u00a0\nklinischen\u00a0 Pr\u00fcfungen\u00a0 mit\u00a0 Arzneimitteln\u00a0 zur\u00a0 Anwendung\u00a0 am\u00a0 Mensche n\u201c\u00a0 (GCP\u2010 \n195\u00a0\n\u00a0Verordnung)\u00a0wie\u00a0folgt\u00a0definiert\u00a0und\u00a0so\u00a0auch\u00a0in\u00a0den\u00a0Bewertungen\u00a0 dieses\u00a0Reports\u00a0\nbehandelt\u00a0(BMJV,\u00a02012):\u00a0\u00a0\n\uf0b7 Unerw\u00fcnschtes\u00a0Ereignis\u00a0(Unerw\u00fcns chtes\u00a0Arzneimittelereignis,\u00a0UAE )\u00a0\nist\u00a0jedes\u00a0nachteilige\u00a0Vorkommnis,\u00a0 das\u00a0einer\u00a0betroffenen\u00a0Person\u00a0 wi\u2010\nderf\u00e4hrt,\u00a0der\u00a0ein\u00a0Pr\u00fcfpr\u00e4parat\u00a0verabreicht\u00a0wurde,\u00a0das\u00a0aber\u00a0nich t\u00a0\nnotwendigerweise\u00a0in\u00a0urs\u00e4chliche m\u00a0Zusammenhang\u00a0mit\u00a0diesem\u00a0Pr\u00e4\u2010\nparat\u00a0steht.\u00a0\u00a0\n\uf0b7 Nebenwirkung\u00a0ist\u00a0jede\u00a0nachteilige\u00a0und\u00a0unbeabsichtigte\u00a0Reaktion\u00a0 auf\u00a0\nein\u00a0Pr\u00fcfpr\u00e4parat,\u00a0unabh\u00e4ngig\u00a0von\u00a0dessen\u00a0Dosierung.\u00a0\u00a0\n\uf0b7 Schwerwiegendes\u00a0 unerw\u00fcnschtes\u00a0 Ereignis\u00a0 oder\u00a0 schwerwiegende\u00a0\nNebenwirkung\u00a0ist\u00a0jedes\u00a0unerw\u00fcnschte\u00a0Ereignis\u00a0oder\u00a0jede\u00a0Nebenwir \u2010\nkung,\u00a0das\u00a0oder\u00a0die\u00a0t\u00f6dlich\u00a0oder\u00a0lebensbedrohend\u00a0ist,\u00a0eine\u00a0stati on\u00e4re\u00a0\nBehandlung\u00a0oder\u00a0deren\u00a0Verl\u00e4nger ung\u00a0erforderlich\u00a0macht\u00a0oder\u00a0zu\u00a0\nbleibender\u00a0 oder\u00a0 schwerwiegender\u00a0 Behinderung\u00a0 oder\u00a0 Invalidit\u00e4t\u00a0\nf\u00fchrt\u00a0oder\u00a0eine\u00a0kongenitale\u00a0Anomalie\u00a0oder\u00a0einen\u00a0Geburtsfehler\u00a0z ur\u00a0\nFolge\u00a0hat.\u00a0\u00a0\n\u00a0 \u00a0 \n196\u00a0\n\u00a011 Abbildungsverzeichnis\u00a0\nAbb.\u00a04.3:\u00a0Ausgaben\u00a0f\u00fcr\u00a0Marketing \u00a0vs.\u00a0F&E\u00a0gro\u00dfer\u00a0pU\u00a0nach\u00a0US\u00a0$\u00a0.. .......................\u00a043 \u00a0\nAbb.\u00a05.1:\u00a0Reduzierung\u00a0des\u00a0pharmak otherapeutischen\u00a0Potenzials\u00a0du rch\u00a0\nTransfer,\u00a0Implementierung\u00a0und\u00a0Umsetzung\u00a0....................... ...................\u00a088 \u00a0\nAbb.\u00a06.1:\u00a0Evaluation\u00a0des\u00a0Nutzens \u00a0und\u00a0der\u00a0Kosten\u00a0neuer\u00a0Arzneimit tel\u00a0im\u00a0NHIS\u00a0...\u00a0123 \u00a0\nAbb.\u00a07.1:\u00a0Der\u00a0dynamische\u00a0Evidenzpreis.......................... ......................................\u00a0131 \u00a0\nAbb.\u00a07.2:\u00a0Eingabemaske\u00a0des\u00a0AIM\u00a0 Fair\u00a0Pricing\u00a0Calculators \u00a0....................................\u00a0137 \u00a0\nAbb.\u00a07.3:\u00a0Eingabemaske\u00a02\u00a0des\u00a0AIM \u00a0Fair\u00a0Pricing\u00a0Calculators\u00a0\u2013\u00a0Lev el\u00a0of\u00a0Innovation\u00a0..\u00a0138 \u00a0\nAbb.\u00a07.4:\u00a0\u201eMonatliche\u00a0und\u00a0mediane\u00a0 Kosten\u00a0von\u00a0Arzneimitteln\u00a0in\u00a0d er\u00a0\nOnkologie\u00a0zum\u00a0Zeitpunkt\u00a0der\u00a0FD A\u2010Zulassung\u00a01965\u00a0bis\u00a02019\u201c\u00a0...... .........\u00a0146\u00a0\nAbb.\u00a07.5:\u00a0Vergleich\u00a0der\u00a0GKV\u2010Nettoausgaben\u00a0in\u00a02019\u00a0mit\u00a0den\u00a0hypot hetischen\u00a0\nAusgaben\u00a0unter\u00a0fairen\u00a0AIM\u2010Preisen\u00a0............................. .........................\u00a0153 \u00a0\nAbb.\u00a08.1:\u00a0 Prescire\u00a0international \u00a0zum\u00a0Thema\u00a0Targin\u00a0............................................. .\u00a0172\u00a0\nAbb.\u00a08.2:\u00a0Empfehlung\u00a0der\u00a0AKd\u00c4\u00a0zu\u00a0Targin\u00a0....................... .....................................\u00a0174 \u00a0\nAbb.\u00a09.1:\u00a0Einsparungen\u00a0aus\u00a0dirigistischen\u00a0und\u00a0Steuerungsma\u00dfnahm en\u00a0der\u00a0\nKrankenkassen\u00a0................................................. ......................................\u00a0185 \u00a0\nAbb.\u00a09.2:\u00a0Interimspreis\u2010Modell\u00a0f\u00fc r\u00a0Arzneimittel\u00a0mit\u00a0beschleunig ter\u00a0Zulassung\u00a0...\u00a0187 \u00a0\nAbb.\u00a09.3:\u00a0Kriterienbasierte\u00a0Pre isfindung\u00a0f\u00fcr\u00a0neue\u00a0Arzneimittel\u00a0 \u2013\u00a0\nWeiterentwicklung\u00a0des\u00a0AMNOG\u00a0................................... .........................\u00a0188 \u00a0\n\u00a0\n12 Tabellenverzeichnis\u00a0\nTabelle\u00a03.1:\u00a0Die\u00a020\u00a0umsatzst\u00e4rks ten\u00a0Hersteller\u00a0von\u00a0Juli\u00a02020\u00a0bi s\u00a0Juni\u00a02021\u00a0in\u00a0\nEuro\u00a0in\u00a0Deutschland\u00a0........................................... ....................................\u00a018 \u00a0\nTabelle\u00a03.2:\u00a0Die\u00a0Herstellerums\u00e4tze \u00a0nach\u00a0Indikationsgebieten\u00a0von \u00a0Juli\u00a02020\u00a0bis\u00a0\nJuni\u00a02021\u00a0in\u00a0Euro\u00a0(Ranking\u00a0i n\u00a0%\u00a0vom\u00a0Industrieumsatz)\u00a0.......... ...............\u00a019 \u00a0\nTabelle\u00a03.3:\u00a0Jahrestherapiekosten \u00a0(oder\u00a0DDD\u2010Kosten)\u00a0f\u00fcr\u00a0monoklo nale\u00a0\nAntik\u00f6rper\u00a0und\u00a0Tyrosinkinasehemmer\u00a0............................ ......................\u00a023 \u00a0\nTabelle\u00a04.1:\u00a0Gesamtbewertungen\u00a0d er\u00a0Innovationsreporte\u00a02013\u00a0bis\u00a0 2020\u00a0auf\u00a0\nATC\u2010Ebene\u00a01\u00a0nach\u00a0 Orphan\u2010Drug \u2010Status\u00a0.................................................\u00a029 \u00a0\nTabelle\u00a04.2:\u00a0Wirkstoffbewertungen \u00a0der\u00a0Innovationsreporte\u00a02013\u00a0b is\u00a02020\u00a0........\u00a034 \u00a0\nTabelle\u00a04.3:\u00a0\u00dcbersicht\u00a0der\u00a0Wirkst offklassen\u00a0von\u00a0neuen\u00a0Arzneisto ffen\u00a0zur\u00a0\nBehandlung\u00a0des\u00a0fortgeschri ttenen\u00a0malignen\u00a0Melanoms\u00a0............ ...........\u00a046\u00a0\nTabelle\u00a04.4:\u00a0Zulassung\u00a0der\u00a0Wirks toffe\u00a0als\u00a0Mono\u2010\u00a0bzw.\u00a0Kombinatio nstherapie\u00a0....\u00a049 \u00a0\nTabelle\u00a04.5:\u00a0\u00dcbersicht\u00a0der\u00a0Nutze nbewertungen\u00a0zum\u00a0 malignen\u00a0Melan om\u00a0..........\u00a051 \u00a0 \n197\u00a0\n\u00a0Tabelle\u00a04.6:\u00a0Bewertungen\u00a0und\u00a0Pre ise\u00a0neuer\u00a0Arzneimittel\u00a0mit\u00a0Indi kation\u00a0\nmalignes\u00a0Melanom\u00a0.............................................. ..................................\u00a052 \u00a0\nTabelle\u00a04.7:\u00a0\u00dcbersicht\u00a0der\u00a0Nutzenbewertungen\u00a0zu\u00a0RRMS\u00a0.......... .........................\u00a061 \u00a0\nTabelle\u00a04.8:\u00a0Arzneimittel\u00a0zur\u00a0Th erapie\u00a0der\u00a0schubf\u00f6rmig\u00a0remittie renden\u00a0\nmultiplen\u00a0Sklerose\u00a0(RRMS)...................................... ...............................\u00a062 \u00a0\nTabelle\u00a05.1:\u00a0Nutzenbewertung\u00a02006\u00a0 \u00fcbersetzt\u00a0in\u00a0fiktives\u00a0Verfahr en\u00a0nach\u00a0\nAMNOG\u00a0......................................................... .........................................\u00a078 \u00a0\nTabelle\u00a05.2:\u00a0Die\u00a020\u00a0f\u00fchrenden\u00a0Pr \u00e4parate\u00a0nach\u00a0Industrieumsatz\u00a0im \u00a0\nJahreszeitraum\u00a0Juli\u00a02020\u00a0bis\u00a0Juni\u00a02021\u00a0........................ ..........................\u00a085 \u00a0\nTabelle\u00a06.1:\u00a0Niveaus\u00a0der\u00a0Verbesse rung\u00a0des\u00a0therapeutischen\u00a0Nutze ns.................\u00a0106 \u00a0\nTabelle\u00a06.2:\u00a0Procedere\u00a0der\u00a0Preisfindung\u00a0in\u00a0Frankreich\u00a0......... ................................\u00a0107 \u00a0\nTabelle\u00a06.3:\u00a0Institutioneller\u00a0Abla uf\u00a0der\u00a0zweistufigen\u00a0Bewertung \u00a0neuer\u00a0\nArzneimittel\u00a0in\u00a0Korea\u00a0......................................... ....................................\u00a0122 \u00a0\nTabelle\u00a07.1:\u00a0Nusinersen\u00a0(Spinraza \u00ae)\u00a0im\u00a0AIM\u00a0Fair\u00a0Pricing\u00a0Calcula tor\u00a0.....................\u00a0141 \u00a0\nTabelle\u00a07.2:\u00a0G\u2010BA\u00a0Bewertungsverfahrenen\u00a0zu\u00a0Nivolumab\u00a0(n=17)\u00a0(G\u2010 BA,\u00a0\n2021e).\u00a0....................................................... ............................................\u00a0148 \u00a0\nTabelle\u00a07.3:\u00a0Vergleich\u00a0der\u00a0Jahres therapiekosten\u00a0innovativer\u00a0Arz neimittel\u00a0auf\u00a0\nBasis\u00a0des\u00a0APU\u00a0zu\u00a0Markteintritt/ak tuellen\u00a0APU\u00a0vs.\u00a0AIM\u00a0Fair\u00a0Prici ng\u00a0\nTool\u00a0.......................................................... ..............................................\u00a0150 \u00a0\nTabelle\u00a07.4:\u00a0Prozentuale\u00a0Preisr eduktion\u00a0vs.\u00a0Effekt\u00a0des\u00a0AIM\u00a0 Fair\u00a0Pricing\u00a0\nCalculators \u00a0.............................................................. ...............................\u00a0151 \u00a0\nTabelle\u00a07.5:\u00a0Potenzielle\u00a0Einspar ungen\u00a0der\u00a0GKV\u00a0bei\u00a0innovativen\u00a0W irkstoffen\u00a0\nunter\u00a0Nutzung\u00a0des\u00a0AIM\u00a0 Fair\u00a0Pricing\u00a0Calculators \u00a0an\u00a0ausgew\u00e4hlten\u00a0\nBeispiel\u2010Arzneimitteln\u00a0bei\u00a0aktuellem\u00a0APU\u00a0...................... .......................\u00a0152 \u00a0\nTabelle\u00a08.1:\u00a0Verordnungsmenge\u00a0 der\u00a0Wirkstoffkombination\u00a0\nOxycodon/Naloxon\u00a0in\u00a0der\u00a0GKV\u00a0im\u00a0Jahr\u00a02019\u00a0...................... ...................\u00a0173 \u00a0\nTabelle\u00a08.2:\u00a0Absch\u00e4tzung\u00a0Grad\u00a0des\u00a0Preiszuschlages\u00a0............. ................................\u00a0176 \u00a0\nTabelle\u00a09.1:\u00a0Faire\u00a0Preise\u00a0f\u00fcr \u00a0Kombinationen\u00a0anhand\u00a0des\u00a0 Fair\u00a0Pricing\u00a0\nCalculators \u00a0.............................................................. ...............................\u00a0183 \u00a0\n\u00a0", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}